"URL","Uniprot ID","PMID","Abstract"
https://pharos.nih.gov/idg/targets/P27037,P27037,27832070,"This locus harbors an evolutionary conserved gene-desert region with non-coding intergenic sequences likely involved in regulation of protein-coding flanking genes ZEB2 and ACVR2A. This region is intensively studied for mutations causing severe developmental/genetic disorders. Our analyses indicate a promising target region for interventions aimed to reduce risks of many major human diseases and mortality."
https://pharos.nih.gov/idg/targets/P27037,P27037,27696331,"TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.("
https://pharos.nih.gov/idg/targets/P27037,P27037,26677222,"Data suggest ALK1 and ACVR2A/ACVR2B, acting as BMP9 co-receptors, rearrange pro-domains of BMP9--pro-domain dimer complex leading to displacement of pro-domains after receptor binding, release of mature non-dimer BPM9, and activation of signaling."
https://pharos.nih.gov/idg/targets/P27037,P27037,26086422,"Adenomyotic tissues express high levels of myostatin, follistatin, and activin type II receptors."
https://pharos.nih.gov/idg/targets/P27037,P27037,26047946,"Activin A inhibited signaling by BMP-6 and BMP-9 by competing for type 2 receptors ACVR2A and ACVR2B."
https://pharos.nih.gov/idg/targets/P27037,P27037,25659497,"Data suggest that an SNP in promoter region of ACVR2A (rs1424954, the pre-eclampsia susceptibility allele) down-regulates 1) expression of ACVR2A in trophoblasts and 2) signal transduction in response to excess activin-A (as seen in pre-eclampsia)."
https://pharos.nih.gov/idg/targets/P27037,P27037,25499008,"The gene ACVR2A was associated with the more severe early onset preeclampsia."
https://pharos.nih.gov/idg/targets/P27037,P27037,23633461,"For ACVR2A SNPs (rs10497025, rs1128919, rs13430086), no statistically significant difference was found between preeclampsia and control groups in terms of genotype and allele frequencies."
https://pharos.nih.gov/idg/targets/P27037,P27037,23263486,"ACVR2A was identified as a subnetwork component in functional association network analysis."
https://pharos.nih.gov/idg/targets/P27037,P27037,22949641,"ACVR2A interaction with Nodal and ADMP regulates head development from the 'organizer', a restricted group of cells in the embryo."
https://pharos.nih.gov/idg/targets/P27037,P27037,22848350,"ACVR2A showed statistically significant differential dose-expression relationship."
https://pharos.nih.gov/idg/targets/P27037,P27037,22723898,"This is the first report on the function of miR-195 in human placental trophoblast cells which reveals an invasion-promoting effect of the small RNA via repressing ActRIIA."
https://pharos.nih.gov/idg/targets/P27037,P27037,22296042,"Activin type IIA receptors are clearly demonstrable throughout the adult human hypothalamus and basal forebrain."
https://pharos.nih.gov/idg/targets/P27037,P27037,22001236,"Exonic selectivity for frameshift mutation within ACVR2 is specifically controlled by individual nucleotides flanking each coding ACVR2 microsatellite."
https://pharos.nih.gov/idg/targets/P27037,P27037,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,20634197,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,20424473,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,20200332,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,20197483,"Mutation in activin type II receptor is associated with colorectal cancer."
https://pharos.nih.gov/idg/targets/P27037,P27037,20011542,"Of 51 microsatellite stable colon tumors, 7 (14%) lost ACVR2, 2 (4%) ACVR1, and 5 (10%) pSMAD2 expression."
https://pharos.nih.gov/idg/targets/P27037,P27037,19574343,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,19503063,"The four most frequently mutated genes in colorectal cancers with microsatellite instability were ACVR2 (92%), TAF1B (84%), ASTE1/HT001 (80%) and TGFBR2 (77%)."
https://pharos.nih.gov/idg/targets/P27037,P27037,19308291,"ActRII signaling is required for prostatic cancer cell and neuroblastoma cell viability, with ActRII mediating cell fate via the regulation of cell adhesion"
https://pharos.nih.gov/idg/targets/P27037,P27037,19126782,"It remains unclear what role, if any, ACVR2A polymorphisms play in pre-eclampsia risk, at least in these Australian families."
https://pharos.nih.gov/idg/targets/P27037,P27037,19126782,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,19064572,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,18941508,"The -1 bp frameshift mutation rates of TGFBR2 and ACVR2 microsatellite sequences are dependent upon the human DNA Mismatch"
https://pharos.nih.gov/idg/targets/P27037,P27037,18781190,"Populations with different ancestors (Iceland/Norway-Australia/New Zealand) demonstrate a common maternal pre-eclampsia susceptibility locus on chromosome 2q22-23, may suggests a general role of this locus, and possibly the ACVR2A gene, in pre-eclampsia."
https://pharos.nih.gov/idg/targets/P27037,P27037,18001154,"Inhibin/activin BA subunit, follistatin, and activin receptor proteins and mRNAs are present in the human fetal palate."
https://pharos.nih.gov/idg/targets/P27037,P27037,17472960,"RGMa facilitates the use of ActRIIA by endogenous BMP2 and BMP4 ligands that otherwise prefer signaling via BMPRII and that increased utilization of ActRIIA leads to generation of an enhanced BMP signal"
https://pharos.nih.gov/idg/targets/P27037,P27037,17258738,"Activin is growth suppressive and enhances migration in colon cancer."
https://pharos.nih.gov/idg/targets/P27037,P27037,16672363,"structure of the ternary complex representing the signaling competent complex of BMP-2 bound to the entire extracellular domains of both its type I receptor, BMPR-Ia, & its type II receptor, ActRII, at a resolution of 2.2 angstroms"
https://pharos.nih.gov/idg/targets/P27037,P27037,16380996,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P27037,P27037,16337854,"demonstrates that truncating mutations of the ACVR2 gene result in a significant reduction in activin mediated cell signaling. Inactivation of ACVR2 is a common event in prostate cancer and may play an important role in the development of prostate cancer"
https://pharos.nih.gov/idg/targets/P27037,P27037,14988818,"Mutations highly frequent in microsatellite unstable(MSI-H) colon cancers and cause loss of ACVR2, indicating biallelic gene nactivation. Loss of activin signaling through mutation of ACVR2 may have role in genesis of MSI-H colorectal cancer."
https://pharos.nih.gov/idg/targets/P27037,P27037,14738881,"Data indicate that activin A and activin receptors IIA and IIB may be involved in the regulation of germ cell proliferation in the human ovary during the period leading up to primordial follicle formation."
https://pharos.nih.gov/idg/targets/P27037,P27037,14691305,"Activin type II receptor gene (ACTRII) is probably involved in both non-microsattelite unstable and microsattelite-unstable colorectal carcinogenesis, but more frequently in the latter subgroup."
https://pharos.nih.gov/idg/targets/P27037,P27037,12667445,"crystal structure of BMP7 in complex with the extracellular domain (ECD) of the activin type II receptor"
https://pharos.nih.gov/idg/targets/P27037,P27037,11969340,"distribution in gestational tissues across human pregnancy and during labour"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,28641113,"LZK cooperates with DLK to promote retinal ganglion cell death in response to axon injury."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,27100796,"REVIEW: Regulation of Beta-Cell Function and Mass by the Dual Leucine Zipper Kinase"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,25999017,"miR-130a inhibited the JNK pathway by targeting MAP3K12, contributing to its anti-apoptotic effect and the maintenance of diabetic endothelial progenitor cell function."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,25341110,"Data suggest that specific pharmacological inhibition of dual leucine zipper kinase (DLK, MAP3K12) may have therapeutic potential in multiple indications of neuronal degeneration."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,21893036,"these findings indicate that DLK participates in cell proliferation and/or survival, at least in part, by modulating the expression of cell cycle regulatory proteins."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,21526495,"The results confirm the significance of apoptosis deregulation in CLL, and suggest a possible relationship between ZIPK expression and the clinical course of the disease."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,19851984,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,19730683,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,19675578,"the DLK-ERK signaling pathway may act as a regulator of the interaction that occurs between Hsp27 and the cytoskeleton during the formation of the cornified cell envelope, a process conferring to the skin its crucial barrier function"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,19146952,"Src-dependent tyrosine phosphorylation recombinant human DLK was important for regulation of its activity. DLK may have a role in PDGF signaling."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,18995835,"DAPK-ZIPK-L13a axis forms a unique regulatory module that first represses, then repermits inflammatory gene expression."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,15695824,"DLK is a signaling molecule implicated in the regulation of keratinocyte terminal differentiation and cornification"
https://pharos.nih.gov/idg/targets/Q12852,Q12852,15611134,"ZIPK is positively regulated by phosphorylation within its kinase domain and contains an inhibitory C-terminal domain that controls enzyme activity."
https://pharos.nih.gov/idg/targets/Q12852,Q12852,14697235,"for the selective expression of ZPK gene, cell-specific negative regulatory element(s) which locate outside of the core promoter region repress the potent basic promoter activity"
https://pharos.nih.gov/idg/targets/Q5TCX8,Q5TCX8,26859459,"results uncover MLK4 as an upstream regulator of NF-kappaB signaling and a potential molecular target for the MES subtype of glioblastomas"
https://pharos.nih.gov/idg/targets/Q5TCX8,Q5TCX8,23319808,"In establishing the role of MLK4 in intracellular signaling, we show it directly phosphorylates MEK1 (MAP2K1) and that MEK/ERK (MAPK1) signaling is impaired in MLK4 knockout cells"
https://pharos.nih.gov/idg/targets/Q5TCX8,Q5TCX8,21602844,"MLK4 is a negative regulator of TLR4 signaling."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28619995,"Disrupting BMPR2 impairs TGFbeta1- and BMP4-mediated elastic fiber assembly and is of pathophysiologic significance in pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28588028,"The SMYD2 may promote BMP signaling by directly methylating BMPR2, which, in turn, stimulates BMPR2 kinase activity and activation of the BMP pathway."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28447104,"This review focuses on recent advances in rescuing BMPRII expression, function or signaling to prevent and reverse pulmonary vascular remodeling in pulmonary arterial hypertension and its feasibility for clinical translation. Furthermore, it summarizes the role of described miRNAs that directly target the BMPR2 gene in blood vessels.  [review]"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28388887,"A burden of rare variants in BMPR2 significantly contributed to the risk of pulmonary arterial hypertension. In the remaining one family, the patient carried a pathogenic variant in a member of potassium channels, KCNK3, which was the first replicative finding of channelopathy in an Asian population."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28356442,"Endothelial BMPR2 signaling in pulmonary arterial hypertension is impaired by deletion of Vegfr3."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28188225,"Cav-1 depletion, oxidative stress-mediated reduction in BMPRII expression, and enhanced TGF-beta-driven SMAD-2/3 signaling promote pulmonary vascular remodeling in inflamed lungs."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28170297,"Affected mutation carriers with heritable pulmonary hypertension have hypermethylation of the BMPR2 promotor compared with their unaffected relatives."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,28017794,"This analysis identified features of unaffected mutation carriers iPSC-induced pluripotent stem cell-derived endothelial cells related to modifiers of BMPR2 signaling or to differentially expressed genes."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27998774,"BMPR2 downregulation may have a role in neuroblastoma"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27959431,"Further investigation on clinical ESCC samples and non-tumorous adjacent tissue found that tumors with triple-positive BMP6, ALK2 and BMPRII had deeper growth than tumors with only BMP6 expression"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27884767,"Pathogenic BMPR2 mutations were identified in 8 of 72 (11.1%) patients with IPAH and 6 of 9 (66.7%) patients with HPAH."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27816994,"HPAH-associated BMPRII mutation increases pulmonary microvascular endothelial cells adhesiveness for monocytes in response to inflammatory mediators."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27780042,"In solid ameloblastoma, positive correlations were observed between the stromal and parenchymal expression of BMP-2 and between the stromal expression of BMP-2 and BMP-4, as well as between the stromal expression of BMPR-II and BMP-4 and the stromal and parenchymal expression of BMPR-II."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27779452,"Decreased expression of bone morphogenetic protein receptor type 2 (BMPR2) is associated with all forms of PAH, and a mutation in this receptor is seen in 70% of patients with the heritable form of PAH (HPAH), and in 20% of sporadic cases of idiopathic PAH."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27537724,"Case Report: sarcoid-like reaction due to pulmonary hypertension in the context of the BMPR2 mutation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27515773,"Bone morphogenetic protein 2 expression increases and may contribute to partitioning of energy storage into visceral and subcutaneous AT depots"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27453251,"In a cohort with idiopathic or hereditary pulmonary arterial hypertension, a possibly associated mutation was found in 11.10% of the idiopathic cases (n = 16) and in 68.18% of the hereditary cases. There were 19 mutations found in BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27317687,"Depletion of BMPR2 mediated by a collection of miRs induced by IL6 and subsequent STAT3 phosphorylation is a novel mechanism participating to fibroproliferative and vascular injuries in idiopathic pulmonary fibrosis."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27273096,"increased BMPR2 signal transduction is linked to fragile X syndrome (FXS) and that the BMPR2-LIMK1 pathway is a putative therapeutic target in patients with FXS and possibly other forms of autism"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27248591,"Mutations in the bone morphogenetic protein receptor type-2 gene (BMPR2) have been identified in patients with pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27196063,"The genetic-interactions among BMPR-2, ALK-1, and 5-HTT polymorphisms, elevated BMP-2 and 5-HT levels and differential gene expression substantiated the strong genetic contribution in high altitude pulmonary edema pathophysiology."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27077124,"his study demonstrated that both rs6435156C > T and rs1048829G > T variants in BMPR2 contributed to increased susceptibility to hronic obstructive pulmonary disease"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27045138,"Increased HMGA1 in pulmonary arterial endothelial cells resulting from dysfunctional BMPR2 signaling can transition endothelium to smooth muscle-like cells associated with pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,27002414,"BMPR2 mutations were identified in congenital heart disease-pulmonary vascular disease patients, with missense mutation of BMPR2 as the dominant mutation type."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26984938,"Pulmonary arterial hypertension patients carrying a BMPR2 mutation have decreased right ventricular function compared to patients without the mutation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26897508,"Study of four patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection found predisposing mutations in the BMPR2, ACVRL1 and ENG genes."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26795434,"Patients with pulmonary arterial hypertension and bone morphogenetic protein receptor type II mutations present at a younger age with more severe disease, and are at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26772960,"establish the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2 osteogenesis"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26739752,"the data in the present study support the notion that the expression levels and plasma membrane levels of BMPRII are determined by two molecular processes-translational regulation of protein synthesis (which provides the major contribution) and endocytosis/degradation (mild modulatory effect)."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26654628,"Studying the methylation pattern of the BMPR2 promoter region in pulmonary arterial hypertension patients and controls revealed a a CpG island, suitable for methylation, in the BMPR2 promoter region, in addition to NIT-2, sex-determining region Y, and heat shock factor transcription factor binding sites.No evidence of methylation was detected in this region in patients and controls."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26589479,"Raf family members and ERK1/2 were constitutively activated after BMPR2 knockdown"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26541523,"In a group of pulmonary arterial hypertension patients, 25.4% harboured heterozygous mutation in the BMPR2 gene."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26406943,"An up-regulated expression of BMP-4 and BMPR-II was observed in the peripheral blood of breast cancer patients especially in the advanced-stage of the disease. Moreover, BMP-4 and BMPR-II expressions were found to be correlated"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26167679,"study shows for the first time that in the regulatory region of the BMPR2 gene the promoter may be important for pulmonary arterial hypertension penetrance"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26151470,"miR-153 is a mechano-sensitive miRNA that regulates osteoblast differentiation by directly targeting BMPR2, and that therapeutic inhibition of miR-153 may be an efficient anabolic strategy for skeletal disorders caused by pathological mechanical loading."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26076038,"BMP9 is identified as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in endothelial cells from subjects with pulmonary arterial hypertension who bear mutations in the gene encoding BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,26030479,"Mutations in BMPR2 underlie most heritable cases and a small proportion of sporadic cases of idiopathic pulmonary arterial hypertension.  Read More: http://www.atsjournals.org/doi/full/10.1164/rccm.201408-1528OC#.Viqgi9KFPyA"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25755766,"our results showed that GDF-5 and BMPRII expressed both in normal and degenerated intervertebral disc tissues, and GDF-5 might have an inhibition effect on degenerated lumbar intervertebral discs"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25723654,"local gene transfection can up-regulate the expression of osteogenic mediators (BMP-2 and TGF-beta1), which may promote cell differentiation and proliferation and stimulate extracellular matrix synthesis and new bone formation in distraction gap."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25698539,"Correlations between C23, BMPRII expression and prognosis of gastric cancer patients."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25688877,"disrupted intracellular trafficking of BMPR2 is involved in the pathogenic mechanism underlying both cysteine and non-cysteine substitutions occurring in the extracellular ligand binding domain and kinase domain of BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25612240,"Combining mutation detection in family members with parental identification, study described three cases of de novo mutation in the BMPR2 gene by different modes in a pulmonary arterial hypertension family. These de novo mutations may account for the wide variety of mutations in BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25501832,"Silencing BMPR2 promoted G2/M cell cycle arrest and apoptosis through caspase-3-dependent pathway via repression of XIAP and induced autophagy of chondrosarcoma cells via XIAP-Mdm2-p53 pathway."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25447587,"BMP2 decreased serum-induced proliferation and increased the pro-apoptotic Bax/Bcl-2 ratio. These effects were attenuated by endothelin-1 pre-treatment"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25429696,"Mutations in BMPR2 encoding bone morphogenetic protein receptor type 2 (BMPRII) is the main genetic risk factor for heritable pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25187962,"The BMPR2 protein containing Thr268fs, Ser863Asn, or Gln433X exhibited abnormal subcellular localization."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,25075125,"BMP type II receptors, BMPR2 and ActR2a, have redundant roles in the regulation of hepatic hepcidin gene expression and iron metabolism."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24936649,"Mutations in BMPR2 gene is associated with pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24881940,"BMPR-2 mutation-positive patient developed pulmonary AVMs reminiscent of HHT."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24814649,"BMP-2 and -4 are produced by vascular smooth muscle cells in atherosclerotic lesions and induce monocyte chemotaxis through direct BMPRII activation"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24728306,"Case Report: BMPR2 missense mutation in chronic thromboembolic pulmonary hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24621962,"a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24605778,"Mutations of BMPR2 have been linked to pulmonary arterial hypertension (PAH). In a case-control study unaffected carriers of this mutation were most often found to have prostacyclin synthase promoter sequence variants, thought to protect against PAH."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24591673,"Letter/Case Report: concurrent pulmonary hypertension and pulmonary fibrosis in BMPR2 mutation positive patient."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24583436,"patient is currently an asymptomatic carrier of the BMPR2 mutation, and that he might develop pulmonary hypertension as a result of this mutation in the future."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24446489,"loss of BMPR2 induced prolonged phospho-p38 MAPK in response to TNF, and this increased GADD34-PP1 phosphatase activity, dephosphorylating eukaryotic translation initiation factor (eIF2alpha), and derepressing GM-CSF mRNA translation"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24398041,"BMPR1a and BMPR2 are downregulated in cardiac remodeling and heart failure"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24378993,"BMPR2 downregulation is mediated by miR-17-92."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24355637,"In this review, the identification of BMPR2 as the major predisposing gene for pulmonary arterial hypertension is investigated."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24337809,"Site-directed mutagenesis reveals that BMPR2 is uniquely glycosylated near its ligand binding domain and at a position that is mutated in patients with heritable pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24274756,"Impaired right ventricle (RV) hypertrophy was associated with triglyceride deposition in mice with mutant Bmpr2 expression in RV. Human RVs with heritable pulmonary arterial hypertension showed lipid deposition and alteration in fatty acid oxidation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24194909,"A BMPR2 mutation did not correlate with a greater incidence of hemoptysis in a hypertension cohort, but its association with worse hemodynamics and greater bronchial arterial hypertrophy may increase the risk of hemoptysis."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24132125,"A 25-year-old female PAH patient with a deletion of BMPR2 exon 3."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24036241,"BMPR2 mutations may have a role in diffusion capacity and in pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24008158,"Simultaneous exposure of pulmonary smooth muscle cells to viral protein(s) and cocaine exacerbates downregulation of BMPR axis that may result in enhanced pulmonary vasculature aberrations in HIV positive drug users."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,24008158,"Treatment of pulmonary arterial smooth muscle cells with HIV-1 gp120 downregulates expression of BMPR-2, BMPR-1A, and BMPR-1B proteins"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23967299,"Endoglin-mediated suppression of prostate cancer invasion is regulated by activin and bone morphogenetic protein type II receptors."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23843612,"Critical roles of Bmp2 in osteoblasts and MSCs are a vital link between bone formation, vascularization and mesenchymal stem cells."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23675998,"The 5-year survival rate after diagnosis of pulmonary arterial hypertension was 88.5% in BMPR2 mutation carriers versus 80.9% in non-carriers in Japanese."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23579436,"Exonic deletions of BMPR2 account for at least part of BMPR2 mutations associated with heritable pulmonary arterial hypertension in Japan, as reported in other populations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23142694,"ALK2 may be an important receptor in ET-1 production during BMPR2 knockdown"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23115311,"BMPR2 carriers had an enhanced hypoxic pressure response when expressed as PVR versus arterial oxygen saturation measured by pulse oximetry"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23098893,"In conclusion, there was no BMPR2 mutation in our cohort study, but 5'UTR repeat polymorphisms in BMPR2 were disclosed with three genetics variations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,23079343,"these results further supports the role of the atlastin-1 of BMP signaling cascade in axonal maintenance and axonal degeneration, which is seen in various types of hereditary spastic paraplegia."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22988237,"the negative regulatory loop of BMP4-miR-302-BMPRII is a potential mechanism for the maintenance and fine-tuning of the BMP4 signaling pathway in various systems"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22961979,"the lateral mobility of BMPRI has a major impact in stabilizing heteromeric BMPRI-BMPRII receptor complexes to differentially stimulate SMAD versus non-SMAD signaling."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22923661,"Study casts doubt on the genetic anticipation of heritable pulmonary hypertenion related to mutations in BMPR2.  The risk of earlier disease does not appear to be passed on to the next generations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22923421,"BMPR2 mutation carriers was higher mPAP, mRVP, and PVR values with significantly greater hemodynamic compromise."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22894880,"This study has identified regions of the BMPR-II molecule that define ligand specificity."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22684006,"miR-100 plays a negative role in osteogenic differentiation and might act through targeting BMPR2"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22632830,"Patients with childhood idiopathic pulmonary arterial hypertension or heritable pulmonary arterial hypertension with BMPR2 mutation have the poorest clinical outcomes."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22341419,"Report significant reduction in BMPR2 expression in pulmonary arteries of patients with failed Fontan circulations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22312021,"study concludes that expression of pulmonary arterial hypertension penetrance signature represents increased risk of developing clinical hereditary pulmonary arterial hypertension (HPAH) and that ROS formation may play a role in pathogenesis of HPAH; results provide molecular insight into NMD BMPR2 related HPAH penetrance"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22293501,"generation of TGF-beta and BMP receptor homo- and hetero-oligomers and its roles as a mechanism capable of fast regulation of signaling by these crucial cytokines [review]"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22129439,"Mutations in BMPR2 are not involved in the pathogenesis of idiopathic portal hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,22048752,"There are no differences of Stro-1(+) cells, BMPRs(+) cells, and BMP7 concentration between male and female patients with total hip replacement."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21962132,"Variation in BMPR2 is associated with dizygotic twinning."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21898662,"These results demonstrate the role of BMPR2 mutation in the pathogenesis of PAH and indicate that variation within the SMAD family represents an infrequent cause of the disease."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21821917,"Data describe a BMPR2-mediated transcriptional complex between PPARgamma and beta-catenin, and suggest that apelin could be effective in treating PAH by rescuing BMPR2 and PAEC dysfunction."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21808054,"Stimulation of BMPRII promotes normal pulmonary artery endothelial cell function by activating eNOS."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21801371,"Identify new BMPR2 mutations in pulmonary arterial hypertension associated with younger age at diagnosis and more severe hemodynamic compromise."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21622843,"Three BMPR2 mutants decreased BMP-dependent Smad phosphorylation and Smad signaling.  New treatment options for PAH should also target receptor localization, rather than just expression level."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21311592,"Combined BMPR2 genotype-phenotype-mRNA expression data as well as evolutionary aspects suggest a role of BMPR2 in the pathophysiology of obesity."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21152263,"BMPR2 were detected in the human retina and retinoblastoma cell lines."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21070126,"The researchers found evidence that polymorphisms in the BMPR2 gene are overrepresented in patients with atrial septal heart defects and exercise-associated pulmonary hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21070126,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,21030519,"BMPR-II mutations in heritable pulmonary arterial hypertension characterized by retention within the endoplasmic reticulum; restoration of cell surface expression of ligand-binding domain mutants leads to partial rescue of BMP signaling"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20955454,"Data indicate that frameshift mutation of BMPR2 gene occurs in GC and CRC with MSI-H, and suggest that the BMPR2 mutation might contribute to cancer pathogenesis by inactivating BMPR2-mediated BMP signaling."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20955454,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20870717,"Expression of BMPR-II protein is constitutively regulated by lysosomal degradation in vascular cells."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20587070,"Low BMPR2 is associated with epithelial ovarian cancer."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20534176,"Pulmonary hypertensive BMPR2 mutation carriers are younger at diagnosis and present with a more severe hemodynamic compromise, irrespective of gender and mutation type."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20534176,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20410205,"Data support cross-regulation among BMP2, KLF9, and KLF13 to maintain progesterone sensitivity in stromal cells undergoing differentiation and suggest that loss of this network compromises establishment of uterine receptivity and implantation success."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20346360,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20096498,"Mutations of the gene that code bone morphogenic protein type 2 receptor (BMPR2) are involved in the pathogenesis of pulmonary arterial hypertension both in it familial and its idiopathic forms."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20096498,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20011660,"The coordinated activity of ActRIIA and BMPRII receptor subunits selectively mediates the chemotactic response to BMP7."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,20002458,"study established the frequency of BMPR2 mutations in Chinese population of pulmonary arterial hypertension patients"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19864167,"the 3q22 locus alone predicts most FPAH cases in BMPR2 mutation carriers, providing strong evidence that BMPR2 and the 3q22 locus interact epistatically"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19844076,"no mutations associated with late-onset sporadic pulmonary hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19844076,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19782107,"the inhibition of apoptosis by BMP2 and GDF5 does not depend on more complex signal transduction pathways such as smad and MAPK signaling but on direct stabilization of XIAP by BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19634078,"Germline mutations in the gene coding bone morphogenetic receptor type 2 (BMPR2) are detectable in the majority of cases of heritable pulmonary arterial hypertension and in a small proportion of cases of idiopathic pulmonary arterial hypertension [review]"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19628780,"late-outgrowth cells isolated from pulmonary arterial hypertension patients with BMPRII(bone morphogenetic protein receptor type II) mutations demonstrated clear differences in angiogenic capacity and proliferation in response to serum"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19578724,"miR-21 may have a potential role in regulating the malignancy and metastatic abilities of prostate cancer cells and in self-renewal of stem cells by regulating the expression of bone morphogenetic protein receptor II"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19552837,"BMPR2 promoter mutation -142G > A may be associated with familial pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19531247,"Copy-number variation in intron 1 in BMPR2 is unlikely to play a role in the pathogenesis of either familial or sporadic pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19531247,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19424179,"cGKI has a dual function in BMP signalling: (1) it modulates BMP receptor/Smad activity at the plasma membrane and (2) after redistribution to the nucleus, it further regulates transcription as a nuclear co-factor for Smads."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19390056,"Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19357154,"a BMPR2 mutation may have a role in pulmonary arterial hypertension in females"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19357154,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19324947,"BMPR-2 mutations are associated with defective Smad signalling compensated for by an activation of p38MAPK signalling, accounting for PASMC proliferation and deficient apoptosis in pulmonary hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19307479,"Pulmonary hypertensive response to exercise and hypoxia in idiopathic/familial PAH relatives appears as a genetic trait with familial clustering, being correlated to but not caused by a BMPR2 mutation"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19307479,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19223935,"Novel promoter and exon mutations of the BMPR2 gene in pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19206171,"Fndings suggest that the levels of expression of WT BMPR2 allele transcripts is important in the pathogenesis of FPAH caused by NMD1 mutations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19195606,"AVICs isolated from stenotic valves had greater expression of TLR2 and TLR4 and a greater BMP-2 response than AVICs from normal valves"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19059957,"the majority of familial cases of PAH disease are due to mutations in transforming growth factor (TGF)-beta superfamily receptor, bone morphogenetic protein receptor,type II; and potential therapeutic approaches aimed at rescuing this signaling pathway"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,19051722,"Because only 10-20% carriers with BMPR2 mutations develop PAH, the existence of environmental factors or modifier genes as 5-HTT(serotonin transporter) and ACE (angiotensin converting enzyme) is highly probable."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18792970,"BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia is reported."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18647753,"failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18621057,"Results showed that type II receptors, such as BMP receptor II, activin receptor IIA, and activin receptor IIB, competed with the pd for binding to the growth factor and displaced the prodomain from the complex."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18503968,"Patients with BMPR2 mutations are less likely to respond to acute vasodilator testing than mutation-negative patients and appear to have more severe disease at diagnosis."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18496036,"The TGFbeta1 SNPs studied modulate age at diagnosis and penetrance of familial pulmonary arterial hypertension in BMPR2 mutation heterozygotes."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18496036,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18436795,"both BMP type II receptor mutation and Id1 knockdown leads to loss of growth suppression by BMPs"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18364108,"the Glu386Val mutation and its absence in healthy controls support the mutation as the cause of familial pulmonary hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18356561,"BMPR2 mutation carriers with PAH present approximately 10 years earlier than noncarriers with more severe hemodynamic compromise at diagnosis."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18356561,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18342887,"The objective of this study was to determine ligand-binding epitopes and specificity determinants in two regions, the hydrophobic patch and the A-loop of the BMPR-II extracellular domain."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18321866,"Stoichiometric imbalance, due to either haplo-insufficiency or loss of optimal receptor-receptor interactions impairs BMPR-II mediated signalling in pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18292470,"there was significant down-regulation of BMPRII (bone morphogenetic protein receptor type II) expression in asthma patients at baseline"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18221724,"The presence of mutations in the gene encoding BMPR2 is not infrequent in patients with idiopathic PAH, suggesting that this family of growth factors may be important in the pathogenesis of the disease"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18187665,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,18159113,"ALK1 plays as notable a role as BMPR2 in the etiology of PAH. Asymptomatic carriers with the ALK1 mutation within the serine - threonine kinase domain are at risk of developing PAH and hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17700526,"Conditional inactivation of BMP type II receptor (BMPRII) in the stroma leads to epithelial hyperplasia throughout the colon with increased epithelial cell proliferation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17641158,"These results demonstrate that the 5'-untranslated region of BMPR2 is considerably longer than previously thought; we identified a double-substitution mutation"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17624341,"Expression of BMP-4 and BMP-7 and their receptors in human ovaries from fetuses as well as adults."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17576816,"Trb3 is a critical component of a novel mechanism for regulation of the bone morphogenetic protein pathway by BMPRII."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17515463,"primary pulmonary arterial smooth muscle cells demonstrated colocalization of BMPRII and RACK1 in vivo. RACK1-BMPRII interaction was reduced when kinase domain mutations occurring in patients with PAH were introduced to BMPRII"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17472960,"RGMa facilitates the use of ActRIIA by endogenous BMP2 and BMP4 ligands that otherwise prefer signaling via BMPRII and that increased utilization of ActRIIA leads to generation of an enhanced BMP signal"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17363346,"negligible change in the emission maximum was observed when bis-ANS binds ecBMPR-II. FRET revealed close proximity between tryptophan residue & bis-ANS binding site."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17322283,"BMP pathway regulates IL-6 in pulmonary tissues and conversely that IL-6 regulates the BMP pathway"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17318011,"Germline mutations in the gene coding for the bone morphogenetic protein receptor II (BMPR2) are present in more than 70% of FPAH and up to 26% of idiopathic, apparently sporadic cases (IPAH)."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17277049,"This protein, in transgenic rats, provide a rationale for the development of gene therapy aimed at improving BMPR2 signaling."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17203235,"HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,17102831,"Atrial septal defect Eisenmenger syndrome may occur without BMPR2 mutation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16982201,"Characterization of this enzyme expressed in E coli cells."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16782755,"Novel signaling network relevant to pulmonary artery hypertension underscored by BMPR2 mutations."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16717148,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16717148,"Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16615932,"Finally, two inhibitors of cyclin-dependent kinase 9 (a dominant negative CDK9 and flavopiridol) repressed activity from the MR and BMPR2 promoters"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16615932,"Treatment of pulmonary arterial smooth muscle cells with HIV-1 gp120 downregulates expression of BMPR-2, BMPR-1A, and BMPR-1B proteins"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16436528,"Human granulosa-like tumor cell line KGN expressed BMP type I (BMPR1A and BMPR1B) and type II receptors (BMPR2) and the BMP signaling molecules SMADs (SMAD1 and SMAD5)."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16429403,"BMPR2 gene rearrangements have a role in mutations in familial and idiopathic pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16429395,"TGF-beta type II receptor BMPR2 is mutated in pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16339917,"The correlation of the SERT promoter polymorphism with age at diagnosis in FPAH suggests a possible relationship between the SERT and BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16339782,"Bone morphogenetic protein regulaates K(V) channel expression and that loss of this signaling pathway in pulmonary artery through a mutation in BMPR2."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16282533,"Treatment of pulmonary arterial smooth muscle cells with HIV-1 gp120 downregulates expression of BMPR-2, BMPR-1A, and BMPR-1B proteins"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16155937,"Our data suggest that the complex formation between c-kit and BMPR-II leads to phosphorylation of BMPR-II at Ser757, which modulates BMPR-II-dependent signaling"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16122479,"Bone morphogenetic protein-2 is the predominant family member expressed in NSCLC and is overexpressed in the majority of human lung carcinomas independent of cell type."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,16002577,"c-Src tyrosine kinase was identified as a binding partner of the BMPR-II C-terminus."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15965979,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15965979,"BMPR2 mutations have a role in short lifetime expectancy in primary pulmonary hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15775752,"BMPR2 gene rearrangements is associated with primary pulmonary hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15699281,"Somatic loss of wild-type BMPR2 alleles is unlikely to play a significant role in the pathogenesis of familial pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15687131,"2 novel mutations were found in BMPR2 from 18 patients developing PAH before 6 years of age, including one partial gene deletion and one nonsense mutation."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15591269,"frequency of BMPR2 mutations in a different population of patients with sporadic idiopathic pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15516492,"Mutations may promote expansion of fibroblasts resistant to antiproliferative, prodifferentiation effects of bone morphogenetic proteins. Possible mechanism for vascular obliteration in familial pulmonary hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15492256,"Human bladder TCC tissues have a frequent loss of BMP-RII expression and that overexpression of BMP-RII leads to restoration of BMP signaling and decreased tumor growth in the human bladder TCC cell line TSU-Pr1."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15358693,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15354178,"Loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15295086,"Pulmonary hypertension in children may have a different genetic background than in adults and we postulate a recessive mode of inheritance in a proportion of infantile cases."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15235019,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15146475,"results indicate that a substantial portion of Japanese primary pulmonary hypertension patients carry BMPR2 mutations with considerable heterogeneity"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15055271,"Mutations of BMPR2 underlie many cases of familial primary pulmonary hypertension."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,15031260,"Loss of BMPRII signaling in mouse smooth muscle (due to dominant negative human transgene)is sufficient to produce the pulmonary hypertensive phenotype."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,14676131,"Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12543773,"Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells."
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12415595,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12358323,"Observational study of gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12358323,"bone morphogenetic protein receptor 2 mutations that appear to be rare in the general population but may combine with exposure to fenfluramine derivatives to greatly increase the risk of developing severe pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12221115,"BMPRII has a role in signal transduction and its mutation can lead to primary pulmonary hopertension"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,12135884,"Bone morphogenetic protein receptor type II is a receptor for growth differentiation factor-9"
https://pharos.nih.gov/idg/targets/Q13873,Q13873,11714695,"signals induced by binding of BMP-2 to preformed receptor complexes activate the Smad pathway, whereas BMP-2-induced recruitment of receptors activates a different, Smad-independent pathway"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,28537769,"A pleiotropic effect of KSR2-rs7973260 was found on the risk of metabolic syndrome, severe hypertriglyceridemia, and diabetes."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,24672054,"KSR2 deficiency affects stromal interaction molecule 1 (STIM1)/ORAI1 puncta formation, which is correlated with cytoskeleton disorganization."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,24209692,"Study explored the role of KSR2 in humans by sequencing 2,101 individuals with severe early-onset obesity and identified multiple rare variants in KSR2 that disrupt signaling through the Raf-MEKERK pathway and impair cellular fatty acid oxidation and glucose oxidation in transfected cells."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,23303246,"study demonstrated that miR-31 upregulated IL-2 expression via reduction of its up-stream kinase suppressor, KSR2, and is a component of T cell activation"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,21441910,"KSR interacts with a regulatory Raf molecule in cis to induce a conformational switch of MEK, facilitating MEK's phosphorylation by a separate catalytic Raf molecule in trans"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,21403620,"The involvement of KSR2 in regulation of cell proliferation was predicted by a KSR2-centered network analysis."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,20945381,"Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,19563921,"KSR-2 may act as a scaffold protein similar as KSR-1 to mediate the MAPK core (RAF-MEK-ERK) signaling but with a distinct RAF isoform specificity; KSR-2 may only mediate the A-RAF signaling while KSR-1 transduces signals only from c-RAF."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,17599832,"These results demonstrate that kinase suppressor of Ras 2 is a direct target of 1,25-dihydroxyvitamin D(3)in HL60 cells, and is required for optimal monocytic differentiation."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,16039990,"We find that while hKSR-2 blocks MEKK3 activation, it has little to no effect on other members of the MAP3K family, including MEKK4, TAK1, and Ras-Raf, suggesting that its effects are selective."
https://pharos.nih.gov/idg/targets/Q6VAB6,Q6VAB6,12975377,"hKSR-2, a new member of the KSR family, negatively regulates Cot-mediated MAP kinase and NF-kappaB pathway signaling"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,27816943,"Recessive mutations in the kinase ZAK - novel cause of congenital myopathy."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,26755636,"ZAK is a key player in mammalian limb patterning in humans and mice."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,26522728,"Gene set enrichment analysis disclosed a significant correlation between ZAK+ colorectal premalignant lesions and gene sets belonging to the MAPK/ERK and motility-related signaling pathways of the reactome database, strongly suggesting that ZAK induces such pro-tumoral reaction cascades in human cancers."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,25013376,"The long non-coding RNA URHC promotes cell proliferation and inhibits apoptosis by repressing ZAK expression through inactivation of the ERK/MAPK pathway."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,24807215,"ZAK kinase isoform TV1 is preferentially upregulated in gastric tumours and cell lines relative to normal samples. This pattern is also observed in colorectal, bladder and breast cancers."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,24170769,"we report that sorafenib suppresses UV-induced apoptosis specifically by inhibiting c-jun-NH(2)-kinase (JNK) activation through the off-target inhibition of leucine zipper and sterile alpha motif-containing kinase (ZAK)"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,23319595,"MRK is a novel RhoC effector that controls LPA-stimulated cell invasion at least in part by regulating myosin dynamics, ERK and p38"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,21305317,"The genes identified KTN1, ROCK1, and ZAK may be responsible for loss of cellular homeostasis in giant cells tumors of bone"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,20408143,"In this study, by applying a novel method, we have identified the phosphorylation sites in human MSK1 mitogen- and stress-activated protein kinase 1, and show that MRK-beta could also activate MSK1 through direct interaction."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,20331627,"decrease of lung cancer cell proliferation by ZAK may involve the ERK and JNK pathways via an AP-1 transcription factor."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,18331592,"data demonstrate that a ZAK isoform(s) is the MAP3Kinase that transduces the ribotoxic stress response"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,15737997,"Mixed lineage kinase 7 (MLK7), a splice variant of the ZAK gene, encodes an isoform which is the MAPKKK required for modulation of the stress-activated MAPKs downstream of anisomycin and UV stimulation."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,15485649,"ZAK induces characteristic hypertrophic growth features, including increased cell size, elevated atrial natriuretic factor expression, and increased actin fiber organization"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,15465036,"Results suggest that a ZAK mediates TGF-beta-induced cardiac hypertrophic growth via a novel TGF-beta signaling pathway."
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,15342622,"Data show that in response to radiation, MRK controls two independent pathways: the Chk2-Cdc25A pathway leading to cell cycle arrest and the p38gamma MAPK pathway"
https://pharos.nih.gov/idg/targets/Q9NYL2,Q9NYL2,12535642,"Results suggest that ZAK might play a role as an upstream signal to suppress the ZZaPK function and decrease E2F expression."
https://pharos.nih.gov/idg/targets/O00238,O00238,28357470,"BMPR1A and the ubiquitous isoform of BMPR1B differed in mode of translocation into the endoplasmic reticulum; and (ii) BMPR1A was N-glycosylated while BMPR1B was not, resulting in greater efficiency of processing and plasma membrane expression of BMPR1A."
https://pharos.nih.gov/idg/targets/O00238,O00238,27720933,"over-expression of CYP2J2 in MDA-MB-468-derived breast cancer cells activates BMPR1B expression that may contribute to increased migration"
https://pharos.nih.gov/idg/targets/O00238,O00238,26926249,"Mutations in three genes (GDF5, NPR2, BMPR1B) have been reported to cause different forms of acromesomelic dysplasia"
https://pharos.nih.gov/idg/targets/O00238,O00238,26805635,"Results show an association between age-induced depletion of the ovarian reserve and BMPR1B receptor density and suggest that the dysregulation of BMP receptor signalling may inhibit the normal steroidogenic differentiation required for maturation in older patients."
https://pharos.nih.gov/idg/targets/O00238,O00238,26701726,"Data show that protein kinase LKB1 physically interacts with BMP type I receptors and requires Smad7 protein to promote downregulation of the receptor."
https://pharos.nih.gov/idg/targets/O00238,O00238,26684357,"Low expression of BMPRIB is associated with breast cancer."
https://pharos.nih.gov/idg/targets/O00238,O00238,26562759,"Using computational analyses with the COREX/BEST algorithm, the study uncovered an overall pattern connecting various regions of BMPR-1B ectodomain, including the four conserved residues in the protein-protein interface."
https://pharos.nih.gov/idg/targets/O00238,O00238,26105076,"Data found a hypomorphic BMPR1B mutation causes du Pan acromesomelic dysplasia"
https://pharos.nih.gov/idg/targets/O00238,O00238,25776145,"Novel mutation in the BMPR1B gene (R486L) in a Polish family and further delineation of the phenotypic features of BMPR1B-related brachydactyly."
https://pharos.nih.gov/idg/targets/O00238,O00238,25758993,"Two novel mutations in BMPR1B were identified in two patients with brachydactyly type A1."
https://pharos.nih.gov/idg/targets/O00238,O00238,25601208,"Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response."
https://pharos.nih.gov/idg/targets/O00238,O00238,24339876,"Disrupting the binding of miR-125b toward BMPR1B would increase protein expression, diminishing abnormal cell proliferation as well as serum and cellular CA125 levels"
https://pharos.nih.gov/idg/targets/O00238,O00238,24129431,"Data indicate missense (c.157T>C, p.(C53R)) or nonsense (c.657G>A, p.(W219*)) mutations in bone morphogenetic protein receptor type IB (BMPR1B) in two consanguineous families with acromesomelic chondrodysplasia-type Grebe."
https://pharos.nih.gov/idg/targets/O00238,O00238,24100446,"Using primary cells and a cell line mimicking CP-CML, we found that myeloid progenitor expansion is driven by the exposure of immature cells overexpressing BMP receptor Ib to BMP2 and BMP4."
https://pharos.nih.gov/idg/targets/O00238,O00238,24021264,"the shear-induced apoptosis and autophagy are mediated by bone morphogenetic protein receptor type (BMPR)-IB, BMPR-specific Smad1 and Smad5, and p38 mitogen-activated protein kinase."
https://pharos.nih.gov/idg/targets/O00238,O00238,24008158,"Treatment of pulmonary arterial smooth muscle cells with HIV-1 Nef downregulates expression of BMPR-2, BMPR-1A, and BMPR-1B proteins"
https://pharos.nih.gov/idg/targets/O00238,O00238,22971142,"A significant association was observed between the 455C allele of BMP4 and increased left ventricular internal diameter systolic (p=0.004) and between 1650T allele of BMPR1B and lower left atrium diameter (p=0.038)."
https://pharos.nih.gov/idg/targets/O00238,O00238,22374147,"Suggest that BMPR1B mutations are associated with the pathogenesis of childhood idiopathic pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/O00238,O00238,22294741,"BMP15 uses preferentially BMPR1B as its type I receptor, suggesting an important role for the BMPR1B receptor in human female fertility"
https://pharos.nih.gov/idg/targets/O00238,O00238,22293501,"generation of TGF-beta and BMP receptor homo- and hetero-oligomers and its roles as a mechanism capable of fast regulation of signaling by these crucial cytokines [review]"
https://pharos.nih.gov/idg/targets/O00238,O00238,21556765,"rs1434536 in the 3'UTR of BMPR1B gene affects the binding ability of miR-125b to BMPR1B mRNA and contributes to the genetic predisposition to localized prostate cancer and patients aged>70 years."
https://pharos.nih.gov/idg/targets/O00238,O00238,21152263,"BMPR1B were detected in the human retina and retinoblastoma cell lines."
https://pharos.nih.gov/idg/targets/O00238,O00238,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O00238,O00238,20673479,"Data show that blocking both endogenous BMPR1A and BMPR1B almost offset the effect of BMP7 on the proliferation of NCI-H460 cell completely."
https://pharos.nih.gov/idg/targets/O00238,O00238,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O00238,O00238,20587070,"Low BMP2 is associated with epithelial ovarian cancer."
https://pharos.nih.gov/idg/targets/O00238,O00238,20201926,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O00238,O00238,19738052,"Results suggest that allele-specific regulation of BMPR1B by miR-125b explains the observed disease risk in breast cancer."
https://pharos.nih.gov/idg/targets/O00238,O00238,19513897,"Decrease BMPR-1B expression led to decreased SMAD1 phosphorylation and correlated witht he malignant grade of human gliomas and a poor prognosis."
https://pharos.nih.gov/idg/targets/O00238,O00238,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O00238,O00238,19451094,"decreased expression of BMPR-IB correlates with poor prognosis in breast cancer patients and leads to increased cell proliferation of breast cancer cells in vitro"
https://pharos.nih.gov/idg/targets/O00238,O00238,19135982,"the interaction of Ror2 with BRIb is specific and independent of post-translational N-glycosylation."
https://pharos.nih.gov/idg/targets/O00238,O00238,18773965,"Our study has provided evidence that BMPR-IB-dependent signaling plays a crucial role in BMP-2 up-regulation of the ALP, OC, Dlx5 and Cbfa1 genes in bone cells, suggesting a role of this receptor in BMP-2-induced osteoblast differentiation in vitro."
https://pharos.nih.gov/idg/targets/O00238,O00238,18619554,"Changes in BMPR1B localization regulate osteogenic responses of bone cells to BMP2."
https://pharos.nih.gov/idg/targets/O00238,O00238,18292470,"there was significant down-regulation of ALK-6 (activin receptor-like kinase 6) expression in asthma patients at baseline; allergy challenge was associated with upregulation"
https://pharos.nih.gov/idg/targets/O00238,O00238,17624341,"Expression of BMP-4 and BMP-7 and their receptors in human ovaries from fetuses as well as adults."
https://pharos.nih.gov/idg/targets/O00238,O00238,17381068,"Our results indicated the potential involvement of ALK6 activation by rhTGFbetas in the synergy between rhTGFbetas and rhBMPs."
https://pharos.nih.gov/idg/targets/O00238,O00238,17363346,"significant shift in the emission maximum from 498 to 510 nm was detected when bis-ANS binds ecBMPR-IB. FRET revealed close proximity between the tyrosine & bis-ANS binding site."
https://pharos.nih.gov/idg/targets/O00238,O00238,17203235,"HGF up-regulates the expression of the bone morphogenetic protein receptors, BMPR-IB and BMPR-II, in prostate cancer cells"
https://pharos.nih.gov/idg/targets/O00238,O00238,17001689,"Results indicate that increased bone morphogenetic protein receptor (BMPR)-IB by TGF-beta1, FGF-2, and PDGF-AB significantly enhances BMP-2-induced osteogenesis in vitro."
https://pharos.nih.gov/idg/targets/O00238,O00238,16436528,"Human granulosa-like tumor cell line KGN expressed BMP type I (BMPR1A and BMPR1B) and type II receptors (BMPR2) and the BMP signaling molecules SMADs (SMAD1 and SMAD5)."
https://pharos.nih.gov/idg/targets/O00238,O00238,16014698,"GDF5 is a novel brachydactyly type A2 causing gene involving BMPR1b impaired activity."
https://pharos.nih.gov/idg/targets/O00238,O00238,15897891,"Anti mullerian hormnoe is a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins."
https://pharos.nih.gov/idg/targets/O00238,O00238,15235019,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O00238,O00238,15192043,"the BMP system is strongly involved in pulmonary artery smooth muscle mitosis through ALK-6, resulting in the progression of vascular remodeling of pulmonary arteries in pulmonary hypertension."
https://pharos.nih.gov/idg/targets/O00238,O00238,14576167,"BMP-2-induced apoptosis was mediated by BMP-RIB in osteoblasts and occurred independently of BMP-2-induced osteoblast differentiation."
https://pharos.nih.gov/idg/targets/O00238,O00238,14523231,"performed linkage analysis in brachydactyly (BD) type A2 and mapped a locus for BD type A2 to 4q21-q25. This interval includes the gene bone morphogenetic protein receptor 1B."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28878015,"these findings demonstrate that Trx1 is a critical regulator of necroptosis that suppresses cell death by maintaining MLKL in a reduced inactive state."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28666573,"this study shows that release of phosphorylated MLKL within extracellular vesicles serves as a mechanism for self-restricting the necroptotic activity of this protein"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28650960,"Data suggest that necroptotic cells externalize phosphatidylserine (PS) after translocation of phosphorylated MLKL to cell membrane; necroptotic cells with exposed PS release extracellular vesicles containing MLKL; inhibition of MLKL after PS exposure can reverse process of necroptosis and restore cell viability."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28412393,"adhesion-induced eosinophil cytolysis takes place through RIPK3-MLKL-dependent necroptosis, which can be counterregulated by autophagy"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28230861,"RIPK3 is a key factor in protection against OLs death and abnormal myelin development via its interaction with MLKL."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,28130493,"this study shows that MLKL is an endogenous activator of the NLRP3 inflammasome, and that MLKL activation provides a mechanism for concurrent processing and release of IL-1beta independently of gasdermin-D"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,27920255,"MLKL octamer formation depends on alpha-helices 4 and 5."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,27756058,"results reveal a pathway for MLKL-dependent programmed necrosis that is executed in the absence of RIPK3 and potentially drives the pathogenesis of severe liver diseases."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,27473085,"Downregulated expression of MLKL is associated with gastric caner."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,27411587,"In AML, MLKL expression is reduced in specific subsets. This is linked to its function in activating the ASC inflammasome."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,27033670,"MLKL forms cation channels that are permeable preferentially to Mg(2+) rather than Ca(2+) in the presence of Na(+) and K(+)."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26933192,"Results from interaction proteomics identified MLKL as a novel HSP90 client protein in HT-29 cells."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26868910,"Phosphorylated MLKL leads to a conformational change, exposure of the N-terminal domain, results in MLKL membrane localization, oligomerization and membrane permeabilization."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26866270,"coexpression of Hsp90 increases MLKL oligomerization and plasma membrane translocation and enhances MLKL-mediated necroptosis. Findings demonstrate that an efficient necrotic response requires a functional Hsp90."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26865533,"Necroptosis signaling is modulated by the kinase RIPK1 and requires the kinase RIPK3 and the pseudokinase MLKL. (Review)"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26853145,"Results show that upon activation, MLKL undergoes oligomerization mediated by the brace domain, being recruited to the plasma membrane through avidity of N-terminal helix bundle for phosphatidylinositol phosphate (PIP)."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26823841,"MLKL was a prognostic biomarker for cervical squamous cell carcinoma"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26704887,"Modelling predicts that a C-terminal helix constrains the activity of MLKL1, but not MLKL2"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26283547,"These data reveal a potential role for RIPK3 as a suppressor of MLKL activation and indicate that phosphorylation can fine-tune the ability of MLKL to induce necroptosis."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,26165695,"MLKL upregulation in SPARC overexpressed cells treated with Ara-C, indicates necrosis as a possible cell death process for the SKM-1 cells under these stringent conditions"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,25766324,"a novel non-enzymatic function of AChE-R is to stimulate RIPK1/MLKL-dependent regulated necrosis (necroptosis). The latter complements a cholinergic system in the ovary, which determines life and death of ovarian cells."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,25748555,"High expression of RIP3 in keratinocytes from toxic epidermal necrolysis patients potentiates MLKL phosphorylation/activation and necrotic cell death."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,25697054,"in the absence of caspase-8 activity, 24(S)-Hydroxycholesterol induces a necroptosis-like cell death which is RIPK1-dependent but MLKL-independent."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,25220470,"MLKL structure determined by nuclear magnetic resonance spectroscopy reveals how different structural elements of the MLKL N-terminal region contribute to MLKL function and membrane permeation."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24813885,"Authors demonstrate that the full four-helical bundle domain (4HBD) in the N-terminal region of MLKL is required and sufficient to induce its oligomerization and trigger cell death."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24813885,"MLKL binding to phosphatidylinositol phosphates is required for plasma membrane rupture"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24703947,"Report role of MLKL/RIP3 pathway in necrotic membrane disruption."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24322838,"MLKL protein expression is significantly upregulated in children, diagnosed with inflammatory bowel disease."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24316671,"This study reveals a crucial mechanism of MLKL-mediated TNF-induced necroptosis."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,24219132,"Data suggest that nucleotide- (ATP-) binding residues of human MLKL have divergently evolved from mouse Mlkl and conventional protein kinases; studies include small-angle X-ray scattering, thermal shift of nucleotide binding, and sequence alignment."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,23720157,"Low expression of MLKL is associated with decreased OS in patients with resected PAC and decreased RFS and OS in the subset of patients with resected PAC who receive adjuvant chemotherapy."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,23612963,"the importance of the RIP3-MLKL interaction in the formation of functional necrosomes and suggest that translocation of necrosomes to mitochondria-associated membranes is essential for necroptosis signaling."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,22421439,"study suggests that MLKL is a key RIP3 downstream component of TNF-induced necrotic cell death"
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,22265413,"Findings implicate MLKL as a key mediator of necrosis signaling downstream of the kinase RIP3."
https://pharos.nih.gov/idg/targets/Q8NB16,Q8NB16,19844255,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,28222164,"Individual differences in task performance during distractions revealed an epistatic interaction of 2 SNPs (COMTMet108/158Val and ANKK1/DRD2TaqIA) in regulating the prefrontostriatal DA system on stimulus-driven attention capture via an electrophysiological mechanism of phase-resetting of gamma neural oscillation to the novel, distracting events."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,28152448,"High frequencies of the DRD2/ANKK1 A1 allele were present in Mexican populations"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,27600277,"The effects of variations in FTO are dependent on dopamine D2 receptor density (determined by the ANKK1 polymorphism). Carriers of both risk alleles might, therefore, be at increased risk of obesity and diabetes."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,27399274,"An association has been found between the DRD2/ANKK1 gene and alcohol use, and cognition."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,27180960,"We found no association between alcohol dependence and ANKK1 Taq 1A polymorphism"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,27154305,"The results of this study suggest that the severity of poor behaviors among those with PTD is related to Val158Met of COMT and Taq1A of ANKK1 variation, and these findings are not simply attributable to PTD alone."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26970175,"pattern of three Taq1 polymorphism of ANKK1 and DRD3 allele frequency, haplotypes and linkage disequilibrium was examined in five Punjabi ethnic groups"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26664790,"Ankyrin repeat and kinase domain containing I (ANKK1) and dopamine D2 receptor (DRD2) genes associated with psychopathic traits. We hypothesized that cognitive phenomena are associated with Taq IA SNP of the ANKK1 gene and with C957T SNP of DRD2."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26624925,"The Taq1A polymorphism (dbSNP rs1800497), located ~9.5 kb downstream from DRD2 and in exon 8 of ANKK1 has been associated with smoking behavior."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26501178,"Results revealed a significant interaction effect of BDNF Val66Met polymorphism and ANKK1 gene (DRD2 Taq1a/ANKK1 polymorphism) on loss aversion"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26114114,"These results support an association between ANKK1 and LTA genetic markers and vulnerability to schizophrenia and show the potential influence of just one copy of the mutant C or G allele in the Egyptian population."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,26110876,"The DRD2/ANKK1 TaqIA polymorphism might contribute to TS susceptibility."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25931179,"Cognitive performance after traumatic brain injury is moderated by ANKK1 genetic variation."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25740917,"The genotypic association of LEPR rs1137101, the allelic association of LEPR rs1137101, and ANKK1 rs1800497 with weight gain remained significant in epilepsy patients receiving valproic Acid."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25684044,"the DRD2/ANKK1 Taq1A (rs1800497) SNP does not present contributions to the development of AD."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25641135,"the rs1800497 locus may be associated with attention deficit hyperactivity disorder.[meta-analysis]"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25633559,"Findings extend those of previous studies reporting a negative relationship of the ANKK1 T allele with cognitive performance after traumatic brain injury."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25500252,"The DRD2/ANKK1 TaqIA polymorphism was significantly associated with increased risk of opioid dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25486867,"Results demonstrate a link between the DRD2/ANKK1-TaqIA polymorphism and neurocognitive deficits related to long-term memory updating, and provide novel evidence that this effect is magnified in aging"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25450229,"This study finding significant excess of rare nonsynonymous variants exclusive to European Americans smokers in ANKK1."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25447970,"The TaqIA genotype A1- is associated with impulse control disorder with a potentially addictive reinforcement and it may differentiate two types of disorders which are part of the impulse control disorders definition in Parkinson's disease patients."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25415204,"analyzed selected SNPs polymorphisms in the DRD2 and ANKK1 genes in patients with alcohol dependence syndrome (169 Caucasian subjects) including a subgroup of individuals (n = 61) who have experienced at least one suicide attempt"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25139281,"The involvement of variants in DRD2 and ANKK1 in the etiology of nicotine dependence (ND) and alcohol dependence, is reported."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25073965,"ANKK1 rs1800497 variant is associated with schizophrenia in females."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,25049133,"BMI gain in young women upon college entry was significantly associated with a ANKK1 SNP previously implicated in substance dependence risk"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,24713612,"Study suggests that the DRD2/ANKK1 polymorphism rs1800497 interacts with ventral striatum activity during reward processing to affect working memory performance"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,24704945,"DRD2/ANKK1 was significantly associated with elevated expression of t-DARPP in the caudate. Also, the A1 allele was significantly correlated with the total score of antemortem psychiatric symptoms."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,24629326,"in alcohol dependence, perceived impaired control is a cognitive mediator of impulsivity-related constructs that may be unaffected by DRD2/ANKK1 and neurocognitive processes underlying the retrieval of verbal information."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,24528631,"individuals who carry the T allele of rs1800497 in the ANKK1 gene reported higher subjective effects in response to acute cocaine administration."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,24247049,"An association between genotypes in the ANKK 1 gene polymorphism and sucrose preference in alcohol dependence has been demonstrated."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23947671,"Upon stratifying for indoor tanning status, one ANKK1 SNP was positively associated with melanoma among non-tanners, while three DRD2 SNPS were positively associated with melanoma among tanners or non-tanners, depending on the SNP."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23840506,"Identification of single nucleotide polymorphisms in dopaminergic genes associated with heroin dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23828101,"Findings of DRD2, ANKK1 and impulsivity are novel; they suggest that reward sensitivity and self-regulatory abilities might modulate the influences of sleep on weight gain"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23740147,"all the patients with prolactinomas respond in the same manner in terms of weight loss under dopaminergic treatment, regardless of the presence of A1 allele of the ANKK1"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23691092,"association of ANKK1/DRD2 further implicates the role of nicotine-related pathways and dopamine signaling in language processing, particularly in comprehension and phonological memory"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23590110,"Studied the distribution pattern of the three DRD2 and ANKK1 TaqI sites and also the frequencies of their haplotypes among Oraons (n = 48) and Mundas (n = 50)--the two linguistically distinct tribal population groups of Jharkhand."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23558112,"The present study showed a significant difference in DRD2 -141C and ANKK1 TaqIA polymorphisms between the AD patients and the controls."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23443985,"ANKK1 TaqIA polymorphism was found to be significantly associated with Alcohol Dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23383291,"COMT and ANKK1-Taq-Ia genetic polymorphisms influence visual working memory."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23303482,"ANKK1 SNP rs877138 and ANKK1 SNP rs4938013 were associated with heroin dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23302056,"results suggest that direct parental social control may effectively suppress the genetic risk of the A1/A1 genotype on marijuana use in adolescence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23203481,"large-scale meta-analysis confirmed the association between the Taq1A polymorphism (located in the gene cluster ANKK1/DRD2) and Alcohol dependence"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23153044,"the presence of the DRD2/ANKK1 TaqIA A1 allele is prospectively associated with increased probability of initiating cigarette smoking and subsequent levels of smoking."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,23118020,"genetic association studies in population in Queensland: Data suggest that an SNP in ANKK1/DRD2 (rs1800497) is associated with risk of drug-induced akathisia in patients with schizophrenia who were treated with second-generation antipsychotics."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22970887,"Results show significant association with SNP in ANKK1 and general alcohol consumption and abuse."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22967772,"The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22893251,"The findings of this study supported a possible role of ANKK1 and DRD2 variability on haloperidol efficacy."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22875483,"For the ANKK1 polymorphism rs1800497, variant genotype & allele showed significant associations with migraine risk. 2 genotype interactions between ANKK1 rs1800497 & DBH rs72393728 polymorphisms showed significant risks."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22728571,"The A1 allele of DRD2/ANKK1 TaqI A interacts with hypoemotionality to predict a novel index of problem drinking"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22698582,"Our study extends and confirms previous results and, for the first time, tested the gene-gene interaction between SLC6A3 and DRD2 in alcohol dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22382052,"The results of this study suggested that the DRD2 C957T polymorphism and the ANKK1 TaqIA polymorphism are key contributors to the genetic susceptibility to nicotine dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,22232965,"It seems accurate to search for associations of polymorphisms in ANKK1 gene with dopaminergic system disorders."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21936764,"Associations were found between ANKK1 haplotype rs4938015C_rs11604671A and age of onset of daily smoking, as well as with hazardous drinking."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21540761,"Those having DRD2/ANKK1 Taq1A variant alleles and a history of depression are likely to experience particular difficulty when trying to stop smoking."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21510979,"subjects with the DRD2/ANKK1 TaqI Al allele exhibit decreased corticostriatal activity in response to negatively charged affective stimuli compared with subjects homozygous for the A2 allele."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21352928,"These results support the epistasis of catechol-O-methyltransferase and ANKK1 phenotypes in the flexible control of contextual information in humans"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21261454,"This study found a double dissociation for temporal discrimination: the DRD2/ANKK1-Taq1a polymorphism (A1+ allele) was associated with significantly greater variability for the 500-msec duration."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21168125,"TTC12-ANKK1-DRD2s seemed to influence smoking behavior mainly in adolescence, and its effect is partially mediated by personality characteristics promoting drug-seeking behavior."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21070510,"Study shows this gene is associated with ASPD without co-morbid alcoholism"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,21041608,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20845092,"Results provide the first evidence of functional ANKK1 differences that are marked by TaqIA and could be associated with vulnerability to addiction."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20577142,"These findings may provide initial evidence that the ALDH2 and DRD2/ANKK1 genes interact in specific subtypes of bipolar disorders."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20410875,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20199723,"DRD2/ANKK1 Taq IA polymorphism is not associated with early infant temperament."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20180986,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20138949,"This study demonestrated that the functional link between DRD2 and ANKK1 could account for the interaction in patient with schizophrenia."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20133381,"This study evaluated the interaction of ANKK1, TTC12, sex, and continental ancestry in tobacco smokers."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,20133381,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19914044,"From the results of this study the alcohol-induced negative reinforcement may explain the greater risk for alcoholism associated with the A1 allele(ANKK1)."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19914044,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19900188,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19897017,"Presence of at least one copy of the A1 allele was associated with significantly higher Extraversion."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19717274,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19692168,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19512960,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19373123,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19339270,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19321766,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19291230,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19283474,"ANKK1 mRNA is present in four cortical regions of the adult human brain. The TaqIA genotype may modulate a subject's susceptibility to alcohol-associated brain damage mediated by excitotoxicity."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19283474,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19046929,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,19025655,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18927395,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18926547,"DRD2/ANKK1 gene variations and some clinical factors may predict individual response to aripiprazole"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18926547,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18828801,"Variants in the two 3'-ends of ANKK1 are linked to the co-regulation of risk for comorbid alcohol and drug dependence."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18828801,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18698520,"results confirm a published association between TAQ1 A (rs1800497) T allele and cognitive outcome measures 1 month after TBI and suggest that a haploblock of polymorphisms in ANKK1, not the adjacent DRD2 gene, has the highest association after TBI"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18698520,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18690118,"We explored associations of gene variants in the dopamine, opioid, and serotonin pathways with smoking reward ('liking') and reinforcement (latency to first puff and total puffs) as a function of negative mood."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18669994,"The TaqI-A of the ANKK1 gene and the C957T of the DRD2 gene are epistatically associated with psychopathic traits in alcohol-dependent patients."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18669994,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18354387,"study found a significant linkage with cigarette consumption and ANKK1 in African Americans, identified a possible causative single nucleotide polymorphism, and showed that the variant alters expression level of NF-kappaB-regulated genes"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18354387,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18259088,"This study finding significant associations between the A1 allele of the DRD2 TaqI A polymorphism and reward-related personality traits."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18075468,"Taq1A polymorphism in DRD2 gene significantly influenced the time course of prolactin response to perphenazine"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18063936,"A significant association was found between the dopamine D2 receptor gene TaqI A genotype and \"Eros\" (a loving style characterized by a tendency to develop intense emotional experiences based on the physical attraction to the partner)."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18058350,"These findings suggest a modest association between DRD2 genotype and quitting behavior in male cigarette smokers in Egypt."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18058343,"These data suggest that bupropion may be effective for smoking cessation only in a subgroup of smokers with the DRD2 Taq1 A2/A2 genotype."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,18037170,"Findings do not support the hypothesis that two of the most prominent dopaminergic candidate loci (DRD2 Taq Ia and COMT Val158Met) effect prepulse inhibition the study does not exclude the relevance of the dopaminergic system in general."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17850642,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17850642,"More extensive genotyping across DRD2 and ANKK1 suggests that the association with alcohol dependence observed in this region may be due to genetic variants in the ANKK1 gene."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17767146,"The Taq1A of D2 dopamine receptor is associated with tardive dyskinesia ."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17761687,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17761687,"association studies of alcohol dependence and 43 SNPs mapped to the gene cluster of NCAM1, TTC12, ANKK1 and DRD2"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17671965,"Polymorphisms TaqI A of the DRD2 is associated with childhood attention deficit hyperactivity disorder"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17669630,"In our study DRD2 C939T was in strong linkage disequilibrium with TaqIA in tardive dyskinesia in schizophrenia."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17453061,"Results of this meta-analysis support the association of the DRD2 Taq1A polymorphism with alcoholism."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17446975,"study supports other family-based association tests that have reported no association between the DRD2 TaqIA polymorphism and alcohol abuse and dependence"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17189962,"Smokers homozygous for the DRD2 TaqI-B2 allele experience progressive improvement in self-reported withdrawal symptoms while smokers with the TaqI-B1 allele show little change."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17120049,"A DRD2 polymorphic TaqIA restriction endonuclease site is associated with increase risk of violence or serious delinquency in male adolescents and young adults (ages 12 to 23)."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17085484,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,17069991,"No support for an association between early onset alcohol use disorders and the DRD2 TaqIA polymorphism."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,16869231,"Utilize the attention network test and find that carriers of the A1 allele show gene-associated functional activation in an anatomically specific, dopamine-rich region of the brain comprising the anterior cingulate gyrus."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,16032443,"alcoholic and non-alcoholic smokers presented a higher frequency of the DRD2 TaqI A1 allele (P = 0.04) than non-smoking controls"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,16026865,"This study investigated two dopaminergic candidate genes (COMT VAL158MET and DRD2 TAQ IA) for endophenotypes of cognitive functioning.  Results showed an interaction effect of DRD2xVAL on interference performance as measured by the STROOP-test."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,15939106,"APM linkage analysis suggested that the DD2R gene TaqI polymorphism had evidence of linkage with blood pressure, as well as with obesity."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,15812318,"for men, but not for women, we observed a strong and specific association between low neuroticism-anxiety and the A1+ allele of the DRD2 TaqI A polymorphism"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,15545020,"the TaqIA1 allele of the dopamine receptor gene D2 has been associated with alcoholism, as well as with other addictive behaviours"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,15542731,"It is suggested that in methamphetamine psychosis the TaqI A polymorphism of dopamine D2 receptor not only regulates prolongation of psychosis symptoms but also influences the form of the temporal lobe."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,15146457,"changes in ANKK1 activity may provide an alternative explanation for previously described associations between the DRD2 Taq1A RFLP and neuropsychiatric disorders such as addiction"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,12762588,"a possible linkage with schizophrenia for the Taq1A marker but not for the Taq1B marker of DRD2 gene."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,12605103,"There is a lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of this gene."
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,12555236,"study suggests that only the TaqI A polymorphism is associated with neuroleptic malignant syndrome, but the -141 C Ins/Del and Ser(9)Gly polymorphisms are not"
https://pharos.nih.gov/idg/targets/Q8NFD2,Q8NFD2,12151753,"Among the aged with cognitive impairments, the homozygous status for the A2 allele of the DRD2 Taq I polymorphism is associated with diminished cognitive performance and increased atrophy in the striatum."
https://pharos.nih.gov/idg/targets/P57078,P57078,27697098,"Overexpression of EZH2 was found in 30 patients (76.9%) and was associated with FIGO stage, histological type, and lymph node metastasis (p < 0.05). In conclusion, our data suggest that RIPK4/EZH2 markers might be used as potential predictors of prognosis in cervical cancer."
https://pharos.nih.gov/idg/targets/P57078,P57078,27667567,"These findings position RIPK4 upstream of a hierarchal IRF6-GRHL3-ELF3 transcription factor pathway in keratinocytes."
https://pharos.nih.gov/idg/targets/P57078,P57078,27014863,"CCL5 and CXCL11 expression were also induced in response to the activation of the PKC pathway, and gene silencing experiments indicated that their inducible expression was dependent on RIPK4 and IRF6. Moreover, gene reporter assays suggested that RIPK4 induces CCL5 and CXCL11 expression by stimulating the transactivation of their promoters by IRF6."
https://pharos.nih.gov/idg/targets/P57078,P57078,26129644,"CHAND and Bartsocas-Papas syndrome might be allelic disorders or RIPK4 mutations could confer varying degrees of phenotypic severity, depending on their localization within or outside functionally important domains."
https://pharos.nih.gov/idg/targets/P57078,P57078,25784454,"The p.Ser376X mutation in RIPK4 impaired its induction of IRF6 transactivator function."
https://pharos.nih.gov/idg/targets/P57078,P57078,25285922,"The protein kinase C-associated kinase (PKK), which is also known as the receptor-interacting protein kinase 4, is a suppressor of tumor growth in squamous cell carcinoma of the skin."
https://pharos.nih.gov/idg/targets/P57078,P57078,25246526,"Ser-413 and Ser-424 in IRF6 are important for its activation by RIPK4"
https://pharos.nih.gov/idg/targets/P57078,P57078,25134534,"we identified an epithelial ovarian cancer susceptibility loci at 10p11.21 (rs1192691 near ANKRD30A, P(meta) = 2.62 x 10(-8))"
https://pharos.nih.gov/idg/targets/P57078,P57078,25096806,"Suppression of PKK expression by RNA interference inhibits phosphorylation of IKKalpha and IKKbeta as well as activation of NF-kappaB in human cancer cell lines; thus, PKK regulates NF-kappaB activation by modulating activation of IKKalpha and IKKbeta."
https://pharos.nih.gov/idg/targets/P57078,P57078,24519546,"Authors found a correlation between RIPK4 expression and TSCC degree of differentiation, age, and gender."
https://pharos.nih.gov/idg/targets/P57078,P57078,24413083,"Data indicate protein-serine-threonine kinases RIPK4 overexpression in transformed fetal hepatocytes."
https://pharos.nih.gov/idg/targets/P57078,P57078,23371553,"phosphorylation of DVL2 by RIPK4 favored canonical Wnt signaling; findings suggest that RIPK4 overexpression may contribute to the growth of certain tumor types"
https://pharos.nih.gov/idg/targets/P57078,P57078,22197488,"The present study's findings show that recessive mutations in RIPK4 cause Bartsocas-Papas syndrome and its variant, the autosomal-recessive form of multiple pterygium syndrome (Aslan type)."
https://pharos.nih.gov/idg/targets/P57078,P57078,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P57078,P57078,19818768,"Data indicate that rip4 gene expression is regulated in a complex manner, which might have therapeutic implications."
https://pharos.nih.gov/idg/targets/P57078,P57078,18511573,"Phosphorylation of protein kinase C delta is associated with activation of vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 receptor in lipopolysaccharide induced macrophages"
https://pharos.nih.gov/idg/targets/P57078,P57078,18025152,"PKK plays a pivotal role in the survival of human Diffuse large B-cell lymphoma (DLBCL) cells and represents a potential target for DLBCL therapy"
https://pharos.nih.gov/idg/targets/P57078,P57078,17039240,"NF-kappaB activity and keratinocyte differentiation are regulated by the RIP4 protein, which has roles in cutaneous wound repair"
https://pharos.nih.gov/idg/targets/P57078,P57078,12676934,"PKK may function in both a kinase-dependent as well as a kinase-independent manner to activate NFkappaB"
https://pharos.nih.gov/idg/targets/P36896,P36896,28214509,"ALK4 is an important profibrotic signaling molecule in the post-MI CF. Haplodeficiency of ALK4 significantly improved LV function and survival rate by attenuating CF in vivo, ameliorated"
https://pharos.nih.gov/idg/targets/P36896,P36896,27733450,"It was concluded that ALK4 inhibition increases myogenesis but also regulates the tight balance of protein synthesis and degradation."
https://pharos.nih.gov/idg/targets/P36896,P36896,27253421,"in a relatively large cohort of athletes from Europe and South America we have shown that the ACVR1B rs2854464 A allele is associated with sprint/power performance in Caucasians but not in Brazilian athletes."
https://pharos.nih.gov/idg/targets/P36896,P36896,26305619,"Data suggest that activin A up-regulates SNAIL expression via ALK4/ACVR1B-induced SMAD signaling in trophoblast cells; elevated SNAIL contributes to up-regulation of MMP2 expression which plays key role in promoting trophoblast cell invasion."
https://pharos.nih.gov/idg/targets/P36896,P36896,26289399,"ALK4 is expressed in male germ cells and Sertoli cells."
https://pharos.nih.gov/idg/targets/P36896,P36896,26149389,"This study demonstrated positive regulation of monocyte/macrophage differentiation by lnc-MC and uncovered an elaborate regulation mechanism composed of PU.1, lnc-MC, miR-199a-5p, and ACVR1B."
https://pharos.nih.gov/idg/targets/P36896,P36896,25258381,"ACVR1B functions as a positive regulator of monocyte/macrophage differentiation. ACVR1B knockdown promoted THP-1 proliferation by increasing Rb phosphorylation. Down-regulation reduced p-Smad2/3 and C/EBPalpha, inhibiting monocyte/macrophage differentiation."
https://pharos.nih.gov/idg/targets/P36896,P36896,24886203,"The deletion of the ACVR1B gene may mediate an aggressive cancer phenotype in pancreatic cancer."
https://pharos.nih.gov/idg/targets/P36896,P36896,23211491,"Findings define a regulatory role of miR-98 in tumor angiogenesis and invasion through repressed ALK4 and MMP11 expression."
https://pharos.nih.gov/idg/targets/P36896,P36896,23159635,"ActRIBCA signaling can promote cell migration in prostate cancer cells via a network of signaling molecules that work together to trigger the process of EMT, and thereby aid in the aggressiveness and progression of prostate cancers."
https://pharos.nih.gov/idg/targets/P36896,P36896,23010638,"Act A protein levels were significantly higher in NTM tissues compared to GTM tissues."
https://pharos.nih.gov/idg/targets/P36896,P36896,22267736,"Inhibin alpha-subunit N terminus interacts with activin type IB receptor to disrupt activin signaling."
https://pharos.nih.gov/idg/targets/P36896,P36896,21377836,"Activin A-ACVRIB/ALK4-Smad-dependent collagen production was augmented in SSc fibroblasts, suggesting the involvement of this signaling mechanism in systemic sclerosis."
https://pharos.nih.gov/idg/targets/P36896,P36896,21063444,"We applied a two-stage fine mapping approach, and are the first to identify and partially replicate genetic variants in the ACVR1B gene that account for genetic variation in human muscle strength."
https://pharos.nih.gov/idg/targets/P36896,P36896,21063444,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36896,P36896,20819778,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36896,P36896,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36896,P36896,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36896,P36896,20347265,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36896,P36896,20226172,"activin A signal is transduced through the activin A type 1 receptor, ALK4, and transactivates several TGF-beta target genes in a SMAD-independent manner."
https://pharos.nih.gov/idg/targets/P36896,P36896,19035567,"Study indicate that the synthetic h-CFC interacts with the ALK4 receptor with a K(D) in micro M range, that the h-CFC overall topology is determined by the presence of three disulfide bridges."
https://pharos.nih.gov/idg/targets/P36896,P36896,17906079,"a regulation mode of miR-24 on erythropoiesis by impeding ALK4 expression."
https://pharos.nih.gov/idg/targets/P36896,P36896,16720724,"findings indicate a new inhibitory function of FKBP12 as an adaptor molecule for the Smad7-Smurf1 complex to regulate the duration of the activin signal through activin type I receptors"
https://pharos.nih.gov/idg/targets/P36896,P36896,15459392,"Dpr2 binds to the TGFbeta receptors ALK5 and ALK4, and accelerates lysosomal degradation of these receptors"
https://pharos.nih.gov/idg/targets/P36896,P36896,15123686,"ALK4 binds to activin at a specific site in order to signal via type II receptors"
https://pharos.nih.gov/idg/targets/P36896,P36896,12665502,"there is only a partial overlap of the binding sites on ALK4 and ALK3 for activin-A and bone morphogenetic protein-2, respectively"
https://pharos.nih.gov/idg/targets/P36896,P36896,12639945,"Activin signaling mediated by ActRIB-Smad2 system in the ovary may thus be essential for the regulation of follicular differentiation."
https://pharos.nih.gov/idg/targets/P36896,P36896,12364468,"data indicate that truncated Alk4 isoforms interfere with activin signaling pathways and thereby may contribute to uncontrolled cell growth"
https://pharos.nih.gov/idg/targets/P36896,P36896,11969340,"distribution in gestational tissues across human pregnancy and during labour"
https://pharos.nih.gov/idg/targets/P36894,P36894,28733457,"both bone morphogenetic protein 2 (BMP2) and BMP6 are proangiogenic in vitro and ex vivo and that the BMP type I receptors, activin receptor-like kinase 3 (ALK3) and ALK2, play crucial and distinct roles in this process."
https://pharos.nih.gov/idg/targets/P36894,P36894,28357470,"BMPR1A and the ubiquitous isoform of BMPR1B differed in mode of translocation into the endoplasmic reticulum; and (ii) BMPR1A was N-glycosylated while BMPR1B was not, resulting in greater efficiency of processing and plasma membrane expression of BMPR1A."
https://pharos.nih.gov/idg/targets/P36894,P36894,27780042,"In solid ameloblastoma, positive correlations were observed between the stromal and parenchymal expression of BMP-2 and between the stromal expression of BMP-2 and BMP-4, as well as between the stromal expression of BMPR-II and BMP-4 and the stromal and parenchymal expression of BMPR-II."
https://pharos.nih.gov/idg/targets/P36894,P36894,27660075,"The present study suggests that HNF-4alpha has a suppressive effect on hepcidin expression by inactivating the BMP pathway, specifically via BMPR1A, in HepG2 cells."
https://pharos.nih.gov/idg/targets/P36894,P36894,27146957,"Several germline variants in Hamartomatous Polyposis Syndrome genes were detected, among them three in ENG, two in BMPR1A, one in PTEN, and one in SMAD4. Although some of the detected variants have been reported previously none could be definitely pathogenic or likely pathogenic."
https://pharos.nih.gov/idg/targets/P36894,P36894,26701726,"Data show that protein kinase LKB1 physically interacts with BMP type I receptors and requires Smad7 protein to promote downregulation of the receptor."
https://pharos.nih.gov/idg/targets/P36894,P36894,26585335,"BMPR1A(+) ASCs show an enhanced ability for adipogenesis in vitro, as shown by gene expression and histological staining."
https://pharos.nih.gov/idg/targets/P36894,P36894,26383923,"Duplication of 10q22.3-q23.3 encompassing BMPR1A gene is associated with congenital heart disease, microcephaly, and mild intellectual disability"
https://pharos.nih.gov/idg/targets/P36894,P36894,26274893,"Authors analyzed human databases from TCGA and survival data from microarrays to confirm BMPR1a tumor promoting functions, and found that high BMPR1a gene expression correlates with decreased survival regardless of molecular breast cancer subtype."
https://pharos.nih.gov/idg/targets/P36894,P36894,26171675,"About half of BMPR1A-related polyps displayed loss of heterozygosity, predominantly in the epithelial compartment, compatible with BMPR1A acting as a tumour suppressor gene."
https://pharos.nih.gov/idg/targets/P36894,P36894,25129392,"This is the first case report to document coding exon 3 duplication in the BMPR1A gene in a patient with juvenile polyposis syndrome."
https://pharos.nih.gov/idg/targets/P36894,P36894,24966941,"The mRNA/protein expressions of BMPR1alpha was higher in the stenotic colon segment tissue than in the normal colon segment tissue of Hirschsrung disease patients."
https://pharos.nih.gov/idg/targets/P36894,P36894,24904118,"results provide evidence that HFE induces hepcidin expression via the BMP pathway: HFE interacts with ALK3 to stabilize ALK3 protein and increase ALK3 expression at the cell surface."
https://pharos.nih.gov/idg/targets/P36894,P36894,24882581,"Results support a novel role for miR-885-3p in tumor angiogenesis by targeting BMPR1A, which regulates a proangiogenic factor."
https://pharos.nih.gov/idg/targets/P36894,P36894,24850914,"Data show that USP15 enhances BMP-induced phosphorylation of SMAD1 by interacting with and deubiquitylating ALK3."
https://pharos.nih.gov/idg/targets/P36894,P36894,24480809,"High BMPR1A expression is associated with glioma tumorigenesis."
https://pharos.nih.gov/idg/targets/P36894,P36894,24398041,"BMPR1a and BMPR2 are downregulated in cardiac remodeling and heart failure"
https://pharos.nih.gov/idg/targets/P36894,P36894,24140593,"BMP15 down-regulates StAR expression and decreases progesterone production in human granulosa cells, likely via ALK3-mediated SMAD1/5/8 signaling."
https://pharos.nih.gov/idg/targets/P36894,P36894,24008158,"Treatment of pulmonary arterial smooth muscle cells with HIV-1 Tat modulates expression of BMPR-2, BMPR-1A, and BMPR-1B proteins"
https://pharos.nih.gov/idg/targets/P36894,P36894,23969729,"findings show that a reduction in the expression of BMPRIA is associated with a poorer prognosis in pancreatic cancer"
https://pharos.nih.gov/idg/targets/P36894,P36894,23593444,"BMP receptor antagonists and silencing of BMP type I receptors with siRNA induced cell death, inhibited cell growth, and caused a significant decrease in the expression of inhibitor of differentiation (Id1, Id2, and Id3) family members."
https://pharos.nih.gov/idg/targets/P36894,P36894,23531103,"Decreased expression of BMPR1A was associated malignant gallbladder lesions."
https://pharos.nih.gov/idg/targets/P36894,P36894,23433720,"Bone morphogenetic protein receptor type 1A missense mutations occurring in patients with juvenile polyposis affected cellular localization in an in vitro model."
https://pharos.nih.gov/idg/targets/P36894,P36894,23399955,"Seventy-seven patients (13%) were found to have colorectal polyposis-associated mutations, including 20 in BMPR1A (3.3%)"
https://pharos.nih.gov/idg/targets/P36894,P36894,22971142,"lack of associations between LVM, values of blood pressure, and the BMP4, BMPR1A, BMPR1B, and ACVR1 genotypes"
https://pharos.nih.gov/idg/targets/P36894,P36894,22886282,"Results suggest that rs7922846 BMPR1A polymorphism may account for subtle variation in kidney size at birth, reflecting congenital nephron endowment."
https://pharos.nih.gov/idg/targets/P36894,P36894,22710174,"analysis of promiscuity and specificity in BMP receptor activation [review]"
https://pharos.nih.gov/idg/targets/P36894,P36894,22519633,"These data support the role of BMPR-1A as an indicator ofosteoarthritis progression in human knees with circumscribed cartilage lesions."
https://pharos.nih.gov/idg/targets/P36894,P36894,22293501,"generation of TGF-beta and BMP receptor homo- and hetero-oligomers and its roles as a mechanism capable of fast regulation of signaling by these crucial cytokines [review]"
https://pharos.nih.gov/idg/targets/P36894,P36894,22210872,"Results suggest that BMPRIA expression identifies thymic NK cell precursors and that BMP signaling is relevant for NK cell differentiation in the thymus."
https://pharos.nih.gov/idg/targets/P36894,P36894,21872883,"Sp1 was found to be a candidate factor that likely plays a role in the transcriptional regulation of BMPR1A."
https://pharos.nih.gov/idg/targets/P36894,P36894,21640116,"Letter: Report the phenotypic spectrum of BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency."
https://pharos.nih.gov/idg/targets/P36894,P36894,21543859,"Crystals of GDF5 and BMP receptor IA complex belonged to a monoclinic space group: either I2, with unit-cell parameters a = 63.81, b = 62.85, c = 124.99 A, beta = 95.9 degrees , or C2, with unit-cell parameters a = 132.17, b = 62.78, c = 63.53 A, beta = 112.8 degrees"
https://pharos.nih.gov/idg/targets/P36894,P36894,21412070,"Juvenile polyps with a SMAD4 germline mutation were predominantly type B, whereas type A was more common among juvenile polyps with a BMPR1A germline mutation."
https://pharos.nih.gov/idg/targets/P36894,P36894,21258932,"Disruption of BMPR1A-mediated BMP1 signalling during the narrow window of early embryogenesis may interfere with normal VBW formation, causing omphalocele phenotype in the Cd chick model."
https://pharos.nih.gov/idg/targets/P36894,P36894,21152263,"BMPR1A were detected in the human retina and retinoblastoma cell lines."
https://pharos.nih.gov/idg/targets/P36894,P36894,20927405,"The crystal structure of the complex of the BMPR-IA bound to the Fab AbD1556 revealed that the contact surface of BMPR-IA overlaps extensively with the contact surface for BMP-2 interaction."
https://pharos.nih.gov/idg/targets/P36894,P36894,20843829,"identified the promoter for BMPR1A, in which mutations may be responsible for as many as 10% of juvenile polyposis cases with unknown mutations"
https://pharos.nih.gov/idg/targets/P36894,P36894,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,20693682,"Crystals BMP receptor type IA bound to the antibody Fab fragment belonged to the monoclinic space group P2(1), with unit-cell parameters a=89.32, b=129.25, c=100.24 A, beta=92.27 degrees"
https://pharos.nih.gov/idg/targets/P36894,P36894,20673479,"Data show that blocking both endogenous BMPR1A and BMPR1B almost offset the effect of BMP7 on the proliferation of NCI-H460 cell completely."
https://pharos.nih.gov/idg/targets/P36894,P36894,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,20587070,"Low BMP2 is associated with epithelial ovarian cancer."
https://pharos.nih.gov/idg/targets/P36894,P36894,20346360,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,19773747,"Germline BMPR1A defect is the disease-causing mutation in 50% of the HMPS families."
https://pharos.nih.gov/idg/targets/P36894,P36894,19502417,"genetic variation in the BMPR1A may play a role in the pathophysiology of human obesity, possibly mediated through effects on mRNA expression"
https://pharos.nih.gov/idg/targets/P36894,P36894,19502417,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,19463221,"The prevalence of germline mutations of BMPR1A and SMAD4 are about 20% each in the patient with JPS."
https://pharos.nih.gov/idg/targets/P36894,P36894,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,19438883,"we describe the significance of a bone morphogenetic protein receptor type 1A gene mutation in an Irish family with hereditary mixed polyposis syndrome."
https://pharos.nih.gov/idg/targets/P36894,P36894,19244313,"5-HT transactivates the serine kinase receptor, BMPR 1A, to activate Smads 1/5/8 via Rho and Rho kinase in in bovine and human pulmonary artery smooth muscle cells"
https://pharos.nih.gov/idg/targets/P36894,P36894,18937504,"The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding."
https://pharos.nih.gov/idg/targets/P36894,P36894,18823382,"The overall prevalence of SMAD4 and BMPR1A point mutations and deletions in JPS was 45% in the largest series of patients to date"
https://pharos.nih.gov/idg/targets/P36894,P36894,18823382,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,18667463,"Loss of Bmpr1a, by decreasing MMP2 and/or MMP9 activity, can account for vascular dilatation and persistence of brain microvessels, leading to the impaired organogenesis documented in the brain."
https://pharos.nih.gov/idg/targets/P36894,P36894,18510548,"patients with 10q23 microdeletions involving the PTEN and BMPR1A genes have variable clinical phenotypes, which cannot be explained merely by the deletion sizes, and are not restricted to severe infantile juvenile polyposis"
https://pharos.nih.gov/idg/targets/P36894,P36894,18262054,"Germline mutation of BMPR1A in a family with juvenile polyposis and colon cancer"
https://pharos.nih.gov/idg/targets/P36894,P36894,18178612,"Large genomic deletions of SMAD4, BMPR1A and PTEN are a common cause of JPS."
https://pharos.nih.gov/idg/targets/P36894,P36894,18160401,"inactivating BMPR-IA and causing a loss of the BMP-2 tumor suppressor function in colon epithelial cells."
https://pharos.nih.gov/idg/targets/P36894,P36894,17873119,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,17873119,"5 nonsense, 2 frameshift, 4 missense and 2 splice site mutations were associated with juvenile polyposis syndrome. A 65-BP deletion in intron 4 included -2 of the splice acceptor side of exon 5."
https://pharos.nih.gov/idg/targets/P36894,P36894,17624341,"Expression of BMP-4 and BMP-7 and their receptors in human ovaries from fetuses as well as adults."
https://pharos.nih.gov/idg/targets/P36894,P36894,17573831,"Linkage analysis suggested a cryptic BMPR1A mutation or the presence of another gene in close proximity to the BMPR1A locus."
https://pharos.nih.gov/idg/targets/P36894,P36894,17513295,"SF3b4, known to be localized in the nucleus and involved in RNA splicing, binds BMPR-IA and specifically inhibits BMP-mediated osteochondral cell differentiation"
https://pharos.nih.gov/idg/targets/P36894,P36894,17101085,"Cooperation between this gene and PTEN gene is deleted on chromoome 10 in juvenile polyposis coli."
https://pharos.nih.gov/idg/targets/P36894,P36894,16886151,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,16672363,"structure of the ternary complex representing the signaling competent complex of BMP-2 bound to the entire extracellular domains of both its type I receptor, BMPR-Ia, & its type II receptor, ActRII, at a resolution of 2.2 angstroms"
https://pharos.nih.gov/idg/targets/P36894,P36894,16525031,"BMPR1A mutation accounts for hereditary mixed polyposis syndrome and inactivating this gene can initiate colorectal tumourigenesis"
https://pharos.nih.gov/idg/targets/P36894,P36894,16436638,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,16436528,"Human granulosa-like tumor cell line KGN expressed BMP type I (BMPR1A and BMPR1B) and type II receptors (BMPR2) and the BMP signaling molecules SMADs (SMAD1 and SMAD5)."
https://pharos.nih.gov/idg/targets/P36894,P36894,16385451,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,16226113,"BMPR1A is a promising marker for evaluating ganglion cells in the enteric nervous system."
https://pharos.nih.gov/idg/targets/P36894,P36894,15940369,"A defect in BMPRIA internalization and increased activation of downstream signaling, suggesting that altered BMP receptor trafficking underlies ectopic bone formation in fibrodysplasia ossificans progressiva."
https://pharos.nih.gov/idg/targets/P36894,P36894,15351706,"BMPR-IA may interact with and modulate the activity of a developmentally relevant splicing factor"
https://pharos.nih.gov/idg/targets/P36894,P36894,15235019,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,12620973,"BMPR1A can act as a minor susceptibility gene for PTEN mutation negative Cowden syndrome"
https://pharos.nih.gov/idg/targets/P36894,P36894,12417513,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,12136244,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36894,P36894,11536076,"Germline mutations in BMPR1A cause a subset of juvenile polyposis syndrome and Cowden syndrome cases."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,28938480,"In granulosa cells from women with PCOS, the regulation of AMH and AMHR2 expression is altered in a way that promotes the overexpression of the AMH/AMHR2 system, and could contribute to the follicular arrest observed in these patients."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,27832628,"No evidence of significant associations of Ile49Ser and -482A>G with reproductive outcomes and polycystic ovary syndrome."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,27664518,"genetic variants of AMH or AMHR2 were not found to be associated with a higher risk for polycystic ovaries syndrome."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,27162065,"The aim of this study was to investigate the density and distribution of single nucleotide polymorphisms (SNPs) anti-Mullerian hormone (AMH) and AMHRII receptors in cryptorchid patients."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,27142041,"Genotyping of the AMH c.146G>T and AMHR2 -482A>G polymorphisms does not provide additional useful information as a predictor of ovarian reserve or ovarian response and treatment outcomes."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,27109000,"a result of VEGF misregulation, AMHR2 overexpression increases AMH binding, which may attenuate follicular or oocyte maturation."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,26933946,"AMHRII 1749C > T and -482A > G genetic variants are associated with the ovarian response to standard gonadotropin stimulation, affecting mainly the follicular growth in IVF."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,26848671,"Neither AMH nor AMHR2 polymorphisms were related to age, BMI, hormone levels or ovarian parameters in the follicular phase in women of late reproductive stage."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,26753790,"A significant subset of GnRH neurons express the AMH receptor."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,26633196,"-482A > G genotype not associated with estradiol levels, ovarian parameters, menstrual cycle length, or pregnancy outcomes in healthy Singapore women"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,26464718,"There is no association between single nucleotide polymorphisms in the AMH/AMHR2 signaling pathway and early ovarian hyperstimulation syndrome in Han Chinese women"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,25972076,"study demonstrated for the first time that human placenta and fetal membranes express and co-localize Anti-Mullerian hormone(AMH) and Anti-Mullerian hormone Receptor II"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,25790842,"AMHR2 rs11170555 and rs3741664 were positively associated with AMH, estradiol and FSH levels."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,25663701,"A significant portion of AMHRII was missing most of its extracellular domain (ECD) and was unfolded and retained in the endoplasmic reticulum."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,25542251,"There was evidence that in specific subgroups of women undergoing IVF/ICSI, AMH and AMHRII SNPs may be related to patients' characteristics and controlled ovarian stimulation and pregnancy outcome"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,25517316,"Data indicate that Muellerian inhibiting substance type II receptor (MISRII) is a promising target for the control of ovarian granulosa cell tumors (GCT) and epithelial ovarian cancers (EOC)."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,24912417,"These findings suggest that patients with primary ovarian insufficiency in China share AMH and AMHR2 genetic variants with those who go through menopause at a normal age."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,24613539,"Antimullerian hormone receptor expression is increased in endometrium from patients with endometriosis."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,24271023,"The possible involvement of AMHRII -482 A>G polymorphism on the malfunction of follicular development in Japanese women."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,24146295,"Within primary ovarian insufficiency population, the AMH Ile(49)Ser and the AMHR2 -482A>G polymorphisms were not associated with age at the time of POI and"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,23969185,"The role of the AMHR2 -482 A>G gene polymorphism in the pathogenesis of polycystic ovary syndrome was suggested by the association of the variant with risk."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,23544102,"A statistically significant interaction between rs10407022 in AMH and rs11170547 in AMHR2 (p = 0.019) associated with age at natural menopause."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,23321213,"Data suggest that up-regulation of AMHR2 and AMH expression in luteal granulosa cells of anovulatory women with polycystic ovary syndrome is due to rising levels of luteinizing hormone (LH) and/or reversal of down-regulation by LH."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,23295284,"likely molecular etiology was found in eight patients with persistent Mullerian duct syndrome. Four mutations in AMH and two in AMHR2 were identified. Three of them are novel mutations, c.556-2A>G, and p.Arg502Leu in AMH; and p.Gly323Ser in AMHR2."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,22962306,"The Mullerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained beta-catenin signaling."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,22584735,"the diversity of clinical symptoms within sibship and lack of correlation between development of Mullerian derivatives and severity of molecular defects suggest highly variable penetrance of abnormal alleles"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20864412,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20861221,"AMH thus exemplifies a new mechanism for receptor engagement in which interaction with the type II receptor promotes pro-region dissociation to generate mature ligand."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20362961,"Association studies of common variants of AMHRII suggests that antimullerian hormone may regulate the primordial graafian follicle recruitment."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20236105,"data demonstrate that polymorphisms in major folliculogenesis genes, GDF9, BMP15, AMH, and AMHR2, are not associated with polycystic ovary syndrome susceptibility."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,20236105,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,19539910,"Genetic variants of AMH and AMHRII genes seem to be associated with infertility."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,19539910,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,19457927,"Mutations of AMHR2 found in persistent Mullerian duct syndrome affect its ligand binding and cellular transport."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,19424576,"Non-epithelial malignant ovarian tumors showed stronger expression of anti-Mullerian hormone receptor type II than that of epithelial tumors."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,19064572,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,18697861,"AMHR genes are overexpressed by granulosa cells from stimulated follicles of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,18310289,"Reduced AMH receptor type 2 is associated with Leydig cell tumours in multiple endocrine neoplasia type 1"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,18230658,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,17988723,"MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,17636279,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,17636279,"The observed association of the AMHR2 -482 A > G polymorphism with natural age at menopause suggests a role for AMH signaling in the usage of the primordial follicle pool in women."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,17337470,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,17337470,"Polymorphisms in the AMH and AMHR2 genes are associated with follicular phase E(2) levels, suggesting a role for AMH in the regulation of FSH sensitivity in the human ovary."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,14750901,"binding domains recognized by a monoclonal antibody and the natural ligand"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,12477536,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16671,Q16671,12462075,"Review. The role of AMHR2 in gonadal development and its mutation in the persistent Mullerian duct syndrome is discussed."
https://pharos.nih.gov/idg/targets/Q16671,Q16671,11588147,"interacts with Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications."
https://pharos.nih.gov/idg/targets/P80192,P80192,28081468,"There was a negatively relationship between miR-15a and MAP3K9 expression in NP cells."
https://pharos.nih.gov/idg/targets/P80192,P80192,26573018,"miR148b directly targeted mitogenactivated protein kinase (MAPK) kinase kinase 9 (MAP3K9), an upstream activator of MAPK kinase/cJun Nterminal kinase (JNK) signaling, suppressing the protein but not the mRNA levels."
https://pharos.nih.gov/idg/targets/P80192,P80192,23836671,"identified three kinases with gain-of-function mutations in lung cancer, namely FGFR4, MAP3K9, and PAK5. Mutations in these kinases are activating toward the ERK pathway, and targeted depletion of the mutated kinases inhibits proliferation"
https://pharos.nih.gov/idg/targets/P80192,P80192,22197930,"It was found that 24% of melanoma cell lines have mutations in the protein-coding regions of either MAP3K5 or MAP3K9."
https://pharos.nih.gov/idg/targets/P80192,P80192,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P80192,P80192,19826002,"estrogen receptor-alpha transcriptional activity is repressed by the Rho/megakaryoblastic leukemia 1 signaling pathway"
https://pharos.nih.gov/idg/targets/P80192,P80192,18976975,"Knockdown of mitogen-activated protein kinase kinase kinase 9 (MAP3K9) by siRNA inhibits HIV-1 replication in HeLa P4/R5 cells"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,28262979,"In lipotoxic hepatocytes, MLK3 activates a MAPK signaling cascade, resulting in the activating phosphorylation of STAT1, and CXCL10 transcriptional upregulation."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,27613090,"Data indicate that BTG2, MAP3K11, RPS6KA1 and PRDM1 as putative targets of microRNA miR-125b."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,26717044,"Increased expression of MAP3K11 is associated with esophageal cancer."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,26406121,"During hepatocyte lipotoxicity, activated MLK3 induces the release of CXCL10-bearing vesicles from hepatocytes, which are chemotactic for macrophages."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,26152725,"MLK3 represents a newly recognized integral component of HER2 biology in HER2+ breast tumors."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,25874865,"MLK3 serves as a common upstream kinase of AMPK and JNK and functions as a direct upstream kinase for AMPK independent of LKB1"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,24912674,"CHIP modulates MLK3 protein levels in response to Geldanamycin and stress stimuli, and CHIP-dependent regulation of MLK3 is required for suppression of SKOV3 ovarian cancer cell invasion."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,24894995,"MLK3 is a critical factor controlling the activity of kinase networks that control the cellular responses to different concentrations of reactive oxygen species."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,24628919,"Signaling pathways associated with the Pro252His mutation in MLK3 are located in the kinase domain which is an important domain for the regulation of downstream signaling pathways."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,24044867,"Data indicate URMC-099 as an orally bioavailable, potent mixed lineage kinase 3 MLK3 inhibitor."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,23906792,"CTGF acting through Rac1 activates the MLK3/JNK signaling pathway, which in turn initiates AP-1 activation and recruitment of c-Jun and c-Fos to the collagen I promoter and ultimately induces collagen I expression in human lung fibroblasts"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,23857585,"NS5A targets MLK3 with multiple downstream consequences for both apoptosis and K(+) homeostasis."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,23172226,"Lysine 63-linked ubiquitination modulates mixed lineage kinase-3 interaction with JIP1 scaffold protein in cytokine-induced pancreatic beta cell death"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22761715,"High MAP3K11 expression is associated with prostate cancer."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22700880,"Findings suggest that the MLK3-JNK-paxillin signaling axis may represent a potential prognostic marker in breast cancer metastasis."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22652451,"The findings establish MLK3 as an important regulator of MMP expression and invasion in ovarian cancer cells."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22566623,"These findings collectively suggest that the MLK3-Pin1 signaling cascade plays a critical role in regulating the cell cycle, centrosome numbers, and oncogenesis."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22509080,"Data show that HBx can induce HepG2 cell apoptosis via a novel active MLK3-MKK7-JNKs signaling module to upregulate FasL protein expression."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,22139075,"Data suggest that MEKK2 and MLK3 represent untargeted kinases in tumor biology for potential therapeutic development."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,21979919,"Mechanism of MAP kinase activation by TNF requires Src-dependent activation of Vav, activation of Rac/Cdc42, and the engagement of the Rac/Cdc42 interaction site on MLK3."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,21880738,"co-expression of MLK3 and beta-catenin resulted in significant G(2)/M arrest."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20937558,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20890305,"These results establish merlin as a potent inhibitor of mixed lineage kinase 3, extracellular signal-regulated kinase, and c-jun N-terminal kinase activation in cancer."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20514022,"MLK3 is critical for breast cancer cell migration and promotes cell transformation."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20158498,"Novel proteolytic processing of MLK3 may negatively control MLK3 signalling to JNK."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20150185,"Studies indicate that the MLK3/JNK1 axis mediates G17-induced gastric cancer cell migration, which can be targeted for designing novel therapeutic strategies for treating gastric malignancies."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,20145118,"Estradiol inhibits the proapoptotic function of MLK3 as a mechanism to limit cytotoxic drug-induced death of ER(+) breast cancer cells."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,19955118,"MLK3 mutations is associated with the mismatch repair deficiency in gastrointestinal cancer."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,19782705,"MLK3 functions to limit IKK activity, and depleting MLK3 helps protect cells from etoposide-induced cell death through activation of IKK-dependent signaling."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,19586614,"K48-linked ubiquitination directs Mixed lineage kinase 3 for proteosomal degradation while K63-linked ubiquitination is important for Mixed lineage kinase 3 kinase activity."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,18851832,"findings demonstrate a scaffolding role for MLK3 in controlling the extent of Rho activation that modulates cell migration"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,18222647,"p38 MAPK inhibitors SB202190 and SB203580 activated JNK via MLK-3/MKK7 pathway."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,17711861,"a direct link between GSK-3beta and MLK3 activation in a neuronal cell death pathway and identify MLK3 as a direct downstream target of GSK-3beta."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,17584736,"MLK2 and -3 are required for activation of JNK and p38 by ectopically expressed GCK"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,16687404,"JNK-mediated feedback phosphorylation of MLK3 regulates its activation and deactivation states by cycling between Triton-soluble and Triton-insoluble forms"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,16537381,"Merlin and MLK3 can interact in situ and merlin can disrupt the interactions between B-Raf and Raf-1 or those between MLK3 and either B-Raf or Raf-1."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,16253996,"Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,15923109,"The MLK3 might be a unique target to selectively inhibit transformed cell proliferation by disrupting mitotic spindle formation resulting in mitotic arrest."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,15258589,"MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,15069087,"These observations support a role for mixed lineage kinases, including MLK3, in the TGF-beta1-induced cell death mechanism."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,15001580,"MLK3 signaling requires Hsp90/p50cdc37"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,14504284,"MLK3 is phosphorylated by Akt2, which results in the disassembly of the JNK complex bound to POSH and down-regulation of the JNK signaling pathway"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,12504027,"ceramide and TNF-alpha are agonists"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,12458207,"negative regulation by protein kinase B leads to cell survival"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,12354290,"Treatment of neurons with HIV-1 gp120 in culture produces apoptotic neuronal death through the mixed lineage kinase 3 (MLK3) signaling pathway"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,12190962,"Treatment of neurons with HIV-1 gp120 in culture produces apoptotic neuronal death through the mixed lineage kinase 3 (MLK3) signaling pathway"
https://pharos.nih.gov/idg/targets/Q16584,Q16584,11969422,"Twelve in vivo MLK3 phosphorylation sites have been identified."
https://pharos.nih.gov/idg/targets/Q16584,Q16584,11713255,"MLK3 may be a negative regulator of the growth-promoting and transforming properties of Rac1"
https://pharos.nih.gov/idg/targets/O43318,O43318,28989054,"nMet accelerated HCC tumorigenesis and metastasis via the activation of TAK1/NF-kappaB pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,28829887,"TAK1 protein expression increased in cartilage tissue from spinal tuberculosis patients."
https://pharos.nih.gov/idg/targets/O43318,O43318,28194669,"Overexpression of TAK1 was strongly associated with positive lymph node metastasis in pancreatic ductal adenocarcinoma."
https://pharos.nih.gov/idg/targets/O43318,O43318,27482120,"Rab1 is regulated by the host in a similar fashion, and that the innate immunity kinase TAK1 and Legionella effectors compete to regulate Rab1 by switch II modifications during infection."
https://pharos.nih.gov/idg/targets/O43318,O43318,27426734,"although TAK1 is located at the crossroad of inflammation, immunity, and cancer, this study reports MAP3K7 mutations in a developmental disorder affecting mainly cartilage, bone, and heart"
https://pharos.nih.gov/idg/targets/O43318,O43318,27426733,"dysregulation of the TAK1 complex produces a close phenocopy of Frontometaphyseal Dysplasia caused by FLNA mutations; furthermore, the pathogenesis of some of the filaminopathies caused by FLNA mutations might be mediated by misregulation of signaling coordinated through the TAK1 signaling complex"
https://pharos.nih.gov/idg/targets/O43318,O43318,27245349,"TAK1 regulates Nrf2 through modulation of Keap-p62/SQSTM1 interaction. This regulation is important for homeostatic antioxidant protection in the intestinal epithelium."
https://pharos.nih.gov/idg/targets/O43318,O43318,27048361,"This paper highlights that targeting the BMP and TGFbeta type I and type II receptors causes a downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells."
https://pharos.nih.gov/idg/targets/O43318,O43318,26928052,"This study suggests that aberrant activity of TAK1 impairs autophagy and subsequently leads to alterations in the vitality of retinal pigment epithelial cells."
https://pharos.nih.gov/idg/targets/O43318,O43318,26823762,"TAK1 may be an important factor involved in the pathogenesis of thyroid cancer, and targeted down-regulation of TAK1 may improve the prognosis of patients with thyroid cancer."
https://pharos.nih.gov/idg/targets/O43318,O43318,26491199,"The data emphasize the central role of TAK1 in controlling signaling cascades and functional responses in primary neutrophils, making it a promising target for therapeutic intervention in view of the role of neutrophils in chronic inflammatory conditions."
https://pharos.nih.gov/idg/targets/O43318,O43318,26468522,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,26406417,"Loss of MAP3K7 are associated with esophageal squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/O43318,O43318,26401039,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,26189595,"Polyubiquitination of Transforming Growth Factor beta-activated Kinase 1 (TAK1) at Lysine 562 Residue Regulates TLR4-mediated JNK and p38 MAPK Activation"
https://pharos.nih.gov/idg/targets/O43318,O43318,26185333,"the TAK1 signaling pathway may represent a suitable target to design new, antifibrotic therapies"
https://pharos.nih.gov/idg/targets/O43318,O43318,25889255,"MiR-377 is an important negative regulator of E2F and MAP3K7/NF-kB signaling pathway in melanoma cells."
https://pharos.nih.gov/idg/targets/O43318,O43318,25770290,"identify coordinate loss of MAP3K7 and CHD1 as a unique driver of aggressive prostate cancer development"
https://pharos.nih.gov/idg/targets/O43318,O43318,25557171,"Data indicate that inhibition of TGF-beta-activated protein kinase 1 (TAK1) reduces chemokine (C-C motif) receptor 7 (CCR7) expression."
https://pharos.nih.gov/idg/targets/O43318,O43318,25383712,"Findings indicate that SHIP2 is a regulator of lymphatic function in humans and that inherited mutations in the INPPL1 gene may act in concert with HGF, and likely MAP3K7, mutations to exacerbate lymphatic phenotypes."
https://pharos.nih.gov/idg/targets/O43318,O43318,25371197,"Data show that the ECSIT (evolutionarily conserved signaling intermediate in Toll pathways) complex, including MEKK7 (TAK1) and TNF receptor-associated factor 6 (TRAF6), plays a role in Toll-like receptor 4 -mediated signals to activate NF-kappa B."
https://pharos.nih.gov/idg/targets/O43318,O43318,25288801,"Data suggest a role for the mitogen-activated protein kinase kinase kinase 7 TAK1-jun-NH2-Terminal Kinase JNK pathway as a critical regulator of NLRP3 protein inflammasome activation."
https://pharos.nih.gov/idg/targets/O43318,O43318,25261726,"TAK1 may be an important oncogene or an effective target for renal cell carcinoma intervention."
https://pharos.nih.gov/idg/targets/O43318,O43318,25189770,"Ubc13 was dispensable for transforming growth factor beta (TGFbeta)-induced SMAD activation but was required for activation of non-SMAD signaling via TGFbeta-activating kinase 1 (TAK1) and p38"
https://pharos.nih.gov/idg/targets/O43318,O43318,25075558,"Data indicate 4-substituted 1H-pyrrolo[2,3-b]pyridines as potent inhibitors against TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)."
https://pharos.nih.gov/idg/targets/O43318,O43318,24912525,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,24911653,"Data suggest TAK1 and IKKbeta (inhibitor of kappaB kinase beta) phosphorylate different serines of IKKbeta; TAK1-catalyzed phosphorylation of IKKbeta at Ser177 is priming event that enables IKKbeta to activate itself by phosphorylating Ser181."
https://pharos.nih.gov/idg/targets/O43318,O43318,24874739,"Nef markedly activated TAK1 in M-CSF-derived M2-MPhi but not in GM-CSF-derived M1-MPhi."
https://pharos.nih.gov/idg/targets/O43318,O43318,24874739,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,24721172,"NLK functions as a pivotal negative regulator of NF-kappaB via disrupting the interaction of TAK1 with IKKbeta."
https://pharos.nih.gov/idg/targets/O43318,O43318,24443058,"TAK1 plays a role in tumor initiation, progression, and metastasis as a tumor prompter or tumor suppressor. An understanding of the role of TAK1 in liver physiology and diseases is required for the development of therapeutic agencies targeting TAK1"
https://pharos.nih.gov/idg/targets/O43318,O43318,24277938,"Data indicate that ribosomal S6 kinase 1 (S6K1) is negatively involved in the toll-like receptorS TLR2 and TLR4 signaling pathway by the inhibition of TAK1 (MAP3K7) activity."
https://pharos.nih.gov/idg/targets/O43318,O43318,24113182,"A dysregulated balance in the activation of TGFbeta-TAK1 and TGFbeta-SMAD pathways is pivotal for TGFbeta1-induced epithelial-mesenchymal transition."
https://pharos.nih.gov/idg/targets/O43318,O43318,24072697,"Results establish TAK1 as an AMPKalpha1 kinase that regulates vascular endothelial growth factor-induced and cytokine-induced angiogenesis by modulating SOD2 expression and the superoxide anion:hydrogen peroxide balance."
https://pharos.nih.gov/idg/targets/O43318,O43318,23760366,"TAK1 (MAP3K7) does not mediate the TGFb-induced phosphorylation of p38 mitogen-activated protein kinases."
https://pharos.nih.gov/idg/targets/O43318,O43318,23705972,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,23534745,"Overexpression of TAK1 predicts a poor prognosis in patients with clear cell renal cell carcinoma, so that TAK1 may serve as a novel prognostic marker"
https://pharos.nih.gov/idg/targets/O43318,O43318,23472066,"14-3-3epsilon associates with TAK1 in a phosphorylation-dependent manner to determine the cell fate of Bleomycin-treated HCC cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,23370768,"our study identifies MAP3K7 deletion as a prominent feature in ERG-negative prostate cancer"
https://pharos.nih.gov/idg/targets/O43318,O43318,23272845,"TAK1 expression correlates with lymph node metastasis and is a negative, independent prognostic factor in resected T3N1-3M0 ESCCs."
https://pharos.nih.gov/idg/targets/O43318,O43318,23229544,"findings suggest that DUSP14 negatively regulates TNF- or IL-1-induced NF-kappaB activation by dephosphorylating TAK1 at Thr-187"
https://pharos.nih.gov/idg/targets/O43318,O43318,23087682,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,23077317,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,22972987,"We found that endothelial TAK1 and TAB2, but not TAB1, were critically involved in vascular formation"
https://pharos.nih.gov/idg/targets/O43318,O43318,22941947,"TAK1 plays central role in both innate and adaptive immunity as well as in DNA damage, osmotic stress, and hypoxia. (Review)"
https://pharos.nih.gov/idg/targets/O43318,O43318,22843747,"Results indicate that TAK1 and p38 kinases appear to be central in the 'priming effect' of LTB(4) on neutrophils to enhance response to Toll-like receptor ligands."
https://pharos.nih.gov/idg/targets/O43318,O43318,22835455,"review focuses on current insights into the mechanism and function of the Smad-independent signaling pathway via TGF-beta-activated kinase 1 and its role in mediating the profibrotic effects of TGF-beta1 in chronic kidney disease. [Review Article]"
https://pharos.nih.gov/idg/targets/O43318,O43318,22802624,"evidence that TAK1 is a target for YopJ-mediated inhibition."
https://pharos.nih.gov/idg/targets/O43318,O43318,22649101,"The phosphorylated form of TAK1 is abundantly expressed in a panel of lymphoma cell lines, including mantle cell, anaplastic large cell, and Hodgkin lymphoma. siRNA inhibited the activation of NF-kappaB and p38 and induced apoptosis in lymphoma cell lines."
https://pharos.nih.gov/idg/targets/O43318,O43318,22590573,"Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein K13 activates NF-kappaB pathway independent of TRAF6, TAK1 and LUBAC"
https://pharos.nih.gov/idg/targets/O43318,O43318,22576335,"Two SNPs, rs282070 located in intron 1 of the MAP3K7 gene, and rs2111699 located in intron 1 of the GSTZ1 gene, were significantly associated (after adjustment for multiple testing) with longevity in stage 2"
https://pharos.nih.gov/idg/targets/O43318,O43318,22490020,"the role of TAK1 in cell death, cell cycle regulation and apoptosis after X irradiation is independent of NF-kappaB, p38 MAPK, and ERK phosphorylation, and dependent, in part, on p21 induction"
https://pharos.nih.gov/idg/targets/O43318,O43318,22467172,"In the grafts containing Tak1-suppressed prostate stem cells, p38 and c-jun-NH(2)-kinase activity was attenuated and proliferation was increased"
https://pharos.nih.gov/idg/targets/O43318,O43318,22384029,"Inhibition of transforming growth factor-activated kinase 1 (TAK1) blocks and reverses epithelial to mesenchymal transition of mesothelial cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,22341466,"TAK1 activity was required for HIV-1 gp41 cytoplasmic domain-mediated NF-kappaB activation, and HIV-1-derived gp41 cytoplasmic domain physically interacted with TAK1 through the same region required for NF-kappaB activation."
https://pharos.nih.gov/idg/targets/O43318,O43318,22341466,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,22341439,"Data suggest that TAK1 functions as a prosurvival mediator in cancer cells displaying hyperactive KRAS-dependent Wnt signaling."
https://pharos.nih.gov/idg/targets/O43318,O43318,22256769,"Study on effect of fushenkeli on expression of TAK1 in human renal tubular epithelial cells and its possible mechanism"
https://pharos.nih.gov/idg/targets/O43318,O43318,22167179,"TAK1 and its adapter protein, TAB2, reciprocally regulate both TAK1- and ASK1-mediated signaling pathways to direct the activations of NF-kappaB and AP-1."
https://pharos.nih.gov/idg/targets/O43318,O43318,22069318,"polyubiquitination of TAK1 is correlated with activation of TAK1 and is essential for activation of NF-kappaB signaling downstream of several receptors"
https://pharos.nih.gov/idg/targets/O43318,O43318,21873447,"TAK1 plays a major role in growth factor-induced phenotypic modulation of airway smooth muscle remodeling."
https://pharos.nih.gov/idg/targets/O43318,O43318,21866272,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21743023,"Results that genetic silencing or inhibition of TAK1 kinase activity in vivo is a potential therapeutic approach to reversal of the intrinsic chemoresistance of pancreatic cancer."
https://pharos.nih.gov/idg/targets/O43318,O43318,21700681,"these studies show that the TAK1-TAB2-TAB3 signaling axis is critical for carcinoma-induced bone lesions, mediating expression of proinvasive and osteolytic factors."
https://pharos.nih.gov/idg/targets/O43318,O43318,21606198,"Data show that DNA damage stimulates the formation of a cytosolic complex of ATM, NEMO, RIP1, and TAK1, and that TAK1 mediates the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage."
https://pharos.nih.gov/idg/targets/O43318,O43318,21575904,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21572451,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21512573,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21512569,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21498517,"TAK1-c-Rel and IRF4 pathways play distinct roles in the maintenance of IL-9-producing Th17 phenotype of HTLV-1-transformed cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,21233843,"The TAK1 regulated inhibition of TNF-alpha-mediated apoptosis via the autocrine action of stem cell factor."
https://pharos.nih.gov/idg/targets/O43318,O43318,21220427,"LPS-induced activation of IRAK4 and TAK1, K63-linked polyubiquitination of IRAK1 and TRAF6, and disrupted IRAK1-TRAF6 and IRAK1-IKKgamma assembly associated with increased A20 expression"
https://pharos.nih.gov/idg/targets/O43318,O43318,21098640,"p38 maintains E-cadherin expression by suppressing TAK1-NF-kappaB signaling, thus impeding the induction of epithelial-to-mesenchymal transition in human primary mesothelial cells."
https://pharos.nih.gov/idg/targets/O43318,O43318,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,20932476,"ATM- and NEMO-dependent ubiquitination of ELKS leads to the ubiquitin-dependent assembly of TAK1/TAB2/3 and NEMO/IKK complexes, resulting in IKK and NF-kappaB activation following genotoxic stimuli."
https://pharos.nih.gov/idg/targets/O43318,O43318,20837137,"TAK1 lysine 158, but not lysine 34, is required for TGF-beta-induced TAK1 polyubiquitination and TGF-beta-induced TRAF6-mediated Smad-independent IKK, JNK and p38 activation."
https://pharos.nih.gov/idg/targets/O43318,O43318,20682854,"The systemic TAK1 gene silencing decreases the frequency of Th1 and Th17 cells, both mediating autoimmunity in experimental arthritis, demonstrating the immunomodulatory potential of TAK1."
https://pharos.nih.gov/idg/targets/O43318,O43318,20677014,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,20585109,"A20 improves cardiac functions and inhibits cardiac hypertrophy, inflammation, apoptosis, and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling."
https://pharos.nih.gov/idg/targets/O43318,O43318,20538596,"Co-expression of TAK1 and TAB1 resulted in a functional and active TAK1-TAB1 complex capable of directly activating full-length heterotrimeric mammalian AMP-activated protein kinase (AMPK) in vitro."
https://pharos.nih.gov/idg/targets/O43318,O43318,20448286,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,20306291,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,20061393,"findings provide the first evidence that TAK1-NLK pathway is a novel regulator of FOXO1"
https://pharos.nih.gov/idg/targets/O43318,O43318,20038579,"Lys(63)-linked polyubiquitination of TAK1 at Lys(158) is essential for its own kinase activation and its ability to mediate its downstream signal transduction pathways in response to TNFalpha and IL-1beta stimulation."
https://pharos.nih.gov/idg/targets/O43318,O43318,19820695,"polyubiquitination of TAK1 regulates the activation of NF-kappaB, which in turn is used by H. pylori CagA for the H. pylori-induced inflammatory response"
https://pharos.nih.gov/idg/targets/O43318,O43318,19760754,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43318,O43318,19687304,"These results demonstrated that TAK1 controls two different signaling pathways, IkappaB kinase-NF-kappaB and MAPK-EGFR, leading to the survival of cells exposed to the death signal from the TNF-alpha receptor."
https://pharos.nih.gov/idg/targets/O43318,O43318,19675569,"results indicate that unanchored polyubiquitin chains directly activate TAK1 and IKK, suggesting a new mechanism of protein kinase regulation"
https://pharos.nih.gov/idg/targets/O43318,O43318,19578758,"periostin is involved in the suppression of cell invasiveness via the TAB1/TAK1 signaling pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,19419968,"novel homeostatic control of keratinocyte proliferation and migration mediated via TAK1 regulation of von Hippel-Lindau tumor suppressor"
https://pharos.nih.gov/idg/targets/O43318,O43318,19410630,"TNFalpha and its downstream TAK1, which are key mediators for NF-kappaB and MAPK pathways, may be involved in the pathogenesis of endometriosis."
https://pharos.nih.gov/idg/targets/O43318,O43318,19284290,"Data indicate that TAK1-D plays a role in the signaling events triggered by selected types of ribotoxic stress."
https://pharos.nih.gov/idg/targets/O43318,O43318,19232515,"These results suggest that FBXW5 negatively regulates TAK1 in the IL-1beta signaling pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,19197243,"TRAIL-induced AMPK activation depends on transforming growth factor-beta-activating kinase 1 (TAK1) and TAK1-binding subunit 2."
https://pharos.nih.gov/idg/targets/O43318,O43318,19074436,"the presence of melittin, TRAIL-induced apoptosis is significantly increased in TRAIL-resistant HCC cells, which may be attributed to melittin-induced TAK1-JNK/p38 activation and melittin-mediated inhibition of IkappaBalpha kinase-NFkappaB."
https://pharos.nih.gov/idg/targets/O43318,O43318,19047046,"as a mediator of SF- and Src-stimulated NF-kappaB activity. Finally, the Src/Rac1/MKK3/6/p38 and Src/TAK1/NF-kappaB-inducing kinase pathways exhibited cross-talk at the level of MKK3."
https://pharos.nih.gov/idg/targets/O43318,O43318,19026643,"These results suggest that Hsp90 is required for the folding and stability of TAK1 but is displaced and no longer required when TAK1 is complexed to TAK1-binding protein-1."
https://pharos.nih.gov/idg/targets/O43318,O43318,18976975,"Knockdown of mitogen-activated protein kinase kinase kinase 7 (MAP3K7) by siRNA inhibits HIV-1 replication in HeLa P4/R5 cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,18950863,"Hsp90 regulates IL-1beta-induced signaling by interacting with TAK1 and maintaining the stability of TAK1, suggesting that Hsp90 might act as the chaperone of TAK1 in immune and inflammatory responses related with IL-1 signal cascades."
https://pharos.nih.gov/idg/targets/O43318,O43318,18758450,"TGF-beta specifically activates TAK1 through interaction of TbetaRI with TRAF6, whereas activation of Smad2 is not dependent on TRAF6."
https://pharos.nih.gov/idg/targets/O43318,O43318,18617512,"Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkappaB and AP-1 activation as well as IL-6 gene expression."
https://pharos.nih.gov/idg/targets/O43318,O43318,18456659,"TAB4 binds TAK1 and polyubiquitin chains to promote specific sites of phosphorylation in TAK1-TAB1, which activates IKK signaling to NF-kappaB."
https://pharos.nih.gov/idg/targets/O43318,O43318,18326498,"suggest that Pellino 3b acts as a negative regulator for IL-1 signaling by regulating IRAK degradation through its ubiquitin protein ligase activity"
https://pharos.nih.gov/idg/targets/O43318,O43318,18316610,"a TAB1:TAK1:IKK beta:NF-kappaB signaling axis forms aberrantly in breast cancer cells and, consequently, enables oncogenic signaling by TGF-beta"
https://pharos.nih.gov/idg/targets/O43318,O43318,18299321,"PP2A functions as a negative regulator in TGF-beta1-induced TAK1 activation"
https://pharos.nih.gov/idg/targets/O43318,O43318,18206350,"Data provide insights into the homeostatic interactions that maintain basal NF-kappaB levels by holding the enzymes MEKK3 and TAK1 in their inactive state."
https://pharos.nih.gov/idg/targets/O43318,O43318,17982039,"two independent and indispensable signaling pathways-1) JAK1-associated PI3K signaling and 2) Act1/TRAF6/TAK1-mediated NF-kappaB activation-are stimulated by IL-17A to regulate gene induction in human airway epithelial cells."
https://pharos.nih.gov/idg/targets/O43318,O43318,17947700,"These signals exert their anti-inflammatory effects by inhibiting phosphorylation of TAK1"
https://pharos.nih.gov/idg/targets/O43318,O43318,17828308,"TAK1 contributes to TGF-beta1-mediated tumor angiogenesis and metastasis via involvement of the TAK1-NF-kappaB-MMP-9 pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,17626013,"p38 negatively regulated TAK1 activity through TAB1 phosphorylation."
https://pharos.nih.gov/idg/targets/O43318,O43318,17608743,"BY acting at the level of TAK1 (MAP3K7) activation, YopJ inhibited TLR-mediated NF-kappaB and MAP kinase activation as well as IRF3 signalling."
https://pharos.nih.gov/idg/targets/O43318,O43318,17559674,"TAK1 as a pivotal upstream kinase and potential therapeutic target to modulate synoviocyte activation in RA."
https://pharos.nih.gov/idg/targets/O43318,O43318,17379600,"IHPK2-TRAF2 binding leads to attenuation of TAK1- and NF-kappaB-mediated signaling and is partially responsible for the apoptotic activity of IHPK2."
https://pharos.nih.gov/idg/targets/O43318,O43318,17363973,"Study shows that Tax functions as an intracellular stimulator of an IKK-activating kinase, Tak1; in addition, Tax physically interacts with Tak1 and mediates the recruitment of IKK to Tak1."
https://pharos.nih.gov/idg/targets/O43318,O43318,17325661,"TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,17276978,"Modulates TGF-beta-dependent cellular responses by targeting SnoN/SKIL for degradation, thereby allowing the activation of TGF-beta target genes."
https://pharos.nih.gov/idg/targets/O43318,O43318,17202147,"HSP27 is required for both IL-1 and TNF-induced signaling pathways for which the most upstream common signaling protein is TAK1."
https://pharos.nih.gov/idg/targets/O43318,O43318,17173073,"HspB8 overload causes melanoma growth arrest and apoptosis through TAK1 activation"
https://pharos.nih.gov/idg/targets/O43318,O43318,17158449,"The TAB2/TAB3 interaction with TAK1 is crucial for the activation of signaling cascades mediated by interleukin-1, tumor necrosis factor, and receptor activator of nuclear factor-kappa B ligand (RANKL)."
https://pharos.nih.gov/idg/targets/O43318,O43318,17114179,"the nuclear factor-kappaB signaling pathway is inhibed by gamma-tocopherol through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis"
https://pharos.nih.gov/idg/targets/O43318,O43318,16893890,"the TAK1-JNK pathway is activated by osmotic stress, while blocking TAK1-mediated NF-kappaB activation; TAO2 regulates TAK1 pathways"
https://pharos.nih.gov/idg/targets/O43318,O43318,16835226,"TAK1 is a functional member of the Snf1/AMPK kinase family"
https://pharos.nih.gov/idg/targets/O43318,O43318,16527194,"A candidate gene in ectodermal dysplasia."
https://pharos.nih.gov/idg/targets/O43318,O43318,16446357,"an LMP1-associated complex containing TRAF6, TAB2, and TAK1 plays an essential role in the activation of JNK"
https://pharos.nih.gov/idg/targets/O43318,O43318,16293250,"TAK1 plays a critical role in T cell activation by controlling production of IL-2."
https://pharos.nih.gov/idg/targets/O43318,O43318,16280329,"LMP1 utilizes two distinct pathways to activate NF-kappaB: a major one through CTAR2/TRAF6/TAK1/IKKbeta (canonical pathway) and a minor one through CTAR1/TRAF3/NIK/IKKalpha (noncanonical pathway)"
https://pharos.nih.gov/idg/targets/O43318,O43318,16260783,"TAK1 is recruited to the TNF-R1 complex via RIP and likely cooperates with MEKK3 to activate NF-kappaB in TNF-alpha signaling"
https://pharos.nih.gov/idg/targets/O43318,O43318,16251197,"Involvement of the TAB2/TRAF6/TAK1 signalling complex in the Edar signal transduction pathway has important implications for understanding of NF-kappaB activation and anhidrotic ectodermal dysplasia in human."
https://pharos.nih.gov/idg/targets/O43318,O43318,16000313,"Arachidonic acid-mediated TAK1 activation is responsible for MAP kinase kinase 6 activation and the ensuing downstream signaling in metastatic human breast carcinoma cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,15917296,"interleukin-1beta and its downstream mediator TAK1 inhibit mothers against decapentaplegic homolog 3 MAD-mediated TGFbeta target gene activation"
https://pharos.nih.gov/idg/targets/O43318,O43318,15764709,"STAT3 enhances the efficiency of its own Ser-727 phosphorylation by acting as a scaffold for the TAK1-NLK kinases"
https://pharos.nih.gov/idg/targets/O43318,O43318,15670770,"Experiments using dominant-negative Tpl2 suggest this kinase functions distal to TRAFs but proximal to the TAK1/TAB1 signaling complex, within the IKK/NFkappaB activation pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,15590691,"characterized the molecular mechanisms of cellular stress-induced TAK1 activation, focusing mainly on the phosphorylation of TAK1 at Thr-187 and Ser-192 in the activation loop; TAB1 and TAB2 were differentially involved in the phosphorylation of TAK1"
https://pharos.nih.gov/idg/targets/O43318,O43318,15277532,"TAK1 binds with Sef, which has a role in JNK activation and apoptosis"
https://pharos.nih.gov/idg/targets/O43318,O43318,15125833,"TAK1 protein kinase mediate IKK activation by BCL10 and MALT1. RNAi-mediated silencing of TAK1 suppressed TCR-dependent IKK activation and interleukin-2 production in T cells"
https://pharos.nih.gov/idg/targets/O43318,O43318,14960582,"Tak1 has a role in Wnt signal transduction and phosphorylation and inhibition of TCF"
https://pharos.nih.gov/idg/targets/O43318,O43318,14592977,"TAB1 participates in a SAPK2a/p38alpha-mediated feedback control of TAK1"
https://pharos.nih.gov/idg/targets/O43318,O43318,12859960,"Results indicate that dominant negative constructs of TAK1 retain the ability to intercept the TGF-beta signaling effectively."
https://pharos.nih.gov/idg/targets/O43318,O43318,12842894,"TAK1 has a role in TNF-alpha induced IKK phosphorylation of NF-kappaB p65"
https://pharos.nih.gov/idg/targets/O43318,O43318,12804775,"Pellino2 interacts with TAK1 and activates the MAP kinase pathway."
https://pharos.nih.gov/idg/targets/O43318,O43318,12589052,"TAK1- and MKK3-mediated activation of p38 are facilitated by Smad7"
https://pharos.nih.gov/idg/targets/O43318,O43318,12547194,"TNFalpha activation of the NF-kappaB pathway is associated with the inducible binding of TAK1 to TRAF2 and both IKKalpha and IKKbeta"
https://pharos.nih.gov/idg/targets/O43318,O43318,12372426,"The TAK1-TAB1 fusion protein is a novel constitutively active mitogen-activated protein kinase kinase kinase that stimulates AP-1 and NF-kappaB signaling pathways"
https://pharos.nih.gov/idg/targets/O43318,O43318,12296995,"TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-kappaB."
https://pharos.nih.gov/idg/targets/O43318,O43318,12242293,"Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol."
https://pharos.nih.gov/idg/targets/O43318,O43318,2648522,"HIV-1 (NL43) Vpr S79A mutant, which no longer binds TAK1, demonstrates impaired ability to trigger TNF-alpha secretion from MT4C5 cells suggesting TAK1/Vpr interaction enhances TNF secretion from HIV-1 infected cells"
https://pharos.nih.gov/idg/targets/O43283,O43283,28641113,"LZK cooperates with DLK to promote retinal ganglion cell death in response to axon injury."
https://pharos.nih.gov/idg/targets/O43283,O43283,26918941,"Data indicate that miR-206's effect on Myc was mediated through MAP3K13."
https://pharos.nih.gov/idg/targets/O43283,O43283,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43283,O43283,12186766,"Chromosomal localization studies involving FISH mapping demonstrated that the human LZK gene is located at 3q27."
https://pharos.nih.gov/idg/targets/O43353,O43353,28545134,"RIP2 kinase auto-phosphorylation is intimately coupled to dimerization."
https://pharos.nih.gov/idg/targets/O43353,O43353,28114344,"study provides structural and dynamic insights into the NOD1-RIP2 oligomer formation, which will be crucial in understanding the molecular basis of NOD1-mediated CARD-CARD interaction in higher and lower eukaryotes"
https://pharos.nih.gov/idg/targets/O43353,O43353,27939575,"Data indicate that receptor-interacting protein 2 (Rip2) polymorphisms are associated with increased risk of subclinical atherosclerosis (SA) and with some clinical and metabolic parameters."
https://pharos.nih.gov/idg/targets/O43353,O43353,27830463,"this study reveals that LRRK2 is a new positive regulator of Rip2 and promotes inflammatory cytokine induction through the Nod1/2-Rip2 pathway."
https://pharos.nih.gov/idg/targets/O43353,O43353,27651416,"Together, the data demonstrate that the NOD2-RIP2 pathway is activated in murine and human visceral leishmaniasis and plays a role in shaping adaptive immunity toward a Th1 profile."
https://pharos.nih.gov/idg/targets/O43353,O43353,27122187,"a new function of PAX5 in regulating RIP1 and RIP2 activation, which is at least involved in chemotherapeutic drug resistance in B-lymphoproliferative disorders, is reported."
https://pharos.nih.gov/idg/targets/O43353,O43353,26646181,"RIP2 and RhoGDI bind to p75(NTR) death domain at partially overlapping epitopes with over 100-fold difference in affinity, revealing the mechanism by which RIP2 recruitment displaces RhoGDI upon ligand binding."
https://pharos.nih.gov/idg/targets/O43353,O43353,26466644,"Barettin has inhibitory activity against two protein kinases related to inflammation, namely the receptor-interacting serine/threonine kinase 2 (RIPK2) and calcium/calmodulin-dependent protein kinase 1alpha (CAMK1alpha)."
https://pharos.nih.gov/idg/targets/O43353,O43353,26463597,"up-regulated in failing hearts"
https://pharos.nih.gov/idg/targets/O43353,O43353,26297639,"RIPK1 and RIPK2 are targets of HIV-1 Protease activity during infection, and their inactivation may contribute to modulation of cell death and host defense pathways by HIV-1"
https://pharos.nih.gov/idg/targets/O43353,O43353,26297639,"HIV-1 PR (WT, not D25N) cleaves over-expressed RIPK2 with high specificity and this cleavage is prevent by addition of Saquinavir (protease inhibitor)"
https://pharos.nih.gov/idg/targets/O43353,O43353,26130752,"that Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia"
https://pharos.nih.gov/idg/targets/O43353,O43353,26040030,"Changes in the expression levels of IRS1, IRS2, RIPK2, RSPO1, and DNA JC15 genes might contribute to the development of insulin resistance and glucose intolerance in the obese boys."
https://pharos.nih.gov/idg/targets/O43353,O43353,25374171,"RIP2 protein, human is involved in human colon tumorigenesis and could be a predictive marker for colon carcinoma progression"
https://pharos.nih.gov/idg/targets/O43353,O43353,24958724,"the NOD1-RIP2 signaling axis is more complex than previously assumed, that simple engagement of RIP2 is insufficient to mediate signaling"
https://pharos.nih.gov/idg/targets/O43353,O43353,24746552,"NOD1 and RIP2 interact with bacterial peptidoglycan on endosomes to promote autophagy and inflammatory signaling."
https://pharos.nih.gov/idg/targets/O43353,O43353,24670424,"NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6."
https://pharos.nih.gov/idg/targets/O43353,O43353,24658576,"Receptor interacting protein-2 plays a critical role in human lung epithelial cells survival in response to Fas-induced cell-death."
https://pharos.nih.gov/idg/targets/O43353,O43353,24642040,"Data indicate that receptor-interacting protein kinase 2 (RIP2) is an activator of the NF-kappa B and c-Jun N-terminal kinase pathways."
https://pharos.nih.gov/idg/targets/O43353,O43353,24366254,"The Nod1/2-Rip2 axis was critical to induce optimal cytokine and chemokine responses to A. baumannii infection."
https://pharos.nih.gov/idg/targets/O43353,O43353,24015287,"LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations."
https://pharos.nih.gov/idg/targets/O43353,O43353,23892723,"Our findings identify RIP2 as a substrate for Pellino3 and Pellino3 as an important mediator in the Nod2 pathway and regulator of intestinal inflammation."
https://pharos.nih.gov/idg/targets/O43353,O43353,23333941,"In an attempt to explore TRAF3 binding partners that may be involved in TRAF3-regulated signaling, a yeast two-hybrid screen of a human spleen cDNA library was undertaken. RIP2 was identified as a TRAF3 binding partner."
https://pharos.nih.gov/idg/targets/O43353,O43353,23300079,"Data suggest that ubiquitin (Ub) binding provides a negative feedback loop upon NOD1 and NOD2 (nucleotide-binding oligomerization domain-containing proteins)-dependent activation of receptor-interacting protein kinase 2 (RIP2)."
https://pharos.nih.gov/idg/targets/O43353,O43353,22993319,"RIPK2 might play an important role in hepatic cell migration. These findings could shed new light on carcinogenesis and on liver regeneration."
https://pharos.nih.gov/idg/targets/O43353,O43353,22828789,"regulates reduced prostaglandin E2 production in chronic periodontitis"
https://pharos.nih.gov/idg/targets/O43353,O43353,22815893,"inositol phosphatase SHIP-1 inhibits NOD2-induced NF-kappaB activation by disturbing the interaction of XIAP with RIP2"
https://pharos.nih.gov/idg/targets/O43353,O43353,22685397,"we demonstrate that Porphyromonas gingivalis infection of human aortic endothelial cells resulted in the rapid cleavage of RIPK1 and RIPK2"
https://pharos.nih.gov/idg/targets/O43353,O43353,22665475,"RIP2 tyrosine kinase activity is not only required for NOD2-dependent autophagy but plays a dual role in this process."
https://pharos.nih.gov/idg/targets/O43353,O43353,22615316,"These findings mechanisms whereby HBeAg modulates intracellular signaling pathways by targeting RIPK2, supporting the concept that HBeAg could impair both innate and adaptive immune responses to promote chronic HBV infection."
https://pharos.nih.gov/idg/targets/O43353,O43353,22504414,"Association has been found between RIPK2 (rs42490) and cancer risk."
https://pharos.nih.gov/idg/targets/O43353,O43353,22484241,"IL-4 failed to up-regulate expression of RP105 at the cell surface. In conclusion, the anti-inflammatory actions of IL-4 occur independently of IL-10, RP105, and the kinase activity of RIPK2"
https://pharos.nih.gov/idg/targets/O43353,O43353,22075569,"RIP2 gene polymorphisms may be associated with susceptibility to systemic lupus erythematosus in the Chinese population."
https://pharos.nih.gov/idg/targets/O43353,O43353,21887730,"GEF-H1 mediated the activation of Rip2 during signaling by NOD2, but not in the presence of the 3020insC variant of NOD2 associated with Crohn's disease. GEF-H1 functioned downstream of NOD2 as part of Rip2-containing signaling complexes."
https://pharos.nih.gov/idg/targets/O43353,O43353,21862576,"the CARD of procaspase-1 is differently involved in the formation of procaspase-1 activating platforms and procaspase-1-mediated, RIP2-dependent NF-kappaB activation."
https://pharos.nih.gov/idg/targets/O43353,O43353,21757725,"Tri-DAP interacts directly with the LRR domain of NOD1 and consequently increases RICK/NOD1 association and RICK phosphorylation activity"
https://pharos.nih.gov/idg/targets/O43353,O43353,21123652,"RIP2 undergoes autophosphorylation on Tyr 474 and this event is necessary for effective NOD2 signaling"
https://pharos.nih.gov/idg/targets/O43353,O43353,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,20800603,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,20645315,"RIP2 polymorphisms are not associated with inflammatory bowel diseases."
https://pharos.nih.gov/idg/targets/O43353,O43353,20025869,"Data suggest that inhibition of rip2 upregulation after wounding might contribute to the reduced and delayed wound re-epithelialization phenotype seen in glucocorticoid-treated patients."
https://pharos.nih.gov/idg/targets/O43353,O43353,20018961,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,19911254,"MS80 inhibits CD40-NF-kappaB pathway via targeting RIP2."
https://pharos.nih.gov/idg/targets/O43353,O43353,19773279,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,19721713,"the NOD2/RIP2 pathway has a role in recognition of Yersinia, but caspase-12 does not modulate innate host defense against Y. pestis"
https://pharos.nih.gov/idg/targets/O43353,O43353,19693652,"Elevated RIP-2 protein levels promote NF-kappaB function via interaction with IKK gamma"
https://pharos.nih.gov/idg/targets/O43353,O43353,19667203,"Data suggest a role for XIAP in regulating innate immune responses by interacting with NOD1 and NOD2 through interaction with RIP2."
https://pharos.nih.gov/idg/targets/O43353,O43353,19573080,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,19406482,"detected on all female reproductive tract tissues"
https://pharos.nih.gov/idg/targets/O43353,O43353,19336552,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43353,O43353,19121870,"alternative mRNA splicing may be involved in the regulation of RIP2 actions, underlying the complexity of RIP2-dependent pathways regulating stress signaling and apoptosis."
https://pharos.nih.gov/idg/targets/O43353,O43353,18566542,"upregulation of RIP2 expression is required for rapid resolution of peritonitis"
https://pharos.nih.gov/idg/targets/O43353,O43353,18426885,"We conclude that the endogenous IL-8 response induced by C. trachomatis infection is dependent upon NOD1 signaling through RIP2 as part of a signal system requiring multiple inputs for optimal IL-8 induction."
https://pharos.nih.gov/idg/targets/O43353,O43353,18359207,"The encapsulation efficiency of RIPK2 is reported."
https://pharos.nih.gov/idg/targets/O43353,O43353,18079694,"Data show that RICK polyubiquitination links TAK1 to IKK complexes, a critical step in Nod1/Nod2-mediated NF-kappaB activation."
https://pharos.nih.gov/idg/targets/O43353,O43353,17851464,"RIPK2 is a marker for resolution of peritoneal dialysis-associated peritonitis."
https://pharos.nih.gov/idg/targets/O43353,O43353,17355968,"NOD2 is responsible for the membrane recruitment of RICK to induce a regulated NF-kappaB signaling and production of proinflammatory cytokines."
https://pharos.nih.gov/idg/targets/O43353,O43353,17075290,"Although polymorphisms in RIP2 are not likely to be associated with the development of asthma, the genetic variants might contribute to asthma severity in the Japanese population"
https://pharos.nih.gov/idg/targets/O43353,O43353,17054981,"mutational analysis shows that interaction of NOD1 with RICK is critically dependent on 3 acidic residues on NOD1 CARD & 3 basic residues on RICK CARD & is likely to have a strong electrostatic component"
https://pharos.nih.gov/idg/targets/O43353,O43353,16920334,"Cop inhibition of cell death, at least to a certain extent, results from its interference with the activation of caspase-1 and caspase-4."
https://pharos.nih.gov/idg/targets/O43353,O43353,16824733,"Results indicate that S176 is a regulatory autophosphorylation site for RIP2 and that S176 phosphorylation can be used to monitor the activation state of RIP2."
https://pharos.nih.gov/idg/targets/O43353,O43353,16582588,"review of the regulation of interactions of CARD6 with RICK and microtubules [review]"
https://pharos.nih.gov/idg/targets/O43353,O43353,16492792,"NOD2-S interacts with both, NOD2 and receptor-interacting protein kinase 2 and inhibits the \"nodosome\" assembly by interfering with the oligomerization of NOD2"
https://pharos.nih.gov/idg/targets/O43353,O43353,16418290,"CARD6 is a regulator of NF-kappaB activation that modulates the functions of RICK protein"
https://pharos.nih.gov/idg/targets/O43353,O43353,16354923,"Caspase-1-mediated cell death is regulated, at least in part, by the balance of Rip2 and Cop; alterations of this balance may contribute to aberrant caspase-1-mediated pathogenesis in Huntington's disease."
https://pharos.nih.gov/idg/targets/O43353,O43353,15620648,"NOD2-dependent ubiquitinylation of NEMO (a key component of the NF-kB signaling complex) is dependent on the scaffolding protein kinase RIP2."
https://pharos.nih.gov/idg/targets/O43353,O43353,14638696,"Rip2 has an important role in TCR-induced NF-kappaB activation and T-cell function"
https://pharos.nih.gov/idg/targets/O43353,O43353,12775719,"role in CARD6 modulation of NF-kappa B activation"
https://pharos.nih.gov/idg/targets/O43353,O43353,12755636,"equilibrium and kinetic folding of a unique protein domain, caspase recruitment domain (CARD), of the RIP-like interacting CLARP kinase (RICK) (RICK-CARD), which adopts a alpha-helical Greek key fold"
https://pharos.nih.gov/idg/targets/O43353,O43353,12138198,"These results implicate RIP2 in a previously unrecognized role: a checkpoint for myogenic proliferation and differentiation."
https://pharos.nih.gov/idg/targets/O43353,O43353,11894098,"Rip2 transduces signals from both innate and adaptive immune responses. Functions downstream of the TLR2/3/4, IL-1 and IL-18 receptors."
https://pharos.nih.gov/idg/targets/O43353,O43353,11894097,"Involvement of receptor-interacting protein 2 in innate and adaptive immune responses"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,28412393,"adhesion-induced eosinophil cytolysis takes place through RIPK3-MLKL-dependent necroptosis, which can be counterregulated by autophagy"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27984090,"The results highlight a new role of TSC2 in protecting glioblastoma against photodynamic therapy-induced cell death, and TSC2 and YWHAZ as new RIP3 partners."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27756058,"results reveal a pathway for MLKL-dependent programmed necrosis that is executed in the absence of RIPK3 and potentially drives the pathogenesis of severe liver diseases."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27748372,"inactivation of RIP1/RIP3 resulted in reduction of SOCS1 protein levels and partial differentiation of AML cells. AML cells with inactivated RIP1/RIP3 signaling show increased sensitivity to IFN-gamma-induced differentiation."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27411587,"Results demonstrate that RIPK3 restricts malignant myeloproliferation by activating the inflammasome, which promotes differentiation and cell death, and that loss of RIPK3 increases leukemic burden in mice. Reduced RIPK3 expression is observed across several human acute myeloid leukemia subtypes."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27411587,"Data identify RIPK3 and the inflammasome as key tumor suppressors in acute myeloid leukemia (AML)."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,27362805,"Renal clear cell carcinoma cells cells express increased amounts of RIPK1 and RIPK3 and are poised to undergo necroptosis in response to TNFR1 signaling."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26900751,"CHIP is a bona fide negative regulator of the RIPK1-RIPK3 necrosome formation leading to desensitization of TNF-mediated necroptosis"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26865533,"Necroptosis signaling is modulated by the kinase RIPK1 and requires the kinase RIPK3 and the pseudokinase MLKL. (Review)"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26769846,"Results suggest that impaired hepatic proteasome function by alcohol exposure may contribute to hepatic accumulation of RIP3 resulting in necroptosis and steatosis while RIP1 kinase activity is important for alcohol-induced inflammation."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26749282,"The expression level of RIP3K was significantly lower in the malignant tumors."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26496737,"The main route of cell death induced by shikonin is RIP1K-RIP3K-mediated necroptosis."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26437789,"CNOT3 suppression promotes necroptosis by stabilizing mRNAs for cell death-inducing proteins, Ripk1 and Ripk3."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26381214,"Results identify a crucial role for RIPK3-PGAM5-Drp1/NFAT signalling in NKT cell activation, and further suggest that RIPK3-PGAM5 signalling may mediate crosstalk between mitochondrial function and immune signalling."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26355347,"RIPK3 expression may allow unmasking the necroptotic signalling machinery in melanoma and points to reactivation of this pathway as a treatment option for metastatic melanoma."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,26269957,"Additionally, later in infection, RIP3 is cleaved by the coxsackievirus B3-encoded cysteine protease 3C(pro), which serves to abrogate RIP3-mediated necrotic signaling and induce a nonnecrotic form of cell death."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25952668,"The RIP3 expression is reduced in tumors compared to normal tissue in 85% of breast cancer patients, suggesting that RIP3 deficiency is positively selected during tumor growth/development."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25906154,"Data implicate the infiltrating macrophages as a source of damaging inflammasomes after photoreceptor detachment in a RIP3-dependent manner and suggest a novel therapeutic target for treatment of retinal diseases."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25888634,"PolyIC stimulation of cervical cancer cells induced necroptotic cell death, which was strictly dependent on the expression of the receptor-interacting protein kinase RIPK3."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25852146,"RIP3 activation following the induction of necroptosis requires the activity of an HSP90 and CDC37 cochaperone complex."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25778401,"Suppression of RIP3-dependent necroptosis by human cytomegalovirus"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25748555,"High expression of RIP3 in keratinocytes from toxic epidermal necrolysis patients potentiates MLKL phosphorylation/activation and necrotic cell death."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25674983,"Herpes simplex virus 1- and 2 ICP6 and ICP10 proteins prevent necroptosis in human cells by inhibiting the interaction between receptor-interacting protein kinase 1 (RIP1) and RIP3, a key step in tumor necrosis factor (TNF)-induced necroptosis."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25575821,"Data suggest that neoalbaconol-induced necroptosis include receptor interacting serine/threonine kinase 1-dependent expression of tumor necrosis factor alpha and receptor interacting serine/threonine kinase 3-dependent generation of reactive oxygen species."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25563840,"Enhanced RIP3 signaling in aneurysmal tissues contributes to abdominal aortic aneursym progression by causing smooth muscle cell necroptosis, as well as stimulating vascular inflammation."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25459880,"RIP3 holds both necroptosis and apoptosis in balance through a Ripoptosome-like platform."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25450619,"RIPK3 serves as a negative regulator of selective autophagy by regulating regulates p62-LC3 complex formation via the caspase-8-dependent cleavage of p62"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25423287,"although JNK activation and RIP3 expression are induced by FS, neither contributes to the liver injury."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25326752,"our results reveal a specific role for the RIP1-RIP3-DRP1 pathway in RNA virus-induced activation of the NLRP3 inflammasome"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,25144719,"RIP3 silencing in leukemia cells results in suppression of the complex regulation of the apoptosis/necroptosis switch and NF-kappaB activity."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24963148,"RIP3-dependent necroptosis mediates non-alcoholic steatohepatitis-induced liver fibrosis via activation of JNK, MCP-1-mediated recruitment of monocytes, and an expansion of intrahepatic biliary/progenitor cells."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24746856,"The results of this study showed that cerebral ischemia activates transcriptional changes that lead to an increase in the endogenous RIP3 protein level."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24703947,"Report role of MLKL/RIP3 pathway in necrotic membrane disruption."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24413151,"targeting the RIP kinase signalling pathway could be an effective therapeutic intervention in retinal degeneration patients."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24322838,"RIP3 protein expression is significantly increased in the inflamed tissue of inflammatory boowel disease pediatric patients."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24314238,"The protein levels of crucial modulators of necroptosis, RIP1 and RIP3, are increased by shikonin treatment in primary tumor tissues."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24095729,"RIP3-mediated MLKL phosphorylation, though important for downstream signaling, is dispensable for stable complex formation between RIP3 and MLKL."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,24059293,"an alanine residue substitution for Ser(89) enhanced RIP1 kinase activity and TNF-induced programmed necrosis without affecting RIP1-RIP3 necrosome formation."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,23612963,"the importance of the RIP3-MLKL interaction in the formation of functional necrosomes and suggest that translocation of necrosomes to mitochondria-associated membranes is essential for necroptosis signaling."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,23071110,"procaspase-8 activity is essential for cell survival by inhibiting both apoptotic and nonapoptotic cell death dependent on receptor-interacting protein kinase 1 (RIP1) and RIP3"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,22817896,"Study shows that RIP1 and RIP3 form an amyloid structure through their RIP homotypic interaction motifs and that this heterodimeric amyloid structure is a functional signaling complex that mediates programmed necrosis."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,22421439,"study suggests that MLKL is a key RIP3 downstream component of TNF-induced necrotic cell death"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,21894190,"FADD: an endogenous inhibitor of RIP3-driven regulated necrosis"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,21153365,"RIP3 is an essential inducer of TNF-induced programmed necrosis"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,20354226,"RIP1 and RIP3 have roles in TNF-induced necrosis"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,19690434,"Gene expression of RIPK3 and RNF216 in PBMC could identify those obese subjects, who will regain more weight after a successful initial weight loss. The mRNA levels of these genes could be nutrigenomic biomarkers for predicting obesity treatment outcome."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,19524512,"The expression of RIP3 in different cell lines correlates with their responsiveness to necrosis induction."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,18533105,"NLS of RIPK3 exhibits several other roles besides apoptotic function."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,18025550,"analysis of human receptor-interacting protein 3 truncation expressed in Escherichia coli"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,17827388,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,17114179,"the nuclear factor-kappaB signaling pathway is inhibed by gamma-tocopherol through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,16844082,"tRIP3 may function upstream of Fas (TNFRSF6)-associated via death domain to induce apoptosis in TNFR-1 signaling pathway"
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,16429275,"Evidence is found for an association between overexpression of RIP3 and homocysteine-induced congenital cardiovascular malformations."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,15896315,"Real-time PCR analysis reveals that the ratio of RIP3 gamma to RIP3 is significantly increased in colon and lung cancers relative to their matched normal tissues, indicating that RIP3 gamma might be a splice form associated with tumorigenesis."
https://pharos.nih.gov/idg/targets/Q9Y572,Q9Y572,15208320,"RIP3 acts a nucleocytoplasmic shuttling protein with nuclear export and import signals"
https://pharos.nih.gov/idg/targets/P53671,P53671,28818508,"High LIMK2 expression is associated with alcoholic hepatitis."
https://pharos.nih.gov/idg/targets/P53671,P53671,28069000,"these results suggested that TUG1 mediates cell growth and chemoresistance of SCLC by regulating LIMK2b via EZH2."
https://pharos.nih.gov/idg/targets/P53671,P53671,27116935,"In turn, LIMK1 and LIMK2 are required for MT1-MMP-dependent matrix degradation and cell invasion in a three-dimensional type I collagen environment."
https://pharos.nih.gov/idg/targets/P53671,P53671,26956845,"We observed marked increases in LIM kinase 2 (LIMK2) and cofilin 1 (CFL1) gene expressions in metabolic syndrome patients."
https://pharos.nih.gov/idg/targets/P53671,P53671,26662719,"LIMK2 (rs149034313) is associated with Behcet's disease. The LIMK2 association is a missense variant with predicted protein damage that may influence functional interactions with proteins involved in cytoskeletal regulation by Rho GTPase, inflammation mediated by chemokine and cytokine signaling pathways, T cell activation, and angiogenesis."
https://pharos.nih.gov/idg/targets/P53671,P53671,25981171,"This study showed that LIMK2 messenger RNA levels was significantly upregulated in subjects with schizophrenia in laminar and cellular samples."
https://pharos.nih.gov/idg/targets/P53671,P53671,25849865,"Actin remodelling factor LIMK2 is a key player in the ciliogenesis control network in which YAP/TAZ and directional vesicle trafficking are integral components."
https://pharos.nih.gov/idg/targets/P53671,P53671,25344584,"Results show that in addition to a potential role in promoting metastasis, changes in LIMK1 and LIMK2 expression and/or activity might contribute to AR function in prostate cancer via regulation of microtubule cytoskeletal dynamics."
https://pharos.nih.gov/idg/targets/P53671,P53671,23991158,"results highlight the exciting possibility of combining specific LIMK2 inhibitors with anticancer drugs in the treatment of multi-drug resistant cancers"
https://pharos.nih.gov/idg/targets/P53671,P53671,23585469,"LIMK2 expression was reduced in intestinal tumours of cancer-prone mice and in human colorectal cancer cell lines and tumours. LIMK2 expression progressively decreased with advancing stage of colorectal cancer."
https://pharos.nih.gov/idg/targets/P53671,P53671,23239465,"Overexpression of LIMK2 is associated with breast cancer growth and invasiveness."
https://pharos.nih.gov/idg/targets/P53671,P53671,23082153,"Nf1/LIMK2 interaction and inhibition allows to directly connect neurofibromatosis type I to actin cytoskeleton remodeling."
https://pharos.nih.gov/idg/targets/P53671,P53671,22883572,"A novel activity of Rho in promoting a complex between fascin-1 and LIMK1/2 that modulates the interaction of fascin-1 with actin, was identified."
https://pharos.nih.gov/idg/targets/P53671,P53671,22492986,"LIMK2 positively regulates the level of Aurora A, thereby engaging in a positive-feedback loop, promoting Aurora-A-mediated oncogenic pathways."
https://pharos.nih.gov/idg/targets/P53671,P53671,22328514,"LIMK2 is a key regulator that acts through different substrates to provide functional links between the actin cytoskeleton and spindle dynamics."
https://pharos.nih.gov/idg/targets/P53671,P53671,21321123,"Filamin-A-dependent activation of the RhoA-ROCK-LIMK-cofilin pathway is a major event in HIV-1 gp120-induced receptor clustering"
https://pharos.nih.gov/idg/targets/P53671,P53671,21079653,"LIMK2 variant isoforms were found to be regulated by p53 through direct interaction with regulatory elements within the LIMK2 gene."
https://pharos.nih.gov/idg/targets/P53671,P53671,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53671,P53671,20190821,"a novel pathway whereby LIMK2b, acting downstream of p53, ensures proper execution of checkpoint arrest by modulating the dynamics of actin polymerization"
https://pharos.nih.gov/idg/targets/P53671,P53671,20047470,"Both LIMK1 and LIMK2 single knock down led to a reduction of invasion and metastatic behavior in the zebrafish xenograft metastasis assay."
https://pharos.nih.gov/idg/targets/P53671,P53671,20041213,"Filamin-A-dependent activation of the RhoA-ROCK-LIMK-cofilin pathway is a major event in HIV-1 gp120-induced receptor clustering"
https://pharos.nih.gov/idg/targets/P53671,P53671,19369647,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53671,P53671,18854154,"Knockdown of LIM domain kinase 2 (LIMK2) by siRNA inhibits the early stages of HIV-1 replication in 293T cells infected with VSV-G pseudotyped HIV-1"
https://pharos.nih.gov/idg/targets/P53671,P53671,18852895,"direct interaction between ROCK1 and LIMK2 in polarised but not blebbing cells; results point to a specific role for the ROCK1:LIMK2 pathway in mesenchymal-mode migration"
https://pharos.nih.gov/idg/targets/P53671,P53671,18000399,"gamma-tubulin associates with phosphorylated LIMK1 and LIMK2 but not with dephosphorylated LIMK1 or LIMK2."
https://pharos.nih.gov/idg/targets/P53671,P53671,17572668,"Filamin-A-dependent activation of the RhoA-ROCK-LIMK-cofilin pathway is a major event in HIV-1 gp120-induced receptor clustering"
https://pharos.nih.gov/idg/targets/P53671,P53671,17294230,"the structure, regulation and function; possible contributions to human disease (Review)"
https://pharos.nih.gov/idg/targets/P53671,P53671,16820362,"analysis of phosphorylation-dependent regulation of unique nuclear and nucleolar localization signals of LIM kinase 2 in endothelial cells"
https://pharos.nih.gov/idg/targets/P53671,P53671,16455074,"LIMK2 may play a role different from that of LIMK1 in regulating mitotic spindle organization, chromosome segregation, and cytokinesis during the cell division cycle."
https://pharos.nih.gov/idg/targets/P53671,P53671,15923181,"PKC-mediated exclusion of LIMK2 from the nucleus might be a mechanism to relieve suppression of cyclin D1 expression by LIMK2"
https://pharos.nih.gov/idg/targets/P53671,P53671,15647284,"a novel pathway emanating from the TGF-beta type I receptor and leading to regulation of actin assembly, via the kinase LIMK2."
https://pharos.nih.gov/idg/targets/O43187,O43187,26250868,"IRAK2 L392V showed intact binding to, but impaired ubiquitination of, tumor necrosis factor receptor-associated factor 6, a vital step in signal transduction"
https://pharos.nih.gov/idg/targets/O43187,O43187,25063738,"Human miR-373 is silenced by histone modification in lung cancer cells and is a negative regulator of the mesenchymal phenotype through downstream IRAK2 and LAMP1 target genes."
https://pharos.nih.gov/idg/targets/O43187,O43187,24973222,"This for the first time implicates human IRAK2 in a human disease and highlights the R214G IRAK2 variant as a potential novel and broadly applicable biomarker for disease or as a therapeutic intervention point."
https://pharos.nih.gov/idg/targets/O43187,O43187,24662294,"Results suggest that D431E-IRAK2 (interleukin-1 receptor-associated kinase-2) increases NF-kappaB activation by promoting TRAF6 ubiquitination by enhancing TNF Receptor-Associated Factor 6 (TRAF6)-IRAK2 interaction."
https://pharos.nih.gov/idg/targets/O43187,O43187,24162774,"HIV-1 gp120 upregulates the expression of interleukin-1 receptor-associated kinase 2 (IRAK2) in human B cells"
https://pharos.nih.gov/idg/targets/O43187,O43187,23724040,"These findings demonstrate an unexpected linkage of the innate immunity machinery to unfolded protein response signaling, revealing IRAK2 as a novel amplifier of the IRE1 pathway."
https://pharos.nih.gov/idg/targets/O43187,O43187,21606490,"Human interleukin-1 receptor-associated kinase-2 is essential for Toll-like receptor-mediated transcriptional and post-transcriptional regulation of tumor necrosis factor alpha."
https://pharos.nih.gov/idg/targets/O43187,O43187,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20937840,"analysis of differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease"
https://pharos.nih.gov/idg/targets/O43187,O43187,20800603,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20485341,"the crystal structure of the MyD88-IRAK4-IRAK2 death domain (DD) complex, which surprisingly reveals a left-handed helical oligomer that consists of 6 MyD88, 4 IRAK4 and 4 IRAK2 DDs"
https://pharos.nih.gov/idg/targets/O43187,O43187,20438785,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20406964,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20332216,"Our data show that interleukin-1R-associated kinase 2 is a novel and critical component of TGFbeta signaling."
https://pharos.nih.gov/idg/targets/O43187,O43187,20200953,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,20056178,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,19423540,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,19240061,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/O43187,O43187,18996842,"TRAF6 and interleukin receptor-associated kinase 2 are novel binding partners for PS1, and IL-1R1 is a new substrate for presenilin-dependent gamma-secretase cleavage"
https://pharos.nih.gov/idg/targets/O43187,O43187,17878161,"IRAK-2 plays a more central role than IRAK-1 in TLR signaling to NFkappaB through TRAF6 ubiquitination"
https://pharos.nih.gov/idg/targets/O43187,O43187,15670593,"CTCF plays a major role in IRAK2 transcription; EMSA revealed a CTCF-binding site within the mouse Irak2 promoter"
https://pharos.nih.gov/idg/targets/P15056,P15056,29310328,"Of these 6 patients, 3 had a BRAF mutation positive primary with a BRAF mutation negative metastatic lesion, while the other 3 had a BRAF mutation negative primary with BRAF mutation positive metastasis.There is an important discordance rate in the BRAF mutation status of melanoma primaries versus brain metastases."
https://pharos.nih.gov/idg/targets/P15056,P15056,29187493,"Data indicate that BRAF, NRAS and C-KIT melanomas constitute distinct clinico-pathological entities."
https://pharos.nih.gov/idg/targets/P15056,P15056,29175303,"Tumor cell content was not associated with mutational rate for EGFR, BRAF and HER2 mutations. DNA quantity was not associated with mutational rate for EGFR, KRAS, BRAF and HER2"
https://pharos.nih.gov/idg/targets/P15056,P15056,29162506,"This study is the first to describe the BRAF (L597Q) mutation in malignant peripheral nerve sheath tumors and the first to implicate a BRAF mutation in neurofibroma biology"
https://pharos.nih.gov/idg/targets/P15056,P15056,29059311,"Adenocarcinomas or adenomas derived from pigmented ciliary epithelium is distinguished from uveal melanoma by the absence of SOX10 expression and presence of the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,29037127,"BRAF mutations were not associated with an elevated risk for distant metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,28972961,"Although BRAF(non-V600E) mutations identified were a rare and unestablished molecular subtype, certain BRAF(non-V600E) mutations might contribute to a lesser benefit of anti-EGFR monoclonal antibody treatment in patients with metastatic colorectal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,28953955,"somatic KRAS mutations in polyps represent a potential molecular marker for the risk of developing advanced neoplasia"
https://pharos.nih.gov/idg/targets/P15056,P15056,28947418,"KIT knockdown increased RAS/MAPK pathway activation in a BRAF(V600E)-mutant melanoma cell line."
https://pharos.nih.gov/idg/targets/P15056,P15056,28877062,"Findings of recurrent BRAF gene rearrangements in spindle cell sarcomas showing morphologic overlap with infantile fibrosarcomas expand the genetic spectrum of fusion-positive spindle cell sarcomas, to include unusual presentations, such as older children and adolescents and predilection for axial location."
https://pharos.nih.gov/idg/targets/P15056,P15056,28862766,"This study demonstrates that idiopathic pulmonary fibrosis-associated lung cancer (IPF-LC) is genetically characterized by the presence of somatic mutations reflecting a variety of environmental exposures on the background of specific germline mutations, and is associated with potentially targetable alterations such as BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,28842324,"MC1R genotype is associated with patient phenotypes with BRAF and NRAS mutations in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,28834810,"BRAF V600E mutation was detected in 6% of glomus tumors, all of which were malignant or glomus tumors of uncertain malignant potential. This mutation may be associated with a malignant phenotype."
https://pharos.nih.gov/idg/targets/P15056,P15056,28822769,"BRAF mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28810144,"Mutation in BRAF gene is associated with Pancreatic Ductal Adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28787433,"BRAF mutation was found to be associated with lymph node metastasis as first metastasis and sentinel lymph node positivity. BRAF and NRAS mutations were associated with CNS and liver metastasis and NRAS mutation with lung metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,28775171,"Case Reports: two cases of gliosarcoma harbouring the BRAF V600E mutation, of which one case appears to have arisen de novo, while the other likely arose from ganglioglioma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28753606,"Short-term treatment of nascent melanoma tumors with PAK inhibitors that block RhoJ signaling halts the growth of BRAF mutant melanoma tumors in vivo and induces apoptosis in melanoma cells in vitro via a BAD-dependent mechanism. As up to 50% of BRAF mutant human melanomas express high levels of RhoJ, these studies nominate the RhoJ-BAD signaling network as a therapeutic vulnerability for fledgling BRAF mutant human tumor"
https://pharos.nih.gov/idg/targets/P15056,P15056,28743501,"Hypoxic postconditioning attenuates apoptosis via inactivation of adenosine A2a receptor through NDRG3-Raf-ERK pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,28727518,"Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001)."
https://pharos.nih.gov/idg/targets/P15056,P15056,28692601,"BRAF rearrangements were only found in myxoinflammatory fibroblastic sarcomas but not in hemosiderotic fibrolipomatous tumor lacking TGFBR3-MGEA5 fusions."
https://pharos.nih.gov/idg/targets/P15056,P15056,28662062,"findings should encourage the genetic evaluation of BRAF mutation. This study highlights the potential of RCM as a supplementary tool in the screening of BRAF-mutated melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,28650561,"we describe patients with craniosynostosis and Noonan syndrome due to de novo mutations in PTPN11 and patients with craniosynostosis and CFC syndrome due to de novo mutations in BRAF or KRAS. All of these patients had cranial deformities in addition to the typical phenotypes of CFC syndrome and Noonan syndrome."
https://pharos.nih.gov/idg/targets/P15056,P15056,28623774,"We found a clinically meaningful discrepancy rate in BRAF status both between primary-metastatic and metastatic-metastatic melanoma lesions."
https://pharos.nih.gov/idg/targets/P15056,P15056,28595259,"Our data show that Signet ring cell colorectal cancer (SRCCa) phenotype comprises two distinct genotypes. The MSI(+)/CIMP(+)/BRAF V600E(+)/CD3(+)/PDL1(+) hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can potentially be targeted by KIT inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,28576751,"Bromodomain and extra-terminal (BET) inhibitors can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,28561662,"Combination BRAF and MEK inhibition has also been shown to improve overall survival in patients with V600E-mutated melanoma. Responses to therapy are often rapid, and treatment is not associated with immune-related adverse events."
https://pharos.nih.gov/idg/targets/P15056,P15056,28504206,"Case Reports: pediatric intracranial and cranial juvenile xanthogranuloma with BRAF V600E mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,28488545,"ytoplasmic immunoexpression of BRAF V600E (VE1) protein was found in three specimens: serous superficial papilloma, serous papillary cystadenoma of borderline malignancy, and partially proliferative serous cystadenoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,28468827,"Data suggest that HMGCS1 (HMG-CoA synthase 1) signals through ketogenesis/acetoacetate to promote cell proliferation and BRAF(V600E)-dependent MEK1 activation in BRAF(V600E)-positive melanoma and colon cancer cells; HMGCS1 co-localizes with HMGCL (HMG-CoA lyase) and BRAF(V600E) in cytosol of melanoma and colon cancer cells. (BRAF = proto-oncogene protein B-raf)"
https://pharos.nih.gov/idg/targets/P15056,P15056,28463756,"The results show that BRAF mutations are associated with a worse prognosis than expected in patients treated with FOLFIRI protocol plus bevacizumab compared with the BRAF wild-type population."
https://pharos.nih.gov/idg/targets/P15056,P15056,28448514,"a new BRAF fusion in pilocytic astrocytoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,28424234,"the rate of BRAF mutation in Irish cohort (28.8%) was lower than international published rates of 40%-60%."
https://pharos.nih.gov/idg/targets/P15056,P15056,28423638,"Data show that combined therapy using HER2 inhibitor and BRAF/MEK inhibitor presented more significant redifferentiation effect on papillary thyroid cancer cells harboring BRAFV600E than BRAF/MEK inhibitor alone."
https://pharos.nih.gov/idg/targets/P15056,P15056,28423545,"BRAF mutation is associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28404629,"functional analysis of human BRaf disease-linked mutations identified BRaf as the key missing signaling effector in the common synaptic NMDA-R-CaMKII-SynGap-Ras-BRaf-MEK-ERK transduction cascade."
https://pharos.nih.gov/idg/targets/P15056,P15056,28393212,"these results suggest that SIRT6 enhances cell aggressiveness in PTC via BRAF/ERK/Mcl1 pathway, and thus may be a promising target in the treatment of the disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,28383426,"BRAFV600E mutation significantly associated with nonsmall cell lung cancer in females and nonsmokers [meta-analysis]"
https://pharos.nih.gov/idg/targets/P15056,P15056,28373167,"These findings identify a dynamic interplay between FZR1 and BRAF with strong implications for cell-fate determination and the tumor suppressor role of FZR1"
https://pharos.nih.gov/idg/targets/P15056,P15056,28342873,"These findings demonstrate that the BRAF V600E mutation down-regulates levels of HMGB1, likely through activation of the mitogen-activated protein kinase (MAPK) signaling pathways."
https://pharos.nih.gov/idg/targets/P15056,P15056,28323937,"BRAF mutations were present in 44.6% of primary papillary thyroid carcinomas, 41.7% of lymph node metastasis, and 23.8% of distant metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,28319896,"BRAF mutations in the genomic DNA extracted from cancer cell lines were tested, allowing sensitive detection of SNM at very low abundances"
https://pharos.nih.gov/idg/targets/P15056,P15056,28295004,"The patients with traditional serrated adenoma showed KRAS and BRAF mutations in 58.4 and 8.3% of cases, respectively. Mutations of these genes were absent.  The study revealed that the subtypes of serrated adenomas substantially differ by sex, age, localization, and molecular genetic characteristics"
https://pharos.nih.gov/idg/targets/P15056,P15056,28292959,"Data suggest that activation of the metalloproteinase ADAM10 by signal peptide peptidase-like 3 (SPPL3) triggered by mutant BRAF(V600E) was a critical transformation event."
https://pharos.nih.gov/idg/targets/P15056,P15056,28281325,"IRP2 expression was associated with mutations in BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,28268064,"BRAF mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28249840,"Mutations in KRAS, NRAS, and BRAF together occur in more than half of all colorectal cancer cases and are often associated with negative responses to the EGFR inhibitors cetuximab and panitumumab.guideline is clear that we should not be giving EGFR inhibitors to patients with RAS mutations and that patients with BRAF V600E mutations have a much worse prognosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,28234922,"Our purpose was the evaluation of microsatellite stability status within conventional colon adenomas and also b-catenin, BRAFV600E and p53 contribution.we noted a 10% frequency of MSI events where MSI-H reached a 5% share occurred within the left colon and rectal polyps. b-catenin nuclear overexpression was noted with a 70% frequency and p53 with close to a 24% frequency."
https://pharos.nih.gov/idg/targets/P15056,P15056,28220299,"BRAF V600E mutation is frequent in pulmonary Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,28214213,"The expression levels of BRAFV600E and NF-kappaB were significantly greater in thyroglobuiln antibody-positive than in thyroglobuiln antibody-negative papillary thyroid carcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,28179313,"Data suggest that genotyping for KRAS and BRAF mutation status is a gold standard for categorizing colorectal cancer (CRC) for clinical decisions."
https://pharos.nih.gov/idg/targets/P15056,P15056,28174173,"FZR1 inhibits BRAF oncogenic functions via both APC-dependent proteolysis and APC-independent disruption of BRAF dimers, whereas hyperactivated ERK and CDK4 reciprocally suppress APC(FZR1) E3 ligase activity"
https://pharos.nih.gov/idg/targets/P15056,P15056,28160058,"Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction in papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,28159677,"BRAF mutations are rare events in KIT/PDGFRA wild-type gastrointestinal stromal tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,28135039,"Study identified BRAF mutations in 1.7% of Chinese patients with non-small-cell lung cancer and seems associated with adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28134726,"NRAS and BRAF mutations are independent events and alternative molecular mechanisms in the primary oral mucosal melanoma tumorigenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,28125730,"Aspirin use after colon cancer diagnosis was associated with improved overall survival in wild-type BRAF tumors. In contrast, aspirin use in BRAF mutated tumors was not associated with an improved survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,28093501,"Thus, the quaternary structure of BRAF complexes is shaped by its activation status, the conformation of its kinase domain, and clinically relevant inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,28092667,"ZNF767-BRAF fusion is associated with mucosal melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,28091917,"Rare mutations in KRAS, NRAS, and BRAF oncogenes have been found in patients with melanoma and colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,28089569,"These findings reveal a signaling basis underlying a pathogenic role of dietary fat in BRAF V600E-expressing melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28074351,"review focuses on the genes, which are frequently mutated in various cancers and are known to be important in the advance and progression of colorectal cancer and melanoma, namely KRAS, NRAS and BRAF"
https://pharos.nih.gov/idg/targets/P15056,P15056,28067893,"Data show that the expression of Interleukin-8 (IL-8) and connective tissue growth factor (CTGF) was significantly reduced by treatment with vemurafenib and trametinib in (V600E)BRAF protein melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,28040692,"BRAF or KRAS mutations are independently associated with shorter time to recurrence, shorter survival after relapse, and overall survival in patients with microsatellite-stable (MSS) subgroups, but not microsatellite-unstable tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,28034324,"The expression of the nuclear and cytoplasmic forms of p16 represent two independent mechanisms, and both seemed to control proliferation in response to oncogenic stimuli, protecting the cell from malignant transformation in BRAF-mutated gastrointestinal stromal tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,28025078,"Report KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer may depend on tumor histology."
https://pharos.nih.gov/idg/targets/P15056,P15056,28006055,"Mutations in BRAFV600E were significantly associated with worse survival after recurrence (SAR) in patients with recurrent stage III colon cancer, and worse SAR for BRAFV600E or KRAS mutant tumors was more strongly associated with distal cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,28002643,"BRAF mutation is not associated with response to chemotherapy in Melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,28000889,"High BRAF mutation rate is associated between primary colorectal cancer and corresponding metastases."
https://pharos.nih.gov/idg/targets/P15056,P15056,27993800,"BRAF-mutant advanced colorectal cancer ( aCRC) confers a markedly worse prognosis independent of associated clinicopathological features. Chemotherapy provides meaningful improvements in outcome throughout treatment lines. Post-progression survival is markedly worse and vigilance is required to ensure appropriate delivery of treatment after first-line progression"
https://pharos.nih.gov/idg/targets/P15056,P15056,27993793,"these data highlight the poor prognosis of patients with metastatic melanoma and BM, despite a targetable 'driver' oncogene mutation(BRAFv600) and evidence of initial drug-responsiveness"
https://pharos.nih.gov/idg/targets/P15056,P15056,27984807,"This study demonstrated the presence of BRAF V600E mutation in Chinese epileptic patients with Glioneuronal tumors, which was significantly correlated with gender and multiple seizure types."
https://pharos.nih.gov/idg/targets/P15056,P15056,27977682,"we demonstrate that small molecule PERK inhibitors exhibit single agent efficacy against BrafV600E-dependent tumors highlighting the clinical value of targeting PERK"
https://pharos.nih.gov/idg/targets/P15056,P15056,27965097,"in response to vemurafenib, BRAF-mutated melanoma and colorectal cancer cells rapidly induced the ISR as a cytoprotective mechanism through activation of general control nonderepressible 2 (GCN2), an eIF2alpha kinase sensing amino acid levels"
https://pharos.nih.gov/idg/targets/P15056,P15056,27943267,"Alcohol intake is associated with an increased risk of KRAS+ and BRAF-/KRAS- tumors originating via specific molecular pathways including the traditional adenoma-carcinoma pathway but not with BRAF+ tumors originating via the serrated pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,27936049,"Extrathyroid invasion, lymph node metastases, and BRAFV600E mutation were the high risk factors of papillary thyroid microcarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27930579,"BRAF mutation and DNA mutation was associated with serrated polyps and hyperplastic polyps in the carcinogenesis of colorectal cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,27928645,"Our data demonstrate that starvation-trigged autophagy, which is BRAF V600E dependent, promotes cancer cell survival in uveal melanoma. Vemurafenib induces autophagic cell death rather than adaptive cell survival in BRAF V600E-mutant melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27923714,"Acquired BRAF V600E Mutation is associated with resistance to osimertinib in lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27923591,"Despite a high specificity for thyroid cancer, BRAF(V600E) mutation has a low overall sensitivity and therefore has a limited diagnostic value as a single screening test."
https://pharos.nih.gov/idg/targets/P15056,P15056,27919446,"Immunohistochemistry is an accurate method to evaluate BRAF proto-oncogene is papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27916952,"multiregion analysis was performed in 60 spatially separated tumor areas according to the pathological tumor node metastasis (pTNM) staging and KRAS, NRAS and BRAF mutations were tested using pyrosequencing.these results suggest the need for multiple RAS testing in different parts of the same tumor and/or more sensitive techniques."
https://pharos.nih.gov/idg/targets/P15056,P15056,27912827,"This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,27911979,"our studies show that BRAFNon-V600 mutations are not prognostic for stage IV melanoma patients, and this information will augment the design and interpretation of current and future clinical trials in this patient population."
https://pharos.nih.gov/idg/targets/P15056,P15056,27911099,"Morphometric variables are predictive markers for papillary thyroid carcinoma cases with positivity for BRAF V600 mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,27888823,"No relation between oropharyngeal squamous cell carcinomas and BRAF gene mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,27870159,"ndings indicate that BRAF V600E is not a consistent squarending in myopericytoma and does not serve as a useful diagnostic immunohistochemistry marker"
https://pharos.nih.gov/idg/targets/P15056,P15056,27866718,"BRAF protein mutation in metastatic lymph nodes maybe responsible for the recurrence of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27864876,"ARMC10-BRAF fusion is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27864688,"genome analysis of wild-type gastrointestinal stromal tumors for mutations should include the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,27863476,"Data indicate the role of immunohistochemical BRAF V600E expression in patients at the time of progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,27860480,"BRAF gene mutation is confirmed by several studies found in malignant melanoma of the skin. The histopathology findings in our group did not confirmed our theory, that since the uveal melanoma itself has the similar origin as skin melanoma, should also contain a BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,27860162,"Desmoplastic infantile astrocytoma/ganglioglioma with rare BRAF V600D mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,27813079,"Increased plasma membrane abundance of PMCA4b in vemurafenib-treated BRAF mutant cells is associated with enhanced Ca2+ clearance."
https://pharos.nih.gov/idg/targets/P15056,P15056,27776007,"Spitzoid neoplasms with BRAF fusion cases were most likely to have high-grade nuclear atypia, to be diagnosed as spitzoid melanoma, to have a positive result by melanoma fluorescence in situ hybridization assay, and to develop copy number gains in the kinase domain of the fusion protein."
https://pharos.nih.gov/idg/targets/P15056,P15056,27775691,"Data show that BRAF inhibitor (BRAFi) treatment failed to affect Nodal protein levels in melanoma tissues."
https://pharos.nih.gov/idg/targets/P15056,P15056,27775641,"Findings suggest that the association of HER2 amplification with BRAF(V600E) mutation and telomere shortening may represent a marker of tumor aggressiveness, and, in refractory thyroid cancer, may warrant exploration as a site for targeted therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,27771229,"BRAF V600E is the predominant mutation in Japanese non-chronically sun-damaged melanoma patients, and that both intra- and inter-tumor mutational heterogeneities exist in primary and metastatic melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,27769870,"BRAF V600E mutations wereencountered in most metanephric stromal tumors, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,27766572,"BRAF mutations were detected in 54 of 115 (47 %) including 51 of V600E and 3 of V600 K in Japanese melanoma cases."
https://pharos.nih.gov/idg/targets/P15056,P15056,27765849,"BRAF(V600E)-mediated MEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonism combined with cobimetinib, suggesting a novel therapeutic strategy against BRAF(V600E)-mutant CRCs."
https://pharos.nih.gov/idg/targets/P15056,P15056,27764839,"Incidence of adverse events was similar regardless of RAS/BRAF status."
https://pharos.nih.gov/idg/targets/P15056,P15056,27760550,"BRAF(V600E) mutation is a common genetic change in isolated hypothalamic-pituitary Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27737711,"No significant impact on prognosis was observed for mutated KRAS, NRAS, and PIK3CA genes or combined RAS mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,27729324,"Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,27718322,"BRAF V600E mutation is associated with cerebellar pilocytic astrocytoma recurring as a ganglioglioma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27689252,"BRAF-positive thyroid cancers most often demonstrate worrisome sonographic features and are frequently associated with positive or suspicious Bethesda cytology."
https://pharos.nih.gov/idg/targets/P15056,P15056,27681305,"findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,27672042,"Japanese patients with sporadic colorectal cancer with BRAF V600E mutation exhibited a significantly shorter overall survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,27671879,"In this report, we describe a 35-year-old female who presented with multifocal ganglioglioma, involving both the conus medullaris and filum terminale. The dominant lesion in the filum terminale was resected, which revealed World Health Organization I grade, p53 mutant, and BRAF wildtype status"
https://pharos.nih.gov/idg/targets/P15056,P15056,27666765,"BRAF V600E mutation in capsular nevi of sentinel lymph nodes may be useful as an adverse predictive biomarker in patients with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27659822,"The V600E mutation is associated with a risk of transformation to high-grade glioma and poor response to chemoradiation approaches and outcome."
https://pharos.nih.gov/idg/targets/P15056,P15056,27630332,"BRAF-mutant lesions are consistently associated with poor prognosis. Consequently, the indications of colorectal liver metastasis resection in this patient group should be reconsidered."
https://pharos.nih.gov/idg/targets/P15056,P15056,27620500,"The authors find that the interaction between sB-Raf and the Hsp90 chaperone system is based on contacts with the M domain of Hsp90, which contributes in forming the ternary complex with Cdc37 as long as the kinase is not stabilized by nucleotide."
https://pharos.nih.gov/idg/targets/P15056,P15056,27600854,"BRAF mutations are closely associated with aggressive clinicopathological characteristics and poorer prognosis in papillary thyroid cancer. [meta-analysis]"
https://pharos.nih.gov/idg/targets/P15056,P15056,27599148,"Study found that BRAF alterations are frequent in dysembryoplastic neuroepithelial tumors (DNTs), particularly BRAF copy number gain which is being reported for the first time in these tumors. Evidence of activation of mTOR and MAPK pathways suggests a role for altered signalling in DNT pathogenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27597420,"The BRAF/MAP2K1-mut LCH cells had a more immature state than BRAF/MAP2K1-wt LCH cells. Authors also found the BRAFV600E and MAP2K1 mutations were significantly associated with pERK expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,27571181,"r-BRAF are very uncommon in papillary thyroid carcinomas (PTC) and are found almost exclusively in PTC with low-risk clinicopathological features."
https://pharos.nih.gov/idg/targets/P15056,P15056,27568671,"Compared to some Asian populations, this study of Filipino papillary thyroid carcinoma patients shows a lower prevalence of BRAF V600E mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,27555670,"IFNgamma inhibits CXCL8 secretion and in turn the migration of a BRAF V600e mutated thyroid cell line"
https://pharos.nih.gov/idg/targets/P15056,P15056,27554081,"The BRAF V600E mutation is now recognized as the causal genetic event of hairy cell leukemia because it is somatic, present in the entire tumor clone, detectable in almost all cases at diagnosis (encompassing the whole disease spectrum), and stable at relapse."
https://pharos.nih.gov/idg/targets/P15056,P15056,27542908,"(V600)BRAF switches on a metabolic reprogramming in melanoma cells, leading to a decreased OXPHOS activity and increased glycolytic ATP, lactate, HIF-1alpha and MCT4 levels."
https://pharos.nih.gov/idg/targets/P15056,P15056,27535135,"Point mutations of BRAF is associated with thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27480103,"BRAF(V600)-mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27466810,"found that BRAF genotyping in weakly and moderately pigmented samples was more efficient when the sample was processed with BSA or purified with a NucleoSpin(R) gDNA Clean-up XS Kit prior to PCR amplification"
https://pharos.nih.gov/idg/targets/P15056,P15056,27460442,"BRAF(V600)-mutation is associated with papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27458004,"Compared with newly diagnosed multiple myeloma, an increased prevalence of mutations in the Ras pathway genes KRAS, NRAS, and/or BRAF (72%), as well as TP53 (26%), CRBN (12%), and CRBN pathway genes (10%) was observed."
https://pharos.nih.gov/idg/targets/P15056,P15056,27454941,"Study of four cases confirms BRAF V600E mutation as a probable driver in a subset of ciliated muconodular papillary tumors (CMPT) of the lung, along with AKT1 mutation, which further supports that CMPT are indolent pulmonary neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,27449293,"Results show that promoter mutations render telomerase reverse transcriptase (TERT) expression dependent on MAPK signal pathway activation due to oncogenic BRAF or NRAS mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,27442672,"A higher number of suspicious US features classified by the TIRADS, but not the BRAF mutation, are associated with lateral lymph node metastasis in patients with PTC, and can aid in the preoperative identification of patients at increased risk of lateral lymph node metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27438990,"Results indicate that MLH1-hypermethylated BRAF wild-type colorectal carcinomas can harbor KRAS mutations and arise from precursor polyps resembling conventional tubular/tubulovillous adenomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,27435270,"There is association between CpG island methylator phenotype and mutation of BRAF in patients with metastatic Colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27433783,"BRAFV600E mutations were associated with younger patient age and localization of melanoma on sun-protected areas of the skin."
https://pharos.nih.gov/idg/targets/P15056,P15056,27416954,"BRAFV600E mutation is associated with astroblastoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27404270,"colorectal cancers with BRAF D594G mutations are similar to those with BRAF wild-type with regard to clinicopathological features, microsatellite instability status, and prognosis. However, colorectal cancers with BRAF D594G mutations are rare."
https://pharos.nih.gov/idg/targets/P15056,P15056,27387551,"This study is the first to report BRAF mutations in a pure adult sample of differentiated thyroid cancer of Saudi Arabian ethnicity."
https://pharos.nih.gov/idg/targets/P15056,P15056,27382031,"The results demonstrated the lack of activity of anti-EGFRs in RAS(KRAS and NRAS) and BRAF wild-type, right-sided tumors, thus suggesting a potential role for primary tumor location in driving treatment choices"
https://pharos.nih.gov/idg/targets/P15056,P15056,27368419,"DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,27358379,"Mutations in KRAS and BRAF were associated with inferior PFS and OS of mCRC patients compared with patients with non-mutated tumors. KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival"
https://pharos.nih.gov/idg/targets/P15056,P15056,27345584,"Here we review the current knowledge about the classification of this tumor subtype and its association with five key features: mutation status of the BRAF or KRAS genes, the CpG island methylation phenotype, microsatellite instability, immune cell infiltration, and overexpression of GTPase RAC1b"
https://pharos.nih.gov/idg/targets/P15056,P15056,27342756,"Studies indicate the clinical importance of BRAF-V600 mutations and BRAF inhibition in the progression to melanoma brain metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27329244,"RNF43 germline and somatic mutation in Serrated Neoplasia pathway associated with BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,27325282,"MET amplification is here identified-clinically and preclinically-as a new mechanism of resistance to EGFR and BRAF dual/triple block combinations in BRAF-mutated colorectal cancer. Switching from EGFR to MET inhibition, while maintaining BRAF inhibition, resulted in clinical benefit after the occurrence of MET-driven acquired resistance."
https://pharos.nih.gov/idg/targets/P15056,P15056,27314237,"Our study provides a rationale to strengthen NK cell immunotherapy through a combination with cetuximab for RAS and BRAF mutant mCRC patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,27296272,"Erdheim-Chester Disease With Cardiovascular Involvement and BRAF V600E Mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,27283860,"BRAF(V600E)-mutation is associated with metastatic non-small cell lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27261210,"The association of BRAF mutations with clinical and pathological features was assessed next in a cohort of 840 KRAS exon 2 wild type CRC patients screened with the Real Time PCR assay."
https://pharos.nih.gov/idg/targets/P15056,P15056,27256275,"The BRAF(V)(600E) mutation is also seen in paediatric cytology and the morphological features showed a high accuracy as both predictive mutational parameters and a helpful aid in management mainly of the aggressive BRAF(V)(600E) mutated carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,27253461,"investigation of MGMT promoter methylation and in particular BRAF V600E mutations represent reliable additional tools to sustain differentiation of Giant Cell Glioblastoma (gcGBM) from Pleomorphic Xanthoastrocytoma (PXA) on a molecular basis. Based on these data specific BRAF kinase inhibitors could represent a promising agent in the therapy of PXA and their use should be emphasized."
https://pharos.nih.gov/idg/targets/P15056,P15056,27249714,"For patients with non-small cell lung cancer with a EGFR mutation and an anaplastic lymphoma kinase mutation(ALK) with brain metastases, several agents have shown intracranial activity. Lapatinib has been tested for patients with brain metastases from breast cancer harboring a HER2 mutation. molecular targeted therapies have shown efficacy in BRAF-positive melanoma brain metastasis"
https://pharos.nih.gov/idg/targets/P15056,P15056,27226552,"using a kinase-inactive mutant of CK2alpha, that RAF-MEK inhibitor resistance did not rely on CK2alpha kinase catalytic function, and both wild-type and kinase-inactive CK2alpha maintained ERK phosphorylation upon inhibition of BRAF or MEK."
https://pharos.nih.gov/idg/targets/P15056,P15056,27220764,"p16 and BRAFV600E are useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,27210749,"These results provide support for the role of BRAF(V600E) in metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27197524,"BRAF IHC is strongly concordant with the BRAF mutation test."
https://pharos.nih.gov/idg/targets/P15056,P15056,27180062,"Functional Na+/I- symporter activity was higher in BRAF(V600E) mutation-positive cases of classical variant papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,27167340,"Data show that long noncoding RNA RMEL3 is required for MAPK and PI3K signaling, and its knockdown decrease BRAFV600E melanoma cell survival and proliferation."
https://pharos.nih.gov/idg/targets/P15056,P15056,27150060,"Data show that 514 of 1170 patients (44%) carried a BRAF mutation, and all models indicated age and histological subtype of melanoma as the two major predictive variables."
https://pharos.nih.gov/idg/targets/P15056,P15056,27147251,"BRAF mutation is correlated with response to therapy in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,27138882,"BRAF(V600E) in papillary thyroid cancer predicts an increased risk of lymph node metastasis, extra-thyroidal extension and reduced disease-free survival. It is an additional useful prognostic biomarker."
https://pharos.nih.gov/idg/targets/P15056,P15056,27138801,"BRAF mutation was significantly related with shorter DFS and OS among stage II/III CRC patients receiving adjuvant chemotherapy after curative resection"
https://pharos.nih.gov/idg/targets/P15056,P15056,27116958,"Braf and Kras genes mutation were reveled in gastritis and adenocarcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,27111917,"HRM appears the less sensitive assay for the detection of BRAF V600 mutations. The RT-ASA, IdyllaTM and IHC assays are suitable for routine molecular diagnostics aiming at the prescription of anti-BRAF therapies"
https://pharos.nih.gov/idg/targets/P15056,P15056,27105117,"Cdc37 performs a quality control of protein kinases, including b-raf, where induced conformational instability acts as a \"flag\" for Hsp90 dependence and stable cochaperone association."
https://pharos.nih.gov/idg/targets/P15056,P15056,27101548,"The BRAF was mutated in 55% (29/53) and NRAS in 11% (5/45) of the primary melanomas sequenced."
https://pharos.nih.gov/idg/targets/P15056,P15056,27098748,"BRAF mutations were not detected in any of the four IM cases examined. One patient with IM died from metastatic disease: this tumour was disomy 3 with 6p and 8q gains. All other patients were alive with no evidence of metastases at study closure."
https://pharos.nih.gov/idg/targets/P15056,P15056,27094161,"New and highly sensitive method to detect BRAF V600 mutations in Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,27087167,"the BRAF pathway is activated in endometriotic cells from patients with endometriosis, and inhibition of the BRAF pathway can significantly decrease proliferation in both epithelial and stromal endometriotic cells in vitro and in vivo"
https://pharos.nih.gov/idg/targets/P15056,P15056,27085458,"BRAF mutations occur frequently in testicular germ cell tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,27084044,"The BRAFV600E antibody (clone VE1) IHC may show non-specific staining, but molecular assays may be useful for the diagnosis of unicystic ameloblastoma, in conjunction with clinical, radiological and histopathological features."
https://pharos.nih.gov/idg/targets/P15056,P15056,27082577,"The BRAF-mutated Colorectal Cancers ,in comparison to KRAS-mutated ones, are associated with a much worse prognosis for the afflicted patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,27080216,"Dabrafenib showed clinical activity in BRAF(V600E)-positive NSCLC. Our findings suggest that dabrafenib could represent a treatment option for a population of patients with limited therapeutic options"
https://pharos.nih.gov/idg/targets/P15056,P15056,27064992,"the prevalence and clinicopathological associations of BRAF V600E and TERT promoter mutations in Chinese PTC patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,27062580,"our results suggest that the mutational spectrum of pediatric AF is more complex than in adult AF, being rich in AKT1 and BRAF, as well as CTNNB1 gene mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,27048246,"we identify recurrent somatic BRAF alterations in high-grade colorectal NET and demonstrate rapid clinical improvement and tumor responses with a combination of BRAF- and MEK-directed therapies."
https://pharos.nih.gov/idg/targets/P15056,P15056,27041569,"These findings identify a key mechanism of tolerance to Ras-Raf pathway inhibitors and suggest that blocking either AMPK or autophagy in combination with these targeted inhibitors could increase tumor regression and decrease the likelihood of eventual recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,27036313,"Increased staining for phosphorylated ERK1/2 does not correlate to BRAF or KRAS mutations in colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,27034263,"BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,27033063,"The prognostic role of BRAF, PIK3CA mutations and ploidy in advanced CRC."
https://pharos.nih.gov/idg/targets/P15056,P15056,27028853,"Data indicate that BRAF inhibitor (BRAFi) have unique paradoxical ERK activation profiles."
https://pharos.nih.gov/idg/targets/P15056,P15056,27009410,"The incidence of conjunctival melanoma increased in Denmark over 50 years. The proportion of BRAF-mutated conjunctival melanoma was constant. BRAF mutations were identified as early events in conjunctival melanoma, associated with a distinct clinicopathological profile."
https://pharos.nih.gov/idg/targets/P15056,P15056,27000992,"The additive effects given by gamma-secretase inhibitor to BRAF inhibitor are due to enhancement of induction of the senescent-like arrest, which is associated with decreased RB phosphorylation and CDK6 expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,26997442,"Low incidence of BRAF mutations in adenocarcinomas of the ampulla of Vater suggest no major role in tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26997441,"BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,26996308,"beta3-alphaC deletions are activating mutations in BRAF. BRAF deltaNVTAP confers CRAF- and dimer-independent activity and is resistant to vemurafenib."
https://pharos.nih.gov/idg/targets/P15056,P15056,26994902,"Study provides evidence of BRAF-KIAA fusion in disseminated glioneuronal lesions occurring in childhood and the first report of a BRAF V600E mutation in children with this disease, representing a potential therapeutic target."
https://pharos.nih.gov/idg/targets/P15056,P15056,26991344,"Our findings indicate that BRAF and KRAS mutations as well as mutation heterogeneity predict poor outcome in CRC patients subsequent to liver resections and might help guide treatment decisions."
https://pharos.nih.gov/idg/targets/P15056,P15056,26989027,"Our data suggest that KRAS, NRAS, and BRAF mutations predict response to cetuximab treatment in metastatic colorectal cancer patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,26980024,"Mutant BRAF represses E-cadherin expression, implicating a catalytic role for BRAF in epithelial-mesenchymal transition."
https://pharos.nih.gov/idg/targets/P15056,P15056,26980021,"There was no statistically significant association between BRAF or MAP2K1 mutation and anatomic site, unifocal versus multifocal presentation, or clinical outcome in Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26974965,"Results indicate that MAPK pathway inhibition leads to changes in the immunological properties of mutant BRAF melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26969876,"The coexistence of BRAF or RAS mutations enhanced the prognostic effects of telomerase reverse transcriptase (TERT) promoter mutations. Furthermore, TERT promoter mutations strengthened the predictions of mortality and recurrence by the ATA and TNM staging systems, particularly for high-risk patients with differentiated thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26960768,"The diagnostic classifier based on profiling of 13 microRNAs was proposed, with total estimated accuracy varying from 82.7 to 99% for different nodule types. Relative expression of six microRNAs appeared significantly different in BRAF(V600E)-positive samples compared to BRAF(V600E)-negative papillary carcinoma samples"
https://pharos.nih.gov/idg/targets/P15056,P15056,26959890,"Growth arrest is accompanied by MAPK-mediated serine/threonine phosphorylation and suppression of a variety of oncogenic drivers that resist treatment by B-Raf(V600E) kinase inhibitors, including ErbB members, c-Met, IGFR, IRS, STAT3 and Akt."
https://pharos.nih.gov/idg/targets/P15056,P15056,26959608,"Thus ERK5 signaling is unlikely to play a role in tumor cell proliferation downstream of KRAS or BRAF or in tumor cells with ERK5 amplification. These results have important implications for the role of ERK5 as an anti-cancer drug target"
https://pharos.nih.gov/idg/targets/P15056,P15056,26951110,"The present cohort identifies that the classic architecture with multicentricity and local recurrence are correlates of BRAF (V600E) harboring pediatric papillary thyroid carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,26950846,"The BRAFV600E mutation was significantly associated with central lymph node metastases in patients undergoing prophylactic central neck dissection when specifically controlling for preoperatively available clinicopathologic variables in all papillary thyroid cancer subtypes."
https://pharos.nih.gov/idg/targets/P15056,P15056,26945035,"This study demonstrated that when whole chromosome 7 gain accompanies the KIAA1549-BRAF fusion, the fusion likely arises first."
https://pharos.nih.gov/idg/targets/P15056,P15056,26943032,"This study, the largest on TERT mutation so far, demonstrates a significant role of BRAF V600E and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma, which is particularly robust and cooperative when the two mutations coexist."
https://pharos.nih.gov/idg/targets/P15056,P15056,26932501,"Results are the first to describe the presence of Wnt signaling pathway abnormalities, manifested by nuclear beta-catenin, in a subset, as well as the lack of BRAF(V600E) mutation in gliosarcoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26927447,"Braf mutations were extremely rare in pancreatic cancer, suggesting that they play a limited role in PC development.[review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26927026,"BRAF V600E mutations were found in the papillary craniopharyngiomas subgroup and were not detectable in papillary craniopharyngiomas samples."
https://pharos.nih.gov/idg/targets/P15056,P15056,26925650,"KRAS mutations are not Associated with Metastatic Colorectal Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26925640,"BRAF mutations are associated with poor response to chemptherapy in Colorectal Peritoneal Carcinomatosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26924424,"BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features."
https://pharos.nih.gov/idg/targets/P15056,P15056,26912807,"BRAF V600E mutation predisposes papillary thyroid carcinoma cells toward invasive phenotypes"
https://pharos.nih.gov/idg/targets/P15056,P15056,26910894,"Mutant BRAF may, in part, drive the histologic progression of colorectal adenomas toward serrated histology"
https://pharos.nih.gov/idg/targets/P15056,P15056,26910217,"The rate of the BRAF V600E mutation in the pediatric population with papillary thyroid carcinoma is significantly lower than that seen in the adult population"
https://pharos.nih.gov/idg/targets/P15056,P15056,26892442,"KRAS and, infrequently, BRAF mutations are observed in a subset of small intestinal adenocarcinomas, and are associated with higher pT classification and more frequent pancreatic invasion"
https://pharos.nih.gov/idg/targets/P15056,P15056,26889698,"The rate of the BRAFV600E mutation increased significantly in papillary thyroid cancer diagnosed in Poland from 2000-2013"
https://pharos.nih.gov/idg/targets/P15056,P15056,26871894,"Positive status of BRAF(V600E) mutation was a significant predictor of multifocality (OR = 1.23; 95%CI = 1.14-1.32), extrathyroidal extension (OR = 2.23; 95%CI = 1.90-2.63), TNM stage (OR = 1.67; 95%CI = 1.53-1.81), lymph node metastasis (OR = 1.67; 95%CI = 1.45-1.93), vascular invasion (OR = 1.47; 95%CI = 1.22-1.79) and recurrence/persistence (OR = 2.33; 95%CI = 1.71-3.18) of Papillary Thyroid Carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26871591,"Apart from BRAF V(600)E, no other recurrent somatic mutation was identified in these hairy cell leukaemia exomes, thereby excluding additional acquired mutations as also prevalent at a near-universal frequency in this form of the disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,26857243,"TERT promoter mutation is an independent predictor for distant metastasis of thyroid neoplasms, but ALK testing is not useful for clinical decision-making in Korean patients with a high prevalence of the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,26848795,"The BRAF V600 mutations were significantly associated with AQP1 expression (P=0.014). Long-term follow-up indicated a reduced progression-free survival (P=0.036) and overall survival (P=0.017) for the AQP1-positive cutaneous melanoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,26838744,"BRAF(V600E) mutation is correlated with a lower expression of Na(+)/I(-) symporter in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26835544,"BRAF mutation subclonality was associated with earlier disease stage in Papillary Thyroid Carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26826419,"Colorectal poorly differentiated neuroendocrine carcinomas frequently harbor BRAF mutations and are associated with poor overall survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,26825960,"Specific inhibition of BRAF oncogene, MEK or p38 signaling was associated with decreases in DIO3 expression in papillary thyroid cancer cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,26825657,"One of the most cited proteins in melanoma is BRAF (about 50-60 % of melanomas harbors activating BRAF mutations), for these the most common is a substitution of valine to glutamic acid at codon 600 (p.V600E)[review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26823860,"We demonstrated that the BRAF (V600E) mutation slightly correlated with the clinicopathological characteristics of papillary thyroid cancer in the Han population"
https://pharos.nih.gov/idg/targets/P15056,P15056,26814611,"A BRAF mutation, p.Val600Ala, was identified in 1 of 8,000 peripheral blood lymphocytes and 1 of 6,000 T lymphocytes from rheumatoid arthritis patients and in 1 of 12,500 peripheral blood lymphocytes and 1 of 12,500 T lymphocytes from controls"
https://pharos.nih.gov/idg/targets/P15056,P15056,26810733,"Our findings present EBI-907 as a potent and promising BRAF inhibitor, which might be useful in broader indications."
https://pharos.nih.gov/idg/targets/P15056,P15056,26810070,"BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology of low-grade neuroepithelial tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,26808395,"Alternative pathways through mutations in BRAF gene are associated with the progression of Colorectal polyps to cancer and may provide insights into the genetic characteristics of skirts."
https://pharos.nih.gov/idg/targets/P15056,P15056,26807515,"MC1R status is associated with BRAF(V600E), BRAF(V600K), and NRAS mutations in cutaneous melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,26802240,"BRAF mutation is playing an important role in the pathogenesis of pyogenic granuloma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26799289,"BRAF mutation is associated with colon cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26796506,"Letter: report frequent BRAF V600E mutations in metanephric stromal tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26790143,"Conclude that PRIMA-1(Met) through its ability to directly reactivate p53, sensitises (V600E/K)BRAF-positive melanoma cells to BRAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26787892,"results reveal a common BRAF(V600E)-directed transcriptional regulatory pathway that mediates epigenetic silencing in unrelated solid tumors and provide strong support for an instructive model of oncoprotein-directed epigenetic silencing"
https://pharos.nih.gov/idg/targets/P15056,P15056,26775732,"BRAF mutations are associated with response to therapy in metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26758762,"Findings suggested that BRAF-activated noncoding RNA may contribute to hepatocellular carcinoma initiation and progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,26753950,"olfactory neuroepithelial progenitor cells with the genetic heritage of bipolar I disorder were more sensitive to glutamate induced apoptosis. Under expression of the BRAF gene and protein, which plays a role in regulating the pro-survival MEK/ERK signaling pathway, may contribute to this apoptotic sensitivity."
https://pharos.nih.gov/idg/targets/P15056,P15056,26750638,"BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26750533,"The significant association of SLP-2 overexpression with unfavorable clinicopathological characteristics and BRAFV600E mutation indicates that SLP-2 may have a role in aggressiveness of BRAF-mutated papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26749005,"BRAF mutation is associated with thyroid neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,26734696,"BRAF V600E mutation is associated with Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26733165,"study suggests an influence of overweight BMI on the status of BRAF (V600E) in patients with PTC, whereas the underlying mechanism need to be further investigated"
https://pharos.nih.gov/idg/targets/P15056,P15056,26732095,"This study discovered oncogenic BRAF deletions with a distinct activation mechanism dependent on the BRAF dimer formation in tumor cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26718898,"It was suggested that somatic point mutations in BRAF, CDKN2A and PI3KCA do not participate in the oncogenesis of Medullary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26718882,"four cases harbored the BRAF-V600E mutation, one case harbored the BRAF-G606R mutation, and three cases harbored deletions in exon 19 of EGFR"
https://pharos.nih.gov/idg/targets/P15056,P15056,26711930,"Clinical data suggest that BRAF mutations define specific subsets of patients with NSCLC; while their oncogenic nature is yet to be established in lung cancer, especially for non-V600E mutations, the value of BRAF mutations to predict the efficacy of targeted agents remains unclear."
https://pharos.nih.gov/idg/targets/P15056,P15056,26711586,"TERT promoter mutations have a limited role in pediatric thyroid carcinoma, but the BRAFV600E mutation may have a role in recurrence in pediatric patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,26710756,"BRAF mutation is not associated with pheochromocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26695089,"BRAFV600E status during melanoma progression was evaluated in a cohort of 54 patients with at least paired-samples. These findings suggest that only VE1-negative tumours would be genotyped to detect other BRAFV600 mutations, and that either primary melanoma or metastasis can be tested using immunohistochemistry, according to the material available."
https://pharos.nih.gov/idg/targets/P15056,P15056,26691448,"These results revealed differences in the genetic profiles of KRAS, NRAS, PIK3CA and BRAF at mutation hotspots between Chinese CRC patients and those of Western countries."
https://pharos.nih.gov/idg/targets/P15056,P15056,26684240,"BRAF V600E mutation is associated with resistance to pazopanib in gastroenteropancreatic neuroendocrine tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26678033,"BRAF mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26671072,"BRAF mutational status correlates with recurrence of papillary thyroid microcarcinoma [review; meta-analysis]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26668268,"Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation"
https://pharos.nih.gov/idg/targets/P15056,P15056,26646323,"Data show that Griffipavixanthone (GPX), a dimeric xanthone isolated from Garcinia esculenta, is a B-RAF and C-RAF inhibitor against esophageal cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26643848,"Twenty-three percent of patients with V600E- and 43% of patients with K601E-mutant melanomas presented with nodal disease at diagnosis compared to just 14% of patients with BRAF wild-type tumors (P = 0.001 and 0.006, respectively). Overall, these mutations represent a significant minority of BRAF mutations, but have distinct clinicopathological phenotypes and clinical behaviors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26632889,"The presence of the BRAFV600E mutation is independently associated with high F-18 FDG uptake on preoperative PET/CT in patients with overt papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26630683,"BRAF-V600 mutation inconsistencies of up to 14.5% can be seen between the primary and metastatic foci in melanoma cases. These findings should be taken into account when planning targeted therapy and deciding on treatment responsiveness/unresponsiveness."
https://pharos.nih.gov/idg/targets/P15056,P15056,26625260,"identification of 7 BRAF-induced genes that are specific for BRAF V600E-driven papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26623721,"Data show that dasatinib induced DNA damage and activated DNA repair pathways leading to senescence only in the kinase-inactivating BRAF kinase (BRAF) mutations (KIBRAF) non-small cell lung cancer (NSCLC) cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26616508,"use of sorafenib has been ineffective in the management of advanced Colorectal cancer (CRC) patients with KRAS mutation, combination of selective BRAF inhibitors plus EGFR inhibitors may represent a good therapeutic strategy in BRAF-mutant CRC."
https://pharos.nih.gov/idg/targets/P15056,P15056,26616061,"Recent reports show a significant radiosensitization of the irradiated healthy tissue in patients with melanoma after the combination of radiotherapy and BRAF(V600) inhibitors, evoking concern in clinical practice"
https://pharos.nih.gov/idg/targets/P15056,P15056,26613644,"The findings suggest that the presence of the BRAFV600E mutation and loss of p16 expression accelerate the growth rate of melanomas in vivo leading to larger melanocytes that are more frequently arranged in nests."
https://pharos.nih.gov/idg/targets/P15056,P15056,26608120,"Report incidence and heterogeneity of genetic changes driving BRAF inhibitor resistance in melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,26600545,"PIK3CA mutations were observed in 32% (8) of the 25 breast cancer tissues examined, Sequencing of exon 2 of KRAS suggested that 20% (5) of the 25 samples harbored a mutation and 16% (4) of BRAF harbored a mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,26600396,"the V600E BRAF mutation occurred in about half of melanoma patients; it was associated with earlier manifestation of melanoma and likely with more aggressive clinical features."
https://pharos.nih.gov/idg/targets/P15056,P15056,26598713,"Chronic lymphocytic thyroiditis was an independent predictor for less aggressiveness in conventional papillary thyroid carcinoma patients regardless of BRAF mutation status."
https://pharos.nih.gov/idg/targets/P15056,P15056,26597176,"The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated. The patient is a carrier of germline variants in immunomodulatory loci associated with prolonged survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,26584635,"Data indicate that among classic and follicular variant papillary thyroid carcinomas (PTCs), mutation of proto-oncogene protein B-raf (BRAF(V600E)) was significantly associated with the smaller size."
https://pharos.nih.gov/idg/targets/P15056,P15056,26582795,"Characterization of TP53 as a downstream effector of miR-3151 provides evidence for a causal link between BRAF mutations and TP53 inactivation"
https://pharos.nih.gov/idg/targets/P15056,P15056,26582644,"Cooperation of BRAF(F595L) and mutant HRAS is associated with histiocytic sarcoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26575603,"In the validation-set (508 pts, RAS wt: 262 (51.6%), BRAFV600E mutated: 49 (9.6%)), right-sided primary, female gender and mucinous histology were confirmed as independent predictors of BRAFV600E mutation with high accuracy"
https://pharos.nih.gov/idg/targets/P15056,P15056,26575115,"NRAS codon 61 is the most frequent genetic alteration in this acromegaly series with Differentiated Thyroid Cancer . Since acromegalic patients have lower prevalance of BRAF V600E mutation, BRAF V600E mutation may not be a causative factor in development ofDifferentiated Thyroid Cancer in acromegaly."
https://pharos.nih.gov/idg/targets/P15056,P15056,26563980,"The vast majority of these tumors harbor the oncogenic BRAF V600E mutation. [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26562024,"Case Report: BRAF kinase domains are a clinically important genomic alteration and therapeutic target."
https://pharos.nih.gov/idg/targets/P15056,P15056,26562020,"Data indicate that mutations in PTEN phosphatase A167T and NRAS protein Q61L, and proto-oncogene protein BRAF V600E were detected in melanoma cell line."
https://pharos.nih.gov/idg/targets/P15056,P15056,26541605,"Vitamin C is selectively toxic to cells with mutant KRAS or BRAF alleles."
https://pharos.nih.gov/idg/targets/P15056,P15056,26530529,"Data indicate that tumors with proto-oncogene proteins BRAF or KRAS mutations were in correlation with elevated serum level of carbohydrate antigen (CA19-9) and carcinoma embryonic antigen (CEA)."
https://pharos.nih.gov/idg/targets/P15056,P15056,26521469,"High frequency and specificity of the V600E BRAF mutation make it a useful biochemical marker for selecting the right surgical strategy for thyroidectomy."
https://pharos.nih.gov/idg/targets/P15056,P15056,26521063,"that BRAF sequencing has been used to discriminate between dedifferentiated papillary thyroid carcinoma and tumor to tumor metastasis"
https://pharos.nih.gov/idg/targets/P15056,P15056,26513490,"Both Glut1 and GLUT3 are strongly expressed by papillary thyroid carcinomas, and their expressions were significantly associated with the presence of the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,26512781,"BRAF mutation is associated with poor response to cetuximab in colorectal carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26511315,"Apart from these distinct Cdc37/Hsp90 interfaces, binding of the B-Raf protein kinase to the cochaperone is conserved between mammals and nematodes."
https://pharos.nih.gov/idg/targets/P15056,P15056,26504080,"B-Raf(V600E) mutation in metastatic melanoma cells up-regulated tissue factor expression on cell membranes and promoted thrombin production"
https://pharos.nih.gov/idg/targets/P15056,P15056,26500331,"BRAF mutation is frequent in early-onset colorectal cancer in Taiwan and is associated with a poorly differentiated histology, a serrated precursor polyp, focal signet ring cell differentiation, lack of microsatellite instability and a poor prognosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26498143,"BRAFV600 mutations are associated with response to BRAF inhibitors in metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26496853,"BRAF-mutated traditional serrated adenoma (TSA) is distinct from KRAS-mutated TSA in predisposing to the acquisition of subsequent serrated neoplasia"
https://pharos.nih.gov/idg/targets/P15056,P15056,26496026,"Monoclonal antibody VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26461266,"The presence or absence of the BRAF mutation and TERT promoter polymorphism was not significantly correlated with survival in Papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26460303,"BRAF V600-Mutation is associated with Colorectal Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26457492,"The presence of BRAF mutation in fine-needle aspiration cytology specimens of nodular goitre may be useful in the assessment of oncological risk."
https://pharos.nih.gov/idg/targets/P15056,P15056,26454767,"PXA in adults PXA may present features distinct from pediatric PXA. Anaplastic features and BRAF mutation may potentially identify specific subgroups with distinct prognoses"
https://pharos.nih.gov/idg/targets/P15056,P15056,26454140,"Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,26448939,"Patients with multifocal PTC whose largest tumor is BRAF-negative can have smaller tumors that are BRAF-positive."
https://pharos.nih.gov/idg/targets/P15056,P15056,26446943,"BRAF mutations in cfDNA are detectable in >75% of late-stage melanoma patients with BRAF mutation-positive tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26446234,"RAS and BRAF wild-type status could help select an elderly and unfit population that could benefit from anti-epidermal growth factor receptor single agent therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,26440707,"Levels of BRAF(mutant) and NRAS(mutant) ctDNA were determined using droplet digital PCR (ddPCR) assays. Among patients with samples available prior to treatment initiation ctDNA and LDH levels were elevated in 12/15 (80%) and 6/20 (30%) (p = 0.006) patients respectively"
https://pharos.nih.gov/idg/targets/P15056,P15056,26438153,"Among 33 BRAF wild-type colorectal carcinomas, 16 had no or weak staining, whereas 15 (45%) had heterogeneous staining. In contrast with colorectal carcinoma, Bond and Ventana VE1 IHC in melanoma and PTC were highly concordant with sequencing results"
https://pharos.nih.gov/idg/targets/P15056,P15056,26433819,"Combination of a BRAF inhibitor plus a MEK inhibitor adds a clear benefit over monotherapy with BRAF inhibitor in unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26426340,"BRAF Mutation is associated with response to therapy in Advanced Melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26425792,"BRAF-mutated conjunctival melanoma (CM) were frequent in younger patients and were rare in tumors involving the extrabulbar conjunctiva."
https://pharos.nih.gov/idg/targets/P15056,P15056,26422023,"BRAFK601E mutant thyroid tumors show better clinical outcomes than BRAFV600E positive tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,26414224,"Case Report: combined \"infiltrating astrocytoma/pleomorphic xanthoastrocytoma\" harboring IDH1 R132H and BRAF V600E mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,26405815,"Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26403329,"consideration needs to put on multiple targets when deciding molecular target therapies for patients with BRAF V600E mutated thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26399561,"Driver mutations are rare in mutational hotspots of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26392334,"A constitutive active MAPK/ERK pathway due to BRAFV600E mutation positively regulates aryl hydrocarbon receptor pathway in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26392102,"BRAF V600-Mutation is associated with Colorectal Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26384810,"BRAF V600E-mutation is associated with response to therapy in glioma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26384551,"Dual inhibition of BRAF(V600E) and MEK reduced but did not prevent SW1736 invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,26381028,"Case Report: erythematous rash as a result of BRAF inhibitor therapy in advance melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26376292,"BRAF and KRAS mutations show together a high prevalence in stage II and III MSI colon cancer and, when combined, are associated with poor survival compared to dWT cancers, which status confers an excellent cancer-specific survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,26362194,"In three cases of papillary carcinoma arising in struma ovarii (PSCS), novel BRAF and KRAS mutations were identified in two of three tumors suggesting that mutations in PCSO may differ from those commonly identified in papillary carcinoma of the eutopic thyroid."
https://pharos.nih.gov/idg/targets/P15056,P15056,26359417,"BRAF V600E mutation in non-tumoral surrounding tissue in patients with colorectal cancer may be used as a valuable marker to foresee clinical outcome or a possible recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,26353041,"BRAF mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26351322,"combined pan-RAF and MEK inhibition can overcome intrinsic and acquired resistance to single-agent RAF/MEK inhibition, supporting dual pan-RAF and MEK inhibition as a novel therapeutic strategy for BRAF- and KRAS-mutant cancers"
https://pharos.nih.gov/idg/targets/P15056,P15056,26343583,"LY3009120 also inhibits various forms of RAF dimers including BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,26343582,"Tumors with non-V600E BRAF mutants are insensitive to these drugs."
https://pharos.nih.gov/idg/targets/P15056,P15056,26339422,"Report BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes."
https://pharos.nih.gov/idg/targets/P15056,P15056,26321697,"no BRAF V600E mutations were found in PMSAs, but KIAA1549-BRAF fusion was identified in intermediate pilomyxoid tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,26319365,"The lesions designated as KAs and BRAF inhibitor-associated verrucous keratoses had a similar mutational profile."
https://pharos.nih.gov/idg/targets/P15056,P15056,26318033,"AKT3 has a role in prostate cancer proliferation through regulation of Akt, B-Raf, and TSC1/TSC2"
https://pharos.nih.gov/idg/targets/P15056,P15056,26314551,"BRAF fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,26306423,"BRAF mutations seem to occur exclusively in the epithelial, but not in the stromal component"
https://pharos.nih.gov/idg/targets/P15056,P15056,26305188,"Report BRAF mutations in selected cohort of patients with pulmonary metastases of malignant melanoma and prognostic implications."
https://pharos.nih.gov/idg/targets/P15056,P15056,26299805,"KRAS and BRAF oncogenes have roles in colorectal cancer development and therapy resistance [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26299074,"BRAF codon 600 mutations not found in Iranian prostate adenocarcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,26297254,"NRASQ61R and BRAFV600E immunohistochemistry coupled with next-generation sequencing allow detection of mutations in melanoma challenging samples."
https://pharos.nih.gov/idg/targets/P15056,P15056,26287849,"BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,26285159,"Data indicate that BRAFV600E, P-cadherin and cadherin 6 protein expressions were correlated with one another."
https://pharos.nih.gov/idg/targets/P15056,P15056,26284586,"Data suggest that combination of proto-oncogene protein B-raf (BRAF) and mTOR serine-threonine kinase (mTOR) inhibition forms the basis of a treatment regimen of thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26282084,"presence of BRAF mutations in melanoma associated with younger age"
https://pharos.nih.gov/idg/targets/P15056,P15056,26274032,"Letter/Case Report: BRAF mutations in metanephric adenofibroma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26271724,"BRAF V600E-mutated microcarcinomas represent a distinct biological subtype"
https://pharos.nih.gov/idg/targets/P15056,P15056,26269601,"neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26259532,"BRAF mutations are associated with Papillary Thyroid Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26258321,"Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive Thyroid cancers were more often associated with stage III/IV disease and recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,26240026,"Combination of mutant-specific BRAF and CD117 ICC with cytopathology may facilitate the PTC-risk stratification in thyroid FNAB specimens."
https://pharos.nih.gov/idg/targets/P15056,P15056,26232865,"Despite its high specificity, our meta-analysis shows that BRAF(V600E) mutation analysis has a low sensitivity in diagnosing papillary thyroid cancer in thyroid nodules"
https://pharos.nih.gov/idg/targets/P15056,P15056,26230187,"BRAF mutations are associated with follicular variant of thyroid papillary carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26225944,"BRAF mutations are infrequent, whereas C-KIT and NRAS mutations are seen with higher frequency in vulvar melanomas than melanomas of other sites."
https://pharos.nih.gov/idg/targets/P15056,P15056,26223933,"Results revealed that in patients with papillary thyroid microcarcinoma (PTMC), BRAF mutation is associated with tumor size, multifocality and aggressive features and may be used as a predictive factor for prognosis of PTMC. [meta-analysis]"
https://pharos.nih.gov/idg/targets/P15056,P15056,26215382,"Data suggest that core-needle biopsy (CNB) + B-Raf proto-oncogene protein BRAF(V600E) mutation analysis can reduce rates of preventable diagnostic surgery."
https://pharos.nih.gov/idg/targets/P15056,P15056,26215201,"BRAFV600E Mutation Status in obese Patient is associated with Papillary Thyroid Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26214416,"This study sought to investigate the correlations of V-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene mutations with the clinicopathologic features of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26208946,"BRAF (V600) -mutation is associated with metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26208478,"Findings suggest that triple therapy directed against BRAF/MEK/ErbB3 may be able to provide durable control of BRAF mutated metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26206478,"Study found that BRAF alterations do not appear to play a prominent role in pediatric oligodendroglioma, and lack of BRAF fusions or BRAF p.V600E separate these tumors from several other pediatric low-grade gliomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,26202550,"BRAF Mutations are associated with Lung Adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26197238,"Studies indicate that more than half of all Erdheim-Chester disease (ECD) patients carry the proto-oncogene protein B-raf mutation BRAF(V600E) and treated with vemurafenib, a BRAF inhibitor, which has proven highly beneficial."
https://pharos.nih.gov/idg/targets/P15056,P15056,26191315,"Case Report: oncocytic papillary thyroid carcinoma with lymphoid stroma (Warthin-like tumor) with BRAF V600E and V600K mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,26190162,"Data show that B-Raf proto-oncogene (BRAF) V600E mutation was identified in 4 of 27 thyroid nodule patients with isthmic lesion."
https://pharos.nih.gov/idg/targets/P15056,P15056,26189429,"Angiogenic/cachectic and pro-inflammatory/immune response factors could play a crucial role in BRAF(V600E)-positive human anaplastic thyroid carcinoma aggressiveness."
https://pharos.nih.gov/idg/targets/P15056,P15056,26187369,"Cytomorphologic features can help select nodules for the BRAF(V600E) mutation test among thyroid nodules read as \"suspicious for malignancy\" on cytology."
https://pharos.nih.gov/idg/targets/P15056,P15056,26182332,"Letter/Case Reports: BRAF-mutant colorectal cancers with axillary lymph node involvement."
https://pharos.nih.gov/idg/targets/P15056,P15056,26182194,"Report acute kidney injury in patients receiving BRAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26181555,"real-time PCR cycle threshold values for the BRAFV600E mutation obtained from fine needle aspirates can be associated with central lymph node metastasis in papillary thyroid microcarcinoma patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,26181250,"Retrospective analysis suggesting that nivolumab has similar efficacy and safety outcomes in patients with wild-type or mutant BRAF, regardless of prior BRAF inhibitor or ipilimumab treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,26172302,"BRAF(V600E) mutation induces MGL ligand expression, thereby providing a direct link between oncogenic transformation and aberrant expression of immunosuppressive glycans in colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,26165597,"The RAS-binding domain of human BRAF protein exhibits allosteric conformational changes upon binding HRAS."
https://pharos.nih.gov/idg/targets/P15056,P15056,26160882,"Colon cancers from Asians have a lower rate of BRAF mutations than blacks or whites."
https://pharos.nih.gov/idg/targets/P15056,P15056,26154146,"BRAF mutation detection in cell block material is feasible and highly specific for papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26153495,"BRAF mutations are associated with metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,26146664,"Report 3-fold increased risk of death for higher-risk melanomas harboring NRAS or BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,26145760,"v-raf murine sarcoma viral oncogene homolog B (BRAF) is preferentially mutated in proximal colon cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,26145173,"Results show that active BRAF upregulates HMGCL via Oct-1 in cancer cells. HMGCL selectively promotes BRAF V600E-dependent phosphorylation and activation of MEK1 pathway by controlling intracellular levels of its product acetoacetate."
https://pharos.nih.gov/idg/targets/P15056,P15056,26143635,"Studies indicate that concurrent inhibition of proto-oncogene protein B-raf (BRAF) and Map kinase kinase (MEK) improved the most effective therapeutic modality as compared as single BRAF or MEK inhibition for patients with metastatic melanoma (MM)."
https://pharos.nih.gov/idg/targets/P15056,P15056,26143373,"Data suggest that the two strands of the BRAF promoter region, the G-rich strand and the C-rich strand, fold into a predominant antiparallel G-quadruplex and into an i-motif, respectively, and that they can coexist at nearly physiological conditions."
https://pharos.nih.gov/idg/targets/P15056,P15056,26138035,"BRAF mutation frequencies depended on histological subtype and localization of primary melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26125698,"BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,26125673,"In 19 cases of papillary tumor of the pineal region, there was a lack of BRAF-V600E mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,26123241,"Case Report: melanoma with BRAF mutation in circulating cell-free DNA despite no detectable mutation in the primary lesion."
https://pharos.nih.gov/idg/targets/P15056,P15056,26122804,"We show for the first time that this important pediatric tumor may harbor the oncogenic BRAFV600E mutation, providing the first insights to their personalized treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,26121270,"Tissue micro array availability, BRAF mutation and KRAS mutation were all independent prognostic factors for colorectal cancer survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,26120069,"The BRAF mutation is a possible indicator for determining the extent of thyroidectomy required but not for the extent of lymph node dissection and prognosis in patients with conventional papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,26115961,"BRAF mutations were associated with central nervous system tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26110571,"Report BRAF mutations and PD-L1 expression in disseminated histiocytoses."
https://pharos.nih.gov/idg/targets/P15056,P15056,26105190,"Presence of BRAF V600E associated with aggressive tumor features in Papillary thyroid carcinoma, including invasion, metastasis, advanced TNM stage at presentation, low response to radioiodine treatment, recurrence, and tumor-related mortality."
https://pharos.nih.gov/idg/targets/P15056,P15056,26102513,"Given the high prevalence of lung cancer and the availability of targeted therapy, Chinese lung ADC patients without EGFR and KRAS mutations are recommended for HER2 and BRAF mutations detection, especially for those never smokers"
https://pharos.nih.gov/idg/targets/P15056,P15056,26090869,"BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias may have a role MEK-ERK pathway activation"
https://pharos.nih.gov/idg/targets/P15056,P15056,26084614,"LOH and TP53 mutations detected in lip squamous cell carcinoma and actinic cheilitis may be associated with tumorigenesis, whereas BRAF mutation does not seem to significantly contribute to LSCC pathogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,26084290,"TRAP1 is a downstream effector of BRAF cytoprotective pathway in mitochondria and TRAP1 targeting may represent a novel strategy to improve the activity of proapoptotic agents in BRAF-driven CRC cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,26083571,"This study confirmed the high frequency of KIAA1549:BRAF fusion in Pilocytic Astrocytomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,26083553,"BRAFV600E expression is homogeneous in melanoma tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,26080065,"BRAF protein immunohistochemistry on fine needle aspiration can be important in the diagnosis of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26075701,"According to results, oral benign peripheral nerve sheath tumours have a low LOH rate, but P53 locus alteration is occasionally found. Additionally, BRAF V600E mutation is either not relevant to the molecular pathogenesis of this group of lesions of the oral cavity, or may occur at very low rates."
https://pharos.nih.gov/idg/targets/P15056,P15056,26071465,"detection of BRAF V600E by immunohistochemistry is useful in the distinction of hairy cell leukemias from other splenic-based lymphomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,26066373,"BRAF-V600E mutations occur predominantly in female smokers with adenocarcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,26055532,"Our data lead us to hypothesize that TERT promoter and BRAF mutations cooperate in cutaneous melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,26045855,"Case Report: BRAFV600 mutant non-small-cell lung cancer which progressed on vemurafenib therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,26036358,"BRAFV600E expression in melanocytes induces Schwannian differentiation in vivo"
https://pharos.nih.gov/idg/targets/P15056,P15056,26032958,"BRAF protein play a role in the mitochondrial fragmentation in melanoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,26014474,"BRAF V600E immunostaining is a helpful marker for pediatric metanephric adenoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25988212,"With respect to diagnostic potential, results obtained using the BRAF(V) (600E) mutation test combined with cytological examination were not significantly different from those obtained with cytological examination only."
https://pharos.nih.gov/idg/targets/P15056,P15056,25985019,"we identified a new SND1-BRAF fusion that appeared to be present in a subpopulation of tumor cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,25975986,"reviews the current knowledge on the use and implications of BRAF mutational status in colorectal tumors, in order to define its present role in the clinical practice"
https://pharos.nih.gov/idg/targets/P15056,P15056,25970686,"KIT-mutated patients had a worse outcome than PDGFRA-mutated or triple-negative (KIT, PDGFRA, BRAF wild-type) cases"
https://pharos.nih.gov/idg/targets/P15056,P15056,25957797,"BRAF immunohistochemistry(IHC) was strongly concordant with BRAF mutation test and had high diagnostic accuracy in BRAF mutation analysis of Papillary thyroid carcinoma.[review; meta-analysis]"
https://pharos.nih.gov/idg/targets/P15056,P15056,25952101,"BRAF V600E Mutation is associated with Melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25950823,"Somatic BRAF mutation was found in a patient with syringocystadenoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25948295,"Data show that proto-oncogene protein B-raf (BRAF) inhibition reduces melanoma glucose uptake per cell, but that this change is no longer significant following normalization for cell volume changes"
https://pharos.nih.gov/idg/targets/P15056,P15056,25938346,"BRAF V600E mutation can be used as a supplementary molecular marker to aid in the diagnosis of Hairy cell leukaemia"
https://pharos.nih.gov/idg/targets/P15056,P15056,25937618,"BRAF V600E Mutation is associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25937573,"The patient carrying a concomitant BRAF mutation in temporal gangliogliomas and focal cortical dysplasia fell into Engel Class II."
https://pharos.nih.gov/idg/targets/P15056,P15056,25929517,"The aim of this study was to evaluate the prognostic role of MMR status, BRAF mutations and specific KRAS point mutation in 762 patients in Chinese population, and several clinicopathologic features to better stratify colorectal cancer patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,25922907,"RNA expression profiles were compared between conventional BRAFwild type and BRAFmutation papillary thyroid carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25920006,"Studies suggest that the role of tumor biomarker V600E mutation of the BRAF proto-oncogene to detect or exclude cancers in patients with fine-needle aspiration (FNA) reports is marginal and should be reconsidered in guidelines."
https://pharos.nih.gov/idg/targets/P15056,P15056,25916409,"Results indicated that rs3748093*A single nucleotide polymorphisms (SNPs) of BRAF proto-oncogene (BRAF) was significantly correlated with an increased risk of papillary thyroid carcinoma (PTC) in a Chinese population."
https://pharos.nih.gov/idg/targets/P15056,P15056,25911848,"Report increased frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran."
https://pharos.nih.gov/idg/targets/P15056,P15056,25908244,"Following B-RAF expression, MIR31HG is located mainly in the cytoplasm."
https://pharos.nih.gov/idg/targets/P15056,P15056,25900832,"BRAF-induced tumorigenesis is IKKalpha-dependent but NF-kappaB-independent"
https://pharos.nih.gov/idg/targets/P15056,P15056,25899783,"BRAF V600 mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25899612,"This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways"
https://pharos.nih.gov/idg/targets/P15056,P15056,25899003,"associate higher expression of the ligand-receptor axis of TFF2 and CXCR4 with BRAF V600E-mutant colon cancer (P = 3.0 x 10(-3) and 0.077, respectively for TCGA; P = 3.0 x 10(-8) and 5.1 x 10(-7) for CIT)"
https://pharos.nih.gov/idg/targets/P15056,P15056,25890285,"A complex mechanism driven by mutation BRAF (V600E) on melanoma tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,25888143,"Histopathological prognostic markers (Breslow thickness, mitotic index, ulceration, tumor infiltrating lymphocytes pattern) did not show any differences depending on BRAF V600E mutational status"
https://pharos.nih.gov/idg/targets/P15056,P15056,25886136,"Among 264 patients, mutations in KRAS exon 2, KRAS exons 3 or 4, NRAS, BRAF and PIK3CA were detected in 34.1%, 3.8%, 4.2%, 5.4% and 6.4%, respectively. Thus, a total of 12.1% of patients without KRAS exon 2 mutations had other RAS mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,25885250,"BRAF V600E mutation is associated with glioblastoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25884297,"Tumor dissemination in colon cancer patients is less likely to occur with the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25870264,"Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition."
https://pharos.nih.gov/idg/targets/P15056,P15056,25870252,"The presence of TC was significantly associated with TERT promoter and BRAF mutations. BRAF did not influence patient outcome."
https://pharos.nih.gov/idg/targets/P15056,P15056,25868080,"The increased activity of the V600E mutant is twofold: increased flexibility of the A-loop which likely promotes the release of the products following phosphorylation of the substrate and an increased energy barrier between the active and inactive state."
https://pharos.nih.gov/idg/targets/P15056,P15056,25862899,"BRAF V600E mutation might be associated with right-sided tumors and subsequently related unexplained iron-deficiency anaemia (IDA) at presentation"
https://pharos.nih.gov/idg/targets/P15056,P15056,25854387,"The BRAFT1799A mutation was found in 38 cases (42.7%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,25854168,"The SMOF412E mutation was not detected in ameloblastoma. The BRAFV600E-activating mutation is a common event in ameloblastomas, occurring regardless of site or histological type. This mutation is also detected in odontogenic carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25851630,"BRAF mutations often affect a limited fraction of transformed metastatic colorectal cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,25843629,"Study reports that mice engineered to overexpress either the full-length murine B-Raf pseudogene Braf-rs1 and its human ortholog, BRAFP1, elicit their oncogenic activity, at least in part, as competitive endogenous RNAs (ceRNAs) that elevate BRAF expression and MAPK activation in vitro and in vivo."
https://pharos.nih.gov/idg/targets/P15056,P15056,25837167,"findings suggest that the BRAF(V600E) mutation can be detected using a PNA clamp real-time PCR in the blood of PTC[ papillary thyroid carcinoma ] patients with lung metastasis"
https://pharos.nih.gov/idg/targets/P15056,P15056,25832798,"these results may not only indicate some future applications of inhibitors targeting B-Raf(v600e), but also benefit B-Raf(v600e) harboring cancer patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25820214,"BRAF V600E mutation is associated with differentiating Rathke's cleft cyst with squamous metaplasia from papillary craniopharyngioma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25819940,"BRAF mutation in cutaneous malignant melanoma plays an important role in the development of skin cancer in Asians. population."
https://pharos.nih.gov/idg/targets/P15056,P15056,25818616,"The most important implication of these findings is that we could begin to treat patients with the BRAF V600E and CDKN2A alteration differently when they are first diagnosed than those with a lower risk for secondary high-grade glioma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25817073,"This work supports the fact that BRAF V600 mutation is not implicated in meningioma tumorigenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,25815786,"No mutations in the BRAF gene were identified in patients with gastric cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,25797743,"Preoperative targeted therapy of advanced BRAF-mutant melanoma is feasible, well tolerated, induces brisk tumor responses, and facilitates correlative science."
https://pharos.nih.gov/idg/targets/P15056,P15056,25795007,"oncogenic activation of BRAF allows tumor cells to co-opt an evolutionarily conserved MHC-I trafficking pathway as a strategy to facilitate immune evasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,25794798,"Chitosan nanoparticle-mediated BRAF siRNA interference evidently reduced the invasion capacity of gastric cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,25794445,"Pediatric oligodendrogliomas (pODGs) can harbor the KIAA1549-BRAF fusion with aberrant MAPK/ERK signaling, and there exists an option of targeting these pathways in such patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25794135,"By this integrated approach, we found that patients with BRAF V600E mutation responded very well to broad acting drugs and there was no relation to prognosis in early-stage myeloma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25784606,"Among the 779 cases, 150 cases were positive for BRAF (V600E) staining, including 38 (of 611, 6%) CRCs, 102 (of 127, 80%) PTCs and 10 (of 41, 24%) malignant melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25767210,"The study demonstrates the activating BRAF mutation (V600E), which is found in multiple human cancers, is a driver of canine invasive cell carcinoma of the bladder, and highlights a urine-based test for quick diagnosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,25767048,"BRAF mutation was frequently detected in younger patients, in thin melanomas, and in melanomas with less ulceration. As BRAF and NRAS mutations are rare in Taiwan, BRAF- or NRAS-targeted therapies may be effective only for selected Taiwanese melanoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25766129,"Our results indicate that the mutations of BRAF and KIT exist in Japanese melanoma patients, however, the cell growth signaling may be regulated by not only these mutated genes, but by other unknown regulatory factors, which may affect the prognosis of melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25762352,"Radiotherapy with concomitant BRAF inhibitor therapy is feasible with an acceptable increase in toxicity. Vemurafenib is a more potent radiosensitizer than dabrafenib."
https://pharos.nih.gov/idg/targets/P15056,P15056,25755776,"No association was established between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma in Chinese patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25752754,"These tumors showed a markedly better prognosis, with molecularly PXA-like tumors frequently harboring BRAF V600E mutations and 9p21 (CDKN2A) homozygous deletion."
https://pharos.nih.gov/idg/targets/P15056,P15056,25752325,"Results suggest that the presence of a BRAF mutation does not necessarily 'drive' more rapid tumour growth but is associated with poorer MSS in patients with early-stage disease"
https://pharos.nih.gov/idg/targets/P15056,P15056,25749811,"BRAF mutation is not associated response to chemotherapy in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25746038,"genetic association studies in populations in Ireland and Belgium: Data suggest that frequency of mutations in BRAF (specifically the V600E mutation) vary by demographic location."
https://pharos.nih.gov/idg/targets/P15056,P15056,25736029,"No BRAF V600E mutations were seen in this cohort of non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25735579,"A pathogenic BRAF(V600E) mutation was identified in a patient with Erdheim-Chester disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,25729732,"Proto-Oncogene Proteins B-raf V600E mutation analysis is considered to be the most useful diagnostic tool for differentiating hairy cell leukemia from related lymphomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25724524,"These findings enhance our understanding of factors cooperating with BRAF inhibition that accelerate keratinocyte oncogenesis as well as broaden the knowledge base of multifactorial mediators of cancer in general."
https://pharos.nih.gov/idg/targets/P15056,P15056,25712893,"BRAF is minimally prognostic in papillary thyroid carcinoma. However, prevalence of the BRAF mutation is 70% in the general population, providing the opportunity for targeted therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,25710724,"Data show that licochalcone A (LicoA) suppresses solar UV-induced cyclooxygenase (COX-2) expression by acting as a potent inhibitor of enzymes PI3K, MEK1, and B-Raf."
https://pharos.nih.gov/idg/targets/P15056,P15056,25710585,"mutation is associated with distinct clinical and histopathologic features of colonic carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,25706985,"Trametinib alone caused upregulation of p-AKT in BRAF non-V600 mutated cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,25704541,"Mutated BRAF mutant protein was detected in 53% of the bile duct adenomas and in none of the cases of bile duct hamartomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,25702102,"All four tumors that recurred were LN+, with infiltrative borders, and lacked the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25690538,"Suggest that continuing vemurafenib treatment beyond progression may be beneficial in BRAF V600 mutated advanced melanoma patients, who prior to progression responded to vemurafenib."
https://pharos.nih.gov/idg/targets/P15056,P15056,25689095,"BRAF mutations in Non-small cell lung cancer are more likely in Adenocarcinoma, and BRAF V600E mutations are more frequent in women and never smokers."
https://pharos.nih.gov/idg/targets/P15056,P15056,25688918,"mutated KRAS and mutated BRAF seem to be prognostic factors in patients with Colorectal cancer who undergo lung metastasectomy."
https://pharos.nih.gov/idg/targets/P15056,P15056,25685929,"analysis of BRAF 3'UTR isoforms in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25674762,"Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,25673558,"Review/Meta-analysis: findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies."
https://pharos.nih.gov/idg/targets/P15056,P15056,25667294,"analysis of BRAF mutation and CDKN2A deletions in childhood secondary high-grade glioma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25666295,"BRAF mutations are associated with Metastatic Colorectal Cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,25663779,"Report low rates of BRAF mutations in Chinese colorectal carcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25647260,"HPV presence was not associated with age, stage or grade of tumours, MSI or mutations in KRAS, TP53 or BRAF genes."
https://pharos.nih.gov/idg/targets/P15056,P15056,25646931,"These findings suggest that prenylation inhibition may be able to target melanoma cells with mutant NRAS or with mutant BRAF and PTEN."
https://pharos.nih.gov/idg/targets/P15056,P15056,25643238,"Case Report: successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25634750,"Report predictive value of immunohistochemistry in detecting BRAF mutations in neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,25632202,"KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected colorectal carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25628445,"BRAF mutations are associated with response to chemotherapy in colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,25627962,"suggests that PIK3CA mutations account for a small fraction of PI3K pathway activation and have a limited impact in interfering with the BRAF/NRAS-driven growth in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,25618114,"BRAF overexpression could be an independent factor causing tumorigenesis in gliomas regardless of phospho-EGFR expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,25616949,"In the management of thyroid nodules with benign cytology but positive BRAF(V600E) mutation, thyroidectomy should be considered in nodules which have 2 or more suspicious US features and are considered discordant on image-cytology correlation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25605225,"high-resolution melt and allele-specific PCR could detect as low as 1.25% KRAS- or BRAF-mutant alleles."
https://pharos.nih.gov/idg/targets/P15056,P15056,25602792,"Data support a role for BRAF V600E immunohistochemistry in diagnostically challenging cases of metanephric adenoma and expand the spectrum of BRAF exon 15 mutations in this uncommon but unique renal neoplasm."
https://pharos.nih.gov/idg/targets/P15056,P15056,25600339,"melanoma cell lines selected for resistance to BRAFi+MEKi, but not those to BRAFi alone, displayed robust drug addiction, providing a potentially exploitable therapeutic opportunity."
https://pharos.nih.gov/idg/targets/P15056,P15056,25593071,"BRAFV600E-mutation-positive papillary thyroid microcarcinoma are more likely to manifest with aggressive clinicopathological characteristics."
https://pharos.nih.gov/idg/targets/P15056,P15056,25588542,"BRAF V600E mutation is associated with Anaplastic thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,25584719,"This is the largest study on the aggressive role of TERT promoter mutations in anaplastic thyroid cancer(ATC), demonstrating an association of TERT C228T with BRAF V600E, older patient age, and tumor distant metastasis in ATC."
https://pharos.nih.gov/idg/targets/P15056,P15056,25581727,"Report BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25576923,"Data suggest that Sema6A and Mical1 may represent new potential therapeutic targets in BRAFV600E melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25551625,"in different macroscopic subtypes of colorectal adenoma, BRAF mutation (V600E) was found in 2 of 36 lateral spreading tumors and 1 of 34 polypoid lesions; mutations in KRAS, BRAF or PIK3CA occurred in a mutually exclusive manner"
https://pharos.nih.gov/idg/targets/P15056,P15056,25543407,"To detect whether the V600E mutation is present or absent in the BRAF gene in melanoma patients is an important component in the evaluation of the biological behavior of tumor cells and their performance of biologically significant functions."
https://pharos.nih.gov/idg/targets/P15056,P15056,25537974,"The association between a host response and lymphovascular invasion and microvessel density in primary cutaneous melanoma with a BRAF mutation suggests that they exhibit potential for strategizing immunotherapies"
https://pharos.nih.gov/idg/targets/P15056,P15056,25527633,"IRS2 copy number gain, IGF-1R, IR-A, and IGFBP6 RNA expression levels, and KRAS and BRAF mutational status were identified as candidate predictive biomarkers for response to BMS-754807."
https://pharos.nih.gov/idg/targets/P15056,P15056,25526463,"BRAFV600E intratumor and intrapatient heterogeneity in melanoma is diminutive, nevertheless, the identified exceptions will have important implications for the clinical management of this disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,25515853,"This is the first observation of a secondary BRAF mutation in a vemurafenib-resistant patient-derived melanoma sample, which confirms the potential importance of the BRAF L505H mutation in the development of therapy resistance."
https://pharos.nih.gov/idg/targets/P15056,P15056,25515650,"Missense mutations were identified in the BRAF and KRAS genes in cutaneous melanoma cell line."
https://pharos.nih.gov/idg/targets/P15056,P15056,25499274,"BRAF V600 mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25499223,"These observations led us to conclude that increased TSH signaling overcomes OIS and is essential for B-RafV600E-induced papillary thyroid carcinogenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,25491441,"The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart."
https://pharos.nih.gov/idg/targets/P15056,P15056,25490969,"global miRNA expression profiles in fresh-frozen metastatic melanomas in relation to clinical outcome and BRAF mutation, were examined."
https://pharos.nih.gov/idg/targets/P15056,P15056,25490715,"BRAF V600E mutation affects patients with large/giant congenital melanocytic nevi, and with neurocutaneous melanocytosis, a novel finding."
https://pharos.nih.gov/idg/targets/P15056,P15056,25482468,"did not find a negative prognostic impact of a positive BRAF V600E mutation status on survival in papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,25479927,"The combined BAP1-BRAFV600E+ immunoprofile appears to be a constant feature of BAP1 tumor syndrome-associated melanocytic lesions"
https://pharos.nih.gov/idg/targets/P15056,P15056,25473895,"truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy"
https://pharos.nih.gov/idg/targets/P15056,P15056,25468810,"The BRAF(V600E) mutation was significantly associated with lymph node metastasis and poor prognosis in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25463315,"We documented three novel mutations in the BRAF gene in cardio-facio-cutaneous syndrome patients and correlated clinical findings with causative mutations in the BRAF or MEK1/MEK2 genes"
https://pharos.nih.gov/idg/targets/P15056,P15056,25456393,"Lymph node specimens with low tumor cellularity due to numerous adjacent lymphocytes may pose a challenge to clinical detection of BRAF mutations of melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25450274,"The consistency of the BRAF gene mutation in peripheral blood and tissue is high."
https://pharos.nih.gov/idg/targets/P15056,P15056,25442675,"The determination of BRAF mutational status is recommended in any cystic sellar lesion and can in most cases be provided by VE1 immunohistochemistry even in specimens of low cellularity."
https://pharos.nih.gov/idg/targets/P15056,P15056,25442222,"BRAF V600E mutation status did not correlate with any clinicopathological parameters"
https://pharos.nih.gov/idg/targets/P15056,P15056,25437913,"Together, this work provides formal proof of an allosteric link between the RAF dimer interface, the activation segment and the catalytic infrastructure."
https://pharos.nih.gov/idg/targets/P15056,P15056,25437182,"Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,25430497,"Preanalytical workflow optimisation may reduce errors in down-stream sequencing in BRAF mutation detection."
https://pharos.nih.gov/idg/targets/P15056,P15056,25429742,"BRAF V600E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR MoAbs."
https://pharos.nih.gov/idg/targets/P15056,P15056,25427581,"In this retrospective analysis, triplet chemotherapy with OCX was well tolerated and achieved encouraging efficacy in metastatic colorectal cancer irrespective of RAS/RAF mutation status."
https://pharos.nih.gov/idg/targets/P15056,P15056,25426645,"there is a lower incidence of brain metastases in patients with BRAF-mutated tumors who took vemurafenib before the diagnosis of brain metastases"
https://pharos.nih.gov/idg/targets/P15056,P15056,25404749,"The frequency of the BRAF mutation in cPTCs with suspicious US features was higher than that of cPTCs with negative US features regardless of the BSRTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,25400776,"Concluded that the presence of BRAF(V600E) mutation in papillary thyroid carcinoma could be preoperatively predictive of extrathyroidal invasion in a Chinese population."
https://pharos.nih.gov/idg/targets/P15056,P15056,25389051,"we describe three interesting cases of paediatric glial and glioneuronal tumours harbouring both BRAF V600E and H3F3A K27M mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,25385688,"Results demonstrate that mutated BRAF is associated with melanomas that are more aggressive.They are also associated with absence of solar elastosis and tumor epitheloid cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,25378232,"BRAF V600E inhibited NIS expression by the upregulation of its promoter methylation.  Specific regions of CpG islands of NIS promoter in BRAF V600E harboring papillary thyroid carcinoma were highly methylated compared with surrounding normal tissue."
https://pharos.nih.gov/idg/targets/P15056,P15056,25376477,"discordancy of BRAF mutation status is not an infrequent finding between primary and metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25370533,"PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25370473,"our data indicate that preexisting MEK1(P124) mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of patients with BRAF-mutant melanoma likely to benefit from combination therapies"
https://pharos.nih.gov/idg/targets/P15056,P15056,25367198,"our study demonstrated the BRAF V600E mutation was an independent prognostic factor for colon cancer patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25363723,"BRAF and NRAS alterations are preserved during in vitro culture in melanoma in a series of patients in which the c-KIT mutation was not detected"
https://pharos.nih.gov/idg/targets/P15056,P15056,25351955,"this study supports the idea that additional NK cell-based immunotherapy (by checkpoint blockade or agonists or cytokines) may combine well with BRAF(V600E) inhibitor therapy to promote more durable responses in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25346165,"BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25337709,"The BRAF(V600E)mutation iss significantly associated with several poor clinicopathologic characteristics, but was not associated with sonographic features, regardless of thyroid tumor size."
https://pharos.nih.gov/idg/targets/P15056,P15056,25337237,"Report BRAF mutation status in colorectal neoplasms and neuroendocrine differentiation in primary/metastatic colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,25332244,"Data indicate an independent prognostic value of BRAF V600E mutation for papillary thyroid cancer (PTC) recurrence in various clinicopathologic categories."
https://pharos.nih.gov/idg/targets/P15056,P15056,25324352,"we identify that analysis of plasma and urinary cfDNA provides a reliable method to detect the BRAF(V600E) mutation and monitor response to therapy in these disorders."
https://pharos.nih.gov/idg/targets/P15056,P15056,25318602,"we detected 15 additional mutated melanoma samples and two additional BRAF V600E mutations in metastatic colorectal cancer samples by the LightMix assay compared to Sanger sequencing."
https://pharos.nih.gov/idg/targets/P15056,P15056,25314065,"B-RAF mutations were frequently detected in aberrant crypt foci."
https://pharos.nih.gov/idg/targets/P15056,P15056,25306614,"710 melanomas included in the study were located in sun non-exposed regions of the skin; this category of tumors was characterized by the highest occurrence of BRAF mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,25273224,"BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene."
https://pharos.nih.gov/idg/targets/P15056,P15056,25267307,"KRAS and BRAF mutation analysis could be used in the selection of patients for anti-EGFR therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,25266729,"BRAF V600E allele frequency is associated with papillary thyroid cancer progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,25262966,"Overexpression of HO-1 in a subset of thyroid cancers is associated with tumour aggressiveness and BRAF V600E expression"
https://pharos.nih.gov/idg/targets/P15056,P15056,25262755,"BRAF mutation status was obtained for 146/160 cases. Overall mutation rate was 24/88 (27.3%) in primary and 25/58 (43.1%) in metastatic melanoma. V600E was the predominant mutation in 21/24 (87.5%) of primary and 23/25 (92%) of metastatic melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25244542,"The frequency of KRAS and BRAF mutations was low; KRAS mutations were detected in 1.6% and BRAF mutations in 4.7% of the biopsies for anal carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25242093,"Data suggest that proto-oncogene potein B-raf (BRAF) V600E mutations are present in rare cases of dendritic cell and histiocytic disorders, and their identifi cation off ers a potential therapeutic target for these neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,25239454,"dual HSP90/TRAP1 inhibitor HSP990 showed activity against the TRAP1 network and high cytostatic potential in BRAF-mutated colorectal carcinoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,25236573,"A high discordant rate was found in Braf mutation statuses between primary and metastatic cutaneous melanoma lesions."
https://pharos.nih.gov/idg/targets/P15056,P15056,25219500,"Results reveal a BRAF(V600E)-directed pathway that mediates silencing of MLH1 and, more generally, is responsible for CpG Island Methylator phenotype."
https://pharos.nih.gov/idg/targets/P15056,P15056,25213729,"BRAF(V600E) status may help to predict clinical outcome of PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,25202140,"33% of Langerhans cell histiocytosis cases with wild-type BRAF and none with BRAFV600E harbored somatic mutations in MAP2K1 (6 in-frame deletions and 1 missense mutation) that induced extracellular signal-regulated kinase (ERK) phosphorylation in vitro."
https://pharos.nih.gov/idg/targets/P15056,P15056,25194980,"6 different BRAF missense mutations were found in 9 of 11 patients with cadiofaciocutaneous syndrome."
https://pharos.nih.gov/idg/targets/P15056,P15056,25188864,"this study sheds light on the pathogenesis of Serous borderline tumor ovarian tumors by showing that BRAF mutation is associated with cellular senescence"
https://pharos.nih.gov/idg/targets/P15056,P15056,25180764,"Targeted therapy in BRAF mutated melanoma; treatment with BRAF inhibitors and in combination with MEK inhibitors. [Review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,25176643,"Methylation of MLH1 is strongly associated with BRAF mutations in sporadic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,25174651,"This study suggests that BRAF mutation-related specific transcripts associate with a poor phenotype in melanoma and provide a nest for further investigation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25165098,"PTEN loss was significantly associated with OS and time to MBM in patients with BRAF(V600) mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,25164765,"Targeted sequencing on primary, metastatic, and normal tissue from colorectal cancer patients found a high degree of concordance for KRAS, NRAS, and BRAF mutations that were identical in both the primary and metastatic tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,25156883,"BRAF(V600E) mutation is associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25156525,"V600E BRAF mutation is associated with synchronous and metachronous thyroid cancer coexisting with Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,25155755,"X-ray crystallography reveals a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK."
https://pharos.nih.gov/idg/targets/P15056,P15056,25154726,"combination of microsatellite instability and BRAF status serves as both a prognostic and predictive marker and may provide much-needed guidance during the planning of therapeutic strategies"
https://pharos.nih.gov/idg/targets/P15056,P15056,25153715,"The potential role of combined MMR and BRAF IHC as prognostic markers in CRC."
https://pharos.nih.gov/idg/targets/P15056,P15056,25148578,"Multiple potential therapeutic targets were identified in metastatic unknown primary and cutaneous melanomas that lacked BRAFV600 and NRAS mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,25139339,"Our data suggest that the poor prognosis of dMMR is driven by the BRAF(MT) status."
https://pharos.nih.gov/idg/targets/P15056,P15056,25120313,"The prevalence of rare BRAF mutations was 0.76% of all BRAF-positive thyroid cancers, and the rare mutations were associated with less aggressive pathologic features."
https://pharos.nih.gov/idg/targets/P15056,P15056,25118810,"activating V600E BRAF mutation can be frequently demonstrated in pediatric Langerhans cell histiocytosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,25116269,"Next Generation Sequencing (NGS) assay revealed three genomic alterations: activating BRAF mutation (V600E), loss of CDKN2A/2B, and APC I1307K. After treatment with BRAF inhibitor (dabrafenib), the child's clinical condition improved progressively."
https://pharos.nih.gov/idg/targets/P15056,P15056,25109331,"loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation"
https://pharos.nih.gov/idg/targets/P15056,P15056,25104559,"It is a major negative mediator of the extracellular signal-related kinase (ERK)/mitogen-activated protein kinase and a substrate of cdk5 in neurons."
https://pharos.nih.gov/idg/targets/P15056,P15056,25085839,"The up-regulation of uPA mRNAs was correlated with high-risk clinicopathological features, including extrathyroid invasion, loss of cellular polarity/cohesiveness, and the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25076244,"Prevalence of BRAF mutations in CRC patients is not high but extremely correlated with MSI and risk categories as BG, whereas they are absent in LS patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25073704,"ETV1 expression is a rare event in human melanoma and seems to be rather based on hyperactivation of MAPK signals, by BRAF (V600E) mutation, than on ETV1 gene amplification."
https://pharos.nih.gov/idg/targets/P15056,P15056,25073438,"KRAS, BRAF, and PIK3CA mutations were evaluated in 204 colorectal carcinoma samples; the frequency of KRAS, BRAF, and PIK3CA mutations was 23.5, 9.8, and 5.9 %, respectively."
https://pharos.nih.gov/idg/targets/P15056,P15056,25070294,"Data indicate that BRAF mutant status and number of positive lymph nodes as the only independent prognostic factors for recurrence-free (RFS) and disease-specific survival (DSS)."
https://pharos.nih.gov/idg/targets/P15056,P15056,25066317,"BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior"
https://pharos.nih.gov/idg/targets/P15056,P15056,25063807,"NRAS expression and increased MAPK activation drive vemurafenib resistance in V600E BRAF+ve melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,25056119,"Enforced expression of RAC1 P29S in sensitive BRAF-mutant melanoma cell lines confers resistance manifested by increased viability."
https://pharos.nih.gov/idg/targets/P15056,P15056,25051202,"BRAF V600 mutations are associated with pathological features in Japanese melanoma patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,25050586,"BRAF mutations were found in 8.7% of colorectal cancer precursor lesions, mainly associated with serrated polyps and absent in adenomas. In CRC cases, 6.5% exhibited BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,25048604,"BRAF(V600E) mutations in primary cutaneous melanomas were associated with residence in locations with medium and high UV indices in mid-life."
https://pharos.nih.gov/idg/targets/P15056,P15056,25046227,"This study demonstrates that IHC analysis is a very sensitive test for evaluation of BRAF mutations in metastatic malignant melanoma and may be useful as an initial screening test."
https://pharos.nih.gov/idg/targets/P15056,P15056,25039399,"The adenocarcinoma showed expression of CK20 and p53, but CK7 in patches. The molecular profile of the adenocarcinoma showed a mutation in KRAS and wild-type BRAF, which might be associated with malignant transformation of intracranial mature teratomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,25034364,"Common BRAF mutations are not present in systemic mastocytosis patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,25031736,"No BRAF mutations were detected in the lesions of 18 cases"
https://pharos.nih.gov/idg/targets/P15056,P15056,25029639,"Data indicate mutation in the proto-oncogene protein B-raf (BRAF) gene at the time of hairy cell leukemia (HCL) diagnosis in two cases."
https://pharos.nih.gov/idg/targets/P15056,P15056,25024077,"Coexisting BRAF V600E and TERT C228T mutations form a novel genetic background that defines PTC with the worst clinicopathologic outcomes, providing unique prognostic and therapeutic implications."
https://pharos.nih.gov/idg/targets/P15056,P15056,25015869,"document two rare cases of massively metastatic spinal cord GGs in adult patients who were negative for BRAF V600E mutations via multiple methods"
https://pharos.nih.gov/idg/targets/P15056,P15056,25013125,"In tDNA, 50 mutations (36 EGFR, 5 ERBB2, 4 KRAS, 3 BRAF, and 2 PIK3CA) were identified, of which 26 were detected in cfDNA. These data demonstrate the feasibility and potential utility of mutation screening in the detection of a range of tumor biomarkers"
https://pharos.nih.gov/idg/targets/P15056,P15056,25010701,"SOX2 expression is partly regulated by BRAF signalling, and an increased SOX2 expression may promote CRC metastasis and mediate a poor patient prognosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,25005754,"Our results highlight the low incidence of BRAF mutations and CIMP in CRC from Saudi Arabia."
https://pharos.nih.gov/idg/targets/P15056,P15056,24993163,"Activating FGFR2-RAS-BRAF mutations play a critical role in the pathogenesis of most cases of ameloblastoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24992171,"The absence of CXCR4 expression and BRAF mutation in cancers with a minor PD component underlined different pathogenic and metastatic processes in comparison with WDCs."
https://pharos.nih.gov/idg/targets/P15056,P15056,24989827,"BRAF testing is a useful adjunct to improve PPV for patients with \"suspicious for PTC\" cytology."
https://pharos.nih.gov/idg/targets/P15056,P15056,24979348,"BRAF mutations in NSCLC were significantly associated with adenocarcinomas ."
https://pharos.nih.gov/idg/targets/P15056,P15056,24978326,"BRAFV600E mutation in primary tumor might be a promising molecular marker to predict the status of 131I uptake in distal metastases."
https://pharos.nih.gov/idg/targets/P15056,P15056,24964857,"Results suggest tha tthe pathological progression from Serrated adenoma through colon carcinoma required the successive events: mutations in BRAF protein, hypermethylation of MLH1 then hypermethylation in AXIN2."
https://pharos.nih.gov/idg/targets/P15056,P15056,24964758,"MSI and the BRAF(V600E) mutation have a prognostic impact in colon cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24958825,"BRAF(V600) mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24958809,"Although there was large variability between patients, FDG uptake decreased with higher daily doses in patients with BRAFV600 mutation-positive melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24954313,"Considering the diagnostic performance and low reproducibility of US, the combination of FNA with BRAFV600E is the most reliable and objective method for diagnosing thyroid malignancy."
https://pharos.nih.gov/idg/targets/P15056,P15056,24950457,"amuvatinib has proapoptotic activity against melanoma cell lines, with selectivity observed for those harboring oncogenic NRAS but not BRAF"
https://pharos.nih.gov/idg/targets/P15056,P15056,24947927,"BRAF mutations are associated with response to chemotherapy in cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24942334,"The 5-year survival rate of colorectal cancer patients with BRAF mutations was significantly decreased."
https://pharos.nih.gov/idg/targets/P15056,P15056,24941944,"Although both, DTIC and TMZ act as alkylating agents through the same intermediate, NRAS and BRAF mutant cells responded differentially only to DTIC."
https://pharos.nih.gov/idg/targets/P15056,P15056,24936068,"a novel role for B-Raf in the selective regulation of alpha4beta1 integrin-mediated adhesion."
https://pharos.nih.gov/idg/targets/P15056,P15056,24926836,"Results show that BRAF-mutated patients were significantly younger at the time of primary melanoma and first diagnosis of metastasis than BRAF wild-type patients but BRAF mutation is not associated with a more aggressive illness."
https://pharos.nih.gov/idg/targets/P15056,P15056,24922189,"Using the PCR test with sense allele-specific primers, mutations in V600 were found in 33 of 51 Russian patients (64.7%) with cutaneous melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24921639,"BRAF V600E immunohistochemistry is reliable for the evaluation of mutational status in colorectal carcinoma regardless of site or prior treatment history, and staining shows a high degree of intratumoral homogeneity."
https://pharos.nih.gov/idg/targets/P15056,P15056,24918823,"BRAF and NRAS mutation status does not influence survival in metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24918610,"The results from this prospective cohort study further support an influence of sex and lifestyle factors on different pathways of colorectal carcinogenesis, defined by KRAS and BRAF mutation status of the tumours."
https://pharos.nih.gov/idg/targets/P15056,P15056,24909403,"BRAF was a significant parameter for predicting multifocality in follicular variant of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24906137,"BET inhibition with I-BET151 appears independent of the BRAF and NRAS mutational status of melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24901049,"The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury."
https://pharos.nih.gov/idg/targets/P15056,P15056,24897065,"suboptimal specificity and PPV limits the diagnostic utility of both antibodies to reliably detect BRAF p.V600E mutations in thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24894769,"Findings suggest a link between Langerhans cell histiocytosis and Erdheim-Chester disease involving the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24893747,"Our results indicate a cross-talk between Braf and p300 in melanoma and demonstrate the importance Braf and p300 expression in the diagnosis and prognosis of melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24885690,"Genetic targeting of BRAF Valine600Aspartate drug resistance mutation identifies dabrafenib as a selective agent against BRAF-resistant colorectal cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,24885594,"While frequency rates of BRAF mutations were quite identical across the different MPM lesions, a significant increase of cKIT (p<0.001) and CyclinD1 (p=0.002) amplification rates was observed between first and subsequent primary melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,24871132,"Treatment of HCL patients with vemurafenib, an inhibitor of mutated BRAF, resulted in normalization of HSPC frequencies and increased myeloid and erythroid output from HSPCs"
https://pharos.nih.gov/idg/targets/P15056,P15056,24866436,"BRAF mutation is associated with melanoma nodal metastases and an unknown primary site."
https://pharos.nih.gov/idg/targets/P15056,P15056,24863948,"Data indicate that BRAF protein overexpression was significantly associated with thyroid extracapsular extension (ECE) and lymph node metastasis (LNM) positive cases."
https://pharos.nih.gov/idg/targets/P15056,P15056,24862939,"BRAF mutation was not associated with negative prognostic indicators or adverse outcomes in PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,24861115,"12% of KRAS negative colorectal cancer showed BRAF gene mutation. Considering that 42% of samples have a KRAS mutation, 54% of patients should not respond to therapies with monoclonal antibodies directed against epidermic growth factor (EGFR) pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,24859998,"The high-resolution melting method developed was shown to be a reliable method for BRAF mutation detection"
https://pharos.nih.gov/idg/targets/P15056,P15056,24859340,"BRAF mutation is asociated with ameloblastoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24857351,"report of a new IDH1 mutation associated with BRAF mutation in a very unusual glial tumor."
https://pharos.nih.gov/idg/targets/P15056,P15056,24848709,"Overexpression of BRAF(V600E) in normal thyroid epithelial (H tori) cells also reduced the effects of Dkk-1 on cell survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,24839220,"BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,24838814,"The BRAF mutation was significantly associated with persistence/recurrence and a potential predictor in patients with classical PTC >10 mm at a BRAF mutation prevalent area"
https://pharos.nih.gov/idg/targets/P15056,P15056,24833563,"RAC1b overexpression constitutes a marker of poor prognosis in KRAS/BRAF WT mCRC patients treated with first-line FOLFOX/XELOX therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,24832158,"Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,24828987,"The present work discusses the most recent and controversial evidence on the BRAF V600E relevance in development and progression of thyroid tumors. [Review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,24821886,"Case Report: KRAS mutated pancreatic adenocarcinoma developing on treatment with combined BRAF and MEK inhibition for metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24806883,"Characteristics and prognosis of colorectal cancer with NRAS mutations are different from those with KRAS or BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,24798740,"analysis of RAS, RET/PTC, and BRAF mutations in advanced stage of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24792487,"BRAF V600E mutation positive pediatric posterior fossa gangliogliomas exhibit no unique imaging features, are associated with shorter progression-free survival, and carry promising treatment implications by BRAF inhibitors"
https://pharos.nih.gov/idg/targets/P15056,P15056,24789721,"BRAF V600E mutation is associated with refractory hairy cell leukemia."
https://pharos.nih.gov/idg/targets/P15056,P15056,24787545,"BRAF(V600E) mutation is not a useful prognostic marker, though it does influence the short- and medium-term outcomes of classic papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24780046,"BRAF V600E is heterogeneously distributed in some papillary thyroid carcinomas(PTCs). The large BRAF V600E neoplastic cell subpopulations found in mutated cases is consistent with the view that the BRAF V600E is acquired early during PTC development."
https://pharos.nih.gov/idg/targets/P15056,P15056,24774510,"This study indicated that mutations of KRAS, PIK3CA and NRAS were rare in advanced gastric cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24770869,"Data demonstrate that the BRAF(V600E) cooperates with either PIK3CA(H1074R) or with silencing of the tumor-suppressor PTEN, to promote development of anaplastic thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24767862,"We conclude that a V600E BRAF mutation may not be helpful in distinguishing sporadic from MTS-associated sebaceous neoplasms"
https://pharos.nih.gov/idg/targets/P15056,P15056,24764675,"colorectal cancers with a BRAF mutation have distinct molecular features and resulted in a poor prognosis in Korean patients with advanced colorectal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24749938,"The presence of dermoscopic peppering and thicker Breslow index ulceration suggest a morphological consequence of immune behaviour in BRAF-mutated melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,24748129,"The percentage of mutant BRAF alleles in papillary thyroid carcinoma is significantly associated with tumor burden and extrathyroidal invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,24746198,"discordant BRAF mutation status is rare when samples from individual PTCs are compared or when samples from individual PTCs and lymph node metastasis at thyroidectomy are compared but occurs more when primary and recurrent metastasis are compared"
https://pharos.nih.gov/idg/targets/P15056,P15056,24742923,"From a practical perspective, small biopsies may not adequately represent a tumor's full mutational profile, particularly for later arising but prognostically important mutations such as those in the KRAS and BRAF genes"
https://pharos.nih.gov/idg/targets/P15056,P15056,24737664,"BRAF-mutant mCRC is associated with worse clinical outcome. Patients with BRAF-mutant tumors develop peritoneal metastases, less frequently present with disease limited to the liver, and have shorter survival after metastasectomy."
https://pharos.nih.gov/idg/targets/P15056,P15056,24735930,"AKTi combined with BRAFi-based therapy may benefit patients with tumors harboring BRAF mutations and particularly PTEN deletions or AKT mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,24733801,"Case Report: patient with V600E BRAF-mutant leptomeningeal melanoma who experienced a complete clinical and radiologic response after dabrafenib treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,24733413,"long-term treatment with BRAF inhibitors can affect the interaction between BRAF/MAPK and Wnt/beta-catenin signaling to affect patient outcomes"
https://pharos.nih.gov/idg/targets/P15056,P15056,24725538,"Response to this therapy suggests that BRAF inhibitors can affect primary CNS lesions when a documented and targetable mutation is present."
https://pharos.nih.gov/idg/targets/P15056,P15056,24721513,"analysis of pro-death autophagic processes responsible for sensitization of BRAF-V600E glioma cells toward UAI-201"
https://pharos.nih.gov/idg/targets/P15056,P15056,24721322,"BRAF(V600E) mutation demonstrated to be an adverse prognostic factor indicating aggressiveness of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24720374,"the BRAF pathway may contribute to the pathogenesis or malignant transformation of histiocytic and dendritic cell neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,24717435,"decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF(V600E)-driven signalling and tumorigenesis in mice and human cell settings"
https://pharos.nih.gov/idg/targets/P15056,P15056,24715106,"Study found BRAF V600E mutations in 81 percent of papillary craniopharyngioma sampled"
https://pharos.nih.gov/idg/targets/P15056,P15056,24714776,"BRAF mutation is associated with melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24713734,"the homebrew dispensation sequence unambiguously identifies all known BRAF mutations in this region, whereas the kit-based dispensation sequence has one unresolvable degeneracy that could be solved with the addition of two injections"
https://pharos.nih.gov/idg/targets/P15056,P15056,24710085,"mutations in BRAF and NRAS are not mutually exclusive because they were simultaneously present in the same tumor specimens"
https://pharos.nih.gov/idg/targets/P15056,P15056,24709886,"A combined inhibition strategy targeting BRAF together with multiple erbB family kinases is potentially beneficial for treating BRAF V600E mutant melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24703243,"Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24691006,"the outcome of 68 patients with advanced colorectal cancer and RAS, BRAF and PI3KCA status according to ALK gene status, is reported."
https://pharos.nih.gov/idg/targets/P15056,P15056,24684646,"analysis of a possible association between AID expression and BRAF mutation in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24679337,"genetic association studies in a population in Iran: Data suggest that a mutation in BRAF (V600E) is associated with prognosis of paritents with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24677749,"This analysis suggests that differences in disease course of PTC in children versus adults are not strongly dependent upon the presence of the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24673746,"Disruption of mutated BRAF signaling modulates thyroid cancer phenotype."
https://pharos.nih.gov/idg/targets/P15056,P15056,24671772,"Data support a central role of BRAF V600E mutation in Erdheim-Chester disease and suggest oncogene-induced senescense as a link to both inflammation and oncogenic mutation in histiocytes playing a role in the disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,24666267,"Mutations in BRAF predict resistance to anti-EGFR therapies."
https://pharos.nih.gov/idg/targets/P15056,P15056,24664307,"Studies indicate that the role of proto-cncogene protein B-raf-MEK-ERK pathway in controlling cell fate as a primary target for deregulated activation in cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24659028,"Increased BRAF mutation is associated with colorectal cancer progression and poor response to therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,24651849,"BRAF mutant/microsatellite stable (MSS) (BRAFmut/MSS) cancers (n = 33) and BRAF mutant/microsatellite unstable (MSI) (BRAFmut/MSI) cancers (n = 30) were compared for presence of copy number aberrations (CNAs) indicative of chromosomal insatbility."
https://pharos.nih.gov/idg/targets/P15056,P15056,24642661,"KRAS and BRAF genes were wild-type in all squamous cell anal carcinoma cases."
https://pharos.nih.gov/idg/targets/P15056,P15056,24639117,"Although it has limitations, the VE1 antibody represents a feasible first-line approach for evaluating BRAF mutation status and may be a valid tool in the selection of samples for molecular analysis"
https://pharos.nih.gov/idg/targets/P15056,P15056,24638167,"BRAF-V600E expression in tissue dendritic cells did not define specific clinical risk groups but was associated with increased risk of recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,24634053,"V600E mutations in 8/15 bile duct adenomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,24625419,"We evaluated the BRAF V600E expression by immunohistochemistry in pulmonary and extrapulmonary Langerhans cell histiocytosis cases"
https://pharos.nih.gov/idg/targets/P15056,P15056,24619974,"findings suggest that subcategorization of AUS by cytomorphology and BRAF V600E mutation status is important for predicting the risk of malignancy"
https://pharos.nih.gov/idg/targets/P15056,P15056,24617711,"In this large cohort, we found TERT promoter mutations to be common, particularly in Follicular thyroid carcinoma and BRAF mutation-positive papillary thyroid carcinoma, and associated with aggressive clinicopathological characteristics."
https://pharos.nih.gov/idg/targets/P15056,P15056,24614711,"Melanomas with associated naevi have a higher frequency of BRAF(V600E) mutations than melanomas unassociated with naevi."
https://pharos.nih.gov/idg/targets/P15056,P15056,24612623,"Most of the Korean patients with multifocal papillary thyroid carcinoma (PTC) had the BRAF(V600E) mutation in one or more tumor foci, and all BRAF(V600E)-positive multifocal PTC showed more aggressive features."
https://pharos.nih.gov/idg/targets/P15056,P15056,24612059,"Serrated colorectal carcinoma as proposed to arise from serrated adenoma is characterized by mutation of BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,24608435,"Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance."
https://pharos.nih.gov/idg/targets/P15056,P15056,24604709,"BRAF V600E mutations may be more prevalent than previously thought in pediatric patients with papillary thyroid carcinoma, but do not correlate with aggressive disease characteristics"
https://pharos.nih.gov/idg/targets/P15056,P15056,24603591,"BRAF mutations are virtually absent in melanomas originating from the vulva or vagina"
https://pharos.nih.gov/idg/targets/P15056,P15056,24594804,"Meta-analysis demonstrated that the BRAF V600E mutation was significantly correlated with adverse pathological features of colorectal cancer and distinct clinical characteristics."
https://pharos.nih.gov/idg/targets/P15056,P15056,24591408,"BRAF mutation is associated with atypia of undetermined significance and papillary carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24588959,"analysis of BRAF mutation and DNA methylation markers on fine needle aspiration biopsy specimens may be a useful strategy to facilitate the diagnosis of malignant thyroid neoplasm"
https://pharos.nih.gov/idg/targets/P15056,P15056,24586605,"BRAF-V600 mutations are not associated with response to chemotherapy in stage IV melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24582505,"Report safety of vemurafenib in diverse population of patients with BRAF(V600) mutated metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24560515,"Although the sensitive pyrosequencing method was used, no EGFR, KRAS or BRAF mutations could be found"
https://pharos.nih.gov/idg/targets/P15056,P15056,24559116,"BRAF mutation was significantly associated with a larger tumor size, extrathyroidal invasion and lymph node metastasis in papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24552757,"BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC."
https://pharos.nih.gov/idg/targets/P15056,P15056,24550319,"Nonsmall cell lung cancer cells with BRAF-V600E, but not other BRAF mutations, initially are sensitive to BRAF-inhibitor treatment, but rapidly acquire resistance to BRAF inhibition."
https://pharos.nih.gov/idg/targets/P15056,P15056,24548081,"BRAF mutation in FVPTC is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography and may be a potential prognostic factor as it is in classical PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,24535907,"Our results demonstrated that the BRAF V600E mutation is a common event in melanomas, representing an important molecular target for novel therapeutic approaches in such tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,24532263,"we identify KIAA1549-BRAF gene fusions in 45 % of 82 low-grade glioma samples"
https://pharos.nih.gov/idg/targets/P15056,P15056,24529209,"Molecular genetic analysis revealed BRAF duplication and a KIAA1549-BRAF fusion gene in 82% of group II tumors, but in none of the group I tumors, and a BRAF:p.V600E mutation in 43% of group I tumors, but in none of the group II tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,24508103,"For the 598 (91%) patients with BRAF(V600E) disease, median overall survival in the vemurafenib group was 13.3 months (95% CI 11.9-14.9) compared with 10.0 months (8.0-14.0) in the dacarbazine group (HR 0.75 [95% CI 0.60-0.93]; p=0.0085)"
https://pharos.nih.gov/idg/targets/P15056,P15056,24503706,"Two cases of classic HCL, 1 showing CD5 expression, were truly BRAF V600E-negative based on negative results by PCR and sequencing despite high-level leukemic involvement"
https://pharos.nih.gov/idg/targets/P15056,P15056,24497953,"B-cell receptor functions differ in hairy cell leukemia displying BRAF V(600)E and mutated IGHV."
https://pharos.nih.gov/idg/targets/P15056,P15056,24496868,"we sought to analyze the nature of IC and EC response and progression in patients with melanoma brain metastases treated with dabrafenib, and hypothesized that metastases respond and progress similarly to BRAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,24493731,"The finding of BRAF mutations in meningeal melanocytomas points to a potential initiating role of BRAF in transformation toward malignancy and could have therapeutic implications in these specific melanocytomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,24489105,"BRAF inhibition causes decreased CXCL8 secretion from melanoma cells and induce an immune response against the tumor associated with increased IFN-gamma, CCL4, and TNF-alpha."
https://pharos.nih.gov/idg/targets/P15056,P15056,24486585,"A novel mechanism for response was discovered whereby high expression level of CAV-1 at the plasma membrane disrupts the BRaf/CRaf heterodimer and thus inhibits the activation of MAPK pathway during dasatinib treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,24484235,"Suggest that some patients with advanced melanoma who are BRAF-mutation positive may benefit from ipilimumab as the first part of their sequential treatment schedule."
https://pharos.nih.gov/idg/targets/P15056,P15056,24475291,"B-RAF is a powerful regulator of hERG channel activity and cell surface hERG protein abundance."
https://pharos.nih.gov/idg/targets/P15056,P15056,24475086,"no significant survival differences were found according to BRAF-V600 tumor mutations in patients with primary melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24471909,"Data show that a high proportion of cases of non-pulmonary Langerhans cell histiocytosis (LCH) and pulmonary LCH (PLCH) expressed the proto-oncogene protein B-raf (BRAF) V600E mutant protein."
https://pharos.nih.gov/idg/targets/P15056,P15056,24471189,"results probably indicate that BRAF mutation may not be the only key factor in melanoma tumorigenesis, and that there should be multiple alternative genetic pathways related to melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24463458,"Resistance mechanisms were identified in 58% progressing tumors and BRAF alterations were common. Gene expression analysis revealed that mitogen-activated protein kinase (MAPK) activity remained inhibited in 21% of resistant tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,24446311,"A subset of patients with RAS(wt) CMML harbors BRAF kinase domain mutations that are potentially capable of activating the MAPK signaling pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,24442520,"Mutational events as well as over-expression of BRAF gene are highly implicated, independently, in the pathogenesis of thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24440976,"The presence of BRAF mutations is positively associated with advanced tumor stage in African American colorectal cancer patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,24433452,"Two V600E-negative hairy-cell leukemias had new pote mutations in exon 11 (F468C and D449E). Another HCL was BRAF wild-type in exons 2-17. All non-HCL lymphomas lacked BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,24425783,"Data reveal a mechanism by which BRAF(V600E) and PI3K signaling cooperate to regulate melanoma proliferation through AKT-independent effects on protein translation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24424406,"The B-RafV600E mutation detected in melanoma is not associated with a chronic exposure to the sun."
https://pharos.nih.gov/idg/targets/P15056,P15056,24417615,"BRAF mutational analysis by melt curve analysis is feasible in routine thyroid cytology, and in our series had a 100% specificity for PTC in subsequent histology. The application of BRAF analysis could be useful for indeterminate cytology"
https://pharos.nih.gov/idg/targets/P15056,P15056,24413733,"Targeted genotyping revealed BRAF p.Val600Glu in 95% of papillary craniopharyngiomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,24410877,"Report detection of BRAF mutations eligible for therapy with vemurafenib in melanoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,24402044,"Despite being an independent predictor of central node metastasis in small papillary thyroid carcinoma, BRAF did not add substantially to the overall prediction of occult central node metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,24398428,"Data indicate that dual targeting of heat-shock proteins 90 (Hsp90) and BRAF(V600E) kinase provided combinatorial benefit in vemurafenib-sensitive melanoma cells in vitro and in vivo."
https://pharos.nih.gov/idg/targets/P15056,P15056,24397598,"the first BRAF V600/601 and KRAS G12-K16 screening study in primary mediastinal B-cell lymphoma that failed to identify hotspot mutations in this specific subtype"
https://pharos.nih.gov/idg/targets/P15056,P15056,24390240,"BRAF mutation decreases tumor response in first-line treatment whether cetuximab was given or not in patients with KRAS wild-type, and anti-EGFR MoAb produces a clear benefit in response rate in patients with BRAF and KRAS wild-type."
https://pharos.nih.gov/idg/targets/P15056,P15056,24389984,"meta-analysis suggested that extrathyroidal extension, lymph node metastasis, disease recurrence, and advanced TNM stage were associated with BRAF(V600E) mutation in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24382015,"study found CYP24A1 expression was increased in papillary thyroid carcinoma compared to benign multinodular goitre; expression was further increased in stage III and IV tumours; a strong correlation found between CYP24A1 overexpression and BRAF(V600E) mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,24375920,"Response to vemurafenib suggests that BRAFV600 is an oncogenic driver in pediatric gliomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,24374844,"Report clinical consequences of high frequency of BRAF mutations in ameloblastoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24372748,"correlation between KRAS or BRAF mutations and prognosis was not observed"
https://pharos.nih.gov/idg/targets/P15056,P15056,24367680,"BRAF V600E-mutation in metastatic colorectal cancer characterizes a subgroup of patients with distinct biologic, clinical and pathological features and is associated with very poor patients' prognosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,24366910,"The study identifies the BRAFV600E mutation as a significant molecular alteration in malignant peripheral nerve sheath tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,24362353,"Braf(V600E)-driven tumors become addicted to autophagy as a means to preserve mitochondrial function and glutamine metabolism"
https://pharos.nih.gov/idg/targets/P15056,P15056,24356563,"The KRAS mutation is not present in about one-third of CRC patients, and therefore other gene mutations need to be investigated to better understand the molecular mechanisms of CRC and its treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,24354346,"there was no correlation between BRAF-positive primary focus of papillary microcarcinoma and more aggressive or recurrent disease"
https://pharos.nih.gov/idg/targets/P15056,P15056,24353007,"Molecular genetic tests revealed BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24345920,"BRAF fusions define a new molecular subset of melanoma, potentially comprising 4% to 8% of \"pan-negative\" cases."
https://pharos.nih.gov/idg/targets/P15056,P15056,24345274,"This study demonstrated that temporal location, reticulin deposition and CD34 expression are associated with BRAF mutation in pleomorphic xanthoastrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24335665,"Provided there is adequate quantity of viable tumor cells, immunohistochemical testing any melanoma sample from a patient with metastatic disease will accurately determine BRAF status."
https://pharos.nih.gov/idg/targets/P15056,P15056,24321241,"These cases further expand the range of glial neoplasia in which epithelioid morphology is encountered, and add to the growing list of biphasic tumors harboring the BRAF V600E mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,24311634,"BRAF-V600E mutation is associated with younger glioblastoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,24309328,"BRAF V600E mutation is a rare event in biliary tract cancer, accounting for only 1% of all subtypes, and is restricted to intrahepatic cholangiocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24301760,"We conclude that a high proportion of PTC cases likely harbors the BRAF V600E mutation. This mutation can be used as an independent factor for predicting the recurrence and distal metastasis of PTC tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,24297085,"The overall survival rate was not significantly different between patients with wild-type BRAF and those with V600E or non-V600E BRAF mutations in an Asian cohort."
https://pharos.nih.gov/idg/targets/P15056,P15056,24295088,"genetic association study in population in Italy: Data suggest rare BRAF variants (found in 1.6% of all thyroid malignancies) cluster around codon V600 in binding pocket named A-loop of kinase domain leading to greater stability of BRAF conformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24267957,"Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful diagnostic adjunctive tool in the evaluation of thyroid nodules also in elderly subjects"
https://pharos.nih.gov/idg/targets/P15056,P15056,24265152,"A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition."
https://pharos.nih.gov/idg/targets/P15056,P15056,24258620,"B-RAF increases the cell surface protein abundance and activity of the type II Na+-coupled phosphate transporters NaPi-IIa and NaPi-IIb."
https://pharos.nih.gov/idg/targets/P15056,P15056,24256466,"Frequency of somatic BRAF mutations in melanocytic lesions from patients in a CDK4 melanoma family."
https://pharos.nih.gov/idg/targets/P15056,P15056,24247620,"BRAF mutation in papillary thyroid carcinoma determined by IHC is associated with significantly increased risk of lymph node recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,24244575,"BRAF p.V600E colon tumors showed significant MEIS1 promoter methylation, which was associated with decreased MEIS1 gene expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,24242331,"associations were identified between miR-31, BRAF and prognosis in CRC"
https://pharos.nih.gov/idg/targets/P15056,P15056,24238398,"Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib"
https://pharos.nih.gov/idg/targets/P15056,P15056,24238153,"The study found a BRAF(V600E) mutation frequency of 54% (seven of 13) in brainstem gangliogliomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,24228637,"BRAF(V600E) mutation is not associated with papillary thyroid microcarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24196789,"As heterogeneity with respect to BRAF mutation status is detected in melanoma patients, subsequent testing of initially wild-type patients can yield different results and thus make BRAF inhibitor therapy accessible."
https://pharos.nih.gov/idg/targets/P15056,P15056,24183461,"Data indicate that the median time to progression (TTP) 8.9 months is close to the promising BRAF- and MEKi combination therapy with median progression-free survival (PFS) 9.4 months."
https://pharos.nih.gov/idg/targets/P15056,P15056,24178368,"study characterized the multiple-dose pharmacokinetics of vemurafenib 240-960 mg twice daily (bid) in BRAF(V600E) mutation-positive metastatic melanoma patients, using the commercial formulation"
https://pharos.nih.gov/idg/targets/P15056,P15056,24167125,"When supplemented with other noninvasive test methods, the B-RAF(V600E) test could be a powerful adjunct with extensive clinical applications for diagnosis of thyroid nodules. (review)"
https://pharos.nih.gov/idg/targets/P15056,P15056,24166180,"Results sugggest that Cdx2 may play a role in the serrated pathway to colorectal cancer with BRAF(V600E), CpG Island Methylator Phenotype (CIMP)-high and mismatch repair (MMR)-deficiency."
https://pharos.nih.gov/idg/targets/P15056,P15056,24164374,"Based on this methodology and other published results for the BRAF mutation, we believe that it is now feasible and cost effective for the UK NHS to BRAF co-test all Thy4/Bethesda Class V thyroid FNAs."
https://pharos.nih.gov/idg/targets/P15056,P15056,24161954,"B-Raf mutations are associated with cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,24152792,"results provide evidence that constitutively activated BRAF(V600E) drives aberrant proliferation of monocyte-lineage cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,24139521,"When genotypes of BRAF/KRAS mutated s-BOTs and corresponding implants were compared, no patient presented with a fully matching mutation profile of s-BOT and all corresponding implants."
https://pharos.nih.gov/idg/targets/P15056,P15056,24139215,"Of 54 intrahepatic cholangiocarcinoma cases, 7.4% were mutant for KRAS, 7.4% were mutant for BRAF, and these were mutually exclusive. These cases were associated with a higher tumor stage and a greater likelihood of lymph node involvement."
https://pharos.nih.gov/idg/targets/P15056,P15056,24124924,"evaluated the potential role of XIAP expression as a novel prognostic marker to predict recurrence, in combination with the BRAF(V600E) mutational status in papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24123003,"HSP60 protein expression may inhibit lymph node metastasis in papillary thyroid carcinomas harboring the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24122611,"No mutations were found in the BRAF gene in a cohort of 84 patients affected by squamous cell anal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24118207,"BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,24117833,"BRAF mutational analysis was performed on tissue from 104 patients: 90 with sarcoma only and 14 with sarcoma and melanoma. In the sarcoma-melanoma group, three sarcomas showed BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,24114843,"EGF, which signals through CRAF, and an activated BRAF mutant also activate PKC and stimulate cell migration through up-regulating RFFL expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,24112705,"The kinase activity of BRAFV600E/L505H was higher than that of BRAFV600E, resulting in cross-resistance to a MEK inhibitor"
https://pharos.nih.gov/idg/targets/P15056,P15056,24112392,"BRAF mutation appears to be associated with distinct, unfavourable clinicopathological characteristics in colorectal cancer - systematic review and meta-analysis"
https://pharos.nih.gov/idg/targets/P15056,P15056,24104864,"The low incidence of BRAF mutation limited assessment of its prognostic impact."
https://pharos.nih.gov/idg/targets/P15056,P15056,24095280,"Data indicate that phosphorylation of BRAF by AMPK disrupts its association with KSR1."
https://pharos.nih.gov/idg/targets/P15056,P15056,24094449,"hypothesize that the level of SPRY2 expression contributes to MAPK/ERK pathway output and accounts for BRAF V600E+ and clinical heterogeneity in papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,24073892,"The BRAF mutation represents an additional risk factor only in some subpopulations of colorectal cancers, in others having limited prognostic value."
https://pharos.nih.gov/idg/targets/P15056,P15056,24057326,"High rate of BRAF-KIAA1549 fusion is associated with pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24052184,"The BRAF mutation was positive in 37 % of papillary thyroid carcinoma patients. It had no prognostic impact. Cause-specific survival of mutation-positive high-risk patients was poorer than CSS of mutation-negative high-risk patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,24039206,"BRAF protein mutation can be reliably detected in patients diagnosed with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,24030686,"There was no significant association between BRAF positivity and tumor multicentricity, lymphovascular invasion, extranodal extension, central neck involvement, advanced stage (stage III or IV), and distant metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,24026210,"We found BRAF mutations in 13/61 of the melanoma lesions and V600K predominated over V600E."
https://pharos.nih.gov/idg/targets/P15056,P15056,24024839,"BRAF mutations were associated with reduced overall survival among patients with cololectal cancer without KRAS mutations in exon 2 and among those with NRAS mutations in exon 3."
https://pharos.nih.gov/idg/targets/P15056,P15056,24006859,"mutations in KRAS codon 61, KRAS codon 146, BRAF, NRAS, or PIK3CA detected in Asian patients were not predictive of clinical benefits from cetuximab treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,23996432,"Significant difference in Progression-free survival (PFS) and overall survival (OS)between patients with BRAF mutated and BRAF wild-type tumours was not detected"
https://pharos.nih.gov/idg/targets/P15056,P15056,23993026,"Mutation occurs at similar frequencies as NRAS in acral lentiginous melanoma of Swedish patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,23987572,"Prevalence and distribution of pathogenetic mutations in BRAF and NRAS genes were evaluated in multiple melanoma lesions from patients with different geographical origin within the same Italian population."
https://pharos.nih.gov/idg/targets/P15056,P15056,23981603,"BRAF(V600E) mutation is predictive for distant metastasis in papillary thyroid carcinoma but not positively."
https://pharos.nih.gov/idg/targets/P15056,P15056,23972510,"BRAF mutations were detected in 2 amelanotic acral melanoma cases"
https://pharos.nih.gov/idg/targets/P15056,P15056,23969188,"the association between BRAF V600E mutation and aggressive features of papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,23965740,"This study demonstrated the absence of consistent recurrent chromosomal alterations in desmoplastic infantile astrocytomas and desmoplastic infantile gangliogliomas and overall rarity of the BRAF mutation in these tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23963522,"detection of BRAF V600E in colorectal cancer specimens by immunohistochemistry is sensitive and specific and may help to identify Lynch syndrome patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,23960272,"BRAF mutation is associated with the serrated morphology of traditional serrated adenoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23959801,"Mortalin mediates a switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase."
https://pharos.nih.gov/idg/targets/P15056,P15056,23941441,"BRAF V600E-mutated protein may be valuable in the diagnostic evaluation of these glioneuronal lesions and the observed association with mTOR activation may aid in the development of targeted treatment involving specific pathogenic pathways"
https://pharos.nih.gov/idg/targets/P15056,P15056,23938765,"Report relatively high frequency of BRAF(V600E) and KIT mutations in amelanotic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23931769,"used a mutation-specific antibody for immunohistochemical detection of the BRAF V600E mutation and correlated expression with clinicopathologic features in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23930206,"The frequencies of EGFR, KRAS, BRAF, and HER-2 mutations in BM-NSCLC were 2.6, 38.5, 0, and 0% respectively."
https://pharos.nih.gov/idg/targets/P15056,P15056,23922205,"These findings demonstrate the presence of mutation-specific clinical differences between different BRAF genotypes in patients with melanoma, and support the incorporation of this information in patient evaluation and clinical trial design."
https://pharos.nih.gov/idg/targets/P15056,P15056,23908594,"Findings support the development of CDK and Raf co-targeting strategies in EGFR/HER-2-overexpressing or RAS/RAF mutant breast cancer (BC)."
https://pharos.nih.gov/idg/targets/P15056,P15056,23907581,"Our studies have identified a previously unrecognized regulatory role of Lys63-linked polyubiquitination in BRAF-mediated normal and oncogenic signalings."
https://pharos.nih.gov/idg/targets/P15056,P15056,23906414,"In our Near Eastern cohort, the BRAF mutation rate varied significantly by geographic location. In patients with multiple dysplastic nevi examined, discordant BRAF mutation status potentially negates an underlying constitutional predilection"
https://pharos.nih.gov/idg/targets/P15056,P15056,23903755,"Suppression of TORC1 activity in response to RAF or MEK inhibitors, as measured by decreased phosphorylation of ribosomal protein S6 (P-S6), effectively predicted induction of cell death by the inhibitor in BRAF-mutant melanoma cell lines."
https://pharos.nih.gov/idg/targets/P15056,P15056,23893412,"Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23893334,"TIMP-1 protein expression is a reliable surrogate marker for BRAF(V600E)-mutated status in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23887306,"Classification of serrated lesions using immunohistochemical evaluation of BRAF V600E mutation may identify lesions with higher potential to progression into sessile serrated adenoma/polyp, and further to BRAF V600E-mutated colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23883275,"Shifted termination assay fragment analysis can detect BRAF V600 mutations in formalin-fixed paraffin-embedded papillary thyroid carcinoma samples."
https://pharos.nih.gov/idg/targets/P15056,P15056,23880961,"BRAF V600E mutations occurs infrequently in endometrial cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23878352,"No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P(interaction) > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification."
https://pharos.nih.gov/idg/targets/P15056,P15056,23861977,"the presence of a BRAF- or NRAS mutation in a nevus was not associated with the risk of malignant transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23860532,"Findings show that KIT and BRAF mutations are only rarely present in SNMMs, whereas NRAS mutations seem to be relatively more frequent."
https://pharos.nih.gov/idg/targets/P15056,P15056,23855428,"The study found a high concordance of BRAF mutation status between paired metastases diagnosed at different time points."
https://pharos.nih.gov/idg/targets/P15056,P15056,23852164,"Patient-derived tumor xenografts provides 'real-time' results in an animal that phenocopies the biology and expected vemurafenib responses of the tumor in a patient with BRAF V600E melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23849768,"Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non responsive colorectal cancer patients for the anti-EGFR treatment is 28.26%."
https://pharos.nih.gov/idg/targets/P15056,P15056,23845441,"demonstrate dose-dependent effects of oncogenic signaling, with physiologic Braf(V600E) expression being sufficient for hyperplasia induction"
https://pharos.nih.gov/idg/targets/P15056,P15056,23845288,"Although BRAF mutation appears to play a role in local tumour progression, it is not a risk factor for poor prognosis or tumour recurrence in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23841470,"BRAF mutations are found in 2 to 4% of non-small cell lung cancers. The mutations harbor non-V600E mutations in 40 to 50% of cases. A phase 2 trial of dabrafenib described 8 responses of 20 patients with BRAF V600E mutant NSCLC"
https://pharos.nih.gov/idg/targets/P15056,P15056,23833303,"Melanomas arising in SSD skin have higher mutation loads and contain a spectrum of molecular subtypes compared with BRAF- and NRAS-mutant tumors indicating multigene screening approaches"
https://pharos.nih.gov/idg/targets/P15056,P15056,23833299,"Although no melanomas had high-level amplification of BRAF, the two patients with progressive disease as their best response had BRAF copy gain in their tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,23822828,"BRAF V600E mutated tumour cells was detected in the cortical tumour component, pronounced leptomeningeal tumoural stroma was predominantly negative for VE1 binding. BRAF V600E mutation affects a subset of desmoplastic infantile astrocytoma/ganglioglioma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23821376,"This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,23817662,"BRAF mutations are associated with lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23817129,"an unexpectedly higher frequency of BRAF mutations was observed in mucosal melanomas in Southern Italy."
https://pharos.nih.gov/idg/targets/P15056,P15056,23806056,"The present study demonstrates that concomitant BRAF mutation and RET/PTC rearrangement is a frequent event in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23802768,"evaluated the survival impact of MET expression in patients with BRAF(V600E/K) advanced melanoma treated with vemurafenib"
https://pharos.nih.gov/idg/targets/P15056,P15056,23800934,"The findings support the hypothesis that BRAF-mutated cells may show resistance to the anticancer effects of aspirin in patients with colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23795354,"Co-amplification of these candidate genes or the CCND1 amplification along with either BRAF or NRAS mutations might be more important for prognosis than the presence of these alterations alone."
https://pharos.nih.gov/idg/targets/P15056,P15056,23791006,"Sinonasal intestinal-type adenocarcinomas share common alterations of the EGFR pathway with colorectal adenocarcinomas, except for a lower frequency of KRAS and BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,23782679,"BRAF mutation rates varied by geographic location but not based on UV radiation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23782496,"BRAF, NRAS, and c-Kit molecular analyses among patients affected by nail apparatus melanoma were investigated."
https://pharos.nih.gov/idg/targets/P15056,P15056,23776587,"The results indicate that BRAF mutant is a predictive biomarker for poor prognosis in mCRC patients undergoing anti-EGFR MoAbs therapy, especially in KRAS WT patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,23775351,"demonstrating that the BRAF(T1799A) mutation is a clonal event in thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,23773459,"BRAF mutations are associated with colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,23771122,"We found that inherited variants of CDKN2A have no effect on the prevalence of BRAF/NRAS mutations in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23763264,"Although moderate or strong cytoplasmic staining is specific for BRAF V600E mutations in colorectal adenocarcinoma, the VE1 monoclonal antibody is insufficiently sensitive to serve as an effective screening tool."
https://pharos.nih.gov/idg/targets/P15056,P15056,23755178,"Both the CRP single nucleotide polymorphism rs7553007 and KRAS/BRAF mutations were independent prognostic factors for colorectal cancer patients with synchronous liver metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,23752636,"BRAF mutation in the elderly is also exclusive of papillary carcinoma and is often significant. Furthermore, it is related to the classic variant and possibly to thyroid extravasation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23744164,"The mutations of EGFR and BRAF genes were not found in HER2-mutated patients with brain metastasis from non-small cell lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23735514,"Selumetinib plus dacarbazine showed clinical activity in patients with BRAF-mutant cutaneous or unknown primary melanoma, reflected by a significant benefit in progression-free survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,23726842,"report that Mps1/AKT and B-Raf(WT)/ERK signaling form an auto-regulatory negative feedback loop in melanoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,23725167,"BRAF mutations are associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23715079,"Case Report: BRAF mutation documented in folliculotropic metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23690527,"We found BRAF(V600E) mutations in the melanocytic nevi to be fully clonal, strongly suggesting that BRAF-activating mutations typically are early initiating events in melanocytic neoplasia."
https://pharos.nih.gov/idg/targets/P15056,P15056,23687957,"BRAFV600E mutation is not associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23673558,"low BRAF as well as NRAS expression levels were associated with a longer progression-free survival in the total population"
https://pharos.nih.gov/idg/targets/P15056,P15056,23660947,"Establishment of molecular subgroups based on KRAS and BRAF mutation status is important and should be considered in future prognostic studies in colorectal carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23657789,"A BRAF mutation-specific (V600E) antibody detected tumors with BRAFV600E mutations and exhibited complete concordance with a DNA-based method."
https://pharos.nih.gov/idg/targets/P15056,P15056,23650027,"Detection of the BRAF V600E mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods"
https://pharos.nih.gov/idg/targets/P15056,P15056,23636013,"Braf mutations were not associated with the risk of lymph node metastasis in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23633454,"The presence of NRAS or BRAF mutations in a mutually exclusive pattern in roughly half (47%) of conjunctival melanomas and the pattern of CNAs argue for conjunctival melanoma being closely related to cutaneous and mucosal melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23625203,"This study demonstrated that either BRAF or RAS mutations were present in two thirds of follicular variants of papillary thyroid carcinomas and these mutations were mutually exclusive."
https://pharos.nih.gov/idg/targets/P15056,P15056,23615046,"BRAF mutation is associated with poor response to anti-EGFR MoAbs and it is an adverse prognostic biomarker of the survival of patients with metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23613396,"K-RAS and B-RAF mutations do not seem to be predictive of treatment outcome as potential biomarkers for bevacizumab therapy in metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23612919,"BRAF alterations are associated with pediatric low grade gliomas and mixed neuronal-glial tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23603840,"We show that (V600E)BRAF upholds the activity of glycolysis and therefore the addiction to glycolysis de facto becomes an addiction to (V600E)BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,23595630,"A combination of solid nodules, nodules with irregular contours, symptomatic nodules, and positive BRAF mutation has high predictive value for malignancy in patients with thyroid follicular lesion of undetermined signifi-cance."
https://pharos.nih.gov/idg/targets/P15056,P15056,23594689,"the clinical pathological relevance of BRAF mutation in cancer (Review)"
https://pharos.nih.gov/idg/targets/P15056,P15056,23588369,"Our findings confirm that BRAF mutations originate in the serrated epithelium of colonic perineuriomas with crypt serration"
https://pharos.nih.gov/idg/targets/P15056,P15056,23584600,"and SSCA followed by Sanger sequencing are effective two-step strategies for the detection of BRAF mutations in the clinical setting."
https://pharos.nih.gov/idg/targets/P15056,P15056,23580256,"The overall BRAF V600E mutation rate was 70.4% and 100% in tall cell variant."
https://pharos.nih.gov/idg/targets/P15056,P15056,23579220,"Accurate diagnosis of rare BRAF mutations is crucial. Pyrosequencing is accurate, highly sensitive, reliable, and time saving to detect rare BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,23571588,"In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with papillary thyroid carcinom"
https://pharos.nih.gov/idg/targets/P15056,P15056,23569304,"Antitumor effects of vemurafenib are mediated by inhibiting oncogenic MAPK signaling in BRAF(V600)-mutant metastatic melanoma. Data suggest that inhibition downstream of BRAF should help to overcome acquired resistance."
https://pharos.nih.gov/idg/targets/P15056,P15056,23552385,"A high percentage of epithelioid giant cell glioblastoma multiformemanifest BRAF V600E mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23549875,"Data indicate that concurrent BRAF and PI3K/mTOR blockade results in induction of apoptosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,23548132,"About one fourth of mCRC cases wild-type for KRAS codons 12 and 13 present other mutations either in KRAS, BRAF, or PIK3CA, many of which may explain the lack of response to anti-EGFR therapy observed in a significant proportion of these patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,23547069,"BRAF V600E mutation may identify a subset of grade 2 diffuse gliomas that have a distinct phenotype, incl. supratentorial location, chronic seizure disorder, and atypical radiographic and histologic features."
https://pharos.nih.gov/idg/targets/P15056,P15056,23544999,"In human BRAF papillary thyroid carcinomas, ERK kinase phosphorylation is decreased compared to normal thyroid glands."
https://pharos.nih.gov/idg/targets/P15056,P15056,23534744,"Molecular analysis of the BRAF T1799A mutation in fine needle aspiration biopsy specimens has high specificity and positive predictive value for papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23533272,"in cells expressing KIAA1549-BRAF, the fusion kinase functions as a homodimer that is resistant to PLX4720 and accordingly is associated with CRAF-independent paradoxical activation of MAPK signaling"
https://pharos.nih.gov/idg/targets/P15056,P15056,23533235,"genetic association studies in population in Italy: Data suggest that V600E mutation in BRAF in subjects with papillary thyroid carcinomas with/without lymph node metastases is not associated with disease progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,23517740,"Aberrant BRAF splice variants with deletions in both kinase and RAS-binding domains in rheumatoid arthritis patients demonstrate that these BRAF splice variants constitutively activate MAPK through CRAF"
https://pharos.nih.gov/idg/targets/P15056,P15056,23511561,"A BRAF mutation was only detected in a single Japanese gastric cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23505540,"follow-up BRAFV600E mutation analysis may be helpful in the diagnosis of selected thyroid nodules negative for BRAFV600E mutation on initial analysis, which are assessed as suspicious malignant on ultrasonography."
https://pharos.nih.gov/idg/targets/P15056,P15056,23496275,"This study confirms that the BRAF mutation is differentially detected in each variant of papillary thyroid cancer and is strongly correlated with unfavorable clinicopathologic factors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23489693,"The novel melanoma cell lines were compared to metastatic cell lines (HBL, LND1), wild type (wt) for MC1R and BRAF genes."
https://pharos.nih.gov/idg/targets/P15056,P15056,23482591,"Results document the expression of RAC1b in normal thyroid cells as well as overexpression in a subset of PTCs. They suggest a possible interplay between BRAF V600E and RAC1b contributing to poor clinical outcome."
https://pharos.nih.gov/idg/targets/P15056,P15056,23482475,"BRAF mutation shows clinical significance in the prognosis of thyroid papillary cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23477830,"melanomas with activation of the BRAF/MAPK pathway have suppressed levels of MITF and PGC1alpha and decreased oxidative metabolism"
https://pharos.nih.gov/idg/targets/P15056,P15056,23476074,"BRAF V600E mutation testing modifies sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules."
https://pharos.nih.gov/idg/targets/P15056,P15056,23463675,"V600R mutation and double (V600E -V600M) mutation were identified in two melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,23463215,"In this manuscript, we provide an overview of the emerging scientific literature on dermatological adverse events arising out of BRAF inhibition."
https://pharos.nih.gov/idg/targets/P15056,P15056,23455323,"The Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23448684,"An analysis of BRAF mutations in fast-growing melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23447565,"MITF-BCL2A1 as a lineage-specific oncogenic pathway in melanoma and underscore its role for improved response to BRAF-directed therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,23444215,"Data indicate that tumor regression was seen in three of five patients with BRAF-mutated, low pAKT melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23442159,"This study demonistrated that Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,23435618,"BRAF V600E mutation was detected in 41/71 (58 %) gangliogliomas by immunohistochemistry, DNA sequencing was concordant in 60 of 62 analyzed cases, and BRAF V600E-mutated protein was localized predominantly to the neuronal compartment."
https://pharos.nih.gov/idg/targets/P15056,P15056,23435375,"BRAF(V600E) increases migration and invasion of thyroid cancer cells via upregulation of Snail with a concomitant decrease of its target E-cadherin."
https://pharos.nih.gov/idg/targets/P15056,P15056,23416953,"study identified two miRNAs (miR-21* and miR-203 that are differentially expressed in papillary thyroid carcinoma tissues with BRAF(V600E) and revealed their associations with clinicopathological features"
https://pharos.nih.gov/idg/targets/P15056,P15056,23416158,"AURKB and WEE1 are targets and biomarkers of therapeutic efficacy, lying downstream of (V600E)B-RAF in melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23412871,"The BRAF gene polymorphism (rs10487888) may not be a genetic determinant for increasing the risk of chronic periodontitis among the Iranian population"
https://pharos.nih.gov/idg/targets/P15056,P15056,23401454,"Studies identified 21 deleterious mutations MLH1, MSH2, MSH6 and BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,23401445,"The role of BRAF V600E as targetable driver mutation in lung adenocarcinoma is strengthened by finding that in vivo expression of V600E in mice leads to development of invasive adenocarcinoma, a phenotype that is reversed when V600E expression is stopped."
https://pharos.nih.gov/idg/targets/P15056,P15056,23388101,"Report BRAF mutations in ovarian serous carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23374602,"BRAF and codon 12 KRAS mutations predict for adverse outcome of colorectal cancer patients receiving cetuximab."
https://pharos.nih.gov/idg/targets/P15056,P15056,23370668,"study suggests that highly aggressive papillary thyroid microcarcinoma may arise in a subset of patients with BRAF(V600E) mutation and tumors greater than 5 mm; multivariate analysis showed that tumor recurrence was not associated with BRAF(V600E)mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23370429,"This is the first report of BRAF V600E mutation in endometrial cancer, indicating that it may contribute to tumorigenesis of endometrial cancer, although at a low frequency compared with KRAS mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,23359496,"Kidins220 is a novel T-cell receptor (TCR)-interacting protein that couples B-Raf to the TCR. Kidins220 is mandatory for sustained Erk signaling and is crucial for TCR-mediated T cell activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23355004,"The detected Merkel cell polyomavirus prevalence in non-small cell lung cancer in combination with the deregulated expression of BRAF and Bcl-2 genes suggests that these events are likely to contribute to the pathogenesis of non-small cell lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23354951,"Alternative splicing of exons 14, 15, 15b, 16b and 16c occurs in a considerable fraction of BRAF mRNA in normal colon and colorectal cancer cells and is independent of the V600E mutational status of the parental allele."
https://pharos.nih.gov/idg/targets/P15056,P15056,23352452,"Ras pathway activation via EGF treatment induced strong binding between B-Raf and C-Raf and a low level of binding between B-Raf and A-Raf."
https://pharos.nih.gov/idg/targets/P15056,P15056,23349307,"Data indicate that besides confirming the constant presence of BRAF-V600E in all patients with hairy cell leukemia, phospho-ERK1/ERK2 expression was observed."
https://pharos.nih.gov/idg/targets/P15056,P15056,23343956,"no association with BRAF-V600E mutation in gastroeosophageal tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,23334329,"Human neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23324583,"BRAF mutations is associated with colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23317446,"Results demonstrated the action of Dabrafenib and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations; these results could be helpful to enlarge the number of patients who may benefit of a more effective targeted treatment"
https://pharos.nih.gov/idg/targets/P15056,P15056,23310942,"This study shows that BRAF mutation occurs in Nigerian colorectal cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,23307859,"High BRAF is associated with metastatic melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23297805,"No point mutations were identified in BRAF codon Val600Glu in the studied colorectal adenocarcinomas in the Turkish population."
https://pharos.nih.gov/idg/targets/P15056,P15056,23290787,"Studies indicate that BRAF mutations are identified in 40-50% of patients with melanoma, and treatment with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor trametinib is associated with improved clinical benefit."
https://pharos.nih.gov/idg/targets/P15056,P15056,23287985,"Pulmonary Langerhans cell histiocytosis appears to be a clonal proliferation that may or may not have BRAF V600E mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,23280049,"Preoperative mutation screening for BRAF(V600E) does not meaningfully improve risk stratification and is unlikely to alter the initial management of patients with indeterminate nodules."
https://pharos.nih.gov/idg/targets/P15056,P15056,23274581,"BRAF mutation is associated with esophageal squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23263826,"we deduce that in the absence of mutation activation, B-Raf overexpression or downregulation is a protective event, since it delays the development of both malignant and benign thyroid tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23253715,"The status of BRAF(V600E) mutation was more frequent in multifocal PTC patients with lymph node metastasis and diagnosis at later age."
https://pharos.nih.gov/idg/targets/P15056,P15056,23246082,"the role of BRAF mutations in melanoma and colorectal cancer, focusing on similarities and differences of BRAF mutations (Review)"
https://pharos.nih.gov/idg/targets/P15056,P15056,23242808,"Data indicate that BRAF and EGF receptor or SRC family kinase inhibition blocked proliferation and invasion of the resistant tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23237741,"Patients with V600R BRAF mutations can be treated successfully with oral BRAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,23235345,"the BRAF V600E mutation is not pathobiologically relevant in primary central nervous system lymphoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23224067,"Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23208503,"results suggest that mutant B-RAF signaling downregulates Tiam1/Rac activity resulting in an increase in N-cadherin levels and a decrease in E-cadherin levels and ultimately enhanced invasion"
https://pharos.nih.gov/idg/targets/P15056,P15056,23207070,"The present study revealed that ESCC of Brazilian patients do not present mutations in hot spots of EGFR, K-RAS and BRAF and only a minor proportion present overexpression of EGFR or HER2."
https://pharos.nih.gov/idg/targets/P15056,P15056,23203004,"BRAF (V600E) is non-associated with Gal-3 expression, whereas it is associated with cytoplasmatic localization of p27kip1 and higher CK19 expression in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23192956,"BRAF (V600E) mutation is associated with papillary thyroid microcarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23192464,"Aim of this work is to provide a detailed comparison of clinical-pathologic features between well-differentiated and poorly differentiated tumors according to their BRAF and RASSF1A status."
https://pharos.nih.gov/idg/targets/P15056,P15056,23190890,"Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,23190154,"Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to neurofibromatosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,23188063,"BRAF mutations were correlated with poor overall survival in the full patient cohort"
https://pharos.nih.gov/idg/targets/P15056,P15056,23179992,"BRAF (V600E) mutation is associated with papillary thyroid carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23163107,"The BRAF(V600E) mutation might be associated with a more aggressive phenotype and a poor prognosis in classic variant of papillary thyroid carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,23161722,"data confirm that among lymphoproliferative disorders, BRAF V600E mutation is restricted to hairy cell leukemia (HCL); no mutations were identified in variant HCL, NMZL, ENMZL, PTLD, PTCL, ALCL, or LGL proliferations"
https://pharos.nih.gov/idg/targets/P15056,P15056,23161556,"BRAF mutation as a new serum marker for papillary thyroid carcinomas were not detectable in patientts diagnosed with thyroid neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,23159116,"V600E point mutation was identified in the BRAF gene in 3 intramucosal nevi and in 2 melanomas. Only 1 blue nevus harbored the GNAQ209 mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,23158172,"BRAF mutational status is predictive of papillary thyroid carcinoma recurrence"
https://pharos.nih.gov/idg/targets/P15056,P15056,23157824,"Codon 12, 13 in KRAS gene and codon 600 in BRAF gene are the most common mutation points in Chinese colorectal cancer. KRAS and BRAF mutations are mutually exclusive. KRAS and BRAF gene mutation is higher in females than that in males."
https://pharos.nih.gov/idg/targets/P15056,P15056,23157823,"In Chinese colorectal carcinoma patients, BRAF mutation is associated with tumor differentiation and primary tumor sites."
https://pharos.nih.gov/idg/targets/P15056,P15056,23157614,"Data indicate that the presence of the BRAF V600E mutation was more frequent in women, but this gender difference was not statistically significant."
https://pharos.nih.gov/idg/targets/P15056,P15056,23153455,"These findings indicate that ABCG2 confers resistance to vemurafenib in A375 cells, suggesting involvement of this transporter in acquired resistance to vemurafenib."
https://pharos.nih.gov/idg/targets/P15056,P15056,23138171,"Clinical characteristics of colorectal cancer with the V600E BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23132792,"BRAFV600E mutation is associated with cervical lymph node metastasis and recurrence in papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23125007,"One hundred and ten patients (51%) were identified who were potentially nonresponders to anti-EGFR therapy:  13/117 (11.1%) had the V600E BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23110075,"Study demonstrates that chromosomal instability commonly occurs in advanced BRAF mutant/MSS colorectal cancers where it may contribute to poorer survival, and further highlights molecular similarities occurring between these and BRAF wild type cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,23098991,"Studied differential miRNA expression in metastatic colorectal cancer by microarrays from primary tumors of 33 patients who had wild-type KRAS/BRAF and third- to sixth-line anti-EGFRmAb treatment, with/without irinotecan."
https://pharos.nih.gov/idg/targets/P15056,P15056,23096702,"We found that NRAS-mutant melanomas were significantly more likely from older patients and BRAF-mutant melanomas were more frequent in melanomas from the trunk."
https://pharos.nih.gov/idg/targets/P15056,P15056,23096133,"BRAF mutation is associated with pleomorphic xanthoastrocytomas with anaplastic features."
https://pharos.nih.gov/idg/targets/P15056,P15056,23095503,"Desmoplastic malignant melanoma: a study of ten cases and status of BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,23088640,"analysis suggests that BRAF mutations occur at a low frequency in chronic lymphocytic leukemia"
https://pharos.nih.gov/idg/targets/P15056,P15056,23069257,"Histopathologic changes suggesting prolapsed rectal mucosa should take precedence over BRAF results in diagnosing sessile serrated adenomas in the rectum."
https://pharos.nih.gov/idg/targets/P15056,P15056,23066120,"The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor for the persistence of the disease independent from other clinical-pathological features in low-risk intrathyroid papillary thyroid carcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,23062653,"BRAF mutation was not found to be significantly associated with lymph node metastasis in patients with papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,23056577,"A systematic review and meta-analysis revealed that BRAF mutation is an absolute risk factor for patient survival in colorectal cancer and melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23055546,"BRAF mutation was associated with lymph node metastases (LNM), advanced stage, extrathyroidal extension, tumor size, male gender, multifocality, absence of capsule, classic PTC, and tall-cell variant papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,23055340,"KRAS and BRAF mutations are infrequent or absent, respectively in Intestinal-type sinonasal adenocarcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,23051629,"Increased BRAF mutation with age along with the lack of a UVR magnitude-BRAF mutation association suggests that duration of exposure rather than UVR exposure dose is the more likely link to acquiring mutations in melanocytic nevi."
https://pharos.nih.gov/idg/targets/P15056,P15056,23041829,"Findings support the potential use of immunohistochemistry as an ancillary screening tool to assess the BRAFV600E mutation status in primary cutaneous melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23039341,"Studied the cytotoxicity and anti-tumour activity of novel MEK inhibitor, E6201, in a panel of melanoma cell lines. Most melanoma cell lines were sensitive or hypersensitive to E6201; the sensitivity correlated with wildtype PTEN and mutant BRAF status."
https://pharos.nih.gov/idg/targets/P15056,P15056,23036672,"We describe 3 patients with BRAF V600E mutation metastatic melanoma in whom treatment with vemurafenib resulted in prompt extracranial disease response but progression of metastatic disease in the brain."
https://pharos.nih.gov/idg/targets/P15056,P15056,23033302,"the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data."
https://pharos.nih.gov/idg/targets/P15056,P15056,23026937,"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,23021375,"EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways have roles in colorectal cancer and treatment [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,23014346,"Braf mutation status is not significantly associated with poor survival for melanoma in Koreans."
https://pharos.nih.gov/idg/targets/P15056,P15056,23010994,"BRAF mutation is suggested to be poor prognostic factors in CRLM."
https://pharos.nih.gov/idg/targets/P15056,P15056,23010278,"B-RAF upregulates SGLT1 activity, an effect requiring vesicle insertion into the cell membrane."
https://pharos.nih.gov/idg/targets/P15056,P15056,23009221,"consistent with previous studies, it was concluded that the incidence of BRAF V600E mutation in adult acute lymphoblastic leukemia, if any, is extremely infrequent"
https://pharos.nih.gov/idg/targets/P15056,P15056,22996177,"This report is the first to identify the rare, variant BRAF V600D mutation in LCH, and provides support for constitutively activated BRAF oncogene-induced cell senescence as a mechanism of regression in congenital, benign LCH."
https://pharos.nih.gov/idg/targets/P15056,P15056,22973979,"found a significantly increased risk of papillary thyroid carcinoma attributed to the SNP variants rs17161747, rs1042179, and rs3748093 for those with a family history of cancer, for smokers, and for both those of age <45 years and nondrinkers"
https://pharos.nih.gov/idg/targets/P15056,P15056,22972589,"Higher response rates and longer time to progression were observed with selumetinib-containing regimens in patients who had melanoma that harbored a BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22946697,"Data indicate that of the 32 cardio-facio-cutaneous syndrome (CFC) patients, 28 (88%) had a known mutation in a gene that is causative for CFC, including BRAF (n = 21), MEK1 (n = 2), MEK2 (n = 4), and KRAS (n = 1)."
https://pharos.nih.gov/idg/targets/P15056,P15056,22941165,"The BRAF V600E mutation is the only independent predictor of compartment lymph node metastasis in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22938585,"Data indicate that KRAS, BRAF, PIK3CA, and AKT1 mutations can be rapidly and accurately detected for cancer diagnosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22932786,"Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV."
https://pharos.nih.gov/idg/targets/P15056,P15056,22931913,"We conclude that the presence of BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in melanoma patients with macroscopic stage III disease."
https://pharos.nih.gov/idg/targets/P15056,P15056,22930283,"BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22926515,"ARAF seems to stabilize BRAF:CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency"
https://pharos.nih.gov/idg/targets/P15056,P15056,22918165,"BRAF(V600E) mutation is an early event in thyroid carcinogenesis, and is associated with distinctive morphology and aggressive features even in papillary thyroid microcarcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,22912864,"Data indicate that mutation frequency in malanoma patients was found witih BRAF(V600) in 51%, NRAS in 19%, PI3K pathway in 41% and PTEN in 22%."
https://pharos.nih.gov/idg/targets/P15056,P15056,22899730,"The presence of a BRAF c.1799T>A (p.V600E) mutation is associated with significantly poorer prognosis after colorectal cancer diagnosis among subgroups of patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22898351,"MSI status, KRAS and BRAF mutation rates varied remarkably among the colonic carcinoma subsites irrespective of right- and left-sided origin."
https://pharos.nih.gov/idg/targets/P15056,P15056,22892521,"The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper."
https://pharos.nih.gov/idg/targets/P15056,P15056,22887810,"A K601E BRAF mutation is associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22880048,"This study reveals a novel molecular mechanism underlying the regulation of feedback loops between the MAPK and AKT pathways."
https://pharos.nih.gov/idg/targets/P15056,P15056,22879539,"High prevalence of BRAF V600E mutations is associated with Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses."
https://pharos.nih.gov/idg/targets/P15056,P15056,22876591,"Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene."
https://pharos.nih.gov/idg/targets/P15056,P15056,22870241,"High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,22863493,"The BRAFV600E occurs exclusively in papillary thyroid carcinoma and papillary carcinoma-derived anaplastic cancer, rising as a specific diagnostic marker for this tumor when identified in cytological / histological exams"
https://pharos.nih.gov/idg/targets/P15056,P15056,22859608,"BRAFV600E mutation is associated with Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22858857,"A review summarizes the role of the BRAF V600E mutation in the development and progression of thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22850568,"This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and indicates that clinical blockade of IL-1 may benefit patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,22833462,"Investigated BRAF and RAF1 alterations in Chinese prostate cancer.Found BRAF truncated in five of 200 informative Chinese cases & RAF1 was truncated in three of 204 informative cases and genomic rearrangements were correlated w/high Gleason scores."
https://pharos.nih.gov/idg/targets/P15056,P15056,22826437,"RAF1(D486N), as well as other kinase-impaired RAF1 mutants, showed increased heterodimerization with BRAF, which was necessary and sufficient to promote increased MEK/ERK activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22826122,"It was concluded that extracellular kinase-mediated up-regulation of c-myc by K-Ras or B-Raf oncogenes disrupts the establishment of apical/basolateral polarity in colon epithelial cells independently of its effect on proliferation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22824468,"Single Nucleotide Polymorphisms in BRAF gene is associated with diseases."
https://pharos.nih.gov/idg/targets/P15056,P15056,22820660,"No BRAF V600E mutations were detected in nonserous epithelial ovarian tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,22820187,"these results link epigenetic genes to methylation and suppression of tumor suppressor genes as a mechanism involved in BRAFV600E-promoted melanoma tumorigenesis and uncover a novel molecular signature that predicts a poor prognosis of melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22814862,"we found no cases of Rosette-forming glioneuronal tumors of the fourth ventricle showing KIAA1549-BRAF gene fusion or BRAF (V600E) mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,22809251,"As has been reported in other common types of melanoma, V600 BRAF mutation is the most common mutation of those tested in spindle cell melanoma. NRAS or KIT mutation appears to be rare, if not completely absent."
https://pharos.nih.gov/idg/targets/P15056,P15056,22799316,"Preoperative BRAF mutation was a predictive factor for occult contralateral papillary thyroid microcarcinoma presence."
https://pharos.nih.gov/idg/targets/P15056,P15056,22798500,"In CRC patients treated with cetuximab, activating mutation signatures for BRAF (58 genes) were developed."
https://pharos.nih.gov/idg/targets/P15056,P15056,22798288,"Data show clinical significance to BRAF(L597) mutations in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22797077,"RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth"
https://pharos.nih.gov/idg/targets/P15056,P15056,22773810,"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1."
https://pharos.nih.gov/idg/targets/P15056,P15056,22772867,"BRAF (V600) mutations are are associated with melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,22770943,"BRAF mRNA expression may help to identify PTC among thyroid nodules independently of the presence of BRAFV600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22767446,"study found a relatively higher B-Raf serine/threonine-protein kinase (BRAF)(V600E) mutation rate in classical type papillary thyroid carcinomas than in other similar studies"
https://pharos.nih.gov/idg/targets/P15056,P15056,22752848,"study reports a novel complex BRAF mutation identified in 4/492 Japanese papillary thyroid carcinoma(PTC) cases; findings suggest the BRAF(V600delinsYM)mutation, is a gain-of-function mutation and plays an important role in PTC development"
https://pharos.nih.gov/idg/targets/P15056,P15056,22751131,"B-Raf/MKK/ERK controls key aspects of cancer cell behavior and gene expression by modulating a network of miRNAs with cross-regulatory functions."
https://pharos.nih.gov/idg/targets/P15056,P15056,22743296,"BRAF V600E mutation is associated with response to vemurafenib in lung adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22742884,"Vemurafenib is effective for advanced melanomas expressing the BRAF V600E mutations [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22740704,"These results clearly prove that the BRAFV600E mutation is not associated with the development of distant metastases or fatal outcome in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,22732794,"BRAF V600E mutation revealed a strong association with specific histological variants of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22730329,"Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22727996,"BRAF V600E mutations are present in approximately 90% of all kidney metanephric adenoma cases, serving as a potential valuable diagnostic tool in the differential diagnosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22706026,"The combined effects of EGFR downregulation, ligand competition, and immune effector function conspire to inhibit tumor growth in xenograft models of cetuximab-resistant BRAF and KRAS mutant cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,22705994,"Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins."
https://pharos.nih.gov/idg/targets/P15056,P15056,22702340,"In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval."
https://pharos.nih.gov/idg/targets/P15056,P15056,22699145,"Data indicate that 14% with pancreatic ductal adenocarcinomas (PDACs) and 7% ampullary adenocarcinomas (A-ACs) had mutations in both KRAS and BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,22694820,"In papillary thyroid cancer, significant correlations between the methylation status of four genes (TIMP3, RASSF1A, RARbeta2 and DCC) and the V600E BRAF mutation were found."
https://pharos.nih.gov/idg/targets/P15056,P15056,22684223,"The presence of BRAF mutations in these adenomatous precursors to colon cancer suggests that they represent sessile serrated adenomas with complete cytologic dysplasia."
https://pharos.nih.gov/idg/targets/P15056,P15056,22681706,"BRAFV600E mutation is associated with lymph node metastasis in multiple papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22649091,"Patient's BRAF mutation was likely responsible for his tumor's marked response to dasatinib, suggesting that tumors bearing kinase-impaired BRAF mutations may be exquisitely sensitive to dasatinib."
https://pharos.nih.gov/idg/targets/P15056,P15056,22639828,"Data suggest that BRAF V600E mutation may not be widespread in hematologic malignancies, excluding hairy-cell leukemia (HCL)."
https://pharos.nih.gov/idg/targets/P15056,P15056,22628551,"Data show that RNF149 (RING finger protein 149) interacts with wild-type BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,22614978,"BRAF/NRAS mutations were identified in 58% of primary melanomas (43% BRAF; 15% NRAS)"
https://pharos.nih.gov/idg/targets/P15056,P15056,22614711,"BRAF p.Val600Lys mutations were present at a relatively high frequency in the cohort of metastatic melanoma patients (27/183, 15%)"
https://pharos.nih.gov/idg/targets/P15056,P15056,22592144,"Immunohistochemical detection of the mutated V600E BRAF protein in papillary thyroid carcinoma may facilitate mutational analysis in the clinical setting."
https://pharos.nih.gov/idg/targets/P15056,P15056,22591444,"Our results suggest that in a small fraction of diffuse gliomas, KIAA1549-BRAF fusion gene and BRAF(v600E) mutation may be responsible for deregulation of the Ras-RAF-ERK signaling pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,22586484,"In the present study, we did not find any significant correlations between KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression and various clinicopathological features in Chinese patients with colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22581800,"BRAF regulates expression of long noncoding RNAs in melanocytes and melanoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,22579930,"KRAS, BRAF, and PIK3CA mutations in colorectal cancer have sustained prevalence rate in the Taiwanese population."
https://pharos.nih.gov/idg/targets/P15056,P15056,22568401,"These results suggest that low-grade diffuse gliomas with 1p/19q loss have frequent BRAF gains"
https://pharos.nih.gov/idg/targets/P15056,P15056,22549934,"The mTOR pathway could be a good target to enhance therapy effects in certain types of thyroid carcinoma, namely in those harboring the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22549727,"abrogation of BRAFV600E-induced senescence contributes to melanomagenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22549559,"Recurrent/persistent PTC in the central compartment typically harbors the BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,22535974,"The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation analysis, indicating that the screening for BRAF mutation in FNAB samples has a relevant diagnostic potential."
https://pharos.nih.gov/idg/targets/P15056,P15056,22535154,"study shows there are clinically and biologically distinct subtypes of BRAF-mutant metastatic melanoma, defined by genotype, with distinct etiology and behavior; cumulative sun-induced damage in primary cutaneous melanoma and older age are associated with V600K BRAF mutations;it establishes prevalence of the BRAF mutation by age-decade"
https://pharos.nih.gov/idg/targets/P15056,P15056,22534474,"BRAF and KIT mutations have been found in Japanese melanoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22531170,"Demonstrate that BRAF V600E mutation-specific antibody can be used in immunohistochemical diagnosis of hairy cell leukemia."
https://pharos.nih.gov/idg/targets/P15056,P15056,22531127,"study concludes that generally, overweight increases the risk of colorectal cancer; taller individuals have an increased risk of developing a tumour with a BRAF mutation or microsatellite instability"
https://pharos.nih.gov/idg/targets/P15056,P15056,22522845,"In signet ring cell carcinoma, BRAF V600E mutation adversely affects survival in microsatellite-stable tumors, but not in high-level microsatellite-unstable tumor"
https://pharos.nih.gov/idg/targets/P15056,P15056,22516966,"Report upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,22515520,"Mutation BRAF transforms cells through cross talk with developmental pathways Hedgehog and Wnt, as well as by deregulation of colorectal cancer related kinase pathways."
https://pharos.nih.gov/idg/targets/P15056,P15056,22515292,"BRAF V600E is common in patients with low-risk papillary thyroid carcinoma but does not predict recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,22514085,"The tumor with T1799A BRAF mutation and tumor sizes of 2 cm or more were clinicopathologic parameters associated with lower STAT1 activity."
https://pharos.nih.gov/idg/targets/P15056,P15056,22510884,"It was shown that the dimer interface within the kinase domain plays a pivotal role for the activity of B-Raf and several of its gain-of-function mutants."
https://pharos.nih.gov/idg/targets/P15056,P15056,22510757,"Patients with serrated polyposis syndrome referred to genetics clinics had a pan-colonic disease with a high polyp burden and a high rate of BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22508706,"The analysis of BRAF mutations by pyrosequencing is useful to refine the risk stratification of patients with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22506009,"The (600DLAT)B-RAF and (V600E)B-RAF mutations were found enriched in DNA and mRNA from the CD1a+ fraction of granuloma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22500044,"Highly sensitive and specific molecular assays such as MEMO sequencing are optimal for detecting the BRAF mutations in thyroid FNAC because these techniques can detect PTC that might be missed by cytology or less sensitive molecular assays."
https://pharos.nih.gov/idg/targets/P15056,P15056,22498935,"No BRAF V600E mutations were indentified in this study of patients with endometrial cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22492957,"BRAF V600E is associated with gliomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,22488961,"prevalence of the BRAF(V600E) mutation increased with increased tumor size"
https://pharos.nih.gov/idg/targets/P15056,P15056,22471666,"An update on malignancies displaying high frequencies of BRAF mutations and the mechanisms underlying the side effects and drug resistance phenomena associated with Raf inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,22471241,"Out of 1041 Korean patients with papillary thyroid carcinoma, 0.4% had rare types of BRAF mutation and three new somatic mutations were identified"
https://pharos.nih.gov/idg/targets/P15056,P15056,22459936,"BRAF mutations play a limited role in the development of sinonasal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22456166,"Report marked differences in the genetic pattern of the BRAF or NRAS mutated and wild-type melanoma subgroups."
https://pharos.nih.gov/idg/targets/P15056,P15056,22451557,"The BRAF(V600E) mutation analysis from FNA specimens for calcified thyroid nodules may be performed for a greater negative predictive value and unveil the malignancy in 25% of indeterminate or nondiagnostic cytology."
https://pharos.nih.gov/idg/targets/P15056,P15056,22435913,"analysis of a patient with pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer [case report]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22431868,"EFVPTC 1 patient BRAFV600E mutation, NVPTC 2 patients, FVPTC 2 patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22431777,"Effective use of PDT in the treatment of BRAF inhibitor-associated KAs and SCCs."
https://pharos.nih.gov/idg/targets/P15056,P15056,22430215,"expression of these oncogenes markedly stimulated ERK1/2 activities and morphologically transformed IECs. Importantly however"
https://pharos.nih.gov/idg/targets/P15056,P15056,22430208,"We propose that , and that persistent phosphorylation of Mps1 through BRAF(V600E) signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22430133,"The prevalence of EGFR, KRAS, BRAF and PIK3CA somatic mutations in 861 randomly selected Chinese patients with non-small cell lung cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,22429583,"Article reviews the current understanding of BRAF gene, its structure, expression, and signal pathway in non-small cell lung cancer. [Review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22427190,"Investigation the prevalence of mutations in the BRAF gene and its correlation with demographic characteristics, tumor location and stage in 100 colorectal carcinoma patients from India."
https://pharos.nih.gov/idg/targets/P15056,P15056,22426956,"genetic association studies in population in Turkey: Data suggest that a mutation in BRAF (V600E; found in 39.45% of patients) is associated with aggressiveness of papillary thyroid neoplasms; lymph node metastasis increases when mutation is present."
https://pharos.nih.gov/idg/targets/P15056,P15056,22426079,"Data indicate that TaqMan(R) Mutation Detection assay is an important technology to consider in the field of mutation detection for KRAS, BRAF and EGFR point mutation screening."
https://pharos.nih.gov/idg/targets/P15056,P15056,22417847,"we have analyzed the prevalence of somatic mutations in the FGFR3, PIK3CA, AKT1, KRAS, HRAS, and BRAF genes in bladder cancers"
https://pharos.nih.gov/idg/targets/P15056,P15056,22398042,"In a cohort of Indian patients with ulcerative colitis, with or without neoplasia, none showed the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22395615,"findings show (V600E)B-RAF copy-number gain as a mechanism of acquired B-RAF inhibitor resistance in 4 out of 20 patients treated with B-RAF inhibitor"
https://pharos.nih.gov/idg/targets/P15056,P15056,22393095,"Patient diagnosed with colon cancer shows poor prognosis with BRAF genetic mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22382362,"Eleven patients displayed Durable Disease Control (DDC) of which 55% had BRAF-V600E mutation positive tumors and 45% did not."
https://pharos.nih.gov/idg/targets/P15056,P15056,22376167,"The V600E BRAF mutation in papillary thyroid carcinomas may contribute to the initiation of the glycolytic phenotype and confers growth advantages in cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,22376079,"evidence presented that ERK activation occurs in a K-ras or B-raf -independent manner in the majority of primary colon cancer cases; B-raf mutations are not associated with mismatch-repair deficiency through loss of hMLH1 or hMSH2 expression"
https://pharos.nih.gov/idg/targets/P15056,P15056,22374786,"The presence of activating GNAS mutations, in association with KRAS or BRAF mutations, is a characteristic genetic feature of colorectal villous adenoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22368298,"review demonstrates that tumour BRAF V600E mutation, and MLH1 promoter 'C region' methylation specifically, are strong predictors of negative MMR mutation status[review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22367297,"A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression."
https://pharos.nih.gov/idg/targets/P15056,P15056,22361037,"This is the first reported study of the relationship between CK20/CK7 immunophenotype, BRAF mutations and microsatellite status in colorectal carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,22358007,"(BRAF(V600E))detected in 141/170 malignant thyroid nodules (82.9%) (140 PTCs and one follicular variant of PTC). BRAF status not associated with US features with the exception of a negative relation between BRAF(V600E) and an irregular shape (p = 0.004)."
https://pharos.nih.gov/idg/targets/P15056,P15056,22339435,"Data suggest that the BRAF V600E mutation does not seem to play a role in myeloid malignant transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22335197,"BRAF V600E mutation-positive papillary thyroid carcinomas (PTCs) displayed infiltrative growth, stromal fibrosis, psammoma bodies, plump eosinophilic tumour cells, and classic fully developed nuclear features of PTC."
https://pharos.nih.gov/idg/targets/P15056,P15056,22331825,"BRAF mutation is an independent prognostic biomarker for colorectal liver metastasectomy."
https://pharos.nih.gov/idg/targets/P15056,P15056,22331186,"BRAFmut as a useful marker in hairy cell leukemia."
https://pharos.nih.gov/idg/targets/P15056,P15056,22317887,"Report of oncogenic BRAF/KRAS mutations in sporadic glomus tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,22317764,"Data indicate that 266 (76.2%) tumors harbored EGFR mutations, 16 (4.6%) HER2 mutations, 15 (4.3%) EML4-ALK fusions, 7 (2.0%) KRAS mutations, and 2 (0.6%) BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,22314188,"Colon adenocarcinomas with BRAF mutations have morphologic characteristics distinct from those with KRAS mutations and BRAF-mutated proximal colonic adenocarcinomas with proficient DNA mismatch repair have an aggressive clinical course."
https://pharos.nih.gov/idg/targets/P15056,P15056,22294102,"No hotspot mutations in Braf were found in oral squamous cell carcinoma in a Greek population."
https://pharos.nih.gov/idg/targets/P15056,P15056,22287190,"BRAF mutation is associated with colorectal serrated adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22282465,"In naive GISTs carrying activating mutations in KIT or PDGFRA a concomitant activating mutation was detected in KRAS (5%) or BRAF (about 2%) genes. I"
https://pharos.nih.gov/idg/targets/P15056,P15056,22258409,"Mutational activation of both BRAF and PIK3CA genes does contribute to hepatocellular tumorigenesis at somatic level in Southern Italian population."
https://pharos.nih.gov/idg/targets/P15056,P15056,22250191,"During therapy with selective BRAF inhibitors, panniculitis with arthralgia represents a new adverse effect that can require dose reduction."
https://pharos.nih.gov/idg/targets/P15056,P15056,22249628,"None of the molecular marker mutations that were analyzed in this study, including the BRAF mutation, predicted lymph node metastasis in classic papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22246856,"BRAF V600E mutation in low and intermediate grade lymphomas is associated with frequent occurrence in hairy cell leukaemia."
https://pharos.nih.gov/idg/targets/P15056,P15056,22245873,"No BRAF mutations were found in colon adenocarcinomas from renal transplant recipients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22235286,"evidence for heterogeneity of the BRAF(V600E) mutation within individual melanoma tumor specimens"
https://pharos.nih.gov/idg/targets/P15056,P15056,22233696,"Sessile serrated adenomas are precursors of sporadic colorectal cancers with microsatellite instability.Identified a novel surface microstructure, the Type II open-shape pit pattern (Type II-O), which was specific to SSAs with BRAF mutation and CIMP."
https://pharos.nih.gov/idg/targets/P15056,P15056,22230299,"One chronic lymphocytic leukaemia patient and one patient with B-prolymphocytic leukaemia were found to harbour the BRAF V600E mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,22228154,"In patients with colorectal adenocarcinoma, there were significant differences between BRAF wild-type and mutant tumors in age, female sex, proximal tumor location, frequency of microsatellite instability, and survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,22227015,"The findings show mutant BRAF-induced oncogenic stress manifests itself by DNA damage and growth arrest by activating the pCHK2-p53-p21 pathway.It also confers tumor-promoting phenotypes such as the up-regulation of GLUT1 and enhances glucose metabolism."
https://pharos.nih.gov/idg/targets/P15056,P15056,22214007,"Although it constitutes a poor prognostic factor in colorectal cancer, it is not conclusive if it interferes with a poor therapeutic effect when cetuximab is used.[review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22210875,"Our results suggest that HCLv and IGHV4-34(+) HCLs have a different pathogenesis than HCLc and that a significant minority of other HCLc are also wild-type for BRAF V600."
https://pharos.nih.gov/idg/targets/P15056,P15056,22210186,"Patients with microsatellite instability tumor phenotype had favorable prognosis, but in those with the V600E BRAF mutation higher recurrence rate was observed."
https://pharos.nih.gov/idg/targets/P15056,P15056,22203991,"These results provide a functional link between oncogenic BRAF and angiogenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22199339,"analysis of BRAF gene mutations in non-small cell lung cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,22199277,"RET mutations may have a role in medullary thyroid carcinoma, while BRAF, AKT1, and CTNNB1 do not; the role of HRAS, KRAS, and NRAS mutations are not determined"
https://pharos.nih.gov/idg/targets/P15056,P15056,22194995,"These data support a model where the continuous regenerative process initiated by oncogenic B-RAF-driven alveolar disruption provides a tumor-promoting environment associated with chronic inflammation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22190283,"B-Raf gene mutation primarily occurs at two loci--the exon 11 glycine loop and the activation area of exon 15--in surgically resected specimens of hepatocellular carcinoma patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22190222,"The BRAF(V600E) mutation was associated with high-risk clinicopathologic characteristics in patients with papillary thyroid cancer (PTC). The BRAF(V600E) mutation may be a potential prognostic factor in PTC patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22189819,"Aberrant gene methylation driven by BRAF(V600E) altered expression of the DNA methyltransferase 1 and histone methyltransferase EZH2 profoundly."
https://pharos.nih.gov/idg/targets/P15056,P15056,22180495,"Findings suggest that the BRAF inhibitor vemurafenib in combination with standard-of-care or novel targeted therapies may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22178589,"Report mutations in KRAS, EGFR, and BRAF in cholangiocarcinoma and identify therapeutic targets for tyrosine kinase inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,22174938,"The antibody response against the catalytic domain of BRAF is not specific for rheumatoid arthritis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22170714,"BRAF mutation in papillary thyroid carcinoma is a later subclonal event, its intratumoral heterogeneity may hamper the efficacy of targeted pharmacotherapy, and its association with a more aggressive disease should be reevaluated."
https://pharos.nih.gov/idg/targets/P15056,P15056,22157687,"BRAF and KRAS mutations were observed in six (46.2%) and four (30.3%) filiform serrated adenomaS, respectively."
https://pharos.nih.gov/idg/targets/P15056,P15056,22156468,"BRAF mutations enhance the predictability of malignancy in thyroid follicular lesions of undetermined significance."
https://pharos.nih.gov/idg/targets/P15056,P15056,22156467,"The BRAF V600E mutation is associated with a higher pathological stage at surgery and a higher rate of recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,22150560,"papillary thyroid cancers in young patients display a low prevalence of the already identified oncogenic alterations; the increasing prevalence with age is mainly due to V600E BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,22147942,"BRAF mutation is associated with inferior survival in stage III colon cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,22147429,"V600E mutation of the BRAF gene reported to be associated with poor prognosis of germ cell tumors in adults prognostic biomarkers cannot necessarily be transferred from one age group to the other."
https://pharos.nih.gov/idg/targets/P15056,P15056,22145942,"Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E."
https://pharos.nih.gov/idg/targets/P15056,P15056,22137342,"thieno[2,3-d]pyrimidines are B-Raf inhibitors"
https://pharos.nih.gov/idg/targets/P15056,P15056,22136270,"Case Report: describe case of follicular thyroid carcinoma with BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22133769,"BRAF mutations are associated with hairy cell leukemia and related lymphoproliferative disorders."
https://pharos.nih.gov/idg/targets/P15056,P15056,22114137,"Overall, no difference existed in microsatellite instability or BRAF mutation frequencies between African Americans and Caucasians with colorectal neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,22105775,"BRAF (V600E) is a prevalent genetic alteration in adult sporadic papillary thyroid carcinoma in Indian cohort and it may be responsible for the progression of its classic variant."
https://pharos.nih.gov/idg/targets/P15056,P15056,22105174,"Murine thyroid tumors carrying the human BRAF(V600E) mutations are exquisitely dependent on the oncoprotein for viability."
https://pharos.nih.gov/idg/targets/P15056,P15056,22072743,"BAG3 protein sustains anaplastic thyroid tumor growth in vitro and in vivo. The underlying molecular mechanism appears to rely on BAG3 binding to BRAF, thus protecting it from proteasome-dependent degradation."
https://pharos.nih.gov/idg/targets/P15056,P15056,22072557,"BRAF V600E mutation is associated with hairy cell leukemia and other mature B-cell neoplasms"
https://pharos.nih.gov/idg/targets/P15056,P15056,22065586,"Ras induces DR5 expression through co-activation of ERK/RSK and JNK signaling pathways"
https://pharos.nih.gov/idg/targets/P15056,P15056,22043994,"This article reviewes the spectrum of KRAS/BRAF genotype and the impact of KRAS/BRAF mutations on the clinicopathological features and prognosis of patients with colorectal cancer. [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,22039425,"study examined the clinical characteristics and outcomes of patients with mutant BRAF advanced cancer; conclude that BRAF appears to be a druggable mutation that also defines subgroups of patients with phenotypic overlap, albeit with differences that correlate with histology or site of mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,22038996,"Results support evaluation of BRAF(V600E)-specific inhibitors for treating BRAF(V600E) malignant astrocytomas (MA) patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,22033631,"high prevalence of BRAF (V600E) mutation is associated with synchronous bilateral papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,22028477,"BRAF V600E mutation is associated with hairy cell leukemia and B-cell neoplasms"
https://pharos.nih.gov/idg/targets/P15056,P15056,22027477,"Postmenopausal hormone therapy was associated with borderline statistically significant risk reductions for BRAF-wildtype tumours among women with prolonged exposure to Postmenopausal hormone therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,22012135,"An integrated approach combining both VE1 mutant protein immunohistochemistry and genetic analysis may increase the diagnostic accuracy of BRAF mutation analysis."
https://pharos.nih.gov/idg/targets/P15056,P15056,22006538,"DNA methylation of each marker was quantified using combined bisulfite restriction analysis (COBRA) and analyzed along with various genetic factors associated with CRC [the BRAF and KRAS mutations, MLH1 methylation and microsatellite instability"
https://pharos.nih.gov/idg/targets/P15056,P15056,21948220,"In malignant FNABs in papillary thyroid carcinoma, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery."
https://pharos.nih.gov/idg/targets/P15056,P15056,21943101,"BRAF mutation V600E significantly induces cell migration and invasion properties in vitro in colon cancer cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,21937738,"A prominent epigenetic mechanism through which BRAF V600E can promote papillary thyroid cancer tumorigenesis by altering the methylation and hence the expression of numerous important genes."
https://pharos.nih.gov/idg/targets/P15056,P15056,21936566,"this novel B-Raf fusion protein (SND-1 was identified as the B-Raf fusion partner) presents a novel target with potential clinical implications in the treatment of patients resistant to c-Met inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,21915661,"Aberrant CIMP was detected in 16% of chromosomal instable tumors and in 44% of both microsatellite instable and microsatellite and chromosomally stable carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,21909080,"CXCR4 expression and BRAF mutation status could cooperatively induce and promote a more aggressive phenotype in papillary thyroid carcinoma through several pathways and specifically increase the tumors' spread outside of the thyroid gland."
https://pharos.nih.gov/idg/targets/P15056,P15056,21906875,"BRAF mutations are of pathogenetic significance in wild type gastrointestinal stromal tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,21903858,"BRAF(V600E) causes upregulation of TIMP-1 via NF-kappaB. TIMP-1 binds then its surface receptor CD63, leading eventually to Akt activation, which in turn confers antiapoptotic behavior and promotion of cell invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,21901162,"In sporadic colorectal tumourspatients, the most frequently mutated gene was APC (68.9% of tumours), followed by KRAS (31.1%), TP53 (27.2%), BRAF (8.7%) and CTNNB1 (1.9%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,21900390,"Studies indicate that BRAF V600E mutation initiates follicular cell transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,21882184,"the BRAF(V600E) mutation should be considered as a poor prognostic marker in papillary thyroid cancer (Meta-Analysis)"
https://pharos.nih.gov/idg/targets/P15056,P15056,21875464,"BRAF V600E mutation has a significant correlation with papillary thyroid carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21871821,"Genetic analysis revealed individual heterozygous mutations in the KRAS (phenotype of CFC/Noonan syndrome) and BRAF genes (phenotype of CFC syndrome)"
https://pharos.nih.gov/idg/targets/P15056,P15056,21863388,"Braf mutation in metastatic melanoma treated with BRAF inhibitor vemurafenib."
https://pharos.nih.gov/idg/targets/P15056,P15056,21835307,"The BRAF/MEK/ERK pathway is upregulated in progressive retinal arterial macroaneurysm patients, caused by mutation in IGFBP7."
https://pharos.nih.gov/idg/targets/P15056,P15056,21826673,"BRAF mutations and llelic loss of susceptibility loci are associated with familial non-medullary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21825258,"study reports that V600E and non-V600E BRAF mutations affect different patients with non-small-cell lung cancer; V600E mutations are significantly associated with female sex and represent a negative prognostic factor"
https://pharos.nih.gov/idg/targets/P15056,P15056,21803329,"BRAF mutation is not indicative for predicting papillary thyroid cancer prognosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,21796448,"Importance of infiltrative growth pattern and invasiveness over presence of BRAF mutation in classic and follicular variant papillary thyroid carcinoma for development of nodal metastases."
https://pharos.nih.gov/idg/targets/P15056,P15056,21788131,"Patients with mutations in BRAF or NRAS gene are frequently present with ulceration, and mutation in BRAF or NRAS gene is indicator for poor prognosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,21774961,"BRAF(V600E) mutation analysis using residual liquid-based preparation cytologic samples is, therefore, a powerful additional diagnostic tool for diagnosis of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21750338,"BRAF mutation of papillary thyroid carcinoma may have differential predictive values for LN metastasis, according to tumor size."
https://pharos.nih.gov/idg/targets/P15056,P15056,21725359,"identified concurrent mutational inactivation of the PTEN and RB1 tumor suppressors as a mechanism for loss of BRAF/MEK dependence in melanomas harboring (V600E)BRAF mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,21716161,"We describe a new mutation of BRAF, T599dup, in a case of anaplastic thyroid carcinoma with tall cell papillary thyroid carcinomas component."
https://pharos.nih.gov/idg/targets/P15056,P15056,21707687,"The application of BRAF(V600E) mutation analysis in US-guided FNAB can improve the diagnostic accuracy of thyroid nodules."
https://pharos.nih.gov/idg/targets/P15056,P15056,21705440,"MEK1(F129L) mutation also strengthened binding to c-Raf, suggesting an underlying mechanism of higher intrinsic kinase activity"
https://pharos.nih.gov/idg/targets/P15056,P15056,21696415,"The frequency of BRAF-KIAA1549 fusion transcripts is significantly lower in adult patients with pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21693616,"Eight of 16 primary tumor samples and 4 of 6 metastatic samples showed BRAF V600E gene mutations and no copy number changes were associated exclusively with metastatic cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,21681432,"The BRAF V600E mutation did not show association with clinical or molecular characteristics of colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21663470,"The BRAF V600E mutation was present in all patients with hairy-cell leukemia who were evaluated."
https://pharos.nih.gov/idg/targets/P15056,P15056,21653734,"Compared with BRAF-wt papillary thyroid cancer, those harboring BRAF(V600E) exhibit downregulated VEGFA, VEGFR, and PDGFRbeta expression, suggesting presence of BRAF mutation does not imply stronger response to drugs targeting VEGF and PDGFB signal pathways."
https://pharos.nih.gov/idg/targets/P15056,P15056,21636552,"introduction of constitutively active BRAF V600E into human cortical stem and progenitor cells initially promotes clonogenic growth in soft agar but ultimately results in dramatically reduced proliferation and arrested growth of the culture."
https://pharos.nih.gov/idg/targets/P15056,P15056,21594703,"BRAF V600E mutation is associated with recurrent papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21587258,"Wnt5a methylation was strongly associated with tumour microsatellite instability tumours after adjustment for age, sex, and tumour location and with BRAF V600E mutation, a marker of CpG island methylator phenotype"
https://pharos.nih.gov/idg/targets/P15056,P15056,21577205,"Studies indicate that Raf kinases are excellent molecular targets for anticancer therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,21570823,"Analysis showed that blood samples with PCR evidence for CMC were heterogeneous for BRAF status under limiting-dilution conditions, suggestive of heterogeneity of CMC"
https://pharos.nih.gov/idg/targets/P15056,P15056,21557216,"MSS/BRAF mutant cancers were more commonly proximal (38/54, 70.3%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,21553007,"BRAF mutations, but not KRAS mutations, were associated with a worse outcome in Chinese colorectal cancer patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,21514245,"Ablation of B-Raf had no significant effect on development of K-Ras oncogene-driven non-small cell lung carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21512141,"Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC)."
https://pharos.nih.gov/idg/targets/P15056,P15056,21498916,"findings support the notion that BRAF(V600E), which can be detected preoperatively in papillary thyroid carcinoma fine-needle aspiration biopsy material, has a potential to contribute to patients stratification into high- and low-risk groups."
https://pharos.nih.gov/idg/targets/P15056,P15056,21483104,"Heterogeneity of KRAS and BRAF mutation status intra-tumorally in colorectal cancer was assessed."
https://pharos.nih.gov/idg/targets/P15056,P15056,21479234,"BRAF V600E mutations are common in the majority of pleomorphic xanthoastrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21457162,"BRAF mutations are specific for serrated adenocarcinoma and identify a subset of serrated adenocarcinomas with gene methylation and a tendency for MSI-H"
https://pharos.nih.gov/idg/targets/P15056,P15056,21456008,"the impact of BRAF mutation and microsatellite instability on prognosis in metastatic colorectal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,21455633,"No V600E mutation was identified in the BRAF gene in any sample."
https://pharos.nih.gov/idg/targets/P15056,P15056,21451543,"Activated BRAF promotes melanoma cell growth by matrix metalloproteinase-1"
https://pharos.nih.gov/idg/targets/P15056,P15056,21447798,"Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,21441910,"KSR interacts with a regulatory Raf molecule in cis to induce a conformational switch of MEK, facilitating MEK's phosphorylation by a separate catalytic Raf molecule in trans"
https://pharos.nih.gov/idg/targets/P15056,P15056,21441079,"In papilary thyroid carcinoma, the BRAFT1799A mutation is associated with age over 60 & a tumor size of 1cm or greater, but not with other clinicopathological characteristics, tumor recurrence or persistence."
https://pharos.nih.gov/idg/targets/P15056,P15056,21431280,"BRAF T1799A mutation may be an early and essential carcinogenic event in nearly all Korean papillary thyroid carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,21430505,"The presence of the BRAF(V600E) mutation may play different roles between medium and giant CMNs in melanocytic tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,21427714,"There were no significant differences in the frequency of BRAF mutations among lesions exhibiting the hyperplastic, adenomatous, or mixed patterns."
https://pharos.nih.gov/idg/targets/P15056,P15056,21426297,"Mutations at the position V600 of BRAF were described in approximately 8% of all solid tumors, including 50% of melanomas, 30 to 70% of papillary thyroid carcinomas and 5 to 8% of colorectal adenocarcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21424530,"This study demonistrated that the role of RAF kinase fusions as a central oncogenic mechanism in the development of pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21424126,"study suggested that both KRAS and BRAF mutations are exclusive, but KRAS and PIK3CA mutations are coexistent"
https://pharos.nih.gov/idg/targets/P15056,P15056,21412762,"BRAF mutation is associated with papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21408138,"Allele-specific qPCR assays for the most frequent activating mutations in EGFR, KRAS, BRAF and PIK3CA in tumor-positive fine needle cytological aspirates were compared against histological material of primary tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,21390154,"K-ras gene mutation is a common event in Chinese colorectal cancer (CRC) patients, but may not be a prognostic factor in CRC , while BRAF is rarely mutated in Chinese CRC patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,21383698,"tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGFbeta-induced epithelial-mesenchymal transition, through a MAPK-dependent process"
https://pharos.nih.gov/idg/targets/P15056,P15056,21383288,"Thus, MEK1(C121S) or functionally similar mutations are predicted to confer drug resistance of neoplasms to combined MEK/RAF inhibition."
https://pharos.nih.gov/idg/targets/P15056,P15056,21383284,"BRAF mutational status yielded no useful prognostic information in predicting recurrence and benefits from adjuvant chemotherapy in colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21362156,"Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,21356389,"IDH1 mutation works with other oncogenic mutations and could contribute to the metastasis in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21351275,"BRAF mutation is associated with selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus"
https://pharos.nih.gov/idg/targets/P15056,P15056,21345796,"B-Raf associates with and stimulates NHE1 activity and that B-Raf(V600E) also increases NHE1 activity that raises intracellular pH."
https://pharos.nih.gov/idg/targets/P15056,P15056,21343559,"The presence of mutant BRAF had no impact on the disease-free interval from diagnosis of first-ever melanoma to first distant metastasis; however, it may have impacted survival thereafter."
https://pharos.nih.gov/idg/targets/P15056,P15056,21332555,"BRAF mutations were rare in colorectal laterally-spreading tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,21326296,"BRAF mutations have a smaller role in the carcinogenesis of malignant melanoma in Chinese Han than in Western patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,21324100,"Data show that BRAF-mutated melanomas occur in a younger age group on skin without marked solar elastosis and less frequently affect the head and neck area, compared to melanomas without BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,21321384,"identifying downstream events from the BRAFV600E/ERK1/2 pathway will eventually identify novel biomarkers that can be used to correlate with disease outcome and overall survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,21317286,"identified BAD serine 134 to be strongly involved in survival signaling of B-RAF-V600E-containing tumor cells and found that phosphorylation of BAD at this residue is critical for efficient proliferation in these cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,21317224,"Studies showed that siRNA knockdown of BIM significantly blunted the apoptotic response in PTEN+ melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,21317202,"Findings suggest that inhibition of Raf-MEK-Erk pathway might offer a novel therapeutic strategy in neuroendocrine tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,21307665,"analysis of gallbladder carcinomas, gallbladder adenomas, and high-grade dysplastic lesions for the BRAF and the KRAS mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,21305640,"78 colorectal tumor samples were mutant for BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,21303778,"Ras/Raf/MAPK and RhoA/ROCKII signalling pathways are abnormally activated in eutopic endometrial stromal cells of patients with endometriosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,21289333,"803 metastatic colorectal cancer samples studied for KRAS exon 2 and BRAF exon 15 mutations; BRAF mutated samples were characterized for mismatch repair function; 344 tumours were mutated -34 involving BRAF mutations (8 of microsatellite instability type)"
https://pharos.nih.gov/idg/targets/P15056,P15056,21285991,"Presence of mutated BRAF is one of the most powerful prognostic factors for advanced and recurrent CRC"
https://pharos.nih.gov/idg/targets/P15056,P15056,21274720,"The analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21274671,"B-Raf mutations, microsatellite instability and p53 protein expression is not associated with sporadic basal cell carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21270111,"Findings suggest inhibition of autophagy in combination with ER stress-inducing agents may represent a means by which to harness autophagy for the therapeutic benefit of B-RAF wild-type melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,21263251,"These findings suggest that BRAF mutations may be associated with the pathogenesis of sessile serrated colorectal adenomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21249150,"the oncogenic effect of BRAF(V600E) is associated with the inhibition of MST1 tumor suppressor pathways, and the activity of RASSF1A-MST1-FoxO3 pathways determines the phenotypes of BRAF(V600E) tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,21239517,"We found that performing BRAF(V600E) mutation analysis on the fine-needle aspiration biopsy specimens was of great help to make a therapeutic decision for thyroid nodules when the fine-needle aspiration biopsy results were equivocal"
https://pharos.nih.gov/idg/targets/P15056,P15056,21224857,"Acquisition of a BRAF mutation is not a founder event, but may be one of the multiple clonal events in melanoma development, which is selected for during the progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,21223812,"The high expression of activated ERK is not caused by BRAF gene mutation in nasal mucosa malignant melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21223556,"B-Raf signaling has a key function in the altered expression of contractile receptors in the cerebrovasculature."
https://pharos.nih.gov/idg/targets/P15056,P15056,21215707,"In melanoma cells, oncogenic (V600E) BRAF signaling downregulates PDE5A through the transcription factor BRN2, leading to increased cGMP and Ca2+ and the induction of invasion through increased cell contractility."
https://pharos.nih.gov/idg/targets/P15056,P15056,21203559,"BRAF alternative splicing is differentially regulated in human and mouse. BRAF exon 9b is required for learning and memory associated with the hippocampus."
https://pharos.nih.gov/idg/targets/P15056,P15056,21190184,"B-Raf(insT) and B-Raf(V600E) , but not B-Raf(wt) , provoke drastic morphological alterations in human astrocytes."
https://pharos.nih.gov/idg/targets/P15056,P15056,21185263,"this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,21176117,"These results show that melanoma cell phenotype is an important factor in MAPK pathway inhibition response, as invasive phenotype cell response is dependent on BRAF mutation status."
https://pharos.nih.gov/idg/targets/P15056,P15056,21167555,"concluded that follicular variant of papillary thyroid carcinoma differs from conventional papillary thyroid carcinoma in the rate of BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,21166657,"The BRAF mutation was frequently detected in patients with superficial spreading melanoma (OR=2.021; P<0.001) and in melanomas arising in nonchronic sun-damaged skin (OR=2.043; P=0.001)."
https://pharos.nih.gov/idg/targets/P15056,P15056,21161938,"KRAS mutations arise more frequently than BRAF mutations in Moroccan patients with colorectal carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,21134562,"BRAF mutations activate the mitogen-activated protein kinase pathway and confer an aggressive thyroid cancer phenotype."
https://pharos.nih.gov/idg/targets/P15056,P15056,21134544,"BRAF mutation in papillary thyroid carcinoma is associated with an increased risk of palpable nodal recurrence and the need for reoperative surgery."
https://pharos.nih.gov/idg/targets/P15056,P15056,21131919,"Primary esophageal melanomas of Caucasian patients harbor mutations of c-Kit, KRAS and BRAF in varied frequencies."
https://pharos.nih.gov/idg/targets/P15056,P15056,21129611,"It therefore appears that BRAF mutations may play a strong negative prognostic role and only a slight role in resistance to anti-EGFR Abs."
https://pharos.nih.gov/idg/targets/P15056,P15056,21107323,"melanomas escape B-RAF(V600E) targeting not through secondary B-RAF(V600E) mutations but via receptor tyrosine kinase (RTK)-mediated activation of alternative survival pathway(s) or activated RAS-mediated reactivation of the MAPK pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,21107320,"identification of MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines"
https://pharos.nih.gov/idg/targets/P15056,P15056,21103049,"Data show that among 181 CRC patients, stratified by microsatellite instability status, DNA sequence changes were identified in KRAS (32%), BRAF (16%), PIK3CA (4%), PTEN (14%) and TP53 (51%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,21102416,"We show a strong association between concordant methylation of >/= 3 of five 3p22 genes with the CpG island methylator phenotype and the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,21102258,"Mutations of EGFR, BRAF, and KRAS in adenocarcinoma were mutually exclusive and inversely correlated with RASSF1A methylation"
https://pharos.nih.gov/idg/targets/P15056,P15056,21098728,"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,21076620,"Data show that BRAF knockdown led to suppression of the expression of the GABPbeta, which involved in regulating HPR1 promoter activity."
https://pharos.nih.gov/idg/targets/P15056,P15056,21068756,"The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,21051183,"findings indicate that somatic mutations in KRAS and PIK3CA but not BRAF oncogenes are closely associated with the development of cholangiocarcinoma in Chinese population"
https://pharos.nih.gov/idg/targets/P15056,P15056,21051183,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,21049459,"Although many studies document BRAF mutation as a prognostic factor in PTC our results underline that it is too early to consider it as a routine clinical predictive factor."
https://pharos.nih.gov/idg/targets/P15056,P15056,21049459,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20979647,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20975100,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20962618,"Describe benign serrated colorectal fibroblastic polyps/intramucosal perineuriomas are true mixed epithelial-stromal polyps (hybrid hyperplastic polyp/mucosal perineurioma) with frequent BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,20959481,"Braf mutation is associated with basal and treatment-induced regulation of the PI3K-AKT pathway as a critical regulator of AZD6244 sensitivity in cutaneous melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20955560,"Anti-BRAF autoantibodies from RA patients preferentially recognize one BRAF peptide: P2"
https://pharos.nih.gov/idg/targets/P15056,P15056,20953721,"BRAF mutation is associated with papillary thyroid microcarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20950194,"BRAF is mutated in a low percentage of follicular variant of papillary thyroid carcinoma, and most of these mutated cases are suspicious or positive on fine-needle aspiration."
https://pharos.nih.gov/idg/targets/P15056,P15056,20947270,"In the present series, no BRAF mutation was detected. The presence of KRAS mutations and loss of PTEN expression were not associated with impaired response to cetuximab-based chemoradiotherapy and 3-year disease free survival."
https://pharos.nih.gov/idg/targets/P15056,P15056,20947270,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20945104,"BRAF(V600E) mutation is associated with thyroid nodules."
https://pharos.nih.gov/idg/targets/P15056,P15056,20945104,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20944096,"Determination of the BRAF mutation and the growth fraction of melanomas may add a prognostic value."
https://pharos.nih.gov/idg/targets/P15056,P15056,20944096,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20881644,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20860430,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20857202,"BRAF V600E mutation is associated with lack of response in wild-type KRAS metastatic colorectal cancer treated with anti-EGFR monoclonal antibodies."
https://pharos.nih.gov/idg/targets/P15056,P15056,20853079,"reduced RKIP mRNA levels and the elevated levels of B-RAF in pT1, grade III tumors vs. normal tissue, corroborate that these genes are involved in the pathogenesis of urinary bladder cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,20843808,"A BRAF aberrant splice variant with an intact kinase domain and partial loss of the N-terminal autoinhibitory domain was identified in fibroblasts from an additional patient, and fibroblast proliferation was inhibited by BRAF-specific siRNA."
https://pharos.nih.gov/idg/targets/P15056,P15056,20840674,"RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components"
https://pharos.nih.gov/idg/targets/P15056,P15056,20840674,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20837233,"BRAF mutation detection in fine needle biopsy may be an adjunct tool for preoperative didagnosis of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20813562,"first report implicating BRAF mutation in OSCC. study supports that mutations in the BRAF gene makes at least a minor contribution to OSCC tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,20813562,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20807807,"Mutant protein kinase elicits significant therapeutic responses in mutant BRAF-driven human melanoma xenografts."
https://pharos.nih.gov/idg/targets/P15056,P15056,20802181,"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,20802181,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20736745,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20720566,"association between MC1 receptor germline variation and BRAF/NRAS mutations in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,20720566,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20703476,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20702649,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20689758,"PLX4032 has robust activity in BRAF mutated melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20679909,"Mutant Braf can be detected in RNA from mixed populations with as few as 0.1% Braf(V600E) mutant cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,20670148,"Traditional DNA sequencing and the somewhat more-sensitive pyrosequencing method can detect multiple alternative BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,20652941,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20647317,"Findings delineate how mutant B-RAF protects melanoma cells from apoptosis and provide insight into possible resistance mechanisms to B-RAF inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,20647301,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20645028,"samples of metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene"
https://pharos.nih.gov/idg/targets/P15056,P15056,20645028,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20640859,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20635392,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20631031,"No significant difference in BRAF alterations was found between pT1 tumors and thyroid capsule invasion and pT3 tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,20631031,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20627194,"PCR is practically applicable to KRAS/BRAF genotyping using small amounts of biopsied colorectal tumor cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,20619739,"if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA exon 20 mutations (in that order) gives additional information about the efficacy of cetuximab plus chemotherapy in metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,20616366,"Using traditional PCR and direct sequencing, we found KRAS mutations in 47 (40%) patients and BRAF(V600E) in 10 (8.5%)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20607849,"V600E BRAF mutation is not associated with seminoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20605766,"in melanomas activation of the MAPK pathway can occur through signaling pathways operating independently of BRAF T1799A"
https://pharos.nih.gov/idg/targets/P15056,P15056,20591910,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20576522,"allele specific Taqman-based real-time PCR assay allows the sensitive, accurate and reliable measurement of BRAF(V600E) mutated DNA in plasma"
https://pharos.nih.gov/idg/targets/P15056,P15056,20573852,"BRAF mutational status of metastases is not required when the primary tumour is BRAF wild type."
https://pharos.nih.gov/idg/targets/P15056,P15056,20571907,"PIK3CA mutations may have a role in KRAS and BRAF wild type colorectal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,20571907,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20570909,"Incidence of cancer in FDRs of index CRC patients with the p.V600E BRAF mutation may be explained by a genetic predisposition to develop cancer through the serrated pathway of colorectal carcinogenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,20570909,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20569675,"reports the low frequency of PIK3CA and B-RAF mutations in astrocytomas, despite the presence of activated ERK and AKT proteins"
https://pharos.nih.gov/idg/targets/P15056,P15056,20569675,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20563851,"HER2, but not EGFR gene amplification, is frequently observed in KRAS and BRAF wild type colorectal cancer patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,20563851,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20543023,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20526288,"The BRAF 1799T>A mutation was found in 5 of 19 (26%) of infiltrative follicular variant of papillary thyroid carcinomas and in none of the encapsulated carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,20526288,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20519626,"Studies identified the oncogenic BRAF V600E mutation in 35 of 61 archived specimens (57%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,20514492,"BRAF mutation may be used a biomarker for the selection of patients with colorectal cancer patients who might benefit from anti-egf receptor monoclonal antibodies."
https://pharos.nih.gov/idg/targets/P15056,P15056,20514492,"Meta-analysis of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20501689,"Observational study of gene-disease association and genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20501503,"The V600E BRAF mutation confers a worse prognosis to stage II and stage III colon cancer patients independently of disease stage and therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,20501503,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20498063,"Knockdown of B-Raf(V600E) resulted in thrombospondin-1 down-regulation and a reduction of adhesion and migration/invasion of human thyroid cancer cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,20496269,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20495538,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20489114,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20485284,"BRAF V600E mutations are associated with MSI-H status and cyclin D1 overexpression and characterize a subgroup of patients with poor prognosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,20485284,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20478260,"Study concludes that the secreted protein IGFBP7 is dispensable for B-RAF(V600E)-induced senescence in human melanocytes."
https://pharos.nih.gov/idg/targets/P15056,P15056,20473281,"Hypoxia-inducible factor-1alpha is expressed in papillary thyroid carcinomas and is regulated not only by hypoxia but also by BRAF(V600E)-mediated signaling pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,20473281,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20460314,"These data demonstrate a high prevalence of B-RAF mutations in the present study population, underscoring the possibility of strong regional differences."
https://pharos.nih.gov/idg/targets/P15056,P15056,20460314,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20454969,"This study identified an exceptionally high frequency of KIAA1549-BRAF fusions in pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20453000,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20445557,"B-RAF(V600E) can protect melanocytes from anoikis independently of cell cycle inhibition"
https://pharos.nih.gov/idg/targets/P15056,P15056,20444249,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20413299,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20410389,"thyroid carcinoma with the BRAF(V600E) mutation tends to be taller than wide and is not associated with the presence of calcifications on ultrasound."
https://pharos.nih.gov/idg/targets/P15056,P15056,20407018,"Activated Raf-1 induces focal adhesion kinase expression and regulates neuroendocrine and metastatic phenotypes in gastrointestinal carcinoid cell line BON."
https://pharos.nih.gov/idg/targets/P15056,P15056,20406109,"The miR-146b expression levels in papillary thyroid carcinoma with BRAF mutation were significantly higher than those without this mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,20381121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20351680,"Mutated in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,20332228,"Studies show FOXD3 is suppressed by B-RAF, uncover a novel role and mechanism for FOXD3 as a negative cell cycle regulator, and have implications for the repression of melanocytic lineage cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,20305537,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20303012,"Our study suggests that mutations of KRAS, not BRAF, may play a role in the pathogenesis of prostate carcinoma in Chinese patients."
https://pharos.nih.gov/idg/targets/P15056,P15056,20303012,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20302979,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20300843,"BRAF mutation is not associated with interval cancers but is a marker of poor prognosis, particularly in microsatellite stable cancers."
https://pharos.nih.gov/idg/targets/P15056,P15056,20300843,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20234366,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20233436,"data support the model of BRAF and K-ras mutations arising in distinct colorectal cancer subsets associated with different clinicopathological and dietary factors, acting as mutually exclusive mechanisms of activation of the same signalling pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,20230995,"pathogenesis of papillary thyroid cancer , and the clinical implications of BRAF(V600E) mutation in the diagnosis, prognosis and potential targeted therapeutic strategies for thyroid cancer [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,20200438,"we measured the prevalence and epidemiologic correlates of the BRAF V600E somatic mutation in cases collected as a part of a population-based case-control study of colorectal cancer in northern Israel."
https://pharos.nih.gov/idg/targets/P15056,P15056,20200438,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20187782,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20186801,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20182446,"High oncogenic BRAF levels trigger autophagy, which may have a role in melanoma tumor progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,20177422,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20162668,"With MSI, specific KRAS and BRAF mutations, 3 distinct prognostic subgroups were observed: patients with (i) KRAS mutation G12D, G12V or BRAFmutation, (ii) KRAS/BRAFwild-type or KRAS G13D mutations in MSS/MSI-L and (iii) MSI-H and KRAS G13D mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,20162668,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20156809,"BRAF activating mutations are a major genetic alteration in this histologic group of pediatric low-grade brain tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,20146801,"Data demonstrate a signaling loop between B-Raf activation and p73 function, and suggest that low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may lead to lack of response to oxaliplatin/cetuximab."
https://pharos.nih.gov/idg/targets/P15056,P15056,20140953,"Formalin-fixed primary melanomas from relapsed and nonrelapsed patients were sequenced for common BRAF and NRAS mutations. BRAF/NRAS mutations were detected in 77% of relapsers and 58% of nonrelapsers and did not predict ulceration or mitotic rate."
https://pharos.nih.gov/idg/targets/P15056,P15056,20118768,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20098682,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20068183,"BRAF(V600E) mutation seems to define a subset of malignant astrocytomas in children, in which there is frequent concomitant homozygous deletion of CDKN2A (five of seven cases)."
https://pharos.nih.gov/idg/targets/P15056,P15056,20051945,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20049644,"BRAF mutations only in metastases is not associated with resistance to anti-EGFR treatment in primary colorectal tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,20049644,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20044755,"BRAF gene rearrangements were more common in cerebellar pilocytic astrocytoma than non-cerebellar tumors; clinical outcome was independent of BRAF status"
https://pharos.nih.gov/idg/targets/P15056,P15056,20043015,"no support for MC1R variants with BRAF mutation for melanoma risk"
https://pharos.nih.gov/idg/targets/P15056,P15056,20043015,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20027224,"CpG island methylator phenotype (CIMP)-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAF(V600E) in CIMP+ colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,20023270,"BRAF V600E detection in the tumor does not induce a higher expression of the B-raf protein or the preferential activation of the p42/44 mitogen-activated protein kinase (MAPK) signaling pathway compared with GISTs without the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,20012784,"Screening for BRAF, RET, KRAS, NRAS, and HRAS mutations, as well as RET-PTC1 and RET-PTC3 rearrangements, was performed on cases of Hashimoto thyroiditis with a dominant nodule"
https://pharos.nih.gov/idg/targets/P15056,P15056,20009493,"BRAFV600E mutation is associated with high-risk clinicopathological characteristics of papillary thyroid carcinoma and worse prognosis of patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,20009493,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,20008640,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19960590,"BRAF T1796A mutation was identified in 27% of papillary thyroid cancer samples and its identification may be used to determine this risk factor of the development of papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19960590,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19959686,"2-fold increased risk of BRAF V600E colonic tumor mutation was observed in current and former cigarette smokers homozygous for the OGG1 polymorphism"
https://pharos.nih.gov/idg/targets/P15056,P15056,19958951,"clinical, cytologic, and pathologic parameters of 106 consecutive surgically treated patients with BRAF-positive PTC were compared with a concurrent cohort of 100 patients with BRAF-negative PTC (papillary thyroid carcinoma)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19956635,"Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19955937,"v-Raf murine sarcoma viral oncogene mutations are common in ovarian serous bordeline tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,19955937,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19935791,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19919912,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19919630,"The BRAF V600E mutational status appears to be of limited diagnostic utility in distinguishing genital naevi that exhibit atypia from those that do not."
https://pharos.nih.gov/idg/targets/P15056,P15056,19917255,"Data show that melanoma cells expressing B-Raf(V600E) display a reduced C-Raf:B-Raf ratio, and further suppression of C-Raf increases MAPK activation and proliferation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19913317,"BRAF mutations are not relevant for rectal carcinogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,19913317,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19908233,"BRAF gene mutation is associated with colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19908233,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19903786,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19893451,"Study identified the previously reported pathogenic mutation of NTRK3 in a KRAS/BRAF wild-type tumor and 2 somatic mutations in the Src family of kinases (YES1 and LYN) that would be expected to cause structural changes."
https://pharos.nih.gov/idg/targets/P15056,P15056,19884556,"BRAF status, EGFR amplification, and cytoplasmic expression of PTEN were associated with outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen."
https://pharos.nih.gov/idg/targets/P15056,P15056,19884556,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19884549,"KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan."
https://pharos.nih.gov/idg/targets/P15056,P15056,19884549,"Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19883729,"The knowledge of BRAF mutation status can facilitate more accurate risk stratification and better decision making at various steps in the management of papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19881948,"BRAF and KRAS oncogenes have different transforming capability in colon cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,19880519,"Hyperactivation of BRAF-MEK signaling activates MAP2 expression in melanoma cells by two independent mechanisms, promoter demethylation or down-regulation of neuronal transcription repressor HES1."
https://pharos.nih.gov/idg/targets/P15056,P15056,19878585,"Suppression of BRAF gene expression inhibited cell proliferation in cells with BRAF(V600E) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19861964,"These data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma. Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection."
https://pharos.nih.gov/idg/targets/P15056,P15056,19861964,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19861538,"BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19855373,"BRAF V600E mutations were seen in 83% of proximal and 74% of distal hyperplastic colonic polyps"
https://pharos.nih.gov/idg/targets/P15056,P15056,19850689,"BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients with residual or metastatic disease and may provide diagnostic information"
https://pharos.nih.gov/idg/targets/P15056,P15056,19850689,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19829302,"data argues against obligatory downregulation in IGFBP7 expression in BRAF mutated melanoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,19826477,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19794125,"As predicted from the genomic organization at this locus, 22 of 36 patients with sporadic pilocytic astrocytomas and B-Raf gene rearrangement also exhibit corresponding homeodomain interacting protein kinase-2 (HIPK2) gene amplification."
https://pharos.nih.gov/idg/targets/P15056,P15056,19765726,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19759551,"analysis of coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations"
https://pharos.nih.gov/idg/targets/P15056,P15056,19752400,"The polyclonality of BRAF mutations in acquired melanocytic nevi suggests that mutation of BRAF may not be an initial event in melanocyte transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19745699,"Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19738460,"Papillary carcinomas of the thyroid with papillary growth and areas of follicular growth have a high frequency of BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,19738388,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19735675,"Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif."
https://pharos.nih.gov/idg/targets/P15056,P15056,19725049,"EPAC-mediated cellular effects require activation of the B-Raf/ERK and mTOR signaling cascades"
https://pharos.nih.gov/idg/targets/P15056,P15056,19724843,"This article focuses on reviewing the impact of the BRAFV600E mutation in the tumorigenesis of Papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19718661,"analysis of the effect on the Ras/Raf signaling pathway of post-translational modifications of neurofibromin"
https://pharos.nih.gov/idg/targets/P15056,P15056,19710016,"DGKeta acts as a novel critical regulatory component of the Ras/B-Raf/C-Raf/MEK/ERK signaling cascade via a previously unidentified mechanism."
https://pharos.nih.gov/idg/targets/P15056,P15056,19710001,"The BRAF(V600E) mutation can be used as a potential prognostic factor in PTMC patients in a BRAF(V600E)-prevalent area."
https://pharos.nih.gov/idg/targets/P15056,P15056,19704056,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19693938,"Whenever necessary BRAF testing may be performed on the residual samples of thyroid nodules, without interfering with routine cytology."
https://pharos.nih.gov/idg/targets/P15056,P15056,19690147,"a dual mechanism that affects the Sprouty2/B-Raf interaction: Sprouty phosphorylation and B-Raf conformation"
https://pharos.nih.gov/idg/targets/P15056,P15056,19686742,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19682280,"This study provides a basis for understanding the molecular processes that are regulated by (V600E)BRAF/MEK signalling in melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,19681119,"Investigated the prevalence of PTPN11, HRAS, KRAS, NRAS, BRAF, MEK1, and MEK2 mutations in a relatively large cohort of primary embryonal Rhabdomyosarcoma (RMS) tumors. No mutation was observed in BRAF and MEK genes."
https://pharos.nih.gov/idg/targets/P15056,P15056,19679059,"Mutations in BRAF protein is associated with Colorectal Carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19679059,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19679016,"Studies indicate that drugs are effective in targeting essential molecular pathways of BRAF, PTEN, Akt and mammalian target of rapamycin."
https://pharos.nih.gov/idg/targets/P15056,P15056,19669908,"Observational study of gene-disease association and DATA ERROR. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19667985,"Studies indicate that in pilocytic astrocytomas, the BRAF fusion gene has been identified as a specific and frequent event leading to potentially targetable mitogen-activated protein kinase pathway activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19659611,"simultaneous depletion of both MITF and BRAF(V600E) significantly inhibited melanoma growth even for the melanoma cell lines resistant to MITF depletion"
https://pharos.nih.gov/idg/targets/P15056,P15056,19652585,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19644722,"BRAFV600E mutation is associated with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19638574,"Sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type KRAS and C-RAF in those with mutant KRAS."
https://pharos.nih.gov/idg/targets/P15056,P15056,19637313,"strong inter-relation between DR4 AND DR5 overexpression and presence of oncogenic KRAS/ BRAF mutations in colon cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19633643,"Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19628078,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19626635,"In this study, 28 matched tumor and serum samples obtained from patients with both benign and malignant thyroid disorders were analyzed for BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19626635,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19624312,"Mutated BRAF is a target in metastatic melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,19603024,"BRAF (P=0.01) mutations predicted reduced progress free survival in response to cetuximab salvage therapy in patients with metastatic colorectal cancer ."
https://pharos.nih.gov/idg/targets/P15056,P15056,19603024,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19603018,"Assessing KRAS and BRAF mutations might help optimising the selection of the candidate metastatic colorectal cancer patients to receive anti-EGFR moAbs."
https://pharos.nih.gov/idg/targets/P15056,P15056,19603018,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19584155,"Results suggest that the mutations of EGFR, KRAS, BRAF between primary tumors and corresponding lymph node metastases should be considered whenever mutations are used for the selection of patients for EGFR-directed tyrosine kinase inhibitor therapy."
https://pharos.nih.gov/idg/targets/P15056,P15056,19584155,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19574281,"BRAF V600E mutation analysis can significantly improve FNAB diagnostic accuracy."
https://pharos.nih.gov/idg/targets/P15056,P15056,19571821,"We observed no association between germline MC1R status and somatic BRAF mutations in melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,19571709,"BRAF mutated tumors occurred with a much greater frequency in proximal colon tumors than in either distal colon or rectal tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,19571295,"study concludes that a BRAF mutation is a negative prognostic marker in patients with metastatic colorectal cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,19571295,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19561230,"BRAF mutations represent an alternative molecular pathway in the early tumorigenesis of a subset of KIT/PDGFRA wild-type GISTs and are per se not associated with a high risk of malignancy."
https://pharos.nih.gov/idg/targets/P15056,P15056,19561230,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19551857,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19547661,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19543740,"Pilocytic astrocytomas had BRAF fusions in 70% of cases but not IDH1 or IDH2 mutations. Diffuse astrocytomas had IDH1 mutations in 76% of cases but not IDH2 mutations or BRAF fusions. Analysis of BRAF and IDH1 separates pilocytic from diffuse astrocytoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19534623,"BRAF V600E may have a role in development of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19534622,"CTNNB1 and BRAF mutations may have roles in the cribriform-morular variant of papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19504446,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19498322,"Results show that activating BRAF somatic mutations may be occasionally found in advanced adrenocortical carcinomas, while CTNNB1 activating mutations are early and common events in adrenal tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,19498322,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19492075,"Targeting NRAS alone or both BRAF and CRAF in combination or both BRAF and PIK3CA together showed delay in tumor growth."
https://pharos.nih.gov/idg/targets/P15056,P15056,19487299,"If BRAF is mutated in the primary thyroid neoplasm, it is likely that the metastases will harbor the defect."
https://pharos.nih.gov/idg/targets/P15056,P15056,19487299,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19483722,"B-Raf/MKK/ERK provides a permissive environment for melanoma genesis by modulating plexin B1."
https://pharos.nih.gov/idg/targets/P15056,P15056,19474002,"data confirm that KRAS and BRAF mutations do occur in the same cell and that BRAF V600E mutation is associated with CIMP+ status."
https://pharos.nih.gov/idg/targets/P15056,P15056,19464601,"The RAS/RAF/MEK/ERK signaling pathway has emerged as a major player in the induction and maintenance of melanoma, particularly the protein kinase BRAF, mutated in approximately 44% of melanoma cases. Review."
https://pharos.nih.gov/idg/targets/P15056,P15056,19461239,"mismatch repair deficiency is not a crucial event for BRAF mutation in melanocytic tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,19440799,"oncogenic properties of KRAS and BRAF but not NRAS, HRAS, and PIK3CA contribute to the tumorigenesis of periampullary and ampullary tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,19430562,"Mutations in BRAF were found 10% patients in the low-grade carcinoma group, however, they were not found in the high-grade carcinoma group. KRAS and BRAF mutations were mutually exclusive, and both mutations were observed in 40%."
https://pharos.nih.gov/idg/targets/P15056,P15056,19430562,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19424639,"Report efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability."
https://pharos.nih.gov/idg/targets/P15056,P15056,19424571,"BRAF V600E mutation is not the target gene for abnormal DNA mismatch repair in patients with sporadic endometrial cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19416762,"Novel BRAF mutation in a patient with LEOPARD syndrome and normal intelligence is reported."
https://pharos.nih.gov/idg/targets/P15056,P15056,19415957,"The T1799A BRAF mutation does not appear to play a role in the tumorigenesis of the cribriform-morular variant of papillary carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19414674,"Observational study of gene-disease association and genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19404918,"Investigated BRAF mutations in 30 bladder tumors. Detected two tumor specimens bearing two different mutations, both of which were found in exon 15. One sample showed the T1799A (V600E) and the other the G1798T (V600L) mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19404918,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19404844,"elevated pERK expression occurs in urothelial carcinoma in the absence of B-Raf mutations and is not correlated with FGFR3 over-expression"
https://pharos.nih.gov/idg/targets/P15056,P15056,19404844,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19398955,"The murine model of mutant BRAF-induced melanoma formation provides an important tool for identifying further genetic alterations that cooperates with BRAF and that may be useful in enhancing susceptibility to BRAF-targeted therapeutics in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19393416,"B-RAF mutation was found to be significantly higher in papillary carcinomas when compared to follicular variant of papillary thyroid carcinomas (55.6% vs 14.3%, P = 0.05)."
https://pharos.nih.gov/idg/targets/P15056,P15056,19393416,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19389934,"a subpopulation of melanocytes possesses the ability to survive BRAF(V600E)-induced senescence"
https://pharos.nih.gov/idg/targets/P15056,P15056,19383316,"The genes whose expression is associated with BRAF mutations are not simply restricted to the MAPK/ERK signaling but also converge to enhanced immune responsiveness, cell motility and melanosomes processing involved in the adaptative UV response"
https://pharos.nih.gov/idg/targets/P15056,P15056,19383313,"REVIEW summarizes the literature on NRAS and BRAF activating mutations in melanoma tumors with respect to available data on histogenetic classification as well as body site and presumed UV-exposure."
https://pharos.nih.gov/idg/targets/P15056,P15056,19378335,"proliferation of cells harboring mutations in B-Raf, but not K-Ras, is exquisitely sensitive inhibition of the MAPK pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,19372556,"Mutation in BRAF is associated with ERK1/2 activation and MEK1/2 inhibitor therapy in colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19370505,"BRAF V600E mutation was significantly found in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19370505,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19369630,"K-ras, EGFR, and BRAF mutations are disproportionately seen in adenocarcinomas of lung with a dominant micropapillary growth pattern compared with conventional adenocarcinoma in our institutional experience."
https://pharos.nih.gov/idg/targets/P15056,P15056,19369630,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19362540,"Targets of phosphorylation by B-Raf signaling are investigated in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19358278,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19355825,"BRAF(V600E) is associated some of the aggressive clinicopathological features of papillary thyroid carcinoma including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,19355825,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19351817,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19344998,"In BRAF mutated colorectal carcinoma cells quercetin, luteolin and ursolic acid decreased Akt phosphorylation"
https://pharos.nih.gov/idg/targets/P15056,P15056,19342899,"Both BRAF and RKIP expression levels exhibit a decrease from normal skin tissue and actinic keratosis, going to squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19289622,"a correlation between a gene mutation--BRAF V600E--and cisplatin resistance in nonseminomatous germ cell tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,19289622,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19282104,"study of KRAS/BRAF mutation status in a large and well-documented cohort of primary and metastatic renal cell carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19276360,"GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,19274086,"oncogenic BRAF(V600E) induces the uncoupling of LKB1-AMPKalpha complexes providing at the same time a possible mechanism in cell proliferation that engages cell growth and cell division in response to mitogenic stimuli"
https://pharos.nih.gov/idg/targets/P15056,P15056,19255327,"Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19240718,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19237633,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19226609,"BRAF* melanomas appear to be associated with a specific profile of DNA copy number aberrations that is distinct from those found in NRAS* and BRAF/NRAS(wt/wt) tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,19208736,"BRAFT1799A mutation or RET/PTC rearrangement, mainly corresponding to follicular variants, maintain a thyroid differentiation expression level close to that of normal tissue."
https://pharos.nih.gov/idg/targets/P15056,P15056,19207009,"the presence of the braf protein mutation increases prohibitin promoter activity and therefore potentially mediates effects of this mutation on the behavior of BRAF protein"
https://pharos.nih.gov/idg/targets/P15056,P15056,19206169,"Findings provide evidence for a wide phenotypic diversity associated with mutations affecting BRAF, and occurrence of a clinical continuum associated with these molecular lesions."
https://pharos.nih.gov/idg/targets/P15056,P15056,19200582,"(novel) mutation in the activation kinase domain of the BRAF (A598V), this mutation led to the up-regulation of the BRAF kinase activity and its downstream signaling factors."
https://pharos.nih.gov/idg/targets/P15056,P15056,19194051,"Expression levels of fibronectin, vimentin and CITED1 were positively correlated with those of BRAFV600E, suggesting pathophysiological links between activated BRAF and overexpression of these genes."
https://pharos.nih.gov/idg/targets/P15056,P15056,19190129,"Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans."
https://pharos.nih.gov/idg/targets/P15056,P15056,19190129,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19190105,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19190079,"Mutation in BRAF is associated with adrenocortical carcinomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,19178815,"Mutations are absent or rare in the kinase domain of B-RAF in Japanese head and neck squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19178815,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19164452,"MLH1-hypermethylated tumors harbor fewer APC and KRAS mutations and more BRAF mutations, suggesting that they develop distinctly from an MGMT methylator pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,19159571,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19152441,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19147753,"BRAF and RET/PTC dual mutations are associated with recurrent papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19147753,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19142971,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19133693,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19127559,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19126563,"Sessile serrated adenomas are encountered commonly in routine endoscopy practice and the histological diagnosis correlates strongly with the presence of BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,19107232,"BRAF pseudogene activation may play a role in thyroid tumor development."
https://pharos.nih.gov/idg/targets/P15056,P15056,19098310,"ERK activation was induced by PKD2 overexpression via B-Raf signaling, providing a possible molecular mechanism of cystogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,19087308,"G12D mutation may be more likely selected in a BRAF mutated context"
https://pharos.nih.gov/idg/targets/P15056,P15056,19079609,"Genetic extinction of BRAF(V600E) in established prostate tumors did not lead to tumor regression, indicating that while sufficient to initiate development of invasive prostate adenocarcinoma, BRAF(V600E) is not required for its maintenance."
https://pharos.nih.gov/idg/targets/P15056,P15056,19064572,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19037234,"NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,19034577,"BRAF(V600E) mutation is assocciated with aggressive papillary thyroid microcarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,19034577,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19033861,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19026650,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19018267,"ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment"
https://pharos.nih.gov/idg/targets/P15056,P15056,19018267,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19016743,"Reverse transcription polymerase chain reaction-based sequencing revealed a fusion product between KIAA1549 and BRAF in pediatric low-grade astrocytomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,19014278,"In Korean patients with papillary thyroid carcinoma, the BRAFV600E mutation is associated with a lower frequency of background Hashimoto thyroiditis and a high frequency of lymph node metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,19014278,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19012001,"The result showed that the mutation rate of PIK3CA in nasopharyngeal carcinomas (n = 73) was 9.6%, whereas both BRAF (n = 65) and RAS (n = 45) were wild type in every specimen with adequate DNA for analysis."
https://pharos.nih.gov/idg/targets/P15056,P15056,19012001,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,19003996,"BRAF-V600E mutation is uncommon in endocrine tumors other than thyroid papillary carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,19001320,"Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,19001320,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18992635,"8% of sporadic colorectal tumors in this study harbor mutation in the BRAF gene."
https://pharos.nih.gov/idg/targets/P15056,P15056,18992635,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18987552,"BRAF mutations may not play an important role in the oncogenesis or therapy of prostate adenocarcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,18985043,"the T1799A BRAF mutation is present in a proportion of posterior uveal melanomas but within these tumours the distribution of the mutation is heterogeneous."
https://pharos.nih.gov/idg/targets/P15056,P15056,18980976,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18974108,"rearrangement, which was not observed in a series of 244 higher-grade astrocytomas, results in an in-frame fusion gene incorporating the kinase domain of the BRAF oncogene"
https://pharos.nih.gov/idg/targets/P15056,P15056,18953432,"study shows high expression of p16(INK4a) or the absence of activated B-RAF correlates with in vivo response of melanoma to cytotoxic drugs"
https://pharos.nih.gov/idg/targets/P15056,P15056,18946221,"Hereditary pancreatitis patients with PRSS1 mutations also had mutations in BRAF and KRAS2."
https://pharos.nih.gov/idg/targets/P15056,P15056,18945298,"BRAF V600E appeared to be the most commonly mutated gene in both the melanocytic aggregate (seven of 18, 39%) and the melanoma (four of 18, 22%)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18840924,"BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan."
https://pharos.nih.gov/idg/targets/P15056,P15056,18840924,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18834226,"With at least 3 markers methylated, new CIMP-positive colorectal cancers were closely associated with proximal tumor location, low frequency of KRAS mutation, and high frequency of BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,18832519,"CIMP-high appears to be an independent predictor of a low colon cancer-specific mortality, while BRAF mutation is associated with a high colon cancer-specific mortality."
https://pharos.nih.gov/idg/targets/P15056,P15056,18806830,"study concludes a single endogenous BRAF(V600E) allele is sufficient to repress BIM & prevent death from growth factor withdrawal; colorectal cancer cells with V600E mutations are addicted to the ERK1/2 pathway for repression of BIM"
https://pharos.nih.gov/idg/targets/P15056,P15056,18798261,"BRAF mutation occurs independently of CpG island methylator phenotype and MSI in all types of serrated polyps and may serve as a marker of serrated pathway of colorectal carcinogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,18794803,"study identified a group of melanomas with low-activity BRAF mutations (G469E- and D594G) that are reliant upon CRAF-mediated survival activity"
https://pharos.nih.gov/idg/targets/P15056,P15056,18794094,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18787396,"These data implicates a mitotic role for B-Raf in regulating spindle formation and the spindle checkpoint in human somatic cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,18782444,"BRAF, KRAS and PIK3CA mutations occur prior to malignant transformation demonstrating that these oncogenic alterations are primary genetic events in colorectal carcinogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,18782444,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18778891,"BRAF mutation is associated with the CpG island methylator phenotype in colorectal cancer from young patients"
https://pharos.nih.gov/idg/targets/P15056,P15056,18778891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18759827,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18757433,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18757341,"KRAS and BRAF mutations can impair response to anti-EGFR therapy for colorectal neoplasms"
https://pharos.nih.gov/idg/targets/P15056,P15056,18718023,"presence of the BRAF (V600E) mutation,the incidence of microsatellite instability high colorectal cancer in populations based study."
https://pharos.nih.gov/idg/targets/P15056,P15056,18716556,"focal gains at chromosome 7q34 and increased BRAF-MEK-ERK signaling are common findings in sporadic pilocytic astrocytomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,18715233,"These data suggest that regulation of BIM expression by BRAF-->MEK-->ERK signaling is one mechanism by which oncogenic BRAF(V600E) can influence the aberrant physiology of melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,18710471,"There is a higher frequency of the BRAF(V600E) mutation in papillary thyroid carcinomas than in normal thyroid tissue."
https://pharos.nih.gov/idg/targets/P15056,P15056,18697864,"Identification and functional characterization of a novel T599I-VKSR(600-603)del BRAF mutation in a patient with follicular variant papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,18682506,"The BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features."
https://pharos.nih.gov/idg/targets/P15056,P15056,18682506,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18676756,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18676742,"CST6, CXCL14, DHRS3, and SPP1 are regulated by BRAF signaling and may play a role in papillary thyroid carcinoma pathogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,18669866,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18668139,"N-RAS(Q61K) and B-RAF(V600E) contribute to melanoma's resistance to apoptosis in part by downregulating Bim expression"
https://pharos.nih.gov/idg/targets/P15056,P15056,18650848,"hyperactivation of the MAPK pathway following activation of an inducible form of oncogenic C-Raf induces a senescence-like proliferation arrest in B-Raf mutant melanoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,18636014,"lung adenocarcinoma of mixed type with a high incidence of papillary and lepidic growth may be worthwhile investigating for BRAF-V600E mutation as more genetically oriented drug therapies emerge."
https://pharos.nih.gov/idg/targets/P15056,P15056,18632627,"co-overexpression of KIT/CDK4 is a potential mechanism of oncogenic transformation in some BRAF/NRAS wild-type melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,18628967,"BRAF regulates melanoma proliferation through the lineage specific factor MITF"
https://pharos.nih.gov/idg/targets/P15056,P15056,18628431,"People of southern European origin had lower risk of colorectal cancers with CIMP and BRAF mutation than people of Anglo-Celtic origin, which may in part be due to genetic factors that are less common in people of southern European origin."
https://pharos.nih.gov/idg/targets/P15056,P15056,18628356,"The frequencies of LOHs of 17q21, 17p13, 10q23, and 22q13 were higher in tumors with lymph node metastasis, suggesting that these LOHs may be important in increased lymph node metastasis."
https://pharos.nih.gov/idg/targets/P15056,P15056,18621636,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18615680,"MLH1 methylation and BRAF mutations are associated with microsatellite unstable colon tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,18615680,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18615679,"V600E BRAF mutation is associated with imatinib-resistant gastrointestinal stromal tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,18615679,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18602919,"Rac1b and B-Raf(V600E) functionally cooperate to sustain colorectal cell viability and suggest they constitute an alternative survival pathway to oncogenic K-Ras"
https://pharos.nih.gov/idg/targets/P15056,P15056,18594528,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18592405,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18567582,"the scaffold protein IQGAP1 couples Ca(2+) and calmodulin signaling to B-Raf function"
https://pharos.nih.gov/idg/targets/P15056,P15056,18532874,"Compared to melanomas without BRAF mutations, melanomas with BRAF mutations showed statistically significantly higher degrees of intraepidermal scatter of melanocytes, and a higher proportion of melanocytes arranged in nests."
https://pharos.nih.gov/idg/targets/P15056,P15056,18519771,"a significant relationship in overall survival in colon cancer patients with defective DNA mismatch repair and the presence of a specific mutation in BRAF (V600E)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18517279,"BRAF mutations in colorectal cancer microsatellite-stable cases are associated with high levels of chromosomal instability that are likely responsible for the adverse outcomes in these cases"
https://pharos.nih.gov/idg/targets/P15056,P15056,18509361,"Shorter overall survival in primary melanoma was associated with the presence of ulceration and BRAF exon 15 mutations, as well as the absence of nuclear activation of Akt and of cytoplasmic activation of ERK."
https://pharos.nih.gov/idg/targets/P15056,P15056,18509003,"study revealed a significant correlation of BRAFV600E mutation with a lower expression of both sodium iodide symporter and thyroperoxidase in papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,18470905,"aberrant methylation of the hMLH1 gene may play a role in BRAF mutation-promoted thyroid tumorigenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,18458053,"oncogenic BRAF inhibition can have a different effect on cell fate depending on the cellular type"
https://pharos.nih.gov/idg/targets/P15056,P15056,18451171,"Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development."
https://pharos.nih.gov/idg/targets/P15056,P15056,18435933,"CpG island methylator phenotype in colorectal neoplasms may result from activating mutations in either BRAF or KRAS."
https://pharos.nih.gov/idg/targets/P15056,P15056,18434602,"Cdk1/cyclin B has a role in regulating B-raf activation at mitosis"
https://pharos.nih.gov/idg/targets/P15056,P15056,18413255,"study describes the biochemical characterization of novel BRAF and MEK germline mutations in cardio-facio-cutaneous syndrome"
https://pharos.nih.gov/idg/targets/P15056,P15056,18408659,"in melanocytic lesions, BRAF(V600E) mutation can affect a subset of the cells and is associated with the type and quantity of sun exposure"
https://pharos.nih.gov/idg/targets/P15056,P15056,18402768,"Aberrant BRAF and INK4A functionally interact to promote growth and survival of melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,18398503,"Results implicate aberrant activation of the MAPK pathway due to gene duplication or mutation of BRAF as a molecular mechanism of pathogenesis in low-grade astrocytomas and suggest inhibition of the MAPK pathway as a potential treatment."
https://pharos.nih.gov/idg/targets/P15056,P15056,18397470,"is commonly activated by somatic point mutation, it may provide possible diagnostic and therapeutic targets in human malignant tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,18383861,"K-RAS and BRAF mutations are a frequent genetic event in our samples of sporadic papillary and medullary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,18383861,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18382358,"Detecting BRAF mutation by pyrosequencing is more sensitive, faster, and less expensive than direct DNA sequencing."
https://pharos.nih.gov/idg/targets/P15056,P15056,18381570,"Thyroid cancers with BRAF mutation are preferentially sensitive to MEK inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,18375819,"BRAF mutation is associated with disease stabilization in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,18368129,"This study confirms that the known MC1R-melanoma risk association is confined to subjects whose melanomas harbor BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,18368129,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18343945,"Our data provide evidence that PIK3CA and BRAF contribute to the tumorigenesis of IPMN/IPMC, but at a lower frequency than KRAS."
https://pharos.nih.gov/idg/targets/P15056,P15056,18337114,"BRAF mutation testing of papillary thyroid carcinoma might improve the diagnosis, prognostic stratification and treatment of these tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,18329792,"RKIP could play an important role in the down-regulation of wild-type BRAF, serving thus as an endogenous inhibitor of the MAPK pathway in nasal polyps and their adjacent turbinate mucosa."
https://pharos.nih.gov/idg/targets/P15056,P15056,18323787,"Mitogen-activated protein kinase (MAPK) activity is subject to regulation even in BRAF/NRAS mutant melanoma cells and that high MAPK pathway signaling may be important only in distinct subsets of tumor cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,18310288,"BRAF-V600E mutation is associated with familial non-medullary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,18310287,"BRAF(V600E) mutation is asscoiated with papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,18310286,"BRAF T1799A mutation is associated with aggressive pathological outcomes of papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,18267069,"A genome-wide RNA-interference screening to identify genes required for an activated BRAF oncogene to block proliferation of fibroblasts and melanocytes revealed that a IGFBP7, has a central role in BRAF-mediated senescence and apoptosis."
https://pharos.nih.gov/idg/targets/P15056,P15056,18246127,"Mutant B-RAF mediates resistance to anoikis via Bad and Bim."
https://pharos.nih.gov/idg/targets/P15056,P15056,18235983,"Follicular histotypes of oncocytic thyroid carcinomas do not carry BRAF mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,18228248,"Important signalling role in T cell development."
https://pharos.nih.gov/idg/targets/P15056,P15056,18227705,"BRAF mutation is not associated with cutaneous melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,18226854,"frequency of the occurrence of BRAF mutation and/or RET/PTC in H4-PTEN positive tumors was extremely high (75%) in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,18224685,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18199160,"A worse clinical outcome was found for CIMP-high, microsatellite stable colorectal cancer with KRAS/BRAF mutation but not for those lacking KRAS/BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,18172070,"Because of the very sensitive pyrophosphorolysis-activated polymerization (PAP)technology, B-RAF mutations were found in cell lines and primary uveal melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,18098337,"BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,18071315,"B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells."
https://pharos.nih.gov/idg/targets/P15056,P15056,18070147,"BRAF(V600E)'alone' does not represent a marker for poor outcome"
https://pharos.nih.gov/idg/targets/P15056,P15056,18061181,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,18060073,"BRAF and MEK1/2 mutations may be more common than anticipated in ovarian cancer which could have important implications for treatment of patients with this disease and suggests potential new therapeutic avenues"
https://pharos.nih.gov/idg/targets/P15056,P15056,18045987,"These results identify Rnd3 as a regulator of cross talk between the RAF/MEK/ERK and Rho/ROCK signaling pathways, and a key contributor to oncogene-mediated reorganization of the actin cytoskeleton and focal adhesions."
https://pharos.nih.gov/idg/targets/P15056,P15056,18045960,"Detection of BRAF improves the diagnosis in fine-needle biopsy with cytological findings suspicious for papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,18042262,"the results of HRAS, BRAF and MAP2K1/2 mutation screening in a large cohort of patients with CS and CFC"
https://pharos.nih.gov/idg/targets/P15056,P15056,18032947,"The BRAF mutation is common in melanomas, but variation in rates across melanoma subtypes points to a complex interplay between BRAF activation and other factors (eg, sun exposure)."
https://pharos.nih.gov/idg/targets/P15056,P15056,18024410,"no BRAF mutations identified in 65 screened JMML patients; this gene is unlikely to play a role in the pathogenesis of JMML."
https://pharos.nih.gov/idg/targets/P15056,P15056,18008004,"mutation of N-RAS or B-RAF, signature genetic lesions present in most MMs, potently induced the expression of cell-surface CD200, a repressor of DC function."
https://pharos.nih.gov/idg/targets/P15056,P15056,18000091,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17972530,"These results suggest that papillary thyroid carcinomas with BRAF (V600E) mutation are more aggressive than those with wildtype BRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,17962436,"In this small study, the T1799A BRAF mutation was identified in almost half of the iris melanoma tissues samples examined. This finding suggests that there may be genetic as well as clinical differences between iris and posterior uveal melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,17942568,"BRAF interacts with PLCepsilon1 in nephrotic syndrome type 3. Both proteins are coexpressed and colocalize in developing and mature glomerular podocytes."
https://pharos.nih.gov/idg/targets/P15056,P15056,17940185,"BRAF mutation represents a novel indicator of the progression and aggressiveness of papillary thyroid cancer (Review)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17924122,"Examined associations between BRAF mutations, morphology, and apoptosis in early colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,17914558,"BRAF mutation is associated as early as the hyperplastic polyp stage followed by microsatellite instability at the carcinoma stage"
https://pharos.nih.gov/idg/targets/P15056,P15056,17911174,"effects of a MEK inhibitor, CI-1040, on thyroid cancer cells, some of which, particularly cell proliferation and tumor growth, seemed to be BRAF mutation or RAS mutation selective"
https://pharos.nih.gov/idg/targets/P15056,P15056,17878251,"MEK inhibition is cytostatic in papillary thyroid cancer and anaplastic thyroid cancer cells bearing a BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,17854396,"Papillary thyroid cancers with no 131I uptake had a high frequency of BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,17786355,"BRAFV600E mutations were found in 41.2% of the papillary thyroid carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17785355,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17785355,"BRAF V600E mutation is associated with high-risk papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,17727338,"BRAF(V600E) mutation detected on fine-needle aspiration biopsy specimens, more than RET/PTC rearrangements, is highly specific for papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,17721188,"Develompment of malignant strumo ovarii with papillary thyroid carcinoma features is associated with BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,17717450,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17717450,"BRAF V600E mutation is primarily present in conventional papillary thyroid cancer; it is associated with an aggressive tumor phenotype and higher risk of recurrent and persistent disease in patients with conventional papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,17714762,"diffuse expression of wild-type and/or mutant B-Raf may be involved in the tumorigenic process"
https://pharos.nih.gov/idg/targets/P15056,P15056,17704260,"5 unreported mutations (T241P, Q262R, G464R, E501V, N581K) were found in cardio-facio-cutaneous syndrome. A hotspot in exon 6 at Q257 was found."
https://pharos.nih.gov/idg/targets/P15056,P15056,17699719,"RNA interference and pharmacologic approaches were used to assess the role of B-Raf activation in the growth of human melanomas and additionally determined if a similar role for mutant B-Raf is seen for colorectal carcinoma cell lines."
https://pharos.nih.gov/idg/targets/P15056,P15056,17696195,"data showed differences in gene expression between nevi with and without the V600E BRAF mutation. Moreover, nevi with mutations showed over-expression of genes involved in melanocytic senescence and cell cycle inhibition"
https://pharos.nih.gov/idg/targets/P15056,P15056,17693984,"Observational study of genotype prevalence, gene-disease association, and genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17693984,"There was no coexistence of BRAF (V600E) mutation in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,17685465,"BRAF V600E mutation in papillary carcinoma of the thyroid may facilitate tumor cell growth and progression once seeded in the lymph nodes."
https://pharos.nih.gov/idg/targets/P15056,P15056,17671688,"PPARbeta/delta has a role in growth of RAF-induced lung adenomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17663506,"KLF6 and p53 mutations are involved in the development of nonpolypoid colorectal carcinoma, whereas K-ras and B-raf mutations are not"
https://pharos.nih.gov/idg/targets/P15056,P15056,17635919,"In contrast to C-RAF that requires farnesylated H-Ras, cytosolic B-RAF associates effectively and with significantly higher affinity with both farnesylated and nonfarnesylated H-Ras."
https://pharos.nih.gov/idg/targets/P15056,P15056,17566669,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17566669,"We conclude that screening for BRAF 15 exon mutation is an efficient tool in the diagnostic strategy for HNPCC"
https://pharos.nih.gov/idg/targets/P15056,P15056,17548320,"influence of B-RAF-specific RNA interference on the proliferation and apoptosis of gastric cancer BGC823 cell line"
https://pharos.nih.gov/idg/targets/P15056,P15056,17542667,"Presence of BRAF V600E in very early stages of papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,17535994,"The heterogeneous distribution of BRAF mutations suggests that discrete tumor foci in multifocal PTC may occur as independent tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,17525723,"T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene"
https://pharos.nih.gov/idg/targets/P15056,P15056,17520704,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17520704,"frequency of the BRAF mutation and the associations between BRAF mutation and clinicopathologic parameters in papillary thyroid carcinoma were evaluated by meta-analysis"
https://pharos.nih.gov/idg/targets/P15056,P15056,17518771,"low rate of RAS-RAF mutations (2/22, 9.1%) observed in Spitz melanocytic nevi suggests that these lesions harbor as yet undetected activating mutations in other components of the RAS-RAF-MEK-ERK-MAPK pathway"
https://pharos.nih.gov/idg/targets/P15056,P15056,17516929,"analysis of a BRAF mutation-associated gene expression signature in melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,17507627,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17507627,"data indicate that both early-life UV exposure and nevus propensity contribute to occurrence of BRAF+ melanoma, whereas nevus propensity and later-life sun exposure influence the occurrence of NRAS+ melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,17488796,"BRAF V600E mutation in PTCs is associated with reduced expression of key genes involved in iodine metabolism"
https://pharos.nih.gov/idg/targets/P15056,P15056,17487504,"c-kit expression is not alternative to BRAF and/or KRAS activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,17487277,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17483702,"Molecular diagnosis and careful observations should be considered in children with Cardio-facio-cutaneous syndrome because they have germline mutations in BRAF and might develop malignancy."
https://pharos.nih.gov/idg/targets/P15056,P15056,17464312,"prevalence of BRAF mutation and RET/PTC were determined in diffuse sclerosing variant of papillary thyroid carcinoma; none of the cases showed a BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,17454879,"MSI is rare in UC-related neoplasia as well as non-neoplastic lesions, and does not contribute to the development of dysplasia."
https://pharos.nih.gov/idg/targets/P15056,P15056,17453358,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17453004,"BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,17440063,"finding of a strong association between BRAF mutations and serrated histology in hyperplastic aberrant crypt foci supports the idea that these lesions are an early, sentinel, or a potentially initiating step on the serrated pathway to colorectal carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,17393356,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17393356,"data suggest that BRAF mutations might be present less frequently than KRAS mutations in Greek patients with colorectal carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17387744,"BRAF(V600E) mutation is identified in a subset of cutaneous metastases from papillary thyroid carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17366577,"mutational analysis of KRAS, BRAF, and MAP2K1/2 in 56 patients with CFC syndrome; comparison of the genotype-phenotype correlation of CFC with that of Costello syndrome suggest a significant clinical overlap but not genotype overlap."
https://pharos.nih.gov/idg/targets/P15056,P15056,17360030,"findings show that RASSF1A hypermethylation and KRAS mutations and BRAF mutations are inversely correlated and play an important role in the development of cervical adenocarcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17355635,"The aim of this study was to identify the effect that BRAF oncogene has on post-transcriptional regulation in papillary thyroid carcinoma by using microRNA analysis."
https://pharos.nih.gov/idg/targets/P15056,P15056,17318013,"B-RAF mutations are a rare event in pituitary tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,17315191,"BRAFV600E represents a detectable marker in the plasma/serum from melanoma patients for monitoring but not diagnostic purposes"
https://pharos.nih.gov/idg/targets/P15056,P15056,17312306,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17309670,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17309670,"BRAF gene plays a \"gatekeeper\" role but does not act as a predisposition gene in the development of low-grade ovarian serous carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,17302867,"Overexpression of B-Raf mRNA and protein may be a feature of nonfunctioning pituitary adenomas, highlighting overactivity of the Ras-B-Raf-MAP kinase pathway in these tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,17297294,"characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer; the two new mutations resulted in constitutive activation of the BRAF kinase and caused NIH3T3 cell transformation"
https://pharos.nih.gov/idg/targets/P15056,P15056,17270239,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17227125,"Copy gain of PDGFB occurs in a subset of tumors showing no evidence of mutated BRAF or rearranged ret, suggesting that copy gain of PDGFB may underlie the increased expression of platelet-derived growth factor described recently in the literature."
https://pharos.nih.gov/idg/targets/P15056,P15056,17199737,"Absence of association between BRAF mutation and activation of MAPK pathway in papillary thyroid carcinoma suggests the presence of mechanisms that downregulate MAPK activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,17195912,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17195912,"there is a subgroup of colorectal carcinomas which develop via the microsatellite instability pathway that carry an alteration of the BRAF gene"
https://pharos.nih.gov/idg/targets/P15056,P15056,17186541,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17186541,"BRAF mutation is associated with thyroid carcinogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,17179987,"The role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancerwill be reviewed."
https://pharos.nih.gov/idg/targets/P15056,P15056,17170014,"RASSF1A methylation was observed in a high frequency in endometrioid endometrial carcinoma whereas K-ras and B-raf mutations were observed in a low frequency"
https://pharos.nih.gov/idg/targets/P15056,P15056,17159915,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17159915,"BRAF(T1799A) mutation is associated with a lower rate of tumor proliferation."
https://pharos.nih.gov/idg/targets/P15056,P15056,17148775,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,17148775,"Previously identified associations between smoking and colon cancer, whether microsatellite unstable or stable, appear to be explained by the association of smoking with BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,17119447,"Association with preexisting nevi and pronounced infiltration of lymphocytes was significantly higher in BRAF mutated melanoma tumours"
https://pharos.nih.gov/idg/targets/P15056,P15056,17119056,"BRAF-V600E mutations are mainly involved in colorectal cancer families characterized by an increased risk of other common malignancies"
https://pharos.nih.gov/idg/targets/P15056,P15056,17097223,"data provide evidence that oncogenic properties of BRAF contribute to the tumorigenesis of intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC), but at a lower frequency than KRAS"
https://pharos.nih.gov/idg/targets/P15056,P15056,17074813,"phosphorylation on both S365 and S429 participate in the differential regulation of B-Raf isoforms through distinct mechanisms"
https://pharos.nih.gov/idg/targets/P15056,P15056,17060774,"BRAF mutation remained a significant prognostic factor for lymph node metastasis (odds ratio = 10.8, 95% confidence interval, 3.5-34.0, P < 0.0001)."
https://pharos.nih.gov/idg/targets/P15056,P15056,17044028,"Activating BRAF mutation is associated with papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,17018604,"Normally, BRAF alone is responsible for signaling to MEK. However, when RAS is mutated in melanoma, melanocytes switch their signaling from BRAF to CRAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,17001349,"data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-kappaB activity and to increased survival of melanoma cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,16987295,"BRAF T1976A mutation is present at high frequency in benign naevi such as Spitz and Reed."
https://pharos.nih.gov/idg/targets/P15056,P15056,16973828,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16964379,"Extracellular signal-regulated kinase-3 (ERK3/MAPK6) is highly expressed in response to BRAF signaling."
https://pharos.nih.gov/idg/targets/P15056,P15056,16960555,"Expression of active mutants of B-Raf induces fibronectin."
https://pharos.nih.gov/idg/targets/P15056,P15056,16959844,"BRAFV600E activates not only MAPK but also NF-kappaB signaling pathway in human thyroid cancer cells, leading to an acquisition of apoptotic resistance and promotion of invasion."
https://pharos.nih.gov/idg/targets/P15056,P15056,16953233,"Concomitant KRAS and BRAF mutations increased along progression of MSS colorectal cancer, suggesting that activation of both genes is likely to harbour a synergistic effect"
https://pharos.nih.gov/idg/targets/P15056,P15056,16946010,"Braf mutations in thyroid tumorigenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,16937524,"BRAF, K-ras and BAT26 are expressed in colorectal polyps and stool"
https://pharos.nih.gov/idg/targets/P15056,P15056,16937524,"BRAF, K-ras and BAT26 are expressed in colorectal polyps and stool [BAT26]"
https://pharos.nih.gov/idg/targets/P15056,P15056,16932278,"Single nucleotide polymorphism found exclusively in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,16924241,"Expression of p27Kip1 in melanoma is regulated by B-RAF at the mRNA level and via B-RAF control of Cks1/Skp2-mediated proteolysis."
https://pharos.nih.gov/idg/targets/P15056,P15056,16918957,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16918136,"BRAF mutations are associated with colorectal cancers"
https://pharos.nih.gov/idg/targets/P15056,P15056,16912199,"B-RAF has been identified as the most mutated gene in invasive cells and therefore an attractive therapeutic target in melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,16879389,"BRAF mutation was frequent in hyperplastic polyps (67%) and sessile serrated adenomas (81%)."
https://pharos.nih.gov/idg/targets/P15056,P15056,16858683,"Aberrant methylation and hence silencing of TIMP3, SLC5A8, DAPK and RARbeta2, in association with BRAF mutation, may be an important step in PTC tumorigenesis and progression."
https://pharos.nih.gov/idg/targets/P15056,P15056,16858395,"Thus, we propose that the hitherto unidentified function of the B-Raf amino-terminal region is to mediate calcium-dependent activation of B-Raf and the following MEK activation, which may occur in the absence of Ras activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,16845322,"BRAF mutation is associated with melanoma and melanocytic nevi."
https://pharos.nih.gov/idg/targets/P15056,P15056,16809487,"findings show that MC1R variants are strongly associated with BRAF mutations in non-chronic sun-induced damage melanomas; in this subtype, risk for melanoma associated with MC1R is due to increase in risk of developing melanomas with BRAF mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,16804544,"CpG island methylator phenotype-positive colorectal tumors represent a distinct subset, encompassing almost all cases of tumors with BRAF mutation"
https://pharos.nih.gov/idg/targets/P15056,P15056,16803888,"Rheb has a central role in the regulation of the Ras/B-Raf/C-Raf/MEK signaling network"
https://pharos.nih.gov/idg/targets/P15056,P15056,16799476,"A subset of Spitz nevi, some with atypical histologic features, possess BRAF mutations. The BRAF mutational status does not separate all Spitz nevi from spitzoid melanomas and non-Spitz types of melanocytic proliferations, contrary to previous reports."
https://pharos.nih.gov/idg/targets/P15056,P15056,16786134,"a BRAFT1799A mutation may have a role in poor differentiation of thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,16773193,"among 23 melanomas located at body sites with chronic UV exposure, only a single tumour harboured the B-raf V599E mutation which was a significantly lower frequency in comparison to melanomas from sun-protected body sites"
https://pharos.nih.gov/idg/targets/P15056,P15056,16728573,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16728573,"B-RAF (V600E) was confirmed to be associated with the papillary growth pattern, but not with poorer differentiated papillary thyroid carcinoma variants."
https://pharos.nih.gov/idg/targets/P15056,P15056,16721785,"BRAF mutations are as uncommon as KRAS mutations in prostate adenocarcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,16691193,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16691193,"UV light is not necessarily required for the acquisition of the BRAF(V600E) mutation, and non-mutagenic effects of UV light to melanocytes may be more important in the nevogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,16687919,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16618717,"Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16601293,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16601293,"BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane"
https://pharos.nih.gov/idg/targets/P15056,P15056,16547495,"Melanoma cells require either B-RAF or phosphoinositide-3 kinase activation for protection from anoikis."
https://pharos.nih.gov/idg/targets/P15056,P15056,16537381,"Merlin and MLK3 can interact in situ and merlin can disrupt the interactions between B-Raf and Raf-1 or those between MLK3 and either B-Raf or Raf-1."
https://pharos.nih.gov/idg/targets/P15056,P15056,16487015,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16474404,"Cardio-facio-cutaneous (CFC) syndrome involves dysregulation of the RAS-RAF-ERK pathway."
https://pharos.nih.gov/idg/targets/P15056,P15056,16462768,"NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level"
https://pharos.nih.gov/idg/targets/P15056,P15056,16452550,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16452469,"wild-type B-Raf-mediated ERK1/2 activation plays a major role in proliferation and transformation of uveal melanocytes; Raf-1 is not involved in this activation"
https://pharos.nih.gov/idg/targets/P15056,P15056,16439621,"findings demonstrate that heterogeneous de novo missense mutations in three genes within the mitogen-activated protein kinase pathway, BRAF, MEK1 and MEK2 cause cardio-facio-cutaneous syndrome"
https://pharos.nih.gov/idg/targets/P15056,P15056,16424035,"gain-of-function BRAF signaling is strongly associated with in vivo tumorigenicity"
https://pharos.nih.gov/idg/targets/P15056,P15056,16417232,"BRAF mutation does not seem to be sufficient to produce MAPK activation in melanocytic nevi."
https://pharos.nih.gov/idg/targets/P15056,P15056,16413100,"The most frequent B-RAF gene alterations are not involved in prostate carcinogenesis"
https://pharos.nih.gov/idg/targets/P15056,P15056,16397024,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16382052,"aberrant B-Raf activity in angiomyolipomas leads to abnormal cellular differentiation and migration [review]"
https://pharos.nih.gov/idg/targets/P15056,P15056,16376942,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16376942,"V599E BRAF mutation was uncommon in Japanese lung cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,16373964,"activating mutations of PDGFR-alpha, c-kit and B-RAF are absent in gliosarcomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,16371460,"V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors."
https://pharos.nih.gov/idg/targets/P15056,P15056,16364920,"Data suggest that B-RAF activates C-RAF through a mechanism involving 14-3-3 mediated heterooligomerization and C-RAF transphosphorylation."
https://pharos.nih.gov/idg/targets/P15056,P15056,16361694,"The authors have developed and run a high-throughput screen to find inhibitors of V600E BRAF using an enzyme cascade assay in which oncogenic BRAF activates MEK1, which in turn activates ERK2, which then phosphorylates the transcription factor ELK1."
https://pharos.nih.gov/idg/targets/P15056,P15056,16354586,"Mutation and elevated expression of BRAF is associated with the development of testicular germ cell tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,16354196,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16354196,"The estimated proportion of attributable risk of melanoma due to variants in BRAF is 1.6%, but the burden of disease associated with this variant is greater than that associated with the major melanoma locus (CDKN2A) which has a risk of 0.2%."
https://pharos.nih.gov/idg/targets/P15056,P15056,16268813,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16199894,"copy number gain may represent another mechanism of BRAF activation in thyroid tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,16181547,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16181240,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16179870,"The oncogenic B-raf mutations V599E and V599K, as early events in melanocyte transformation, persist throughout metastasis with important prognostic implications."
https://pharos.nih.gov/idg/targets/P15056,P15056,16179867,"As the BRAF oncogene is frequently found to be mutated in human cutaneous melanomas, it may constitute a risk factor for melanoma formation within CMN and DMN."
https://pharos.nih.gov/idg/targets/P15056,P15056,16174717,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16174717,"In patients with papillary thyroid cancer, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence."
https://pharos.nih.gov/idg/targets/P15056,P15056,16172610,"selective reduction in catalytic activity and expression of B-Raf but not Raf-1 suggest that B-Raf may be playing an important role in altered ERK signaling in brain of suicide subjects, and thus in the pathophysiology of suicide"
https://pharos.nih.gov/idg/targets/P15056,P15056,16144912,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16144912,"Mutations of the BRAF gene are partly involved in the malignant transformation of the endometrium."
https://pharos.nih.gov/idg/targets/P15056,P15056,16143028,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16129781,"These data suggest that MITF is an anti-proliferation factor that is down-regulated by B-RAF signaling and that this is a crucial event for the progression of melanomas that harbor oncogenic B-RAF."
https://pharos.nih.gov/idg/targets/P15056,P15056,16123397,"The results showed that conjunctival nevi, similar to skin nevi, have a high frequency of oncogenic BRAF mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,16098042,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16098042,"Although BRAF and NRAS mutations are likely to be important for the initiation and maintenance of some melanomas, other factors might be more significant for proliferation and prognosis in subgroups of aggressive melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,16096377,"BRAF mutation in melanoma is most likely to occur prior to the development of metastatic disease"
https://pharos.nih.gov/idg/targets/P15056,P15056,16079850,"sustained BRAF(V600E) expression in human melanocytes induces cell cycle arrest, which is accompanied by the induction of both p16(INK4a) and senescence-associated acidic beta-galactosidase (SA-beta-Gal) activity, a commonly used senescence marker"
https://pharos.nih.gov/idg/targets/P15056,P15056,16024606,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16015629,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,16007203,"Single-cell clones with efficient knockdown of (V 600 E)B-RAF could be propagated in the presence of basic fibroblast growth factor but underwent apoptosis or senescence-like growth arrest upon withdrawal of this growth factor"
https://pharos.nih.gov/idg/targets/P15056,P15056,16007166,"determination of mutation specific gene expression profiles in papillary thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,15998781,"Role of BRAF mutation in facilitating metastasis and progression of papillary thyroid cancer in lymph nodes."
https://pharos.nih.gov/idg/targets/P15056,P15056,15994075,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,15980887,"BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to papillary thyroid carcinoma and anaplastic thyroid carcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,15968271,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,15968271,"The increasing frequency of BRAF mutations as a function of age could help account for the well documented but poorly understood observation that age is a relevant prognostic indicator for patients with papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,15935100,"B-raf V599E and V599K oncogenic mutations are likely to affect melanocyte-specific pathways controlling proliferation and differentiation"
https://pharos.nih.gov/idg/targets/P15056,P15056,15904951,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,15880523,"Anaplastic thyroid carcinomas which are derived from papillary carcinomas are due to BRAF and p53 mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,15842051,"These results suggest that BRAF mutations do not have a role in tumorigenesis of neuroendocrine gastroenteropancreatic tumors."
https://pharos.nih.gov/idg/targets/P15056,P15056,15824163,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,15791648,"B-raf mutations surrounding Thr439 found in human cancers are unlikely to contribute to increased oncogenic properties of B-raf"
https://pharos.nih.gov/idg/targets/P15056,P15056,15791479,"The data of this study suggest that activating mutations of B-RAF are not a frequent event in gliomas; nevertheless, when present they are associated with high-grade malignant lesions."
https://pharos.nih.gov/idg/targets/P15056,P15056,15782118,"BRAF mutations proved to be absent in tumors from hereditary nonpolyposis colorectal cancer syndrome (HNPCC) families with germline mutations in the MMR genes MLH1 and MSH2."
https://pharos.nih.gov/idg/targets/P15056,P15056,15765445,"Mutations in the BRAF protooncogene (V599E)may be an alternative pathway of tumorigenesis of familial colorectal cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,15710605,"autoinhibition was negatively regulated by acidic substitutions at phosphorylation sites within the activation loop"
https://pharos.nih.gov/idg/targets/P15056,P15056,15705790,"KSHV-infected cell lines expressed higher levels of B-Raf and VEGF-A; B-Raf-induced VEGF-A expression was demonstrated to be sufficient to enhance tubule formation in endothelial cells"
https://pharos.nih.gov/idg/targets/P15056,P15056,15702478,"We found mutations in p53, K-ras, and BRAF genes in 35%, 30%, and 4% of tumors, respectively, and observed a minimal or no co-presence of these gene alterations."
https://pharos.nih.gov/idg/targets/P15056,P15056,15653554,"a novel Ras-independent ERK1/2 activation system in which p110gamma/Raf-1/MEK1/2 and PKA/B-Raf/MEK1/2 cooperate to activate ERK1/2."
https://pharos.nih.gov/idg/targets/P15056,P15056,15632082,"Data suggest that Rit is involved in a novel pathway of neuronal development and regeneration by coupling specific trophic factor signals to sustained activation of the B-Raf/ERK and p38 MAP kinase cascades."
https://pharos.nih.gov/idg/targets/P15056,P15056,15630448,"AKAP9-BRAF fusion was preferentially found in radiation-induced papillary carcinomas developing after a short latency, whereas BRAF point mutations were absent in this group"
https://pharos.nih.gov/idg/targets/P15056,P15056,15577314,"BRAF mutations are associated with conjunctival neoplasms"
https://pharos.nih.gov/idg/targets/P15056,P15056,15538400,"mutated in childhood acute lymphoblastic leukemia."
https://pharos.nih.gov/idg/targets/P15056,P15056,15489648,"Mutations of BRAF or KRAS oncogenes are early events in the serrated polyp neoplasia pathway. CpG island methylation plays a role in serrated polyp progression to colorectal carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,15488754,"REVIEW: our understanding of B-RAF as an oncogene and of its role in cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,15373778,"BRAF(V599E) mutation is seven times higher in lesions with structural changes and 13 times higher in growing lesions as compared with lesions without changes"
https://pharos.nih.gov/idg/targets/P15056,P15056,15339934,"Data provide evidence that B-Raf is a positive regulator of T cell receptor-mediated sustained ERK activation, which is required for NFAT activation and the full production of IL-2."
https://pharos.nih.gov/idg/targets/P15056,P15056,15331929,"we found 19 cases (38%) to harbor somatic B-raf exon 15 mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,15330192,"Mutations within the BRAF gene are useful markers for the differential diagnosis between Spitz nevus and malignant melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,15313890,"Data suggest that SPRY2, an inhibitor of ERK signaling, may be bypassed in melanoma cells either by down-regulation of its expression in WT BRAF cells, or by the presence of the BRAF mutation."
https://pharos.nih.gov/idg/targets/P15056,P15056,15277467,"In this study, this BRAF mutation was demonstrated in some conjunctival melanoma tissue samples, suggesting that some conjunctival melanomas may share biological features in common with cutaneous melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,15273715,"mutated in papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,15263001,"B-Raf and ERK are activated by cyclic AMP after calcium restriction"
https://pharos.nih.gov/idg/targets/P15056,P15056,15191558,"activation of this gene may be one of the early events in the pathogenesis of some melanomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,15186612,"BRAF mutations are rather rare in solitary cold adenomas and adenomatous nodules and do not explain the molecular etiology of ras mutation-negative cold thyroid nodules."
https://pharos.nih.gov/idg/targets/P15056,P15056,15179189,"in contrast to cutaneous melanoma, BRAF does not appear to be involved in the pathogenesis of uveal melanoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,15161700,"mucosal melanomas of the head and neck do not frequently harbor an activating mutation of BRAF"
https://pharos.nih.gov/idg/targets/P15056,P15056,15150271,"B-Raf kinase activity regulation by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent"
https://pharos.nih.gov/idg/targets/P15056,P15056,15145515,"Radiation-induced tumors have a low prevalence of BRAF point mutations and high prevalence of RET/PTC rearrangements"
https://pharos.nih.gov/idg/targets/P15056,P15056,15140228,"The finding of tandem mutations in thin melanomas makes it more likely that they arise as a simultaneous rather than sequential event."
https://pharos.nih.gov/idg/targets/P15056,P15056,15126572,"BRAF(V599E) is more common genetic alteration found to date in adult sporadic papillary thyroid carcinomas (PTCs). It is unique for this thyroid cancer histotype, and it might drive the development of PTCs of classic papillary subtype."
https://pharos.nih.gov/idg/targets/P15056,P15056,15104286,"These results suggest that the BRAF mutation is unlikely to be involved in gastric carcinogenesis."
https://pharos.nih.gov/idg/targets/P15056,P15056,15077125,"ovarian serous cystadenomas do not contain mutations in either BRAF or KRAS genes"
https://pharos.nih.gov/idg/targets/P15056,P15056,15014028,"BRAF mutation may be acquired during development of metastasis but is not a significant factor for primary melanoma development and disease outcome."
https://pharos.nih.gov/idg/targets/P15056,P15056,15009715,"mutations in the BRAF gene and to some extent in the N-ras gene represent early somatic events that occur in melanocytic nevi"
https://pharos.nih.gov/idg/targets/P15056,P15056,15009714,"possible cooperation between BRAF activation and PTEN loss in melanoma development."
https://pharos.nih.gov/idg/targets/P15056,P15056,15001635,"The lack or low prevalence of BRAF mutation in other thyroid neoplasms is consistent with the notion that other previously defined genetic alterations on the same signaling pathway are sufficient to cause tumorigenesis in most thyroid neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,14966563,"These studies identify isoprenylcysteine carboxyl methyltransferase as a potential target for reducing the growth of K-Ras- and B-Raf-induced malignancies."
https://pharos.nih.gov/idg/targets/P15056,P15056,14961576,"Mutations in BRAF gene is associated with malignant melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,14734469,"BRAF mutations are frequently present in sporadic colorectal cancer with methylated hMLH1"
https://pharos.nih.gov/idg/targets/P15056,P15056,14724583,"RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas; the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma"
https://pharos.nih.gov/idg/targets/P15056,P15056,14722037,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P15056,P15056,14719068,"New enriched PCR-RFLP assay for detecting mutations of BRAF codon 599 mutation in pleural mesotheliomas."
https://pharos.nih.gov/idg/targets/P15056,P15056,14695993,"BRAF mutations are associated with proximal colon tumors with mismatch repair deficiency and MLH1 hypermethylation."
https://pharos.nih.gov/idg/targets/P15056,P15056,14695152,"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression"
https://pharos.nih.gov/idg/targets/P15056,P15056,14691295,"Our data indicate that BRAF gene mutations are rare to absent events in uveal melanoma of humans."
https://pharos.nih.gov/idg/targets/P15056,P15056,14688025,"Mutations were found in exon 15 in colorectal adenocarcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,14668801,"Missense mutation is marker of colonic but not gastric cancer."
https://pharos.nih.gov/idg/targets/P15056,P15056,14639609,"Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,14618633,"None of the cases of gastric cancer showed braf mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,14612909,"BRAF is occasionally mutated in NHL, and BRAF mutation may contribute to tumor development in some NHLs"
https://pharos.nih.gov/idg/targets/P15056,P15056,14602780,"BRAF mutations are restricted to papillary carcinomas and poorly differentiated and anaplastic carcinomas arising from papillary carcinomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,14534542,"BRAF mutations were seen in stomach neoplasms."
https://pharos.nih.gov/idg/targets/P15056,P15056,14522897,"Uceal melanomas arise independent of oncogenic BRAF and NRAS mutations."
https://pharos.nih.gov/idg/targets/P15056,P15056,14513361,"BRAF mutations, which are present in a variety of other human cancers, do not seem to be involved in gastric cancer development"
https://pharos.nih.gov/idg/targets/P15056,P15056,14507635,"Both BRAF and FBXW7 mutations functionally activate kinase effectors important in pancreatic cancer and extend potential options for therapeutic targeting of kinases in treatment of phenotypically distinct pancreatic adenocarcinoma subsets."
https://pharos.nih.gov/idg/targets/P15056,P15056,14501284,"Our findings of a high frequency of BRAF mutations at codon 599 in benign melanocytic lesions of the skin indicate that this mutation is not sufficient by itself for malignant transformation."
https://pharos.nih.gov/idg/targets/P15056,P15056,12970315,"mutation of BRAF gene could be a potentially useful marker of prognosis of patients with advanced thyroid cancers"
https://pharos.nih.gov/idg/targets/P15056,P15056,12931219,"Mutations are not detectable in plasma cell leukemia and multiple myeloma."
https://pharos.nih.gov/idg/targets/P15056,P15056,12917419,"3 cell lines derived from human choroidal melanoma express B-Raf containing the V599E mutation and showed a 10-fold increase in endogenous B-RafV599E kinase activity and a constitutive activation of the MEK/ERK pathway that is independent of Ras"
https://pharos.nih.gov/idg/targets/P15056,P15056,12893203,"Mucinous ovarian cancers without a KRAS mutation have not sustained alternative activation of this signaling pathway through mutation of the BRAF oncogene."
https://pharos.nih.gov/idg/targets/P15056,P15056,12881714,"The BRAF(V599E) mutation appears to be an alternative event to RET/PTC rearrangement rather than to RAS mutations, which are rare in PTC. BRAF(V599E) may represent an alternative pathway to oncogenic MAPK activation in PTCs without RET/PTC activation."
https://pharos.nih.gov/idg/targets/P15056,P15056,12879021,"BRAF has a role in in squamous cell carcinoma of the head and neck through uncommon mutations"
https://pharos.nih.gov/idg/targets/P15056,P15056,12855697,"B-Raf has a role in extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy"
https://pharos.nih.gov/idg/targets/P15056,P15056,12824225,"Data suggest that BRAF T1796A activating mutation is not common in primary uveal melanoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,12821662,"B-raf is involved in adhesion-independent ERK1/2 signaling in melanocytes"
https://pharos.nih.gov/idg/targets/P15056,P15056,12810628,"13 germline BRAF variants, 4 of which were silent mutations in coding regions & 9 nucleotide substitutions in introns, were found in melanoma patients and melanoma family, but none appeared statistically likely to be a melanoma susceptibility gene."
https://pharos.nih.gov/idg/targets/P15056,P15056,12778069,"gene is mutated in skin melanoma, but not in uveal melanomas"
https://pharos.nih.gov/idg/targets/P15056,P15056,12753285,"cAMP activates ERK and increases proliferation of autosomal dominant polycystic kindey epithelial cells through the sequential phosphorylation of PKA, B-Raf and MAPK in a pathway separate from the classical receptor tyrosine kinase cascade"
https://pharos.nih.gov/idg/targets/P15056,P15056,12697856,"activating BRAF mutations may be an important event in the development of papillary thyroid cancer"
https://pharos.nih.gov/idg/targets/P15056,P15056,12670889,"High prevalence of BRAF mutations in thyroid cancer is genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma."
https://pharos.nih.gov/idg/targets/P15056,P15056,12644542,"results demonstrate that the mutational status of BRAF and KRAS is distinctly different among histologic types of ovarian serous carcinoma, occurring most frequently in invasive micropapillary serous carcinomas and its precursors, serous borderline tumors"
https://pharos.nih.gov/idg/targets/P15056,P15056,12619120,"The V599E BRAF mutation appears to be a somatic mutation associated with melanoma development and/or progression in a proportion of affected individuals."
https://pharos.nih.gov/idg/targets/P15056,P15056,12447372,"High frequency of BRAF mutations in nevi"
https://pharos.nih.gov/idg/targets/P15056,P15056,12198537,"BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA"
https://pharos.nih.gov/idg/targets/P15056,P15056,12068308,"somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers"
https://pharos.nih.gov/idg/targets/P15056,P15056,8621729,"MEK1 interacts with B-Raf."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,27939424,"IRAK-M functions to modulate inflammatory signaling pathways and is critical in maintaining immune system homeostasis in the gut. However, increased IRAK-M is associated with increased disease pathogenesis and increased cancer severity in human patients."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,27150039,"Data indicate a strong positive correlation between interleukin-1 receptor-associated kinase 3 (IRAK-M) and pSTAT3 protein in colorectal cancer (CRC)."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,26309029,"Alpha-Melanocyte-Stimulating Hormone Suppresses TLR2-Mediated Functional Responses through IRAK-M in Normal Human Keratinocytes"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,25852282,"IRAK3 methylation was associated with tumor stage and poor prognosis of hepatocellular carcinoma patients."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,25746953,"HIF1alpha is a regulator of monocyte functional re-programming in sepsis via regulating IRAKM expression."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,25595781,"IRAK-M expression is upregulated in peripheral blood cells from idiopathic pulmonary fibrosis patients"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,25481771,"The structure function of the death domain of human IRAK-M"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,24074582,"These data indicate the enhancing effect of IRAK-M on epithelial human rhinovirus-16 infection, which is partly through the autophagic pathway."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,23588345,"our study demonstrates that patients carrying IRAK-M+22148 G haplotype are more susceptible to sepsis than patients carrying IRAK-M+22148 A haplotype, suggesting that IRAK-M+22148 G haplotype might be a risk factor for sepsis."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,23376919,"IRAK-M mediates TLR7-induced MEKK3-dependent second wave NFjB activation to produce inhibitory molecules"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,22886503,"these data identify an important signaling regulator in human macrophages that is used by surfactant to control the long-term alveolar inflammatory response, i.e., enhanced IRAK-M activity."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,22634523,"the tested variations of IRAK-M and SIGIRR genes do not confer a relevant role in the susceptibility to systemic lupus erythematosus in European-descent populations"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,22272346,"Data suggest further evaluation of IRAK3 as a diagnostic and prognostic marker, and as a target for intervention."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,22154382,"these data indicate that epithelial IRAK-M overexpression in T(H)2 cytokine-exposed airways inhibits TLR2 signaling, providing a novel mechanism for the increased susceptibility of infections in asthmatic patients."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,22070913,"The results confirm the importance of the IRAK3 in asthma pathogenesis in the European populations"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,21987497,"The upregulation of IRAK-M in macrophages is involved in the local immunosuppression around implants, and may contribute to septic and aseptic implant loosening."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,21297081,"Common SNPs in the IRAK3 gene may be determinants of sepsis-induced acute lung injury."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,21278795,"Data demonstrates that TGF-beta-dependent induction of IRAK-M expression is an important, clinically relevant mechanism by which tumors may circumvent anti-tumor responses of macrophages."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,21098228,"Intact IRAK-M is strongly expressed in resting human alveolar macrophages but is cleaved in patients with pneumonia via neutrophil-mediated induction of caspase-6 (CASP-6) activity."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20448286,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20438785,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20406964,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20331378,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,20237496,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19561104,"inhibition of LPS-induced NFKB and ERK activation by acute alcohol leads to hyporesponsiveness of monocytes to LPS due to increased IRAK-M; chronic alcohol sensitizes monocytes to LPS through decreased IRAK-M expression and activation of NFKB and ERK"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19423540,"Nine SNPs distributed across eight genetic regions (ALOX5, IRAK3, ITGB2, NCF2, NFKB1, SELP, SOD1, and STAT1) were associated with risk of glioma with P value of <0.01."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19423540,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19414798,"IRAK-M is a major mediator of globular adiponectin-induced endotoxin tolerance in primary macrophages"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19372141,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19264973,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19114913,"Immunosuppression in sepsis caused by B. pseudomallei is associated with an upregulation of IRAK-M and an indicator of poor outcome."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19013233,"Analysis of single single nucleotide polymorphisms and haplotypes did not reveal a significant association between polymorphisms in the IRAK-M gene and atopic dermatitis in this cohort."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,19013233,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,18987746,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,18354163,"observed striking up-regulation of IRAK-M in monocytes, but without concomitant proinflammatory cytokine production"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,18156187,"Porphyromonas gingivalis lipopolysaccharide upregulates IRAK-M in macrophages."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17982103,"LPS tolerance in human endotoxemia models is associated with IRAK-M up-regulation."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17558906,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17558906,"no evidence to suggest association between inflammatory bowel disease, Crohn's disease (CD), ulcerative colitis (UC) or subsets of CD & UC and IRAK-M; an interaction was found between IRAK-M and CARD15 in UC patients"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17503328,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17503328,"IRAK-M is involved in the pathogenesis of early-onset persistent asthma."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,17379480,"These findings indicate that IRAK-M selectively attenuates p38 activation and inhibits innate immunity through stabilizing MKP-1."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,16437636,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,16432636,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,15728517,"IRAK-M is rapidly upregulated in human monocytes pre-exposed to tumor cells and could be involved in deactivation of tumor-infiltrating monocytes mediated by tumor cells."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,14592437,"Thus, our data indicate that IRAK-M could play a pivotal role in the process of endotoxin tolerance in human monocytes and provide evidence that PI3K is involved in regulating its expression."
https://pharos.nih.gov/idg/targets/Q9Y616,Q9Y616,12054681,"Identification and characterization of murine IRAK-M"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28871172,"the cytoplasmic retinoic acid receptor gamma (RARgamma) controls receptor-interacting protein kinase 1 (RIP1)-initiated cell death when cellular inhibitor of apoptosis (cIAP) activity is blocked."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28570668,"UL45 promoted the UL48-RIP1 interaction and re-localization of RIP1 to the UL48-containing virion assembly complex."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28498503,"we provide evidence that p62 is implicated in the activation of NF-kappaB signaling that is partly dependent on RIP1"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28453927,"Data suggest that pro-death signals through TIR-domain-containing adapter-inducing interferon-beta (TRIF) are regulated by autophagy and propose that pro-apoptotic signalling through TRIF/RIPK1/caspase-8 occurs in fibrillary platforms."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28292463,"SIRT2 and RIPK1 were localized to the syncytiotrophoblast, villous leukocytes and vasculature in all preterm placentas. A significant reduction in SIRT2 protein expression in both preeclampsia and fetal growth restricted placentas was identified. RIPK1 mRNA expression was significantly increased in preeclampsia placentas. Immunofluorescence identified both SIRT2 and RIPK1 in the cytotrophoblast cytoplasm."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28270653,"TRAIL can enhance RIP1 and c-FLIPL expression in HepG2 cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28159673,"RIPK1 inhibits the transcriptional activity of VDR."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28087739,"Results show that downregulation of RIP1 results in increased resistance to SN38, implying a requirement for RIP1 in mediating cytotoxicity through the TNF/TNFR signaling pathway."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,28017612,"RIPK1 collaborates with TRAF2 to inhibit murine and human hepatocarcinogenesis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27831558,"RIPK1 kinase activity is a pertinent therapeutic target to protect liver against excessive cell death in liver diseases."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27748372,"inactivation of RIP1/RIP3 resulted in reduction of SOCS1 protein levels and partial differentiation of AML cells. AML cells with inactivated RIP1/RIP3 signaling show increased sensitivity to IFN-gamma-induced differentiation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27738385,"CYLD Promotes TNF-alpha-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27699664,"High expression of RIP1 is associated with hepatocellular carcinoma."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27493188,"By promoting both inflammation and cell death, RIPK1 may be a common mediator of axonal pathology in amyotrophic lateral sclerosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27476169,"Upregulated expression of RIP1 is associated with triple-negative breast cancer."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27362805,"Renal clear cell carcinoma cells cells express increased amounts of RIPK1 and RIPK3 and are poised to undergo necroptosis in response to TNFR1 signaling."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27129772,"Hyperglycemic Conditions Prime Cells for RIP1-dependent Necroptosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27041566,"Ripk1 is directly involved in apoptosis/necroptosis. In osteosarcoma cells( OS) , small interfering RNA against Ripk1 prevented cell death induced by the sequestration of miR-155-5p. Collectively, we show that miR-148a-3p and miR-155-5p are species-conserved deregulated miRNA in OS"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,27035122,"Data indicate that RIP-1 promote the growth and invasion of gastric cancer in vitro and in vivo, additionally providing evidence that targeting RIP-1 may be useful in the treatment of gastric cancer."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26992898,"Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26865533,"Necroptosis signaling is modulated by the kinase RIPK1 and requires the kinase RIPK3 and the pseudokinase MLKL. (Review)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26749282,"Positive significant correlation was found for RIP1K expression."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26575016,"Report role of RIP1 in Smac mimetic mediated chemosensitization of neuroblastoma cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26522725,"Data show that pan-caspase inhibitors facilitated 5-fluorouracil (5-FU)-induced necroptosis mediated by secretion of tumor necrosis factor alpha (TNF-alpha) driven by nuclear factor kappaB (NF-kappaB) and required RIP1 kinase."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26496737,"The main route of cell death induced by shikonin is RIP1K-RIP3K-mediated necroptosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26460489,"Down-regulating RIP1 promotes oxaliplatin induced Tca8113 cells apoptosis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26313915,"CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26297639,"RIPK1 and RIPK2 are targets of HIV-1 Protease activity during infection, and their inactivation may contribute to modulation of cell death and host defense pathways by HIV-1"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26297639,"PR cleavage of RIPK1 disrupts RIPK1 function"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26195820,"cFLIP-mediated and caspase-8-dependent limited cleavage of RIP1 is a new layer of mechanism that promotes NF-KB activation and lymphoma survival."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26086143,"Studies indicate that RIP kinases RIPK1 and RIPK3 directly regulate inflammatory signaling."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,26018731,"These results identify upregulation of RIPK1 as an important resistance mechanism of melanoma cells to tunicamycin- or thapsigargin-induced endoplasmic reticulum stress."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25939870,"ZFP36 controls RIP1 levels in glioma neural stem cell lines."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25910754,"Data suggest that TP63 (tumor protein p63) and microRNA-101 are involved in regulation of necroptosis in squamous cell carcinoma (SCC); here, modulation of RIPK1 with miR-101-3p mimic/inhibitor affects sensitivity of SCC cells to cisplatin."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25908842,"RIP1 represses basal autophagy in part due to its ability to regulate the TFEB transcription factor;RIP1 activates ERK, which negatively regulates TFEB though phosphorylation of serine 142"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25880091,"In contrast, both necrostatin-1, a RIP1 kinase inhibitor, and Enbrel, a TNFalpha-blocking antibody, do not interfere with BV6/Drozitumab-induced apoptosis, demonstrating that apoptosis occurs independently of RIP1 kinase activity or an autocrine TNFalpha loop."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25817730,"results indicate that a TNFR1/RIPK1/P38 axis is present in adenosine-induced apoptosis of colonic cancer cells. This axis triggers apoptosis and plays crucial roles in relay of the death signaling"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25766324,"a novel non-enzymatic function of AChE-R is to stimulate RIPK1/MLKL-dependent regulated necrosis (necroptosis). The latter complements a cholinergic system in the ovary, which determines life and death of ovarian cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25754842,"Data show that toll-like receptor 3/TRIF protein signalling regulates cytokines IL-32 and IFN-beta secretion by activation of receptor-interacting protein-1 (RIP-1) and tumour necrosis factor receptor-associated factor 6 (TRAF6) in cornea epithelial cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25724678,"RIP1 is an oncogenic driver in melanoma, which leads to potential targeting of its NF-kappaB-dependent activation mechanism as a novel approach to treat this disease."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25697054,"in the absence of caspase-8 activity, 24(S)-Hydroxycholesterol induces a necroptosis-like cell death which is RIPK1-dependent but MLKL-independent."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25674983,"Herpes simplex virus 1- and 2 ICP6 and ICP10 proteins prevent necroptosis in human cells by inhibiting the interaction between receptor-interacting protein kinase 1 (RIP1) and RIP3, a key step in tumor necrosis factor (TNF)-induced necroptosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25583602,"These data demonstrate that RIP1 is essential for the regulation of death receptor mediated autophagy and apoptosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25575821,"Data suggest that neoalbaconol-induced necroptosis include receptor interacting serine/threonine kinase 1-dependent expression of tumor necrosis factor alpha and receptor interacting serine/threonine kinase 3-dependent generation of reactive oxygen species."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25476903,"RIPK1 indirectly regulates caspase-8 activation, in part via interaction with the ER stress sensor IRE1."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25459879,"Receptor Interacting Protein Kinase-1 (RIPK1), a key player in inflammation and cell death. [Review]"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25326752,"our results reveal a specific role for the RIP1-RIP3-DRP1 pathway in RNA virus-induced activation of the NLRP3 inflammasome"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25277242,"A reduction in the expression of RIP-1 in gallbladder cancer cells can exert inhibitory effects on the ability of cells to grow and invade in vitro."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,25096578,"mitochondrial reactive oxygen species generator 2,3-dimethoxy-1,4-naphthoquinone elicits necrosis characterized by the involvement of RIP1 and Drp1."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24980648,"In this study,dual ensemble screening, a novel computational strategy was used to identify diverse and potent inhibitors against RIPK1"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24902904,"RIPK1 can activate RIPK3 in response to receptor signaling, but also acts as a negative regulator of spontaneous RIPK3 activation in the cytosol."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24832602,"beta-lapachone induces programmed necrosis through the NQO1-dependent ROS-mediated RIP1-PARP1-AIF pathway."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24821786,"RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24762656,"The mechanism by which FLIP nitrosylation regulates NF-kappaB activity involves RIP1 binding and redistribution, whereas TRAF2 binding and distribution are unaffected."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24583643,"Maintenance of glycolysis by RIP1 is pivotal to cancer cell energy homeostasis and DNA integrity."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24425875,"a chemoresistant role for RIP1 that maintains inhibitor of apoptosis protein (IAP) expression by release of microRNA-146a-mediated catalase suppression, where intervention within this pathway may be exploited for chemosensitization."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24398693,"the C-terminal domain of c-FLIPL specifically inhibits the interaction of the caspase 8 prodomain with the RIP1 death domain and, thereby, regulates caspase 8-dependent NF-kappaB activation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24361886,"structure-based mutations of TNFR-1 (P367A and P368A), TRADD (F266A), and RIP1 (M637A and R638A) disrupted formation of the death domain (DD) complex and prevented stable interactions among those DDs"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24314238,"The protein levels of crucial modulators of necroptosis, RIP1 and RIP3, are increased by shikonin treatment in primary tumor tissues."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24079414,"This review focuses on the functional roles of RIP1 in regulating multiple cellular mechanisms--{REVIEW}"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,24059293,"an alanine residue substitution for Ser(89) enhanced RIP1 kinase activity and TNF-induced programmed necrosis without affecting RIP1-RIP3 necrosome formation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23840441,"Shikonin mediated necroptosis in glioma cells is associated with the up-regulated expression of RIP-1 and oxidative stress."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23770847,"our study implicates RIP1 ubiquitination as a critical component of API2-MALT1-dependent lymphomagenesis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23545938,"crucial mediator of CD30-induced cell death in anaplastic large-cell lymphoma cells"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23313255,"Data suggest that USP4 (ubiquitin specific peptidase 4) down-regulates RIP1-mediated TNF-alpha (tumor necrosis factor-alpha) activation and promotes TNF-alpha-induced apoptosis via deubiquitination of RIP1 in head/neck squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23071110,"procaspase-8 activity is essential for cell survival by inhibiting both apoptotic and nonapoptotic cell death dependent on receptor-interacting protein kinase 1 (RIP1) and RIP3"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,23051914,"These results reveal a critical role for the MAPK8 activation pathway through TRAF2 and RIPK1 for TNFSF10-induced autophagy that blunts apoptosis in cancer cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22927431,"IAP inhibitors and lexatumumab synergistically trigger apoptosis in a RIP1-dependent but TNFalpha-independent manner in RMS cells"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22922561,"Formation of the death domain complex between FADD and RIP1 proteins in vitro"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22891283,"RIP is required for cell culture supernatant-induced apoptosis, but not for classical Fas-mediated apoptosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22858542,"Results demonstrate that in the absence of caspase 6 activity, intrinsic triggers of apoptosis induce the receptor-interacting-kinase-1-dependent production of pro-inflammatory cytokines."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22848449,"recruitment of NEMO to ubiquitinated RIP1 is a key step in the TNFR1 signaling pathway that determines whether RIP1 triggers a necrotic death response."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22837689,"The mechanism by which Nec-1 sensitizes shikonin-induced apoptosis appears to be the inhibition of RIP1 kinase-dependent phosphorylation of ERK1/2."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22817896,"Study shows that RIP1 and RIP3 form an amyloid structure through their RIP homotypic interaction motifs and that this heterodimeric amyloid structure is a functional signaling complex that mediates programmed necrosis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22685397,"we demonstrate that Porphyromonas gingivalis infection of human aortic endothelial cells resulted in the rapid cleavage of RIPK1 and RIPK2"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22674009,"Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22659130,"USP2 isoforms can control the ubiquitination status of many proteins but from a panel of potential targets only the protein level of RIP1 was increased."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22580278,"These data indicate that the interaction between ARD1 and RIP1 plays an important role in the DNA damage-induced NF-kappaB activation, and that the acetyltransferase activity of ARD1 and its localization in to the nucleus are involved in such stress response."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22362767,"Intermediate domain of receptor-interacting protein kinase 1 (RIPK1) determines switch between necroptosis and RIPK1 kinase-dependent apoptosis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22179575,"De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,22173242,"findings provide first evidence that IAP inhibitors present a promising strategy to prime childhood ALL cells for chemotherapy-induced apoptosis in a RIP1-dependent manner"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21613257,"we demonstrate that the immune specific cell surface molecule Toso exhibits antiapoptotic effects on death receptor signaling by a novel regulatory mechanism involving the adaptor kinase RIP1"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21606198,"Data show that DNA damage stimulates the formation of a cytosolic complex of ATM, NEMO, RIP1, and TAK1, and that TAK1 mediates the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21576359,"Data demonstrate that NF-kappaB protects cells from IFN-gamma/RIP1-mediated necroptosis by transcriptionally activating a survival response that quenches ROS to preserve mitochondrial integrity."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21525013,"TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21460625,"C42 enhances the cellular autophagic process, which requires both PARP and RIP-1 participation, preceding and possibly augmenting, the caspase-dependent apoptotic cell death"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21458669,"Extensive DNA lesions stimulated 2 sequential NF-kappaB activation phases, requiring ATM and NEMO/IKK-gamma: first TNF-alpha-TNFR1 feedforward signaling, promoting the second phase and driving RIP1 phosphorylation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21419663,"Conjugation of ubiquitin chains to RIP1 facilitated assembly of the RIG-I complex, resulting in enhanced phosphorylation of IRF3"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21383699,"ANXA1 can constitutively activate NF-kappaB in breast cancer cells through the interaction with the IKK complex"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21282461,"The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21266470,"TNFalpha-duced NF-kappaB activation is attenuated by RIP1 through stabilization of TRAF2."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21148036,"RIP1-dependent caspase activation contributes to polyinosinic-polycytidylic acid-induced soluble tumor necrosis factor receptor 1 (TNFR1) shedding indicative of innate immune responses to viral infections in human airway epithelial (NCI-H292) cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21113135,"The authors demonstrate that c-IAP1 and UbcH5 family promote K11-linked polyubiquitination of receptor-interacting protein 1 (RIP1) in vitro and in vivo."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20825417,"Results indicate an important role of RIP1 in apoptosis induced by combined treatment with TNFalpha and MeBS."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20805296,"Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20801175,"PR cleavage of RIPK1 disrupts RIPK1 function"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20567846,"The RIPK1 and CASP7 polymorphisms can be considered as possible prognostic markers for survival after curative resection in patients with colorectal cancer."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20567846,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20550618,"Data show that miR-155 can inhibit necrosis and improve cell survival by repressing the receptor interacting protein1, RIP1, without affecting cardiomyogenic differentiation potential."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20354226,"RIP1 and RIP3 have roles in TNF-induced necrosis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,20056645,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19910467,"USP21 plays an important role in the down-regulation of TNFalpha-induced NF-kappaB activation through deubiquitinating RIP1."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19890662,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19778795,"Both RIP and caspase-8 may play important roles in the occurrence and progression of oral squamous cell carcinoma and oral precancerous lesions."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19773279,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19641134,"RIP1 is necessary for the most efficient activation of downstream caspases by Fas when treated with membrane-bound Fas ligand, but not with agonistic antibodies or cross-linked soluble Fas ligand."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19632771,"RIP1 is important in maintaining resistance to TRAIL-induced apoptosis in breast tumor cells and highlight the potential therapeutic benefit of the combination of Hsp90 inhibitors and TRAIL against breast tumor cells."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19629486,"Data show that the polymorphisms of LTA (rs1041981) and RIPK1 (rs2272990) may correlate with TTP in patients with DLBCL treated with R-CHOP."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19573080,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19336552,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19219602,"Clinical trial of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,19151112,"glomerular and tubular expression of TNF-alpha, (TNF receptor-associated death domain protein)TRADD, RIP(receptor-interacting protein) and TRAF-2 (TNF receptor-associated factor-) was significantly up-regulated in Lupus nephritis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18990758,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18941233,"Induction of NF-kappa B depends upon the adaptor receptor-interacting protein kinase (RIP)1, acting via a RIP homotypic interaction motif-dependent interaction with DNA-dependent activator of IFN regulatory factors (DAI)."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18813792,"the simultaneous downregulation of uPAR and MMP-9 induces apoptosome-mediated apoptosis through FADD-associated protein RIP and caspase 9"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18635966,"The protein encoded by the hybrid transcript lacks the putative kinase domain of RIP1, but potently stimulates NFkappaB, AP-1 and Ets-1 activity."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18621737,"c-IAP1 and c-IAP2 are required for TNFalpha-stimulated RIP1 ubiquitination and NF-kappaB activation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18570872,"cIAP1 and cIAP2 promote cancer cell survival by functioning as E3 ubiquitin ligases that maintain constitutive ubiquitination of the RIP1 adaptor protein."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18450748,"activation and formation of TICAM-1 signalosomes with NF-kappaB and interferon regulatory factor-3 requires oligomerization induced at two different sites and RIP1 binding"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18442983,"cytomegalovirus M45 protein provides a direct cell type-dependent replication benefit to the virus while modulating other biological processes signaling via the RIP1 adaptor such as activation of Toll-like receptor (TLR)3 and other mediators of cell death"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18178551,"Cezanne forms a novel negative feedback loop in pro-inflammatory signaling and that it suppresses NF-kappaB activation by targeting RIP1 signaling intermediaries for deubiquitination"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,18067272,"Data demonstrated that CK1alpha interacted with and phosphorylated RIP1 at the intermediate domain. Finally, we showed that CK1alpha enhanced RIP1-mediated NF-kappaB activation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17996648,"In response to autocrine TNFalpha signaling, the Smac mimetic promotes formation of a RIPK1-dependent caspase-8-activating complex, leading to apoptosis"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17951993,"These results suggested that HPB-ALL cells have a caspase-independent RIP kinasedependent pathway for Fas ligation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17638906,"RIP and c-FLIP-mediated assembly of the death-inducing signaling complex in nonrafts is a critical upstream event in TRAIL resistance"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17448597,"TNFRSF is upregulated after radical prostatectomy for prostatic neoplasms."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17389591,"TNF-induced TRAF2-RIP1-AIP1-ASK1 complex formation and for the activation of ASK1-JNK/p38 apoptotic signaling."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17306544,"findings show ubiquitination of RIP1 inhibits TNF-induced apoptosis first through an NF-kappaB-independent mechanism, then through an NF-kappaB-dependent mechanism; in absence of ubiquitination, RIP1 serves as a proapoptotic signaling molecule"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17301840,"We describe how RIP1 acts as a key integrator of signalling pathways initiated by stimulation of death receptors, bacterial or viral infection, genotoxic stress and T-cell homeostasis."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17296724,"RIP may serve as a general activator of IRF7, responding to and transmitting the signals from various stimuli, and that ubiquitination may be a general mechanism for enhancing the activity of IRF7."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,17235653,"The expression of receptor-interacting protein 1 (RIP1) in peripheral blood mononuclear cells was significantly decreased in SLE patients."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,16825191,"RIP is one of the critical components involved in mediating DNA damage-induced, p53-independent cell death"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,16611992,"TRADD and RIP1 compete for recruitment to the TNFR1 signaling complex and the distinct programs of cell death."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,16603398,"Activation of IKK by TNF-alpha requires site-specific ubiquitination of RIP1."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,16543241,"This study provides the first genetic evidence that the ubiquitination of RIP is required for TNFalpha-induced NF-kappaB activation."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,16260783,"TAK1 is recruited to the TNF-R1 complex via RIP and likely cooperates with MEKK3 to activate NF-kappaB in TNF-alpha signaling"
https://pharos.nih.gov/idg/targets/Q13546,Q13546,15572679,"RIP-dependent recruitment of MEKK3 plays a specific role in TNF-alpha signaling."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,15121855,"FAK overexpression in human tumors provides a survival signal function by binding to RIP and inhibiting its interaction with the death receptor complex."
https://pharos.nih.gov/idg/targets/Q13546,Q13546,14532286,"cells pre-stimulated through TNFR-2 prior to subsequent activation of TNFR-1, showed enhanced cell death and recruitment of RIP to the TNFR-1 complex; deficiency of RIP rescued the infected cells from TNF-induced cytotoxicity"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,29088270,"By CRISPR/Cas9-induced inactivation of TLR9, MyD88, IRAK4 and IRAK1 we confirm that BZLF1 repression is dependent on functional TLR9 and MyD88 signaling, and identify IRAK4 as an essential element for TLR9-induced repression of BZLF1 expression upon BCR cross-linking"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,28924041,"Data suggest that IRAK4 activity regulates activation of IRF5, TAK1, and IKKB in monocytes; IRAK4 activation of TAK1-IKKB-IRF5 axis leads to induction of cytokines and interferons following TLR7/TLR8 stimulation. (IRAK4 = interleukin-1 receptor-associated kinase 4; IRF5 = interferon regulatory factor-5; TAK1 = MAPK kinase kinase 7; IKKB = I-kappa B kinase; TLR = toll-like receptor)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,28512203,"Data suggest that, in monocytes and macrophages, the interleukin-1B- (IL1B)-stimulated trans-autophosphorylation of IRAK4 is initiated by MYD88- (myeloid differentiation primary response gene 88)-induced dimerization of IRAK4. In contrast, IRAK1 (interleukin-1 receptor-associated kinase 1) is inactive in unstimulated monocytes/macrophages and is converted to an active protein kinase in response to IL1B."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,27888910,"IRAK4 - Gene involved in innate immunity that have been associated with Chronic Rhinosinusitis."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,27869651,"data show that in pericytes, MyD88 and IRAK4 are key regulators of 2 major injury responses: inflammatory and fibrogenic."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,27840174,"AMPK activation inhibited IL-1beta-stimulated CXCL10 secretion, associated with reduced interleukin-1 receptor associated kinase-4 (IRAK4) phosphorylation."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,27062898,"the polymorphisms in TLR-MyD88-NF-kappaB signaling pathway confer genetic susceptibility to Type 2 diabetes mellitus and diabetic nephropathy."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,26698383,"Siblings with compound heterozygosity for two mutations: a frameshift mutation at one allele (c.1146delT (p.G383fs)), and an in-frame duplication variant at the other (c.255_260dup6 (p.D86_L87dup)) leading to fatal pneumococcal meningitis is described."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,26472314,"missense mutation results in immunological deficiency phenotype"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,26075815,"This is the first study to show an association between single nucleotide polymorphisms in IRAK1, IRAK4 and MyD88, and the presence of severe invasive pneumococcal disease."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25922567,"Src, Syk, IRAK1, and IRAK4 have roles in anti-inflammatory responses mediated by dietary flavonoid Kaempferol"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25886387,"findings suggest that rare, functional variants in MYD88, IRAK4 or IKBKG do not significantly contribute to IPD susceptibility in adults at the population level"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25707370,"The estimated prevalence of IRAK4 gene polymorphism found in a Portuguese Caucasian population was 26.8 % (CI 95%) [20.1, 34.7 %]. A model to predict the inflammatory response in the maxillary sinus in the presence etiological factors of dental origin was constructed."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25479567,"Studies indicate that interleukin-1 receptor-associated kinase 4 protein (IRAK4), a serine/threonine kinase, plays a key role in both inflammation and oncology diseases."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25344726,"delineation of the latter responses identified a narrow repertoire of transcriptional programs affected by loss of MyD88 function or IRAK4 function"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25320238,"by bolstering the IgM(+)IgD(+)CD27(+) B-cell subset, IRAK-4 and MyD88 promote optimal T-independent IgM antibody responses against bacteria in humans."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,25201411,"Data show that dimerization is crucial for IRAK4 autophosphorylation in vitro and ligand dependent signaling in cells."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,24690905,"High mRNA levels of IRAK1 and IRAK4 correlated with VKH disease activity."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,24567333,"IRAK4 is regulated by Interleukin 1/Toll-like receptor-induced autophosphorylation"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,24316379,"these studies suggest that not only the loss of protein expression but also the defect of Myddosome formation couldcause IRAK4 and MyD88 deficiency syndromes."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23595970,"Studied the TMZ-induced changes in the proteome of the glioma-derived cell line (U251) by 2D DIGE. We found 95 protein spots to be significantly altered in their expression after TMZ treatment."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23591012,"Dominant negative mutants of IRAK4 and GAK show strong apoptotic effects in A498 cells under anoxia."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23519847,"these data highlight an unexpected role of IRAK4, Akt, and mTOR in the regulation of tolerance in human monocytes"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23264652,"During bacterial infection, PGN-mediated TLR2 signaling induces miR-132/-212 to downregulate IRAK4."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23255009,"Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23100432,"This study demonstrated that IRAK4 activation acts normally to regulate microglial activation status and influence amyloid homeostasis in the brain."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23041547,"Evaluates the effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma cells where their functions are largely unexplored."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23027530,"We report the association of two tag SNPS (i.e., rs1461567 and rs4251513) distributed in the IRAK4 gene with brain and ocular alterations in congenital toxoplasmosis."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,23002119,"IgM(+)IgD(+)CD27(+) but not switched B cells were strongly reduced in MYD88-, IRAK-4-, and TIRAP-deficient patients, but not UNC-93B-deficient patients."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,22932140,"The IRAK4 SNPs rs3794262 and rs4251481 were associated with allergy to dust mites, but not other types of allergic rhinitis."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,22606974,"The results indicated that IRAK-4 gene silencing in MG63 cells inhibited cell proliferation and function and increase apoptosis, which may be related to the decreased Bcl-2/Bax ratio and inhibition of the protein expression."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,22059479,"investigation of signaling components that induce activation of post-transcriptional mechanism for IkappaB-zeta induction/activation: Activation of IRAK1 or IRAK4, but not TRAF6, is sufficient."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21738793,"The results demonstrated a gender- and allergen-dependant association pattern between polymorphisms in IRAK-4 and AR in Chinese population."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21576904,"genetic polymorphism is associated with increased prevalence of gram-positive infection and decreased response to toll-like receptor ligands"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21220427,"LPS-induced activation of IRAK4 and TAK1, K63-linked polyubiquitination of IRAK1 and TRAF6, and disrupted IRAK1-TRAF6 and IRAK1-IKKgamma assembly associated with increased A20 expression"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21205819,"evidence that the structure-function similarities that we have identified between LYK3 and IRAK-4 may be more widely applicable to plant RLKs in general."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21166654,"These results indicate that IL-1beta-induced IL-6 production in A549 cells is mediated by both PI3K and IRAK4 and suggest that involvement of PI3K in the IL-1-induced IL-6 production is cell type specific."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,21160042,"Although IRAK4 kinase activity is essential for human plasmacytoid dendritic cell activation, it is dispensable in B, T, dendritic, and monocytic cells, which is in contrast with an essential active kinase role in comparable mouse cell types."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20966070,"Two variants found in the MyD88 death domain, S34Y and R98C, showed severely reduced NF-kappaB activation due to reduced homo-oligomerization and IRAK4 interaction"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20621347,"IRAK-4-deficient patients have defects in T-cell activation."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20588308,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20503287,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20485341,"the crystal structure of the MyD88-IRAK4-IRAK2 death domain (DD) complex, which surprisingly reveals a left-handed helical oligomer that consists of 6 MyD88, 4 IRAK4 and 4 IRAK2 DDs"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20448286,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20438785,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20406964,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20400509,"Mal is a substrate for IRAK1 and IRAK4 with phosphorylation promoting ubiquitination and degradation of Mal, which may serve to negatively regulate signaling by TLR2 and TLR4"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20105294,"Data demonstrate that the vast majority of LPS-responsive genes in IRAK4-deficient monocytes were greatly suppressed, an observation that is consistent with the described role for IRAK4 as an essential component of TLR4 signalling."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20104875,"A detailed kinetic characterization of the phosphoryl transfer activity of IRAK-4 toward a peptide substrate derived from the activation loop of IRAK-1 is described.  IRAK-4 obeys a sequential kinetic pathway."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,20056178,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19898481,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19703016,"IRAK-4, which is essential for virtually all TLR signalling, was suppressed, whereas the precursor for the antibiotic peptide Dermcidin was up-regulated in HIV-infected cells."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19592493,"analysis of an oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19505919,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19423540,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19258923,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19254290,"These results demonstrate a clear association between polymorphisms in the IRAK4 gene and serum IgE levels in patients with chronic rhinosinusitis and asthma"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19254290,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19181383,"In human cells the non-kinase functions of IRAK-4 are essential, whereas the kinase activity of IRAK-4 appears redundant with that of IRAK-1."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19120481,"patients with congenital deficiencies show enhanced susceptibility to pyogenic bacteria such as Staphylococcus or Pneumococcus"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19074885,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,19006693,"IRAK-4-, MyD88-, and UNC-93B-deficient patients did not display autoreactive antibodies in their serum or develop autoimmune diseases, suggesting that IRAK-4, MyD88, and UNC-93B pathway blockade may thwart autoimmunity in humans."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,18987746,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,18503546,"These results demonstrate that downregulation of IRAK-4 requires activation of the MyD88-dependent pathway and that the death domains of both MyD88 and IRAK-4 are important for this downregulation."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,18174872,"Two cases of IRAK-4 deficiency that presented with unusual S. aureus infections that were not accompanied by the expected constitutional symptoms or hematologic and acute phase responses are reported."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,18079163,"These results suggested that the expression of IRAK-4 alone is sufficient to cause the degradation of IRAK-1; the autophosphorylation of IRAK-1 is not necessary to terminate the TLR-induced activation of NF-kappaB."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17997719,"Pellino isoforms may be the E3 ubiquitin ligases that mediate the IL-1-stimulated formation of K63-pUb-IRAK1 in cells, which may contribute to activation of IKKbeta and transcription factor NF-kappaB, as well as signalling pathways dependent on IRAK1/4"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17917042,"Inherited human IRAK-4 deficiency, a recently described primary immunodeficiency leading to recurrent, invasive, pyogenic bacteria infection, and invasive pneumococcal disease in particular, is reviewed."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17893200,"IRAK-4-dependent human Toll-like receptors appear to play a redundant role in protective immunity to most infections, at most limited to childhood immunity to some pyogenic bacteria"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17878374,"suggest the existence of an IRAK-4-independent TLR9-induced transduction pathway leading to PI3K activation"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17703412,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17675297,"kinase-inactive IRAK proteins can associate with Pellino proteins, thus excluding the possibility that their inability to regulate Pellino degradation is due to lack of association with the Pellino proteins"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17548806,"ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1beta-mediated activation of NF-kappaB transcriptional activity."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17507369,"IL-1RAcP, MyD88, and IRAK-4 are the stable components of the endogenous type I interleukin-1 (IL-1) receptor signaling complex"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17217339,"We conclude that IRAK-4 phosphorylates p47phox and regulates NADPH oxidase activation after LPS stimulation."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17161373,"crystallographic analysis of IRAK-4 kinase in complex with inhibitors"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17141195,"The present data indicate that the kinase activity of IRAK-4 is dependent on the autophosphorylations at T342, T345, and S346 in the activation loop."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,17046325,"Although each system seems to possess distinct activation mechanisms, interleukin-1 receptor-associated kinase (IRAK)-4 is essential for NF-kappaB activation in Toll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,16907704,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,16537705,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,16286015,"The TLR-7-, TLR-8-, and TLR-9-dependent induction of IFN-alpha/beta and -lambda is strictly IRAK-4 dependent and paradoxically redundant for protective immunity to most viruses in humans"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,15905496,"This study demonstrates several mechanisms by which overexpression of truncated, kinase-deficient forms of IRAK-4 in a patient with recurrent bacterial infections may disrupt signaling induced by lipopolysaccharide or IL-1."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,15825022,"Systemic shigellosis in a person with a primary immunodeficiency, expanding the spectrum of infections associated with IRAK-4 deficiency is reported."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,15292196,"IRAK-4 is an integral part of the IL-1R signaling cascade and is capable of transmitting signals both dependent on and independent of its kinase activity"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,15084582,"IRAK4 is required for the efficient recruitment of IRAK to the IL-1 receptor complex"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,12925671,"Results suggest that IRAK-4 is pivotal in the development of a normal inflammatory response initiated by bacterial or nonbacterial insults."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,12860405,"Pellino2 interacts with kinase-active as well as kinase-inactive IRAK1 and IRAK4"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,12637671,"described 3 children with inherited IRAK-4 deficiency who developed pyogenic bacterial infections; findings suggest the TIR-IRAK signaling pathway is crucial for protective immunity against specific bacteria but redundant against most other microorganisms"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,12496252,"Pellino 1 is required for interleukin-1-mediated signaling through its interaction with the interleukin-1 receptor-associated kinase 4-IRAK-tumor necrosis factor receptor-associated factor 6 complex"
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,12297423,"Gene targeting studies show that IRAK-4 has an essential role in mediating signals initiated by IL-1R and TLR engagement. Review."
https://pharos.nih.gov/idg/targets/Q9NWZ3,Q9NWZ3,11960013,"a novel member of the IRAK family with the properties of an IRAK-kinase"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,27696331,"TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.("
https://pharos.nih.gov/idg/targets/Q13705,Q13705,26848890,"the A allele of genetic variant rs2276541 in ACVR2B is associated with lean muscle mass"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,26289399,"ActR-IIB is expressed in male germ cells and Sertoli cells."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,26086422,"Adenomyotic tissues express high levels of myostatin, follistatin, and activin type II receptors."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,26047946,"Activin A inhibited signaling by BMP-6 and BMP-9 by competing for type 2 receptors ACVR2A and ACVR2B."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,25203845,"miR-21 interacts directly with the 3'-untranslated region of ACVR2B mRNA. Mechanical stretch suppressed ACVR2B protein levels in periodontal ligament stem cells. Gain- and loss of function of ACVR2B mediated the osteogenic differentiation of PDLSCs."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,25051287,"We found that the AAAAA, AGGAG, and AGGGA haplotypes in ACVR2B were associated with susceptibility to Premature Ovarian Failure when they also had at least one CATAG haplotype in ADAMTS19."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,22431721,"The interaction between all five miRNAs and ACVR2B was verified by an in vitro assay."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,22395277,"After eccentric exercise, postmenopausal women not using hormone therapy (HT) expressed lower levels of ActRIIb while postmenopausal women using HT showed a heightened response."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,22296042,"Activin type IIB receptors are clearly demonstrable throughout the adult human hypothalamus and basal forebrain."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,21864452,"Mutations in Activin A Receptor Type IIB were identified in 4 of the 47 patients (8.5%) with heterotaxy syndrome.  Our results expand the mutation spectrum of monogenic heterotaxy syndrome with associated cardiac anomalies."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,21353874,"discussion of crystal structure of kinase domain of ActRIIB; structural analysis may be of help in developing selective inhibitors [REVIEW]"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,20466801,"Inhibition of negative regulators of skeletal muscle by a soluble form of activin type IIB receptor (ACE-031) increases muscle mass independent of fiber-type expression."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,20424473,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,17893364,"The high-resolution structure of human ActRIIB kinase domain in complex with adenine establishes the conserved bilobal architecture consistent with all other catalytic kinase domains."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,17347381,"These results indicate that haplotype structure at the ACVR2B and follistatin loci may contribute to interindividual variation in skeletal muscle mass and strength, although these data indicate sex-specific relationships."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,15123686,"activin signaling via type II receptors requires a specific sequence for ALK4 binding"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,14738881,"Data indicate that activin A and activin receptors IIA and IIB may be involved in the regulation of germ cell proliferation in the human ovary during the period leading up to primordial follicle formation."
https://pharos.nih.gov/idg/targets/Q13705,Q13705,12782414,"analysis of expression and cellular compartmentalization of the activin receptors ActRIIA, ActRIIB and ActRIB, the inhibin co-receptor (betaglycan), and activin signaling proteins Smads 2, 3 and 4, and growth regulatory role during lactation"
https://pharos.nih.gov/idg/targets/Q13705,Q13705,11969340,"distribution in gestational tissues across human pregnancy and during labour"
https://pharos.nih.gov/idg/targets/P37173,P37173,28987542,"High TGFBR2 expression is associated with mesenchymal to epithelial transition of breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,28679693,"we describe and characterize the functional impact of a novel VUS in the TGFBR2 kinase domain (c.1255G>T; p.Val419Leu), in a patient with the clinical diagnosis of Marfan syndrome spectrum. Our results establish that the V419L variant leads to aberrant TGF-beta signaling and confirm the diagnosis of Loeys-Dietz syndrome in this patient."
https://pharos.nih.gov/idg/targets/P37173,P37173,28633389,"TGF-beta type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset PE. Endoglin was increased in both subtypes."
https://pharos.nih.gov/idg/targets/P37173,P37173,28633253,"this is the first clinical report to demonstrate a potential causal association between TGFB2 gene mutations and aortic root dilatation in combination with the myxomatous degeneration of both atrioventricular valves."
https://pharos.nih.gov/idg/targets/P37173,P37173,28472799,"YAP-1 promotes Tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription."
https://pharos.nih.gov/idg/targets/P37173,P37173,28420207,"these findings delineate the important function of the TGFbeta signaling pathway in the early development of kidney and TbetaRII was shown to be able to promote the expression of Six2 through Smad3 mediating transcriptional regulation and in turn activate the proliferation of MM cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,28376875,"Depending on the TGFBR2 expression status of their donor cells, shed exosomes show distinct proteomic signatures and promote altered cytokine secretion profiles in recipient cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,28344185,"A novel mutation in the TGFBR2 gene was identified in a patient with Loeys-Dietz syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,28209612,"miR-520f inhibited tumor cell invasion by directly targeting ADAM9 and the TGFbeta receptor TGFBR2."
https://pharos.nih.gov/idg/targets/P37173,P37173,28184932,"High TGFBR2 expression is associated with glioma."
https://pharos.nih.gov/idg/targets/P37173,P37173,28182693,"Molecular modeling and molecular dynamic simulation of the effects of variants in the TGFBR2 kinase domain as a paradigm for interpretation of variants obtained by next generation sequencing."
https://pharos.nih.gov/idg/targets/P37173,P37173,27879313,"Aortic diseases in patients with TGFBR1 or TGFBR2 mutations show the same prevalence of systemic features and the same global survival."
https://pharos.nih.gov/idg/targets/P37173,P37173,27853171,"USP11 may contribute to the pathogenesis of pulmonary fibrosis by stabilization of TbetaRII and promotion of TGFbeta-1 signaling."
https://pharos.nih.gov/idg/targets/P37173,P37173,27835699,"Gasdermin C is upregulated by inactivation of Tgfbr2 in the presence of mutated Apc, promoting colorectal cancer cell proliferation."
https://pharos.nih.gov/idg/targets/P37173,P37173,27770373,"Cell invasion (matrigel) was reduced only in the Hs578T cells (p < 0.01). Silencing decreased the expression of the prometastatic molecules S100A4 and TGFbetaR2 in both cell lines and CD44 in Hs578T cells. We conclude that ECM1 is a key player in the metastatic process and regulates the actin cytoskeletal architecture of aggressive breast cancer cells at least in part via alterations in S100A4 and Rho A."
https://pharos.nih.gov/idg/targets/P37173,P37173,27763636,"ZNF32 was found to directly bind to the TGF-betaR2 (transforming growth factor-beta receptor 2) promoter to promote its expression."
https://pharos.nih.gov/idg/targets/P37173,P37173,27756824,"Inhibition of TGFBR2 had the similar effect as miR-9 overexpression."
https://pharos.nih.gov/idg/targets/P37173,P37173,27696331,"TGF-beta receptor mediated telomerase inhibition, telomere shortening and breast cancer cell senescence.("
https://pharos.nih.gov/idg/targets/P37173,P37173,27527810,"results suggest a role for prostatic expression of TGF-B, IL-1a, TGFBRI and TGFBRII as prognostic markers for prostate cancer. The rational combination of novel agents directed toward the inactivation of TGF-B, IL-1a, TGFBRI and TGFBRII could disrupt complementary tumor cell proliferation pathways."
https://pharos.nih.gov/idg/targets/P37173,P37173,27445263,"Although TGFbeta1/2 receptors are downregulated in breast cancer, their expression in tumors is an indicator of aggressive breast cancer phenotype."
https://pharos.nih.gov/idg/targets/P37173,P37173,27401208,"Our results suggest that cholest-4-en-3-one inhibits TGF-b signaling may be due, in part to the translocation of TGF-b receptor from non-lipid raft to lipid raft microdomain in plasma membranes. Our findings also implicate that cholest-4-en-3-one may be further explored for its potential role in colorectal cancer correlate to TGF-b deficiency."
https://pharos.nih.gov/idg/targets/P37173,P37173,27344285,"The results showed that transfection of CD34(+) cells with SiRNA targeting TGF-bRII and their co-culture with human bone marrow mesenchymal stromal cells (MSCs) could considerably increase the number of progenitors"
https://pharos.nih.gov/idg/targets/P37173,P37173,27304191,"MiR-130 is up-regulated in gastric cancer (GC) tissues and directly targets TGF-beta type II receptor (TGFbetaR2)."
https://pharos.nih.gov/idg/targets/P37173,P37173,27234600,"Polymorphism of TGFBR2 is associated with coronary artery disease."
https://pharos.nih.gov/idg/targets/P37173,P37173,27156840,"TGFBR2 signaling can affect Notch1 glycosylation via regulation of glycosyltransferase LFNG expression and provide a first mechanistic example for altered glycosylation in microsatellite instability colorectal tumor cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,27139629,"Apo and inhibitor-bound TGFBR2 kinase structures are presented at high resolution (<2 A)."
https://pharos.nih.gov/idg/targets/P37173,P37173,27120811,"miR-17-5p negatively regulated TGFBR2 expression by directly binding to the 3'UTR of TGFBR2 mRNA, thereby promoting gastric cancer cell growth and migration."
https://pharos.nih.gov/idg/targets/P37173,P37173,27098600,"Our study uncovers a novel mechanism that miR-19a-3p/19b-3p inhibits autophagy-mediated fibrogenesis by targeting TGF-beta R II."
https://pharos.nih.gov/idg/targets/P37173,P37173,27048361,"This paper highlights that targeting the BMP and TGFbeta type I and type II receptors causes a downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,27017362,"A genetic investigation found a TGFbetaR2 gene mutation, leading to the diagnosis of Loeys-Dietz syndrome type2."
https://pharos.nih.gov/idg/targets/P37173,P37173,27017342,"Study demonstrated that the TGFBR2 mutation was not present in the sample of cervico-cerebral artery dissection patients (CCAD); however, a positive association was identified between the MTHFR-C677T polymorphism and genetically confirmed Mexican mestizo spontaneous CCAD patients"
https://pharos.nih.gov/idg/targets/P37173,P37173,26867007,"AT2R downregulates the expression of TGF-betaRII in human proximal tubule cells"
https://pharos.nih.gov/idg/targets/P37173,P37173,26858153,"CD44 and TGFBR2 are the functional targets of miR-373, which are responsible for the tumor suppressive functions of miR-373"
https://pharos.nih.gov/idg/targets/P37173,P37173,26823785,"results suggested that high CDKN1A/p21 and low TGFBR2 expression was closely correlated with adverse pathological parameters and poor prognosis in breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,26780887,"Reduced expression of TGF-beta type II receptor and extracellular matrix components in response to reduced fibroblast size/mechanical force was fully reversed by restoring size/mechanical force"
https://pharos.nih.gov/idg/targets/P37173,P37173,26670566,"Results found TGFBR2 to be significantly related to the regulated phosphoproteome in glioblastoma as a result of integrative upstream kinase/ regulator analyses and experimentally validated as a novel regulator of glioblastoma stem cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,26652004,"This work details a novel mechanism by which cellular tension regulates TGFbeta receptor organization, multimerization, and function."
https://pharos.nih.gov/idg/targets/P37173,P37173,26572508,"Exogenous expression of miR-142-5p inhibitor resulted in a significant reduction of viral titer indicating proviral role of miR-142-5p. Functional studies of hsa-miR-142-5p identified its role in transforming growth factor beta (TGFbeta) signalling as TGFbeta receptor 2 and SMAD3 were degraded during both hsa-miR-142-5p overexpression and rotavirus infection."
https://pharos.nih.gov/idg/targets/P37173,P37173,26551005,"High levels of TbetaRII expression were associated with lymph node metastasis, increasing tumor clinical stage, and poorer 5-year disease-free survival in patients with breast cancer. TbetaRII may be a potential prognostic marker for breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,26542979,"MiR-1343 reduces the expression of both TGF-beta receptor 1 and 2 by directly targeting their 3'-UTRs."
https://pharos.nih.gov/idg/targets/P37173,P37173,26511382,"TGF-beta2 induces Grb2 to recruit PI3-K to TGF-RII that activates JNK/AP-1-signaling and augments invasiveness of Theileria-transformed macrophages."
https://pharos.nih.gov/idg/targets/P37173,P37173,26505114,"Data (including data from studies in transgenic mice) suggest intraislet pancreatic duct cells are capable of giving rise to insulin-secreting beta-cells; Tgfbr2/transforming growth factor-beta type II receptor appears to involved in this process."
https://pharos.nih.gov/idg/targets/P37173,P37173,26498065,"Findings suggest that the upregulation of miR-590-5p promotes cellular malignant behavior via the target gene TGFbetaRII in vulvar squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,26356817,"TGFBR2 is regulated by an epigenetic auto-feedback regulation in non-small cell lung cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,26301661,"we reported a sporadic Japanese case of LDS with a novel TGFBR2 p.Y424H mutation, which appeared to cause pregnancy-related fatal aortic/arterial dissections."
https://pharos.nih.gov/idg/targets/P37173,P37173,26252213,"TGFbetaR2 is a potential prognostic tumor biomarker for chemotherapy."
https://pharos.nih.gov/idg/targets/P37173,P37173,26169464,"Case Report: endovascular repair of a left vertebral artery aneurysm in a patient with transforming growth factor beta receptor II mutation."
https://pharos.nih.gov/idg/targets/P37173,P37173,26168957,"TGFbRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,26115412,"Ibeta3 co-localized with TGF-beta RII on rigid but not compliant films. Tumor-produced Ibeta3 plays a crucial role in disease progression. Rigid mineralized bone matrix can alter gene expression and bone destruction in an Ibeta3/TGF-beta-dependent manner."
https://pharos.nih.gov/idg/targets/P37173,P37173,26114631,"Growth differentiation factor-15 (GDF-15) exhibited TGFBR2-dependent transcriptional upregulation causing increased intracellular and extracellular protein levels in colorectal carcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,26078295,"Depletion of IQGAP1 leads to increased TGFBR2 with TGFbeta signaling, explaining in part how reduced IQGAP1 promotes tumor growth"
https://pharos.nih.gov/idg/targets/P37173,P37173,26073093,"Studied folding and crystallization of the type II TGF-beta receptor extracellular domain using the non-detergent sulfobetaine-201, which acts as a pharmacological chaperone."
https://pharos.nih.gov/idg/targets/P37173,P37173,26037400,"these results revealed no correlation between the normalized expression of TGF-beta2, TGF-betaRI, or TGF-betaRII and EDSS scores"
https://pharos.nih.gov/idg/targets/P37173,P37173,26022443,"TGFBR2 rs6785358 polymorphism contributes to congenital ventricular septal defect (CVSD) susceptibility, and the G allele may increase the risk of CVSD."
https://pharos.nih.gov/idg/targets/P37173,P37173,26017485,"In sporadic AAA patients we found one pathogenic (TGFBR2 p.Ile525Phefs*18) and seven VUS"
https://pharos.nih.gov/idg/targets/P37173,P37173,25928368,"TGF-beta1 gene C509T polymorphism might be associated with decreased risk of lung adenocarcinoma in Chinese females exposed to cooking oil fumes, but no association was observed TGFBR2 gene G875A polymorphism"
https://pharos.nih.gov/idg/targets/P37173,P37173,25882708,"Our results show that LTBP4 interacts with TGFBR2 and stabilizes TGFbeta receptors by preventing their endocytosis and lysosomal degradation in a ligand-dependent and receptor kinase activity-dependent manner."
https://pharos.nih.gov/idg/targets/P37173,P37173,25849327,"TGFBR2 variants may have prognostic and predictive value in ER-negative breast cancer patients treated with adjuvant chemotherapy."
https://pharos.nih.gov/idg/targets/P37173,P37173,25833830,"Acquisition of low TGFBR2 expression is a contributing factor to endocrine resistance in breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,25826292,"TGF-betaRII and its mRNA levels were lower in older women than in younger ones. Age affects TGF-beta signalling in leukocytes by altering the expression levels of its receptors."
https://pharos.nih.gov/idg/targets/P37173,P37173,25736321,"TGFbeta signaling remains active in some MSI-H CRC cells despite the presence of frameshift mutations in the TGFBR2 gene because the mutated gene still expresses a functional protein."
https://pharos.nih.gov/idg/targets/P37173,P37173,25631750,"these results suggest that simvastatin may inhibit A549 cell proliferation and downregulate TGF-betaRII expression by inhibiting activation of ERK."
https://pharos.nih.gov/idg/targets/P37173,P37173,25617554,"Our result suggested that SNP rs6785358 of TGFBR2 gene was associated with increased risk of congenital heart defects in Han Chinese men"
https://pharos.nih.gov/idg/targets/P37173,P37173,25551793,"data indicated that miR-301a correlated with the metastatic and invasive ability in human colorectal cancers and miR-301a exerted its role as oncogene by targeting TGFBR2"
https://pharos.nih.gov/idg/targets/P37173,P37173,25542272,"A cytoplasmic predominant TGF-betaRII expression pattern and a higher pSmad2 expression were associated with decreased breast cancer survival."
https://pharos.nih.gov/idg/targets/P37173,P37173,25501507,"Furthermore, downregulation of TGFbetaR2 by siRNA showed the same effects on the proliferation and apoptosis as miR-34a mimic in H1299 cells"
https://pharos.nih.gov/idg/targets/P37173,P37173,25472963,"The transcriptionl activation of TGFBR2 in CD8+ T lymphocytes is regulated by Kruppel-like factor, KLF10."
https://pharos.nih.gov/idg/targets/P37173,P37173,25443138,"MicroRNA-19a enhances proliferation of bronchial epithelial cells by targeting TGFbetaR2 gene in severe asthma."
https://pharos.nih.gov/idg/targets/P37173,P37173,25374194,"There is a possibility of TGFBR2 genetic polymorphism and the risk of cancer development."
https://pharos.nih.gov/idg/targets/P37173,P37173,25323858,"Regulation of TGFBR2 expression is a direct target of miR145 in vascular smooth muscle cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,25315765,"Results show that metastatic differentiation and genetic heterogeneity of diffuse gastric cancer and reveal the potential metastatic role of TGFBR2 loss-of-function."
https://pharos.nih.gov/idg/targets/P37173,P37173,25234828,"Identified a 137-bp region upstream of the transcriptional start site that exhibited high promoter activity and was repressed 60% by UV irradiation, where all other TbetaRII promoter constructs exhibited either low promoter activities or no regulation by UV."
https://pharos.nih.gov/idg/targets/P37173,P37173,25233932,"we observed the coordinated loss of E-cadherin (CDH1) and transforming growth factor beta receptor II (TGFBR2) in esophageal squamous tumors."
https://pharos.nih.gov/idg/targets/P37173,P37173,25222187,"Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that FGFR2 and TGFBR2 act as drivers of gastric cancer in primary and metastasis respectively."
https://pharos.nih.gov/idg/targets/P37173,P37173,25169976,"PDGF receptor-alpha promotes TGF-beta signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-beta receptors."
https://pharos.nih.gov/idg/targets/P37173,P37173,24973511,"The moderate overexpression of TGF-beta1 and TbetaRII mRNA in PTC tissues."
https://pharos.nih.gov/idg/targets/P37173,P37173,24846200,"The TGFBR2 aberrant splicing was tumor-specific."
https://pharos.nih.gov/idg/targets/P37173,P37173,24793577,"genetic testing revealed new mutations in FBN1, TGFbetaR1, TGFbetaR2 and ACTA2 detected in patients with clinical diagnosis of Marfan Syndrome, Loeys-Dietz Syndrome and Thoracic Aortic Aneurysms and Dissections."
https://pharos.nih.gov/idg/targets/P37173,P37173,24687999,"Results suggest that TGFBR2 harbors variants that increase the risk of essential and affect blood pressure homeostasis as well as efficacy of antihypertensive agents in a Chinese population."
https://pharos.nih.gov/idg/targets/P37173,P37173,24606633,"The present study reports an involvement of miR-93-mediated TGFbR2 down-regulation in NPC aggressiveness, thus giving extended insights into molecular mechanisms underlying cancer aggressiveness."
https://pharos.nih.gov/idg/targets/P37173,P37173,24597762,"In cerebellar granule cells, TGFbetaRII activates the Akt/mTOR pathway which is mediated by GDF15 and Kv2.1."
https://pharos.nih.gov/idg/targets/P37173,P37173,24551192,"Antibodies against TGF-beta or a TGF-beta receptor inhibitor SB431452 reverse HIV-1 Vpu-mediated profibrogenic activation of LX2 cells, suggesting that TGF-beta mediates these effects"
https://pharos.nih.gov/idg/targets/P37173,P37173,24550076,"Treatment with the anti-oxidant N-acetylcysteine reduces ROS elevation and normalizes TGF-beta signaling and target gene expression."
https://pharos.nih.gov/idg/targets/P37173,P37173,24447338,"Antibodies against TGF-beta or a TGF-beta receptor inhibitor SB431452 reverse HIV-1 Vpu-mediated profibrogenic activation of LX2 cells, suggesting that TGF-beta mediates these effects"
https://pharos.nih.gov/idg/targets/P37173,P37173,24443223,"TGFb1 rs1800469 C>T polymorphism was significantly associated with decreased risk of conotruncal heart defects. TGFbetaR2 and VEGF polymorphisms may not play a role in the susceptibility of conotruncal heart defects."
https://pharos.nih.gov/idg/targets/P37173,P37173,24344637,"TGFBR2 mutations in patients with dural ectasia in Loeys-Dietz syndrome"
https://pharos.nih.gov/idg/targets/P37173,P37173,24336330,"TGFBR2 expression in cancer-associated fibroblasts is associated with survival outcome in pre-menopausal breast cancer"
https://pharos.nih.gov/idg/targets/P37173,P37173,24284203,"these findings demonstrated that c/EBPalpha and c/EBPbeta determine the lineage commitment of hepatoblasts by negatively and positively regulating the expression of a common target gene, TGFBR2, respectively."
https://pharos.nih.gov/idg/targets/P37173,P37173,24279395,"he expression of TGFbeta receptors (TGFbetaRI and TGFbetaRII) and FGF2 in the lens epithelium of the MCT mice was stronger than that of the wild-type ddY mice at 4 weeks and weaker than that of the wild-type ddY mice at 15 weeks after birth."
https://pharos.nih.gov/idg/targets/P37173,P37173,24243761,"TGFBR1 and TGFBR2 mutations do not play a major role in isolated myxomatous valve dystrophy. Screening for FLNA mutations is recommended in familial myxomatous valvular dystrophy, particularly if X-linked inheritance is suspected."
https://pharos.nih.gov/idg/targets/P37173,P37173,24151081,"This study suggests that miR-200b plays a tumour-promoting role by targeting CDKN1B (p27/kip1) in colorectal cancers."
https://pharos.nih.gov/idg/targets/P37173,P37173,24141771,"Results show that epigenetic loss of TGFBR2 expression in prostatic fibroblasts, initiated by interactions with Prostate cancer results in the promoter methylation and silencing of DNA damage repair mediators."
https://pharos.nih.gov/idg/targets/P37173,P37173,24093773,"The present study evaluated the serum levels of specific metalloproteinases (MMP-2 and MMP-9) and investigated the gene TGFBR in 28 patients with aortic valve disease associated with ascending aortic dilatation."
https://pharos.nih.gov/idg/targets/P37173,P37173,24037531,"Results suggest that the AR and miR-21 axis exerts its oncogenic effects in prostate tumors by downregulating TGFBR2, hence inhibiting the tumor-suppressive activity of TGFbeta pathway."
https://pharos.nih.gov/idg/targets/P37173,P37173,24034922,"The SNP (rs1495592) in TGFBR2 gene may not be associated with development of Kawasaki disease (KD)in children, but it is associated with Ccprpnary artery lesions in children with KD."
https://pharos.nih.gov/idg/targets/P37173,P37173,23970096,"Mutation of TGF-beta receptor II facilitates human bladder cancer progression through altered TGF-beta1 signaling pathway."
https://pharos.nih.gov/idg/targets/P37173,P37173,23951322,"The TGFBR2-875G>A contribution to an early relapse in androgen-deprivation therapy patients supports the involvement of TGFbeta1 pathway in castration-resistant prostate cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,23913824,"oral cancers with TGFBR2 downregulation comprise a different group with more aggressive nature; TGFBR2 transcript levels may be developed as a promising prognostic biomarker"
https://pharos.nih.gov/idg/targets/P37173,P37173,23899993,"The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGFBR1 or TGFBR2."
https://pharos.nih.gov/idg/targets/P37173,P37173,23883197,"The synonymous single nucleotide polymorphism (rs2228048, Asn389Asn) of the TGFBR2 gene may be associated with development of acute rejection in Korean kidney transplantation recipients."
https://pharos.nih.gov/idg/targets/P37173,P37173,23750746,"stress induced production of TGF-beta2 by BEC can modify liver allograft function by enhancing the de-differentiation of local epithelial cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,23734265,"Data indicate that the activation of MAPK and PI3K pathways resulted in TGF-beta1 signaling by down-regulating Nm23-H1 expression and up-regulating the expression of TbetaRI and TbetaRII, favoring further activation of multiple signaling pathways."
https://pharos.nih.gov/idg/targets/P37173,P37173,23726841,"novel role for miR-211 in the regulation of TGFbetaRII and c-Myc during tumorigenesis being revealed should help to develop anti-head and neck squamous cell carcinoma therapies"
https://pharos.nih.gov/idg/targets/P37173,P37173,23690952,"ZEB1 and TGFBR2 identified as direct targets of miR-655"
https://pharos.nih.gov/idg/targets/P37173,P37173,23548068,"Variation in transforming growth factor beta receptor 2 tagged-SNP rs6550005 was associated with preeclampsia in white women while variation in rs6550005, rs1346907, and rs877572 was associated with preeclampsia in black women."
https://pharos.nih.gov/idg/targets/P37173,P37173,23454766,"IQGAP1 in the tumor microenvironment suppresses TGFBR2 and TGF-beta dependent myofibroblastic differentiation to constrain tumor growth."
https://pharos.nih.gov/idg/targets/P37173,P37173,23395552,"Data suggest miR-21 plays a critical role in the production of pro-inflammatory cytokines IFN-gamma and IL-17A in dnTGF-betaRII transgenic mice."
https://pharos.nih.gov/idg/targets/P37173,P37173,23312833,"Case Report: treatment of aneurysms of the subclavian and vertebral arteries in Ehlers-Danlos syndrome with TGFBR2 mutation."
https://pharos.nih.gov/idg/targets/P37173,P37173,23290524,"c-Cbl conjugates neural precursor cell-expressed, developmentally downregulated 8 (NEDD8), a ubiquitin-like protein, to TbetaRII at Lys556 and Lys567."
https://pharos.nih.gov/idg/targets/P37173,P37173,23248962,"There may he abnormal gene expression of TbetaR II in pathological scar epidermis."
https://pharos.nih.gov/idg/targets/P37173,P37173,23228659,"association of polymorphisms of the TGFBR2 gene with ossification of the posterior longitudinal ligament was confirmed in this study along with a novel unreported, nucleotide variation in intron 1"
https://pharos.nih.gov/idg/targets/P37173,P37173,23220853,"an association between TGF-betaRII-negative tumor and higher risk of metastasis to lungs and bones was verified."
https://pharos.nih.gov/idg/targets/P37173,P37173,23178117,"MED12 is in part cytoplasmic where it negatively regulates TGF-betaR2 through physical interaction. MED12 suppression therefore results in activation of TGF-betaR signaling, which is both necessary and sufficient for drug resistance."
https://pharos.nih.gov/idg/targets/P37173,P37173,23157888,"The SNP rs764522 of TGFBR2 is associated with increased risk of essential hypertension in the elderly Han Chinese population."
https://pharos.nih.gov/idg/targets/P37173,P37173,23099432,"TGFbetaRIIb expression is a regulatory mechanism for TGFbeta2 signal transduction."
https://pharos.nih.gov/idg/targets/P37173,P37173,22972928,"A transgenic model suggests a role for TGFBR2 signaling in dendritic cells (DCs) to prevent autoimmunity primarily through maintenance of DCs in their immature and tolerogenic state."
https://pharos.nih.gov/idg/targets/P37173,P37173,22912877,"Data indicate that MiR-106a inhibits the expression of transforming growth factor-beta receptor 2 (TGFBR2), leading to increased colorectal cancer (CRC) cell migration and invasion."
https://pharos.nih.gov/idg/targets/P37173,P37173,22848678,"a critical negative regulation level of TGF-beta signaling mediated by HILI (human PIWIL2) by its ability to interact with Hsp90 and promote TbetaR degradation"
https://pharos.nih.gov/idg/targets/P37173,P37173,22739178,"TGF-beta1 and its receptors including TGF-betaRI and TGF-betaRII are abnormally expressed in the peripheral blood of immune thrombocytopenic purpura patients."
https://pharos.nih.gov/idg/targets/P37173,P37173,22734312,"We report a 13-year-old girl with Loeys-Dietz syndrome (LDS) caused by a known transforming growth factor beta receptor II (TGFBR2) gene mutation, who developed aortic root dilatation and saccular aneurysm of the internal carotid artery."
https://pharos.nih.gov/idg/targets/P37173,P37173,22684895,"miR-590-5p promotes proliferation and invasion in human hepatocellular carcinoma cells by directly targeting TGF-beta RII. [mir-590-5p]"
https://pharos.nih.gov/idg/targets/P37173,P37173,22672900,"Data indicate that abrogation of TGFbeta signaling through introduction of a dominant negative TGFbeta receptor II (TGFbetaRII) in non-metastatic FETalpha colon cancer cells permits metastasis to distal organs, but does not reduce invasive behavior."
https://pharos.nih.gov/idg/targets/P37173,P37173,22651914,"analysis of evolution of the TGF-beta superfamily and how they signal through a single pair of receptors, known as TbetaR-I and TbetaR-II [review]"
https://pharos.nih.gov/idg/targets/P37173,P37173,22617150,"TGF-beta family signaling through Smads is conceptually a simple and linear signaling pathway, driven by sequential phosphorylation, with type II receptors activating type I receptors, which in turn activate R-Smads [review]"
https://pharos.nih.gov/idg/targets/P37173,P37173,22585622,"Results demonstrate that HES (hairy and enhancer of split), the main transcription factor downstream of Notch, induces strong transactivation of TGF-ssRII by binding the TGF-betaRII promoter through its DNA-binding domain."
https://pharos.nih.gov/idg/targets/P37173,P37173,22571197,"N-linked glycosylation is essentially required for the suGFccessful cell surface transportation of TGFbetaRII, suggesting a novel mechanism by which the TGF-beta sensitivity can be regulated by N-linked glycosylation levels of TGFbetaRII."
https://pharos.nih.gov/idg/targets/P37173,P37173,22539603,"Single nucleotide polymorphism in TGFBR2 is associated with breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,22431140,"TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle."
https://pharos.nih.gov/idg/targets/P37173,P37173,22425785,"The molecular mechanism that controls TssRII fate in IL-1ss treated cells, was investigated."
https://pharos.nih.gov/idg/targets/P37173,P37173,22399565,"reduced TGF-beta-RII expression in human non-small cell lung cancer is a negative prognostic marker associated with more aggressive tumor behavior and worse clinical outcome"
https://pharos.nih.gov/idg/targets/P37173,P37173,22391627,"The abnormal expression of ALK1 and TGFbR2 were found to be independent contributors to nasopharyngeal carcinogenesis."
https://pharos.nih.gov/idg/targets/P37173,P37173,22314103,"promoter methylation may exist in the early stage of esophageal squamous cell carcinoma and play important role in gene silencing"
https://pharos.nih.gov/idg/targets/P37173,P37173,22310065,"Report down-regulation of TGFBR2 in human abdominal aortic aneurysms."
https://pharos.nih.gov/idg/targets/P37173,P37173,22290546,"the rs1805110T allele is associated with susceptibility to HBV-related hepatocellular carcinoma in males"
https://pharos.nih.gov/idg/targets/P37173,P37173,22278155,"Data suggest that TGF-beta, TGF-betaR1, TGF-betaR2, Smad4, pSmad2/3, and E-cadherin are closely related to tumor-node-metastasis (TNM) stage of colorectal cancer (CRC)."
https://pharos.nih.gov/idg/targets/P37173,P37173,22259224,"A novel missense TGFBR2 mutation p.V453E (c.1358T>A) in the proband and two relatives of a Chinese family is associated with a type 2 Marfan syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,22095581,"report on two LDS patients with mutations in TGFBR2. It appears that LDS can be associated with low bone mass and high bone turnover but increased matrix mineralization of trabecular bone"
https://pharos.nih.gov/idg/targets/P37173,P37173,22093616,"a novel gain-of-function TbetaRII mutation enhances TGF-beta signaling, leading to more invasive phenotypic changes in human OSCC"
https://pharos.nih.gov/idg/targets/P37173,P37173,22072622,"miR-21 plays an important role in regulating stemness by modulating TGFbetaR2 signaling in colon cancer cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,22028617,"Results suggest a mechanism for the downregulation of TbetaRII in lung cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,21978186,"The evidence suggests that TGFBR1 and TGFBR2 are not susceptibility genes for intracranial aneurysm in this population"
https://pharos.nih.gov/idg/targets/P37173,P37173,21949851,"TGFBR2 mutations are not associated with the microsatellite instability-high colorectal cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,21924348,"atypical protein kinase C isoforms regulate transforming growth factor beta (TGFB) signaling by altering cell surface TGFB receptor trafficking and degradation"
https://pharos.nih.gov/idg/targets/P37173,P37173,21855067,"This study suggests that two common genetic polymorphisms in TGFBR2 are associated with the risk of developing abdominal aortic aneurysm"
https://pharos.nih.gov/idg/targets/P37173,P37173,21815248,"TGFBR1, TGFBR2, and ACTA2 mutations were found in 4 families with thoracic aortic aneurysms and dissections and predominantly fusiform intracranial aneurysms."
https://pharos.nih.gov/idg/targets/P37173,P37173,21789464,"in 4 families linkage with the FBN1 and TGFBR2 genes was excluded, and no mutations were identified in the coding region of TGFBR1, indicating the existence of other genes involved in Marfan syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,21785915,"TGFBR1 Int7G24A and TGFBR2 G-875A polymorphisms may play important roles in the risk of gastric cardia adenocarcinoma in North China."
https://pharos.nih.gov/idg/targets/P37173,P37173,21757750,"Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death"
https://pharos.nih.gov/idg/targets/P37173,P37173,21737283,"This study provided that TGFR-beta2-875 G/G genotype is a risk factor for brain arteriovenous malformation."
https://pharos.nih.gov/idg/targets/P37173,P37173,21725601,"RNA interference (RNAi) technology was used to silence the expression of TGF-beta receptor, type II (TGFbetaRII) in the LAC cell line, A549, and its effects on cell proliferation, invasion and metastasis were examined."
https://pharos.nih.gov/idg/targets/P37173,P37173,21701930,"Global comparison of gene expression profiles identified 2 striking differences in treated tumors relative to untreated tumors: a marked increase in IGBFP3 and concomitant decrease in TGFb-R2 gene and protein expression."
https://pharos.nih.gov/idg/targets/P37173,P37173,21666718,"study concludes that miR-370 is a miRNA that is associated with GC progression by downregulating TGFbeta-RII"
https://pharos.nih.gov/idg/targets/P37173,P37173,21609163,"The synonymous SNP (rs2228048, Asn389Asn) of the TGFBR2 gene was found to be associated with the development of intracerebral hemorrhage in the South Korean population."
https://pharos.nih.gov/idg/targets/P37173,P37173,21454688,"Restoration of transforming growth factor-beta receptor II expression in colon cancer cells with microsatellite instability increases metastatic potential in vivo"
https://pharos.nih.gov/idg/targets/P37173,P37173,21423151,"These results provide evidence that the two TbetaRI:TbetaRII heterodimers bind and mediate TGF-beta3 signalling."
https://pharos.nih.gov/idg/targets/P37173,P37173,21352603,"The restoration of the expression of TbetaRII and TbetaRIII in oral cancerous tissues may represent a novel strategy for the treatment of oral carcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,21324918,"Case Report: Loeys-Dietz syndrome can result from TGF-bR2 mutations in the absence of obvious physical features and can exhibit a fulminant course."
https://pharos.nih.gov/idg/targets/P37173,P37173,21295082,"CD109 regulates TGF-beta receptor endocytosis and degradation to inhibit TGF-beta signaling."
https://pharos.nih.gov/idg/targets/P37173,P37173,21270064,"findings indicate that TGFBR2 gene mutations are responsible for sCAD in 3.6% (95% CI 0.0 to 8.4) of cases."
https://pharos.nih.gov/idg/targets/P37173,P37173,21249319,"Expression of TssRII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,21172820,"TbetaRII alone is able to mediate TGFbeta signaling to ERK1/2 without participation of TbetaRI."
https://pharos.nih.gov/idg/targets/P37173,P37173,21170488,"Studies indicate that endoglin (CD105) interacts with type I and type II TGF-beta receptors and modulates TGF-beta signaling."
https://pharos.nih.gov/idg/targets/P37173,P37173,21131601,"Data suggest a novel mechanism for MEK1 in regulating the sensitivity to TGF-beta signaling by stabilizing TbetaRII."
https://pharos.nih.gov/idg/targets/P37173,P37173,21098638,"The balance between defects in Smad and ERK signaling might be an important determinant of phenotypic severity in disorders related to mutations in TGFBR2."
https://pharos.nih.gov/idg/targets/P37173,P37173,20878063,"The simultaneous expression of Endoglin (CD105), transforming growth factor (TGF)-beta1 and TGF-beta receptor (R) II were quantified in normal human colon, pre-malignant dysplastic tissue, and invasive colon cancer specimens"
https://pharos.nih.gov/idg/targets/P37173,P37173,20864512,"Observational study of gene-disease association, gene-gene interaction, and genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20840324,"TGFBRII protein expression in benign prostatic hyperplasia is associated with prostate gland volume and with CD4 T-lymphocyte prostatitis."
https://pharos.nih.gov/idg/targets/P37173,P37173,20805453,"The TGFBR2 metagene(s) showed significant association with a better outcome in ER-positive breast tumors (without stratification by proliferative status) in two of the three data sets."
https://pharos.nih.gov/idg/targets/P37173,P37173,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20701609,"miR-21 expression in cord and increased TGFBR2 expression is associated with antenatal IgE production and development of allergic rhinitis"
https://pharos.nih.gov/idg/targets/P37173,P37173,20662850,"the connective tissue weakness does not relate to mutations in the genes FBN1, TGFBR1 and TGFBR2"
https://pharos.nih.gov/idg/targets/P37173,P37173,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20628007,"TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections."
https://pharos.nih.gov/idg/targets/P37173,P37173,20628007,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20621662,"Downregulation of TGF beta R-II expression by cigarette smoke-induced Egr-1 may contribute to smoking-induced premature skin aging."
https://pharos.nih.gov/idg/targets/P37173,P37173,20599261,"Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20587546,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20565851,"TGFbetaRII mutations are relatively late events in the genesis of colorectal cancer with microsatellite instability."
https://pharos.nih.gov/idg/targets/P37173,P37173,20518838,"All 3 SNPs tested were significantly different between nonsegmental vitiligo patients & controls (rs2005061, rs3773645, & rs3773649). Haplotype 1 (CG) and haplotype 2 (GA) of the linkage disequilibrium block were associated with a risk of NSV."
https://pharos.nih.gov/idg/targets/P37173,P37173,20518838,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20457266,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20428796,"The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts."
https://pharos.nih.gov/idg/targets/P37173,P37173,20410122,"Disruption of TGF-beta due to ttranscriptional dysregulation of TGF-beta receptor type II is associated with polyglutamine-induced motor neuron damage in spinal and bulbar muscular atrophy."
https://pharos.nih.gov/idg/targets/P37173,P37173,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20374083,"upregulation of the TGFbeta2 level is a common pathological feature of Alzheimer's disease (AD) brains and suggests that it may be closely linked to the development of neuronal death related to AD."
https://pharos.nih.gov/idg/targets/P37173,P37173,20358619,"study presents 2 patients with Loeys-Dietz syndrome with significant skeletal fragility; one was heterozygous for a c.923T > C transition in exon 4 of TGFBR2; the other was heterozygous for a c.1561 T > C transition in exon 7 of TGFBR2"
https://pharos.nih.gov/idg/targets/P37173,P37173,20237496,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20197483,"Mutation in transforming growth factor beta receptor II is associated with colorectal cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,20165854,"The expression of TGF-beta1, its receptor TGFbetaRII, and signaling proteins Smad4 and Smad7 was observed in the majority of colorectal cancer specimens."
https://pharos.nih.gov/idg/targets/P37173,P37173,20157331,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,20144264,"Mutations of the TGFBR2 gene in Chinese patients with Marfan-related syndrome are reported."
https://pharos.nih.gov/idg/targets/P37173,P37173,20139972,"TGFBR2 forms an endocytic complex with PTH1R in response to PTH and regulates signalling by PTH and TGF-beta. TGFBR2 directly phosphorylates the PTH1R cytoplasmic domain, which modulates PTH-induced endocytosis of the PTH1R-TGFBR2 complex."
https://pharos.nih.gov/idg/targets/P37173,P37173,20101701,"a missense mutation of TGFBR2 may have a role in aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B [case report]"
https://pharos.nih.gov/idg/targets/P37173,P37173,20101206,"Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics."
https://pharos.nih.gov/idg/targets/P37173,P37173,20079749,"Elf3 amino acid residues within the flanking region, including Trp361, are important for the structural integrity of the protein as well as for the Efl3 DNA binding and transactivation activity."
https://pharos.nih.gov/idg/targets/P37173,P37173,20073064,"Low TbetaR-II protein level is due to augmented ubiquitin-dependent degradation and may be involved in lowering of TGF-beta signaling pathway in renal cell carcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,20067791,"Data show that exon junction complex (EJC) downstream of a PTC plays an inhibitory role in translation of TGFbetaR2 mRNA."
https://pharos.nih.gov/idg/targets/P37173,P37173,19996017,"Clinical outcomes appear similar between treated patients with TGFBR2 mutations and individuals with FBN1 mutations in Marfan syndrome and related disorders."
https://pharos.nih.gov/idg/targets/P37173,P37173,19959123,"The researchers found an association between a common TGFRB2 polymorphism and the risk of sudden cardiac arrest coupled with ventricular arrhythmias in the presence of coronary artery disease."
https://pharos.nih.gov/idg/targets/P37173,P37173,19959123,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19937272,"Our data provide evidence that TGF-beta signaling patterns vary by age and pathologic features of prognostic significance including ER expression"
https://pharos.nih.gov/idg/targets/P37173,P37173,19916025,"Mutations and/or alterations in expression of TGF-beta receptors and loss of Smad 4 are frequent in human ovarian cancers."
https://pharos.nih.gov/idg/targets/P37173,P37173,19914962,"TGF-betaRII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative breast cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19888426,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19886734,"We show differences in expression of glycosaminoglycans are related to the over-expression of TGF-beta and TGF-betaRII in cultured fibroblasts from hereditary gingival fibromatosis and gingival fibroblasts treated with CyA."
https://pharos.nih.gov/idg/targets/P37173,P37173,19883511,"two novel mutations in the TGFBR1 and TGFBR2 genes in two patients affected with Loeys-Dietz syndrome (LDS) and showing marked phenotypic variability."
https://pharos.nih.gov/idg/targets/P37173,P37173,19737884,"These data show that trichostatin a induces the expression of TbetaR-II mRNA and activates the TbetaR-II promoter in retinoblastoma cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,19672284,"Genetic variations in TGFBR2 associate with abdominal aortic aneurysm in a Dutch population."
https://pharos.nih.gov/idg/targets/P37173,P37173,19672284,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19639654,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19626999,"Compared with human fallopian tubes without adhesions or atresias, the expression of TGFbeta1, TGFBR1 and TGFBR2 all increased significantly in adhesion cases."
https://pharos.nih.gov/idg/targets/P37173,P37173,19624886,"TGF-betaRII expression was related with depth of invasion, lymph node metastasis, tumor differentiation, and Lauren classification of gastric cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,19601999,"polymorphism in TGFBR2 are associated with altered secretion of OPN, supporting a role for transforming growth factor beta in OPN production."
https://pharos.nih.gov/idg/targets/P37173,P37173,19601999,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19578796,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19548309,"TGFbetaR2 hypermethylation is associated with multiple myeloma."
https://pharos.nih.gov/idg/targets/P37173,P37173,19542084,"Individuals with TGFBR2 mutations are more likely to dissect at aortic diameters <5.0 cm than individuals with TGFBR1 mutations."
https://pharos.nih.gov/idg/targets/P37173,P37173,19542084,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19538865,"Low expression of Smad4 and TbetaRII may promote metastasis of oral squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P37173,P37173,19533785,"Out of 41 probands with Marfan syndrome, six were identified to have novel TGFBR2 mutations (one frameshift and five missense mutations)."
https://pharos.nih.gov/idg/targets/P37173,P37173,19533785,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19503063,"The four most frequently mutated genes in colorectal cancers with microsatellite instability were ACVR2 (92%), TAF1B (84%), ASTE1/HT001 (80%) and TGFBR2 (77%)."
https://pharos.nih.gov/idg/targets/P37173,P37173,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19434696,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19426152,"loss of TGFbetaRII in hepatocellular carcinoma triggers activation of the TNF pathway known to be regulated by TGF-beta(1) network"
https://pharos.nih.gov/idg/targets/P37173,P37173,19424605,"1167Cright curved arrow T (Asn389Asn) polymorphism of TGFBR2 were most significantly associated with chronic kidney disease in low-risk individuals."
https://pharos.nih.gov/idg/targets/P37173,P37173,19366699,"Critical role of type II receptors in balancing BMP9 signaling via ALK1 and emphasize the essential role for BMPR-II in a subset of BMP9 responses in pulmonary artery endothelial cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,19356148,"These results indicate that the extracellular domain of TbetaRII mediates receptor partitioning into membrane rafts and efficient entrance into caveolin-positive endosomes."
https://pharos.nih.gov/idg/targets/P37173,P37173,19351817,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19339270,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19336370,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19335617,"Data show that co-expressing constitutively active type I and type II receptors resulted in the phosphorylation of both R-Smad subclasses in a ligand-independent manner."
https://pharos.nih.gov/idg/targets/P37173,P37173,19299629,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19293232,"The TGFBR2 presence reduced binding of probes specific for a core substitution and increased branch length in N-glycosylation, even reaching a P-value of 0.0016."
https://pharos.nih.gov/idg/targets/P37173,P37173,19229971,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,19193655,"hENT1 is down-regulated by activation of TbetaRII by TGF-beta1 in endothelium from umbilical veins."
https://pharos.nih.gov/idg/targets/P37173,P37173,19161338,"High-affinity binding of TGF-beta1/3 to TGF-betaRII is primarily due to hydrogen bonding between Arg25 and 94 of TGF-beta1/3, and Glu119 and Asp32 of TbetaR-II. Arg25 and 94 are substituted by Lys in TGF-beta2, which binds with low affinity to TbetaR-II."
https://pharos.nih.gov/idg/targets/P37173,P37173,19147499,"TGF-beta1 elevates TbetaRII homodimerization to some degree and strongly enhances TbetaRI.TbetaRII heteromeric complex formation."
https://pharos.nih.gov/idg/targets/P37173,P37173,19088080,"the TGFbeta pathway activation leads to recruitment of a KLF14-mSin3A-HDAC2 repressor complex to the TGFbetaRII promoter, as well as the remodeling of chromatin to increase histone marks that associate with transcriptional silencing."
https://pharos.nih.gov/idg/targets/P37173,P37173,19020727,"sTbetaRII attenuates the biological activities of TGF-beta in colorectal cancer"
https://pharos.nih.gov/idg/targets/P37173,P37173,19006214,"report of somatic mosaicism of a TGFBR2 missense mutation, c.1336G>A (D446N)in a patient with Loeys-Dietz syndrome; DNA from leukocytes, buccal cells, hair root cells, & nails in the father indicated 52%, 25%, 0%, & 35% of cells harbored the mutation"
https://pharos.nih.gov/idg/targets/P37173,P37173,18941508,"The -1 bp frameshift mutation rates of TGFBR2 and ACVR2 microsatellite sequences are dependent upon the human DNA Mismatch repair background"
https://pharos.nih.gov/idg/targets/P37173,P37173,18829577,"DHT decreases the level of TGF-beta receptor II (TbetaRII) through a transcriptional mechanism."
https://pharos.nih.gov/idg/targets/P37173,P37173,18781618,"Mutations and polymorphisms in TGFBR1 and TGFBR2 in patients with Marfan syndrome, Loeys-Dietz syndrome and related disorders are described."
https://pharos.nih.gov/idg/targets/P37173,P37173,18781618,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,18724388,"the frequent loss of stromal TGF-beta type II receptor expression in prostate cancer can relieve the paracrine suppression of Wnt3a expression"
https://pharos.nih.gov/idg/targets/P37173,P37173,18721526,"Mutations in TGFBR1 and TGFBR2 rarely cause sporadic BAV."
https://pharos.nih.gov/idg/targets/P37173,P37173,18721526,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,18683732,"The expression level of TGF-betaR II in CD8+ T cells of oral lichen planus did not increase compared with the controls."
https://pharos.nih.gov/idg/targets/P37173,P37173,18648910,"the expression levels of TbetaRII and Smad2 in Sertoli Cell-Only Syndrome testes were upregulated compared to that in the normal controls."
https://pharos.nih.gov/idg/targets/P37173,P37173,18598696,"The roles played by the ecto/transmembrane (ecto/TM) domains and endodomains of RI and RII TGF-beta receptors in these processes by transfecting 293 or HeLa cells with different combinations of receptor mutants, was analysed."
https://pharos.nih.gov/idg/targets/P37173,P37173,18550062,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,18546940,"The high expression of genes coding TGFbetaRI, TGF-betaRII and TGF-betaRIII receptors in all the polyps and healthy tissues, show readiness to transduction of TGFbeta"
https://pharos.nih.gov/idg/targets/P37173,P37173,18514338,"A significant elevation in expression of TGFBR2 in oral squamous cell carcinoma cells was seen in carbon and neon-irradiated cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,18453574,"mature human M2 macrophages made permissive to TGF-beta by glucocorticoid-induced surface expression of TGF-betaRII activate in response to TGF-beta1"
https://pharos.nih.gov/idg/targets/P37173,P37173,18398939,"Mesenchymal stem cells from patients with osteoarthritis showed significantly increased total TGF-beta, TGF-beta1 isoform, TBR-II, and TBR-III mRNA expression compared to controls."
https://pharos.nih.gov/idg/targets/P37173,P37173,18382895,"The exogenous tTGFbetaRII can efficiently trap TGF-beta I from access to wild-type receptors and can suppress TGF-beta I triggered signals. Thus it may potentially be clinically applied to scar therapy."
https://pharos.nih.gov/idg/targets/P37173,P37173,18339844,"Cancer-associated missense mutations of the T beta RII gene (TGFBR2) are associated with at least two different phenotypes."
https://pharos.nih.gov/idg/targets/P37173,P37173,18334936,"Filtering bleb scarring is associated with an abundant expression of TGF-beta receptors in activated fibroblasts and the deposition of the fibrogenic ED-A fibronectin splice-variant."
https://pharos.nih.gov/idg/targets/P37173,P37173,18264665,"TGFBR2 mutations are not a major factor in spontaneous spinal CSF leaks."
https://pharos.nih.gov/idg/targets/P37173,P37173,18243111,"TGF-beta complexes assemble cooperatively through recruitment of the low-affinity (type I) receptor by the ligand-bound high-affinity (type II) pair."
https://pharos.nih.gov/idg/targets/P37173,P37173,18202754,"TGF-beta1, TbetaRI, and TbetaRII loss of expression correlates with differentiation in human oral squamous cell carcinomas"
https://pharos.nih.gov/idg/targets/P37173,P37173,18199825,"KSHV evades both the antiproliferative effects of TGF-beta signaling by silencing TbetaRII gene expression and immune recognition by suppressing TGF-beta-responsive immune cells through the elevated secretion of TGF-beta1"
https://pharos.nih.gov/idg/targets/P37173,P37173,18174230,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,18097622,"The aim of this study was to analyse the profile of TGF-beta1 and the expression of its receptor (TbetaR I, TbetaR II and TbetaR III-betaglycan) genes in IPAH and in secondary forms of pulmonary arterial hypertension [Eisenmenger's syndrome patients]."
https://pharos.nih.gov/idg/targets/P37173,P37173,18095113,"sequencing of exon 4 of the transforming growth factor-beta receptor type II gene, which showed a band shift by single-strand conformation polymorphism, disclosed a single nucleotide polymorphism"
https://pharos.nih.gov/idg/targets/P37173,P37173,18084123,"Molecular genetic analysis demonstrated a heterozygous missense mutation of the transforming growth factor-beta receptor II gene in both the patient and his father, which thus caused Loeys-Dietz syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,18053089,"IL-1beta decreases TbetaRII expression by inducing Sp3 via NFkappaB"
https://pharos.nih.gov/idg/targets/P37173,P37173,18043895,"TGFbeta2 and TbetaRII have roles in the antiestrogenic activity of tamoxifen metabolites in breast cancer"
https://pharos.nih.gov/idg/targets/P37173,P37173,17985359,"Both genomic instability and clonal selection of transforming growth factor beta resistant cells contribute to the high frequency of TGFBR2 mutations in microsatellite unstable colon cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,17950544,"Mutations at the mononucleotide repeats within the TGF-betaRII gene occurred in certain basal cell carcinomas, not always in association with microsatellite instability ."
https://pharos.nih.gov/idg/targets/P37173,P37173,17875924,"Mutant p53 attenuates TGF-beta1 signaling. This was exhibited by a reduction in SMAD2/3 phosphorylation and an inhibition of both the formation of SMAD2/SMAD4 complexes and the translocation of SMAD4 to the cell nucleus."
https://pharos.nih.gov/idg/targets/P37173,P37173,17845732,"The identification of the splice variants T beta RIB and the novel isoform T beta RIIC in man clearly contributes to the growing complexity of the TGF-beta family."
https://pharos.nih.gov/idg/targets/P37173,P37173,17692120,"TGF-beta receptor 2 downregulation in tumor-associated stroma is associated with colon carcinoma"
https://pharos.nih.gov/idg/targets/P37173,P37173,17680270,"genetic variants in transforming growth factor beta receptor II may modulate the risk of esophageal squamous cell carcinoma"
https://pharos.nih.gov/idg/targets/P37173,P37173,17680270,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17676583,"it was observed the progression of premalignant lung lesions toward carcinoma in situ is accompanied by a decrease in TBR II expression and apoptosis and an increase in the expression of Ki-67 and MC"
https://pharos.nih.gov/idg/targets/P37173,P37173,17676485,"Alterations in TGF-betaRII, BAX, IGFIIR, caspase-5, hMSH3 and hMSH6 genes of microsatellite instability are rare in urinary bladder carcinoma and they are not associated with microsatellite instability or the presence of p53 mutations."
https://pharos.nih.gov/idg/targets/P37173,P37173,17653092,"RANTES signaling is required for invasion in TGFbetaRII-deficient neoplastic cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,17652900,"mutations in the TGFBR1,2 gene may be associated with greater phenotypic heterogeneity than previously reported"
https://pharos.nih.gov/idg/targets/P37173,P37173,17637743,"TGF-beta signaling in reactive stroma is angiogenic and tumor promoting and is mediated in part through a TbetaRII/Smad3-dependent upregulation of FGF-2 expression and release."
https://pharos.nih.gov/idg/targets/P37173,P37173,17634290,"Sequential cytoplasmic truncations resulted in receptor missorting to apical surfaces, and they indicated an essential targeting element(s) near the receptor's C terminus."
https://pharos.nih.gov/idg/targets/P37173,P37173,17566598,"the defective TGFBR2 expression might contribute to the carcinogenesis and/or development of large cell carcinoma"
https://pharos.nih.gov/idg/targets/P37173,P37173,17562261,"Genetic variants of TGFB1 and TGFBR2 genes may contribute to the risk of developing gastric cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,17562261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17560608,"TGFBR2 gene is reported to be linked to schizophrenia."
https://pharos.nih.gov/idg/targets/P37173,P37173,17560608,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17470566,"This review of 5 cases describes patients with musculoskeletal abnormalities and a TGFBR2 mutation in the neonatal period who are subsequently diagnosed with Loeys-Dietz syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,17427197,"High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC."
https://pharos.nih.gov/idg/targets/P37173,P37173,17418587,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17365852,"TGF-beta receptor type II and its mRNA were found in platelets."
https://pharos.nih.gov/idg/targets/P37173,P37173,17339425,"data suggest that promoter methylation plays an important role in T beta RII gene silencing and subsequent development of a TGF-beta1-resistant phenotype by some B-cell lymphoma cells"
https://pharos.nih.gov/idg/targets/P37173,P37173,17330129,"Genetic testing revealed in patient with diffuse and rapidly progressing vascular disease a de novo mutation in transforming growth factor receptor 2."
https://pharos.nih.gov/idg/targets/P37173,P37173,17319955,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17319955,"common variants in TGFBR2 gene do not strongly influence genetic susceptibility to diabetic nephropathy in an Irish Caucasian population."
https://pharos.nih.gov/idg/targets/P37173,P37173,17270239,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17270239,"TGFBR2 mutation is associated with CpG island methylator phenotype-high colorectal cancer and indirectly with RUNX3 methylation"
https://pharos.nih.gov/idg/targets/P37173,P37173,17194537,"These results also indicate that the CSF level assay of TGF-beta1, TbetaR-II and LRG is useful for the diagnosis of patients with INPH, and TGF-beta1, TbetaR-II and LRG may be involved in the pathogenesis of the disease."
https://pharos.nih.gov/idg/targets/P37173,P37173,17187359,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,17187359,"The variant alleles of the promoter polymorphisms, TGFB1 C-509T and TGFBR2 G-875A, were associated with a significantly decreased risk of gastric cancer."
https://pharos.nih.gov/idg/targets/P37173,P37173,17146441,"mutations of the amino-acid residues, D55 and E142 of TbetaR-II, resulted in loss of TGF-beta binding and downstream signaling activity"
https://pharos.nih.gov/idg/targets/P37173,P37173,17117417,"Mutated TGFBR2 seems to play an important role in the abrogation of transforming growth factor beta signal transduction in giant cell carcinoma cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,17112860,"TGF-beta RII was not upregulated in cyclosporine-induced gingival growth in patients after kidney transplantation."
https://pharos.nih.gov/idg/targets/P37173,P37173,17107667,"epidermal growth factor (EGF)-mediated induction of TbetaRII expression may participate in a synergistic interplay between EGF and TGF-beta signaling pathway"
https://pharos.nih.gov/idg/targets/P37173,P37173,17087113,"The expression of TGFbetaR I and TGFbetaR II protein in nasal polyps tissues was significant increased than that in chronic rhinosinusitis tissues."
https://pharos.nih.gov/idg/targets/P37173,P37173,17086361,"The human TbetaRII overexpressed in highly malignant K-ras-transformed thyroid cell clones is a functional receptor essential for a strong reduction of adhesive & migratory behaviour of these cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,16928994,"Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease (Loeys-Dietz syndrome)"
https://pharos.nih.gov/idg/targets/P37173,P37173,16885183,"Results from this family provides further evidence that mutations in TGFbetaR2 cause a distinct syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,16849474,"Mice transgenic for directed expression of a dominant negative TGF beta receptor type II, under the CD4 promoter lacking the CD8 silencer, spontaneously develop features characteristic of primary biliary cirrhosis."
https://pharos.nih.gov/idg/targets/P37173,P37173,16835936,"A comprehensive genetic analysis of TGFBR2 was performed in patients with Marfan syndrome or Marfan-related phenotypes."
https://pharos.nih.gov/idg/targets/P37173,P37173,16824508,"Signaling through Tgfbr2 regulates the maintenance of boundaries in the sclerotome and developing axial skeleton in transgenic mice."
https://pharos.nih.gov/idg/targets/P37173,P37173,16733295,"levels of TGFbeta-1 and TGFbeta R-2 were increased in the intimal matrices, smooth muscle cells, and macrophages, as well as in endothelial cells of atherosclerotic aorta"
https://pharos.nih.gov/idg/targets/P37173,P37173,16673206,"reduced transforming growth factor-beta type II receptor expression may play a critical role in determining the malignant phenotype of human adrenocortical carcinoma"
https://pharos.nih.gov/idg/targets/P37173,P37173,16573164,"The mutation rate of Poly A site of transforming growth factor-beta1 receptor type II in multiple sites keloid was significant higher than that in single site keloid."
https://pharos.nih.gov/idg/targets/P37173,P37173,16549496,"Down-regulation of TbetaRII in dermal cells or up-regulation of TbetaRII in epidermal cells reverses their migratory responses to serum and plasma, respectively."
https://pharos.nih.gov/idg/targets/P37173,P37173,16528739,"Results of this analysis appear to exclude a role for the TGFBR1- or TGFBR2-mediated pathway effect in Kabuki syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,16428382,"changes in TbetaRII levels by EGF are EGF receptor-kinase-dependent and are controlled by signals downstream of MEK1/2"
https://pharos.nih.gov/idg/targets/P37173,P37173,16388503,"prostate cancer cells mediate growth inhibition and differentiation of bone marrow endothelial cells through alteration of TGFbetaRII-mediated signal transduction."
https://pharos.nih.gov/idg/targets/P37173,P37173,16380996,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,16283890,"Identification of a novel TGFBR2 gene mutation in a Korean patient with Loeys-Dietz aortic aneurysm syndrome; no mutation in TGFBR2 gene in 30 patients with classic Marfan's syndrome."
https://pharos.nih.gov/idg/targets/P37173,P37173,16108056,"TGFBR2 mutations is associated with deregulation of cdk4 and colon cancer"
https://pharos.nih.gov/idg/targets/P37173,P37173,15976377,"Repression of type II TGF-beta receptor may act as significant determinant of lung adenocarcinoma invasiveness, an early step in tumor progression toward metastasis."
https://pharos.nih.gov/idg/targets/P37173,P37173,15942678,"blockade of TGF-beta after intramuscular transfer of the soluble type II TGF-beta receptor gene suppressed hepatic fibrosis"
https://pharos.nih.gov/idg/targets/P37173,P37173,15861007,"Identification of TGFBR2 mutations in Marfan syndrome type II provided the direct evidence of the relation in humans."
https://pharos.nih.gov/idg/targets/P37173,P37173,15824172,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,15811425,"UV-induced down-regulation of TbetaRII and the concerted over-expression of Smad7 may trigger the inhibition of the TGF-beta-induced phosphorylation of Smad2."
https://pharos.nih.gov/idg/targets/P37173,P37173,15731757,"possible role of heterozygous mutation in a newly described human phenotype that includes widespread perturbations in cardiovascular, craniofacial, neurocognitive and skeletal development"
https://pharos.nih.gov/idg/targets/P37173,P37173,15647279,"transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex are induced by Trichostatin A"
https://pharos.nih.gov/idg/targets/P37173,P37173,15522964,"thrombin via PAR1 induced the internalization of endoglin and type-II TGF-beta receptor (TbetaRII) but not type-I receptors in human ECs"
https://pharos.nih.gov/idg/targets/P37173,P37173,15350299,"The first characterized nonepithelial tumors in hereditary nonpolyposis colorectal cancer seem to carry a limited panel of dna replication errors, including a frameshift at the TGFBR2 gene."
https://pharos.nih.gov/idg/targets/P37173,P37173,15305380,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,15235604,"Our studies show that RDH12 is associated with retinal dystrophy and encodes an enzyme with a unique, nonredundant role in the photoreceptor cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,15146427,"an increased TGFbetaRI:TGFbetaRII ratio may underlie aberrant TGFbeta signaling in systemic sclerosis and contribute to elevated basal collagen production"
https://pharos.nih.gov/idg/targets/P37173,P37173,15102771,"combined production of the immunosuppressants IL-10 and TGF-beta, as well as coexpression of TGF-beta RI and RII (required for cellular response to TGF-beta), may act to down-modulate host anti-Mycobacterium tuberculosis immunity"
https://pharos.nih.gov/idg/targets/P37173,P37173,15017149,"NMR analysis of the extracellular domain of the human TGFbeta type II receptor in complex with monomeric TGFbeta3"
https://pharos.nih.gov/idg/targets/P37173,P37173,15009106,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,14976186,"each of the five Ets proteins influences the TbetaR-II promoter in a unique manner because of important differences in their biochemical properties or their patterns of cellular expression"
https://pharos.nih.gov/idg/targets/P37173,P37173,14760070,"TGFBR2 has a role in progression of estrogen receptor-negative breast cancer"
https://pharos.nih.gov/idg/targets/P37173,P37173,14727154,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,14704634,"expression values for TGF 1 and its receptors I, II, and III were twice as high in the group of patients with a diagnosis of high-grade lymphomas as in the group of patients diagnosed with low-grade lymphomas"
https://pharos.nih.gov/idg/targets/P37173,P37173,14601051,"TbetaRII in transgenic mice plays a critical role in maintaining the nondifferentiated character of virgin mammary gland epithelium."
https://pharos.nih.gov/idg/targets/P37173,P37173,14582709,"ERT mediates the expression of TGF-beta RII, and the transcriptional inhibition of ets-related transcription factor could be a one of the mechanisms of colonic carcinogenesis"
https://pharos.nih.gov/idg/targets/P37173,P37173,12970754,"We observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic renal cell carcinomas [RCC}. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and loss of TBR2 leads to acquisition of a metastatic phenotype."
https://pharos.nih.gov/idg/targets/P37173,P37173,12915548,"Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cells."
https://pharos.nih.gov/idg/targets/P37173,P37173,12873459,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,12840808,"role of a CCAAT box and three GC boxes in the regulation of the TbetaR-II promoters in embryonal carcinoma-differentiated cells"
https://pharos.nih.gov/idg/targets/P37173,P37173,12825850,"Human breast tumors were screened for TGFBR2 mutation and/or altered expression of TGFBR2 protein. TGFBR2 was expressed in the epithelium and stroma of tumors, and was higher in patients having positive lymph nodes and/or negative ER and PR expression."
https://pharos.nih.gov/idg/targets/P37173,P37173,12736050,"The loss of TbetaR-II expression in the primary tumor is associated with clinical stage (P <0.01) and predicts a significantly lower survival rate in renal cell carcinoma patients."
https://pharos.nih.gov/idg/targets/P37173,P37173,12607775,"TGF-beta2 receptor expression in peritoneal fibroblasts was increased by hypoxia or hypoxia plus TGF-beta1, but decreased by TGF-beta1 alone."
https://pharos.nih.gov/idg/targets/P37173,P37173,12515396,"This protein was expressed locally in the media and adeventitia at injected arterial segments without any significant dissemination to remote areas."
https://pharos.nih.gov/idg/targets/P37173,P37173,12479849,"Coding region microsatellite mutations characteristic of defective mismatch repair Identification of TGFbetaRII coding region microsatellite mutations in vivo implicates this gene in the pathogenesis of human T-LBL/ALL."
https://pharos.nih.gov/idg/targets/P37173,P37173,12215842,"Differential rates of frameshift alterations in four repeat sequences of hereditary nonpolyposis colorectal cancer tumors.These repeats consisted of (A)10 in the TGF beta RII, (G)8 in the BAX, (A)8 in the CASP1, and (CCA)7 in the APP genes."
https://pharos.nih.gov/idg/targets/P37173,P37173,12202987,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,12174910,"data suggest the existence of a further definite subgroup of diffuse-type gastric carcinomas with altered TGFbeta-IIR expression, independent from a mutator phenotype with TGFbeta-IIR gene mutations"
https://pharos.nih.gov/idg/targets/P37173,P37173,12077447,"TGFBII receptors were purified and refolded; they have an apparent molecular weight of 14 kDa as by size-exclusion chromatography"
https://pharos.nih.gov/idg/targets/P37173,P37173,12060054,"present in diabetic foot ulcer"
https://pharos.nih.gov/idg/targets/P37173,P37173,11850637,"crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex"
https://pharos.nih.gov/idg/targets/P37173,P37173,11820800,"TGF beta type II receptor mRNA concentration on the surface of human osteoblasts is increased by 1 alpha,25-dihydroxyvitamin D3 due to changes in receptor mRNA stability not associated with an increase in the rate of gene transcription."
https://pharos.nih.gov/idg/targets/P37173,P37173,11777969,"Overexpression of a dominant negatively acting mutant of TGFBR2 in primitive hemopoietic progenitor cells renders them transiently unresponsive to both autocrine and paracrine TGF-beta signaling and leads to their enhanced survival and proliferation."
https://pharos.nih.gov/idg/targets/P37173,P37173,11744689,"treatment with the HDAC inhibitor induces TbetaRII promoter activity by the recruitment of the PCAF protein to the NF-Y complex, interacting with the inverted CCAAT box in the TbetaRII promoter"
https://pharos.nih.gov/idg/targets/P37173,P37173,11741970,"Altogether, these results identify a mechanism by which RhoB antagonizes TGF-beta action through transcriptional down-regulation of AP1 in T beta R-II promoter."
https://pharos.nih.gov/idg/targets/P37173,P37173,11251969,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37173,P37173,11158177,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,28927913,"Study showed that rs706819, rs2293094, and rs11169953 polymorphisms in the ACVRL1 gene are associated with higher susceptibility to brain arteriovenous malformations."
https://pharos.nih.gov/idg/targets/P37023,P37023,27528762,"Activin receptor-like kinase (ALK)1 is a transforming growth factor beta (TGF-beta) type I receptor predominantly expressed in actively proliferating endothelial cells (ECs)."
https://pharos.nih.gov/idg/targets/P37023,P37023,27528761,"Bone morphogenetic protein (BMP)9 and BMP10 are high affinity ligands for activin receptor-like kinase 1 (ALK1)."
https://pharos.nih.gov/idg/targets/P37023,P37023,27381467,"c.1027C > T(p.Gln343) mutation within the ACVRL1 gene in family with hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/P37023,P37023,27316748,"Two novel missense mutations and two recurrent mutations in the ACVRL1 gene are associated with pulmonary arterial hypertension in in Chinese families."
https://pharos.nih.gov/idg/targets/P37023,P37023,27248821,"Data indicate that simultaneous targeting of molecules that control distinct phases of angiogenesis, such as ALK1 and VEGFR, is a valid strategy for treatment of metastatic renal cell carcinoma (mRCC)."
https://pharos.nih.gov/idg/targets/P37023,P37023,27196063,"The genetic-interactions among BMPR-2, ALK-1, and 5-HTT polymorphisms, elevated BMP-2 and 5-HT levels and differential gene expression substantiated the strong genetic contribution in high altitude pulmonary edema pathophysiology."
https://pharos.nih.gov/idg/targets/P37023,P37023,26897508,"Study of four patients with pulmonary arterial hypertension associated with human immunodeficiency virus infection found predisposing mutations in the BMPR2, ACVRL1 and ENG genes."
https://pharos.nih.gov/idg/targets/P37023,P37023,26821948,"Report interaction between ALK1 signaling and connexin40 in the development of arteriovenous malformations."
https://pharos.nih.gov/idg/targets/P37023,P37023,26720610,"Short hairpin-mediated downregulation of either ALK5 or ALK1 resulted in a strong inhibition of TGFbeta-induced chondrogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,26677222,"Data suggest ALK1 and ACVR2A/ACVR2B, acting as BMP9 co-receptors, rearrange pro-domains of BMP9--pro-domain dimer complex leading to displacement of pro-domains after receptor binding, release of mature non-dimer BPM9, and activation of signaling."
https://pharos.nih.gov/idg/targets/P37023,P37023,26662187,"ALK1 expression and microvessel density are increased in oral lichen planus , particularly in atrophic/erosive OLP type."
https://pharos.nih.gov/idg/targets/P37023,P37023,26655846,"Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway."
https://pharos.nih.gov/idg/targets/P37023,P37023,26176610,"This work was designed to examine the pathogenicity of 23 nucleotide variations in ACVRL1 gene detected in more than 400 Hereditary Hemorrhagic Telangiectasia syndrome patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,25970827,"The preponderance of ACVRL1 mutations was due to founder mutations, specifically, c.830C>A (p.Thr277Lys), which was found in 24 families from the same geographical area of Norway."
https://pharos.nih.gov/idg/targets/P37023,P37023,25847705,"The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations."
https://pharos.nih.gov/idg/targets/P37023,P37023,25799559,"bone morphogenic proteins within the serum of cell culture medium are potent inducers of endothelial Hey1 and Hey2 gene expression within the first few hours after medium change"
https://pharos.nih.gov/idg/targets/P37023,P37023,25466244,"P7170 inhibited the phosphorylation of AKT1."
https://pharos.nih.gov/idg/targets/P37023,P37023,25279424,"endoglin and ALK1 have been identified as potential therapeutic targets for antibody treatment in various cancers."
https://pharos.nih.gov/idg/targets/P37023,P37023,24936649,"Mutations in ACVRL1 gene is not associated with pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/P37023,P37023,24323303,"Results do not replicate the association between polymorphism in ACVRL1 protein and BAVM in this Dutch population."
https://pharos.nih.gov/idg/targets/P37023,P37023,24319055,"Endoglin and ACVRL1 contribute to several novel networks, including TGF-beta dependent and independent ones, critical for vascular function and potentially defective in hereditary hemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,24305026,"In chronic subdural hematomas, the expression of ALK-1 was slightly increased in the dura and markedly up-regulated in the outer membrane."
https://pharos.nih.gov/idg/targets/P37023,P37023,24189493,"Consistent with the aberrant upregulation of ACVRL1 and downstream Smad signaling, abrogation of EDD led to deregulated vessel development and endothelial cell motility."
https://pharos.nih.gov/idg/targets/P37023,P37023,23919827,"Results show that mutations of ACVRL-1 protein is a genetic predisposing factor for HHT associated PH in Chinese patients"
https://pharos.nih.gov/idg/targets/P37023,P37023,23707512,"shows role of ALK-1 in many process related to cardiovascular homeostasis, and the involvement of this protein in the development of cardiovascular diseases, suggesting the possibility of using the ALK-1/smad-1 pathway as a powerful therapeutic target"
https://pharos.nih.gov/idg/targets/P37023,P37023,23460919,"A novel intron mutation in ACVRL1 gene is associated with familial hereditary hemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,23447486,"ACVRL1 gene expression is significantly corellated with advanced tumor stages and it is a useful marker for prognosis."
https://pharos.nih.gov/idg/targets/P37023,P37023,23124896,"Defective trafficking and retention in the endoplasmic reticulum of mutant ALK1 protein is a possible mechanism of hereditary haemorrhagic telangiectasia type 2 in some patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,23048070,"ALK1 is upregulated in endothelial cells during vascular injury by a synergistic cooperative mechanism between KLF6 and specificity protein 1."
https://pharos.nih.gov/idg/targets/P37023,P37023,22799562,"Alk1 extracellular domain binds with high affinity to BMP-9."
https://pharos.nih.gov/idg/targets/P37023,P37023,22718755,"The structure reveals that the high specificity of ALK1 for BMP9/10 is determined by a novel orientation of ALK1 with respect to BMP9, which leads to a unique set of receptor-ligand interactions"
https://pharos.nih.gov/idg/targets/P37023,P37023,22677372,"Inheritance of ACVRL1 single nucleotide polymorphisms marginally contributed to the risk of cutaneous telangiectasiae."
https://pharos.nih.gov/idg/targets/P37023,P37023,22632830,"Patients with childhood idiopathic pulmonary arterial hypertension or heritable pulmonary arterial hypertension with ALK1 mutation carriers tended to have worse outcomes than mutation noncarriers."
https://pharos.nih.gov/idg/targets/P37023,P37023,22493445,"data suggest that both the VEGF/VEGF receptor and the BMP9/ALK1 pathways are essential for stimulating angiogenesis, and targeting both pathways simultaneously may be an attractive strategy to overcome resistance to antiangiogenesis therapy"
https://pharos.nih.gov/idg/targets/P37023,P37023,22391627,"The abnormal expression of ALK1 and TGFbR2 were found to be independent contributors to nasopharyngeal carcinogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,22277251,"Alk1 interacts with cav-1 in human dermal fibroblasts and Transforming Growth Factor beta enhances this association."
https://pharos.nih.gov/idg/targets/P37023,P37023,22233626,"PTPN14 has a role in angiogenesis and/or arteriovenous fate, acting via EphrinB2 and ACVRL1/activin receptor-like kinase 1"
https://pharos.nih.gov/idg/targets/P37023,P37023,22087763,"The balance in signalling through either ALK-1 or ALK-5 regulates leptin expression in mesenchymal stem cells."
https://pharos.nih.gov/idg/targets/P37023,P37023,22028876,"insight into the potential structure of ALK1(EC) and into the structural effects of type 2 Hereditary Haemorrhagic Telangiectasia associated mutations"
https://pharos.nih.gov/idg/targets/P37023,P37023,22013081,"Two angiogenesis-associated transcripts (Egfl7 and Acvrl1) showed lower expression in early-onset PE versus late-onset pre-eclampsia and versus gestational age-matched controls."
https://pharos.nih.gov/idg/targets/P37023,P37023,21967607,"A novel endoglin mutation (c.1-127C > T); and a novel ACVRL1 mutation (c.252_253insC; p.Val85fsX168). It was shown for the first time that a 5'-UTR mutation can prevent translation of endoglin among hereditary hemorrhagic telangiectasia patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,21546842,"Studies indicate that mutations in at least five genes are thought to result in hereditary hemorrhagic telangiectasia, but mutations in ENG and ACVRL1/ALK1 cause approximately 85% of cases."
https://pharos.nih.gov/idg/targets/P37023,P37023,21212415,"ALK1 may play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies."
https://pharos.nih.gov/idg/targets/P37023,P37023,21158752,"Study identified 52 unique, novel mutations by sequencing - 25 in ACVRL1 and 27 in ENG."
https://pharos.nih.gov/idg/targets/P37023,P37023,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,20587022,"The demethylation of CpG islands, led to an increase in ACVRL1 transcription, whereas in vitro hypermethylation resulted in the abolishment of Sp1-dependent transcriptional activation of ACVRL1."
https://pharos.nih.gov/idg/targets/P37023,P37023,20501893,"Mutations of ACVRL1 fit with a functional haploinsufficiency model affecting BMP9 signaling in Hereditary hemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,20424473,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,20414677,"This report describes the results of molecular diagnosis of mutations in the ENG and ACVRL1 genes in a series of 600 consecutive probands with HHT-related clinical features."
https://pharos.nih.gov/idg/targets/P37023,P37023,20346360,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,20124460,"ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth"
https://pharos.nih.gov/idg/targets/P37023,P37023,20065063,"Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,20056902,"Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of heritable pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/P37023,P37023,20056902,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,19903896,"a novel aspect of ALK1 signaling in regulating lymphatic development and suggests that targeting ALK1 pathway might provide additional control of lymphangiogenesis in human diseases."
https://pharos.nih.gov/idg/targets/P37023,P37023,19592636,"These studies support CK2beta as an important regulator of ALK-1 signaling and ALK-1-mediated functions in endothelial cells."
https://pharos.nih.gov/idg/targets/P37023,P37023,19508727,"this study is a further contribution to the determination of already known ACVRL1 mutations in hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/P37023,P37023,19508727,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,19506300,"ALK1 and ALK5 are both essential for correct regulation of VEGF, and that disruption of either pathway leads to disease."
https://pharos.nih.gov/idg/targets/P37023,P37023,19494318,"age-related shift in ALK1/ALK5 ratio in murine cartilage and a strong correlation between ALK1 and MMP-13 expression in human cartilage"
https://pharos.nih.gov/idg/targets/P37023,P37023,19366699,"Critical role of type II receptors in balancing BMP9 signaling via ALK1 and emphasize the essential role for BMPR-II in a subset of BMP9 responses in pulmonary artery endothelial cells."
https://pharos.nih.gov/idg/targets/P37023,P37023,19357124,"Results highlight ALK1 mutations associated with a variable PAH phenotype, including pulmonary arteriovenous malformations and severe PAH presenting early in life."
https://pharos.nih.gov/idg/targets/P37023,P37023,19270816,"mutational analysis of the ACVRL1 gene in Korean patients with hereditary hemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,19051722,"ALK1 mutations play a critical role in PAH without HHT (hereditary hemorrhagic telangiecasia) as well as in PAH with HHT."
https://pharos.nih.gov/idg/targets/P37023,P37023,18972447,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,18949376,"the VEGF plasma levels as well as the VEGF tissue expression in HHT patients with ENG gene mutations did not differ significantly to those of HHT patients with ACVRL1 gene mutations or mutations for both the genes."
https://pharos.nih.gov/idg/targets/P37023,P37023,18855162,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,18829861,"Overexpression of ALK1 promoted remodeling of newly formed blood vessels and prevented further angiogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,18673552,"ALK1 mutations (HHT2) were predominant over ENG mutations (HHT1) in our Spanish population"
https://pharos.nih.gov/idg/targets/P37023,P37023,18607909,"in hereditary hemorrhagic telangiectasia all 4 ENG mutations and one of the ACVRL1 mutations were new and had not been described previously in other populations"
https://pharos.nih.gov/idg/targets/P37023,P37023,18543223,"The hereditary hemorrhagic telangiectasia family is caused by a 145delG mutation of ACVRL1 gene, resulting in frameshift and a new stop codon at codon 53."
https://pharos.nih.gov/idg/targets/P37023,P37023,18498373,"identified ACVRL1 mutations in hereditary hemorrhagic telangiectasia, including 4 unknown, and found that ACVRL1, and not ENG, mutations are predictive for liver disease"
https://pharos.nih.gov/idg/targets/P37023,P37023,18498373,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,18333754,"both ALK1 and ALK5 are needed for TGF-beta-induced phosphorylation of intracellular mediators Smad1/5, whereas only ALK5 is essential for TGF-beta1-induced phosphorylation of Smad3"
https://pharos.nih.gov/idg/targets/P37023,P37023,18312453,"4 large novel deletions in ALK1 gene in a group of 45 clinically confirmed hereditary haemorrhagic telangiectasia families. 2 families, the whole ALK1 gene was deleted. 1 spanned at least 216 kb & included LOC728503, ANKRD33, ACVR1B, GRASP, & NR4A1"
https://pharos.nih.gov/idg/targets/P37023,P37023,18309101,"BMP9 is indeed the ALK1 ligand present in human serum"
https://pharos.nih.gov/idg/targets/P37023,P37023,18285823,"reports haplotype analyis of 13 ACVRL1 mutations, which have been found in patients from France and Italy. One specific mutation (c.1112dupG) is repsonsible for the high frequence in Ain and Jura areas"
https://pharos.nih.gov/idg/targets/P37023,P37023,18187665,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,18159113,"ALK1 plays as notable a role as BMPR2 in the etiology of PAH. Asymptomatic carriers with the ALK1 mutation within the serine - threonine kinase domain are at risk of developing PAH and hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/P37023,P37023,18065769,"Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae."
https://pharos.nih.gov/idg/targets/P37023,P37023,17786384,"Mutation analysis in ENG and ACVRL1 genes was performed in hereditary hemorrhagic telangiectasia patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,17620321,"These results support a significant role for ALK1 as a negative regulator of endothelial cell migration and suggest the implication of JNK and ERK as mediators of this effect."
https://pharos.nih.gov/idg/targets/P37023,P37023,17388964,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,17388964,"identification of a mutated ENG (HHT1) or ALK-1 (HHT2) gene now enables a genotype-phenotype correlation"
https://pharos.nih.gov/idg/targets/P37023,P37023,17311849,"These results suggest that BMP-9 is a physiological ALK1 ligand that plays an important role in the regulation of angiogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,17224686,"Mutations in ACVRL1 gene is associated with symptomatic lung involvement and cerebral abscesses in hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/P37023,P37023,17219009,"These data indicate that loss-of-function mutations in a single allele of the ALK1 locus are sufficient to contribute to defects in maintaining endothelial integrity."
https://pharos.nih.gov/idg/targets/P37023,P37023,17068149,"Bone Morphogenetic Protein 9 (BMP9) and BMP10 are two specific ALK1 ligands"
https://pharos.nih.gov/idg/targets/P37023,P37023,16941203,"The presence of mutations in the ALK-1 gene in ten patients with underlying connective tissue diseases was investigated"
https://pharos.nih.gov/idg/targets/P37023,P37023,16861286,"mutation causes truncation of the ALK-1 protein at the post-transcriptional level; the plasma thrombomodulin may provide an easy diagnostic indicator in HHT patients"
https://pharos.nih.gov/idg/targets/P37023,P37023,16785228,"ALK1 is a preferred TGFbeta receptor kinase for endoglin threonine phosphorylation in HUVECs and endoglin phosphorylation has a role in the regulation of endothelial cell adhesion and growth by ALK1"
https://pharos.nih.gov/idg/targets/P37023,P37023,16776339,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,16776339,"The results of this study link ACVRL1 (HHT Type 2 gene) to the formation of the clinically sporadic variants of vascular malformations of the CNS most commonly seen in patients with HHT, that is, AVMs and DAVFs."
https://pharos.nih.gov/idg/targets/P37023,P37023,16752392,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,16705692,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,16542389,"An analysis of the genotype-phenotype correlation is consistent with a more common frequency of pulmonary arteriovenous malformations in patients with ENG mutations than in patients with ACVRL1 mutations in our collective."
https://pharos.nih.gov/idg/targets/P37023,P37023,16540754,"Molecular analysis identified mutations in the ACVRL1 gene in patients affected with hereditary hemorrhagic telengiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,16525724,"Results showed 12 novel mutations in ACVRL1 gene causing hereditary hemorrhagic teleangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,16470589,"expression analysis of Endoglin and ALK1 in Spanish patients with hereditary hemorrhagic telangiectasia"
https://pharos.nih.gov/idg/targets/P37023,P37023,16429404,"ENG and ALK-1 genes may have roles in hereditary haemorrhagic telangiectasia in the Italian population"
https://pharos.nih.gov/idg/targets/P37023,P37023,16179574,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,16179574,"a polymorphism in ALK1 but not a polymorphism in ENG may have a role in development of sporadic brain arteriovenous malformations"
https://pharos.nih.gov/idg/targets/P37023,P37023,15951295,"HHT is an angiogenic disorder characterized by an over-expression of VEGF, TGF-beta1 and ALK1"
https://pharos.nih.gov/idg/targets/P37023,P37023,15880681,"These results demonstrate the importance of ACVRL1 and ENG mutations in German hereditary hemorrhagic telangiectasia (HHT) patients displaying mutation frequencies over 80%."
https://pharos.nih.gov/idg/targets/P37023,P37023,15712271,"11 of 16 mutations in the ALK1 gene were novel single base pair substitutions in exons 4, 7, 8, & 9. The 1st de novo ALK1 mutation found causes a previously unreported c.1133C>A substitution of a highly conserved residue (p.P378H)."
https://pharos.nih.gov/idg/targets/P37023,P37023,15712270,"5 new mutations were found in hereditary hemorrhagic telangiectasia: c.149G>A, c.246delC, c.1273T>G, c.1274_1276delTCT, and c.1377+1G>A."
https://pharos.nih.gov/idg/targets/P37023,P37023,15687131,"The ALK-1 mutant R484Q within the highly conserved NANDOR box region was found in an infant with idiopathic pulmonary arterial hypertension."
https://pharos.nih.gov/idg/targets/P37023,P37023,15611116,"retroviral gag- and gag-pol-like proteins interact with ALK1"
https://pharos.nih.gov/idg/targets/P37023,P37023,15517393,"Mutation found in 40% of hereditary hemorrhagic telangiectasia patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,15024723,"Mutational analysis of the ACVRL1 gene in hereditary hemorrhagic telangiectasia patients."
https://pharos.nih.gov/idg/targets/P37023,P37023,14684682,"missense mutations of ALK-1 cause pulmonary hypertension in patients with hereditary haemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/P37023,P37023,14580334,"ALK5 mediates a TGFbeta-dependent recruitment of ALK1 into a TGFbeta receptor complex; ALK5 kinase activity is required for optimal ALK1 activation."
https://pharos.nih.gov/idg/targets/P37023,P37023,12920067,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P37023,P37023,12920067,"A questionnaire based study provides evidence that the hereditary hemorrhagic telangiectasia (HHT) phenotype caused by mutations in endoglin (HHT1) is distinct from, and more severe than, HHT caused by mutations in ALK1 (HHT2)."
https://pharos.nih.gov/idg/targets/P37023,P37023,12453878,"7 angiogenesis-related genes were found among 13 genes significantly induced or suppressed by a constitutively active ALK-1. ALK-1 is implicated in the maturation phase of angiogenesis."
https://pharos.nih.gov/idg/targets/P37023,P37023,12393874,"signaling regulated by the nuclear receptor LXRbeta"
https://pharos.nih.gov/idg/targets/P37023,P37023,12114496,"Identification of 13 new mutations in the ACVRL1 gene in a group of 52 unselected Italian patients affected by hereditary haemorrhagic telangiectasia."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28546219,"iNOS-derived NO plays a crucial role during atherosclerosis by regulating the endocytic-lysosomal degradation of ILK in endothelial cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28522687,"We conclude that ILK is critical for maintaining the collecting duct epithelium and renal function and is a key intermediate for periostin activation of signaling pathways involved in cyst growth and fibrosis in PKD."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28339614,"ILK aids trophoblast syncytialization via downregulation of CDH1, perhaps through an ILK-PARP1-SNAI1 pathway"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28188308,"Data indicate a regulatory role for tetraspanin 8 (Tspan8) in melanoma progression by modulating cell-matrix interactions through beta1 integrin - integrin-linked kinase (ILK) axis and establish Tspan8 as a negative regulator of ILK activity."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28138714,"Overexpression of ILK therefore promoted the proliferation of SHG44 human glioma cells, reduced apoptosis and reduced sensitivity to TMZ via decreasing the activity of caspase3."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28097141,"These findings suggest that emodin inhibited the EMT of EOC cells via ILK/GSK-3beta/Slug signaling pathway"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,28069177,"During human endometrial decidualization, ILK is essential for morphologic transformation of endometrial stromal cells through organization of the actin cytoskeleton."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27683053,"High expression of ILK is associated with bladder cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27576342,"Results show that ILK is overexpressed in metastasis of bladder cancer and the up-regulation of ILK could increase cell proliferation, change cell morphology and regulate cell cycle promoting epithelial-mesenchymal transition."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27539661,"These data suggest a novel link between Tiam1 and RhoG/ILK /ELMO2 pathway as upstream effectors of the Rac1-mediated phagocytic process in trabecular meshwork cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27503933,"Our results define ILK as a key mechanotransducer in modulating breast cancer stem-like cells development in response to tissue mechanics and oxygen tension."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27315599,"silencing of ILK attenuates the abnormal proliferation and migration of human Tenon's capsule fibroblasts induced by TGF-beta2."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27130230,"Emodin inhibits the migration and invasion abilities of human endometrial stromal cells by by facilitating the mesenchymal-epithelial transition through targeting integrin-linked kinase."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27111285,"Using in vitro studies, we demonstrated that ILK and PI3K/AKT inhibitors suppressed the contraction of fibroblast-populated collagen lattices, inhibited fibroblast migration, and interrupted the effect of TGF-beta1 on promoting alpha smooth muscle actin (alpha-SMA) expression in fibroblasts."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27099440,"ILK overexpression improved the proliferation, metastasis, and invasion ability of colorectal tumor cells, and this effect may be mediated by the NF-kappaB/rel/A signaling pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27090767,"This study is the first to identify EMILIN-1 and ILK as prospective markers of islet regenerative function in human mesenchymal stem cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,27034956,"periostin enhanced invasion and migration abilities of EECs and facilitated the epithelial-mesenchymal transition of endometrial epithelial cell through ILK-Akt signaling pathway"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26959113,"The current data support MT1-MMP as an additional ILK substrate and show that modulation of ILK expression and activity inhibit MT1-MMP-related pro-metastatic behaviors of ovarian cancer cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26887611,"High ILK expression is associated with pancreatic ductal adenocarcinomas."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26837762,"findings describe a TNFalpha-NF-kappaB-mediated mechanism by which ILK expression is induced in the lymph node microenvironment and propose that ILK promotes leukemogenesis by enabling CLL cells to cope with centrosomal defects acquired during malignant transformation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26693891,"Twist-ITGB1-FAK/ILK pathway and their downstream signaling network dictate the Twist-induced EMT process in human mammary epithelial cells and breast cancer cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26616862,"KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26549818,"integrin linked kinase may play a role in cell proliferation, and cell migration in aggressive thyroid cancers."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26531674,"Results indicated that ILK is imperative in the development and progression of oral squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26467393,"high extracellular concentration of phosphate induced senescence in cultured smooth muscle through the activation of IGF-1 receptor and ILK overexpression"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26460618,"our data suggest an essential role of PINCH1, ILK and ILKAP for the radioresistance of p53-wildtype glioblastoma multiforme cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26210487,"Overexpression of ILK is associated with arteriosclerosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,26176204,"ILK inhibition and knockdown effects senescence in an Rb-dependent manner."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25998224,"knockdown of ILK inhibits glioma cell migration, invasion and proliferation through upregulation of E-cadherin and downregulation of cyclin D1. Our results suggest that ILK may serve as a promising therapeutic target for glioma."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25964055,"ILK may have an important role in the progression of NSCLC, possibly through up-regulation of Snail and MRP1."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25805567,"Overexpression of CD29 decreased E-cadherin, but increased fibronectin, vimentin, ILK activity."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25760437,"RNA silencing of ILK increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25759370,"Periostin enhanced ensometrial stromal cell migration, invasion, and adhesion due to the ILK1/Akt signal pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25738875,"PARVA promotes metastasis by modulating ILK signalling pathway in lung adenocarcinoma"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25657336,"our study shows that ILK regulates the EMT in RCC cells, and targeting ILK suppresses invasion and metastasis through inhibition of the EMT in RCC."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25398317,"An increase in integrin-linked kinase non-canonically confers NF-kappaB-mediated growth advantages to gastric cancer cells by activating ERK1/2"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25218472,"Thymosin beta4 induces invasion and migration of human colorectal cancer cells through the ILK/AKT/beta-catenin signaling pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25208486,"ILK mediates cardiomyocyte force transduction through regulation of SERCA-2a and phosphorylation of phospholamban."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,25160619,"A major ILK binding site in the kindlin-2 FERM domain for regulating cell adhesion has been mapped."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24911651,"critical function for ILK in mitotic cytoskeletal organization"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24789658,"Data demonstrate that p34SEI-1 induces the activation of either AKT or ILK signaling on HER2/neu expression status."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24360977,"A pivotal role of ILK in epithelial-mesenchymal transition and metastasis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24356468,"integrin-linked kinase (ILK) plays a critical role in the suppression of the Hippo pathway via phospho-inhibition of MYPT1-PP1, leading to inactivation of Merlin"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24299190,"we conclude that the CRC cells survival and invasion enhanced by hypoxia are mediated by ILK, and ILK may be an important potential therapeutic target for CRC."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24260102,"These findings indicate that wild type ILK and the non-oncogenic ILK(R211A) mutation comprise a cardioprotective module with Hsp/c70."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24064223,"A significant negative correlation between JWA and ILK in melanoma biopsies."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24045896,"A novel role for ILK in glioma invasion and metastasis processes via downregulation of CDH1."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,24040439,"TGF-beta/Smad, integrin/integrin-linked kinase (ILK) and wnt/beta-catenin signaling pathways are involved in epithelial to mesenchymal transition in human renal fibrogenesis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23863169,"discusses the recent advances on the structural and functional characterization of ILK and the long-standing debate regarding its reported kinase activity"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23832543,"Data indicate that integrin-linked kinase 1 (ILK1) may be an important molecular marker for predicting the carcinogenesis, progression, and prognosis of breast cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23801886,"findings suggest that ILK promotes lung cancer cell migration and invasion via NF-kappaB-mediated upregulation of MMP-9"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23784942,"It was found that ILK downregulation significantly decreased angiogenesis, increased apoptosis, and decreased invasiveness of osteosarcoma cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23783575,"ILK knockdown attenuates the biological behavior of PCa cells by decreasing Akt activity, demonstrating that ILK is involved in the development and progression of PCa."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23748822,"Down-regulation of integrin-linked kinase reduced the metastatic potential of gastric tumor cells by regulating metastasis-related gene expression, by inhibiting the Akt pathway as well as the activity of transcription factors"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23747271,"Report a new pathway of glioma radioresistance via Report the regulation of radiation-induced centrosome duplication and therefore mitotic cell death by ILK, HIF-1alpha and survivin."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23739974,"ILK is necessary for normal oligodendrocyte development and reinforces the bridge between actin cytoskeleton and cell membrane."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23729269,"Down-regulation of E-cadherin correlated significantly with ILK over-expression."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23707970,"ILK could be a novel diagnostic and therapeutic target for tongue cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23703635,"RI might play a novel role in the development of bladder cancer through regulating EMT and the ILK signaling pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23624332,"ILK activity changes may act as a mechanism in response to different stimuli such as H2O2 in the induced TGF-beta1 up-regulation in pathological or even physiological conditions."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23435415,"Study identifies Hsp27 as a novel target of ILK-p38beta signaling complexes, playing a key role in bladder cancer cell migration."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23186335,"FAK expression was positively correlated with ILK expression but negatively correlated with PTEN expression in SACC tissues. FAK and ILK expression was positively associated with advanced stage"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23108908,"ILK overexpression is associated with tumor progression and a poor prognosis in CRC patients and may represent a novel potential prognostic marker for patients with CRC."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23065574,"study suggested that positive ILK and PRDX1 expressions are closely related to the progression and poor prognosis of gallbladder cancer"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,23027626,"ILK is a therapeutically targetable mediator of ERG-induced epithelial-to-mesenchymal transition (EMT) and transformation in prostate cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22938462,"findings show ILK gene transcription and protein expression may be involved in the development of bladder transitional cell carcinoma"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22814720,"Studied the expression of ILK in clear cell renal carcinomas (CCRC) as a possible prognostic indicator. ILK immunostaining was significantly increased in high-grade in comparison to low-grade CCRCs."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22767580,"ILK identified as a new partner for ADAM12L cellular functions; data suggest a new role for ADAM12L in mediating the functional association of ILK with beta1 integrin to regulate cell adhesion/survival through a PI3K/Akt signaling pathway"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22683084,"ILK promotes lung cancer cell migration and invasion through the induction of EMT process"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22677169,"Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22666394,"ILK represents a novel regulatory checkpoint during human cardiomyogenesis"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22658851,"ILK does not play a prominent role in the promotion or sustenance of established multiple myeloma."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22638656,"results suggest ILK may have an important role in progression and metastasis of oral squamous cell carcinoma, possibly through epithelial-mensenchymal transition involving up-regulation of Snail and consequent aberrant expression of E-cadherin and N-cadherin"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22616551,"the targeting of ILK with siRNA significantly inhibited cell attachment, spreading, migration and microfilament dynamics in corpus cavernosum smooth muscle cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22570869,"Knockdown of ILK inhibited bladder cancer proliferation and invasion, changed cell morphology, more importantly, suppressed bladder cancer epithelial-mesenchymal transition as well as tumor growth and metastasis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22568984,"Through its association with ELMO2, ILK plays key roles in the regulation of Rho GTPases and cross-talk pathways between adhesion and growth factor receptors."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22490953,"Downregulation of integrin-linked kinase inhibited cell proliferation and induced apoptosison retinoblastoma cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22482400,"Data show that integrin linked kinase (ILK) over-expression could promote cell proliferation, inhibit cell apoptosis and increase mitosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22441983,"results also identify the integrin-linked kinase (ILK) and alpha-parvin proteins as a new molecular partner and target, respectively, of the Lnk adaptor."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22345562,"IGFBP requires ILK to induce cell motility. The IGFBP2/integrin/ILK/NF-kappaB network functions as a physiologically active signaling pathway in vivo by driving glioma progression"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22340785,"ILK mainly expressed in scar tissue with formation time shorter than 6 months, and it may affect scar vascularization by regulating gene expressions of KDR and Flt-1."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22310280,"demonstrate a requirement for ILK function in TGFbeta-1-induced EMT in mammary epithelial cells and identify the ILK/Rictor complex as a potential molecular target for preventing/reversing EMT"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,22194624,"Integrin-linked kinase regulates vasomotor function by preventing endothelial nitric oxide synthase uncoupling in atherosclerosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21941415,"Data show that targeting ILK with siRNA suppresses the growth of gastric cancer cells both in vitro and in vivo, suggesting that ILK plays an important role in gastric cancer progression."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21939655,"Wild type integrin-linked kinase (ILK) reversed the poor mobility of CREG knock-down HUVECs."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21928230,"Suggest that activation of ILK activated the Wnt/beta-catenin signaling pathway in damaged podocytes in focal segmental glomerulosclerosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21828040,"mda-9/syntenin, a positive regulator of cancer metastasis, regulates the activation of Akt (also known as protein kinase B) by facilitating ILK adaptor function during adhesion to type I collagen (COL-I) in human breast cancer cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21778429,"A molecular pathway links integrin-linked kinase signaling to the contractile vascular smooth muscle cell gene program."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21719054,"Integrin-linked kinase plays a role in tumorigenesis in neuroblastoma cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21688303,"results suggest that ILK gene transfection is an effective approach to augment angiogenic properties of EPCs in vitro and providing basis for clinical cell-based gene therapy in patients with pre-eclampsia"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21680733,"Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21643011,"the N-terminus of myopodin binds integrin-linked kinase (ILK) both in vivo and in vitro"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21639857,"In osteoblasts exposed to dexamethasone, ILK expression was slightly increased, whereas there was substantial reduction in that of beta1 integrin."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21621326,"Tbeta(4) increases migration of colon cancer cells via activating Rac1 by elevating IQGAP1/ILK complexes"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21601006,"ILK might be involved in the development of bladder cancer, and could serve as a novel potential therapy target for human bladder cancer"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21553049,"Knocking down ILK gene expression with siRNA inhibited the elevation of VEGF and ICAM-1 induced by high glucose treatment in retinal pigment epithelium cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21521694,"Streptococcus pyogenes M49 plasminogen/plasmin binding facilitates keratinocyte invasion via integrin-integrin-linked kinase (ILK) pathways and protects from macrophage killing"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21351095,"Our study suggests that ILK is overexpressed in invasive bladder cancer and plays an important role in the EMT of bladder cancer via the control of E-cadherin and MMP-9 expression."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21347395,"the clinical relevance of ILK in hepatocarcinogenesis"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21339732,"Cten expression is of prognostic significance in colorectal carcinoma, and delineate a Cten-ILK pathway controlling cell motility and possibly promoting metastasis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21278793,"analysis of the downstream targets of IL-6 signaling showed an increased activity of the signal transducer and activator of transcription 3 (STAT3) in ILK-overexpressing cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21234586,"ILK promoted proliferation and suppressed apoptosis via repressing phosphorylations of the JNK signal pathway in human retinoblastoma cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21196412,"This review will focus on recent advances made towards understanding the role of ILK signaling axis in progression of hormonal cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21177334,"Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21084641,"Integrin-linked kinase activity increased rapidly 5 min after strain induction in both human Caco-2 and rat intestinal epithelial cell-6 (IEC-6)cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,21035499,"Data show that N-cadherin expression in melanoma cells is dependent on integrin linked kinase signaling and the translocation of beta-catenin to the nucleus."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20857141,"These results suggest that ILK is involved in lung fibrosis in a tissue-specific manner"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20838384,"ILK regulates the expression of Her2/neu through TWIST and YB-1, lending support to the use of ILK inhibitors in the treatment of aggressive Her2/neu-positive tumors."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20838383,"Data show that ILK performs its centrosome clustering activity in a centrosome-dependent, manner through the microtubule regulating proteins TACC3 and ch-TOG."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20827300,"ILK is a bona fide protein kinase"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20725137,"Beta-arrestin-1 is involved in a distinct signalling mechanism linking the endothelin-1 /ET A receptor axis to phosphoinositide 3-kinase /integrin-linked kinase /Akt in HEY ovarian cancer cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20625942,"ILK protein was expressed in myeloma cell lines and kinase activity was elevated when cocultured with bone marrow stromal cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20546345,"ILK overexpression in basal cell carcinoma is implicated in tumour progression probably through the induction of an epithelial-mesenchymal transition-related molecular profile."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20495362,"Cancer cell lines in which ILK functioned as a growth suppressor displayed elevated JNK1 expression relative to cells in which ILK functioned as an oncogene."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20493167,"both SDF-1- and angiotensin II-triggered signaling ILK is a central mediator of rac1-induced oxidative stress and hypertrophy implicating ILK as a new therapeutic target for treatment of cardiac hypertrophy."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20460506,"ILK interaction with MCM7 and MCM7 phosphorylation may be a critical event in ITGA7 signaling pathway, leading to tumor suppression."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20305688,"ILK has a critical role in the initiation phase of ErbB2 tumor induction."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20232298,"Hypoxia enhances BMP-2 expression in osteoblasts by an HIF-1alpha-dependent mechanism involving the activation of ILK/Akt and mTOR pathways."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20164304,"Data from functional molecular imaging demonstrated that beta-parvin plays a regulatory role in the ILK-mediated Akt (also called protein kinase B) signaling cascades, suggesting that beta-parvin might be a crucial modulator of cell survival."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20113654,"integrin linked kinase might be involved in the process of renal glomerular histopathologic damage and the production of proteinuria in children with Henoch schonlein purpura nephritis (HSPN)."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20091050,"In 23 of 25 cases of ductal pancreatic adenocarcinoma, ILK expression showed extensive positivity (>50%), while two cases did not demonstrate any ILK staining."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,20005845,"The crystal structure of the ILK KD bound to its cytoskeletal regulator, the C-terminal calponin homology domain of alpha-parvin is presented."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19885839,"Integrin-linked kinase regulates migration and proliferation of human intestinal cells under a fibronectin-dependent mechanism."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19676046,"Results suggest that ILK1 might represent a novel and useful prognostic marker for astrocytoma and play a role during the development and progression of the disease."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19633364,"ILK mediated pressure-stimulated adhesion through regulating phosphorylation of AKT and FAK."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19567202,"Data show that vacA-deficient H. pylori appears to upregulate ILK expression, which modulates the expression of eNOS and as a result, stimulates the production of ROS."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19541809,"increased ILK activity mediates epithelial to mesenchymal transition and the progression of renal fibrosis"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19489119,"the Shigella flexneri effector OspE reinforces host cell adherence to the basement membrane by interacting with integrin-linked kinase"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19478459,"restoration of JNK1 in alveolar rhabdomyosarcoma reestablished a tumor-suppressive function for integrin-linked kinase"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19463178,"ILK-facilitated trophoblast syncytialization is dependent, at least in part, on ILK catalytic activity while hormonal differentiation appears dependent on both ILK-associated protein interactions and catalytic activity"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19409087,"ILK is inhibited by QLT0267, which, when combined with docetaxel, reduces P-AKT and alters F-actin architecture"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19334037,"Data demonstrated significantly upregulated integrin-linked kinase as a function of alphavbeta3 in two ovarian cancer cell lines, and proved co-localization at the surface of alphavbeta3-overexpressing adherent cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19153670,"integrin-linked kinase has roles in mitosis [review]"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19147542,"Fish oil inhibits ILK expression thereby inhibiting non-small cell lung carcinoma growth in a cell line."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19118218,"pneumococci exploit the vitronectin-alphavbeta3-integrin complex as a cellular receptor for invasion and this integrin-mediated internalization requires the cooperation between the host signalling molecules ILK, PI3K and Akt."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19118217,"EphA1 regulates cell morphology and motility through the ILK-RhoA-ROCK pathway."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19074270,"zincs are coordinated by PINCH1 LIM1, and suggests that conformational flexibility and twisting between the 2 zinc fingers within the LIM1 domain may be important for ILK binding."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,19020711,"ILK overexpression during liver oncogenesis and cirrhosis correlates with activation of Akt but not with other conventional ILK targets"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18823942,"These data extend current knowledge about the role of ILK in endothelial progenitor cells biology and implicate ILK as a therapeutic target in coronary artery disease."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18813944,"ILK expression may be implicated in human laryngeal carcinoma and its localization in the nucleus possibly proposes novel nuclear functions of this molecule"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18773488,"ILK silencing inhibited binding of PARP-1 to SIRE"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18727519,"The mRNA levels of integrin beta1 and ILK protein were significantly higher in laryngeal carcinoma than in the surrounding tissue and vocal cord polyps."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18660489,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18635968,"These studies demonstrate the importance for keratinocyte proliferation of ILK regulation through changes in its subcellular localization, and establish ILKAP and CRM1 as pivotal modulators of ILK subcellular distribution and activity in these cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18505933,"Elevated levels of ILK are associated with cellular differentiation in high turnover tissues but not generally with a malignant phenotype. ILK is not a general molecular target for cancer therapy but rather an indicator of differentiation."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18464290,"Both integrins, v3 and v5, are involved in the glioma cell radioresistance through the integrin-linked kinase (ILK) and the small GTPase RhoB, at least by regulating the radiation-induced mitotic cell death."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18327965,"25 ILK-interacting proteins were identified in immunoprecipitates, and when ILK is complexed with tubulin and RuvB-like 1, alpha-parvin and PINCH are not present, suggesting that ILK has the ability to form distinct protein complexes throughout the cell."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18283114,"These data demonstrate a critical and unexpected function for ILK in the organization of centrosomal protein complexes during mitotic spindle assembly and DNA segregation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18252715,"a new signaling connection from ILK to cofilin for dynamic actin polymerization during cell adhesion, depending on the activity of ILK-associated c-Src."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18214046,"ILK expression does not appear to have a role in predicting outcome in patients with resected Hepatocellular cancer"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18080083,"Regulation of cell-matrix contacts and beta-catenin signaling in vascular smooth muscle by integrin-linked kinase: implications for intimal thickening."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,18037995,"tPA induces LRP-1 tyrosine phosphorylation, which in turn facilitates the LRP-1-mediated recruitment of beta1 integrin and downstream ILK signaling, thereby leading to myofibroblast activation."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17951996,"ILK mediated the effect of epithelial to mesenchymal transition in proximal tubular epithelial cells stimulated by CTGF"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17656471,"PINCH-1, through its interaction with integrin-linked kinase, plays important role in regulating TGF-beta1-mediated epithelial-to-mesenchymal transition and could be potential future therapeutic target to prevent progression of renal disease."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17646580,"A mutation (785C>T [Ala262Val]) is associated with loss of endothelial cells & cardiac dysfunction. It negatively affects cardiac mechanosensation. ILK maintains embryonic cardiomyocyte shape and ventricle morphology."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17575101,"ILK knockdown decreased the invasion ability of melanoma cells and the formation of anchorage-independent colonies in soft agar"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17563721,"Occurrence of ILK expression with lens epithelial cells differentiation is consistent with positive regulatory function of ILK, revealed in a model of epithelial-mesenchymal transition in vitro."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17553790,"ILK may provide a linkage between kAE1 and the underlying actin cytoskeleton to stabilize kAE1 at the basolateral membrane, resulting in higher levels of cell surface expression"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17498677,"Connective tissue growth factor (CTFG) induces the expression of integrin-linked kinase (ILK) protein in HK-2 cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17468516,"PI3K/ILK/Akt/NF-kappaB axis is a promising target for therapeutic intervention in renal cell carcinoma."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17420447,"ILK is a substrate for p21-activated kinase 1 (PAK1); mutation of PAK1 phosphorylation sites on ILK to alanine reduces cell motility and cell proliferation."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17335036,"ILK transfection can support cell survival in the absence of matrix interactions and enable fundamental studies of three-dimensional cell function in response to extrinsic signals, independently of matrix-ligand interactions."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17298394,"findings show integrin-linked kinase activity is indispensable for streptococcal M1-induced paxillin recruitment and phosphorylation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17213807,"Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17187779,"This study suggests that ILK serves as a key mediator in TGFbeta1 regulation of uPA/PAI-1 system critical for the invasiveness of human ovarian cancer cells. And ILK is a potential target for cancer therapy."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17143519,"Identification of ILK as a player in hypoxia survival signaling employed by cancer cells further validates ILK as a unique target for cancer therapy."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,17107957,"R-Ras and ILK have roles upstream of GSK-3beta in the regulation of neuronal polarity"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16987993,"Cell adhesion and/or its related molecular basis regulate epigenetic mechanisms leading to a loss of ILK transcription, which in turn regulates cell adhesion property in a feedback linkage."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16951248,"Review highlights the role of integrin-linked kinase (ILK) as a novel component of the cardiac mechanical stretch sensor."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16836071,"ILK may participate in invasion and metastasis of laryngeal squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16818815,"Endogenous ILK is a novel and physiological upstream responder of numerous intracellular molecules involved in hypoxic stress in endothelial cellss and may control the recruitment of peogenitor cells to ischemic tissue."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16799642,"ILK activity can modulate acute Wnt3a mediated beta-catenin phosphorylation, stabilization and nuclear activation in a PI3K-independent manner."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16648553,"functions as a downstream mediator of the ET-1/ET(A)R axis to potentiate aggressive cellular behavior in ovarian cancer cells."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16611685,"ILK may act as a pro-survival factor and play a role in protecting mesangial cells from hyperglycaemic osmotic stress"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16421303,"ILK is a critical effector in a signaling pathway necessary for granule cell proliferation and cerebellar development."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,16407822,"Strong expression of ILK in cancerous tissues is involved with aggressive capability in pancreatic cancer."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15905178,"matrix-derived mechanical forces sensed by beta1 integrin are capable of modulating ILK activity which regulates fibroblast viability via an Akt-dependent mechanism"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15882985,"Dissociation of ILK from Hsp90 shortened its half-life by promoting proteasome-dependent degradation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15867245,"Finding suggests that therapies directed against ILK and its downstream signaling targets may have the potential to enhance the efficacy of gemcitabine-based chemotherapy."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15802621,"ILK overexpression protects vascular endothelium cells and progenitor cells from anchorage- or nutrient-deprived stress and enhances neovascularization"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15467740,"loss of ParvB expression is a novel mechanism for upregulating ILK activity in tumors"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15313908,"Data provide evidence that ILK signaling modulates the cellular radiation response involving diverse signaling pathways and through changes in f-actin-based processes such as focal adhesion formation, cell adhesion, and spreading."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15304053,"ILK regulates alpha 2 beta 1 in HEL cells, is activated in platelets and associates with beta 1-integrins"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15073119,"59 kDa immunoreactive integrin-linked kinase is upreguated in the blood and peritoneal fluid of ovarian cancer patients before, but not after chemotherapy"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,15044083,"Taken together, these data suggest that PI3K-ILK-Akt pathway that is independent of the TGFbeta-induced Smad pathway is required for TGFbeta-mediated epithelial to mesenchymal transition."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,14749128,"essential role of ILK in two key aspects of tumor angiogenesis: VEGF expression by tumor cells and VEGF-stimulated blood vessel formation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,14679308,"integrin-lined kinase plays an important role in vascular morphogenesis"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,14555513,"Increased expression of integrin-linked kinase is correlated with melanoma progression"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,14551191,"PINCH1 and ILK are essential for prompt cell spreading and motility; PINCH1 and ILK, like alpha-parvin, are crucial for cell survival; PINCH1 and ILK are required for optimal activating phosphorylation of PKB/Akt of the survival pathway"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12960424,"ILK kinase activity, or expression, results in the inhibition of cell attachment, cell migration, F-actin organization"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12925691,"ILK is a critical mediator for tubular EMT and likely plays a crucial role in the pathogenesis of chronic renal fibrosis"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12884912,"ILK has a role in oncogenic transformation and progression to invasive and metastatic phenotypes [review]"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12778079,"Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest and involve this enzyme in vitro."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12771992,"Overexpression of integrin-linked kinase is associated with sporadic human colon cancer"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12686550,"role in protein kinase B/Akt activation."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12654898,"Cells that are depleted of this enzyme undergo extensive apoptosis."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12642872,"role in alpha(v)integrin in regulating cell proliferation in ovarian cancer cells"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12432066,"Assembly of the PINCH-ILK-CH-ILKBP complex precedes and is essential for localization of each component to cell-matrix adhesion sites"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12372433,"the ILK-affixin complex has a role in integrin-cytoskeleton linkage during platelet aggregation"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12164932,"Ganglioside loss promotes survival primarily by activating integrin-linked kinase/Akt without phosphoinositide 3-OH kinase signaling."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12152651,"Integrin-linked kinase transiently associates with and phosphorylates beta3 in a PI3-kinase dependent manner"
https://pharos.nih.gov/idg/targets/Q13418,Q13418,12020426,"Ionizing radiation strongly induced the expression of functional beta1-integrin and ILK in the two lung cancer cell lines, A549 and SKMES1."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,11931630,"Integrin-linked kinase phosphorylates the myosin phosphatase target subunit at the inhibitory site in platelet cytoskeleton."
https://pharos.nih.gov/idg/targets/Q13418,Q13418,11856758,"Role of integrin-linked kinase in leukocyte recruitment"
https://pharos.nih.gov/idg/targets/P53667,P53667,27665963,"Therefore, miR-138/LIMK1/cofilin may be considered a potential therapeutic target for the treatment of non-small cell lung cancer"
https://pharos.nih.gov/idg/targets/P53667,P53667,27273096,"increased BMPR2 signal transduction is linked to fragile X syndrome (FXS) and that the BMPR2-LIMK1 pathway is a putative therapeutic target in patients with FXS and possibly other forms of autism"
https://pharos.nih.gov/idg/targets/P53667,P53667,27178114,"LIMK1 expression is negatively regulated in granular layers-negative psoriatic epidermis or IL-22/IL-24-treated hyperproliferative reconstituted epidermis. These findings suggest a novel regulatory mechanism and a potent role of LIMK1 in psoriatic epidermis."
https://pharos.nih.gov/idg/targets/P53667,P53667,27153537,"Report structural basis for noncanonical substrate recognition of cofilin-1/LIMK1 to regulation actin cytoskeleton dynamics."
https://pharos.nih.gov/idg/targets/P53667,P53667,27116935,"In turn, LIMK1 and LIMK2 are required for MT1-MMP-dependent matrix degradation and cell invasion in a three-dimensional type I collagen environment."
https://pharos.nih.gov/idg/targets/P53667,P53667,25981171,"This study showed that LIMK1 messenger RNA levels was significantly upregulated in subjects with schizophrenia in laminar and cellular samples."
https://pharos.nih.gov/idg/targets/P53667,P53667,25884247,"Gene knockdown/rescue experiments reveal that LIMK1 palmitoylation is essential for normal spine actin polymerization, for spine-specific structural plasticity and for long-term spine stability."
https://pharos.nih.gov/idg/targets/P53667,P53667,25661344,"LIMK1 is overexpressed in gastric cancer."
https://pharos.nih.gov/idg/targets/P53667,P53667,25529997,"LIMK1 is overexpressed in endometrial stromal cells."
https://pharos.nih.gov/idg/targets/P53667,P53667,25359780,"CXCL12/CXCR4 signaling has a role in docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIMK1"
https://pharos.nih.gov/idg/targets/P53667,P53667,25344584,"Results show that in addition to a potential role in promoting metastasis, changes in LIMK1 and LIMK2 expression and/or activity might contribute to AR function in prostate cancer via regulation of microtubule cytoskeletal dynamics."
https://pharos.nih.gov/idg/targets/P53667,P53667,25307528,"LIMK1 has a role in regulating human trophoblast invasion/differentiation and is down-regulated in preeclampsia"
https://pharos.nih.gov/idg/targets/P53667,P53667,25190487,"Data show that the downregulation of miR-138 induced the upregulation of Limk1 in ovarian cancer (OC) cells suggesting that these 2 genes may play a key role in the migration and invasion of OC cells."
https://pharos.nih.gov/idg/targets/P53667,P53667,25107909,"the functional relevance of the LRAP25-MRCK complex in LIMK1-cofilin signaling and the importance of LRAP adaptors as key determinants of MRCK cellular localization and downstream specificities."
https://pharos.nih.gov/idg/targets/P53667,P53667,25019203,"miR-20a is involved in the tumor inhibition of cutaneous squamous cell carcinoma by directly targeting LIMK1 gene."
https://pharos.nih.gov/idg/targets/P53667,P53667,24858712,"miR-20a plays a role as a tumor suppressor in thyroid cancer cells and targets LIMK1"
https://pharos.nih.gov/idg/targets/P53667,P53667,24778234,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,24696479,"ROCK1- and LIMK1-regulated phosphorylation of cofilin played a role in retrovirus release from host cells and in cell-cell transmission events."
https://pharos.nih.gov/idg/targets/P53667,P53667,24390089,"Ectopic expression of LIMK1 dramatically dampened mir-27b action of cancer inhibition."
https://pharos.nih.gov/idg/targets/P53667,P53667,24063279,"These results indicate that the overexpression of LIMK1 is tightly associated with an aggressive phenotype of lung cancer cells, knockdown of LIMK1 suppressed cell migration and invasion, enhanced chemosensitivity, suggesting a potential therapeutic target for lung cancer."
https://pharos.nih.gov/idg/targets/P53667,P53667,24039253,"Thus this study provides evidence for a novel role of LIMK1 and SSH-1L in selectively regulating endothelial cell inflammation associated with intravascular coagulation."
https://pharos.nih.gov/idg/targets/P53667,P53667,23702034,"DAPK functions as a scaffold for the LIMK/cofilin complex and triggers a closer interaction of both proteins under TNF stimulation."
https://pharos.nih.gov/idg/targets/P53667,P53667,23700283,"the conserved region in the LIMK1 3' UTR is involved in regulating LIMK1 expression at the post-transcriptional level"
https://pharos.nih.gov/idg/targets/P53667,P53667,23620575,"LIMK1 plays a novel role in selectively mediating GPIb-IX-dependent TXA2 synthesis and thrombosis."
https://pharos.nih.gov/idg/targets/P53667,P53667,23338717,"Overexpression of LIMK1 is associated with the development and progression of glioblastoma multiforme."
https://pharos.nih.gov/idg/targets/P53667,P53667,23294842,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,23239465,"Overexpression of LIMK1 is associated with breast cancer growth and invasiveness."
https://pharos.nih.gov/idg/targets/P53667,P53667,23167938,"The authors believe that the Williams-Beuren syndrome chromosome region can be a possible target for further investigation as the genetic basis of keratoconus."
https://pharos.nih.gov/idg/targets/P53667,P53667,23086941,"BDNF-induced TrkB dimerization led to LIMK1 dimerization and transphosphorylation independent of TrkB kinase activity, which could further enhance the activation and stabilization of LIMK1"
https://pharos.nih.gov/idg/targets/P53667,P53667,22906279,"LIMK1 is associated with the development of ovarian cancer and with the level of tumour differentiation in patients with ovarian carcinoma."
https://pharos.nih.gov/idg/targets/P53667,P53667,22883572,"A novel activity of Rho in promoting a complex between fascin-1 and LIMK1/2 that modulates the interaction of fascin-1 with actin, was identified."
https://pharos.nih.gov/idg/targets/P53667,P53667,22715593,"demonstrated that LIMK1, a key regulator of actin cytoskeleton, was overexpressed at both mRNA and protein levels in MG63/VCR cells and the higher LIMK1 protein level was correlated with higher level of phosphorylated cofilin"
https://pharos.nih.gov/idg/targets/P53667,P53667,22632162,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,22214762,"Aur-A physically associates with LIMK1 and activates it through phosphorylation, which is important for its centrosomal and spindle pole localization."
https://pharos.nih.gov/idg/targets/P53667,P53667,21923909,"Data describe the role of LIMK1-mediated CFL1 pathway and actin dynamics in retinoid receptor mediated function and show that LIMK1-mediated phosphocycling of CFL1 plays a role in maintaining actin homeostasis and receptor activity."
https://pharos.nih.gov/idg/targets/P53667,P53667,21923909,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,21868383,"LIMK1 has a dual role in regulating lamellipodium extension by decelerating actin retrograde flow and polymerization."
https://pharos.nih.gov/idg/targets/P53667,P53667,21682918,"LIMK1 activity in both the cytoplasmic and nuclear compartments promotes breast cancer progression."
https://pharos.nih.gov/idg/targets/P53667,P53667,21321123,"LIM kinase 1 modulates cortical actin and CXCR4 cycling and is activated by HIV-1 to initiate viral infection."
https://pharos.nih.gov/idg/targets/P53667,P53667,21321123,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,21228795,"evealed a SNP, rs6460071 located on LIMK1 gene (P = 0.00069) to be significantly associated with increased risk of intracranial aneurysm"
https://pharos.nih.gov/idg/targets/P53667,P53667,21219645,"LIM kinase1 modulates function of membrane type matrix metalloproteinase 1 in prostate cancer cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,20873970,"Changes in the expression of cytoskeletal regulatory proteins such as LIMK and cofilin may play a role in weakening thoracic aortic medial tissue, as a precondition to thoracic aortic dissection."
https://pharos.nih.gov/idg/targets/P53667,P53667,20694560,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,20622363,"High LIMK1 is associated with cervical cancer dysplasia."
https://pharos.nih.gov/idg/targets/P53667,P53667,20347121,"FXa induced myosin light chain phosphorylation and LIMK1 activation resulting in cofilin inactivation"
https://pharos.nih.gov/idg/targets/P53667,P53667,20100465,"LIMK1 mediates both the mesenchymal and amoeboid modes of invasion of HT1080 cells."
https://pharos.nih.gov/idg/targets/P53667,P53667,20061392,"phosphorylation of annexin 1 regulates the angiogenic effect that is associated with the activation of the p38/LIM kinase 1 axis by VEGF"
https://pharos.nih.gov/idg/targets/P53667,P53667,20047470,"Both LIMK1 and LIMK2 single knock down led to a reduction of invasion and metastatic behavior in the zebrafish xenograft metastasis assay."
https://pharos.nih.gov/idg/targets/P53667,P53667,20041213,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,19778628,"DGCR6L, a novel PAK4 interacting protein, regulated PAK4-mediated migration of human gastric cancer cells via LIMK1."
https://pharos.nih.gov/idg/targets/P53667,P53667,19734939,"the p57(Kip2) control of LIMK-1 ultimately affects cell mobility negatively."
https://pharos.nih.gov/idg/targets/P53667,P53667,19662944,"findings indicate that spatial deficits associated with Williams Syndrome also affect large-scale spatial processing and suggest that hemizygous deletion of LIMK1 is not sufficient to account for any of the spatial deficits associated with this syndrome."
https://pharos.nih.gov/idg/targets/P53667,P53667,19056482,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,18978953,"LIMK1 may mediate TGF-beta-dependent signaling during ocular inflammation."
https://pharos.nih.gov/idg/targets/P53667,P53667,18566305,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,18424072,"These results support a model whereby hepatocyte growth factor-stimulated cell migration also requires a cofilin phosphorylation step that is mediated by PAK4."
https://pharos.nih.gov/idg/targets/P53667,P53667,18096821,"PDGF participates in actin dynamics by dual regulation of cofilin activity via LIMK and SSH1L in aortic smooth muscle cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,18079118,"LIMK1-mediated cofilin phosphorylation is required for accurate spindle orientation by stabilizing cortical actin networks during mitosis."
https://pharos.nih.gov/idg/targets/P53667,P53667,18028908,"LIMK1 phosphorylation of p25 blocks p25 activity, thus promoting microtubule disassembly."
https://pharos.nih.gov/idg/targets/P53667,P53667,18000399,"gamma-tubulin associates with phosphorylated LIMK1 and LIMK2 but not with dephosphorylated LIMK1 or LIMK2."
https://pharos.nih.gov/idg/targets/P53667,P53667,17572668,"CCR5 expression inhibits HIV-1 gp120-induced LIMK1 activation and cofilin phosphorylation in CD4/CXCR4 expressing 293T cells"
https://pharos.nih.gov/idg/targets/P53667,P53667,17512523,"These findings demonstrate a cell-type dependent functional interaction between parkin and LIMK1 and provide new evidence that links parkin and LIMK1 in the pathogenesis of familial PD."
https://pharos.nih.gov/idg/targets/P53667,P53667,17294230,"the structure, regulation and function; possible contributions to human disease (Review)"
https://pharos.nih.gov/idg/targets/P53667,P53667,17287949,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,16763828,"Taken together, our novel findings presented in this paper implicate that LIMK1 signaling indeed plays a pivotal role in the regulation of EGFR trafficking through the endocytic pathway in invasive tumor cells."
https://pharos.nih.gov/idg/targets/P53667,P53667,16611674,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P53667,P53667,16611674,"Elastin and LIMK1 SNPs effect in the at-risk haplotype possibly by weakening the vascular wall and promoting the development of IA"
https://pharos.nih.gov/idg/targets/P53667,P53667,16455074,"LIMK1 may play a role different from that of LIMK2 in regulating mitotic spindle organization, chromosome segregation, and cytokinesis during the cell division cycle."
https://pharos.nih.gov/idg/targets/P53667,P53667,16381000,"results suggested an important role for LIMK1 signaling in breast cancer tumor growth, angiogenesis and invasion and a regulatory connection between LIMK1 and the uPA system"
https://pharos.nih.gov/idg/targets/P53667,P53667,16204183,"Rnf6 controls cellular LIMK1 concentrations and indicate a new function for the ubiquitin/proteasome system in regulating local growth cone actin dynamics"
https://pharos.nih.gov/idg/targets/P53667,P53667,15897190,"LIMK1 activity is required for thrombin-induced modulation of microtubule destabilization and actin polymerization"
https://pharos.nih.gov/idg/targets/P53667,P53667,15660133,"a multi-protein complex consisting of SSH-1L, LIMK1, actin, and the scaffolding protein, 14-3-3zeta, is involved, along with the kinase, PAK4, in the regulation of ADF/cofilin activity"
https://pharos.nih.gov/idg/targets/P53667,P53667,15220930,"LATS1 is a novel cytoskeleton regulator that affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1."
https://pharos.nih.gov/idg/targets/P53667,P53667,15189451,"LIMK1 is cleaved and activated during antiFas antibody-induced apoptosis.  Expression of an N-terminally truncated LMK1 fragment induced membrane blebbing."
https://pharos.nih.gov/idg/targets/P53667,P53667,15023529,"LIMK1 is enriched in both axonal and dendritic growth cones of E18 hippocampal pyramidal neurons where it is found in punctae that extend far out into filopodia, as well as in a perinuclear region identified as Golgi."
https://pharos.nih.gov/idg/targets/P53667,P53667,14530263,"LIM-kinase 1 is translocated to the nucleus after being bound by p57kip2"
https://pharos.nih.gov/idg/targets/P53667,P53667,12821664,"LIMK1 has a role in regulating cell division and invasive property of prostate cancer cells; the effect is not mediated by phosphorylation of cofilin"
https://pharos.nih.gov/idg/targets/P53667,P53667,12777619,"LIM kinase 1 (LIMK1), a critical regulator of actin dynamics, plays a regulatory role in tumor cell invasion."
https://pharos.nih.gov/idg/targets/P53667,P53667,12323073,"identification as interaction partner of 14-3-3 zeta"
https://pharos.nih.gov/idg/targets/P53667,P53667,11925442,"Mitosis-specific activation of LIM motif-containing protein kinase and roles of cofilin phosphorylation and dephosphorylation in mitosis."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,28003362,"These results suggest that Rap1 activation of ERKs requires PKA phosphorylation and KSR binding."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,27195677,"praja2 regulates KSR1 stability and mitogenic signaling."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,26673620,"Upregulation of KSR1 is associated with Colorectal cancer."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,26549023,"Data show that neurofibromin 2 (Merlin) suppresses proliferation and adhesion, at least partly, through inhibiting kinase suppressor of Ras 1 (KSR1) and DCAF1 protein."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,25962735,"the relative mRNA copy values of KSR1, ERK1 and ERK2 in the cancer tissues were 2.43 +/- 0.49, 2.10 +/- 0.44 and 3.65 +/- 0.94..EGb 761 enhanced the chemotherapy sensitivity through suppression of the KSR1-mediated ERK1/2 pathway in gastric cancer"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,25608512,"KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in papillary thyroid cancer."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,25287073,"KSR1 rs2241906 variants may predict survival in patients with advanced ERalpha+ BC treated with adjuvant TAM."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,25002533,"Data show that caveolin-1 is necessary for optimal KSR1-dependent ERK activation by growth factors and oncogenic Ras."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,24909178,"KSR1 stabilizes BRCA1 by reducing BRCA1 ubiquitination, inhibits tumor growth through BRCA1, and regulates BRCA1 stability via elevated BARD1 abundance and increased BRCA1-BARD1 interaction"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,24129246,"Our findings integrate KSR1 into a network involving DBC1 and SIRT1, which results in the regulation of p53 acetylation and its transcriptional activity."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,24095280,"Data indicate that phosphorylation of BRAF by AMPK disrupts its association with KSR1."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,23416464,"Elevated levels of phosphorylated KSR were detected in the nuclear fractions."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,23250398,"the atypical C1 domain, the CC-SAM domain is required to target KSR-1 to the plasma membrane."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,22752157,"VRK2A can form a high molecular size complex with both MEK1 and KSR1; the KSR1 complex assembled and retained by VRK2A in the endoplasmic reticulum can have a modulatory effect on the signal mediated by MAPK,locally affecting the magnitude of its responses"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,21829671,"simulations constitute a multi-dimensional exploration of how EGF-dependent EGFR endocytosis and ERK activation are dynamically affected by scaffolds KSR and MP1, co-regulated by Cbl-CIN85 and Endophilin A1"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,21555152,"Genetic disruption of the scaffolding protein, Kinase Suppressor of Ras 1 (KSR1), differentially regulates GM-CSF-stimulated hyperproliferation in hematopoietic progenitors expressing activating PTPN11 mutants D61Y and E76K."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,21435442,"KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,20945381,"Oncoprotein Cot1 represses kinase suppressors of Ras1/2 and 1,25-dihydroxyvitamin D3-induced differentiation of human acute myeloid leukemia cells."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,19718030,"DC-SIGN was constitutively associated with a signalosome complex consisting of the scaffold proteins LSP1, KSR1 and CNK and the kinase Raf-1."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,19188442,"KSR1 regulated the threshold required for MAPK activation in T cells without affecting the nature of the response."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,18719367,"Down-regulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,18426801,"human 14-3-3gamma binds to the ERK1/2 molecular scaffold KSR1, which is mediated by the C-terminal stretch of 14-3-3gamma"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,18332145,"Human KSR1 proteins promote assembly of multivalent Raf.MEK complexes that are required for c-Raf kinase activation and functional coupling of active kinases to downstream substrates."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,16732322,"1,25D selectively increases the expression of the gene encoding kinase suppressor of Ras-1 (KSR-1) in HL60 cells"
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,15899786,"KSR1-mediated regulation of ERK activity represents a novel determinant of CDDP sensitivity of cancer cells."
https://pharos.nih.gov/idg/targets/Q8IVT5,Q8IVT5,15520853,"KSR1 kinase activity is essential for anti-apoptotic protection of the intestinal epithelium [review]"
https://pharos.nih.gov/idg/targets/P51617,P51617,28882891,"These results suggest that the IRAK1-binding protein OPTN negatively regulates IL-1beta/LPS-induced NF-kappaB activation by preventing polyubiquitination of TRAF6."
https://pharos.nih.gov/idg/targets/P51617,P51617,28512203,"Data suggest that, in monocytes and macrophages, the interleukin-1B- (IL1B)-stimulated trans-autophosphorylation of IRAK4 (interleukin-1 receptor-associated kinase 4) is initiated by MYD88- (myeloid differentiation primary response gene 88)-induced dimerization of IRAK4. In contrast, IRAK1 is inactive in unstimulated monocytes/macrophages and is converted to an active protein kinase in response to IL1B."
https://pharos.nih.gov/idg/targets/P51617,P51617,28271077,"the Xq28 region containing TMEM187 and IRAK1 (rs13397, rs1059703, and rs1059702) with rheumatoid arthritis (RA)susceptibility; results replicated association of the 3 Xq28 polymorphisms with RA risk in Tunisian and French populations and suggested that RA susceptibility is associated with TMEM187-IRAK1 polymorphisms in women"
https://pharos.nih.gov/idg/targets/P51617,P51617,28207326,"The IRAK1 rs3027898 was not associated with RA, whereas C allele of miR-146a rs2910164 was found to be protective."
https://pharos.nih.gov/idg/targets/P51617,P51617,27790836,"Data indicate the complexity of interactions between Pin1 and activated IRAK1, suggesting that phosphorylation of neighboring Ser/Thr-Pro motifs in proteins might provide competitive advantage at cellular concentrations for engaging with Pin1."
https://pharos.nih.gov/idg/targets/P51617,P51617,27619757,"Study shows that IRAK1 was over-expressed in human hepatocellular carcinoma (HCC) tumor tissues and provides evidence that IRAK1 promotes cell proliferation and protects against apoptosis in HCC."
https://pharos.nih.gov/idg/targets/P51617,P51617,27533309,"IRAK1 is a direct target of miR-146b and has functional roles to inhibit various aggressive papillary thyroid carcinoma cell activities."
https://pharos.nih.gov/idg/targets/P51617,P51617,27497395,"IRAK1 expression was not significantly increased in tympanic membrane of otitis media patients."
https://pharos.nih.gov/idg/targets/P51617,P51617,27454822,"High IRAK1 expression is associated with multiple myeloma."
https://pharos.nih.gov/idg/targets/P51617,P51617,27338330,"our data strongly suggest that AQCA-mediated suppression of inflammatory responses could be managed by a direct interference of signaling cascades including IRAK and Syk, linked to the activation of NF-kappaB and AP-1."
https://pharos.nih.gov/idg/targets/P51617,P51617,27270491,"IRAK1 regulates lipid accumulation by modulating CD36-mediated uptake and ABCA1-, ABCG1-dependent cholesterol efflux."
https://pharos.nih.gov/idg/targets/P51617,P51617,26527316,"Our findings reveal that IRAK1 promotes cell survival and is an attractive therapeutic target in head and neck squamous cell carcinomas"
https://pharos.nih.gov/idg/targets/P51617,P51617,26503059,"IRAK1 overexpression drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment in breast cancer."
https://pharos.nih.gov/idg/targets/P51617,P51617,26320741,"TLR4- and TLR2-induced IRAK-ERK pathway cross-talks with p67phox-Nox-2 for reactive oxygen species generation, thus regulating IL-1beta transcription and processing in monocytic cells."
https://pharos.nih.gov/idg/targets/P51617,P51617,26151128,"miR146a has an important promoting effect on the apoptosis of granulosa cells by targeting IRAK1 and TRAF6 via the caspase cascade pathway"
https://pharos.nih.gov/idg/targets/P51617,P51617,26142671,"These data demonstrated that these three single nucleotide polymorphisms (rs3027898, rs1059702, rs1059703) in IRAK1 were associated with autoimmune diseases risk."
https://pharos.nih.gov/idg/targets/P51617,P51617,26075815,"This is the first study to show an association between single nucleotide polymorphisms in IRAK1, IRAK4 and MyD88, and the presence of severe invasive pneumococcal disease."
https://pharos.nih.gov/idg/targets/P51617,P51617,25955717,"Data suggest that TLR2 (toll like receptor 2) is down-regulated by microRNA-UL112-3p from human Cytomegalovirus; microRNA-UL112-3p also down-regulates TLR2-induced post-translational activation of IRAK1 signaling."
https://pharos.nih.gov/idg/targets/P51617,P51617,25922567,"Src, Syk, IRAK1, and IRAK4 have roles in anti-inflammatory responses mediated by dietary flavonoid Kaempferol"
https://pharos.nih.gov/idg/targets/P51617,P51617,25550857,"expression of IRAK1 in lung cancer was significantly higher compared with that in normal lung tissues and was correlated with TNM stage, lymphatic metastasis and tumor size."
https://pharos.nih.gov/idg/targets/P51617,P51617,25505246,"MicroRNA-146a and microRNA-146b regulate human dendritic cell apoptosis and cytokine production by targeting TRAF6 and IRAK1 proteins."
https://pharos.nih.gov/idg/targets/P51617,P51617,25472883,"HIV-1 Tat specifically associates with IRAK1 promoter to downregulate IRAK1 expression in T cells"
https://pharos.nih.gov/idg/targets/P51617,P51617,25458699,"results firstly indicated that IRAK1 and MECP2 genes are crucial risk factors for AITDs."
https://pharos.nih.gov/idg/targets/P51617,P51617,25341731,"IRAK1 was constitutively phosphorylated in PEL and required for survival, implicating IRAK1 and TLR signaling as a driver pathway in PEL"
https://pharos.nih.gov/idg/targets/P51617,P51617,25294684,"IL-1beta stimulation causes sequential phosphorylation of IRAK-1, c-Jun N-terminal kinase, and p300 and enhances recruitment of the p300/CBP/NF-Y complex to Gankyrin promoter"
https://pharos.nih.gov/idg/targets/P51617,P51617,25269878,"This meta-analysis suggests that the miR-499 rs374644 and IRAKI rs3027898 polymorphisms are associated with susceptibility to inflammatory arthritis. [review]"
https://pharos.nih.gov/idg/targets/P51617,P51617,25203887,"The IRAK1 polymorphism is a strong independent predictor of multiple organ failure and mortality postinjury and represents a common variant with prognostic potential."
https://pharos.nih.gov/idg/targets/P51617,P51617,24857403,"A direct interaction between IRAK1 and vasodilator-stimulated phosphoprotein (VASP) is regulated in part by assembly of IRAK1."
https://pharos.nih.gov/idg/targets/P51617,P51617,24709033,"IRAK1 rs1059702 genetic variant do not play a significant role in giant cell arteritis susceptibility or severity."
https://pharos.nih.gov/idg/targets/P51617,P51617,24690905,"High mRNA levels of IRAK1 and IRAK4 correlated with VKH disease activity."
https://pharos.nih.gov/idg/targets/P51617,P51617,24469975,"Data indicate that acetyl-11-keto-beta-boswellic acid (AKBA) is able to decrease Th17 differentiation by inhibition of IL-1beta signaling via reduction of IL-1 receptor-associated kinase 1 (IRAK1) phosphorylation."
https://pharos.nih.gov/idg/targets/P51617,P51617,24302991,"miR-146a enhances the oncogenicity of oral carcinoma by concomitant targeting of the IRAK1, TRAF6 and NUMB genes."
https://pharos.nih.gov/idg/targets/P51617,P51617,23867959,"Female very low birth weight infants heterozygous for the X-linked IRAK1 (rs1059703) SNP had lessgram negative bacterial infections."
https://pharos.nih.gov/idg/targets/P51617,P51617,23794009,"Significantly lower levels of IRAK-1 was found in CAD patients with the CC genotype."
https://pharos.nih.gov/idg/targets/P51617,P51617,23633945,"results indicate that miR-21 is upregulated during hepatitis C virus infection and negatively regulates IFN-alpha signaling through MyD88 and IRAK1"
https://pharos.nih.gov/idg/targets/P51617,P51617,23444193,"The data suggest the existence of two independent signals within the Xq28 region, one in IRAK1 related to pulmonary fibrosis and another in MECP2 related to diffuse cutaneous systemic sclerosis."
https://pharos.nih.gov/idg/targets/P51617,P51617,23435933,"The polymorphisms rs3027898 and rs1059702 of IRAK1 gene are associated with systemic lupus erythematosus in the Chinese Han population."
https://pharos.nih.gov/idg/targets/P51617,P51617,23428850,"Data suggest that the lupus-associated variant in the MECP2/IRAK1 locus has the potential to affect all 3 epigenetic mechanisms: DNA methylation, microRNA expression, and histone modification."
https://pharos.nih.gov/idg/targets/P51617,P51617,23396947,"IRAK1 regulates interferon (IFN)-beta and proinflammatory cytokine production downstream of Toll-like receptor (TLR)3."
https://pharos.nih.gov/idg/targets/P51617,P51617,23383610,"IRAK1, CHEK1 and BUB1 are overexpressed in, and may play an important role in ovarian cancer."
https://pharos.nih.gov/idg/targets/P51617,P51617,23233309,"Single nucleotide polymorphisms encoding for pPhe196Ser and pSer532Leu confers enhanced IRAK1 activity and, consequently, enhanced susceptibility to rheumatoid arthritis, as compared to the minor haplotype."
https://pharos.nih.gov/idg/targets/P51617,P51617,23041547,"Evaluates the effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4 in melanoma cells where their functions are largely unexplored."
https://pharos.nih.gov/idg/targets/P51617,P51617,23018031,"expression of miR-146a was up-regulated both in lesions and PBMCs of psoriatic patients, and positively correlated with IL-17 expression, whereas the target gene IRAK1 expression was expressed differentially in lesions and peripheral blood."
https://pharos.nih.gov/idg/targets/P51617,P51617,22904263,"These data suggest contributions of both IRAK1 and MECP2 to systemic lupus erythematosus susceptibility."
https://pharos.nih.gov/idg/targets/P51617,P51617,22896623,"Reanalysis of the array data set identified myeloid differentiation primary response protein 88 (MYD88) in addition to IRAK1 as a potential target of Kaposi's sarcoma-associated herpesvirus microRNAs."
https://pharos.nih.gov/idg/targets/P51617,P51617,22851693,"Knockdown of beta-TrCP1 and beta-TrCP2 attenuated the K48-linked ubiquitination and degradation of IRAK1."
https://pharos.nih.gov/idg/targets/P51617,P51617,22759955,"IRAK1 plays an important role in TNF-alpha-induced nulcear factor kappa B activation in human bone marrow mesenchymal stem cells."
https://pharos.nih.gov/idg/targets/P51617,P51617,22451023,"functional SNP IRAK1 rs3027898 C/A variant allele is associated with the development of rheumatoid arthritis."
https://pharos.nih.gov/idg/targets/P51617,P51617,22059479,"investigation of signaling components that induce activation of post-transcriptional mechanism for IkappaB-zeta induction/activation: Activation of IRAK1 or IRAK4, but not TRAF6, is sufficient."
https://pharos.nih.gov/idg/targets/P51617,P51617,22033459,"Results indicate that stimulation of TLRs induces proteasome-dependent downregulation of TRAF6, and that TRAF6 associated with ubiquitinated IRAK-1 is degraded together by the proteasome."
https://pharos.nih.gov/idg/targets/P51617,P51617,22033216,"decreased expression in the peripheral mononuclear cells of patients with Sjogren's syndrome"
https://pharos.nih.gov/idg/targets/P51617,P51617,21933552,"The functional polymorphism in exon 5 and the variant haplotype of IRAK1 gene mediate susceptibility to and severity of sepsis. IRAK1 might be a genetic risk factor for the occurrence and development of sepsis in the Chinese population."
https://pharos.nih.gov/idg/targets/P51617,P51617,21898345,"There is an association between IRAK1 and systemic sclerosis (SSc), demonstrating that a sex chromosome gene directly influences SSc susceptibility and its phenotypic heterogeneity."
https://pharos.nih.gov/idg/targets/P51617,P51617,21804018,"the results obtained demonstrate for the first time that IRAK1 and PKCdelta functionally interact to regulate IL-1beta production in monocytic cells"
https://pharos.nih.gov/idg/targets/P51617,P51617,21708940,"NSMase-2- and PP2A-dependent regulation of IRAK-1 degradation is a novel mechanism to fine tune the magnitude of IL-1beta response."
https://pharos.nih.gov/idg/targets/P51617,P51617,21640790,"Up-regulated miRNA-146a targets several inflammation-related mRNAs, including those encoding complement factor-H (CFH) and interleukin-1 receptor associated kinase-1 (IRAK-1), resulting in significant decreases in their expression."
https://pharos.nih.gov/idg/targets/P51617,P51617,21537341,"These results indicate a crucial role for IRAK-1 in bacterial lipoprotein -induced tolerance, and suggest IRAK-1 as a potential target for manipulation of the TLR-mediated inflammatory response during microbial sepsis."
https://pharos.nih.gov/idg/targets/P51617,P51617,21220427,"LPS-induced activation of IRAK4 and TAK1, K63-linked polyubiquitination of IRAK1 and TRAF6, and disrupted IRAK1-TRAF6 and IRAK1-IKKgamma assembly associated with increased A20 expression"
https://pharos.nih.gov/idg/targets/P51617,P51617,21160042,"Although IRAK4 kinase activity is essential for human plasmacytoid dendritic cell activation, it is dispensable in B, T, dendritic, and monocytic cells, which is in contrast with an essential active kinase role in comparable mouse cell types."
https://pharos.nih.gov/idg/targets/P51617,P51617,20937840,"analysis of differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kappaB in stressed human astroglial cells and in Alzheimer disease"
https://pharos.nih.gov/idg/targets/P51617,P51617,20890200,"IRAK1 variant haplotype is associated with prolonged ventilation in septic shock."
https://pharos.nih.gov/idg/targets/P51617,P51617,20890200,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20870441,"Significant difference was observed in the distribution of IRAK1 rs3027898 genotypes between rheumatoid arthritis patients and controls."
https://pharos.nih.gov/idg/targets/P51617,P51617,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20619458,"Leptin increases the expression of IRAK-1 in human monocytes."
https://pharos.nih.gov/idg/targets/P51617,P51617,20542134,"In conclusion, Helicobacter pylori-induced miR-146a plays a potential role in a negative feedback loop to modulate the inflammation by targeting IRAK1 and TRAF6."
https://pharos.nih.gov/idg/targets/P51617,P51617,20500689,"Marginally significant difference was observed in distribution of IRAK1 rs1059703 genotypes between patients with psoriatic arthritis and controls (P = 0.058), but no difference was observed in miRNA-146a rs2910164 distribution (P = 0.394)."
https://pharos.nih.gov/idg/targets/P51617,P51617,20500689,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20463618,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20448286,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20400509,"Mal is a substrate for IRAK1 and IRAK4 with phosphorylation promoting ubiquitination and degradation of Mal, which may serve to negatively regulate signaling by TLR2 and TLR4"
https://pharos.nih.gov/idg/targets/P51617,P51617,20092701,"Reduced IRAK-1 protein expression is an important mechanism in the development of bacterial lipoprotein-induced tolerance."
https://pharos.nih.gov/idg/targets/P51617,P51617,20056178,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,20044140,"IRAK-1 forms a close complex with PKCepsilon as well as VASP, and participates in phorbol 12-myristate 13-acetate-induced phosphorylation of VASP."
https://pharos.nih.gov/idg/targets/P51617,P51617,19948975,"Observational study of gene-disease association, gene-gene interaction, gene-environment interaction, and genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19838195,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19716405,"DSCR1-1S isoform positively modulates IL-1R-mediated signaling pathways by regulating Tollip/IRAK-1/TRAF6 complex formation."
https://pharos.nih.gov/idg/targets/P51617,P51617,19505919,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19329491,"forward genetic studies in human systemic lupus erythematosus and the mechanistic studies in mouse models establish IRAK1 as a disease gene in lupus, capable of modulating at least 2 key checkpoints in disease development"
https://pharos.nih.gov/idg/targets/P51617,P51617,19329491,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19288030,"Results suggest that ALOX5AP, IRAK1, and FABP2 are susceptibility loci for CKD among Japanese individuals with type 2 diabetes mellitus."
https://pharos.nih.gov/idg/targets/P51617,P51617,19282863,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,19264973,"multiple SNP associations were replicated in both IRAK-3 and ORMDL3, these likely reflect a single disease susceptibility locus in each gene"
https://pharos.nih.gov/idg/targets/P51617,P51617,19181383,"In human cells the non-kinase functions of IRAK-4 are essential, whereas the kinase activity of IRAK-4 appears redundant with that of IRAK-1."
https://pharos.nih.gov/idg/targets/P51617,P51617,19166933,"Over-expression of interleukin-1 receptor-associated kinase-1 led to increased constitutive and cytokine induced production of Chemokines, CC."
https://pharos.nih.gov/idg/targets/P51617,P51617,19166926,"Interleukin-1 Receptor-Associated Kinase is held in a closed, inactive conformation via an intramolecular mechanism involving its C-terminal domain and possibly the death domain."
https://pharos.nih.gov/idg/targets/P51617,P51617,19104650,"Leishmania can exploit a host protein tyrosine phosphatase, namely SHP-1, to directly inactivate IRAK-1."
https://pharos.nih.gov/idg/targets/P51617,P51617,19025640,"TLR-ligands can render DCs tolerant with respect to TNF gene expression by a mechanism that likely involves blockade of signal transduction at the level of IRAK-1."
https://pharos.nih.gov/idg/targets/P51617,P51617,18987746,"Significant & strong 2- & 3-locus interactions between SNPs in TOLLIP (rs4963060), TLR4 (rs6478317) & IRAK1 (rs1059703)were associated with the response to whole-cell vaccine pertussis vaccination in 490 1-yr-old children."
https://pharos.nih.gov/idg/targets/P51617,P51617,18987746,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,18566305,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,18474871,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,18411265,"signals from the IL-1 receptor segregate into at least two separate pathways at the level of IRAK1; one couples through TRAF6 to NFkappaB activation while a second utilizes a TRAF6-independent pathway that is responsible for mRNA stabilization"
https://pharos.nih.gov/idg/targets/P51617,P51617,18347055,"The sites of IRAK-1 ubiquitination were mapped to Lys134 and Lys180, and arginine substitution of these residues impaired IL-1R/TLR-mediated IRAK-1 ubiquitination."
https://pharos.nih.gov/idg/targets/P51617,P51617,18276832,"Both cytosolic and nuclear actions of IRAK-1 participate in the activation of NF-kappaB-dependent transcriptional events."
https://pharos.nih.gov/idg/targets/P51617,P51617,18079163,"These results suggested that the expression of IRAK-4 alone is sufficient to cause the degradation of IRAK-1; the autophosphorylation of IRAK-1 is not necessary to terminate the TLR-induced activation of NF-kappaB."
https://pharos.nih.gov/idg/targets/P51617,P51617,18070982,"TRAF6 is involved but with different mechanisms of IRAK-1-induced activation of NF-kappaB."
https://pharos.nih.gov/idg/targets/P51617,P51617,18050247,"SELP and IRAK1 were identified as novel SLE-associated genes with a high degree of significance, suggesting new directions in understanding the pathogenesis of systemic lupus erythematosus."
https://pharos.nih.gov/idg/targets/P51617,P51617,17997719,"Pellino isoforms may be the E3 ubiquitin ligases that mediate the IL-1-stimulated formation of K63-pUb-IRAK1 in cells, which may contribute to activation of IKKbeta and transcription factor NF-kappaB, as well as signalling pathways dependent on IRAK1/4"
https://pharos.nih.gov/idg/targets/P51617,P51617,17920759,"Constitutive association of MyD88 with IRAK1 was observed in all three of HTLV-I-transformed T cells, but not in HTLV-I-negative T cells"
https://pharos.nih.gov/idg/targets/P51617,P51617,17905570,"MyD88, IRAK1 and TRAF6 proteins are crucial early mediators for the IL-1-induced MMP-13 regulation through MAPK pathways and AP-1 activity."
https://pharos.nih.gov/idg/targets/P51617,P51617,17878161,"IRAK-2 plays a more central role than IRAK-1 in TLR signaling to NFkappaB through TRAF6 ubiquitination"
https://pharos.nih.gov/idg/targets/P51617,P51617,17785851,"Variant IRAK-1 is associated with alterations in multiple intracellular events that are likely to contribute to increased NF-kappa B activation and inflammatory responses in individuals with this commonly occurring IRAK-1 variant haplotype."
https://pharos.nih.gov/idg/targets/P51617,P51617,17675297,"kinase-inactive IRAK proteins can associate with Pellino proteins, thus excluding the possibility that their inability to regulate Pellino degradation is due to lack of association with the Pellino proteins"
https://pharos.nih.gov/idg/targets/P51617,P51617,17548806,"ST2825 interfered with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1beta-mediated activation of NF-kappaB transcriptional activity."
https://pharos.nih.gov/idg/targets/P51617,P51617,17382928,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,17382928,"variation in the IRAK1 gene is associated with C-reactive protein concentration in Caucasian women in the Diabetes Heart Study"
https://pharos.nih.gov/idg/targets/P51617,P51617,17276401,"Death domain of IRAK-1 is a multimerization domain which mediates association towards MyD88, Tollip, Irak-4 & Irak-1."
https://pharos.nih.gov/idg/targets/P51617,P51617,17053167,"ozLDL inhibited NF-kappaB and IRAK-1-associated signaling which may impair immune function and promote apoptosis"
https://pharos.nih.gov/idg/targets/P51617,P51617,16907704,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,16831874,"Data show that IRAK-1 acts as the essential upstream adaptor that recruits BCL10 to the TLR4 signaling complex and mediates signaling to NF-kappaB through the BCL10-MALT1-TRAF6-TAK1 cascade."
https://pharos.nih.gov/idg/targets/P51617,P51617,16537705,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,16528020,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,16477006,"The critical IRAK1 role in LMP1-induced NF-kappaB activation is in mediating p65/RelA S536 phosphorylation through an effect on p38 or other p65 S536 kinases."
https://pharos.nih.gov/idg/targets/P51617,P51617,16203735,"Monarch-1 associates with IRAK-1 but not MyD88, resulting in the blockage of IRAK-1 hyperphosphorylation"
https://pharos.nih.gov/idg/targets/P51617,P51617,16107720,"following stimulation by exogenous CD26, Tollip and IRAK-1 dissociate from caveolin-1, and IRAK-1 is then phosphorylated in the cytosol, leading to the upregulation of CD86 via activation of NF-kappaB"
https://pharos.nih.gov/idg/targets/P51617,P51617,16024789,"Presence of a regulated, alternative splice variant of IRAK1 that functions as a kinase-dead, dominant-negative protein adds further complexity to the variety of mechanisms that regulate Toll/IL-1 receptor signaling and subsequent inflammatory response."
https://pharos.nih.gov/idg/targets/P51617,P51617,15829295,"Only LPS, not taxol, caused a dramatic decrease in IRAK1 protein levels."
https://pharos.nih.gov/idg/targets/P51617,P51617,15647277,"the Hsp90.Cdc37 molecular chaperone module has a central role in interleukin-1 receptor-associated-kinase-dependent signaling by toll-like receptors"
https://pharos.nih.gov/idg/targets/P51617,P51617,15523691,"study shows that PBMCs of patients with advanced gastric cancer show poor production of TNF and IL-12p40 in response to stimulation with tumor cells in vitro & this unresponsiveness is associated in some patients with diminished IRAK-1 expression in vivo"
https://pharos.nih.gov/idg/targets/P51617,P51617,15465816,"IRAK1 is essential for lipopolysaccharide-induced interleukin-10 gene expression"
https://pharos.nih.gov/idg/targets/P51617,P51617,15069085,"Involvement of CD14/TLR4, CR3, and phosphatidylinositol 3-kinase in the degradation of IL-1 receptor-associated kinase in response to LPS."
https://pharos.nih.gov/idg/targets/P51617,P51617,14752294,"IRAK-1 is the central kinase involved in the activation of the macrophage at distant sites during septic shock"
https://pharos.nih.gov/idg/targets/P51617,P51617,12860405,"Pellino2 interacts with kinase-active as well as kinase-inactive IRAK1 and IRAK4"
https://pharos.nih.gov/idg/targets/P51617,P51617,12856330,"phosphorylates Stat1 on serine 727 in response to interleukin-1 and affects gene expression"
https://pharos.nih.gov/idg/targets/P51617,P51617,12619925,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P51617,P51617,12619925,"association of a haplotype (196Phe/532Ser) in the interleukin-1-receptor-associated kinase (IRAK1) gene with low radial bone mineral density in two independent populations"
https://pharos.nih.gov/idg/targets/P51617,P51617,12391239,"In lipopolysaccharide (LPS)-tolerant monocytes IRAK-1 is not activated in response to LPS restimulation, although protein and mRNA levels remain normal or slightly up-regulated."
https://pharos.nih.gov/idg/targets/P51617,P51617,12138165,"Identification of threonine 66 as a functionally critical residue of the protein"
https://pharos.nih.gov/idg/targets/P51617,P51617,12055225,"Down-regulation of the common Toll-like receptor intracellular signaling factor IRAK in vitro will lead to a state of cross-tolerance and decreased IL-1 beta and TNF-alpha production upon subsequent challenge with multiple microbial toxins."
https://pharos.nih.gov/idg/targets/P51617,P51617,11953430,"Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5."
https://pharos.nih.gov/idg/targets/P51617,P51617,11777917,"proximal signaling molecules involved in LPS-induced NF-kappa B activation have a requisite involvement in LPS-induced apoptosis and that the pathways leading to NF-kappa B activation and apoptosis diverge downstream of IRAK-1."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,26406402,"Loss of ALK7 expression are associated with invasion, metastasis of the pancreatic ductal adenocarcinoma."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,26289399,"Alk7 is expressed in male germ cells and Sertoli cells."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,23793810,"ACVR 1C is a tumor suppressor, and lowered ACVR 1C expression is an important marker for the metastasis, invasion, and prognosis of gallbladder cancer."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,23765385,"Our findings suggested that the ALK7 gene polymorphism rs13010956 was significantly associated with metabolic syndrome risk in females and may be involved in cardiovascular remodeling in metabolic syndrome patients."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,22086737,"reduction or lack of ALK7 expression may account for the loss of its ligand sensitivity of breast cancer cells, thereby leading to breast tumor progression."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,21356369,"These findings suggest that the Nodal/ALK7 pathway plays important roles in human placentation and that its abnormal signaling may contribute to the development of preeclampsia."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,19275893,"Microarray analysis showed that adipose tissue expressed activin type I and II receptors and that the expression of activin receptor-like kinase 7 was adipose tissue specific."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,18951876,"One of the direct target genes in the ALK7 signaling pathway is the insulin gene in pancreatic beta-cells, and that PDX-1 is directly involved in this pathway through interaction with Smad2 and Smad3."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,18784254,"The antiproliferative effect of Nodal/ALK7 on ovarian cancer cells is in part mediated by cyclin G2."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,18480259,"GDF3 regulates adipose-tissue homeostasis and energy balance under nutrient overload in part by signaling through the ALK7 receptor"
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,16603637,"ALK7-induced apoptosis is at least in part through two Smad-dependent pathways, Bax/Bcl-2 and Xiap."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,15196700,"AB and activin B and is responsible for activin-mediated secretion of insulin from pancreatic beta cell line, MIN6."
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,15150278,"the Nodal-ALK7 pathway inhibits cell proliferation by inducing G(1) cell cycle arrest"
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,15107418,"ALK7 induces apoptosis through activation of the traditional TGF-beta pathway components"
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,12606401,"ALK7 and its isoforms are expressed in human placentae of different stages of pregnancy and that their expression is developmentally regulated"
https://pharos.nih.gov/idg/targets/Q8NER5,Q8NER5,12063393,"cDNA cloning, expression studies and chromosome mapping"
https://pharos.nih.gov/idg/targets/P10398,P10398,26891695,"The constitutive or induced re-localization of A-Raf to the plasma membrane compromises its ability to efficiently sequester and inactivate MST2, thus rendering cells susceptible to apoptosis"
https://pharos.nih.gov/idg/targets/P10398,P10398,26508523,"This review discusses the regulation of A-Raf protein expression, and the roles of A-Raf in apoptosis and cancer, with a special focus on its role in resistance to Raf inhibitors.  [review]"
https://pharos.nih.gov/idg/targets/P10398,P10398,25674762,"Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC."
https://pharos.nih.gov/idg/targets/P10398,P10398,25608663,"analysis of FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma"
https://pharos.nih.gov/idg/targets/P10398,P10398,25097033,"Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration."
https://pharos.nih.gov/idg/targets/P10398,P10398,24652991,"The study identifies somatic activating ARAF mutations in Langerhans cell histiocytosis."
https://pharos.nih.gov/idg/targets/P10398,P10398,24447338,"The amplified luminescent proximity homogeneous assay (AlphaScreen) identifies the interaction of HIV-1 Gag with ARAF"
https://pharos.nih.gov/idg/targets/P10398,P10398,24114843,"Galpha12-ARAF-ERK pathway stimulates RFFL transcription through the transcription factor c-Myc."
https://pharos.nih.gov/idg/targets/P10398,P10398,23591895,"show that Araf antagonizes mesendoderm induction and patterning activity of Nodal/Smad2 signals in vertebrate embryos by directly inhibiting Smad2 signalling"
https://pharos.nih.gov/idg/targets/P10398,P10398,23352452,"Ras pathway activation via EGF treatment induced strong binding between B-Raf and C-Raf and a low level of binding between B-Raf and A-Raf."
https://pharos.nih.gov/idg/targets/P10398,P10398,22926515,"study investigated role of ARAF in cancer cell signaling and examined the role of ARAF in mediating paradoxical activation of the MAPK pathway in cells treated with RAF inhibitors; ARAF seems to stabilize BRAF:CRAF complexes in cells treated with RAF inhibitors and regulate cell signaling in a subtle manner to ensure signaling efficiency"
https://pharos.nih.gov/idg/targets/P10398,P10398,20145135,"hnRNP H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription."
https://pharos.nih.gov/idg/targets/P10398,P10398,18662992,"Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites."
https://pharos.nih.gov/idg/targets/P10398,P10398,16980614,"These data reveal that B-RAF is an important mediator of neuronal survival, migration, and dendrite formation and that A-RAF cannot fully compensate for these functions."
https://pharos.nih.gov/idg/targets/P10398,P10398,15736953,"A-Raf residues are identified that bind to specific phosphoinositides, possibly as a mechanism to localize the enzyme to particular membrane microdomains rich in these phospholipids."
https://pharos.nih.gov/idg/targets/P10398,P10398,14688025,"mutation analysis of the conserved regions in the ARAF gene in human colorectal adenocarcinoma"
https://pharos.nih.gov/idg/targets/P10398,P10398,14684750,"A-Raf kinase is negatively regulated by trihydrophobin 1"
https://pharos.nih.gov/idg/targets/P10398,P10398,11952167,"In a two-hybrid screen of human fetal liver cDNA library, TH1 was detected as a new interaction partner of A-Raf; this specific interaction may have played a critical role in the activation of A-Raf."
https://pharos.nih.gov/idg/targets/P10398,P10398,8621729,"A-Raf interacts with MEK1 and activates MEK1 by phosphorylation."
https://pharos.nih.gov/idg/targets/P36897,P36897,28815607,"combined inhibition of ALK5 and CTGF is required to prevent TGFbeta-induced nodule formation in tri-cellular cultures"
https://pharos.nih.gov/idg/targets/P36897,P36897,28633389,"TGF-beta type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset preeclampsia. Endoglin was increased in both subtypes."
https://pharos.nih.gov/idg/targets/P36897,P36897,28632033,"ALK5 is an important mediator of HTFs fibrosis. ALK5 is a potential therapeutic target to suppress scar formation after filtration surgery."
https://pharos.nih.gov/idg/targets/P36897,P36897,28625921,"Coronin 1B constitutively binds to TGF beta receptor I in vascular smooth muscle cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,28574613,"Results show that TGFBR1 expression is regulated in bladder cancer cell through its desumoylation by SENP2."
https://pharos.nih.gov/idg/targets/P36897,P36897,28522256,"Higher proportions of early-onset Diffuse Gastric Cancers (DGCs) contained somatic mutations in CDH1 or TGFBR1 compared with late-onset DGCs. A smaller proportion of early-onset DGCs contained somatic mutations in RHOA. CDH1 alterations, but not RHOA mutations, were associated with shorter survival times. Female predominance in early-onset DGC may be related to relatively high rates of somatic CDH1 and TGFBR1 mutations."
https://pharos.nih.gov/idg/targets/P36897,P36897,28489883,"Overexpression of truncated ALK5 in a B-cell line counteracted BMP-7-induced apoptosis, whereas overexpression of truncated ALK4 had no effect."
https://pharos.nih.gov/idg/targets/P36897,P36897,28146434,"Low TGFBR1 expression is associated with oral cancer progression."
https://pharos.nih.gov/idg/targets/P36897,P36897,27885255,"This study shows that TFAP2C promoted lung tumor progression by upregulation of TGFBR1 and consequent activation of PAK1 signaling."
https://pharos.nih.gov/idg/targets/P36897,P36897,27879313,"Aortic diseases in patients with TGFBR1 or TGFBR2 mutations show the same prevalence of systemic features and the same global survival."
https://pharos.nih.gov/idg/targets/P36897,P36897,27543359,"BIX02189 is a potent inhibitor of TGF-beta type I receptor that can block the lung tumor metastatic activity of TGF-beta1."
https://pharos.nih.gov/idg/targets/P36897,P36897,27527810,"results suggest a role for prostatic expression of TGF-B, IL-1a, TGFBRI and TGFBRII as prognostic markers for prostate cancer. The rational combination of novel agents directed toward the inactivation of TGF-B, IL-1a, TGFBRI and TGFBRII could disrupt complementary tumor cell proliferation pathways."
https://pharos.nih.gov/idg/targets/P36897,P36897,27445263,"Although TGFbeta1/2 receptors are downregulated in breast cancer, their expression in tumors is an indicator of aggressive breast cancer phenotype."
https://pharos.nih.gov/idg/targets/P36897,P36897,27248167,"PAR2 is crucial for TGF-beta1-induced cell motility by its ability to sustain expression of ALK5. Therapeutically targeting PAR2 may thus be a promising approach in preventing TGF-beta-dependent driven metastatic dissemination in PDAC and possibly other stroma-rich tumour types."
https://pharos.nih.gov/idg/targets/P36897,P36897,27234654,"In luciferase assays, the risk-associated allele for rs868 was associated with half the luciferase expression in the presence of miRNA let-7b-5p compared with protective allele, suggesting more binding of let-7b-5p and less TGFBR1 expression. Thus, rs868 potentially is acolorectal ca CRC risk-causing allele. Our results support the concept that rs868 is associated with lower TGFBR1 expression thereby increasing CRC risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,27171242,"These results suggest that polymorphisms in TGFB1, TGFBR1, SNAI1 and TWIST1 may modulate endometrial cancer susceptibility, both separately and corporately."
https://pharos.nih.gov/idg/targets/P36897,P36897,27112580,"In this small cohort, the results did not reach significance to identify the TFGBR1*6A allele as a major modifier for aortic dilation, ectopia lentis, or systemic features associated with MFS or other connective tissue disorders."
https://pharos.nih.gov/idg/targets/P36897,P36897,27105506,"Data show that twist-related protein 1 (Twist1) requires TGF-beta type-I receptor (TGFBR1)-activation for activation for epithelial-mesenchymal transition (EMT)-induction."
https://pharos.nih.gov/idg/targets/P36897,P36897,27048361,"This paper highlights that targeting the BMP and TGFbeta type I and type II receptors causes a downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,26872091,"Data suggest that transient suppression of TGFbeta receptor I (TGFbeta receptor) signaling may improve the outcome of islet transplantation."
https://pharos.nih.gov/idg/targets/P36897,P36897,26766164,"Evidence supporting a genetic basis includes the autosomal dominance of Bicuspid aortic valve inheritance patterns, and the identification of mutations in transforming growth factor beta receptor 1."
https://pharos.nih.gov/idg/targets/P36897,P36897,26720610,"Short hairpin-mediated downregulation of either ALK5 or ALK1 resulted in a strong inhibition of TGFbeta-induced chondrogenesis."
https://pharos.nih.gov/idg/targets/P36897,P36897,26652004,"This work details a novel mechanism by which cellular tension regulates TGFbeta receptor organization, multimerization, and function."
https://pharos.nih.gov/idg/targets/P36897,P36897,26620926,"miR-181b functions as a tumor suppressor and has an important role in proliferation, chemosensitivity to DDP and metastasis of NSCLC by targeting TGFbetaR1/Smad signaling pathway."
https://pharos.nih.gov/idg/targets/P36897,P36897,26616150,"Studies indicate that the transforming growth factor beta receptor I 6A (TbetaR-I 6A) allele was associated with breast cancer risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,26583432,"Data show that signal transducing adaptor proteins APPL1 and APPL2 are required for TGFbeta-induced nuclear translocation of TGFbeta type I receptor (TbetaRI)-ICD and for cancer cell invasiveness of prostate and breast cancer cell lines."
https://pharos.nih.gov/idg/targets/P36897,P36897,26583147,"the level of TGFBR1 and early osteogenic differentiation were abolished in the DPSCs transfected with siRNA for GnT-V knockdown...GnT-V plays a critical role in the hexosamine-induced activation of TGF-b signaling and osteogenic differentiation"
https://pharos.nih.gov/idg/targets/P36897,P36897,26548632,"Protease activated receptor-1 mediated dual kinase receptor transactivation stimulates the expression of glycosaminoglycan synthesizing genes and transforming growth factor beta receptor 1"
https://pharos.nih.gov/idg/targets/P36897,P36897,26542979,"MiR-1343 reduces the expression of both TGF-beta receptor 1 and 2 by directly targeting their 3'-UTRs."
https://pharos.nih.gov/idg/targets/P36897,P36897,26472812,"results indicate the critical role of TGF-beta R1/Smad2/3 signaling in carbon nanotube-induced fibrogenesis by upregulating collagen production in lung fibroblasts"
https://pharos.nih.gov/idg/targets/P36897,P36897,26357964,"Data show that macitentan interferes with the profibrotic action of transforming growth factor-beta (TGF-beta), blocking the endothelin receptor type A (ET-1 receptor) portion of the ET-1/TGF-beta receptor complex."
https://pharos.nih.gov/idg/targets/P36897,P36897,26187313,"Blocking TGFBR1 receptor up-regulated p21 expression while inhibiting breast tumor cell growth."
https://pharos.nih.gov/idg/targets/P36897,P36897,26165686,"Women who carry the TGFBR1*6A allele are at lower risk of developing breast cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,26152726,"The cancer-driven alteration of WWP1 culminates in excessive TbetaRI degradation and attenuated TGFbeta1 cytostatic signaling, a consequence that could conceivably confer tumorigenic properties to WWP1."
https://pharos.nih.gov/idg/targets/P36897,P36897,26150340,"we showed significantly higher HDAC6 levels in GBM from the patients and further showed evidence supporting TGFbeta receptor signaling pathway as a downstream target of HDAC6 in glioblastoma multiforme"
https://pharos.nih.gov/idg/targets/P36897,P36897,26074400,"Int7G24A polymorphism of gene TGFBR1 involved in the TGF-beta signaling pathway had a significantly increased risk for cancer development. (Meta-analysis)"
https://pharos.nih.gov/idg/targets/P36897,P36897,26037400,"these results revealed no correlation between the normalized expression of TGF-beta2, TGF-betaRI, or TGF-betaRII and EDSS scores"
https://pharos.nih.gov/idg/targets/P36897,P36897,25998683,"The direct fusion of clathrin-coated and caveolae vesicles during TGF-beta receptor endocytic trafficking, which leads to the formation of the multifunctional sorting device, caveolin-1-positive early endosomes, for TGF-beta receptors."
https://pharos.nih.gov/idg/targets/P36897,P36897,25893292,"these findings demonstrate that syntenin may act as an important positive regulator of TGF-b signaling by regulating caveolin-1-mediated internalization of TbRI; thus, providing a novel function for syntenin that is linked to cancer progression"
https://pharos.nih.gov/idg/targets/P36897,P36897,25882708,"Treatment with a TGFBR1 kinase inhibitor, endocytosis inhibitors or a lysosome inhibitor, normalized the levels of TGFBR1 and TGFBR2."
https://pharos.nih.gov/idg/targets/P36897,P36897,25826292,"TGF-betaRI and its mRNA levels were lower in older women than in younger ones. In elderly women, only TGF-betaRIota expression correlated negatively with miRNA-21 expression in PBMCs. Age affects TGF-beta signalling in leukocytes by altering its receptor expression."
https://pharos.nih.gov/idg/targets/P36897,P36897,25715477,"We examined nine exons of transforming growth factor b receptor type 1 (TGFbR1) gene in patients with chronic heart failure with different types of heart remodelling"
https://pharos.nih.gov/idg/targets/P36897,P36897,25502482,"Donor rs868 AA genotype was associated with worse clinical course of recurrent hepatitis C and more severe symptoms of hepatitis C and fibrosis during follow-up after liver transplantation."
https://pharos.nih.gov/idg/targets/P36897,P36897,25273091,"TGFbetaR1 signaling as a process dysregulated across HPV-related cancers."
https://pharos.nih.gov/idg/targets/P36897,P36897,25173755,"Mutations in genes such as AKT2, CCNA1, MAP3K4, and TGFBR1, were associated significantly with Epstein-Barr-positive gastric tumors, compared with EBV-negative tumors."
https://pharos.nih.gov/idg/targets/P36897,P36897,25169976,"PDGF receptor-alpha promotes TGF-beta signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-beta receptors."
https://pharos.nih.gov/idg/targets/P36897,P36897,25110237,"Chinese Han family a pathogenic mutation (rs111426349, c.1459C >T) (TGFBR1) of familial thoracic aortic aneurysm was confirmed, which result in the amino acid substitution p.R487W."
https://pharos.nih.gov/idg/targets/P36897,P36897,24981199,"Results find little evidence for an association between the TGFBR1*6A allele and colorectal cancer risk in certain families."
https://pharos.nih.gov/idg/targets/P36897,P36897,24978044,"Reduced let-7b might be involved in the pathogenesis of chronic thromboembolic pulmonary hypertension by affecting ET-1 and TGBR1 expression and function of arterial endothelial and smooth muscle cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,24954139,"Characteristic TGFbetaR1 expression pattern in keratoacanthoma can facilitate histopathologic distinction from squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P36897,P36897,24939309,"Data suggest that ubiquitin specific peptidase 15 (USP15) may play a role in the pathogenesis of psoriasis through regulating the type I TGFbeta receptor (TbetaR-I)/Smad7 pathway."
https://pharos.nih.gov/idg/targets/P36897,P36897,24880985,"a case-control study and systematic literature review found that sporadic, but not familial colorectal cancer, was associated with TGFBR1*6A polymorphism."
https://pharos.nih.gov/idg/targets/P36897,P36897,24860093,"the hyaluronan receptor CD44 interacts with both PDGFRbeta and TbetaRI."
https://pharos.nih.gov/idg/targets/P36897,P36897,24816588,"Data show that tacrolimus-induced NAD(P)H-oxidase 4 (Nox4) expression in by aberrant TGF-beta receptor signalling."
https://pharos.nih.gov/idg/targets/P36897,P36897,24793577,"genetic testing revealed new mutations in FBN1, TGFbetaR1, TGFbetaR2 and ACTA2 detected in patients with clinical diagnosis of Marfan Syndrome, Loeys-Dietz Syndrome and Thoracic Aortic Aneurysms and Dissections."
https://pharos.nih.gov/idg/targets/P36897,P36897,24771066,"These results suggest that ZNF580 mediates eNOS expression and endothelial cell migration/proliferation via the TGF-b1/ALK5/Smad2 pathway, and thus plays a crucial role in vascular endothelial cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,24747516,"We review here the investigations leading to the discovery of loss of function mutations in TGFBR1 that are responsible for the disease"
https://pharos.nih.gov/idg/targets/P36897,P36897,24558198,"data demonstrate that miR-142-3p influences the proliferation of non-small cell lung cancer cells through repression of TGFbetaR1"
https://pharos.nih.gov/idg/targets/P36897,P36897,24551192,"Antibodies against TGF-beta or a TGF-beta receptor inhibitor SB431452 reverse HIV-1 Vpu-mediated profibrogenic activation of LX2 cells, suggesting that TGF-beta mediates these effects"
https://pharos.nih.gov/idg/targets/P36897,P36897,24512448,"TbR-I 6A allele and 6A/6A genotype are associated with the ovarian cancer risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,24399296,"Findings indicate that tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) was required for the interaction between TGFbeta type I receptor (TbetaRI) and presenilin 1 (PS1)."
https://pharos.nih.gov/idg/targets/P36897,P36897,24367547,"Lumican binds ALK5 to promote epithelium wound healing"
https://pharos.nih.gov/idg/targets/P36897,P36897,24347165,"Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-beta signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts."
https://pharos.nih.gov/idg/targets/P36897,P36897,24344637,"TGFBR1 mutations in patients with dural ectasia in Loeys-Dietz syndrome"
https://pharos.nih.gov/idg/targets/P36897,P36897,24344132,"ACLP stimulates the fibroblast-to-myofibroblast transition by promoting SMA expression via TGFbeta signaling and promoting collagen expression through a TGFbeta receptor-independent pathway."
https://pharos.nih.gov/idg/targets/P36897,P36897,24333532,"We describe two patients with a novel missense mutation in TGFBR1 presenting with highly elevated levels of IgE and severe eczema similar to autosomal-dominant Hyper-IgE syndrome."
https://pharos.nih.gov/idg/targets/P36897,P36897,24279395,"The expression of TGFbeta receptors (TGFbetaRI and TGFbetaRII) and FGF2 in the lens epithelium of the MCT mice was stronger than that of the wild-type ddY mice at 4 weeks and weaker than that of the wild-type ddY mice at 15 weeks after birth."
https://pharos.nih.gov/idg/targets/P36897,P36897,24243761,"TGFBR1 and TGFBR2 mutations do not play a major role in isolated myxomatous valve dystrophy. Screening for FLNA mutations is recommended in familial myxomatous valvular dystrophy, particularly if X-linked inheritance is suspected."
https://pharos.nih.gov/idg/targets/P36897,P36897,23899993,"The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGFBR1 or TGFBR2."
https://pharos.nih.gov/idg/targets/P36897,P36897,23832740,"High TGFBR-1 expression is associated with metastasis in non-small cell lung cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,23734265,"Data indicate that the activation of MAPK and PI3K pathways resulted in TGF-beta1 signaling by down-regulating Nm23-H1 expression and up-regulating the expression of TbetaRI and TbetaRII, favoring further activation of multiple signaling pathways."
https://pharos.nih.gov/idg/targets/P36897,P36897,23624079,"Overexpression of Dlg5 enhances the degradation of TGFBRI."
https://pharos.nih.gov/idg/targets/P36897,P36897,23548068,"Variation in tagged-SNP rs10739778 was associated with preeclampsia in black women."
https://pharos.nih.gov/idg/targets/P36897,P36897,23358096,"Rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology of multiple self-healing squamous epithelioma (MSSE)."
https://pharos.nih.gov/idg/targets/P36897,P36897,23349840,"Data indicate that upregulation of TbetaRI (TGFbeta receptor 1) expression by cAMP was dependent on transcription."
https://pharos.nih.gov/idg/targets/P36897,P36897,23166821,"ALK5-mediated phosphorylation of DeltaNp63alpha is required for the anti-clonogenic effects of TGFBeta and ectopic expression of ALK5(IKD) mimics these effects."
https://pharos.nih.gov/idg/targets/P36897,P36897,22911926,"Genotyped five tagging single nucleotide polymorphisms (SNPs) to represent common variants in the whole TGFBR1 gene."
https://pharos.nih.gov/idg/targets/P36897,P36897,22905183,"TGFBR1*6A and IVS7+24G>A polymorphisms of TGFBR1 are associated with the susceptibility of cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,22848678,"a critical negative regulation level of TGF-beta signaling mediated by HILI (human PIWIL2) by its ability to interact with Hsp90 and promote TbetaR degradation"
https://pharos.nih.gov/idg/targets/P36897,P36897,22803051,"several polymorphisms detected in the TGFbeta1 gene and its receptor associated with benign and malignant breast tumors"
https://pharos.nih.gov/idg/targets/P36897,P36897,22773947,"USP11 augments TGFbeta signalling by deubiquitylating ALK5."
https://pharos.nih.gov/idg/targets/P36897,P36897,22739178,"TGF-beta1 and its receptors including TGF-betaRI and TGF-betaRII are abnormally expressed in the peripheral blood of immune thrombocytopenic purpura patients."
https://pharos.nih.gov/idg/targets/P36897,P36897,22706160,"Results uncover USP4 as an important determinant for crosstalk between TGF-beta/TGF-beta type I receptor and AKT signalling pathways."
https://pharos.nih.gov/idg/targets/P36897,P36897,22651914,"analysis of evolution of the TGF-beta superfamily and how they signal through a single pair of receptors, known as TbetaR-I and TbetaR-II [review]"
https://pharos.nih.gov/idg/targets/P36897,P36897,22617150,"TGF-beta family signaling through Smads is conceptually a simple and linear signaling pathway, driven by sequential phosphorylation, with type II receptors activating type I receptors, which in turn activate R-Smads [review]"
https://pharos.nih.gov/idg/targets/P36897,P36897,22532183,"In patients with aortic dissection and aortic aneurysm, cytoplasmic staining of TGFbeta1 receptor shows aortic wall structures in disarray and intimal disruption."
https://pharos.nih.gov/idg/targets/P36897,P36897,22496417,"The Smad7-APC complex links the TGFbeta type I receptor to the microtubule system to regulate directed cellular extension and migratory responses evoked by TGFbeta."
https://pharos.nih.gov/idg/targets/P36897,P36897,22473997,"a cancer-specific nuclear translocation of TbetaRI; its potential function in regulating nuclear RNA processing, as well as a novel gain-of-function mechanism of TGF-beta signaling in cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,22414221,"Disease-associated TGFBR1 mutations were found to be inactivating for canonical TGF-beta signaling."
https://pharos.nih.gov/idg/targets/P36897,P36897,22344298,"Our results show that USP15 regulates the TGF-beta pathway and is a key factor in glioblastoma pathogenesis"
https://pharos.nih.gov/idg/targets/P36897,P36897,22314103,"promoter methylation may exist in the early stage of esophageal squamous cell carcinoma and play important role in gene silencing"
https://pharos.nih.gov/idg/targets/P36897,P36897,22292045,"TGFBR1 intralocus epistatic interaction as a risk factor for colorectal cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,22290546,"the rs1805110T allele is associated with susceptibility to HBV-related hepatocellular carcinoma in males"
https://pharos.nih.gov/idg/targets/P36897,P36897,22278155,"Data suggest that TGF-beta, TGF-betaR1, TGF-betaR2, Smad4, pSmad2/3, and E-cadherin are closely related to tumor-node-metastasis (TNM) stage of colorectal cancer (CRC)."
https://pharos.nih.gov/idg/targets/P36897,P36897,22136666,"TGFBR1 as a new candidate prognostic biomarker after acute myocardial infarction"
https://pharos.nih.gov/idg/targets/P36897,P36897,22100658,"Our study suggests there might be an association between the TGFbeta1 29C>T polymorphism and CVD risk in long-term breast cancer survivors."
https://pharos.nih.gov/idg/targets/P36897,P36897,22096025,"Mutations of TGFBR1 are associated with Skin tumors induced by sorafenib."
https://pharos.nih.gov/idg/targets/P36897,P36897,22088447,"Gene polymorphisms of TGF-beta1 in 869T > C and PAI-1 4G/5G may affect the susceptibility to IPF in Han ethnicity."
https://pharos.nih.gov/idg/targets/P36897,P36897,22087763,"The balance in signalling through either ALK-1 or ALK-5 regulates leptin expression in mesenchymal stem cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,22078045,"Dominant mutations in this gene cause Ferguson-Smith disease. Review."
https://pharos.nih.gov/idg/targets/P36897,P36897,22015652,"We have shown that TGF-beta1 expression in gastric tumor tissue with HER2/neu-negative status is of prognostic relevance in gastric cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,22006998,"A selective inhibitor of the TGFbetaR-I kinase can potentiate radiation responses in glioblastoma by coordinately increasing apoptosis."
https://pharos.nih.gov/idg/targets/P36897,P36897,21978186,"No association found for this gene for susceptibility to intracranial aneurysm"
https://pharos.nih.gov/idg/targets/P36897,P36897,21962132,"Variation in TGFBR1 is associated with dizygotic twinning."
https://pharos.nih.gov/idg/targets/P36897,P36897,21924348,"atypical protein kinase C isoforms regulate transforming growth factor beta (TGFB) signaling by altering cell surface TGFB receptor trafficking and degradation"
https://pharos.nih.gov/idg/targets/P36897,P36897,21858550,"Two polymorphisms of TGFBR1 may confer low-penetrance susceptibility of colorectal cancer risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,21821041,"The TbetaR-I pre-helix extension is structurally ordered in the unbound form and its flanking prolines are essential for binding."
https://pharos.nih.gov/idg/targets/P36897,P36897,21815248,"TGFBR1, TGFBR2, and ACTA2 mutations were found in 4 families with thoracic aortic aneurysms and dissections and predominantly fusiform intracranial aneurysms."
https://pharos.nih.gov/idg/targets/P36897,P36897,21785915,"TGFBR1 Int7G24A and TGFBR2 G-875A polymorphisms may play important roles in the risk of gastric cardia adenocarcinoma in North China."
https://pharos.nih.gov/idg/targets/P36897,P36897,21751154,"we have proposed that TGF-beta regulates the activation state of the endothelium via two opposing type I receptor/Smad pathways, activin receptor-like kinase (ALK)1 and ALK5--{REVIEW}"
https://pharos.nih.gov/idg/targets/P36897,P36897,21677877,"Data indicate that the addition of a TGF-betaRI kinase inhibitor to the present clinical standard (radiation plus TMZ) has the potential to improve clinical outcome in human glioblastoma."
https://pharos.nih.gov/idg/targets/P36897,P36897,21629263,"TGFBR1 has a specific role in TGFbeta mediated tumor invasion."
https://pharos.nih.gov/idg/targets/P36897,P36897,21539622,"CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation."
https://pharos.nih.gov/idg/targets/P36897,P36897,21478266,"TGF-beta1-induced monocyte migration, requiring ALK5 kinase activity and signalling via PI3K and p38. TGF-beta1-driven monocyte motogenicity is fully functional in diabetic conditions."
https://pharos.nih.gov/idg/targets/P36897,P36897,21441952,"in lung cancer cells, SCUBE3 could serve as an endogenous autocrine and paracrine ligand of TGF-beta type II receptor, which could regulate TGF-beta receptor signaling and modulate EMT and cancer progression"
https://pharos.nih.gov/idg/targets/P36897,P36897,21429769,"Data indicate that expression of TGF-ss1 and TGF-ssR1 could be used as biological markers of bladder carcinoma."
https://pharos.nih.gov/idg/targets/P36897,P36897,21423151,"These results provide evidence that the two TbetaRI:TbetaRII heterodimers bind and mediate TGF-beta3 signalling."
https://pharos.nih.gov/idg/targets/P36897,P36897,21358634,"dideoxy sequencing of TGFBR1 identified 11 distinct monoallelic mutations in 18 affected families with multiple self-healing squamous epithelioma"
https://pharos.nih.gov/idg/targets/P36897,P36897,21304536,"ALK-1 and ALK-5 are both expressed by the majority of AML patients. In addition, ALK-5 expression has a significant negative impact on complete remission achievement and long-term survival of patients"
https://pharos.nih.gov/idg/targets/P36897,P36897,21295082,"CD109 regulates TGF-beta receptor endocytosis and degradation to inhibit TGF-beta signaling."
https://pharos.nih.gov/idg/targets/P36897,P36897,21225232,"A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression."
https://pharos.nih.gov/idg/targets/P36897,P36897,21224855,"Germline allele specific expression of TGFBR1 does not confer an increased risk of colorectal cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,21172820,"TbetaRII alone is able to mediate TGFbeta signaling to ERK1/2 without participation of TbetaRI."
https://pharos.nih.gov/idg/targets/P36897,P36897,21170488,"Studies indicate that endoglin (CD105) interacts with type I and type II TGF-beta receptors and modulates TGF-beta signaling."
https://pharos.nih.gov/idg/targets/P36897,P36897,21127043,"GATA6 plays a crucial role for endothelial cell function and survival, at least in part, by suppressing autocrine TGFbeta expression and ALK5-dependent signaling."
https://pharos.nih.gov/idg/targets/P36897,P36897,21068203,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,21030067,"Following TGF-beta1 treatment, the activity of serine/threonine phosphatase and recruitment of PP2A-Balpha by TbetaRI increased in benign cells, but not in malignant cells. Defective recruitment of PP2A-Balpha by TbetaRI causes TGF-beta1 overexpression in cancer cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,20924066,"blocking ALK5 may be useful in blocking the profibrotic effects of TGFbeta in gingival fibroblasts."
https://pharos.nih.gov/idg/targets/P36897,P36897,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20705955,"two alleles in TGFBR1 are not always equally expressed, constituting a subtle quantitative trait that is weakly associated with the risk for colorectal cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,20663871,"Smad7 thus has an additional mode of interaction with TGF-beta family type I receptors not possessed by Smad6, which may play roles in mediating the inhibitory effects unique to Smad7."
https://pharos.nih.gov/idg/targets/P36897,P36897,20662850,"the connective tissue weakness does not relate to mutations in the genes FBN1, TGFBR1 and TGFBR2"
https://pharos.nih.gov/idg/targets/P36897,P36897,20634891,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20599261,"Observational study of gene-disease association, gene-gene interaction, and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20587546,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20571025,"Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor."
https://pharos.nih.gov/idg/targets/P36897,P36897,20538960,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20503287,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20500843,"Single nucleotide polymorphisms in TGFBR-1 is associated with colorectal cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,20458730,"Data demonstrates the capacity of glucosamine to promote the osteogenic differentiation of human dental pulp stem cells, and the underlying mechanism involves a TGF-beta receptor 1-dependent Smad signal pathway."
https://pharos.nih.gov/idg/targets/P36897,P36897,20453000,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20445748,"Results showed development of gastric carcinoma is accompanied by markedly decreased cytotoxic function of NK cells and by elevated IL-10 and TGF-beta1 serum levels."
https://pharos.nih.gov/idg/targets/P36897,P36897,20437058,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20429896,"TGFBR1*6A, a dominant polymorphism of TGFBR1, is associated with increased susceptibility and metastasis spread of osteosarcoma in a Chinese population."
https://pharos.nih.gov/idg/targets/P36897,P36897,20429896,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20428796,"The aim of this study was to investigate the effect of TGF-beta1 targeting by antisense oligonucleotides on the RNA synthesis and protein expression of TGF-beta isoforms and their receptors in keloid-derived fibroblasts."
https://pharos.nih.gov/idg/targets/P36897,P36897,20427239,"The detection of GDF9 and TGFbetaR1 at both at the protein and mRNA levels suggests that GDF9 may have functions in human preantral follicles."
https://pharos.nih.gov/idg/targets/P36897,P36897,20403997,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,20368424,"Neither genetic variation nor allele-specific expression at TGFBR1 is likely to be a major colorectal cancer risk factor."
https://pharos.nih.gov/idg/targets/P36897,P36897,20354825,"Int7G24A is a polymorphism of TGFBR1 that is associated with the susceptibility and distant metastasis of osteosarcoma."
https://pharos.nih.gov/idg/targets/P36897,P36897,20101206,"Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics."
https://pharos.nih.gov/idg/targets/P36897,P36897,20101143,"Using microarray gene expression profiling of human lung tumors, dysregulation of transforming growth factor-beta signaling was identified as an important mediator of tumor invasion."
https://pharos.nih.gov/idg/targets/P36897,P36897,20086175,"findings reveal a hyperactive TGFbeta-TGFbetaR-Smad2 signaling axis needed to maintain epigenetic silencing of critical EMT genes and breast cancer progression."
https://pharos.nih.gov/idg/targets/P36897,P36897,20052600,"The data suggest that vitamin D fulfillment is prerequisite for the TGF-beta1 genotype in exerting its full effect on the fracture prevalence."
https://pharos.nih.gov/idg/targets/P36897,P36897,19998449,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19936899,"elevated mucosal expression in ulcerative colitis"
https://pharos.nih.gov/idg/targets/P36897,P36897,19930569,"The Int7G24A variant of transforming growth factor-beta receptor type I represents a risk factor for colorectal cancer in the male Spanish population."
https://pharos.nih.gov/idg/targets/P36897,P36897,19930569,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19916025,"Mutations and/or alterations in expression of TGF-beta receptors and loss of Smad 4 are frequent in human ovarian cancers."
https://pharos.nih.gov/idg/targets/P36897,P36897,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19908237,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19883511,"two novel mutations in the TGFBR1 and TGFBR2 genes in two patients affected with Loeys-Dietz syndrome (LDS) and showing marked phenotypic variability."
https://pharos.nih.gov/idg/targets/P36897,P36897,19882361,"TGFBR1*6A/9A polymorphism is associated with cancer susceptibility, increasing the risk of breast and ovarian cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,19882361,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19863607,"The results suggest that the genetic polymorphisms of IL-4R and TGF-beta1 are associated with the risk of colorectal cancer in a Korean population."
https://pharos.nih.gov/idg/targets/P36897,P36897,19736306,"Upon TGF-beta1 stimulation ALK5 phosphorylates Smad2 and 3 with a negative impact on ALK2-Smad1, 5 and 8 signaling in prostate cancer cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,19711426,"Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation."
https://pharos.nih.gov/idg/targets/P36897,P36897,19692168,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19690145,"an association between a TGFBR1 haplotype and risk for non-small-cell lung cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,19690145,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19688145,"Study data demonstrates downregulated TGFBR1 expression in psoriatic skin."
https://pharos.nih.gov/idg/targets/P36897,P36897,19672284,"Genetic variations in TGFBR1 associate with abdominal aortic aneurysm in a Dutch population."
https://pharos.nih.gov/idg/targets/P36897,P36897,19672284,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19639654,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19639490,"role in activating the nerve growth factor (NGF) system in pancraetic stellate cells (PSC) via TGF-beta."
https://pharos.nih.gov/idg/targets/P36897,P36897,19626999,"Compared with human fallopian tubes without adhesions or atresias, the expression of TGFbeta1, TGFBR1 and TGFBR2 all increased significantly in adhesion cases."
https://pharos.nih.gov/idg/targets/P36897,P36897,19625176,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19608716,"Secreted by epithelial cells and macrophages and can cause fibrotic changes in lung tissue"
https://pharos.nih.gov/idg/targets/P36897,P36897,19601999,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19595713,"Data show that inhibition of TACE activity or expression enhanced the cell surface TbetaRI levels and TGF-beta-induced Smad3 and Akt activation."
https://pharos.nih.gov/idg/targets/P36897,P36897,19592635,"Elevated serum concentrations of the cytokine TGF-beta1 indicate an increased risk for type 2 diabetes. TGF-beta1 may be upregulated to counterbalance metabolic and immunological disturbances preceding type 2 diabetes."
https://pharos.nih.gov/idg/targets/P36897,P36897,19586667,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19542084,"In families w/TGFBR1 mutations, men died younger than women based on Kaplan-Meier survival curves. Women often presented with dissections and aneurysms of arteries other than the ascending thoracic aorta."
https://pharos.nih.gov/idg/targets/P36897,P36897,19542084,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19538729,"Results suggest that the TGFBR1*6A allele does not confer an increased risk of colorectal cancer in the Spanish population."
https://pharos.nih.gov/idg/targets/P36897,P36897,19538729,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19509225,"we find that germline allele-specific expression of TGFBR1, as assayed in lymphoblastoid and colon epithelial cells of colon cancer patients, is a relatively rare event"
https://pharos.nih.gov/idg/targets/P36897,P36897,19506300,"ALK1 and ALK5 are both essential for correct regulation of VEGF, and that disruption of either pathway leads to disease."
https://pharos.nih.gov/idg/targets/P36897,P36897,19505916,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19494318,"age-related shift in ALK1/ALK5 ratio in murine cartilage and a strong correlation between ALK1 and MMP-13 expression in human cartilage"
https://pharos.nih.gov/idg/targets/P36897,P36897,19453261,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19426152,"loss of TGFbetaRII in hepatocellular carcinoma triggers activation of the TNF pathway known to be regulated by TGF-beta(1) network"
https://pharos.nih.gov/idg/targets/P36897,P36897,19401691,"No substantial support for the hypothesis that the polymorphic variants TGFBR1*6A or Int7G24A contribute to familial colorectal cancer risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,19401691,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19390964,"Study shows that there is no association between TGFBR1*6A and breast cancer risk."
https://pharos.nih.gov/idg/targets/P36897,P36897,19390964,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19375841,"Sustained co-cultivation with human placenta-derived MSCs enhances TGFBR1 signaling in human breast epithelial cells, leading to EMT and differentiation."
https://pharos.nih.gov/idg/targets/P36897,P36897,19336370,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19299629,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19299112,"There is disregulation in expression of the TGFB1 gene and its receptors as well during isolated Raynaud phenomenon as in systemic sclerosis."
https://pharos.nih.gov/idg/targets/P36897,P36897,19293232,"The ACVR2 influenced core 1 mucin-type O-glycosylation differentially, upregulation by ACVR2."
https://pharos.nih.gov/idg/targets/P36897,P36897,19258923,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19255252,"Smurf2 promotes trophoblast cell migration and invasion, and this function may involve downregulation of TGF-beta type I receptor."
https://pharos.nih.gov/idg/targets/P36897,P36897,19229971,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19214138,"Bioinformatic and functional analysis of TGFBR1 polymorphisms are reported."
https://pharos.nih.gov/idg/targets/P36897,P36897,19170196,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19147499,"TGF-beta1 elevates TbetaRII homodimerization to some degree and strongly enhances TbetaRI.TbetaRII heteromeric complex formation."
https://pharos.nih.gov/idg/targets/P36897,P36897,19116361,"these data are consistent with a role for the activin receptor-like kinase 5 in the progression of idiopathic pulmonary arterial hypertension"
https://pharos.nih.gov/idg/targets/P36897,P36897,19036501,"analysis of genetic polymorphisms of transforming growth factor-beta1 and its receptors and colorectal cancer susceptibility"
https://pharos.nih.gov/idg/targets/P36897,P36897,19012493,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,19004027,"7 different common variants in TGFB1 and TGFBR1 were not associated with an increased risk of bladder cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,19004027,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18978678,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18925687,"Behcets disease cases had lower incidence of TGFBR1(transforming growth factor beta receptor 1) *6A polymorphism compared with controls"
https://pharos.nih.gov/idg/targets/P36897,P36897,18925687,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18781618,"Mutations and polymorphisms in TGFBR1 and TGFBR2 in patients with Marfan syndrome, Loeys-Dietz syndrome and related disorders are described."
https://pharos.nih.gov/idg/targets/P36897,P36897,18781618,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18778720,"177 colorectal cancer patients were genotyped for either the major form of the TGFBR1 receptor gene, homozygous for an internal segment of 9 alanines (9A/9A), or the lesser form, heterozygous for the polymorphism containing 6 alanines (9A/6A)."
https://pharos.nih.gov/idg/targets/P36897,P36897,18778720,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18758450,"TGF-beta specifically activates TAK1 through interaction of TbetaRI with TRAF6, whereas activation of Smad2 is not dependent on TRAF6."
https://pharos.nih.gov/idg/targets/P36897,P36897,18721526,"Mutations in TGFBR1 and TGFBR2 rarely cause sporadic BAV."
https://pharos.nih.gov/idg/targets/P36897,P36897,18721526,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18711258,"The G-308A TNF-alpha promoter polymorphism is a risk factor for asthma and furthermore suggests that the patients with high producer alleles for TNF-alpha (-308) and TGF-beta (-509) have the highest risk of getting this disease in the Punjabi population."
https://pharos.nih.gov/idg/targets/P36897,P36897,18703712,"study showed that germline allele-specific expression(ASE)of the TGFBR1 gene is a quantitative trait occuring in 10 to 20% of colorectal cancer (CRC) patients & 1 to 3% of controls; estimates suggest ASE confers a substantially increased risk of CRC"
https://pharos.nih.gov/idg/targets/P36897,P36897,18683732,"The expression of TGF-betaR I increased in CD8+ T cells of oral lichen planus compared to controls."
https://pharos.nih.gov/idg/targets/P36897,P36897,18676680,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18550062,"ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm"
https://pharos.nih.gov/idg/targets/P36897,P36897,18550062,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18546940,"The high expression of genes coding TGFbetaRI, TGF-betaRII and TGF-betaRIII receptors in all the polyps and healthy tissues, show readiness to transduction of TGFbeta"
https://pharos.nih.gov/idg/targets/P36897,P36897,18541723,"MT1-MMP-dependent TGFbeta signaling through Alk5 is also required for PGE(2)-induced endothelial cord formation in vitro, and Alk5 kinase activity is required for PGE(2)-induced neovascularization in vivo."
https://pharos.nih.gov/idg/targets/P36897,P36897,18474728,"TGF-beta receptor I kinase has a role in the pathobiology of ineffective hematopoiesis"
https://pharos.nih.gov/idg/targets/P36897,P36897,18469808,"T beta RI sumoylation controls responsiveness to TGF-beta, with implications for tumour progression"
https://pharos.nih.gov/idg/targets/P36897,P36897,18456797,"Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5."
https://pharos.nih.gov/idg/targets/P36897,P36897,18421475,"reduced TGF beta R1 expression could contribute to the development of malignant phenotype of non-small cell lung cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,18333754,"both ALK1 and ALK5 are needed for TGF-beta-induced phosphorylation of intracellular mediators Smad1/5, whereas only ALK5 is essential for TGF-beta1-induced phosphorylation of Smad3"
https://pharos.nih.gov/idg/targets/P36897,P36897,18316594,"TGFBR1*6A may contribute to cancer progression through RhoA activation in a TGF-beta signaling-independent manner"
https://pharos.nih.gov/idg/targets/P36897,P36897,18252868,"A direct effect of TGF-beta signaling via ALK5 on the regulation of TNF-alpha synthesis in macrophages"
https://pharos.nih.gov/idg/targets/P36897,P36897,18243111,"TGF-beta complexes assemble cooperatively through recruitment of the low-affinity (type I) receptor by the ligand-bound high-affinity (type II) pair."
https://pharos.nih.gov/idg/targets/P36897,P36897,18223258,"TGF-beta mediates its effects on proteoglycan synthesis in VSMCs via the ALK5/Smad2/3 phosphorylation pathway as well as via the p38 MAP kinase signaling cascade."
https://pharos.nih.gov/idg/targets/P36897,P36897,18202754,"TGF-beta1, TbetaRI, and TbetaRII loss of expression correlates with differentiation in human oral squamous cell carcinomas"
https://pharos.nih.gov/idg/targets/P36897,P36897,18174246,"TGF-beta-mediated activation of the ALK5-Smad 3 pathway plays a role in SHH promoted motility and invasiveness of gastric cancer cells"
https://pharos.nih.gov/idg/targets/P36897,P36897,18174230,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,18097622,"The aim of this study was to analyse the profile of TGF-beta1 and the expression of its receptor (TbetaR I, TbetaR II and TbetaR III-betaglycan) genes in IPAH and in secondary forms of pulmonary arterial hypertension [Eisenmenger's syndrome patients]."
https://pharos.nih.gov/idg/targets/P36897,P36897,18095342,"Pronounced changes in the expression and localization of the TGF-beta receptors Tgfbr1 were noted as mouse lungs progressed through the canalicular, saccular, and alveolar stages of development."
https://pharos.nih.gov/idg/targets/P36897,P36897,17936924,"A highly significant association between the 6Ala allele of TGFBR1 gene and patients with Marfan syndrome is demonstrated for the first time."
https://pharos.nih.gov/idg/targets/P36897,P36897,17936924,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17890272,"Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development."
https://pharos.nih.gov/idg/targets/P36897,P36897,17848956,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17848956,"the TGFBR1(*)6A variant may be associated with an increased risk of low-risk familial breast cancer and might be a marker for poorly differentiated breast cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,17848193,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17845732,"The identification of the splice variants T beta RIB and the novel isoform T beta RIIC in man clearly contributes to the growing complexity of the TGF-beta family."
https://pharos.nih.gov/idg/targets/P36897,P36897,17705854,"4 new variants of T beta RI in malignant effusion tumor cells identified; characterization of 2 elements controlling its stability & transcriptional activation; expression of one variant bestowed cancer cells with growth advantage in presence of TGFbeta"
https://pharos.nih.gov/idg/targets/P36897,P36897,17703412,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17657819,"ALK5-dependent Smad3 signaling is the responsible pathway inducing CTGF expression."
https://pharos.nih.gov/idg/targets/P36897,P36897,17652900,"mutations in the TGFBR1,2 gene may be associated with greater phenotypic heterogeneity than previously reported"
https://pharos.nih.gov/idg/targets/P36897,P36897,17649947,"The mRNA expression of TGF-beta R I in keloid was higher than that in hyperplasic scars and normal skin."
https://pharos.nih.gov/idg/targets/P36897,P36897,17607123,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17607123,"no evidence to support the hypothesis that TGFBR1*6A is associated with lung cancer."
https://pharos.nih.gov/idg/targets/P36897,P36897,17575241,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17575241,"data provide limited support for the hypothesis that sequence variation in TGFBR1 defined by the TGFBR1*6A allele confers an elevated risk of colorectal cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,17507611,"Our analysis definitely excludes the possibility of the TGFBR1*6A allele increasing the risk of colorectal neoplasia in our sample population."
https://pharos.nih.gov/idg/targets/P36897,P36897,17365852,"mRNA codifying for TbetaRI was found in platelets."
https://pharos.nih.gov/idg/targets/P36897,P36897,17319955,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,17319955,"common variants in TGFBR1 gene do not strongly influence genetic susceptibility to diabetic nephropathy in an Irish Caucasian population."
https://pharos.nih.gov/idg/targets/P36897,P36897,17238135,"a distinct BMP and TGFbeta-receptor repertoire may explain the reduced chondrogenic capacity of adipose tissue stromal cells in vitro"
https://pharos.nih.gov/idg/targets/P36897,P36897,17203972,"Epac1 inhibits TGFbeta-dependent regulation of cell migration and adhesion through TbetaRI"
https://pharos.nih.gov/idg/targets/P36897,P36897,17087113,"The expression of TGFbetaR I and TGFbetaR II protein in nasal polyps tissues was significant increased than that in chronic rhinosinusitis tissues."
https://pharos.nih.gov/idg/targets/P36897,P36897,17072348,"Enhances tumor invasion and angiogenesis by stimulating expression of matrix metalloproteinase MMP-9."
https://pharos.nih.gov/idg/targets/P36897,P36897,16998703,"The mRNA expressions of TGFbeta receptor type I (TGFbetaRI) in hMSCs increased with the length of cell culture."
https://pharos.nih.gov/idg/targets/P36897,P36897,16980081,"Synthesis of TGFbeta-1 and type I TGFbeta-receptor increases over time in recipients developing chronic allograft nephropathy."
https://pharos.nih.gov/idg/targets/P36897,P36897,16947635,"The majority of systemic sclerosis (SSc) fibroblasts exhibit elevated levels of transforming growth factor beta type I receptor (TGFbetaRI)."
https://pharos.nih.gov/idg/targets/P36897,P36897,16928994,"Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease (Loeys-Dietz syndrome)"
https://pharos.nih.gov/idg/targets/P36897,P36897,16857807,"TGF-beta type I receptor kinase has a role in progression of growth and metastasis of mouse mammary carcinoma"
https://pharos.nih.gov/idg/targets/P36897,P36897,16835936,"A comprehensive genetic analysis of TGFBR1 was performed in patients with Marfan syndrome or Marfan-related phenotypes."
https://pharos.nih.gov/idg/targets/P36897,P36897,16806156,"ALK5 plays unique, non-redundant cell-autonomous roles during facial development in K14-Cre transgenic mice."
https://pharos.nih.gov/idg/targets/P36897,P36897,16528739,"Results of this analysis appear to exclude a role for the TGFBR1- or TGFBR2-mediated pathway effect in Kabuki syndrome."
https://pharos.nih.gov/idg/targets/P36897,P36897,16428477,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,16428477,"Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer"
https://pharos.nih.gov/idg/targets/P36897,P36897,16407286,"HCV NS5A modulates TGF-beta signaling through interaction with TbetaR-I"
https://pharos.nih.gov/idg/targets/P36897,P36897,16314481,"TGFbeta1/ALK5 may alleviate scarring in chronic fibrotic disease."
https://pharos.nih.gov/idg/targets/P36897,P36897,16170343,"reports the first molecular analysis of MSSE tumours showing loss of heterozygosity of the MSSE region, with loss of the normal allele, providing the first evidence that MSSE is a tumour suppressor gene"
https://pharos.nih.gov/idg/targets/P36897,P36897,15961557,"Pituitary cells, which demonstrate reduced expression of dopamine beta2 receptor, also show reduction of TGFbeta1 type I receptor."
https://pharos.nih.gov/idg/targets/P36897,P36897,15955593,"the Int7G24A variant of the TGFBR1 gene predisposes to small cell lung cancer risk (meta-analysis)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15938776,"The high expressions of TGF-beta1 and TGFbR1 play important roles in spontaneous abortion."
https://pharos.nih.gov/idg/targets/P36897,P36897,15863158,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15860866,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15833881,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15731757,"possible role of heterozygous mutation in a newly described human phenotype that includes widespread perturbations in cardiovascular, craniofacial, neurocognitive and skeletal development"
https://pharos.nih.gov/idg/targets/P36897,P36897,15661740,"IL-6 increases trafficking of TGF-beta1 receptors to non-lipid raft-associated pools resulting in augmented TGF-beta1 Smad signaling"
https://pharos.nih.gov/idg/targets/P36897,P36897,15599934,"Genetic alterations reflecting mismatch repair of TGFBR1 gene do not occur in small bowel carcinoid tumors."
https://pharos.nih.gov/idg/targets/P36897,P36897,15546867,"TGF-beta induces biglycan expression through ALK5 and GADD45beta"
https://pharos.nih.gov/idg/targets/P36897,P36897,15505640,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15498571,"Bikunin neither decreased expression of TGF-beta receptors (TbetaRI and TbetaRII) in cancer cells nor altered the specific binding of 125I TGF-beta1 to the cells."
https://pharos.nih.gov/idg/targets/P36897,P36897,15496141,"NEDD4-2 functions like Smurfs 1 and 2 in that it associates with TGF-beta type I receptor via Smad7, and induces its ubiquitin-dependent degradation"
https://pharos.nih.gov/idg/targets/P36897,P36897,15459392,"Dpr2 binds to the TGFbeta receptors ALK5 and ALK4, and accelerates lysosomal degradation of these receptors"
https://pharos.nih.gov/idg/targets/P36897,P36897,15385056,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15382067,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15382067,"Mutation in the TGFBR1 gene is associated with carcinomas of the kidney and bladder"
https://pharos.nih.gov/idg/targets/P36897,P36897,15305380,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,15247277,"sphingosine 1-phosphate receptors and the transforming growth factor beta-type I receptor serine/threonine kinase are essential for activation of Smad3 by lysophospholipids"
https://pharos.nih.gov/idg/targets/P36897,P36897,15178549,"endogenous IGFBP-3 directly inhibits proliferation of human intestinal smooth muscle cells by activation of TGF-betaRI and Smad2, an effect that is independent of its effect on IGF-I-stimulated growth."
https://pharos.nih.gov/idg/targets/P36897,P36897,15155736,"transforming growth factor-beta signaling has a role in receptor RI induction by histone deacetylase activity inhibition in breast cancer cells"
https://pharos.nih.gov/idg/targets/P36897,P36897,15146427,"that an increased TGFbetaRI:TGFbetaRII ratio may underlie aberrant TGFbeta signaling in SSc and contribute to elevated basal collagen production"
https://pharos.nih.gov/idg/targets/P36897,P36897,15102771,"combined production of the immunosuppressants IL-10 and TGF-beta, as well as coexpression of TGF-beta RI and RII (required for cellular response to TGF-beta), may act to down-modulate host anti-Mycobacterium tuberculosis immunity"
https://pharos.nih.gov/idg/targets/P36897,P36897,15009106,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,14718519,"Blocking Smad7 expression by RNA interference inhibits association of GADD34-PP1c complex with TbetaRI."
https://pharos.nih.gov/idg/targets/P36897,P36897,14704634,"expression values for TGF 1 and its receptors I, II, and III were twice as high in the group of patients with a diagnosis of high-grade lymphomas as in the group of patients diagnosed with low-grade lymphomas"
https://pharos.nih.gov/idg/targets/P36897,P36897,14597484,"a C-to-T single-nucleotide polymorphism (C-509T) in the TGF-beta1 gene promoter may be associated with altered gene expression and asthma phenotype"
https://pharos.nih.gov/idg/targets/P36897,P36897,12947057,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,12873459,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,12607775,"TGF-beta1 receptor expression in peritoneal fibroblasts was increased by hypoxia or hypoxia plus TGF-beta1, but decreased by TGF-beta1 alone."
https://pharos.nih.gov/idg/targets/P36897,P36897,12446693,"elucidation of smad requirement in transforming growth factor-beta type I receptor-induced responses"
https://pharos.nih.gov/idg/targets/P36897,P36897,12358857,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,12202987,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,12145287,"CD44 interaction with the TGF-betaRI kinase promotes activation of multiple signaling pathways required for ankyrin-membrane interaction, tumor cell migration, and oncogenic events during HA and TGF-beta-mediated metastatic breast tumor progression"
https://pharos.nih.gov/idg/targets/P36897,P36897,12082094,"Hypertrophic maturation of chondrocytes in induced by the TGF-beta type I receptors."
https://pharos.nih.gov/idg/targets/P36897,P36897,12060054,"present in diabetic foot ulcer"
https://pharos.nih.gov/idg/targets/P36897,P36897,11867510,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P36897,P36897,11820800,"TGF beta type I receptor mRNA concentration on the surface of human osteoblasts is increased by 1 alpha,25-dihydroxyvitamin D3 due to changes in receptor mRNA stability not associaed with an increase in the rate of gene transcription."
https://pharos.nih.gov/idg/targets/P36897,P36897,11746979,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28723952,"we conclude that LRRK2 G2019S mutation most likely originated in a Berber founder who lived at least 5000 years ago."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28679601,"Semiquantitative DaT-SPECT could be used to predict early conversion to Parkinson disease (PD) in asymptomatic carriers of the LRRK2 G2019S mutation. Rate of conversion to PD at 4 years in this cohort aged approximately 64 years was 12%. The slope of DaT binding decline on DaT-SPECT imaging seems to be similar across different stages of the premotor period."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28647363,"These results indicate that LRRK2 and alpha-synuclein participate in the dysregulation of CADPS2 by altering transcription and support the hypothesis that synaptic dysfunctions, through different mechanisms, might contribute to the neuronal defects of diseases such as Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28582422,"The Parkinson's disease-associated LRRK2 mutant G2019S impairs DRD1 internalization, leading to an alteration in signal transduction. The mutant forms of LRRK2 also affect receptor turnover by decreasing the rate of DRD2 trafficking from the Golgi complex to the cell membrane."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28453723,"Data elucidate the mechanism underlying the increased microtubules association of select pathogenic LRRK2 mutants or of pharmacologically kinase-inhibited LRRK2, with implications for downstream microtubule-mediated transport events."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28406934,"DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28321439,"Study created a conditional LRRK2 G2019S (LRRK2 GS) mutant and a functionally negative control, LRRK2 G2019S/D1994A (LRRK2 GS/DA). Overexpression of LRRK2 GS in mouse forebrain induced behavioral deficits and alpha-synuclein pathology in a kinase-dependent manner."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28320779,"Overexpression of CHIP decreased intracellular protein levels of both G2385R mutant and wild-type LRRK2, while short interfering RNA CHIP knockdown had the opposite effect"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202711,"Structural interface between LRRK2 and 14-3-3 delta protein has been presented."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202680,"Studies indicate a functional interaction between leucine-rich repeat kinase 2 (LRRK2) and protein kinase A (PKA) cross-talk in neuron and microglia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202674,"studies suggest that leucine-rich repeat kinase 2 (LRRK2) found in exosome isolates from CSF may be an indicator of fluctuations of LRRK2 expression in the brain."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202670,"Studies indicate that protein aggregation of alpha-synuclein and tau, is intimately linked to the effects of leucine-rich repeat kinase 2 (LRRK2) mutations in Parkinson's disease (PD) brains."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202669,"Studies suggest that leucine-rich repeat kinase 2 (LRRK2) may be capable of interacting with different proteins at different times and places, therefore, controlling a plethora of diverse functions based on the different complexes formed."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202668,"Leucine-rich repeat kinase 2 (LRRK2) can interact with several Rab proteins, and such ractions may serve to recruit LRRK2 to distinct subcellular organelles to phosphorylate select substrate proteins involved in membrane trafficking events."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202667,"Studies indicate alterations in the catalytic activities of the leucine rich repeat kinase 2 (LRRK2) mutants and increased phosphorylation of select substrate proteins known to be crucial for membrane trafficking between specific cellular compartments."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202666,"Studies indicate that Innate immunity involves macrophages and microglia, in which endogenous leucine-rich repeat kinase 2 (LRRK2) expression is precisely regulated and expression is strongly up-regulated upon cell activation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202665,"Studies indicate that overexpression of pathogenic mutant leucine-rich repeat kinase 2 (LRRK2) is sufficient to induce an apoptotic-like cell death in isolated neurons."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28202664,"In addition to disease modeling, leucine-rich repeat kinase 2 (LRRK2) konckin (KI) mice represent a valuable resource for pharmacological studies."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28158614,"Our results suggest LRRK2 may be involved in a wide variety of cellular processes and the results from this screen provide an important genetic resource for further evaluation of LRRK2 function"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28131193,"The LRRK2 R1441C mutation was found in a Chinese early-onset Parkinson Disease patient for the first time. Literature review found that the manifestations of LRRK2-R1441C carriers were indistinguishable from sporadic Parkinson Disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28102045,"Inflammation seems to be associated with the presence of a specific clinical subtype in PDLRRK2 that is characterized by a broad and more severely affected spectrum of motor and non-motor symptoms"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28099919,"we have identified a novel genetic association between the autophagy-related LRRK2 gene and susceptibility to SLE."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,28071824,"There was no significant difference between nonmanifesting family members with and without a LRRK2 mutation in any of the 5 HRV parameters investigated."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27913672,"Structural model suggests that regulation of the leucine-rich repeat kinase 2 (LRRK2) kinase domain is mediated by the N-terminal part of the protein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27913671,"Studies indicate the protective R1398H variant within the leucine-rich repeat kinase 2 (LRRK2) GTPase domain as a valuable control for pathogenic mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27913670,"Studies indicate there are alternative screening approaches that could be taken to investigate compounds that modulate leucine-rich repeat kinase 2 (LRRK2) cellular functions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27913669,"Studies suggest that leucine-rich repeat kinase 2 (LRRK2) does not depend on guanine nucleotide exchange factors or GTPase-activating proteins for activation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27913668,"Once localized to membranes, leucine-rich repeat kinase 2 (LRRK2) then influences downstream events, evidenced by changes in the autophagy-lysosome pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27884177,"Study found elevated LRRK2 levels in CD14++ and CD16+ monocyte subsets of Parkinson's disease patients, but not in patients' B-cells; and a dysregulation of monocyte subpopulations was detected in LRRK2 overexpressing mice."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27863501,"The results of this study strengthen the link between LRRK2 and the innate immunity system underscoring the involvement of inflammatory pathways in the neurodegenerative process in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27839916,"LRRK2 G2385R genotype may not be associated with cognitive dysfunction in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27832104,"One LRRK2 variant, A211V, exhibited a modest increase in kinase activity, whereas only the pathogenic mutants G2019S and I2020T displayed significantly altered auto-phosphorylation. Each of the variants tested induced apoptotic death of cultured neurons similar to pathogenic LRRK2 in a FADD-dependent manner."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27830463,"this study reveals that LRRK2 is a new positive regulator of Rip2 and promotes inflammatory cytokine induction through the Nod1/2-Rip2 pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27814993,"interaction between LRRK2 and PARK16 loci variants do not influence risk of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27812199,"a pivotal role of LRRK2 in hematopoietic fate decision"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27798102,"Carriers of additional Mendelian gene variants have younger ages at onset (AAO). The effect of additional Mendelian variants in LRRK2 G2019S mutation carriers, of which ATP13A2 variation is particularly common, may account for some of the variation in penetrance"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27794539,"phosphoproteomic and interactome study in the Drosophila brain provides a systematic analyses of R1441C hLRRK2-induced pathobiological mechanisms in this model. We demonstrate for the first time that the R1441C mutation located within the LRRK2 GTPase domain induces the enhanced phosphorylation of SV proteins in the brain"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27777137,"the important contribution of LRRK2 G2019S mutations to parkinsonism in Brazilian families."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27709685,"In contrast to PD, common LRRK2 variants do not appear to play a major role in determining PSP and corticobasal degeneration risk."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27699718,"This study demonstrated suggested that although olfactory function in LRRK2-PD patients is impaired, it is similar to that in Parkinson's Disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27692902,"Genetic variability in DNM3 modifies age of onset for LRRK2 Gly2019Ser parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27653520,"Asymptomatic LRRK2 mutation carriers showed functional connectivity changes in striatocortical and nigrocortical circuits compared with noncarriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27631370,"propose that the interplay between LRRK2 and p62 may contribute to the pathophysiological function and homeostasis of LRRK2 protein"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27613114,"Four cases were heterozygous for the LRRK2 c.6055G > A mutation, giving an allele frequency of 1.4 % in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27449028,"Parkinson's disease is associated with mutations in LRRK2 gene in Ashkenazi Jews."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27430880,"The G2019S mutation is associated with increased asymmetry and variability among nonmanifesting participants and patients with PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27423549,"each mutation in LRRK2 and ARHGEF7 demonstrated its unique functional property, which may contribute to the pathogenesis of Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27399248,"This study showed that LRRK2, PARK2 and ATP13A2 are under copy number variations influence in patient with Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27384489,"R1628P polymorphism of the LRRK2 gene contributes to Parkinson's disease susceptibility in Asian, especially Chinese, populations.[meta-analysis]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27314038,"This is the first report of LRRK2 I2020T and G2385R GTPase activities and shows that most of the LRRK2 mutations that are pathogenic or a risk factor altered either kinase or GTPase activity, suggesting that their physiological consequences are caused by altered enzyme activities."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27220776,"This study showed that Parkinson disease patients as well as those with LRRK2 mutations present with increased levels of the pro-inflammatory serum markers indicating a common disease status-specific pattern."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27133195,"the C allele, GC and CC genotype of LRRK2 R1628P variants contribute to the susceptibility of Parkinson disease in Asian. [meta-analysis]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27111571,"We discovered a new missense mutation in the LRRK2 gene, c.4321C>A (p.R1441S).  LRRK2 p.R1441S represents the fourth pathogenic mutation observed within codon 1441 and its discovery adds to the remarkable complexity of a mutational hotspot within the ROC domain of the LRRK2 protein"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27093107,"decreased levels of miRNAs targeting LRRK2 might result in a gain of function for LRRK2, and by extension, loss of neuronal viability"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27091104,"G2385R and G2019S Parkinson's disease appear to have motor differences"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27063942,"LRRK2 transgenic mice develop motor impairment and selective activation of CB2 receptor partially reversed the deficits."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27041685,"The CSF protein profile differs in LRRK2-associated PD and idiopathic PD, suggesting that pathophysiological mechanisms different from IPD underlie LRRK2-associated PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27023913,"Knockdown of either ULK1 or DLP1 expression with shRNAs suppresses LRRK2 G2019S expression-induced mitochondrial clearance, suggesting that LRRK2 G2019S expression induces mitochondrial fission through DLP1 followed by mitophagy via an ULK1 dependent pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,27004687,"This is the first study indicating that Sp1 signaling plays an important role in the regulation of human LRRK2 gene expression."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26985725,"The present study demonstrates that MB expression of hLRRK2 in flies recapitulates the clinical features of the sleep disturbances in PD, and that melatonin attenuates hLRRK2-induced sleep disorders and synaptic dysfunction, suggesting the therapeutic potential of melatonin in PD patients carrying LRRK2 mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26965688,"Pathogenic mutations in LRRK2 comprise the most common cause of familial, late-onset Parkinson's disease, and are found both in hereditary as well as sporadic forms of the disease. (Review)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26947123,"Mutation in the PARK8 locus encoding for the leucine-rich repeated kinase 2 protein (LRRK2 also named dardarin) is the most frequent cause of autosomal-dominant forms of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26930193,"Data show that cyclin-dependent kinase 5 (Cdk5) could phosphorylate the adjacent S1627 in the leucine-rich repeat kinase 2 (LRRK2) R1628P mutant."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26917005,"Peripheral inflammation is higher in a percentage of Parkinson subjects carrying the LRRK2 G2019S mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26894577,"PP2A is a new interacting partner of LRRK2"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26865512,"Elevated ratio of phosphorylated LRRK2 to total LRRK2 in urine predicted parkinsonian phenotypes in male LRRK2 carriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26844546,"The results support a preferential association of LRRK2 variants with excessive pro-inflammatory responses in Leprosy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26824392,"Pathogenic LRRK2 variants mapping to different functional domains increase phosphorylation of Rab GTPases and this strongly decreases their affinity to regulatory proteins."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26747879,"none of the G2019S or R1441G/C/H mutations of LRRK2 were found in any of the 125 screened patients with Idiopathic REM Sleep Behavior disorder."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26744328,"Our findings demonstrate that SP1 attenuates mutant LRRK2-induced PD-like phenotypes and plays a neural protective role."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26687033,"LRRK2 p.Gly2385Arg can explain most if not all of the PD association at rs1994090 in East Asians, but other nonsynonymous variants are independent."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26686514,"Asymptomatic carriers of the R1441G-leucine-rich repeat kinase 2 mutation have evidence of dopaminergic nigrostriatal denervation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26675812,"Parkinson disease is likely a pathogenically heterogeneous condition and it suggests the existence of specific mechanisms involved in LRRK2-associated PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26651604,"Induced pluripotent stem cells - derived sensory neurons with Parkinson's Disease-related LRRK2 G2019S mutation exhibited normal neurite length but had large microtubule-containing neurite aggregations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26600626,"The LRRK2 p.G2019S mutation is not an important causal factor of Parkinson Disease in Colombia having similar frequencies to those reported in other Latin American populations"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26536050,"Results indicate that non-manifesting carriers of the G2019S mutation in the leucine-rich repeat kinase 2 gene have a specific cognitive profile with executive functions"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26519280,"Fibroblasts isolated from skin biopsy specimens from patients with genetic forms of Parkinson's disease, carriers of mutations in LRRK2 and PARK2 genes, and from a healthy volunteer were reprogrammed into induced pluripotent stem cells."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26468079,"This study demonstrated that The sleep phenotype in leucine-rich repeat kinase 2 mutations parallels that of idiopathic PD, except for absent rapid eye movement sleep behavior disorder here in the presymptomatic and symptomatic stages."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26403521,"The assays offer a high-throughput method of monitoring LRRK2 kinase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26384650,"Phosphorylation of p53 by LRRK2 induces p21(WAF1/CIP1) expression and apoptosis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26375402,"p21-activated kinase 6 (PAK6) as a novel interactor of leucine-rich repeat kinase 2 (LRRK2), a kinase involved in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26366513,"This study demostrated that G2019S LRRK2 mutation parkinson disease and REM sleep behavior disorder."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26365310,"Lrrk2 phosphorylates and inhibits focal adhesion kinase."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26355680,"findings suggest that the alteration of Notch signaling in mature neurons is a component of PD etiology linked to LRRK2"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26346174,"Cognitive impairments are not correlated with different LRRK2 S1647T polymorphisms in Chinese Parkinson's individuals."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26311745,"Parkinson disease LRRK2 risk variant carriers showed greater motor progression compared with noncarrier patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26310572,"The LRRK2-R1441C Parkinson disease-related mutation results in decreased GTPase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26306001,"Most asymptomatic LRRK2 with possible surrogate markers of parkinson's disease such as abnormal dopamine transporter imaging-SPECT"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26268663,"This study showed the presence of six LRRK2 p.G2019S and nine GBA p.N370S mutation carriers in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26268594,"LRRK2 facilitates tau phosphorylation indirectly by recruiting tau or cdk5 rather than by directly phosphorylating tau"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26234753,"LRRK2 A419V variant is a risk factor for Parkinson's disease in Asian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26213354,"This sttudy showed that the Novel LRRK2 mutations in Parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26177462,"Sleep complaints are frequent in LRRK2-Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26159606,"In C. elegans carrying human LRRK2 and alpha-synuclein, expressing alpha-synuclein with G2019S or WT LRRK2 caused age-related synergistic inhibition of autophagy and increase in degeneration of dopaminergic neurons, especially in those expressing G2019S LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26123485,"Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26062626,"Penetrance of LRRK2 G2019S in Ashkenazi Jews is only 26% and lower than reported in other ethnic groups."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26056228,"I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3beta signaling pathway"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26014385,"LRRK2 regulates intracellular Tau levels, contributing to the progression of the pathology caused by the LRRK2-mediated proteasome impairment."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26011561,"results are consistent with increased iron load in LRRK2- and Parkin-mutation carriers. The increased R2* in asymptomatic PD-mutation carriers suggests that iron deposition occurs early during the preclinical phase of the disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,26009181,"we review current knowledge about the link between LRRK2, TPC- and Rab-mediated vesicular trafficking to and from the late endosome related to Parkinson's disease ."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25962553,"In this meta-analysis, sporadic Parkinson's disease is characterized by a sex effect, with more affected men than women, LRRK2-associated Parkinson's disease lacks a sex effect."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25952961,"A rare association of LRRK2 and GBA mutations in a Brazilian family with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25939886,"Calyculin A treatment prevents inhibitor and PD mutant induced dephosphorylation and reverts LRRK2 to a lesser ubiquitinated species, thus directly implicating phosphatase activity in LRRK2 ubiquitination"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25926623,"The interaction between G2019S LRRK2 and actin-regulatory proteins can be blocked by LRRK2 kinase inhibitors, although we did not find evidence that LRRK2 phosphorylated these interacting proteins"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25899316,"Comprehensive mutation screening of selected exons of LRRK2 was performed in 486 Serbian Parkinson disease patients showed that G2019S is the most common, pathogenic mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25888648,"Recently, using animal models, several attempts have been made to understand if LRRK2 may mediate sensitivity to environmental neurotoxicants."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25842821,"In this review LRRK2 influence on protein aggregation, cytoskeletal dynamics, apoptosis rate and inflammatory response is discussed."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25840672,"Mutations of the LRRK2 gene in Parkinson's disease patients were associated with less cognitive and neuropsychiatric impairment."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25834052,"LRRK2 kinase inhibition decreases HIV-1 Tat-induced phosphorylation of p38 MAPK and JNK in microglia cells"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25830304,"neither the expression of wild type or mutant LRRK2, nor the inhibition of LRRK2 kinase activity affect neurite complexity and cellular adhesion"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25821816,"These data suggest that most of the variants despite being located in different domains of LRRK2 appear to exert a potential pathogenic effect possibly through an increased kinase activity, supporting a gain of function mechanism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25809001,"Carriers of the G2019S LRRK2 mutation have subtle non-motor symptoms, possibly early/prodromal features of Parkinson."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25804954,"LRRK2 and tau do not interact to exacerbate behavioral, biochemical or pathological abnormalities in neurodegeneration and that LRRK2 and tau exert their pathogenic effects through independent mechanisms."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25786808,"Data showed that whole-blood mRNA signatures correlating with LRRK2 genotype and with PD disease state."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25761573,"we demonstrated an association between a known PD risk variant, LRRK2 R1628P, with ET. Subjects carrying the R1628P variant had twice the risk of developing ET."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25731749,"These observations suggest a potential role for kinase activity in LRRK2-associated Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25703537,"reviewed current knowledge on the link between LRRK2 and several diseases, including PD, AD, CD, leprosy, and cancer, and discussed the possibility of targeting LRRK2 in such diseases"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25650144,"This cross-sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2-related Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25648416,"Interactions involving LRRK2, a protein of largely unknown function linked to familial forms of Parkinson's disease. [Review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25605758,"results suggest that LRRK2 kinase activity functions as a Rab5b GTPase activating protein and thus, negatively regulates Rab5b signalling"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25521227,"Findings confirm that LRRK2 is a susceptible gene to leprosy in Han Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25511328,"An association analysis of R1628P and G2385R polymorphisms of LRRK2 showed that they are not risk factors for multiple system atrophy in a Chinese Han population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25500533,"Phosphorylation of LRRK2 by casein kinase 1alpha regulates trans-Golgi clustering via differential interaction with ARHGEF7."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25487881,"The Parkinson's disease motor phenotype and motor scores were similar in the LRRK2-associated Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25446991,"findings reveal a previously unidentified target of LRRK2 G2019S, showing that Bcl-2 serves as a point of crosstalk between LRRK2 G2019S-mediated mitochondrial disorder and dysregulation of autophagy"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25434972,"Genetic carriers for LRRK2 were more likely to manifest the postural instability gait difficulty in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25427558,"LRRK2 and clathrin-light chains co-localize on endosomes and inhibit Rac1 activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25416817,"TPC2 is thus a potential drug target within a pathogenic LRRK2 cascade that disrupts Ca(2+)-dependent trafficking in Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25401981,"This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially hormone-related cancer and breast cancer in women."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25401511,"Lewy body pathology is not present in all patients with LRRK2-related Parkinson disease. The mutation p.G2019S is more frequently associated with LB pathology compared with other LRRK2 mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25394383,"novel insights into the multiple mechanisms that dictate the association between LRRK2 and mitophagy in sporadic Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25378673,"Findings provide evidence that LRRK2 exonic variants may contribute to susceptibility to multiple system atrophy"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25360523,"Rab32 may regulate the physiological functions of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25353650,"Data indicate that leucine rich repeat kinase 2 (LRRK2) is genetically linked to Parkinson's disease (PD) and the potent LRRK2 inhibitors PF-06447475 is brain penetrant."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25316291,"LRRK2 containing pathogenic Roc-COR domain mutations associates with deacetylated microtubules, and inhibits axonal transport and locomotor deficits."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25301747,"Results suggest that LRRK2 alters actin dynamics and F-actin structure both in brain neurons and skin fibroblasts, indicate that LRRK2-dependent changes in the cytoskeleton might have functional consequences on postsynaptic NMDA receptor localization"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25243190,"Screened the G2385R and R1628P variants of the LRRK2 gene in 1,202 Malaysian subjects consisting of 695 Parkinson's disease cases and 507 controls."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25228699,"Data indicate that a unique ATP-binding pocket structure in leucine-rich repeat kinase 2 (LRRK2) allows for potent and specific activity-selective and mutant-selective small molecule inhibitors."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25201882,"LRRK2 regulates the anterograde endoplasmic reticulum (ER)-Golgi transport through anchoring Sec16A at the endoplasmic reticulum exit sites (ERES)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25174890,"This study demonistrated that LRRK2 mutation(R1441C) cause the abnormalitie of nuclear of midbrain dopaminergic neurons."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25127457,"This study demonistrated that significant differences were not detected between R1441G-PD and i-PD in cognitive, depression and anxiety scales."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25107341,"This study provided that G2019S LRRK2 confers a hyperkinetic phenotype."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25080504,"Regulation of Rab7 activity by mutant LRRK2 in Parkinson's disease impairs membrane trafficking at very late stages of the endocytic pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25062988,"Study suggests that non-motor symptoms are quite common in Chinese Parkinson's disease population and that there are no differences in the non-motor symptom phenotype between patients with and without LRRK2 G2385R and R1628P variants"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25048644,"This stuidy do not support an association between LRRK2-G2019S mutation and an increased cancer risk."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25027012,"Results suggest that the LRRK2 G2385R variants contribute to the susceptibility of Parkinson's disease (PD) especially in Chinese PD. Meanwhile, it is possible that age is not the risk factor to facilitate G2385R gene mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25017139,"Fibroblasts from Parkinson's disease patients with the G2019S LRRK2 mutation display a higher sensitivity to MPP+ induced autophagy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25008396,"Disease penetrance affects populations of LRRK2 parkinsonism in Tunisia and Norway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,25000966,"Neuroimaging using dopaminergic PET did not recapitulate prior studies in human LRRK2 mutation carriers. LRRK2 p.G2019S rats do not develop overt neurodegeneration; however, they do exhibit behavioral abnormalities."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24997548,"Certain LRRK2 variants appear to be generally distributed between p.R1628P and risk of developing PD in the appropriated sample-sized cohort"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24973808,"is a causative gene of autosomal dominant familial Parkinson's disease (PD)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24957201,"A discussion on the diversity of mechanisms of different pathogenic mutations and risk factor variants of LRRK2 (review)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24947832,"LRRK2 protein is redistributed from cytoplasm to filamentous aggregates after inhibition, but LRRK1 is not."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24942733,"Arsenite stress stimulates LRRK2 self-association and association with protein phosphatase 1alpha, decreases kinase activity and GTP binding in vitro, and induces translocation of LRRK2 to centrosomes"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24916379,"These data establish that LRRK2 can protect neurons from apoptotic insult through a survival pathway in which LRRK2 signals to activate Akt, and then inhibits FOXO1."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24903616,"The LRRK2*G2019S mutation status has no discernible effect on the rate of motor disease progression in Ashkenazi-Jewish Parkinson's disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24863511,"No mutations were found in both patients and controls which can be attributed to the relatively small sample size and selection bias."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24849765,"The present high-resolution melting assay is a reliable and rapid method for genotyping R1628P and G2385R loci in LRRK2 gene."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24836358,"Basal phosphorylation status varied among Ser910, 935 and 955 mutants.  T2035A kinase-inactive mutant underwent basal phosphorylation in a similar manner to WT LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24830390,"This study provides the evidence that mutant (G2019S) LRRK2 causes early-phase dysfunctions of SNpc dopaminergic neurons and impairment of corticostriatal LTD in the (G2019S) LRRK2 transgenic mouse."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24816003,"Parkinson's disease patients with LRRK2 mutations are more likely to be women, suggesting a stronger genetic load compared to idiopathic Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24794857,"This work shows that LRRK2 activity is regulated by RGS2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24788225,"LRRK2 controls monocyte attachment to endothelial cells. LRRK2 overexpression induces VCAM-1 expression and NF-kappa b transcriptional activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24777780,"Findings suggest that the interaction LRRK2-SNCA regulating their expression as the molecular basis underlying the observed Lewy Body associations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24758914,"a significant association between SNP rs66737902 in LRRK2 and the risk of developing Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24754922,"Yeast-two-hybrid screening using human LRRK2 kinase domain as bait identified microtubule associated protein 1B (MAP1B) as a LRRK2 interactor."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24729340,"changes Gly2019Ser and Gly2385Arg of LRRK2 are a rare cause of Parkinson's disease in Mexican-mestizo population"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24725412,"Study shows that ribosomal protein s15 is a key pathogenic LRRK2 substrate in Drosophila and human neuron Parkinson's disease models."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24695735,"The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24687852,"These data demonstrate a critical role of the WD40 domain within LRRK2 function."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24652679,"Results indicate that mutant LRRK2 does not affect PGRN mRNA expression or intracellular PGRN protein levels/PGRN degradation in cell culture"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24633735,"LRRK2-G2019S expression derived from human BAC constructs causes LRRK2 to be expressed in additional brain neuron subtypes in the rat such as striatal cholinergic interneurons and the substantia nigra pars compacta"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24631561,"the LRRK2 variants are unlikely to be actively involved in schizophrenia in Han Chinese."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24591621,"The R1441H mutation causes a twofold reduction in GTPase activity without affecting the structure, thermal stability, and GDP-binding affinity of its GTPase domain, Roc."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24576675,"Both the loss of capacity of LRRK2 pathogenic mutants to protect against oxidative stress and their enhancement of dysfunction may be important for the development of PD during the aging process."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24559644,"Its variant alone was associated with an increased risk for PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24482120,"G2019S carriers do not manifest changes in gray matter volume or diffusivity parameters in Parkinson's disease-related structures prior to the appearance of motor symptoms."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24470158,"This manuscript provides a detailed assessment of the possible functions of each of the six putative domains of LRRK2, and how their structure and function may be affected by Parkinsonism-associated variations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24403142,"LRRK2 levels are more important than kinase activity per se in predicting toxicity and implicate synuclein as a major mediator of LRRK2-induced neurodegeneration."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24398085,"Methylation of LRRK2 DNA is a useful diagnostic biomarker in Parkinson's disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24375786,"This study provide evidence that the novel A1442P mutant and the previously investigated R1441C pathogenic mutant exhibit increased intracellular degradation, a property reportedly demonstrated for the pathogenic LRRK2 kinase domain mutant I2020T."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24360742,"It appears to be critically involved in inflammatory pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24357540,"THis study did not detect an overall lower rate of cancers in patients with PD in comparison with cancer registry data or in LRRK2 mutation carriers in comparison with iPD patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24351927,"LRRK2 kinase activity is modulated by PKA-mediated binding of 14-3-3 to S1444; 14-3-3 interaction with LRRK2 is hampered in R1441C/G/H-mediated Parkinson Disease pathogenesis"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24339985,"two new missense mutations (R767H and S885N) regarding LRRK2 in PD patients were identified."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24326068,"The selective fluorescent NAADP analog, Ned-19, stained the same subcellular regions as LysoTracker, suggesting that these stores are the targets of NAADP action."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24275654,"Data indicate that leucine-rich repeat kinase 2 (LRRK2) selectively interacts with three beta-tubulin isoforms: TUBB, TUBB4, and TUBB6."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24262189,"Based on current literature, genetic testing of LRRK2 (particularly for G2019S) certainly has a clinical role, though it is applicable primarily in select scenarios and in certain at-risk populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24251413,"The significant increase in the expression of uncoupling protein 2 (UCP2) was only detected in affected individuals with the G2019S mutation in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24243757,"Parrkin disease in Ashkenazi Jews LRRK2 G2019S mutation carriers is similar to idiopathic PD but is characterized by more frequent lower extremity involvement at onset and PIGD without the associated cognitive impairment."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24211199,"These data highlight the autophagy and lysosomal pathways as read outs for pathogenic LRRK2 function and as a marker for disease, and provide insight into the mechanisms linking LRRK2 function and mutations"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24167564,"LRRK2 affects the levels of dopamine receptor D1 on the membrane surface in neuronal cells"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24148854,"Results link LRRK2 mutations to mtDNA damage and validate a new cellular phenotype that can be used for examining pathogenic mechanisms."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24123150,"Among patients with Parkinson disease, the G2019S mutation in the LRRK2 gene is apparently associated with increased gait variability, an increased fall risk, and the postural instability sub-type."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24095219,"Mutations in the LRRK2 gene are the most frequent genetic cause associated with autosomal dominant Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24080176,"study found no association between the LRRK2 gene and Alzheimer's disease (AD), suggesting that LRRK2 gene variants may not affect the development of AD in Han Chinese individuals"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24046064,"This study found that the G2385R variant was significantly associated with motor complications and that this variant was an independent risk factor for motor fluctuation in females."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24040382,"analysis of linkage disequilibrium of LRRK2 across different races"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24018986,"The findings of this study suggested that 22q11.2 deletions represent a novel genetic risk factor for early-onset PD with variable neuropathological presentation reminiscent of LRRK2-associated PD neuropathology"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24015287,"LRRK2 and RIPK2 variants in the NOD 2-mediated signaling pathway are associated with susceptibility to Mycobacterium leprae in Indian populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,24014121,"The results of this study supported the idea that genetic risk factors in LRRK2 for Parkinson disease are ethnicity-specific."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23967090,"this study provides novel insights into LRRK2 expression, splicing and regulation with a potential link to the etiology of CD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23963289,"This study identified three novel LRRK2 mutations and reported a higher frequency in Calabria in Italy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23938341,"The mutations in LRRK2 can cause Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23937295,"Results show sporadic Parkinson's Disease cases seem to have marked olfactory impairment already at the time of diagnosis, hyposmia is not as prominent in LRRK2 PD as in sporadic cases, and healthy LRRK2 mutation carriers have preserved sense of smell"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23937259,"identified PP1 (protein phosphatase 1) as a key LRRK2 phosphatase in physiological and pathological conditions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23932063,"In Israeli Jews with Parkinson's disease, outcome of subthalamic stimulation was not influenced by LRRK2 G2019S mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23924436,"study characterized the autophosphorylation of LRRK2 and identified Thr1348, Thr1349 and Thr1357 as the major autophosphorylation sites; results highlight the differential effects of familial mutations in LRRK2 on its conformation and enzymatic properties"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23916833,"The resulting data demonstrate that inhibition of LRRK2 kinase activity stimulates macroautophagy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23913756,"study details the allele frequencies for the novel Parkinson disease risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K-R1398H-K1423K)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23895867,"LRRK2 genetic screening should be taken into account in atypical Parkinson disease cases"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23886663,"these results define a pathway for LRRK2 extracellular release, clarify one function of the LRRK2 14-3-3 interaction and provide a foundation for utilization of LRRK2 as a biomarker in clinical trials."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23842774,"The most common mutations in an AD gene involved in FP is the LRRK2 gene whereas mutations in several other genes including the Parkin gene causes an autosomal recessive inherited form of PD"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23824357,"Our study suggests that LRRK2 G2019S does not predispose to breast cancer in a western European population"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23820587,"This study confirmed the associations of LRRK2 with parkinson disease susceptibility and fail to show significant associations of alzheimer disease genome-wide association study (GWAS) top hits with PD susceptibility in a Korean population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23771111,"A419V is not an important LRRK2 risk variant in our Asian cohort of patients with PD. Our data are further supported by a literature review which showed that 4 out of 6 published studies reported a negative association of this variant in PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23764467,"Carriers of the LRRK2 mutation had less autonomic impairment than those with idiopathic Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23726462,"This comprehensive study confirms that p.Gly2019Ser mutation of LRRK2 is the most important genetic cause of Parkinson's disease known so far in"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23664753,"Its mutation is the most common cause of genetic-related parkinsonism. (review)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23628791,"LRRK2 down-regulation potentiates manganese toxicity in both control and DAT-transfected cell as well as potentiates dopamine toxicity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23624603,"This study provides the first evidence that G2385R polymorphism of LRRK2 gene is a risk factor for sporadic Parkinson's disease in Han-Chinese population of south-eastern China."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23588498,"No pathogenic LRRK2 mutations are found in Chamorro participants on Guam who have amyotrophic lateral sclerosis and parkinsonism-dementia complex."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23531835,"Several mutations in LRRK2 and PARK2 were identified in a cohort of 216 unrelated Slovak patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23507417,"This results are consistent with a recently published study that also did not find significant interactions of either smoking or caffeine intake with SNPs in SNCA, MAPT, or LRRK2 genes"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23472874,"study found LRRK2 G2019S induced dysregulation of CPNE8, MAP7, UHRF2, ANXA1, and CADPS2; LRRK2 G2019S induced increased extracellular-signal-regulated kinase 1/2 phosphorylation; results reveal molecular details for the pathogenesis of mutant LRRK2 and possible new targets for the development of new therapeutics for patients with Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23455607,"LRRK2 has a self-perpetuating inhibitory effect on chaperone-mediated autophagy which could underlie toxicity in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23421816,"The R1628P variant within LRRK2 plays a protective role in a Han Chinese population with Alzheimer's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23389884,"he observed p.S1761R carrier frequency in Parkinson disease patients of Spanish ancestry is less than 1 per 1,000"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23379419,"Because the G2019S mutation lies in the DXG motif (DYG in LRRK2 but DFG in most other kinases) of the activation loop, we explored the structural consequence of the mutation on loop dynamics using an enhanced sampling method called metadynamics."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23357204,"Non-manifesting G2019S mutation of LRRK2 carriers and non-carriers performed similarly on the task and on all other assessed measures"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23325906,"Thr results of this study indicated that altered premotor biomarker in LRRK2 G2019S-associated PD was SN hyperechogenicity, whereas abnormal DaT-SPECT predominated in older, unaffected mutation carriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23318930,"These findings suggest that LRRK2 and microtubules mutually interact both in non-neuronal cells and in neurons"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23300640,"a significant decrease in plasma total alpha-synuclein levels in idiopathic PD"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23268655,"Our data support the concept that the LRRK2 G2385R mutation may be involved in the pathogenesis of autosomal-dominant Parkinson's disease in a Chinese family."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23250886,"This study demonistrated that asymptomatic LRRK2-G2019S mutation carriers have a functional impairment in the striatum."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23241745,"These data suggest that Ser(1292) autophosphorylation may be a useful indicator of LRRK2 kinase activity in vivo and may contribute to the cellular effects of certain Parkinson's disease mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23241358,"GTPase activity regulates kinase activity of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23227859,"The proband, with restless legs syndrome, and her sister were analyzed for mutations in LRRK2 gene and resulted to carry one heterozygous G2019S mutation in LRRK2 gene. The father, one sister, two cousins and one uncle were affected by Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23220480,"these findings suggest the possibility of a dominant-negative mechanism of neurodegeneration in PD caused by I2020T LRRK2 mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23190742,"LRRK2 kinase inhibition decreases HIV-1 Tat-induced phosphorylation of p38 MAPK and JNK in microglia cells"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23183827,"LRRK2 interactions with alpha-synuclein in Parkinson's disease brains."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23182315,"genetic variants of both SNCA and LRRK2 genes are associated with susceptibility to sporadic Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23125283,"Downregulation of miR-205 may contribute to pathogenic elevation of LRRK2 protein in the brains of patients with sporadic Parkinson's disease, while overexpression of miR-205 may suppress the abnormal upregulation of LRRK2 protein in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23115130,"common variation within LRRK2 conveys susceptibility for Parkinson's disease in individuals of European ancestry."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23082216,"A potential interaction of LRRK2 and 4E-BP1 in mammalian cells and brain, is investigated."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23075850,"results identify the nucleus as a previously unknown cellular organelle in Parkinson's disease pathology and may help to open new avenues for Parkinson's disease diagnoses as well as for the potential development of therapeutics targeting this fundamental cell structure"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23074843,"Data suggest that the mutation LRRK2 G2019S may be a rare cause of Parkinson disease in the Hungarian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,23055502,"The revelance of a mitochondrial-associated pathway was linked to LRRK2 and parkin-related pathogenesis in animal models of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22998870,"The results of this study propose a model in which LRRK2 kinase activity is part of an EndoA phosphorylation cycle that facilitates efficient vesicle formation at synapses."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988882,"REVIEW of LRRK2 biology"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988880,"The LRRK2 gene are the most common cause of Parkinson's disease and a functional association between LRRK2 and autophagy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988879,"The knowledge of the link between LRRK2 and autophagic-lysosomal clearance, including regulation of Ca2+-dependent events involving NAADP."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988878,"REVIEW: LRRK2 is highly expressed in tissue and circulating immune cells and is suggestive of a potential role for LRRK2 in innate immunity"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988877,"The LRRK2 has been associated with the process of autophagy regulation. Autophagy is an intracellular catabolic mechanism whereby a cell recycles or degrades damaged proteins and cytoplasmic organelles."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988875,"The evidence regarding a potential role of LRRK2 in the regulation of membrane trafficking from vesicle generation to the movement along cytoskeleton and finally to vesicle fusion with cell membrane."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988874,"The given the pathological events occurring at the synapses of PD patients, the presynaptic site may represent a promising target for early diagnostic therapeutic intervention."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988873,"REVIEW: cellular phosphorylation of LRRK2 and the relation to it's function/dysfunction"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988872,"The function of LRRK1 and both the physiological and the pathological roles of LRRK2 are only beginning to unfold."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988870,"bioinformatic analyses of the human LRRK2 amino acid sequence to predict the repeat size, number and likely boundaries for the armadillo repeat, ankyrin repeat, the leucine-rich repeat and WD40 repeat regions of LRRK2"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988868,"The kinase and GTPase activity of LRRK2 seem to be important in regulating LRRK2-dependent cellular signalling pathways."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988867,"The LRRK2 mutants can promote the redistribution of LRRK2 from diffuse cytosolic staining to more discrete structures, at least at high expression levels achieved in transfection experiments."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988866,"The GTPase function is therefore a pivotal functionality within the LRRK2-mediated signalling cascade which includes partners encoded by other LRRK2 domains as well as other cellular signalling partners."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988865,"The common G2019S mutation increases kinase activity in vitro suggests that altered phosphorylation of LRRK2 targets may have pathological outcomes."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988863,"results implicate compartment-specific synaptic dysfunction caused by altered protein synthesis, cytoskeletal dynamics and mitochondrial transport in LRRK2 pathogenesis and offer a new paradigm for understanding and ultimately treating LRRK2-related Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988862,"The pathogenic mutations in LRRK2 impair the nigrostriatal dopaminergic pathway, and LRRK2 plays an essential role in the dynamic regulation of autophagy function in vivo."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22988861,"The LRRK2 (leucine-rich repeat kinase 2) is a gene of unknown function that has been linked to a number a human diseases, including PD (Parkinson's disease), IBD (inflammatory bowel disease), leprosy and cancer."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22981185,"we provide further evidence that confirms LRRK2 G2385R and LRRK2 R1628P to be the common genetic risk factors for PD in a Han Chinese population from Southern China."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22956510,"This systematic review included information from >5800 unique cases.The weighted mean proportion of cases with PARK2 (parkin), PINK1, and PARK7 (DJ-1) mutations was 8.6%, 3.7%, and 0.4%, respectively. PINK1 mutations were more common in Asian subjects."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22952710,"several compounds such as IKK16, CHK1 inhibitors and GW441756 can inhibit LRRK2 Ser935 phosphorylation in cells and LRRK2 kinase activity in vitro"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22952686,"purified and active LRRK1 and LRRK2 can form dimers in their full-length conformation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22914834,"Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22914360,"the presence of the G2019S LRRK2 mutation, one of the most prevalent in LRRK2, is accompanied by a deregulation of autophagy basal levels dependent on the MAPK1/3 (ERK2/1) pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22842796,"The A allele of the LRRK2 gene G2385R polymorphism is correlated with an increased risk of PD, particularly at an age of >/=50 years."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22807999,"LRRK2 A419V variant is not a major risk factor for Parkinson's disease in different Chinese populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22773119,"The G2019S mutation in LRRK2 induces autophagy via MEK/ERK pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22736029,"LRRK2 missense mutation(G2019S) causes uncoupling protein-mediated mitochondrial depolarization."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22703868,"The LRRK2 G2019S mutation status has no discernable effect on the prevalence of levodopa-induced dyskinesias or on levodopa-induced dyskinesias latency in Israeli levodopa-treated Parkinson disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22689969,"data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22684232,"LRRK2 has minimal role as a candidate and susceptibility gene in Parkinson's disease pathogenesis among East Indians."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22669510,"Our results support the notion that SNCA variants can modify the pathogenic effect of LRRK2 mutations as described previously for Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22658533,"In a Chinese cohort of Parkinson's disease (PD) patients, multiple PD-associated genetic factors modify both penetrance and patients' ages at onset of Asian-specific LRRK2 parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22652643,"results suggest a previously undefined signaling mechanism underlying the neurotoxic effect of LRRK2 (G2019S), in which LRRK2 (G2019S) triggers oxidative stress in cells"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22639965,"The results of this study provided insights into the pathobiology of LRRK2 and suggest that LRRK2 G2019S may induce neuronal dysfunction or cell death by disturbing normal mitochondrial fission/fusion dynamics and function."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22612223,"C-terminus of LRRK2 plays an important role in maintaining enzymatic function of the protein and G2385R mutation may be associated with Parkinson's disease in a way that is different from kinase-activating mutations"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22607035,"Scientific evaluation of a patent aiming for the development of pyrazolopyridine derivatives as LRRK2 kinase inhibitors, a potential therapeutic target for combating Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22594666,"[review] The detrimental effects caused by Parkinson's disease LRRK2 mutations may initiate in the periphery and extend to the central nervous system as a consequence of increased levels of pro-inflammatory factors permeable to the blood brain barrier."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22575234,"Meta-analysis found genetic associations between four LRRKS variants (G2019S, G2385R, R1628P and A419V) and increased Parkinson isease (PD) risk; there was no evidence of statistically significant association between P755L and PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22575062,"This study demonstrated an association of the G2385R allele with risk for PD in a northern Han Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22567899,"Increased spontaneous apoptosis of peripheral blood lymphocytes is strongly associated with LRRK2 mutations in Parkinson's disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22534020,"Human I2020T LRRK2 transgenic mouse exhibited impaired locomotive ability accompanied by several dopaminergic neuron abnormalities."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22528366,"Overexpression of LRRK2 resulted in the altered splicing of two genes associated with Parkinson's disease, with an increased inclusion of exon 10 of microtubule-associated protein tau"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22525366,"LRRK2 I2020T mutation, a pathogenic mutation associated with PARK8, and found abnormal tau phosphorylation depositions in the brainstem."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22503729,"Our result indicated that SCNA, LRRK2, UCHL1, HtrA2 and GIGYF2 genes' mutations might not be a main reason for Chinese Autosomal dorminant Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22488887,"study reports the identification of a pair of identical twins with the G2109S mutation who are discordant for Parkinson's disease by more than 10 years"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22486164,"Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most prevalent genetic cause of both familial (PARK8 type with autosomal dominant inheritance) and sporadic parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22445250,"The LRRK2 p.Gly2019Ser mutation was not detected in Zambian patients with Parkinson's disease.and A novel LRRK2 missense variant (p.Ala1464Gly) of possible pathogenic role was found in one case."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22441981,"In this review we discuss recent advances and unanswered questions in understanding the pathophysiology of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22436655,"In a South Indian population, none of the samples (26 familial Parkinson Disease, 114 sporadic PD) were found to be positive for LRRK2 mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22433811,"Comparative analyses of the age-at-onset and main neurological symptoms in 13 patients with LRRK2-associated PD (8 with G2019S, 2 - V1613A and 1 - R1441C) and 80 PD patients without mutations in the LRRK2 gene did not reveal any differences."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22423108,"The basic pathobiology of LRRK2 indicates an important role for the GTPase domain and GTPase activating protein ArfGAP1 in LRRK2-mediated toxicity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22418733,"We showed a significant association of LRRK2 A419V variant among early onset PD in the ethnic Han Chinese population but not among late onset PD"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22415848,"Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22393539,"There is a role for LRRK2 function in vesicle trafficking and microtubule dynamic.Mutations in LRRK2 contribute to both familial and sporadic Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22357653,"endogenous or human LRRK2 and A53T alpha-synuclein do not interact together to influence the number of nigrostriatal dopaminergic neurons."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22342962,"enhanced neuroinflammation may contribute to neurodegeneration in Parkinson's disease patients carrying LRRK2 mutations"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22323743,"Ashkenazi Jewish patients with PD who harbor the G2019S LRRK2 mutation are more likely to have a concomitant non-skin cancer than noncarriers"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22315971,"These results suggest that changes in LRRK2 expression or activity lead to corresponding changes in mitochondrial function, autophagy, and protein translation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22303461,"LRRK2 plays an important role as a physiological regulator for phosphorylation-mediated dissociation of tau from microtubules."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22302802,"LRRK2 regulates responses in immune cells of the brain and further implicates microglial involvement in late-onset Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22253261,"LRRK2's role as a signaling hub in the cell could lead to diverse pathologies"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22251894,"The Parkinson's disease-causing mutations are likely to affect putative leucine-rich repeats in LRRK2 inter- and intramolecular interactions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22243833,"This study identified modest associations with common variants in SNCA and LRRK2 and a trend suggestive of an overrepresentation of rare variants in cases compared to controls for several genes."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22228096,"LRRK2 regulates mitochondrial dynamics in neurons by increasing mitochondrial DLP1 through its direct interaction with DLP1, and LRRK2 kinase activity plays a critical role in this process."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22204929,"The data of this study supported a role for LRRK2 in autophagy, raise the possibility that deficits in autophagy contribute to the pathophysiology of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22166428,"This review summarizes Parkinson's disease (PD)-related pathologies and abnormal motor functions, providing valuable insight into the potential LRRK2-mediated pathogenesis of PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22162019,"This report describing an Asian Parkinson's disease family with the p.Tyr1699Cys mutation in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22080837,"observations identify a novel effect of LRRK2 PD mutations and highlight a potential role for microtubules in the pathogenesis of LRRK2-related neurodegeneration"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22077787,"Through unclear mechanisms, LRRK2 kinase regulates cytoskeleton architecture through control of protein translation, phosphorylation of cytoskeletal proteins, and response to cellular stressors."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22056842,"Cognitive functions were similarly affected in Parkinson's disease patients with and without LRRK2 G2019S mutation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22047502,"The monomer form of LRRK2 is predominant within cells, and that dimerization is dispensable for its enzymatic activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22038903,"This study demonistrated that indicated that mutations interfering with LRRK2 ROC-COR domain dimerization lead to typical Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,22004453,"phosphorylation of serines 955 and 973; phosphorylation of Ser955 and 973 is disrupted in context of Parkinson's disease associated mutations; conclude mechanisms of regulation of Ser910/935/955/973 phosphorylation are similar and physiologically relevant"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21989859,"Transcranial sonography shows hyperechogenicity of the substantia nigra in both patients' cohorts as well as in asymptomatic LRRK2 mutation carriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21972245,"Ribosomal and glycolytic biological functions were significantly up-regulated in LRRK2 G2019S transgenic mice compared with LRRK2 knockout mice."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21961647,"The increased kinase activity of the G2019S mutant is substrate-dependent."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21954089,"LRRK2 Gly2019Ser mutation among Parkinson's disease patients in Cantabria (Spain) is high-frequency and reduced-penetrance."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21924942,"LRRK2 variants are an independent genetic risk factor for typical Parkinson disease, but BDNF variants can greatly increase LRRK2-induced risk for patients with an onset age of older than 60 indicating an additive effect between the 2 genes."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21922152,"LRRK2 down-regulation was associated with a clearly decreased 4E-BP1 protein in a breast cancer cell line"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21898123,"Possible interactions between genetic factors in the microtubule-associated protein tau (MAPT) region and the LRRK2 gene influence the clinical course of Parkinson disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21885347,"The results for LRRK2 show that several rare and common genetic variants in the same gene can have independent effects on disease risk. LRRK2, and the pathway in which it functions, is important in the cause and pathogenesis of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21858031,"Data show that while kinase activity of LRRK2 requires an intact ROC-GTPase domain, it is independent of GDP or GTP binding to ROC."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21857923,"Findings establish a critical functional link between LRRK2 and ER stress."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21850687,"Mutations in LRRK2 increases PRDX3 phosphorylation resulting in oxidative stress induced neuronal cell death in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21842440,"This study suggested that pathogenic LRRK2 mutation in any of our sporadic and apparently familial Ghanaian Parkinson's disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21816655,"This study provides no statistically significant evidence of gene-gene interaction effects for SNCA, MAPT and LRRK2 genes for Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21806997,"Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21799870,"LRRK2 is unlikely to play a direct role in modulation of gene expression"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21796139,"These observations support the possibility that p.G2385R is associated with an increased risk of PD (Parkinson's disease)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21753163,"Although tremor is a more common presenting feature of LRRK2-PD than iPD and some nonmotor features differed in degree, the phenotype is largely overlapping."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21753159,"Olfaction is impaired in LRRK2 G2019S-mutation related PD, although less overall than other PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21749573,"Further functional studies are required to elucidate the potential therapeutic implications involving the dimerization of Dapk1 and Lrrk2 proteins as risk factors for Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21738687,"Results provide further evidence for the emerging role of LRRK2 in immune cells and regulation at the transcriptional and translational level."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21720016,"results suggest that overexpression of LRRK2, especially G2019S mutant, whose functions remain unclear, initiate the aggregate formation, release and transmission of alpha-synuclein"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21714003,"From the results of this study suggested that the lifelong penetrance of LRRK2-G2019S mutation usually does not exceed 25% to 35%, unless family history suggests otherwise."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21699405,"The G2019S mutation in the LRRK2 gene is quite common in Egyptian patients with sporadic Parkinsons disease, and is associated with a higher degree of motor effect but does not seem to affect mentation or behavioral aspects of the disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21698001,"Transgenic rats recapitulated the initiation process of dopaminergic dysfunction caused by pathogenic mutation in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21696411,"Our data suggest that widespread dysregulation of LRRK2 mRNA expression may contribute to the pathogenesis of IPD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21679126,"Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) play a major role in the development of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21676337,"discusion of recent progress in understanding how LRRK2 mutations lead to Parkinson disease and how this might have therapeutic implications [review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21661047,"This studty identified two novel mutation related to Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21658387,"Data show that LRRK2 directly phosphorylates Akt1, a central molecule involved in signal transduction for cell survival and prevention of apoptosis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21641848,"Healthy LRRK2 mutation carriers presented subclinical parkinsonian motor and non-motor signs in the apparent absence of olfactory loss"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21641266,"Families of patients with LRRK2 mutations and susceptibility alleles need to be informed about the current lack of disease preventative strategies and the implications surrounding incomplete penetrance [review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21632271,"The frequency of Lrrk2 p.Q1111H varies greatly in Latin American populations and suggests that this variant may have originated in an Amerindian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21611983,"The results of the present study suggest a potential predictive value of olfactory and MIBG data in a clinical context. Both R1441G and G2019S mutations produced similar results in this study."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21611978,"The results of this study suggested that possible association between premorbid mood disorders and leucine-rich repeat kinase Parkinson's disease, warranting further evaluation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21552986,"The resullts of this study speculated that the role of Lrrk2 in immune cells may also be relevant to the susceptibility of developing PD or its progression."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21538529,"G2019S is not ubiquitously the most common leucine-rich repeat kinase 2 mutation; in Campania R1441C is more frequent."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21494637,"Expression of G2019S mutant LRRK2 induces the degeneration of nigrostriatal pathway dopaminergic neurons in an age-dependent manner."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21483109,"LRRK2 G2019S mutation does not contribute to Parkinson's disease in South India. Our findings support the current view that G2019S-associated PD may be population-specific."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21454543,"pathological mutations in LRRK2 attenuates activation of Rac1, causing disassembly of actin filaments, leading to neurite retraction."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21449009,"The frequency of mutations was greater in Puerto Ricans than in non-Puerto Ricans (25.0% vs 1.0%, Fischer's exact test, P = .01). Mean age at onset and sex did not differ between groups"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21406209,"LRRK2 Pro755Leu variant rarely increased risk for PD in ethnic Chinese population in Asia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21370995,"LRRK2 can interact directly with uMtCK to block its entry into mitochondria and its subsequent processing."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21362567,"Dopaminergic neurons derived from G2019S-induced pluripotent stem cells showed increased expression of key oxidative stress-response genes and alpha-synuclein protein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21353620,"The study concluded that the lrrk2 p.Gly2019Ser mutation is a rare cause of disease in this Danish cohort of patients with neurodegenerative disorders."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21312285,"The results suggested that the TCS findings of patients with the common G2019S mutation in the LRRK2 gene are not substantially different from idiopathic parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21307259,"The LRRK2 modulates synaptic vesicle trafficking and distribution in neurons and in consequence participates in regulating the dynamics between vesicle pools inside the presynaptic bouton"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21280089,"association between the LRRK2-G2019S mutation carriers and gait; during dual-tasking and fast-walking, gait variability and the amplitude of the dominant peak of the accelerometer signal were significantly altered among the carriers"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21238487,"Autosomal dominant missense mutations in the gene for leucine-rich repeat kinase 2 (LRRK2/PARK8) are the most common known cause of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21234781,"absence of G2019S, I2012T, and I2020T in 624 ethnic Chinese Parkinson's disease patients from Taiwan"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21221623,"MIBG cardiac uptake in parkinsonian patients with LRRK2 mutations is abnormal but less impaired than in idiopathic Parkinson's disease , a finding that might be attributed to neuropathological heterogeneity among LRRK2 patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21220347,"Data indicate that MET and LRRK2 cooperate to promote efficient tumor cell growth and survival in these cancers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21168496,"Mutant human LRRK2 is highly expressed in the hippocampus in the dorsal root ganglia and subventricular zone of adult transgenic mice."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21167764,"Leucine-rich repeat kinase 2 (LRRK2 S1647T) genetic variant is associated with increased risk of Parkinson's disease in a Taiwanese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21159540,"our study demonstrates the association of LRRK2 R1398H with decreased risk of Parkinson's disease in a Han Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21115957,"Our results provide evidence for impaired mitochondrial function and morphology in LRRK2(G2019S) mutant patient tissue."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21088684,"The leucine-rich repeat kinase 2 (LRRK2)mutation is related to Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21073465,"LRRK2 Tyr1699Cys kinase domain strengthens intra-molecular catalytic core interactions which alter the inter-molecular dimerization ultimately leading to altered GTPase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21072187,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21060682,"Together the identification of LRRK2's phosphorylation consensus motif, and the functional consequences of its phosphorylation, provide insights into downstream LRRK2-signaling pathways"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,21048939,"Downstream effects of phosphorylation of ARHGEF7 through LRRK2 could be (i) a feedback control mechanism for LRRK2 activity as well as (ii) an impact of LRRK2 on actin cytoskeleton regulation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20969957,"This review discusses recent advances in understanding the impact of mutations in LRRK2, which have yielded insights into synaptic dysfunction as a possible early pathogenic mechanism in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20949042,"detected four arrayed Ste20 serine/threonine kinase family members (TAOK3, STK3, STK24, STK25) as novel LRRK2 substrates and LRRK2 interacting proteins, respectively"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20939082,"dopamine turnover was found to be elevated in asymptomatic LRRK2 mutation carriers at increased risk of Parkinson Disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20933457,"behavioral abnormalities, mostly depression and hallucinations, were more frequent in the LRRK2 G2019S carriers"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20933457,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20921534,"These observations indicate that LRRK2 is an IFN-gamma target gene, and it might be involved in signaling pathways relevant to Crohn's disease pathogenesis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20881132,"Expression of LRRK2 transgenes increases the recruitment of autoactivated Shaggy protein, thus inducing hyperphosphorylation and mislocalization of tau with resultant dendrite degeneration."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20850369,"The phenotype and assay described provides a means to develop therapeutic agents that modulate the toxic gain-of-function conferred by mutant Lrrk2"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20818658,"Odor identification is diminished in LRRK2 parkinsonism but not to the same extent as in idiopathic Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20818658,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20818610,"our findings indicate an increased risk of nonskin cancers in LRRK2 G2019S mutation carriers, which may be related to toxic gain of function of mutated LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20818610,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20729864,"Disease-segregating mutations in LRRK2 lead to neurotoxicity in Parkinson disease, and inhibitors of this enzyme may protect against Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20727385,"LRRK2 mutations Gly2019Ser, Arg1441Gly, and Arg1441His may be rare causes of Parkinson's disease among Mexican-mestizos."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20727385,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20722494,"Mutations R1441G, R1441C, R1441H, G2019S, Y1699C, I2020T, and I2012T were not found in 320 Eastern Indian Parkinson disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20722494,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721916,"This study indicated that Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721916,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721913,"The present study underscores the importance of the LRRK2 gene in the Tunisian parkinson disease population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721913,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721910,"Our data, while limited by a small sample size, show that in LRKK2 G2019S mutation carriers, phenoconversion to PD can occur late in life."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20721910,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20720502,"The localization of LRRK2 protein in the core of a subset of Lewy bodies (LB) demonstrates the contribution of LRRK2 to LB formation and Parkinson disease pathogenesis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20711177,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20697102,"PARK16 single nucleotide polymorphisms (SNPs)are found to be associated with a decreased risk in Parkinson's disease (PD), while PARK1 and PARK8 SNPs are associated with an increased risk of PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20697102,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20673920,"The present study confirms that the LRRK2 Gly2385Arg variant is a risk factor for sporadic parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20673920,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20671708,"LRRK2 interacts with the microRNA (miRNA) pathway to regulate protein synthesis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20669305,"Genetic studies have revealed a novel pathogenic LRRK2 mutation c.4309 A>C (p.Asn1437His) that co-segregates with disease manifestation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20669299,"investigated the frequency of common LRRK2 variants by complete exon sequencing in a series of publicly available African American Parkinson's disease patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20669299,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20659558,"We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20629711,"LRRK2 S1647T increases the risk of Parkinson's disease in southern China"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20629711,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20626563,"a new model is proposed for a possible function of LRRK2 and the consequence of the G2019S LRRK2 pathogenic mutation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20595391,"Using phospho-specific antibodies, study found that all three putative autophosphorylation sites are phosphorylated in LRRK2, and two are important sites that regulate LRRK2 kinase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20571044,"Our results and those of others also suggest that LRRK2 R1628P may have originated in the area of modern Thailand thousands of years ago."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20544233,"This reveals that the four South African G2019S-positive probands (three Caucasian and one of mixed ancestry) share a common ancestor with the other haplotype 1-associated Parkinson's disease families reported worldwide."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20515039,"multiple events, including altered protein-protein interactions and post-translational modifications, contribute to the regulation of LRRK2 function, through modulation of membrane association and complex assembly"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20506312,"Studies indicate that molecular genetic analyses have identified five disease genes associated with familial Parkinson disease; SNCA, PARK2, PINK1, PARK7 and LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20483373,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20473834,"Data suggest that LRRK2 mutations do not appear to be a common cause of Parkinson's disease in Extremadura, Spain."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20473834,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20443975,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20413974,"The frequency of LRRK2 G2019S is 30-41% in familial PD and 30-39% in apparently sporadic Parkinson disease in North Africa."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20386743,"results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20382224,"Our transgenic LRRK2 C. elegans models recapitulate key features of PD including progressive neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and reduction in dopamine levels."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20379614,"Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20232069,"The cerebral cortex in familial PD linked with G2019S LRRK2 is affected in a similar way than that seen in sporadic parkinson disease without cognitive impairment."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20197701,"The clinical and pathological data reviewed suggested specific mutations may be associated with alternative PSP-like degeneration phenotypes. different effect on Lrrk2 kinase activity may play a role in such heterogeneity a role in such heterogeneity"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20197411,"G2019S mutation of LRRK2 arose independently at least twice in humans."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20186690,"Data provided the first evidence that multiple LRRK2 variants excert an individual effect and together modulate the risk of PD among Chinese."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20186690,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20182943,"We compared Mini-Mental State Examination performance and self-reported cognitive impairment in early onset Parkinson diseaseparticipants genotyped for mutations in parkin, leucine-rich repeat kinase-2, and glucocerebrosidase"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20182943,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20108944,"Systematically mapped LRRK2 phosphorylation sites by mass spectrometry. Our analysis revealed a high degree of constitutive phosphorylation in a narrow serine-rich region preceding the LRR-domain."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20096956,"These data show that the G2019S mutation affects the entire body and highlight some of the molecular events observed in the brain"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20090955,"results suggest that 4E-BP is a relatively poor direct substrate for LRRK2"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20074637,"LRRK2 was associated to a small but significant induction of SNCA, which was suppressed by treatment with the selective MAPK/ERK kinase inhibitor U0126."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20067578,"These data demonstrate that MKKs and LRRK2 function in similar biological pathways, and support a role for LRRK2 in modulating the cellular stress response."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20018961,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20018409,"The LRRK2 R1628P variant increases the risk of Alzheimer disease in our population and our in vitro findings suggest that it is a functional variant and predisposes to apoptosis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20018409,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20008657,"Early-onset Parkinson disease G2019S LRRK2 carriers are more likely to manifest the tremor dominant phenotype."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20008657,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20004703,"Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,20001906,"This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinson's disease-associated mutants do not appear to have reduced GTP hydrolysis activities."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19945904,"Estimated frequencies of the LRRK2 G2019S mutation in Parkinson's disease in different populations were found to be variable"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19915576,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19915575,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19912990,"These results suggest that higher susceptibility of I2020T mutant LRRK2 to intracellular degradation than the wild-type molecule may be one of the mechanisms involved in the neurodegeneration associated with this LRRK2 mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19890007,"A mutation in LRRK2 causes a gain-of-function effect that promotes the rearrangement of actin cytoskeleton."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19879329,"We identified a novel mutation in LRRK2 gene, which was the first mutation of LRRK2 found in the mainland Chinese population with familial Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19878656,"these results suggest the possibility that in PD and related synucleinopathies, oxidative stress upregulates alpha-syn and Lrrk2 expression, paving the way for pathological interactions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19854095,"This study supports that the LRRK2 G2385R variant may be a genetic risk factor for sporadic Parkinson's disease n the Korean population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19854095,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19847307,"LRRK2 may have a role in the development of Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19847307,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19833102,"these results indicate a novel molecular feature characteristic to I(2020)T LRRK2, and provide a new insight into the mechanism of neurodegeneration caused by LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19826009,"Some PD-associated mutations that increase kinase activity in vitro significantly increase the proportion of dimer structures relative to total LRRK2 protein"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19824698,"Ser1403, Thr1404, Thr1410, Thr1491 located within the ROC domain, as well as Thr1967 and Thr1969 in the kinase domain, were identified as the autophosphorylation sites of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19822953,"LRRK2 p.G2019S mutation is not common among Alzheimer's disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19822953,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19804413,"LRRK2 in Parkinson's disease [review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19800393,"Four novel sequence variations (IVS49+178A>G, p.R1725Q, p.Q1823K, and p.D2175H) may be associated with PD status, albeit they may be very rare non-disease associated variations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19770575,"These data demonstrate the key role of LRRK2 in regulating autophagy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19769964,"LRRK2 kinase domain increases the generation of ROS and causes enhanced neurotoxicity under H(2)O(2) treatment"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19760754,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19756366,"LRRK2 protein distribution coincides with brain areas most affected by Parkinson's disease. The G2019S mutation is believed to be responsible for up-regulation of LRRK2 kinase activity, which may ultimately play a role in neuronal loss (Review)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19741132,"Transgenic Drosophila overexpressing LRRK2 variant G2019S, but not the wild-tpe protein, exhibit late-onset loss of dopaminergic neurons accompanied by locomotion deficits."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19735093,"This is the first neuropathological study of parkinson disease associated with brain with the R1441G mutation in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19733152,"These data suggest that the kinase and GTPase activities of LRRK2 may exhibit complex autoregulatory interdependence."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19726410,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19714762,"Multiple single nucleotide polymorphisms in LRRK2 gene is associated with 12q12 locus with Crohn Disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19699188,"Our results confirm that the LRRK2 R1628P variant contributes to the pathogenesis of Parkinson's disease in Chinese Han populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19699188,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19692353,"Ubiquitous expression of hLRRK2 increased lifespan and fertility of the flies."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19680143,"LRRK2 normally localizes to the endosomal-lysosomal compartment within morphologically altered neurons in neurodegenerative diseases, particularly in the brains of patients with Lewy body diseases."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19672984,"The data of this study confirmed that the LRRK2 R1628P variant is associated with an increased risk to develop late onset Parkinson's disease in the ethnic Han-Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19672984,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19640926,"Data demonstrate the functional involvement of LRRK2 in the endosomal-autophagic pathway and the recruitment to specific membrane microdomains suggesting a novel function for this important PD-related protein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19640773,"The Gly2385Arg variant of LRRK2 may not be a major risk factor for AD in pure Han Chinese patient."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19640773,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19625511,"data suggest that LRRK2 plays an important role in modulating the response to mitochondrial inhibition and that mutations in LRRK2 may selectively enhance dopaminergic neurons' susceptibility to a stressor associated with Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19625296,"The LRRK2 Roc-COR domain and the DVL1 DEP domain were necessary and sufficient for LRRK2-DVL1 interaction."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19576176,"G2019S mutation in Lrrk2 may cause Parkinson disease by generating pathological levels of phosphorylated alpha synuclein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19570025,"In this review, LRRK2 mutations are discussed as a surprisingly common cause of inherited Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19559761,"These findings suggest that the interaction between LRRK2 and EF1A may reciprocally modulate their physiological function."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19545277,"LRRK2 binds and phosphorylates brain tubulin-beta, enhancing tubulin polymerization in the presence of microtubule-associated proteins (MAPS) which may contribute to increased neurite outgrowth."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19538213,"We screened a cohort of 88 clinically confirmed progressive supranuclear palsy (PSP) patients for mutations in exon 31. there is no evidence that mutations in exon 31 of LRRK2 are a major risk factor for PSP."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19538213,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19536328,"LRRK2 stability is regulated by the E3 ubiquitin ligase CHIP"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19535993,"Our data identify the ability of LRRK2 to form inclusion-like aggregates that do not associate with alpha-synuclein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19527940,"The LRRK2 mutation is not associated with essential tremor."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19527940,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19513331,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19489756,"low frequency alleles distributed throughout LRRK2 are a genetic background to a third of Parkinson's disease cases."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19489756,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19473361,"G2019S and R1441G are common LRRK2 mutations in Parkinson's disease (PD) patients in southern Spain. PARKIN mutations override clinical features in LRRK2-associated PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19473361,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19472409,"all LRRK2 variants reported are interpreted and their contribution to Parkinson disease is examined"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19458969,"LRRK2 or GBA mutations have roles in the initial presentation of Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19412725,"The G2019S*LRKK2 mutation is more prevalent in Ashkenazi Parkinson disease patients than in controls or non-Ashkenazi patients, and its contribution to malignant melanoma predisposition in Jewish individuals needs to be explored further"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19412725,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19405094,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19397894,"These observations suggest that LRRK2 I2020T may prove resistant to inhibition with ATP-competitive kinase inhibitors in vivo or in cellular systems."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19357115,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19353692,"In Iranian Parkinson's disease patients at least 0.5% of young cohort and in 3.5% of the familial cases was associated with a mutation in the five exons of LRRK2 screened."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19353692,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19343804,"LRRK2(G2385R) mutations appear to be rare among Japanese patients with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19343804,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19330201,"In PARK2 and PARK8 patients, the frequency of mutation was 10.1%, predominantly in women but PARK8 patients did not have a relevant family history of Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19330201,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19308469,"Data suggest that the R1441G mutation of Lrrk2 originated in the Basque population and that dispersion of the mutation then occurred through short-range gene flow that was largely limited to nearby regions in Spain."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19302196,"Our findings present evidence of a new class of molecular targets for mutant LRRK2 that link to neurotoxicity, cellular stress, cytoskeletal dynamics and vesicular transport"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19283415,"Data suggest that Ashkenazi Jews with LRRK2 G2019S mutation share a common ancestor who lived approximately 1,830 (95% CI 1,560-2,160) years ago, around the second century, after the second Jewish Diaspora."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19224617,"This study found that modest Modest associations (uncorrected P < 0.05) were observed for common variants around LRRK2 in Australia patient with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19224617,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19205068,"In this study identified the familial cases (late onset), 1 patient had a novel LRRK2 variant, Q923H."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19205068,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19204172,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19196961,"HSP90 forms a complex with LRRK2, and inhibition of HSP90 chaperone activity by 17AAG leads to proteasomal degradation of LRRK2, resulting in increased cell viability"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19172321,"Results reveal a Turkish patient heterozygous for the G2019S mutation sharing the Japanese haplotype, and is the first time that the G2019S-associated Japanese haplotype has been reported in a different population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19076219,"only the most prevalent clinical mutation,G2019S, results in a robust enhancement of kinase activity with LRRKtideas the substrate"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19065525,"structure, function, mutation type and pathogenic mechanism of LRRK2 in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19041274,"No association was found between age at onset in patients with LRRK2-linked Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19029519,"PET study of presymptomatic members of our LRRK2 kindred revealed dopaminergic dysfunction that progressed over time."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19025767,"current state of knowledge regarding the domain structure, amino acid substitutions, and potential functional roles of LRRK2; role in Parkinsion disease [review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19021752,"it has been suggested that LRRK2 functions as an upstream regulator of Parkinson's disease pathogenesis; this minireview explores this model, in the context of current understanding of the biochemistry of LRRK2, alpha-synuclein & tau [review]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19020907,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,19006185,"A new LRRK2 mutation L1165P was associated with hippocampal neurofibrillary tangles. phospho-Ser-129-containing alpha-synuclein & cytoplasmic TDP-43 inclusions in the temporal cortex were seen in this pt and one with R793M but not those with G2019S."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18986508,"Lifetime penetrance of LRRK2 in relatives of families with multiplex Parkinson's disease is greater than reported in sporadically ascertained LRRK2 cases."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18986508,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18981379,"study found that dyskinesias were significantly more frequent in North African Parkinson disease patients with the G2019S mutation than in noncarriers"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18981379,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18980856,"LRRK2 mutations in Parkinson disease are widely distributed across South America but might differ by region in prevalence."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18980856,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18973807,"The identification of autosomal-dominant mutations in the leucine-rich repeat kinase 2 gene (LRRK2) in a significant proportion of cases in some populations redefine the role of genetic susceptibility in Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18973254,"The most common LRRK2 mutation, G2019S, was not detected in this cohort, suggesting that this mutation does not play a major role in Dutch early-onset Parkinson disease patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18973254,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18952485,"This study demenestrated that pathogenic variant (R1441H) has been identified in four probands of diverse ethnicity with parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18936941,"Data show that the proportion of LRRK2-immunopositive glial cytoplasmic inclusions is negatively associated with an increase in neuronal loss and alpha-synuclein-immunopositive dystrophic axons in multiple system atrophy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18927607,"No pathogenic mutations were found in LRRK2 protein and are not a frequent cause of Parkinson disease in Nigeria."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18927607,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18923807,"LRRK2 P755L is a non-disease-associated polymorphism in sporadic Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18923807,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18848304,"No case of LRRK2 gly2019ser mutation were found in parrkinson disease in Basque."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18809839,"Odor identification is diminished in LRRK2 G2019S mutation parkinsonism but the asymptomatic carriers of the mutation had normal olfaction."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18809839,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18805725,"LRRK2 G2019S and R1441C mutations associated with Parkinson's disease were not an uncommon mutation in a Sardinian population. The detection of the G2019S variant in ten unaffected relatives confirms a reduced penetrance of the underlying mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18805725,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18804399,"This study of PARK8-linked parkinsonism affecting several members of the same pedigree shows that the same gene mutation can induce diverse neuropathologies, even if the clinical picture and PET findings are virtually identical."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18781329,"LRRK2 R1628P may have a role in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18752982,"This study suggests that the LRRK2 gene may be a risk factor or the cause for a very small fraction of Parkinson's disease in American white population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18752982,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18718805,"From the results of this study were unable to identify a presymptomatic marker of LRRK2-related parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18716801,"The Arg1628Pro variant is a second risk factor for Parkinson's disease in the Han Chinese population. Adding the estimated effects of Arg1628Pro and Gly2385Arg variants yields a total population attributable risk of approximately 10%."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18716801,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18704525,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18701920,"chronic inactivation of 4E-BP by LRRK2 with pathogenic mutations deregulates protein translation, eventually resulting in age-dependent loss of DA neurons"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18675914,"Cells expressing LRRK2 mutants suffer a loss of protection normally derived from wild-type LRRK2, making them more vulnerable to oxidative stress."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18666856,"Genetic screening of the G2019S mutation of the LRKK2 gene in Southwestern European, North African. and Sepahrdic Jewish subjects is reported."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18666856,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18665323,"The high frequency of Lrrk2 G2019S in the Ashkenazi and its absence in the Yemenite Jews suggests a specific ancestral pattern of inheritance in Ashkenazi Jews."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18665323,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18644660,"A report on the relationship between age at onset, clinical course and genotype in a family with combined LRRK2 G2019S and Parkin exon 2 deletions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18634852,"LRRK2 may have direct functional role(s) in the neurophysiology of A9 midbrain doopaminergic neurons"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18621566,"The G2019S mutation frequency of the LRRK2 gene is rather low in overall patients (0.8%) and in the familial group (1.7%), suggesting that it may be an uncommon cause of Parkinson's disease in Southern Italy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18621566,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18617409,"We identified no patients with any of the studied mutations/polymorphisms. Very low prevalence of the LRRK2 G2019S mutation has been reported in other southern European populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18617409,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18602856,"Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are an important cause of late-onset, familial and sporadic Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18556235,"findings indicate that the role of LRRK2 gene in conferring susceptibility to essential tremor is not relevant in Italian population"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18544747,"Insights into the molecular effects of some of the Parkinson disease-associated mutations of LRRK2, but may also help to improve understanding of intrinsic control mechanism between GTPase and a protein kinase within the same protein."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18541113,"The wide clinical-pathologic variability associated with LRRK2 mutations points to the existence of strong modifiers, which are still unknow."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18539535,"LRRK2 Gly2019Ser in Arab-Berber patients from Tunisia considerably increases susceptibility to neuronal degeneration, although the process might be mediated by many triggers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18539535,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18539534,"Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18539534,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18523869,"clinical phenotypes and [(18)F]-dopa PET findings for subjects with R1441H or G2385R resembled those of patients with idiopathic PD; however, their lymphoblastoid cell lines showed increased apoptosis following exposure to a proteosome inhibitor"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18523869,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18523722,"The mean age of Parkinsonism onset among LRRK2 G2385R carriers was 42.7 years old for early-onset compared to 74.3 for late-onset patients. LRRK2 G2385R mutation appears to be as prevalent among early-onset as late-onset patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18523722,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18486522,"In this study found two individuals were heterozygous for the common p.G2019S mutation in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18486522,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18484993,"the overall prevalence of the G2019S mutation in LRRK2 in German Parkinson's disease patients is apparently somewhat lower than in patients from other nearby European countries"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18484993,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18464276,"PARK8 might be the second most important disease causing gene in early-onset Parkinson's disease Brazilian patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18464276,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18450497,"We conclude that the Gly2385Arg variant is not associated with primary dystonia in Taiwan."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18450497,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18445495,"Results suggest that LRRK2, in conjunction with its interaction with Rab5b, plays an important role in synaptic function by modulating the endocytosis of synaptic vesicles."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18435766,"investigate the frequency of LRRK2 mutations in a sample of Russian Parkinson's disease patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18435766,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18434642,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18412265,"Herein we show evidence for leucine-rich repeat kinase 2 (LRRK2) c.4883G>C (R1628P) as a Parkinson Disease risk factor in ethnic Chinese populations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18412265,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18397888,"LRRK2 is a dimer that undergoes intramolecular autophosphorylation"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18379513,"The clinical picture of all patients with the LRRK2-G2019S mutation was typical for levodopa-responsive parkinsonism and age of disease onset varied widely (from 39 to 71 years)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18379513,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18378882,"Observational study of gene-disease association and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18353371,"LRRK2 G2019S mutation occurred in patients with parkinsonism associated with either typical brainstem LB pathology or non-specific nigral degeneration, were not encountered in other neurodegenerative disorders associated with synuclein and tau deposition."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18353371,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18338801,"Role of LRRK2 in cell signaling and its impact on proliferation, differentiation, and survival of neurons and mutation in Parkinson disease [REVIEW]"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18337586,"Age of onset and clinical features in Lrrk2 Arg1441Cys patients are similar to idiopathic and Lrrk2 Gly2019Ser parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18322396,"LRRK2 is directly associated with the pathological structures of Parkinson's disease, dementia with Lewy bodies, and other related disorders using highly specific antibodies to LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18322385,"Overexpression of human LRRK2 strongly protects Caenorhabditis elegans against cellular responses to the mitochondrial toxin rotenone."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18316234,"The LRRK2 Gly2385Arg variant is not a significant risk factor for ET in the population of this study."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18316234,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18272292,"LRRK2 are active in the adult human cortex cerebri, hippocampus and striatum. Also seen in the young human thymus and tubular parts of the adult human kidney."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18265005,"The lack of functional data, absence of segregation of the variant with disease, and the presence of the variant in apparently healthy individuals suggest that P755L is possibly a rare polymorphism in the Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18265005,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18230735,"The ROC domain may regulate LRRK2 kinase activity as a dimer, possibly via the C-terminal of ROC (COR) domain as a molecular hinge."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18214993,"At a subcellular level, endogenous LRRK2 colocalizes with alpha/beta-tubulin in primary hippocampal neurons and interacts with microtubules, a structural component of the cell that is critically involved in the pathogenesis of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18213618,"sequencing of all coding exons in a series of 275 PD cases and 275 neurologically normal controls and analysis of the LRRK2 locus for whole gene multiplications or deletions"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18213618,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18211709,"This study found mutations in LRRK2 genes. Seven of the studied patients showed pathogenic mutations, in compound heterozygosity for LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18211709,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18201824,"Our findings suggest that the LRRK2 p.G2019S mutation has a substantial contribution to PD susceptibility among Brazilian population and add new clues to current research of this disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18201824,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18201193,"LRRK2 p.2385G>R substitution contributes to the development of PD in ethnic Han-Chinese population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18197194,"prevalence of mutations in two major functional domains of the leucine-rich repeat kinase 2 gene (LRRK2) in Belgian Parkinson's disease (PD) patients (N=304) of which 18.1% were familial PD patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18182054,"These results indicate an active role for autophagy in neurite remodeling induced by pathogenic mutation of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18098275,"Results suggest a broader clinical heterogeneity related to LRRK2 mutations."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18097693,"changes in the expression profiles of SH-SY5Y cells, a dopaminergic neuroblastoma cell line, induced by a depletion of LRRK2 levels by RNA interference"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18097165,"Mutations in LRRK2 as a cause of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,18045479,"Endogenous human LRRK2 expression is detected during development in temporal lobe."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17999435,"The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17978862,"show that the LRRK2 sequence and expression patterns are conserved between pig and human"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17971075,"an association of LRRK2 with possible early-stage alpha-synuclein pathology in the brainstem of Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17960808,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17960808,"LRRK2 Gly2385Arg variant is a potential ethnic-specific genetic risk factor of Parkinson's disease within Chinese Han ethnicity"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17938369,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17938369,"Our data suggest that the LRRK2 G2019S mutation plays an important role in the causality of familial and sporadic Parkinson disease (PD) in Israel and that gender affects its frequency among patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17914064,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17914064,"The clinical presentation of LRRK2-associated neurodegenerative disease may be more heterogeneous than previously assumed."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17880562,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17880562,"glycine2019serine mutation of LRRK2 suggests a pivotal role in Greek patients with sporadic-late onset Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17868389,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17846883,"we did not detect the G2019S mutation in any of 769 Italian Alzheimer disease patients"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17846883,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17804834,"Results identify five novel variants in LRRK2, which correlate with familial later-onset Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17803033,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17803033,"In our cohort, we were unable to detect any of the known mutations in these exons or identify novel mutations within the LRRK2 gene."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17803032,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17803032,"We performed a case-control association study in 125 French-Canadian (FC) patients with PD and 95 FC controls and found that common variants in LRRK2 are unlikely to be a significant cause of late-onset PD in this founder population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17720280,"The common Gly2385Arg Asian variant of LRRK2 is unlikely to play a major role or modulate the risk of Alzheimer's disease in this Asian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17720280,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17706965,"LRRK2 may play a central role in integrating pathways involved in neuronal cell signaling and the pathogenesis of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17659642,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17659642,"The relevance of Gly2385Arg as a genetic risk factor of parkinson disease may be restricted to selected Asian races."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17639429,"Lrrk2 is linked to frontotemporal atrophy of PPND type caused by N279K tau mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17625107,"The results fit with the concept that in LRRK2 PD, parkinsonism, cardiac sympathetic denervation, and baroreflex failure can result from a common pathogenetic process."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17622782,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17622782,"The results also show that G2019S represents approximately half of the LRRK2 mutations in United States PD cases with a family history of the disease. We have identified two novel mutations in LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17614198,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17614198,"Lrrk2 G2019S may play an important role in Parkinson's disease on the South American Continent"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17611037,"Lrrk2 immunohistochemical staining was present in the subventricular zone, a region containing stem cells that give rise to both neurons and glia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17596714,"The LRRK2 G2019S mutation is as frequent in families with possible autosomal recessive PD (2.2%) as in the sporadic cases published elsewhere (1.9%)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17584768,"autophosphorylation of LRRK2 is an intermolecular reaction and targets two residues within the activation segment, the G2019S mutation enhances the catalytic activity of LRRK2."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17540608,"Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17540608,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17523199,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17523199,"This study detected a novel missense mutation (S973N) in a patient with familial, late-onset and dopa-responsive PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17512502,"Involvement of LRRK2 in the molecular pathogenesis of familial and sporadic parkinsonism, with enzyme localization in the nigrostriatal dopaminergic pathway."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17482357,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17482357,"Therefore, we conclude that LRKK2 P755L variant is a rare cause of Caucasian PD and has no diagnostic utility in genetic testing of this population of patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17470139,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17470139,"LRRK2 G6055A mutation in Italian patients with familial or sporadic Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17469194,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17469194,"The G2019S mutation of the LRRK2 gene is a very common genetic determinant among the Portuguese patients with Parkinson's disease, and the R1441H mutation is also present in this population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17447891,"Only one of the mutations analysed, namely G2019S, stimulated kinase activity. Four mutations inhibited LRRK2 kinase activity (R1941H, I2012T, I2020T and G2385R), whereas the remainder (R1441C, R1441G, Y1699C and T2356I) did not influence activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17440812,"dysfunction of LRRK2 protein leads to neurodegeneration in parkinson disease--REVIEW"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17433753,"A founding haplotype for the G2019 (6055G>A) mutation of the LRRK2 gene was identified in our data and it is shared by families from Tunisia, US, European and Middle Eastern countries."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17427941,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17427941,"G2019S mutation carriers share the same ancestors who migrated to Australia originally from Europe and that other LRRK2 mutations (R1441H and A1442P) can be found in this population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17419834,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17409193,"Studies of protein domains in LRRK2 (LRR and WD40) show that disease-associated mutant LRRK2 cell toxicity is due to mitochondria-dependent apoptosis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17395370,"study indicated that the I2020T mutation, an essential pathogenic mutation of PARK8-related Parkinson's disease, had occurred independently in the two Parkinson's disease families"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17394548,"mutations in LRRK2 are more prone to form inclusion bodies in transfected cells and are more toxic than equivalent mutations in LRRK1"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17388990,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17388990,"frequency of the LRRK2 G2019S was 0.7% amongst the sporadic Parkinson's disease patients (2/291) and 7.7% amongst familial Parkinson's disease (1/13) in Russia"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17385669,"The results of this pilot project indicate significant alterations in key signalling proteins in leukocytes from patients with PD, and were most pronounced in G2019S-associated PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17377919,"Common variaations occur in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17353388,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17353388,"We identified 2 novel variants. Although the phenotype of LRRK2 mutation carriers closely resembles that of typical PD, the age at onset was younger (29 years in 1 patient) than previously described, and 3 patients were improved by deep brain stimulation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17352347,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17341485,"Study describes the localization of LRRK2 in Golgi apparatus, plasma membrane and synaptic vesicles in HeLa and SH-SY5Y cells."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17335904,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17324517,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17314670,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17314670,"Our results suggest that the LRRK2 G2385R variant is a risk factor for sporadic Parkinson disease in the Asian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17260967,"binding of GTP to the ROC domain regulates the kinase activity of LRRK2 as well as its phosphorylation by other kinase(s)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17253937,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17253937,"The R1441G mutation was absent in our Parkinson's disease sporadic cases, but the G2019S mutation was present in 2 of them (1.9%)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17235449,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17235449,"These results confirm that the G2019S mutation is a relevant cause of sporadic Parkinson's disease cases in the Italian population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17230458,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17230458,"it is concluded that the G2019S mutation in the LRRK2 gene is unlikely to be associated with multiple system atrophy"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17225181,"Comparison of evolutionary interspecies sequences of LRRK1 and LRRK2 suggests they diverged from a common founder gene implicated in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17222580,"Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17222106,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17222106,"LRRK2 mutations are present in patients with autosomal dominant Parkinson's disease (AdPD)and sporadic PD patients of Greek origin."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17216639,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17215492,"This study provides accurate estimates of G2019S penetrance by minimizing the selection bias."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17200152,"Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17187665,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17187665,"These data suggest that the G2385R variant contributes significantly to the etiology of PD in ethnic Han Chinese individuals."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17179858,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17179858,"A novel P755L mutation in LRRK2 gene associated with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17160203,"The recent identification of a common genetic variant (LRRK2 G2385R) which is associated with a two-fold increased risk of sporadic Parkinson's Disease (PD) in two independent Chinese populations in Singapore and Taiwan."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17151837,"This study identified a LRRK2 mutation leading to the G2019S amino acid substitution in a 79-year-old woman with frontotemporal lobar degeneration with ubiquitinated neuronal intranuclear inclusions and a possible family history of tremor."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17149721,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17116211,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17116211,"Possibility of genetic testing for the G2019S mutation in patients with sporadic Parkinsin disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17115391,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17115391,"The frequency of mutations in Tunisian families was 42% (38/91) and in U.S. families 2.6% (1/39), with the unique opportunity to compare homozygous (n = 23) and heterozygous (n = 109) Tunisian carriers of G2019S substitutions."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17097110,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17097110,"Hispanic female was heterozygous for the LRRK2 R1441G mutation, and six other cases including 2 non-Jewish/non-Hispanic whites, 3 Ashkenazi Jewish, and 1 Hispanic, were found to be heterozygous for the LRRK2 G2019S mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17083102,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17080443,"Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17078063,"These results indicate that, although the G2019S mutation remains the most common mutation identified in familial PD patients, other mutations in LRRK2 are infrequent."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17060595,"R1441H LRRK2 mutation underlies disease entities representing transitional forms between Parkinson Disease and progressive supranuclear palsy."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17052850,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17050822,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17050822,"The G2019S mutation is a risk factor in both early- and late-onset Parkinson disease and confirms the previous report of a greater frequency of the G2019S mutation in Jewish than in non-Jewish cases with Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17044089,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17044089,"In Russia the frequency of the G2019S mutation was greater in familial PD (2 [3.9%] of 51) than in sporadic PD (1 [0.6%] of 157)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17020475,"Observational study of genetic testing. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17019612,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17019612,"heterozygous Gly2385Arg genotype remained associated with an increased risk of Parkinson disease compared to wild type genotype (odds ratio = 2.67, 95% CI: 1.43-4.99, P = 0.002)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17017534,"LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism--REVIEW"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,17017533,"LRRK2 mutations are relatively common genetic causes of familial and sporadic Parkinson disease--REVIEW"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16991141,"Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16966681,"The Parkinson disease gene LRRK2: evolutionary and structural insights."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16966502,"Parkinson disease related to LRRK2 is characterized by typical clinical features, and the similarities between patients with homozygous and heterozygous mutations do not support a gene dosage effect."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16966501,"Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16966498,"Mutation of LRRK2 are the most common cause of Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16939701,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16928343,"LARRK2 displays a clinical, and a pathologic, phenotype that resembles very closely the common forms of patkonson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16865326,"We screened 54 patients with ALS for seven known Lrrk2 pathogenic substitutions in the Roc, COR and kinase domains. No mutations were observed suggesting that this locus does not have a major influence on the ALS phenotype."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16822348,"Pathogenic mutations in the LRRK2 gene cause a significant proportion of clinically typical, late-onset PD. This review summarizes the current knowledge on the contribution of LRRK2 mutations in understanding parkinsonism."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16817197,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16781064,"Glucocerebrosidase and LRRK2 mutations are discrete risk factors for parkinsonism in both Ashkenazi Jewish and non-Jewish subjects."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16758483,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16750929,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16750929,"Clinical features in carriers were those of typical, idiopathic Parkinson's disease; however, behavioural abnormalities were frequent (87%), suggesting a more widespread limbic involvement in G2019S carriers."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16750377,"Neurons and neuronal cell lines undergo cell death after expression of this mutant protein in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16750377,"The toxic effects of mutant LRRK2 protein can be prevented by altering the kinase domain so that the protein is \"kinase-dead\"."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16728648,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16671078,"In patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16643318,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16633828,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16633828,"Our findings suggest that the LRRK2 Gly2385Arg is the first identified, functionally relevant variant, which acts as common risk factor for sporadic PD in the population of Chinese ethnicity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16632201,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16632201,"LRRK2 mutation has a relatively high frequency in the population o fAshkenazi Jewish , is not fully penetrant for parkinsonism in the elderly, and does not appear to be commonly associated with late-onset dementia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16622859,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16622859,"Mutation frequency raised from 1.2% in early onset PD to 4.0% in late onset Parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16622854,"Heterozygous misssense mutations in exon 41 are common in Parksinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16616379,"This review places the PD-associated mutations of leucine-rich repeat kinase 2 (LRRK2) in a structural and functional framework, with the ultimate aim of deciphering the molecular basis of LRRK2-associated pathogenesis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16614029,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16614029,"Our objectives were to determine G2019S mutation frequency in an unselected, community based cohort of idiopathic PD cases from the UK and to describe phenotypic characteristics among carriers"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16602113,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16602113,"We highlight the first case of LRRK2 R1441C mutation in late onset sporadic PD of non-European ancestry. Furthermore, extensive mutational screen found LRRK2 mutations to be rare among patients who presented with PSP, MSA, CBGD, and AP."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16533964,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16533964,"The G2019S mutation frequency in PD patients from northeast Spain is similar to that reported in other European regions. The R1441G mutation is very uncommon in Catalonia."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16511860,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16511860,"The extreme rarity of the G2019S mutation in Taiwan in Parkinson disease suggests the occurrence of this mutation resulted from a common European founder"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16467219,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16467219,"This is the first comprehensive analysis of common variability within LRRK2 as a risk factor for Parkinson's disease (PD)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16437559,"Lrrk2 G2019S was observed in approximately 2% (n = 8) of Parkinson's disease/Lewy body disease cases (n = 405)."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16436782,"The G2019S mutation appears to be an important cause of both familial and sporadic Parkinson's disease in a group of Ashkenazi Jewish subjects."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16436781,"the frequency of the G2019S mutation in this gene is remarkably high in North African Arabs with familial Parkinsons's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16352719,"LRRK2 may be involved in a pathogenic pathway with other parkinson's disease (PD) -related proteins such as parkin, which may help illuminate both familial and sporadic PD"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16333314,"LRRK2 mutations are frequent in autosomal dominant Parkinson's disease, and they cluster in the C-terminal half of the encoded protein"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16321986,"The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16298482,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16275903,"examination of mutations responsible for Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16272257,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16272257,"the G2019S mutation in LRRK2 is the most common genetic determinant of Parkinson's disease identified so far"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16269541,"results suggest a gain-of-function mechanism for LRRK2-linked disease with a central role for kinase activity in the development of Parkinson disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16269443,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16269443,"The first evidence that common genetic variation within LRRK2 contributes to the risk of sporadic PD in the Chinese population was provided."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16254973,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16254973,"We have therefore no evidence for the existence of a common variant in LRRK2 that has a strong influence on Parkinson's disease risk"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16251215,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16250030,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16250030,"LRRK2 G2019S is the single most common pathogenic mutation linked to neurodegenerative disease to date."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16247070,"Sequence analysis of 29 exons coding for functional domains of LRRK2 in 160 nondominant Parkinson disease patients was performed. Two novel variants (R1067Q and IVS33 + 6 T>A) were found, which are likely to be pathogenic in five patients."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16240353,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16240353,"LRRK2 mutations appear to be a common cause of autosomal dominant PD, particularly in North Africa."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16172858,"Lrrk2 pathogenic substitutions may have a role in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157909,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157909,"These data confirm the important contribution of LRRK2 to PD susceptibility in a clinic-based population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157908,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157908,"Thus LRRK2 mutations only rarely cause idiopathic PD."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157901,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16157901,"The common coding variations in the LRRK2 gene neither constitute strong PD risk factors nor modify the age at onset; however, the possibility of a modest risk effect remains to be assessed in large datasets."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16149095,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16149095,"G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16145815,"analysis of a common founder effect in the G2019S mutation of LRRK2 dating from the 13th century"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16115731,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16115731,"It can be concluded that the G 2019 S and I 2020 T mutations in exon 41 of LRRK 2 gene are rare causes of Parkinson disease in a Polish population."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16102903,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16102903,"We screened for the most common LRRK 2 mutation in a series of patients with Parkinson's Disease, Alzheimer's disease, Progressive Supranuclear Palsy, Multiple System Atrophy and frontotemporal dementia, as well as in neurologically normal controls."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16087219,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,16001413,"A healthy octogenarian shows that a G2019S mutation carrier can live to old age free parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15955629,"Observational study of genotype prevalence and gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15955629,"This longitudinal analysis provides preliminary evidence that changes in platelet MAO activity and cholesterol, which may reflect changes in central serotonergic activity are associated with attention deficit in adolescents."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15955578,"The LRRK2 mutation as a cause of Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15929036,"the G2019S mutation of LRRK2 is responsible for 1 to 2% of Parkinson disease patients in a North American population"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15925109,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15884041,"Missense mutation Gly2019Ser of LRRK2 gene is associated of parkinson disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15880653,"missense mutation in the kinase domain of the LRRK2 gene in members with autosomal dominant Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15852371,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15732108,"we describe two families with autosomal dominant Parkinson's disease caused by a LRRK2 G2019S mutation."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15726496,"our study demonstrates that LRRK2 G2019S accounts for parkinsonism in several families within Europe and North America. Our work highlights the fact that a proportion of clinically typical, late-onset PD cases have a genetic basis."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15680457,"Observational study of genotype prevalence. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15680457,"LRRK2 gene heterozygous mutation (Gly2019 ser) CAUSE dominantly inherited Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15680456,"confirm association of LRRK2 heterozygous mutation (Gly2019 ser)with neurodegeneration, and identify a common mutation associated with dominantly inherited Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15680455,"a single LRRK2 mutation (a novel mutation (Gly2019 ser) causes Parkinson's disease in 5% of individuals with familial disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15541309,"LRRK2 may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,15541308,"missense mutations segregating with PARK8-linked Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,14691730,"PARK8 locus is responsible for the disease in a subset of families of white ancestry with autosomal dominant parkinsonism"
https://pharos.nih.gov/idg/targets/Q5S007,Q5S007,11891824,"A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,28135716,"TNNI3K overexpression promoted mouse embryonic stem cells differentiating into beating cardiomyocytes and induced up-regulating expression of cTnT by PKCepsilon signal pathway"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,24925317,"we demonstrate that mutation of TNNI3K, encoding a heart-specific kinase known to modulate murine cardiac conduction and myocardial function, underlies a familial syndrome of electrical and myopathic heart disease in humans."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,24899531,"using novel genetic animal models and newly developed small-molecule TNNI3K inhibitors, we demonstrated that TNNI3K-mediated IR injury occurs through impaired mitochondrial function and is in part dependent on p38 MAPK."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,23085512,"TNNI3K mediates cell signaling to modulate cardiac response to stress."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,21314842,"Results suggest that TNNI3K overexpression induces cardiomyocytes hypertrophy and accelerates hypertrophy in hypertrophic cardiomyocytes."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,20808825,"Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,20628086,"Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,20569525,"The finding of a de novo mutation in TNNI3 (R204H) enabled a genetic diagnosis and counselling. We suggest that the previously reported overlap of functional and morphologic phenotypes in sarcomeric genes may also be a feature of TNNI3 mutations."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,19925440,"[review] TNNI3K is a novel cardiac troponin I-interacting kinase gene that may be involved in the development of cardiac hypertrophy."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,18552163,"TNNI3K promotes cardiomyogenesis, enhances cardiac performance, and protects the myocardium from ischemic injury by suppressing p38/JNK-mediated apoptosis."
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,18205602,"coexpression of AOP-1 inhibited TNNI3K kinase activity"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,17660584,"TNNI3K exhibits dual-specific kinase activity and forms dimers or oligomers that may be necessary for its activation"
https://pharos.nih.gov/idg/targets/Q59H18,Q59H18,12721663,"cloning of TNNI3K which interacts specifically with cardiac troponin I; data suggest that TNNI3K is a cardiac-specific kinase and plays important roles in the cardiac system"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,28733457,"both bone morphogenetic protein 2 (BMP2) and BMP6 are proangiogenic in vitro and ex vivo and that the BMP type I receptors, activin receptor-like kinase 3 (ALK3) and ALK2, play crucial and distinct roles in this process."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,28646109,"Data suggest BMP9/GDF2 and BMP10 synergize with TNFA to increase monocyte recruitment to vascular endothelial cells; process appears to be mediated mainly via ALK2/ACVR1 (which exhibits protein kinase activity). These studies used in vitro flow monocyte adhesion assay. (BMP9 = growth differentiation factor 2; BMP10 = bone morphogenetic protein 10; TNFA = tumor necrosis factor alpha; ALK2/ACVR1 = activin A receptor type 1)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,28459464,"Authors demonstrated that the BMP type I receptor ALK-2 (encoded by the ACVR1 gene) has crucial roles in apoptosis induction of patient-derived glioma-initiating cells (GICs), TGS-01 and TGS-04."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,28075462,"Low ALK2 expression is associated with invasiveness of breast cancer."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27959431,"Further investigation on clinical ESCC samples and non-tumorous adjacent tissue found that tumors with triple-positive BMP6, ALK2 and BMPRII had deeper growth than tumors with only BMP6 expression"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27713089,"the Fibrodysplasia Ossificans Progressiva mutation ACVR1(R206H) is more sensitive to a number of natural ligands."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27565519,"The effects of ACVR1/ALK2 mutations causing fibrodysplasia ossificans progressiva are extended to the central nervous system. Brainstem hamartomatous lesions and dysmorphisms, variably associated with dentate nucleus and basal ganglia signal abnormalities and/or calcifications, may represent useful disease hallmarks."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27530160,"The ACVR1 R206H mutation may not directly increase the formation of mature chondrogenic or osteogenic cells."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27256111,"Fibrodysplasia ossificans progressiva (FOP) syndrome is caused by mutation of the gene ACVR1. Developed is a simplified one-step procedure by simultaneously introducing reprogramming and gene-editing components into human fibroblasts derived from patient with FOP. The one-step-mediated ALK2 gene-corrected induced pluripotent stem cells restored global gene expression pattern."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,27182040,"The clinical manifestations, the disease course, and the molecular findings of involvement of ACVR1 gene in this family are suggestive of \"FOP variant\" or an unusual ACVR1-related skeletal dysplasia"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26869672,"Activin-A is increased in the airway of asthmatics and peaks during asthma exacerbations.Activin-A signalling pathways are dysregulated in severe asthma."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26776312,"Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26621707,"Fibrodysplasia ossificans progressiva-ACVR1 abnormally transduces bone morphogenetic protein signaling in response to Activin-A."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26597752,"The higher PE activin A concentrations resulted in abnormal endothelial functions, which may contribute to the systemic maternal vascular endothelial cell dysfunction observed in the disorder."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26133550,"Changes in the binding site residue(e.g. pre-hinge region in ALK2) or side chain orientation (e.g. Tyr219 in caALK2 vs. wtALK2), or ligand modification (e.g. DMH1 vs. LDN193189) causes distinct binding profiles and selectivity among BMP inhibitors."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26097044,"A report of two patients has been presented with multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva caused by the ACVR1 c.772G>A; R258G mutation."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,26058333,"Genetic analysis of ACVR1 identified the recurrent allelic variant c.617 G>A; p.R206H in 12 of 14 Fibrodysplasia Ossificans Progressiva (FOP)patients. One of the remaining patients had a previously reported allele c.1067G>A; p.G356D in the 9th exon and the second allele c.983G>A; p.G328E in the 8th exon of ACVR1."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,25271001,"clinically aggressive stem cell-like subtype of hepatocellular carcinoma characterized by miR-148a-ACVR1-BMP-Wnt circuit"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,25101911,"compounds demonstrated consistent binding to a panel of mutant and wild-type ALK2 proteins"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24798338,"ALK2 (R206H) mutation increases osteoclast formation through TGF-beta. The activation of activin-like kinase signaling enhanced osteoclast formation through TGF-beta expression during heterotopic ossification in muscle tissues."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24705254,"ACVR1 mutations in diffuse intrinsic pontine gliomas were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24705252,"Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24705251,"Recurrent somatic mutations in ACVR1 found in diffuse intrinsic pontine gliomas."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24705250,"Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24347165,"Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-beta signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24162774,"HIV-1 gp120 upregulates the expression of activin A receptor, type I (ACVR1) in human B cells"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,24047559,"The findings provide novel insights into the molecular mechanisms that regulate expression of the ACVR1 gene and that could be targets of new strategies for future therapeutic treatments."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,23918320,"heterozygous mutation i.e., c.617(G>A)in ACVR1 was detected in patients with rare genetic disorder - Fibrodysplasia ossificans progressiva"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,23260810,"Disease causing mutations in the ACVR1 gene identified in Turkish patients diagnosed as fibrodysplasia ossificans progressiva."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,23227223,"Functional analysis of the 3'UTR region by Luciferase reporter assays showed that it plays an inhibitory role on ACVR1/Alk-2 gene expression."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,23169291,"Study suggests that activin A contributes to the malignant phenotype of malignant pleural mesothelioma (MPM) cells via regulation of cyclin D and may represent a valuable candidate for therapeutic interference."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,23142694,"ALK2 may be an important receptor in ET-1 production during BMPR2 knockdown"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22977237,"The crystal structure of the cytoplasmic domain of ALK2 in complex with the inhibitors FKBP12 and dorsomorphin."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22971142,"Presence of the 455C allele of BMP4 and the 8474T allele of ACVR1 gene was significantly associated with decreased left ventricular ejection fraction (LVEF) (p=0.0004 and p=0.046, respectively)."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22949078,"Constitutive activation of ALK2 such as that caused by the Fibrodysplasia Ossificans Progressiva mutation inhibits the generation and maintenance of human induced pluripotent stem cells."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22884369,"Luminal iron levels govern intestinal tumorigenesis after Apc loss in vivo."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22748444,"Confirmation of the presence of this recurrent mutation facilitates diagnostic accuracy in affected persons in South Africa, and allows researchers to narrow the search for molecular targets for rational intervention to the ACVR1/ALK2 domain."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22630080,"Fibrodysplasia ossificans progressiva has been linked to an autosomal dominant mutation on chromosome 2, to the gene encoding activin receptor-like kinase 2 (ALK2), a BMP type I receptor"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,22408438,"miR-148a is an important mediator of ACVR1, thus offering a new potential target for the development of therapeutic agents against Fibrodysplasia ossificans progressiva."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21878751,"miR-30c expression was increased during adipogenesis of multipotent adipose-derived stem cells; miRNA target prediction revealed 2 putative direct targets of miR-30c, PAI-1 and ALK2, both inversely regulated to miR-30c during adipogenesis and responsive to miR-30c overexpression"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21668474,"copy number alterations at 2q24 can be involved in ACVR1 overexpression, which is associated with longer overall survival in laryngeal carcinomas"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21617230,"Low activin A in the cytosol is associated with upper urinary tract urothelial carcinoma."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21377447,"These findings suggest that ALK2(L196P) is an activated BMP receptor equivalent to ALK2(R206H) and that ALK2(L196P) activity may be suppressed in vivo by a novel molecular mechanism in fibrodysplasia ossificans progressiva patients with this mutation."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21297076,"ACVR1 is associated with acute lung injury in mice"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,21248739,"These data indicate that in the context of a Down's syndrome background, ALK2-mediated reduction of BMP signaling may contribute to congenital heart defects."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20736820,"in two cases of fibrodysplasia ossificans progressiva, heterozygous missense mutation 617G>A (R206H) was found"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20734064,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20716560,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20677014,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20634197,"Meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20577760,"Progressive heterotopic ossification along with congenital malformation of the great toes, the two major clinical features that define classic FOP, led to a suspicion of FOP and to the definitive screening of the ACVR1 gene"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20463014,"The impact of ACVR1 R206H mutation on BMP signaling and its downstream signaling cascades in murine myogenic C2C12 cells and HEK 293 cells, was studied."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,20011542,"Of 51 microsatellite stable colon tumors, 7 (14%) lost ACVR2, 2 (4%) ACVR1, and 5 (10%) pSMAD2 expression."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19996292,"BMP9 acts as a proliferative factor for immortalized ovarian surface epithelial cells and ovarian cancer cell lines, signaling predominantly through an ALK2/Smad1/Smad4 pathway, the major BMP9 receptor in endothelial cells."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19929436,"The R206H mutation in ALK2 confers constitutive activity to the mutant receptor, sensitizes mesenchymal cells to BMP-induced osteoblast differentiation, and stimulates new bone formation."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19896889,"The discovery of the FOP metamorphogene reveals a highly conserved target for drug development and identifies a fundamental defect in the BMP signaling pathway that when triggered by injury and inflammation transforms one tissue into another."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19796185,"a variant of fibrodysplasia ossificans progressiva phenotypes are associated with specific mutations in ACVR1 gene"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19736306,"Endoglin is phosphorylated on cytosolic domain threonine residues by the TGF-beta type I receptors ALK2 in prostate cancer cells. In the presence of constitutively active ALK2, endoglin did not inhibit cell migration"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19574343,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19543505,"ACVR1 gene mutations were found heterozygous point mutation of c.617G>A; p.R206H in Myositis Ossificans."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19506109,"Dominant-negative ALK2 allele associates with congenital heart defects."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19400542,"NOG & 617G>A activin A type I receptor(ACVRI)mutations in 27 fibrodysplasia ossificans patients; 5 NOG mutations found in 7 patients; 617G>A mutation in ACVR1 gene found in 14 patients; with 1 exception, 617G>A & NOG mutations were mutually exclusive"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19335617,"Data show that co-expressing constitutively active type I and type II receptors resulted in the phosphorylation of both R-Smad subclasses in a ligand-independent manner."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19330033,"two further unique mutations (c.605G>T and c.983G>A) in this gene in two FOP patients; disparate missense mutations mapped to the GS and kinase domains of the protein supports the disease model of mild kinase activation"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19300893,"This study aimed to investigate the ACVR1 gene mutation in Chinese FOP patients. Direct sequence analysis of genomic DNA and restriction enzyme digestion demonstrated the presence of a single heterozygous mutation in the ACVR1 gene in both patients."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19299629,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19148527,"activin inhibits the growth of SNU-16 cells by inducing apoptosis through caspase activation."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19085907,"Study showed that all patients examined have heterozygous ACVR1 missense mutations in conserved amino acids."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19064572,"Observational study and meta-analysis of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,19028479,"The serum activin A level, increased in AMI, was positively correlated with peak CK and CK-MB levels which are measures of infarction size."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18952055,"ALK2(G356D) activities found in Japanese fibrodysplasia ossificans progressiva patient were weaker than those of ALK2(R206H), and they were suppressed by a specific inhibitor of the BMP-regulated Smad pathway."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18854405,"ALK2 signalling contributes to the disturbed folliculogenesis in polycystic ovary syndrome (PCOS) patients."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18854405,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18830232,"The novel amino-acid substitution is predicted to influence either the conformation/stability of the GS region or the binding affinity with FKBP12, resulting in a less stringent inhibitory control on the ACVR1 kinase activity."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18684712,"ALK2(R206H) with Smad1 or Smad5 induced osteoblastic differentiation that could be inhibited by Smad7 or dorsomorphin."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18292470,"there was significant down-regulation of ALK-2 expression in asthma patients at baseline; allergy challenge was associated with upregulation"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18234825,"Together, these findings show that TGFbeta superfamily activation of Smad2/3 is required for repression of spontaneous differentiation under strain."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,18019378,"Various mutations may occur in myositis ossificans nuclear families."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,17572636,"In both the wild-type ACVR1 model and template crystal structures (TbetaRI), the conserved arginine appears to form a salt bridge with an invariant aspartate residue."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,17496924,"knockdown of ALK2, but not TGFbetaRI (ALK5), abrogated endoglin-mediated decreases in cell motility and constitutively active ALK2 was sufficient to restore a low-motility phenotype in endoglin deficient cells"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,17351709,"Study examined 3 Japanese patients with Fibrodysplasia ossificans progressiva for ACVR1 mutations and identified the 617G>A mutation in all 3 patients; results suggest that the mutation in the ACVR1 gene is common and recurrent in the global population."
https://pharos.nih.gov/idg/targets/Q04771,Q04771,16642017,"We mapped fibrodysplasia ossificans progressiva to chromosome 2q23-24 by linkage analysis and identified an identical heterozygous mutation (617G --> A; R206H) in the glycine-serine (GS) activation domain of ACVR1"
https://pharos.nih.gov/idg/targets/Q04771,Q04771,11969340,"distribution in gestational tissues across human pregnancy and during labour"
https://pharos.nih.gov/idg/targets/P04049,P04049,28743511,"RhoA/ROCK and Raf-1/CK2 pathway are responsible for TNF-alpha-mediated endothelial cytotoxicity via regulation of the vimentin cytoskeleton."
https://pharos.nih.gov/idg/targets/P04049,P04049,27841865,"Although Raf-1 gene is not mutated, an abnormality of Raf-1 kinase feedback regulation enhances its antiapoptotic function, and Raf-1 can still be a pharmaceutical target to increase chemotherapy or radiotherapy sensitivity in these cancer cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,27810072,"Oncogenic NFIA:RAF1 fusion activation of the MAPK pathway is associated with pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,27703006,"This finding suggests that stringent assemblage of Hsp90 keeps CRAF kinase equipped for participating in the MAPK pathway. Thus, the role of Hsp90 in CRAF maturation and activation acts as a limiting factor to maintain the function of a strong client like CRAF kinase."
https://pharos.nih.gov/idg/targets/P04049,P04049,27670374,"RAF1 plays a critical role in maintaining the transformed phenotype of CRC cells, including those with mutated KRAS."
https://pharos.nih.gov/idg/targets/P04049,P04049,27391150,"Mutational activation of Kit-, Ras/Raf/Erk- and Akt- pathways indicate the biological importance of these pathways and their components as potential targets for therapy."
https://pharos.nih.gov/idg/targets/P04049,P04049,27368419,"DiRas3 binds to KSR1 independently of its interaction with activated Ras and RAF."
https://pharos.nih.gov/idg/targets/P04049,P04049,27363278,"Data show that when microRNA miR-125b was over-expressed in THP-1 macrophages, the expression of Raf1 proto-oncogene serine/threonine protein kinase (RAF1) was reduced to promote the apoptosis of macrophages."
https://pharos.nih.gov/idg/targets/P04049,P04049,27167344,"Results indicate that des-gamma-carboxy prothrombin (DCP) antagonizes the inhibitory effects of Sorafenib on hepatocellular carcinoma (HCC) through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways."
https://pharos.nih.gov/idg/targets/P04049,P04049,27153315,"IGF2BP2 as a post-transcriptional regulatory mRNA-binding factor, interfering with Raf-1 degradation by miR-195, that contributes to Colorectal carcinogenesis."
https://pharos.nih.gov/idg/targets/P04049,P04049,26981887,"RAF1 may have a role in survival in hepatocellular carcinoma, and indicate whether sorafenib should be used as a postoperative adjuvant"
https://pharos.nih.gov/idg/targets/P04049,P04049,26973648,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,26649302,"our study suggested that black rice anthocyanins extract suppress metastasis in breast cancer cells by targeting the RAS/RAF/MAPK pathway"
https://pharos.nih.gov/idg/targets/P04049,P04049,26646323,"Data show that Griffipavixanthone (GPX), a dimeric xanthone isolated from Garcinia esculenta, is a B-RAF and C-RAF inhibitor against esophageal cancer cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,26513016,"Up-regulation of Raf-1 is associated with triple-negative breast cancer."
https://pharos.nih.gov/idg/targets/P04049,P04049,26295714,"This study provides the molecular basis for C-Raf C-terminal-derived phosphopeptide interaction with 14-3-3zeta protein and gives structural insights responsible for phosphorylation-mediated protein binding."
https://pharos.nih.gov/idg/targets/P04049,P04049,26100670,"Besides mediating the anticancer effect, pDAPK(S308) may serve as a predictive biomarker for Raf inhibitors combination therapy, suggesting an ideal preclinical model that is worthy of clinical translation."
https://pharos.nih.gov/idg/targets/P04049,P04049,26048984,"DJ-1 directly binds to the kinase domain of c-Raf to stimulate its self-phosphorylation, followed by phosphorylation of MEK and ERK1/2 in EGF-treated cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,26004137,"a model that CD166 regulates MCAM through a signaling flow from activation of PI3K/AKT and c-Raf/MEK/ERK signaling to the inhibition of potential MCAM ubiquitin E3 ligases, betaTrCP and Smurf1."
https://pharos.nih.gov/idg/targets/P04049,P04049,25817574,"Suggest an interrelated kinase module involving c-Raf/PI3K/Lyn and perhaps Fgr functions in a nontraditional way during retinoic acid-induced maturation or during rescue of RA induction therapy using inhibitor co-treatment in RA-resistant leukemia cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,25755752,"Raf-1 may be an important biomarker in predicting the prognosis of chordoma patients."
https://pharos.nih.gov/idg/targets/P04049,P04049,25713071,"Data indicate that cyclic AMP signaling reduces the expression of sirtuin 6 deacetylase via inhibition of the c-Raf-MEK1-ERK1/2 pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,25706034,"Abnormal activation of the Ras/MAPK pathway may play a significant role in the development of pulmonary vascular disease in the subset of patients with Noonan syndrome and a specific RAF1 mutation."
https://pharos.nih.gov/idg/targets/P04049,P04049,25684575,"In the presence of Raf1, the RasQ61L mutant has a rigid switch II relative to the wild-type and increased flexibility at the interface with switch I, which propagates across Raf-Ras binding domain."
https://pharos.nih.gov/idg/targets/P04049,P04049,25674762,"Aberrant expression of A-, B-, and C-RAF, and COT is frequent in PTC; increased expression of COT is correlated with recurrence of PTC."
https://pharos.nih.gov/idg/targets/P04049,P04049,25512530,"approach identified 18 kinase and kinase-related genes whose overexpression can substitute for EGFR in EGFR-dependent PC9 cells, and these genes include seven of nine Src family kinase genes, FGFR1, FGFR2, ITK, NTRK1, NTRK2, MOS, MST1R, and RAF1."
https://pharos.nih.gov/idg/targets/P04049,P04049,25473895,"truncated RAF1 and BRAF proteins, recently described as products of genomic rearrangements in gastric cancer and other malignancies, have the ability to render neoplastic cells resistant to RTK-targeted therapy"
https://pharos.nih.gov/idg/targets/P04049,P04049,25355599,"our study demonstrated that miR-455-RAF1 may represent a new potential therapeutic target for colorectal carcinoma treatment."
https://pharos.nih.gov/idg/targets/P04049,P04049,25265753,"Studied the promoter methylation and RNA expression profiles of ERK and RAF1 genes with risk of oral squamous cell carcinoma (OSCC) along with the promoter methylation status of ERK and RAF1 genes."
https://pharos.nih.gov/idg/targets/P04049,P04049,25027403,"These data suggest that miR-7-5p functions as a tumor suppressor gene to regulate glioblastoma microvascular endothelial cell proliferation potentially by targeting the RAF1 oncogene"
https://pharos.nih.gov/idg/targets/P04049,P04049,25022756,"Results show that ubiquitination and levels of RAF-1 is controlled by both Shoc2 and HUWE1."
https://pharos.nih.gov/idg/targets/P04049,P04049,24969872,"Including several anti-apoptotic Bcl-2 family members and c-Raf."
https://pharos.nih.gov/idg/targets/P04049,P04049,24863296,"Authors demonstrate that the N-terminus of human Raf1 kinase (hRaf11-147aa) binds with human RKIP (hRKIP) at its ligand-binding pocket, loop \"127-149\", and the C-terminal helix by nuclear magnetic resonance experiments."
https://pharos.nih.gov/idg/targets/P04049,P04049,24777450,"analysis of RAF1 mutations in cohorts of South Indian, North Indian and Japanese patients with childhood-onset dilated cardiomyopathy"
https://pharos.nih.gov/idg/targets/P04049,P04049,24486585,"A novel mechanism for response was discovered whereby high expression level of CAV-1 at the plasma membrane disrupts the BRaf/CRaf heterodimer and thus inhibits the activation of MAPK pathway during dasatinib treatment."
https://pharos.nih.gov/idg/targets/P04049,P04049,24427333,"The higher expression of RAF1 mRNA and the activation of AKT/ERK proteins in vinorelbine-resistant non-small cell lung cancer cell lines may confer resistance to vinorelbine"
https://pharos.nih.gov/idg/targets/P04049,P04049,24371145,"Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5).extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1."
https://pharos.nih.gov/idg/targets/P04049,P04049,24223781,"4 genes (EGFR, ERBB2, PTK2, and RAF1) with five SNPs (rs11238349, rs17172438, rs984654, rs11773818, and rs17172432) might be pivotal factors in the development of prostate cancer."
https://pharos.nih.gov/idg/targets/P04049,P04049,24108181,"We hypothesize a potential direct or indirect role for SRC, RAF1, PTK2B genes in neurotransmission and in central nervous system signaling processes."
https://pharos.nih.gov/idg/targets/P04049,P04049,23923067,"activation of RAF1-MEK1-ERK/AKT axis may determine the resistance of non-small cell lung cancer cell lines bearing wild type EGFR to erlotinib"
https://pharos.nih.gov/idg/targets/P04049,P04049,23760062,"Expression of miR-195 or knockdown of Raf-1 can similarly reduce tumor cell survival."
https://pharos.nih.gov/idg/targets/P04049,P04049,23737487,"we identified multiple C-RAF mutations that produced biochemical and pharmacologic resistance in melanoma cell lines"
https://pharos.nih.gov/idg/targets/P04049,P04049,23610963,"Antisense oligonucleotides targeting BCL-2 and C-RAF transcripts in tumor cell lines increases sensitivity to cytotoxic effect of etoposide."
https://pharos.nih.gov/idg/targets/P04049,P04049,23559827,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,23554973,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,23517740,"Aberrant BRAF splice variants with deletions in both kinase and RAS-binding domains in rheumatoid arthritis patients demonstrate that these BRAF splice variants constitutively activate MAPK through CRAF"
https://pharos.nih.gov/idg/targets/P04049,P04049,23360980,"The ability of MEK to activate C-Raf was only partially dependent on MEK kinase activity but required MEK binding to C-Raf, suggesting that the binding results in a conformational change that increases C-Raf susceptibility to phosphorylation"
https://pharos.nih.gov/idg/targets/P04049,P04049,23352452,"Ras pathway activation via EGF treatment induced strong binding between B-Raf and C-Raf and a low level of binding between B-Raf and A-Raf."
https://pharos.nih.gov/idg/targets/P04049,P04049,23157514,"DiRas3 interacts with C-RAF and downregulates MEK1 activity to restrict cell migration."
https://pharos.nih.gov/idg/targets/P04049,P04049,23118896,"these findings establish RanBPM as a novel inhibitor of the ERK pathway through an interaction with the c-Raf complex and a regulation of c-Raf stability"
https://pharos.nih.gov/idg/targets/P04049,P04049,23105109,"The dominant effect of prolonged USP15 depletion upon signal amplitude is due to a decrease in CRAF levels while allowing for the possibility that USP15 may also function to dampen MAPK signaling through direct stabilization of BRAP."
https://pharos.nih.gov/idg/targets/P04049,P04049,23087049,"results suggest a novel mechanism that the interaction of Raf-1 with cytoskeletal actin is critical for Raf-1 redistribution and airway smooth muscle cell proliferation during activation with the growth factor"
https://pharos.nih.gov/idg/targets/P04049,P04049,23076151,"SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor."
https://pharos.nih.gov/idg/targets/P04049,P04049,22935974,"osteosarcoma patients whose tumors expressed raf-1 had a poorer clinical outcome than those whose tumors did not."
https://pharos.nih.gov/idg/targets/P04049,P04049,22926515,"ARAF seems to stabilize BRAF:CRAF complexes in cells treated with RAF inhibitors and thereby regulate cell signaling in a subtle manner to ensure signaling efficiency"
https://pharos.nih.gov/idg/targets/P04049,P04049,22922483,"Determination of a 1:1 stoichiometry for the diphosphorylated peptide binding to one 14-3-3zeta dimer with isothermal titration calorimetry was supported by the crystal structure of the 14-3-3zeta/C-RAFpS233,pS259 complex."
https://pharos.nih.gov/idg/targets/P04049,P04049,22907845,"Gefitinib reverses the MDR protein gene expression and restores sensitivity of pancreatic cancer cells resistant to gemcitabine via RAF1/ERK signaling pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,22833462,"Investigated BRAF and RAF1 alterations in Chinese prostate cancer.Found BRAF truncated in five of 200 informative Chinese cases & RAF1 was truncated in three of 204 informative cases and genomic rearrangements were correlated w/high Gleason scores."
https://pharos.nih.gov/idg/targets/P04049,P04049,22826437,"RAF1(D486N), as well as other kinase-impaired RAF1 mutants, showed increased heterodimerization with BRAF, which was necessary and sufficient to promote increased MEK/ERK activation."
https://pharos.nih.gov/idg/targets/P04049,P04049,22752602,"Data indicate that erufosine caused dose-dependent decreases in the phosphorylation of PI3K (p85), Akt (PKB) at Thr 308 and cRaf in both MCF-7 and MDA-MB 231 cell lines."
https://pharos.nih.gov/idg/targets/P04049,P04049,22738312,"These findings demonstrate that overexpression of Raf-1, p-Raf-1 or both could be considered as a new independent prognostic biomarker for poor survival rates for non-small cell lung cancer patients"
https://pharos.nih.gov/idg/targets/P04049,P04049,22711539,"unknown role for ML-IAP in controlling C-RAF stability and cell migration."
https://pharos.nih.gov/idg/targets/P04049,P04049,22605333,"The consequence of complex formation is a DiRas3-mediated recruitment and anchorage of C-RAF to components of the membrane skeleton, suppression of C-RAF/B-RAF heterodimerization, and inhibition of C-RAF kinase activity."
https://pharos.nih.gov/idg/targets/P04049,P04049,22556409,"PP242 mTOR inhibitor activates ERK in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance"
https://pharos.nih.gov/idg/targets/P04049,P04049,22464151,"RKIP expression may serve as a novel clinical biomarker in patients with esophageal squamous cell carcinoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,22447278,"amplification of Raf1, MEK/MAPK oncogenic signaling during tumor growth promotes the genesis of metastatic lesions from primary tumors by activating the mesenchymal epithelial transition."
https://pharos.nih.gov/idg/targets/P04049,P04049,22421411,"Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines."
https://pharos.nih.gov/idg/targets/P04049,P04049,22389993,"LEOPARD syndrome, both with proven mutations in the RAF1 gene not previouslyreported"
https://pharos.nih.gov/idg/targets/P04049,P04049,22282237,"Raf-1/JNK /p53/p21 pathway may be involved in apoptosis, and NFkappaB1 may play a possible role in inhibiting apoptosis."
https://pharos.nih.gov/idg/targets/P04049,P04049,22262839,"Data show that bilirubin interacts with the Raf/ERK/MAPK pathway, effect on cyclin D1 and Raf content, altered retinoblastoma protein profile of hypophosphorylation, calcium influx, and YY1 proteolysis."
https://pharos.nih.gov/idg/targets/P04049,P04049,22225925,"Cellular Raf-1 levels determine endometrial stromal cell motility and morphology."
https://pharos.nih.gov/idg/targets/P04049,P04049,22138288,"Ras/Raf-1/MEK/ERK signal pathway is important for chemokine ligand CCL2-induced migration activity and matrix metalloproteinase (MMP)-9 expression."
https://pharos.nih.gov/idg/targets/P04049,P04049,22131876,"Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression."
https://pharos.nih.gov/idg/targets/P04049,P04049,22110214,"High RAF1 is associated with hepatocellular carcinoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,22103831,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,22096607,"ndings demonstrate that Pak1 phosphorylates BAD directly at S111, but phosphorylated S112 through Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,22081024,"CRAF is required for mitotic progression. Phospho-Ser338 CRAF is upregulated in mitosis and localizes to the mitotic spindles in human cell lines and tumor biopsies."
https://pharos.nih.gov/idg/targets/P04049,P04049,22020327,"These results demonstrate that replicative and oxidative stresses are not required for RAF-induced senescence, and this senescence is readily reversed upon loss of cyclin-dependent kinases."
https://pharos.nih.gov/idg/targets/P04049,P04049,21917714,"Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF."
https://pharos.nih.gov/idg/targets/P04049,P04049,21892329,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,21881167,"Report cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,21871886,"study demonstrates a novel role of the Raf/MEK/ERK pathway in regulating AR expression in certain PCa types and provides an insight into PCa responses to its aberrant activation"
https://pharos.nih.gov/idg/targets/P04049,P04049,21808062,"The H-Ras-ERK-induced and HO-1-mediated pathway could protect renal cancer cells from apoptosis."
https://pharos.nih.gov/idg/targets/P04049,P04049,21617351,"Downregulation of RKIP increased the level of free Raf-1 and thereby elevated the mitochondrial translocation of Raf-1 during HBx-mediated hepatocarcinogenesis."
https://pharos.nih.gov/idg/targets/P04049,P04049,21577205,"Studies indicate that Raf kinases are excellent molecular targets for anticancer therapy."
https://pharos.nih.gov/idg/targets/P04049,P04049,21514245,"c-Raf plays a unique role in mediating K-Ras signaling in non-small cell lung carcinoma and makes it a suitable target for therapeutic intervention."
https://pharos.nih.gov/idg/targets/P04049,P04049,21215703,"EZH2 expression-mediated downregulation of DNA damage repair leads to accumulation of recurrent RAF1 gene amplification in breast tumor initiating cells (BTICs), which activates p-ERK-beta-catenin signaling to promote BTIC expansion."
https://pharos.nih.gov/idg/targets/P04049,P04049,21207082,"Hepatitis B virus could up-regulate Raf1 expression by enhancing the activity of its promoter in a dose-dependent manner, and HBs and HBx may be involved in this process."
https://pharos.nih.gov/idg/targets/P04049,P04049,21122381,"JNK1, Raf-1 and Livin may be involved in the carcinogenesis of sporadic colorectal tubular adenoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,21048031,"Observational study of gene-disease association and gene-environment interaction. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,20868603,"Raf-1 over-expression was an independent prognostic factor of poor survival in hepatocellular carcinoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,20854332,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,20688353,"Reduction in Raf-1 kinase inhibitory protein expression in gallbladder carcinoma contributes to invasion and metastasis and is a significant prognostic marker in patients with gallbladder carcinoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,20679480,"Findings suggest that modulating the C-RAFSer(259)/14-3-3 protein-protein interaction with a stabilizing small molecule may yield a novel potential approach for treatment of diseases resulting from an overactive Ras-RAF-MAPK pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,20630999,"Results suggest that RAGE, NOX, and H-Ras/Raf-1 are implicated in the up-regulation of HSF1 or PAI-1 in vascular EC under diabetes-associated metabolic stress."
https://pharos.nih.gov/idg/targets/P04049,P04049,20543023,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,20489206,"Leukotriene B(4) BLT receptor signaling regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of Ras/Raf/ERK/p42 AUF1 pathway"
https://pharos.nih.gov/idg/targets/P04049,P04049,20404846,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,20389169,"Based on our results, it is possible that a subtle dysfunction (expression) of the RAF1 gene is involved in the development of the most common male reproductive tract disorder - unilateral or bilateral cryptorchidism"
https://pharos.nih.gov/idg/targets/P04049,P04049,20372086,"Raf-1 was dominant in terms of promoting both cell cycle progression and preventing apoptosis when compared to Akt-1"
https://pharos.nih.gov/idg/targets/P04049,P04049,20364151,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,20302979,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,20234004,"Infection with Chlamydia trachomatis led to the Akt-dependent, increased phosphorylation (and inactivation) of Raf-1 at serine-259."
https://pharos.nih.gov/idg/targets/P04049,P04049,20230813,"Study demonstrates that human TAP-1 regulates signaling in vertebrate cells, acting at a previously uncharacterized step of the Ras pathway by inhibiting the ability of Raf to translocate to activated Ras at the cell membrane."
https://pharos.nih.gov/idg/targets/P04049,P04049,20086174,"Data show T117/T384 as Akt phosphorylation sites in MST2, and mutation of these sites inhibited MST2 binding to Raf-1 but enhanced binding to RASSF1A, accentuating downstream c-jun N-Terminal Kinase and p38 MAPK signaling and promoting apoptosis."
https://pharos.nih.gov/idg/targets/P04049,P04049,20071468,"Results indicate that the Shoc2 scaffold protein modulates Ras-dependent Raf1 activation in a Ca(2+)- and calmodulin-dependent manner."
https://pharos.nih.gov/idg/targets/P04049,P04049,20052757,"dephosphorylation of S259 is the primary pathogenic mechanism in the activation of RAF1 mutants located in the CR2 domain as well as of downstream ERK"
https://pharos.nih.gov/idg/targets/P04049,P04049,19953625,"Noonan syndrome (NS) is an autosomal dominant disorder caused by mutations in several proteins, including RAF1, which may later involve tumor onsets."
https://pharos.nih.gov/idg/targets/P04049,P04049,19917255,"Data show that melanoma cells expressing B-Raf(V600E) display a reduced C-Raf:B-Raf ratio, and further suppression of C-Raf increases MAPK activation and proliferation."
https://pharos.nih.gov/idg/targets/P04049,P04049,19913121,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,19895838,"Data show that RAF not only neutralizes BAD's pro-apoptotic activity but activates it for a new function as a pore."
https://pharos.nih.gov/idg/targets/P04049,P04049,19881545,"Bcl-2-associated anthanogene 1 (BAG-1)'s effects were associated with an activation of RAF-1-a known binding partner of BAG-1, enhanced signaling through the MAP kinase pathway and a decrease in BIM expression."
https://pharos.nih.gov/idg/targets/P04049,P04049,19825990,"Thus, the short hairpin-looped ODN-Raf, targeting the same region of c-raf-1 as miR-125b, is a multifunctional molecule reducing the expression of oncoproteins and stimulating cell death."
https://pharos.nih.gov/idg/targets/P04049,P04049,19812696,"analysis of molecular pertubations allowing dysplasia to progress further to adenocarcinoma induced by exaggerted c-Raf kinase activity"
https://pharos.nih.gov/idg/targets/P04049,P04049,19802003,"Data show that in hypoxic conditions or coexpressed with a constitutively active form of HIF-1alpha, c-Kit mutants activate the Ras/Raf/Mek/Erk pathway, stimulate proliferation and transform melanocytes."
https://pharos.nih.gov/idg/targets/P04049,P04049,19801192,"Studies provide models for Ras in association with Raf kinase, RalGDS and PI3Kalpha and PI3Kgamma."
https://pharos.nih.gov/idg/targets/P04049,P04049,19737955,"The C-Raf expression is up-regulated in a subset of melanomas but not in nevi, suggesting that it might be a valuable diagnostic marker and therapeutic target."
https://pharos.nih.gov/idg/targets/P04049,P04049,19730683,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,19718030,"DC-SIGN was constitutively associated with a signalosome complex consisting of the scaffold proteins LSP1, KSR1 and CNK and the kinase Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,19710016,"DGKeta acts as a novel critical regulatory component of the Ras/B-Raf/C-Raf/MEK/ERK signaling cascade via a previously unidentified mechanism."
https://pharos.nih.gov/idg/targets/P04049,P04049,19638615,"Data show that in the presence of negative feedback, changes in the rate of Ras-c-Raf binding have little effect on ERK activation."
https://pharos.nih.gov/idg/targets/P04049,P04049,19638574,"Sorafenib inhibits NSCLC cell growth by targeting B-RAF in cells with wild-type KRAS and C-RAF in those with mutant KRAS."
https://pharos.nih.gov/idg/targets/P04049,P04049,19633425,"Data show that sorafenib inhibited the raf/ MEK/ERK signal pathway, and downregulated cyclin D1 and Rb levels."
https://pharos.nih.gov/idg/targets/P04049,P04049,19595761,"Phosphorylation of S621 turns over rapidly and is enriched in the activated pool of endogenous Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,19492075,"Targeting NRAS alone or both BRAF and CRAF in combination or both BRAF and PIK3CA together showed delay in tumor growth."
https://pharos.nih.gov/idg/targets/P04049,P04049,19380724,"GILZ1 and SGK1 provide a physical and functional link between the PI3K- and Raf-1-dependent signaling modules"
https://pharos.nih.gov/idg/targets/P04049,P04049,19363522,"Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma."
https://pharos.nih.gov/idg/targets/P04049,P04049,19357705,"loss of RKIP is a functional somatic event in carriers of C-RAF germline mutations, which contributes to the development of t-AML"
https://pharos.nih.gov/idg/targets/P04049,P04049,19298812,"Results identify a nuclear redistribution of Raf1 during the retinoic acid-induced differentiation of HL-60 cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,19206169,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,19133693,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,19122653,"dectin-1 activates two independent signaling pathways, one through Syk and one through Raf-1, to induce immune responses."
https://pharos.nih.gov/idg/targets/P04049,P04049,19058874,"Vitamin D3-triggered differentiation of human myeloid leukemia cells depends on downregulation of Akt, which dissociates from Raf1 and activates MAPK signaling."
https://pharos.nih.gov/idg/targets/P04049,P04049,19047752,"Alpha-adducin and Raf-1 kinase are redistributed and localized to the inclusion membrane in Chlamydia and Chlamydophila infected cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,19037990,"RAF may induce cell proliferation through hypermethylation of tumor suppressor gene p16INK4A"
https://pharos.nih.gov/idg/targets/P04049,P04049,19020799,"Mutations in the RAF1 are associated with Noonan syndrome."
https://pharos.nih.gov/idg/targets/P04049,P04049,19020799,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,19011619,"These data show an unexpected role of XIAP and cellular-inhibitor of apoptosis proteins in the turnover of C-RAF protein, thereby modulating the MAPK signalling pathway and cell migration."
https://pharos.nih.gov/idg/targets/P04049,P04049,19001375,"the molecular interactions of arrestin2 and arrestin3 and their individual domains with the components of the two MAPK cascades, ASK1-MKK4-JNK3 and c-Raf-1-MEK1-ERK2"
https://pharos.nih.gov/idg/targets/P04049,P04049,18952605,"phosphatidate promotes ERK phosphorylation in intact cells but does not activate Raf in vitro"
https://pharos.nih.gov/idg/targets/P04049,P04049,18794803,"study identified a group of melanomas with low-activity BRAF mutations (G469E- and D594G) that are reliant upon CRAF-mediated survival activity"
https://pharos.nih.gov/idg/targets/P04049,P04049,18715846,"The state of activation of components of mTOR, Ras/Raf kinase/ERK, and nuclear factor (NF)-kappaB signal transduction pathways, as well as cell cycle protein analyte correlates in gastric adenocarcinoma cases, was examined."
https://pharos.nih.gov/idg/targets/P04049,P04049,18708364,"AhR is a master regulator of c-raf and propose cross-talk between AhR and the mitogen-activated protein kinase signaling pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,18660489,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,18592002,"RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1a."
https://pharos.nih.gov/idg/targets/P04049,P04049,18483265,"the Rb/Raf-1 interaction has a role in cell proliferation and angiogenesis"
https://pharos.nih.gov/idg/targets/P04049,P04049,18472967,"Increased Raf-1 kinase is associated with glioma formation"
https://pharos.nih.gov/idg/targets/P04049,P04049,18465753,"PAK5 is a potent regulator of Raf-1 activity and may control Raf-1 dependent signaling at mitochondria"
https://pharos.nih.gov/idg/targets/P04049,P04049,18356164,"C-RAF is the only isoform that directly binds mitochondria"
https://pharos.nih.gov/idg/targets/P04049,P04049,18316782,"These results suggest that oncogenic ras-p21 induces phosphorylation of both raf-Ser259 and Ser338 and that raf-Ser 259 phosphorylation may be effected by activated JNK."
https://pharos.nih.gov/idg/targets/P04049,P04049,18294816,"Loss-of-function RKIP mutants still appear to bind to Raf-1. However the stability of the complexes formed between mutants and the N-region Raf-1 phosphopeptide were drastically reduced."
https://pharos.nih.gov/idg/targets/P04049,P04049,18241070,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/P04049,P04049,18182859,"These results suggest that 0.05 Gy of ionizing radiation stimulates cell proliferation through the transient activation of Raf and Akt in CCD-18 Lu cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,18064632,"GRP78 may stabilize Raf-1 to maintain mitochondrial permeability and thus protect cells from endoplasmic reticulum stress-induced apoptosis."
https://pharos.nih.gov/idg/targets/P04049,P04049,18006502,"Raf-1 in beta-cells led to a striking loss of Bad phosphorylation at serine 112 and an increase in the protein levels of both Bad and Bax"
https://pharos.nih.gov/idg/targets/P04049,P04049,17998336,"activated Ras, Golgi apparatus-localized Lck is needed for the full activation of Raf-1"
https://pharos.nih.gov/idg/targets/P04049,P04049,17889508,"A pathway comprising PKCs>Raf-1>MEK-1>ERK-1/-2 mediates the effect of gastrin on the CgA promoter, and strongly suggests that enhanced phosphorylation of Sp1 and CREB is crucial for CgA transactivation through the G protein-coupled CCK-B/gastrin receptor."
https://pharos.nih.gov/idg/targets/P04049,P04049,17724343,"reveal a paradigm of spatial regulation of Raf kinase by RKTG via sequestrating Raf-1 to the Golgi apparatus and thereby inhibiting the ERK signaling pathway"
https://pharos.nih.gov/idg/targets/P04049,P04049,17635919,"In contrast to C-RAF that requires farnesylated H-Ras, cytosolic B-RAF associates effectively and with significantly higher affinity with both farnesylated and nonfarnesylated H-Ras."
https://pharos.nih.gov/idg/targets/P04049,P04049,17614099,"Raf-1 may interfere with the role of Rad24 by competing with Rad24 for binding to Cdc25 in DNA repair, bypassing the checkpoint pathway through Cdc25 activation."
https://pharos.nih.gov/idg/targets/P04049,P04049,17603483,"Study reports that 18 of 231 individuals with Noonan syndrome and 2 of 6 individuals with LEOPARD syndrome without PTPN11 mutations have missense mutations in RAF1, which encodes a serine-threonine kinase that activates MEK1 and MEK2."
https://pharos.nih.gov/idg/targets/P04049,P04049,17603482,"Study identified 5 mutations in RAF1 in 10 individuals with Noonan syndrome; those with mutations causing changes in the CR2 domain of RAF1 had hypertrophic cardiomyopathy, while those with mutations leading to changes in the CR3 domain did not."
https://pharos.nih.gov/idg/targets/P04049,P04049,17572489,"results show overexpression of RAF-1 in mantle cell leukemia compared with tonsilar B-lymphocytes"
https://pharos.nih.gov/idg/targets/P04049,P04049,17462920,"different pathogens (ie. Mycobacterium tuberculosis, M. leprae, Candida albicans, measles virus, and HIV-1) interacted with DC-SIGN to activate the Raf-1-acetylation-dependent signaling pathway to modulate signaling by different TLRs"
https://pharos.nih.gov/idg/targets/P04049,P04049,17462920,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,17428866,"Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress"
https://pharos.nih.gov/idg/targets/P04049,P04049,17397260,"The results suggest that multiple cellular signaling pathways can reactivate the virus in a genetically homogeneous cell population. Further analysis revealed that the Raf/MEK/ERK/Ets-1 pathway mediates Ras-induced reactivation."
https://pharos.nih.gov/idg/targets/P04049,P04049,17332776,"The interaction between eEF-1A and C-Raf increases eEF-1A stability and induces a survival activity."
https://pharos.nih.gov/idg/targets/P04049,P04049,17277048,"in human airway smooth muscle cells: TNF-alpha transactivation of the EGF receptor, with subsequent raf-1 kinase-mediated activation of adenylyl cyclase are two linked signaling pathways"
https://pharos.nih.gov/idg/targets/P04049,P04049,17243098,"Data suggest that Raf-1 may interfere with the role of Rad24 by competing with Rad24 for binding to Cdc25 or a direct phosphorylation of Cdc25, bypassing the checkpoint pathway in DNA repair through Cdc25 activation."
https://pharos.nih.gov/idg/targets/P04049,P04049,17097642,"The Raf kinase inhibitory protein (RKIP) binds to Raf-1 interfering with binding of the MEK substrate and potentially also Raf-1 activation."
https://pharos.nih.gov/idg/targets/P04049,P04049,17064357,"Based on these findings, we speculate that Raf-1 is activated to effectively mediate Ras-dependent signals in Alzheimer's disease."
https://pharos.nih.gov/idg/targets/P04049,P04049,17018604,"cAMP suppresses CRAF in melanocytes. This suppresses the oncogenic potential of CRAF. When RAS is mutated in melanoma, the cells switch their signaling from BRAF to CRAF, dysregulating cAMP signaling & allowing CRAF to signal to MEK."
https://pharos.nih.gov/idg/targets/P04049,P04049,16964381,"These studies identify XIAP as a new substrate of Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,16924233,"These findings support a role of Slug in mediating Raf 1-induced transcriptional repression of occludin and subsequent epithelial to mesenchymal transition."
https://pharos.nih.gov/idg/targets/P04049,P04049,16909118,"findings identify MEK/ERK as a new signaling pathway activated by NPM/ALK and indicate that the pathway represents a novel therapeutic target in the ALK-induced malignancies"
https://pharos.nih.gov/idg/targets/P04049,P04049,16883571,"These findings support the thesis that Raf-1 signals cell proliferation and cell differentiation through different intermediary proteins."
https://pharos.nih.gov/idg/targets/P04049,P04049,16862215,"Nicotine induces cell proliferation by beta-arrestin-mediated activation of the Src and Rb-Raf-1 pathways om ;img camcer."
https://pharos.nih.gov/idg/targets/P04049,P04049,16803888,"Rheb has a central role in the regulation of the Ras/B-Raf/C-Raf/MEK signaling network"
https://pharos.nih.gov/idg/targets/P04049,P04049,16707572,"This work provides new insight into how the cell microenvironment may influence Raf-1 expression to modulate cell-Fibronectin interactions in 3D."
https://pharos.nih.gov/idg/targets/P04049,P04049,16575407,"Rodent and human tumor cells containing constitutively activated Raf/Raf/MEK/ERK pathways were resistant to mda-5-induced killing."
https://pharos.nih.gov/idg/targets/P04049,P04049,16569214,"intracellular generation of NO* by nNOS leads to S-nitrosylation of H-Ras, which interferes with Raf-1 activation and propagation of signalling through ERK1/2"
https://pharos.nih.gov/idg/targets/P04049,P04049,16565089,"CD44 interaction with LARG and EGFR plays a pivotal role in Rho/Ras co-activation, PLC epsilon-Ca2+ signaling, and Raf/ERK up-regulation required for CaMKII-mediated cytoskeleton function and in head and neck squamous cell carcinoma progression"
https://pharos.nih.gov/idg/targets/P04049,P04049,16537381,"Merlin and MLK3 can interact in situ and merlin can disrupt the interactions between B-Raf and Raf-1 or those between MLK3 and either B-Raf or Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,16465392,"inhibition of Raf-1 using an antisense raf oligonucleotide (AS-raf-ODN) to identify downstream targets of Raf-1 using microarray gene expression analysis"
https://pharos.nih.gov/idg/targets/P04049,P04049,16364920,"Data suggest that B-RAF activates C-RAF through a mechanism involving 14-3-3 mediated heterooligomerization and C-RAF transphosphorylation."
https://pharos.nih.gov/idg/targets/P04049,P04049,16332724,"data suggest that Raf-1 is the predominant Raf isoform responsible for regulating cellular growth in ovarian cancer cells and may be particularly important in high grade serous ovarian cancers"
https://pharos.nih.gov/idg/targets/P04049,P04049,16301319,"Erbin has a regulatory role in the Ras-Raf-MEK pathway and may inhibit ERK activation by disrupting the Sur-8-Ras/Raf interaction"
https://pharos.nih.gov/idg/targets/P04049,P04049,16266749,"Coll I activates the ERK/MAP Kinase pathway in Jurkat T cells through the activation of Ras and Raf-1."
https://pharos.nih.gov/idg/targets/P04049,P04049,16239230,"PP2A ABalphaC and ABdeltaC holoenzymes function as positive regulators of Raf1-MEK1/2-ERK1/2 signaling by targeting Raf1"
https://pharos.nih.gov/idg/targets/P04049,P04049,16172610,"selective reduction in catalytic activity and expression of B-Raf but not Raf-1 suggest that B-Raf may be playing an important role in altered ERK signaling in brain of suicide subjects, and thus in the pathophysiology of suicide"
https://pharos.nih.gov/idg/targets/P04049,P04049,16086581,"results suggest that activated JNK can, in turn, activate not only jun but also raf that, in turn, activates MEK that can then cross-activate JNK in a positive feedback loop"
https://pharos.nih.gov/idg/targets/P04049,P04049,16029117,"Activation of raf-1 leads to cessation of cell growth and suppression of calcitonin and chromogranin A production"
https://pharos.nih.gov/idg/targets/P04049,P04049,15925322,"Raf-1 may mediate its anti-apoptotic function by interrupting ASK1-dependent phosphorylation of ALG-2."
https://pharos.nih.gov/idg/targets/P04049,P04049,15899852,"Raf-1 phosphorylation on serine 338 (S338) is a critical step in EGF aktivation of ERK that is lost in nonadherent cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,15849194,"Pak1-dependent Raf-1 phosphorylation regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association"
https://pharos.nih.gov/idg/targets/P04049,P04049,15845549,"activation is regulated by CNK1"
https://pharos.nih.gov/idg/targets/P04049,P04049,15711535,"essential role of Ras-induced conformational change in mitogen-activated protein kinase kinase activation by c-Raf"
https://pharos.nih.gov/idg/targets/P04049,P04049,15710605,"regulated by an N-terminal autoinhibitory domain whose actions are blocked by interaction with Ras"
https://pharos.nih.gov/idg/targets/P04049,P04049,15674327,"Role for caspase-9 mediated cleavage of Raf-1 in the negative feedback regulation of hematopoietic cell apoptosis induced by growth factor withdrawal."
https://pharos.nih.gov/idg/targets/P04049,P04049,15666389,"the HER2/Raf-1/AP-1 axis may promote the development of androgen insensitive prostate cancer, leading to early relapse"
https://pharos.nih.gov/idg/targets/P04049,P04049,15662129,"Raf-1 may be involved in angiogenesis by controlling the expression of angiogenesis-related factors; study provides a possible strategy for the treatment of tumor angiogenesis by targeting Raf-1"
https://pharos.nih.gov/idg/targets/P04049,P04049,15657590,"The induction of the raf-1/MEK1 pathway blocks IGF-1-mediated intracellular neuroendocrine hormone regulation. This pathway may be a therapeutic target in gastrointestinal carcinoid tumor therapy."
https://pharos.nih.gov/idg/targets/P04049,P04049,15653554,"a novel Ras-independent ERK1/2 activation system in which p110gamma/Raf-1/MEK1/2 and PKA/B-Raf/MEK1/2 cooperate to activate ERK1/2."
https://pharos.nih.gov/idg/targets/P04049,P04049,15618521,"proteomic analysis of Raf-1 signaling complexes was used to show that Raf-1 counteracts apoptosis by suppressing the activation of mammalian sterile 20-like kinase (MST2)"
https://pharos.nih.gov/idg/targets/P04049,P04049,15591313,"findings indicate that ligation of retinol to a specific site embedded in the regulatory domain is an important feature of c-Raf regulation in the redox pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,15485920,"Raf-1 links mitogenic signaling to Retinoblastoma Protein and that disruption of this interaction could aid in controlling proliferative disorders"
https://pharos.nih.gov/idg/targets/P04049,P04049,15470083,"Raf1 potentiates drug-stimulated cyclic AMP accumulation in cells expressing adenyl cyclcase 6 after activation of multiple signaling pathways."
https://pharos.nih.gov/idg/targets/P04049,P04049,15451031,"Raf1 and MAPK-activated protein kinase 2 are activated by L-ascorbic acid in acute myeloid leukemia cells."
https://pharos.nih.gov/idg/targets/P04049,P04049,15314064,"Raf1 kinase is released when it is hyperphosphorylated and activated during oxidative and other stresses"
https://pharos.nih.gov/idg/targets/P04049,P04049,15211515,"Changes in flexibility upon protein-protein complex formation of H-Ras & the Ras-binding domain of C-Raf1 have been investigated using the molecular framework approach FIRST and molecular dynamics simulations of in total approximately 35 ns length."
https://pharos.nih.gov/idg/targets/P04049,P04049,15122343,"RAF1 promotes herpesvirus 8 infection."
https://pharos.nih.gov/idg/targets/P04049,P04049,15067053,"Despite the effects of constitutively active Raf on pro-B cell expansion in Raf transgenic mice, Raf activation is not sufficient to rescue early B cell development in IL-7 receptor-deficient mice."
https://pharos.nih.gov/idg/targets/P04049,P04049,15041731,"Ovarian cancers demonstrate differential sensitivity to antisense oligonucleotides targeted against Raf-1, and target expression levels."
https://pharos.nih.gov/idg/targets/P04049,P04049,14688025,"mutation analysis of the conserved regions in the RAF1 gene in human colorectal adenocarcinoma"
https://pharos.nih.gov/idg/targets/P04049,P04049,14623285,"together, our data suggest that the synergistic activation of Raf-1 kinase in response to PMA and H(2)O(2) occurs via mechanisms that involve an interaction of Raf-1 kinase and PKC-epsilon."
https://pharos.nih.gov/idg/targets/P04049,P04049,12954639,"Raf-1 has a role in modulating integrin-stimulated ERK activation when bound to CAMKII"
https://pharos.nih.gov/idg/targets/P04049,P04049,12925535,"a functional phosphatidate binding site is necessary for Raf-1 function in embryonic development"
https://pharos.nih.gov/idg/targets/P04049,P04049,12865432,"Raf is regulated through phosphorylation and N terminus-C terminus interaction"
https://pharos.nih.gov/idg/targets/P04049,P04049,12851216,"results show that raf-1 protein induction suppresses neuroendocrine marker and hormone production in human gastrointestinal carcinoid cells via a pathway dependent on MEK activation"
https://pharos.nih.gov/idg/targets/P04049,P04049,12843393,"findings implicate Raf-1 as a pivotal regulator of endothelial cell survival during angiogenesis"
https://pharos.nih.gov/idg/targets/P04049,P04049,12734410,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,12717443,"Sprouty4 binds to Raf1 through its carboxy-terminal cysteine-rich domain, and this binding is necessary for the inhibitory activity of Sprouty4."
https://pharos.nih.gov/idg/targets/P04049,P04049,12691824,"Raf1 may have a role in antineoplastic drug resistance"
https://pharos.nih.gov/idg/targets/P04049,P04049,12682854,"The 1,25(OH)(2)D3-responsive element in cystatin A gene is identical to TRE, T2 (-272 to -278). Suppression of Raf-1/MEK1/ERK1,2 signaling pathway increases cystatin A expression of normal human keratinocytes."
https://pharos.nih.gov/idg/targets/P04049,P04049,12663662,"serum stimulation of fibroblasts in floating matrices does not result in ERK translocation to the nucleus and there was decreased serum activation of upstream members of the ERK signaling pathway, MEK and Raf."
https://pharos.nih.gov/idg/targets/P04049,P04049,12626521,"c-Raf1 activation occurs without serine 338 phosphorylation"
https://pharos.nih.gov/idg/targets/P04049,P04049,12551923,"phosphorylation by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition"
https://pharos.nih.gov/idg/targets/P04049,P04049,12490852,"Activation of the ras/raf-1 signal transduction pathway leads to prominent phenotypic changes that resemble differentiation of gastrointestinal carcinoid cells in vitro."
https://pharos.nih.gov/idg/targets/P04049,P04049,12429936,"Raf activation increased the expression of cyclin A, cyclin D, cyclin E, and p21(Cip1), which are associated with G(1) progression"
https://pharos.nih.gov/idg/targets/P04049,P04049,12391160,"These data suggest that GILZ contributes, through protein-to-protein interaction with Raf-1 and the consequent inhibition of Raf-MEK-ERK activation, to regulating the MAPK pathway and to providing a further mechanism underlying GCH immunosuppression."
https://pharos.nih.gov/idg/targets/P04049,P04049,12244094,"Results indicate that the phosphorylation of Ser(338) and Tyr(341) on Raf-1 exerts an important effect on reconfiguring the two MEK1-binding sites."
https://pharos.nih.gov/idg/targets/P04049,P04049,12087097,"effects of paclitaxel on Raf-1 phosphorylation in ovarian cancer cells"
https://pharos.nih.gov/idg/targets/P04049,P04049,12010819,"targeted expression inhibits juvenile myelomonocytic leukemia cell growth"
https://pharos.nih.gov/idg/targets/P04049,P04049,11948406,"PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway."
https://pharos.nih.gov/idg/targets/P04049,P04049,11756411,"These data show that Ser-259 dephosphorylation contributes to Raf-1 activation by supporting its membrane accumulation rather than by increasing the specific activity of the kinase"
https://pharos.nih.gov/idg/targets/P04049,P04049,11463741,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,9658081,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,9624170,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,8887682,"HIV-1 Tat activates PRKCQ (PKC-theta) kinase activity, which leads to RELA (NFkB), NRAS, RAF1, MAP2K1 (MEK1), MAP2K2 (MEK2), MAPK3 (ERK1), and MAPK1 (ERK2) activation, in Jurkat T cells that stably express Tat"
https://pharos.nih.gov/idg/targets/P04049,P04049,8621729,"c-Raf interacts with MEK1 and activates MEK1 by phosphorylation."
https://pharos.nih.gov/idg/targets/Q15569,Q15569,25849865,"Actin remodelling factor TESK1 is a key player in the ciliogenesis control network in which YAP/TAZ and directional vesicle trafficking are integral components."
https://pharos.nih.gov/idg/targets/Q15569,Q15569,20237496,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q15569,Q15569,18216281,"enhanced TESK1 activity results in increased stress fibers (via phospho-cofilin), but this can be blocked by elevating Spred1"
https://pharos.nih.gov/idg/targets/Q15569,Q15569,15817463,"the association between actopaxin and TESK1, which is likely regulated by phosphorylation of actopaxin, regulates TESK1 activity and subsequent cellular spreading on fibronectin"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,27829680,"A novel LRRK1 mutation has been identified in two siblings in an Indian family with osteosclerotic metaphyseal dysplasia."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,27055475,"LRRK1 plays a critical role in the regulation of bone mass in humans."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,26192437,"LRRK1 regulates mitotic spindle orientation downstream of PLK1 through CDK5RAP2-dependent centrosome maturation."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,25413345,"We find that LRRK1-mediated phosphorylation of CLIP-170 causes the accumulation of p150(Glued) (also known as DCTN1) a subunit of dynactin, at microtubule plus ends, thereby facilitating the migration of EGFR-containing endosomes."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,24947832,"LRRK1 carries out distinct functions from LRRK2 by interacting with different cellular proteins."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,24241507,"LRRK1 mutations may have a role in Parkinson's disease"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,22988872,"The function of LRRK1 and both the physiological and the pathological roles of LRRK2 are only beginning to unfold."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,22952686,"purified and active LRRK1 and LRRK2 can form dimers in their full-length conformation"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,22337768,"feedback down-regulation of LRRK1 kinase activity by EGFR plays an important role in the appropriate endosomal trafficking of EGFR"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,18272292,"LRRK1 are active in the adult human cortex cerebri, hippocampus and also seen in the young human thymus."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,18045479,"LRRK1 genes encode low levels of expressed mRNA corresponding to low levels of protein during development."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,17394548,"mutations in LRRK2 are more prone to form inclusion bodies in transfected cells and are more toxic than equivalent mutations in LRRK1"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,17324517,"Observational study of gene-disease association. (HuGE Navigator)"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,17324517,"Two rare coding variants ss65713826 and ss65713830 were more frequent in patients than controls in norwegain Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,17225181,"Comparison of evolutionary interspecies sequences of LRRK1 and LRRK2 suggests they diverged from a common founder gene implicated in Parkinson disease."
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,16243488,"We report the molecular characterization of human LRRK1 and show for the first time that LRRK1 is a functional protein kinase and a GDP/GTP-binding protein. We propose a model in which LRRK1 cycles between a GTP-bound active and a GDP-bound inactive state"
https://pharos.nih.gov/idg/targets/Q38SD2,Q38SD2,16243488,"LRRK1 binds GTP and GDP via its Roc domain and autophosphorylation activity is selectively triggered by GTP. Kinase activity was decreased following introduction of mutations homologous to those of LRRK2 that have been associated with Parkinson's disease."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,28947795,"MST interaction with MOB1 is not essential for development and tissue growth control."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,28214207,"We identified a direct target of miR-155 as MAP3K10 in osteosarcoma"
https://pharos.nih.gov/idg/targets/Q02779,Q02779,23760366,"MAP3K4 is sufficiently mediate the TGFbeta-induced phosphorylation of p38 MAPK in MEFs and HaCaT cells."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,23178452,"A novel and important role for MAP3K10 in the proliferation and chemoresistance of pancreatic ductal adenocarcinoma."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,21979919,"Mechanism of MAP kinase activation by TNF requires Src-dependent activation of Vav, activation of Rac/Cdc42, and the engagement of the Rac/Cdc42 interaction site on MLK3."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,21979919,"Mechanism of MAP kinase activation by TNF requires Src-dependent activation of Vav, activation of Rac/Cdc42, and the engagement of the Rac/Cdc42 interaction site on MLK2 and 3."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,21678419,"This study showed that show that RUNX3 is a principal and evolutionarily conserved component of the MST pathway."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,20596961,"Data show that miR-181b contributed to proliferation of AML cells by targeting MLK2."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,19801649,"Mixed lineage kinase phosphorylates transcription factor E47 and inhibits TrkB expression to link neuronal death and survival pathways"
https://pharos.nih.gov/idg/targets/Q02779,Q02779,19332348,"Hippocalcin and MLK2 were colocalized in the halo of Lewy bodies in Parkinson disease patients, and neither protein was detected in normal pigmented neurons."
https://pharos.nih.gov/idg/targets/Q02779,Q02779,17584736,"MLK2 and -3 are required for activation of JNK and p38 by ectopically expressed GCK"
https://pharos.nih.gov/idg/targets/Q02779,Q02779,15062575,"demonstrate Alien-MLK2 interaction and also show that MLK2 is able to phosphorylate Alien; Alien, DAX-1 and thyroid hormone receptor mediated transcriptional silencing is strongly enhanced in the presence of active MLK2"
https://pharos.nih.gov/idg/targets/Q02779,Q02779,12105200,"MLK2 has a role in vesicle formation and endosome recycling by binding to clathrin"
